<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7008609\results\search\tropicalVirus\results.xml">
   <result pre="closely related to and cocirculates with Venezuelan equine encephalitis and" exact="Chikungunya" post="viruses (2). MAYV is maintained in an enzootic cycle"/>
   <result pre="showed that two MAYV genotypes are co-circulating in Mato Grosso." exact="DENV" post="negative samples were tested by using multiplex-nested-PCR to identify"/>
   <result pre="basin presented symptoms of febrile illness. After testing negative for" exact="DENV" post="and CHIKV, MAYV was confirmed by RT-PCR and subsequently"/>
   <result pre="34 samples that were negative for Zika, leptospirosis, dengue, and" exact="Chikungunya" post="were tested for Mayaro. Five of the samples were"/>
   <result pre="does not include the 16 imported cases of Mayaro. CHIKV," exact="Chikungunya" post="virus; DENV, dengue virus; HI, hemagglutination inhibition; IgM MAC-ELISA,"/>
   <result pre="in samples that tested negative for leptospirosis, dengue, Chikungunya, and" exact="Zika" post="(38) and that had originated from individuals in the"/>
   <result pre="DMaiaILLacerda NogueiraMMayaro fever in an HIV-infected patient suspected of having" exact="Chikungunya" post="fever201649564865247. Estofolete CF, Tasso Oliveira Mota M, Vedovello D,"/>
   <result pre="M. Mayaro fever in an HIV-infected patient suspected of having" exact="Chikungunya" post="fever. 2016;49(5):648-52. 48.BruniniSFrançaDDSSilvaJBSilvaLNSilvaFPASpadoniMet al.High Frequency of Mayaro Virus IgM"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7010294\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : People and places : Geographical locations :"/>
   <result pre="the knowledge, perceptions and role of personal protective technologies in" exact="Zika" post="prevention in Colombia Perceptions of Zika virus and personal"/>
   <result pre="personal protective technologies in Zika prevention in Colombia Perceptions of" exact="Zika" post="virus and personal protective technologies in Colombia MendozaCarolinaConceptualizationData curationFormal"/>
   <result pre="of disease in groups most susceptible to adverse outcomes from" exact="Zika" post="virus. However, achieving high uptake and compliance with PPT"/>
   <result pre="insight into the knowledge and concerns of pregnant women surrounding" exact="Zika" post="and their opinions regarding PPT, particularly repellent clothing, a"/>
   <result pre="in Colombia. The discussions revealed shortfalls in basic knowledge of" exact="Zika" post="virus, with several pregnant participants reporting being unaware of"/>
   <result pre="the potential for Zika-related congenital malformations. Although participants generally considered" exact="Zika" post="to be a significant personal threat, most rated it"/>
   <result pre="PPT in populations most at risk of adverse outcomes from" exact="Zika" post="infection requires engaging key users in open dialogue to"/>
   <result pre="that educational campaigns should strongly emphasize the risks associated with" exact="Zika" post="during pregnancy, and discuss safety profiles of approved synthetic"/>
   <result pre="elevated risk of severe disease, such as pregnant women in" exact="Zika" post="endemic regions, may help mitigate adverse outcomes from Zika"/>
   <result pre="in Zika endemic regions, may help mitigate adverse outcomes from" exact="Zika" post="virus infection. To explore ways of increasing the appeal"/>
   <result pre="identifier number DOI 10.5281/zenodo.3596686 (https://doi.org/10.5281/zenodo.3596686). Introduction An epidemic outbreak of" exact="Zika" post="virus was declared in Colombia in early October 2015"/>
   <result pre="Colombia with approximately 2.5 million inhabitants, a total of 15,181" exact="Zika" post="cases were reported [2]. In Villavicencio, a city with"/>
   <result pre="In Villavicencio, a city with just over 500,000 inhabitants, 2278" exact="Zika" post="cases were reported to the public health surveillance system"/>
   <result pre="which 368 (17.2%) were in pregnant women [4]. While the" exact="Zika" post="virus usually causes a mild and self-limiting febrile illness,"/>
   <result pre="quadrupled during the epidemic to 11.6 cases per 10,000 births[5]." exact="Zika" post="infection has also been associated with a variety of"/>
   <result pre="adults, including encephalitis, Guillain-Barre Syndrome[6, 7] and immune-mediated thrombocytopenia[8]. The" exact="Zika" post="virus is a flavivirus, closely related to dengue, and"/>
   <result pre="transmission route [9]. Aedes aegypti and Aedes albopictus are competent" exact="Zika" post="vectors [10] and are abundant in Colombia [11–13], with"/>
   <result pre="with the former species responsible for most cases of urban" exact="Zika" post="transmission [14]. Aedes aegypti is a highly anthropophilic and"/>
   <result pre="are detected [17, 18]. With a lack of treatment for" exact="Zika" post="and its associated pathologies, measures that can effectively reduce"/>
   <result pre="sense of control over mosquito bite prevention. During the recent" exact="Zika" post="epidemic, the Colombian Ministry of Health and Social Protection"/>
   <result pre="of certain U.S. Environmental Protection Agency (EPA)-registered topical repellents for" exact="Zika" post="prevention was also strongly recommended by the U.S. Centers"/>
   <result pre="to: 1) gain an understanding of the perceived importance of" exact="Zika" post="and other arboviruses in this setting, 2) identify context"/>
   <result pre="arboviruses in this setting, 2) identify context specific knowledge of" exact="Zika" post="transmission and pathology, 3) discern routine and desired mosquito"/>
   <result pre="containing the cities of Cali and Villavicencio, respectively, experienced different" exact="Zika" post="incidence between 2016–2017, with the Pan American Health Organization"/>
   <result pre="told that the aim was to identify their concerns about" exact="Zika" post="and their opinions around different personal protection methods. The"/>
   <result pre="had any concerns about Zika. They were also given a" exact="Zika" post="fact sheet developed by the U.S. CDC. Data analysis"/>
   <result pre="families in total, representing: common mosquito control methods, arbovirus concerns," exact="Zika" post="knowledge, sources of Zika knowledge, changes to control behaviours"/>
   <result pre="common mosquito control methods, arbovirus concerns, Zika knowledge, sources of" exact="Zika" post="knowledge, changes to control behaviours during the Zika outbreak,"/>
   <result pre="sources of Zika knowledge, changes to control behaviours during the" exact="Zika" post="outbreak, ideal mosquito control tools, and views around PPT."/>
   <result pre="order to gain insights into the knowledge and perceptions of" exact="Zika" post="virus before and after the outbreak occurred in Colombia,"/>
   <result pre="the individuals performing the field work. Results The importance of" exact="Zika" post="and other arboviruses The magnitude of the perceived threat"/>
   <result pre="was historically more consistent year-on-year, compared with the relatively emergent" exact="Zika" post="and chikungunya epidemics, and, therefore, carried a greater risk"/>
   <result pre="to non-pregnant females, male participants were less likely to consider" exact="Zika" post="as a primary arboviral concern, expressing greater fears over"/>
   <result pre="concern, expressing greater fears over dengue and chikungunya. &quot;I had" exact="Zika" post="but it wasn’t so serious. I had joint pain"/>
   <result pre="home we’re more concerned about chikungunya, classic dengue, and hemorrhagic" exact="Dengue" post="[than Zika].�? (Male interview 1, Villavicencio). Pregnant women tended"/>
   <result pre="tended to be more likely than non-pregnant women to consider" exact="Zika" post="the arbovirus of primary concern. Discussion among pregnant women"/>
   <result pre="on concerns of the complications that can arise from congenital" exact="Zika" post="transmission, particularly microcephaly and cognitive impairment. I think we"/>
   <result pre="worry about viral diseases but we worry even more about" exact="Zika" post="because…it affects primarily the foetus. (FGD11, Pregnant, Cali). Chikungunya"/>
   <result pre="about Zika because…it affects primarily the foetus. (FGD11, Pregnant, Cali)." exact="Chikungunya" post="and yellow fever were least reported as the arbovirus"/>
   <result pre="that it carried the most severe chronic symptoms. Knowledge concerning" exact="Zika" post="transmission and pathology The majority of respondents in both"/>
   <result pre="both the pregnant and non-pregnant groups reported an awareness of" exact="Zika" post="as a disease threat and described mosquitoes as the"/>
   <result pre="general arbovirus description (e.g. causes a rash, fever), or confused" exact="Zika" post="with chikungunya, reporting a belief that they were alternate"/>
   <result pre="alternate names for the same disease. &quot;I thought chikungunya and" exact="Zika" post="were the same. I’ve just realised that they’re different�?"/>
   <result pre="told about Zika-related congenital abnormalities. &quot;I didn’t [know about congenital" exact="Zika" post="syndrome], I’m so scared now that I’m going to"/>
   <result pre="(P1): &quot;When I was hospitalized, a doctor told me that" exact="Zika" post="is more dangerous in pregnant women because it mostly"/>
   <result pre="mosquito reduction and bite prevention activities in response to the" exact="Zika" post="outbreak. Several respondents in both the pregnant and non-pregnant"/>
   <result pre="the pregnant and non-pregnant groups reported being so alarmed by" exact="Zika" post="that they incorporated more rigorous mosquito abatement activities into"/>
   <result pre="the more frequent use of insecticidal sprays. &quot;Now [since the" exact="Zika" post="outbreak], we sleep under a mosquito net, fumigate more"/>
   <result pre="being because the mosquito proliferation and bite prevention advice for" exact="Zika" post="was the same as that disseminated in recent chikungunya"/>
   <result pre="citronella, not like something weird�?. (FGD7, Non-pregnant, Cali). During a" exact="Zika" post="outbreak, pregnant women would be the primary target group"/>
   <result pre="for repellents for their children. Discussion The major burden of" exact="Zika" post="morbidity is shared disproportionately by the children and families"/>
   <result pre="shared disproportionately by the children and families affected by congenital" exact="Zika" post="syndrome. The targeting of pregnant women with enhanced bite-prevention"/>
   <result pre="has been recommended by the U.S. CDC for protection from" exact="Zika" post="infection [20]. Repellent clothing has also been proposed as"/>
   <result pre="of hemorrhagic dengue reported since the early 1990s [33, 34]," exact="Zika" post="is relatively emergent, with the first cases reported in"/>
   <result pre="with the first cases reported in 2015. A perception of" exact="Zika" post="as being of lower severity than dengue was also"/>
   <result pre="been reported among women of reproductive age in Peru, where" exact="Zika" post="was ranked as the least severe of the mosquito-borne"/>
   <result pre="diseases [35]. Although pregnant women were generally better informed about" exact="Zika" post="than non-pregnant women and were more likely to consider"/>
   <result pre="Zika than non-pregnant women and were more likely to consider" exact="Zika" post="to be the arbovirus of primary personal concern, the"/>
   <result pre="possibility of congenital Zika. This lack of basic knowledge about" exact="Zika" post="was further highlighted by a frequent conflation by participants"/>
   <result pre="further highlighted by a frequent conflation by participants of the" exact="Zika" post="and chikungunya viruses. A lack of knowledge about congenital"/>
   <result pre="chikungunya viruses. A lack of knowledge about congenital effects of" exact="Zika" post="virus was also found among residents of communities in"/>
   <result pre="of respondents reported an awareness of a causal relationship between" exact="Zika" post="infection in pregnancy and microcephaly in newborns [36]. Moreover,"/>
   <result pre="reveal gaps in awareness of some of important aspects of" exact="Zika" post="transmission and pathology in Colombia, and highlight the need"/>
   <result pre="recommended by the U.S. CDC as a tool for reducing" exact="Zika" post="transmission [20]. Moreover, safety and toxicology reviews of DEET"/>
   <result pre="about a potential role for repellent clothing in protecting against" exact="Zika" post="and other arboviral diseases, provided the active ingredients were"/>
   <result pre="risk of this compared to the extreme fetal pathologies of" exact="Zika" post="led the U.S. CDC to recommend permethrin impregnated clothing"/>
   <result pre="survey in Peru felt that the only preventative action for" exact="Zika" post="was larval source reduction, since repellents were too expensive"/>
   <result pre="the wearing of long-sleeved clothing for bite prevention during the" exact="Zika" post="outbreak was very infrequent, with the most common reason"/>
   <result pre="in development, the repertoire of tools immediately available for controlling" exact="Zika" post="transmission is extremely limited. PPT represents one of the"/>
   <result pre="revealed a high-risk population in Colombia with variable knowledge of" exact="Zika" post="and its transmission, with many participants reporting little to"/>
   <result pre="highlight significant gaps in the knowledge of key aspects of" exact="Zika" post="disease and bite-prevention among women in Colombia. The discussions"/>
   <result pre="PachecoO, GilboaSM, et al.Preliminary Report of Microcephaly Potentially Associated with" exact="Zika" post="Virus Infection During Pregnancy—Colombia, January-November 2016. MMWR Morb Mortal"/>
   <result pre="et al.Raised Frequency of Central Nervous System Malformations Related to" exact="Zika" post="Virus Infection in Two Birth Defects Surveillance Systems in"/>
   <result pre="MonsS, LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control study. Lancet."/>
   <result pre="de LamballerieX, HubertB, PiorkowskiG, et al.Evidence of Sexual Transmission of" exact="Zika" post="Virus. N Engl J Med. 2016;374(22):2195–8. Epub 2016/04/13. 10.1056/NEJMc160444927074370"/>
   <result pre="of Aedes aegypti, Ae. albopictus, and Culex quinquefasciatus Mosquitoes as" exact="Zika" post="Virus Vectors, China. Emerg Infect Dis. 2017;23(7):1085–91. Epub 2017/07/15."/>
   <result pre="zika en Colombia. Bogotá D.C. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-provionales-abordaje-clinico-gestantes-expuestas-zika-colombia.pdf 2016 [cited 2018]. 20CDC." exact="Zika" post="virus—prevent mosquito bites https://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html [cited 2018 30/12]. 21LalaniT, YunH,"/>
   <result pre="Attitudes, and Practices about the Prevention of Mosquito Bites and" exact="Zika" post="Virus Disease in Pregnant Women in Greece. Int J"/>
   <result pre="Protection of Permethrin-Treated Clothing against Aedes aegypti, the Vector of" exact="Dengue" post="and Zika Virus, in the Laboratory. PLoS One. 2016;11(5):e0152805"/>
   <result pre="Permethrin-Treated Clothing against Aedes aegypti, the Vector of Dengue and" exact="Zika" post="Virus, in the Laboratory. PLoS One. 2016;11(5):e0152805 Epub 2016/05/18."/>
   <result pre="everywhere&quot;: A qualitative exploration of knowledge, attitudes and practices towards" exact="Zika" post="virus among women of reproductive age in Iquitos, Peru."/>
   <result pre="Yepes-MayorgaAdriana, AriasAlejandro, FranzFabiano, ThomasJoanne, HuddleJamo, et al.A cross-sectional survey on" exact="ZIKV" post="in Honduras: Implications for governance and risk communication approaches."/>
   <result pre="and practices of women of childbearing age testing negative for" exact="Zika" post="virus in Kentucky, 2016. Prev Med Rep. 2018;10:20–3. Epub"/>
   <result pre="reproductive health knowledge, attitudes and practices in relation to the" exact="Zika" post="virus outbreak in northeast Brazil. PLoS One. 2018;13(1):e0190024 Epub"/>
   <result pre="GoldmanRH. Insect Repellants During Pregnancy in the Era of the" exact="Zika" post="Virus. Obstet Gynecol. 2016;128(5):1111–5. 10.1097/AOG.000000000000168527548647 46FritzellC, RaudeJ, AddeA, DusfourI,"/>
   <result pre="Emergence of a New Arbovirus: Implications for the Control of" exact="Chikungunya" post="Virus in French Guiana. PLoS Negl Trop Dis. 2016;10(11):e0005081"/>
   <result pre="10.1371/journal.pntd.000508127802275 47HeydariN, LarsenDA, NeiraM, Beltran AyalaE, FernandezP, AdrianJ, et al.Household" exact="Dengue" post="Prevention Interventions, Expenditures, and Barriers to Aedes aegypti Control"/>
   <result pre="EssenB, LamiasMJ, ShulmanH, Hernandez-VirellaWI, TaraporewallaAJ, et al.Measures Taken to Prevent" exact="Zika" post="Virus Infection During Pregnancy—Puerto Rico, 2016. MMWR Morb Mortal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7011785\results\search\tropicalVirus\results.xml">
   <result pre="10.1080/22221751.2018.1561157 : Letter Naturally infected Aedes aegypti collected during a" exact="Zika" post="virus outbreak have viral titres consistent with transmission Emerging"/>
   <result pre="the McLaughlin Fellowship Fund (SRA). fig-count: table-count: equation-count: ref-count: page-count:" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus (arbovirus) of the"/>
   <result pre="of Uganda in 1947 [1]. Although serologic evidence indicates that" exact="ZIKV" post="has circulated in Africa and Asia for decades [2],"/>
   <result pre="infection were documented in the literature before 2007 [3]. Subsequently," exact="ZIKV" post="began causing outbreaks on islands in the Pacific before"/>
   <result pre="Guillain–Barré syndrome in previously healthy individuals as well as Congenital" exact="Zika" post="Syndrome in infants whose mothers were infected during pregnancy"/>
   <result pre="has been generally accepted that the principal urban vector of" exact="ZIKV" post="is the yellow fever mosquito, Aedes (Stegomyia) aegypti, although"/>
   <result pre="have found any evidence of natural C. quinquefasciatus infection by" exact="ZIKV" post="[6,7]. However, in both reports, the amount of ZIKV"/>
   <result pre="by ZIKV [6,7]. However, in both reports, the amount of" exact="ZIKV" post="as measured by RNA titres using RT-qPCR was unlikely"/>
   <result pre="Guedes et al. correctly pointed out that no quantification of" exact="ZIKV" post="titres from A. aegypti field collections has been reported"/>
   <result pre="identified A. aegypti as the principal vector during a 2015" exact="ZIKV" post="outbreak in Chiapas State, Mexico by testing mosquito pools"/>
   <result pre="standard virus titration curve (equation: Titre in FFUe/mL = 2E + 10e-.696(Ct), R2 = .988 using" exact="ZIKV" post="reference strain Mex1-44, isolated from one of these pools)"/>
   <result pre="virus present was inconsistent with transmission-competence. Although in our experience" exact="ZIKV" post="titres extrapolated from real-time PCR Ct values can vary"/>
   <result pre="chain reaction assays of mosquito pools collected during a Mexican" exact="Zika" post="virus outbreak. Pool ID Mosquito species Gender #/Pool CT"/>
   <result pre="pools of mosquitos gathered in close proximity to suspected human" exact="ZIKV" post="patients during a Mexican outbreak had large amounts of"/>
   <result pre="ZIKV patients during a Mexican outbreak had large amounts of" exact="ZIKV" post="RNA present; three of these pools yielded viral isolates"/>
   <result pre="only mosquito species to be directly incriminated via both experimental" exact="ZIKV" post="transmission and surveillance results [5,9,12]. Given the preponderance of"/>
   <result pre="of evidence in support of A. aegypti as the principal" exact="ZIKV" post="vector, and lack of direct evidence for a role"/>
   <result pre="Trop Med Hyg.1952;46:12. [2]ADHaddow, AJSchuh, CYYasuda, et al.Genetic characterization of" exact="Zika" post="virus strains: geographic expansion of the Asian lineage. PLoS"/>
   <result pre="[5]BoyerS, CalvezE, Chouin-CarneiroT, et al.An overview of mosquito vectors of" exact="Zika" post="virus. Microbes Infect.2018; doi:10.1016/j.micinf.2018.01.006. [6]DRGuedes, MHPaiva, MMDonato, et al.Zika"/>
   <result pre="[8]AyresC, GuedesD, PaivaM, et al.Response to: &quot;lack of evidence for" exact="Zika" post="virus transmission by Culex mosquitoes�?. Emerg Microbes Infect.2017;6:e91. doi:"/>
   <result pre="Microbes Infect.2017;6:e91. doi: 10.1038/emi.2017.8629044194 [9]GuerboisM, Fernandez-SalasI, SRAzar, et al.Outbreak of" exact="Zika" post="virus infection, Chiapas State, Mexico, 2015, and first confirmed"/>
   <result pre="New World mosquito species, Shows a low vector competence for" exact="Zika" post="virus relative to Aedes aegypti. Viruses. 2018;10; doi:10.3390/v10080434. [11]YPKuo,"/>
   <result pre="a mouse model for the complete mosquito-mediated transmission cycle of" exact="Zika" post="virus. PLoS Negl Trop Dis. 2018;12:e0006417. doi: 10.1371/journal.pntd.000641729668683 [12]ATCiota,"/>
   <result pre="Dis. 2018;12:e0006417. doi: 10.1371/journal.pntd.000641729668683 [12]ATCiota, SMBialosuknia, SDZink, et al.Effects of" exact="Zika" post="virus strain and Aedes mosquito species on vector competence."/>
   <result pre="YQDeng, et al.Culex pipiens quinquefasciatus: a potential vector to transmit" exact="Zika" post="virus. Emerg Microbes Infect. 2016;5:e102. doi: 10.1038/emi.2016.10227599470"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7018131\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences: Epidemiology : Medicine"/>
   <result pre="and temporal distribution of dengue in Brazil, 1990 - 2017" exact="Dengue" post="in Brazil AndrioliDenise CatarinaConceptualizationData curationFormal analysisInvestigationMethodologySupervisionValidationVisualizationWriting – original draftWriting"/>
   <result pre="medium, provided the original author and source are credited.pone.0228346.pdf Abstract" exact="Dengue" post="is a viral disease caused by an arbovirus of"/>
   <result pre="the Epidemiological Bulletins and publications of the Ministry of Health." exact="Dengue" post="incidence increased in all Brazilian regions and the interepidemic"/>
   <result pre="2003-2018. The authors did not have special access privileges. Introduction" exact="Dengue" post="is the most common viral disease in the world"/>
   <result pre="two decades, the introduction and simultaneous circulation of chikungunya and" exact="Zika" post="virus, whose symptoms are similar to those of dengue"/>
   <result pre="pose additional challenges to the current epidemiological scenario of Brazil." exact="Dengue" post="control actions and knowledge on its propagation contribute to"/>
   <result pre="Grande do Sul; SC—Santa Catarina; SP—São Paulo; SE—Sergipe; TO–Tocantins. Discussion" exact="Dengue" post="has become one of the greatest public health challenges"/>
   <result pre="serve to identify potentialities and potential weaknesses of the National" exact="Dengue" post="Control Program (Programa Nacional de Controle da Dengue, PNCD)."/>
   <result pre="introduced in Brazil in 1990, when the first cases of" exact="Dengue" post="Hemorrhagic Fever were confirmed [34]. The 2002 epidemic reflected"/>
   <result pre="tropical diseases. PLoS Negl Trop Dis2014; 8(7):e286510.1371/journal.pntd.000286525058013 3World Health Organization." exact="Dengue" post="and Severe Dengue [Internet]. World Health Organization; 2018a. [cited"/>
   <result pre="Negl Trop Dis2014; 8(7):e286510.1371/journal.pntd.000286525058013 3World Health Organization. Dengue and Severe" exact="Dengue" post="[Internet]. World Health Organization; 2018a. [cited 20 Nov 2018]."/>
   <result pre="PLoS Negl Trop Dis2012; 6(8):e176010.1371/journal.pntd.000176022880140 5collab: Brazilian Ministry of Health." exact="Dengue" post="[Internet]. Brasília: Brazilian Ministry of Health; 2018 [cited 17"/>
   <result pre="análise da situação de saúde e da epidemia pelo vírus" exact="Zika" post="e por outras doenças transmitidas pelo Aedes aegypti [Internet]."/>
   <result pre="international travel. Med Clin North Am2008; 92(6):1377–139010.1016/j.mcna.2008.07.00219061757 15World Health Organization." exact="Dengue" post="Control [Internet]. World Health Organization; 2018b. [cited 13 Oct"/>
   <result pre="from: https://palaeo-electronica.org/2001_1/past/past.pdf 24TeixeiraMG, SiqueiraJBJr, FerreiraGLC, BricksL, JointG. Epidemiological Trends of" exact="Dengue" post="Disease in Brazil (2000–2010): A Systematic Literature Search and"/>
   <result pre="of Aedes aegypti: Effects of Temperature and Implications for Global" exact="Dengue" post="Epidemic Potential. PLoS ONE2014; 9(3):e8978310.1371/journal.pone.008978324603439 33LoweR, Stewart-IbarraAM, PetrovaD, García-DíezM,"/>
   <result pre="Lancet Planetary Health2017; 1:e142–e151. 10.1016/S2542-5196(17)30064-529851600 34SiqueiraJB, MartelliCM, CoelhoGE, SimplícioAC, HatchDL." exact="Dengue" post="and Dengue Hemorrhagic Fever, Brazil, 1981–2002. Emerg Infect Dis."/>
   <result pre="Health2017; 1:e142–e151. 10.1016/S2542-5196(17)30064-529851600 34SiqueiraJB, MartelliCM, CoelhoGE, SimplícioAC, HatchDL. Dengue and" exact="Dengue" post="Hemorrhagic Fever, Brazil, 1981–2002. Emerg Infect Dis. 2005; 11(1):48–53."/>
   <result pre="Said RFC, Hoffmann JL, Martins J, Barbiratto SB et al." exact="Dengue" post="no Brasil: tendências e mudanças na epidemiologia, com ênfase"/>
   <result pre="PantojaJA, RodriguesSGet al.Air Travel Is Associated with Intracontinental Spread of" exact="Dengue" post="Virus Serotypes 1–3 in Brazil. PLoS Negl Trop Dis2014;"/>
   <result pre="MorrisonAC, RitchieSA, et al.A Critical Assessment of Vector Control for" exact="Dengue" post="Prevention. PLoS Negl Trop Dis2015; 9(5):e000365510.1371/journal.pntd.000365525951103 43RoizD, WilsonAL, ScottTW,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019145\results\search\tropicalVirus\results.xml">
   <result pre="Available at https://www.worldweatheronline.com/. 16.Sebrango-RodríguezCRet al. (2017) Real-time parameter estimation of" exact="Zika" post="outbreaks using model averaging. Epidemiology &amp;amp; Infection145, 2313–2323.28566102 17.TsoularisA"/>
   <result pre="Simple framework for real-time forecast in a data-limited situation: the" exact="Zika" post="virus (ZIKV) outbreaks in Brazil from 2015 to 2016"/>
   <result pre="Global Health6, e680–ee90.29731398 34.HeDet al. (2017) A comparison study of" exact="Zika" post="virus outbreaks in French Polynesia, Colombia and the State"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019302\results\search\tropicalVirus\results.xml">
   <result pre="7019302 doi: 10.3390/v12010123viruses-12-00123 : Brief Report Multi-Approach Investigation Regarding the" exact="West Nile" post="Virus Situation in Hungary, 2018 https://orcid.org/0000-0002-3503-8901ZanaBrigitta12ErdélyiKároly3NagyAnna4MezeiEszter5NagyOrsolya4https://orcid.org/0000-0002-2492-6890TakácsMária4BakonyiTamás67ForgáchPetra6Korbacska-KutasiOrsolya8FehérOrsolya8MalikPéter3UrsuKrisztina3KertészPéter9KepnerAnett10MartinaMáté10SüliTamás10LanszkiZsófia12TóthGábor Endre12KuczmogAnett12https://orcid.org/0000-0002-6006-9873SomogyiBalázs1JakabFerenc12https://orcid.org/0000-0001-9775-3065KemenesiGábor12*[1], brigitta.zana@gmail.comlanszkizsofi@gmail.comtoth.gabor.endre@gmail.comkuczmog@hotmail.comsobalbundi@gmail.comjakab.ferenc@pte.hu[2], [3],"/>
   <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The" exact="West Nile" post="virus is endemic in multiple European countries and responsible"/>
   <result pre="we summarized and analyzed the genetic and serologic data of" exact="WNV" post="infections from multiple Hungarian public health institutions, universities, and"/>
   <result pre="data through 2018. Wild birds were excellent indicator species for" exact="WNV" post="circulation in each year. Our efforts resulted in documenting"/>
   <result pre="multiple phylogenetic subclades with Balkans and Western-European progenitor sequences of" exact="WNV" post="circulating among human and animal populations in Hungary prior"/>
   <result pre="the epidemic of 2018 was not caused by recently introduced" exact="WNV" post="strains. Unfortunately, Hungary has no country-wide integrated surveillance system"/>
   <result pre="ecological background factors driving the evolution of future epidemics. co-circulation" exact="West Nile" post="encephalitis horse goshawk epizootic epidemiology virus isolation 1. Introduction"/>
   <result pre="Introduction Along with other widely distributed flaviviruses, such as the" exact="Dengue" post="virus or Yellow Fever virus, the West Nile virus"/>
   <result pre="such as the Dengue virus or Yellow Fever virus, the" exact="West Nile" post="virus is a major public health concern throughout multiple"/>
   <result pre="different [2,3]. Among genetic variants, lineage 1 and lineage 2" exact="West Nile" post="virus (ffWNV) strains pose the largest human health risk"/>
   <result pre="degree of infectivity and neuroinvasiveness was attributed to lineage 1" exact="WNV" post="until the appearance of a large number of lineage"/>
   <result pre="until the appearance of a large number of lineage 2" exact="WNV" post="strains in South Africa with elevated infectivity and neuroinvasive"/>
   <result pre="South Africa with elevated infectivity and neuroinvasive properties [4]. The" exact="West Nile" post="virus is transmitted by mosquitoes belonging to the Culex"/>
   <result pre="Until 2004, only the presence of lineage 1 and 3" exact="WNV" post="strains appeared in Europe [3]. Following the first emergence"/>
   <result pre="in Europe [3]. Following the first emergence of lineage 2" exact="WNV" post="in Hungary in 2004 [10], this genetic variant was"/>
   <result pre="200–300 human cases annually since the emergence of lineage 2" exact="WNV" post="[12,13,14,15]. According to the seasonal reports of the European"/>
   <result pre="work, we presented epidemic and epizootic data regarding the 2018" exact="WNV" post="situation in Hungary, along with genomic data in reference"/>
   <result pre="obtained from the University of Veterinary Medicine Budapest, and animal-derived" exact="WNV" post="sequences were provided by the University of Veterinary Medicine,"/>
   <result pre="further performed in Hungary, examining the adjacent area of horse" exact="WNV" post="cases in Dunaföldvár in 2018. We conducted a follow-up"/>
   <result pre="of these horse cases in order to assess the overwintering" exact="WNV" post="infection capacity regarding local mosquitoes (Table S2). Larvae collection"/>
   <result pre="histology, and polymerase chain reaction (PCR) were performed, and partial" exact="WNV" post="sequences were obtained from positive cases. 2.2. Nucleic Acid"/>
   <result pre="Samples Mosquito, horse, and northern goshawk samples were subjected to" exact="WNV" post="specific TaqMan real time reverse transcription PCR as described"/>
   <result pre="analyzer platform (Applied Biosystems). 2.4. Molecular Diagnostics of the Human" exact="WNV" post="Infections Diagnostic WNV TaqMan real-time RT-PCR screening of human"/>
   <result pre="Biosystems). 2.4. Molecular Diagnostics of the Human WNV Infections Diagnostic" exact="WNV" post="TaqMan real-time RT-PCR screening of human clinical specimens was"/>
   <result pre="the 5′-UTR and part of the capsid gene of the" exact="WNV" post="genome. Primer and probe sequences were described previously [21]."/>
   <result pre="kit (Applied Biosystems, CA, USA). 2.5. Serological Diagnosis of Human" exact="WNV" post="Cases The laboratory diagnosis regarding human WNV infections across"/>
   <result pre="Diagnosis of Human WNV Cases The laboratory diagnosis regarding human" exact="WNV" post="infections across the entire territory of Hungary was performed"/>
   <result pre="viral encephalitis. Due to the milder form of the human" exact="WNV" post="infections, commonly referred to as West Nile fever, patients"/>
   <result pre="form of the human WNV infections, commonly referred to as" exact="West Nile" post="fever, patients afflicted with exanthema, fever, myalgia, and/or arthralgia"/>
   <result pre="fever, myalgia, and/or arthralgia were also investigated and involved in" exact="WNV" post="screening during the transmission season. First-line serological methods included"/>
   <result pre="IgA antibodies and commercial enzyme-linked immunosorbent assays (ELISAs) for determining" exact="WNV" post="IgM response (West Nile Virus IgM Capture DxSelect™; Focus"/>
   <result pre="DxSelect™; Focus Diagnostics, DiaSorin Molecular LLC, Cypress, CA, USA) and" exact="WNV" post="IgG avidity (West Nile virus (WNV) avidity determination, (Euroimmun"/>
   <result pre="(WNV) avidity determination, (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany). Confirmation by" exact="WNV" post="microneutralization assay was performed in all cases. Serological cross-reactivity"/>
   <result pre="Acute infections were defined and reported as confirmed or probable" exact="WNV" post="infections in accordance with the EU case definition criteria."/>
   <result pre="24-well plate. An amount of 200 µL of supernatant from" exact="WNV" post="PCR-positive mosquito pool homogenates, goshawk, and horse brain tissue"/>
   <result pre="tree was visualized in FigTree v1.4.4 program. Human-derived partial NS3" exact="WNV" post="sequences were compared via their identity scores. The preliminary"/>
   <result pre="transmission season of 2018, n = 225 autochthonous and imported" exact="WNV" post="cases were reported to the ECDC. In total, n"/>
   <result pre="n = 53 patients were found to be positive for" exact="WNV" post="RNA by diagnostic PCR screening, while only those samples"/>
   <result pre="from n = 46 patients (27.7%) were eventually confirmed by" exact="WNV" post="nested RT-PCR and sequencing. Comprehensively, the results suggest a"/>
   <result pre="showed a nine-fold increase in the cumulative number of human" exact="WNV" post="cases [28]. The geographic distribution of infected birds coincided"/>
   <result pre="from January to November 2018, we identified 14 cases of" exact="WNV" post="related mortality. The first WNV case was detected on"/>
   <result pre="we identified 14 cases of WNV related mortality. The first" exact="WNV" post="case was detected on 2 July in a hooded"/>
   <result pre="future may prove beneficial in the early detection of seasonal" exact="WNV" post="circulation. During the entomological surveillance regarding infected horse cases"/>
   <result pre="in the swimming pool were found to be PCR-positive for" exact="WNV" post="RNA. However, we measured an extremely low viral load,"/>
   <result pre="Anopheles maculipennis, Culiseta annulata) were found to be negative for" exact="WNV" post="RNA, which supports the previous observation regarding low-level infection"/>
   <result pre="regarding low-level infection rates being sufficient for the persistence of" exact="WNV" post="in overwintering mosquito populations [33]. In addition to the"/>
   <result pre="(Table S1). 3.1.2. Equine Serologic Survey Equine cases related to" exact="WNV" post="are reported through the Animal Disease Notification System (ADNS)"/>
   <result pre="the number of cases implies an approximately 30-fold increase in" exact="WNV" post="cases among equines. 3.1.3. In Vitro Virus Propagation Attempts"/>
   <result pre="lines. Following the third blind passage, we could not detect" exact="WNV" post="RNA in the supernatants of lysed cells by the"/>
   <result pre="samples. 3.2. Phylogenetic Analysis The maximum likelihood phylogenetic analysis regarding" exact="WNV" post="strains resulted in two bush-like groups, representing the two"/>
   <result pre="in two bush-like groups, representing the two major subclades of" exact="WNV" post="strains circulating simultaneously in Central Europe as previously described"/>
   <result pre="by others [35]. Our phylogenetic analysis revealed that the circulating" exact="WNV" post="strains of 2018 were segregated into two different subgroups,"/>
   <result pre="to members of the Balkans subclade, while the other contained" exact="WNV" post="strains mainly from Southern and Western European countries. One"/>
   <result pre="segregated outside the two groups, advisably indicating the order of" exact="WNV" post="strains emergence in time and route of introduction to"/>
   <result pre="Italy, where mostly endemic clades persist [37], we reported two" exact="WNV" post="strains simultaneously co-circulating in Hungary. In our study, human-derived"/>
   <result pre="the more detailed work about the evolutionary dynamics of lineage-2" exact="WNV" post="[35]. 4. Conclusions During the transmission season of 2018,"/>
   <result pre="of 2018, several Central-Eastern European countries reported elevated numbers of" exact="WNV" post="infection cases among humans. In total, more than a"/>
   <result pre="2018 compared to 2017, thus exceeding the total number of" exact="WNV" post="cases from the past seven years [8]. Hungary was"/>
   <result pre="likely caused by endemic strains rather than recently introduced novel" exact="WNV" post="strains. We identified the presence of multiple phylogenetic subclades"/>
   <result pre="urgent need for a country-wide, organized surveillance system regarding the" exact="West Nile" post="virus. Acknowledgments Technical and administrative assistance provided by Nikolett"/>
   <result pre="References 1.GrayT.J.WebbC.E.A review of the epidemiological and clinical aspects of" exact="West Nile" post="virusInt. J. Gen. Med.2014719320310.2147/IJGM.S5990224748813 2.KemenesiG.DallosB.OldalM.KutasA.FöldesF.NémethV.ReiterP.BakonyiT.BányaiK.JakabF.Putative novel lineage of West"/>
   <result pre="West Nile virusInt. J. Gen. Med.2014719320310.2147/IJGM.S5990224748813 2.KemenesiG.DallosB.OldalM.KutasA.FöldesF.NémethV.ReiterP.BakonyiT.BányaiK.JakabF.Putative novel lineage of" exact="West Nile" post="virus in Uranotaenia unguiculata mosquito, HungaryVirusdisease20142550050310.1007/s13337-014-0234-825674630 3.PapaA.BakonyiT.XanthopoulouK.VázquezA.TenorioA.NowotnyN.Genetic characterization of"/>
   <result pre="Nile virus in Uranotaenia unguiculata mosquito, HungaryVirusdisease20142550050310.1007/s13337-014-0234-825674630 3.PapaA.BakonyiT.XanthopoulouK.VázquezA.TenorioA.NowotnyN.Genetic characterization of" exact="West Nile" post="virus lineage 2, Greece, 2010Emerg. Infect. Dis.20111792092210.3201/eid1705.10175921529413 4.VenterM.SteylJ.HumanS.WeyerJ.ZaaymanD.BlumbergL.LemanP.A.PaweskaJ.SwanepoelR.Transmission of"/>
   <result pre="Nile virus lineage 2, Greece, 2010Emerg. Infect. Dis.20111792092210.3201/eid1705.10175921529413 4.VenterM.SteylJ.HumanS.WeyerJ.ZaaymanD.BlumbergL.LemanP.A.PaweskaJ.SwanepoelR.Transmission of" exact="West Nile" post="virus during horse autopsyEmerg. Infect. Dis.20101657357510.3201/eid1603.09104220202454 5.NappS.PetrićD.BusquetsN.West Nile virus"/>
   <result pre="Eastern EuropePathog. Glob. Health201811223324810.1080/20477724.2018.148356729979950 6.CiotaA.T.KramerL.D.Vector-virus interactions and transmission dynamics of" exact="West Nile" post="virusViruses201353021304710.3390/v512302124351794 7.PaphitouN.I.TourvasA.FloridouD.RichterJ.TryfonosC.ChristodoulouC.The first human case of neuroinvasive West Nile"/>
   <result pre="of West Nile virusViruses201353021304710.3390/v512302124351794 7.PaphitouN.I.TourvasA.FloridouD.RichterJ.TryfonosC.ChristodoulouC.The first human case of neuroinvasive" exact="West Nile" post="virus infection identified in CyprusJ. Infect. Public Health20171089189310.1016/j.jiph.2017.02.00328233724 8.ZannoliS.SambriV.West"/>
   <result pre="an emerging pathogenIntervirology20115417118410.1159/00032832021576931 10.BakonyiT.IvanicsE.ErdélyiK.UrsuK.FerencziE.WeissenböckH.NowotnyN.Lineage 1 and 2 strains of encephalitic" exact="West Nile" post="virus, central EuropeEmerg. Infect. Dis.20061261862310.3201/eid1204.05137916704810 11.BakonyiT.FerencziE.ErdélyiK.KutasiO.CsörgőT.SeidelB.WeissenböckH.BruggerK.BánE.NowotnyN.Explosive spread of a"/>
   <result pre="EuropeEmerg. Infect. Dis.20061261862310.3201/eid1204.05137916704810 11.BakonyiT.FerencziE.ErdélyiK.KutasiO.CsörgőT.SeidelB.WeissenböckH.BruggerK.BánE.NowotnyN.Explosive spread of a neuroinvasive lineage 2" exact="West Nile" post="virus in Central Europe, 2008/2009Vet. Microbiol.2013165617010.1016/j.vetmic.2013.03.00523570864 12.Hernández-TrianaL.M.JeffriesC.L.MansfieldK.L.CarnellG.FooksA.R.JohnsonN.Emergence of west"/>
   <result pre="of a mosquito-borne diseaseFront. Public Health2014227110.3389/fpubh.2014.0027125538937 13.KuroltI.C.KrajinovićV.TopićA.KuzmanI.BaršićB.MarkotićA.First molecular analysis of" exact="West Nile" post="virus during the 2013 outbreak in CroatiaVirus Res.2014189636610.1016/j.virusres.2014.04.01724809948 14.ECDC:"/>
   <result pre="RT-PCR assay for detection and quantification of both lineages of" exact="West Nile" post="virus RNAJ. Clin. Virol.20063617718210.1016/j.jcv.2006.02.00816675298 20.VázquezA.Sánchez-SecoM.P.PalaciosG.MoleroF.ReyesN.RuizS.ArandaC.MarquésE.EscosaR.MorenoJ.et al.Novel flaviviruses detected in"/>
   <result pre="different species of mosquitoes in SpainVector-Borne Zoonotic Dis.20121222322910.1089/vbz.2011.068722022811 21.LinkeS.EllerbrokH.NiedrigM.NitscheA.PauliG.Detection of" exact="West Nile" post="virus lineages 1 and 2 by real-time PCRJ. Virol."/>
   <result pre="by real-time PCRJ. Virol. Methods200714635535810.1016/j.jviromet.2007.05.02117604132 22.ChaskopoulouA.DovasC.ChaintoutisS.BouzalasI.AraG.PapanastassopoulouM.Evidence of enzootic circulation of" exact="West Nile" post="virus (Nea Santa-Greece-2010, lineage 2), Greece, May to July"/>
   <result pre="online: https://www.R-project.org/(accessed on 13 November 2019) 28.NagyA.MezeiE.NagyO.BakonyiT.CsonkaN.KaposiM.KoroknaiA.SzomorK.RigóZ.MolnárZ.et al.Extraordinary increase in" exact="West Nile" post="virus cases and first confirmed human Usutu virus infection"/>
   <result pre="in Hungary, 2018Eurosurveillance201924190003810.2807/1560-7917.ES.2019.24.28.190003831311619 29.ErdélyiK.UrsuK.FerencziE.SzerediL.RátzF.SkáreJ.BakonyiT.Clinical and pathologic features of lineage 2" exact="West Nile" post="virus infections in birds of prey in HungaryVector-Borne Zoonotic"/>
   <result pre="HungaryVector-Borne Zoonotic Dis.2007718118810.1089/vbz.2006.058617627436 30.HubálekZ.KosinaM.RudolfI.MendelJ.StrakováP.TomešekM.Mortality of Goshawks (Accipiter gentilis) Due to" exact="West Nile" post="Virus Lineage 2Vector-Borne Zoonotic Dis.20181862462710.1089/vbz.2018.228930063186 31.RizzoliA.BolzoniL.ChadwickE.A.CapelliG.MontarsiF.GrisentiM.de la PuenteJ.M.MuñozJ.FiguerolaJ.SoriguerR.et al.Understanding"/>
   <result pre="Nile Virus Lineage 2Vector-Borne Zoonotic Dis.20181862462710.1089/vbz.2018.228930063186 31.RizzoliA.BolzoniL.ChadwickE.A.CapelliG.MontarsiF.GrisentiM.de la PuenteJ.M.MuñozJ.FiguerolaJ.SoriguerR.et al.Understanding" exact="West Nile" post="virus ecology in Europe: Culex pipiens host feeding preference"/>
   <result pre="virus emergenceParasit. Vectors2015821310.1186/s13071-015-0831-425888754 32.NappS.MontalvoT.Piñol-BaenaC.Gómez-MartínM.B.Nicolás-FranciscoO.SolerM.BusquetsN.Usefulness of Eurasian Magpies (Pica pica) for" exact="West Nile" post="virus Surveillance in Non-Endemic and Endemic SituationsViruses20191171610.3390/v11080716 33.RudolfI.BetášováL.BlažejováH.VenclíkováK.StrakováP.ŠebestaO.MendelJ.BakonyiT.SchaffnerF.NowotnyN.et al.West"/>
   <result pre="al.West Nile virus in overwintering mosquitoes, central EuropeParasit. Vectors20171045210.1186/s13071-017-2399-728969685 34.BakonyiT.GajdonG.K.SchwingR.VoglW.HäbichA.C.ThallerD.WeissenböckH.RudolfI.HubálekZ.NowotnyN.Chronic" exact="West Nile" post="virus infection in kea (Nestor notabilis)Vet. Microbiol.201618313513910.1016/j.vetmic.2015.12.01226790946 35.ChaintoutisS.C.PapaA.PervanidouD.DovasC.I.Evolutionary dynamics"/>
   <result pre="in kea (Nestor notabilis)Vet. Microbiol.201618313513910.1016/j.vetmic.2015.12.01226790946 35.ChaintoutisS.C.PapaA.PervanidouD.DovasC.I.Evolutionary dynamics of lineage 2" exact="West Nile" post="virus in Europe, 2004–2018: Phylogeny, selection pressure and phylogeographyMol."/>
   <result pre="Phylogenet. Evol.201914110661710.1016/j.ympev.2019.10661731521822 36.WollantsE.SmoldersD.NaesensR.BruynseelsP.LagrouK.MatthijnssensJ.Van RanstM.Use of Next-Generation Sequencing for Diagnosis of" exact="West Nile" post="Virus Infection in Patient Returning to Belgium from HungaryEmerg."/>
   <result pre="Infect. Dis.2018242380238210.3201/eid2412.18049430457549 37.VeoC.Della VenturaC.MorenoA.RovidaF.PercivalleE.CanzianiS.TorriD.CalzolariM.BaldantiF.GalliM.et al.Evolutionary Dynamics of the Lineage 2" exact="West Nile" post="Virus That Caused the Largest European Epidemic: Italy 2011–2018Viruses20191181410.3390/v1109081431484295"/>
   <result pre="Largest European Epidemic: Italy 2011–2018Viruses20191181410.3390/v1109081431484295 Figure 1 Geographical distribution of" exact="West Nile" post="virus (WNV) polymerase chain reaction (PCR)-positive cases at the"/>
   <result pre="level and cumulative incidence rates of autochthonous and imported human" exact="WNV" post="infections at NUTS 3 level of Hungary, from 2014"/>
   <result pre="Hungary, from 2014 through 2017. The total number of human" exact="WNV" post="cases between 2014 and 2017: n = 103. Black"/>
   <result pre="units for statistics level 3. IR: Incidence rates (number of" exact="WNV" post="human infections/100,000 inhabitants). Figure 2 Geographical distribution of West"/>
   <result pre="of WNV human infections/100,000 inhabitants). Figure 2 Geographical distribution of" exact="West Nile" post="virus (WNV) PCR-positive cases at LAU 2 level and"/>
   <result pre="LAU 2 level and cumulative incidence rates of autochthonous human" exact="WNV" post="infections at NUTS 3 level of Hungary, 2018. The"/>
   <result pre="level of Hungary, 2018. The total number of autochthonous human" exact="WNV" post="cases in 2018: n = 215. Black dots indicate"/>
   <result pre="units for statistics level 3. IR: Incidence rates (number of" exact="WNV" post="human infections/100,000 inhabitants). Figure 3 Geographical distribution of enzootic"/>
   <result pre="WNV human infections/100,000 inhabitants). Figure 3 Geographical distribution of enzootic" exact="WNV" post="cases. Color background of each county represents the number"/>
   <result pre="between 2010 and 2018. Progenitor African, Hungarian, and a Serbian" exact="WNV" post="lineage 2 strains are highlighted with blue outline, while"/>
   <result pre="case from Hungary to Belgium [36]. Figure 5 Human-derived, partial" exact="WNV" post="NS3 sequences from the 2018 season. The figure represents"/>
   <result pre="season. The figure represents similarity scores of all available human-derived" exact="WNV" post="partial NS3 sequences from 2018. The two dominant genetic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019415\results\search\tropicalVirus\results.xml">
   <result pre="(arboviruses) have received much global attention recently due to the" exact="Zika" post="virus epidemic in the Americas. The major human arboviruses"/>
   <result pre="in Sudan 2.1. Mosquito-Borne Viral Diseases 2.1.1. Yellow Fever Virus" exact="Yellow fever" post="virus (YFV; Flaviviridae) is endemic in Sudan and infections"/>
   <result pre="cases and 1500 deaths, was reported from 1940 to 1941." exact="YFV" post="was detected in humans, non-human primates, wild and domestic"/>
   <result pre="[27]. A survey in 1973 confirmed the active circulation of" exact="YFV" post="in the area and indicated a high prevalence of"/>
   <result pre="exposure (95%) among the nonvaccinated population of central Sudan [28]." exact="YFV" post="was detected in the Northern Province of Sudan in"/>
   <result pre="spill over into the neighboring country of Chad [32]. 2.1.2." exact="Dengue" post="Virus Dengue virus (DENV; Flaviviridae) is endemic in Sudan"/>
   <result pre="into the neighboring country of Chad [32]. 2.1.2. Dengue Virus" exact="Dengue" post="virus (DENV; Flaviviridae) is endemic in Sudan and its"/>
   <result pre="on the Red Sea coast, Port Sudan city [36,37,38,39]. Recently," exact="DENV" post="has been emerging throughout the country (Figure 2). Indeed,"/>
   <result pre="for the first time during an outbreak in 2016/17 [42,43]." exact="DENV" post="infections were reported from the population of east, north,"/>
   <result pre="febrile illness, following heavy rain and flooding [5,6,35]. Studies of" exact="DENV" post="infection among pregnant women in East Sudan showed that"/>
   <result pre="DENV-2 [42]. Additionally, studies reported a high prevalence (67%) of" exact="DENV" post="infections in Sudan and up to 89% in the"/>
   <result pre="in these areas were infected repeatedly, and reported that all" exact="DENV" post="(1–4) serotypes are circulating in the area [52,53]. Recently,"/>
   <result pre="of dengue fever in the Darfur area, western Sudan [54]." exact="DENV" post="transmission in Sudan is heterogeneous in space and time,"/>
   <result pre="water supply, storing drinking water, and geographical location [41,53]. 2.1.3." exact="West Nile" post="Virus West Nile virus (WNV, Flaviviridae) is endemic in"/>
   <result pre="drinking water, and geographical location [41,53]. 2.1.3. West Nile Virus" exact="West Nile" post="virus (WNV, Flaviviridae) is endemic in Sudan with infections"/>
   <result pre="and 1953–1954 (Figure 3) [6,35,55,56]. Salim and Porterfield suggested that" exact="WNV" post="circulates enzootically in central Sudan, and this was confirmed"/>
   <result pre="in 1981 by Omer et al. [28,57]. Country-wide epidemics of" exact="WNV" post="infection were reported in 1994, 1996, and 1999, with"/>
   <result pre="associated with heavy rainfall and flooding [5,6,58]. An outbreak of" exact="WNV" post="infection in 2002, southern Sudan, was accompanied by severe"/>
   <result pre="encephalitis among 31 children under 12 years of age [59]." exact="WNV" post="infections have been recently identified in Darfur region, West"/>
   <result pre="in knowledge about the epidemiology and risk factors associated with" exact="WNV" post="infection, and local vectors have never been investigated. 2.1.4."/>
   <result pre="WNV infection, and local vectors have never been investigated. 2.1.4." exact="Zika" post="Virus The first evidence of Zika virus (ZIKV; Flaviviridae)"/>
   <result pre="never been investigated. 2.1.4. Zika Virus The first evidence of" exact="Zika" post="virus (ZIKV; Flaviviridae) circulation in Sudan was reported in"/>
   <result pre="A recent study reported a high rate of exposure to" exact="ZIKV" post="with 62.7% of 845 blood samples collected from all"/>
   <result pre="more specific neutralization test) [60]. Considering the recent association of" exact="ZIKV" post="infection in pregnant women with congenital defects in their"/>
   <result pre="congenital defects in their infants, and the wide distribution of" exact="ZIKV" post="in Sudan (present in seven of 18 states of"/>
   <result pre="seven of 18 states of the country (Figure 4)), studying" exact="ZIKV" post="and it is epidemiology in Sudan is remarkably limited."/>
   <result pre="and it is epidemiology in Sudan is remarkably limited. 2.1.5." exact="Chikungunya" post="Virus Chikungunya virus (CHIKV; Togaviridae) is endemic with frequent"/>
   <result pre="is epidemiology in Sudan is remarkably limited. 2.1.5. Chikungunya Virus" exact="Chikungunya" post="virus (CHIKV; Togaviridae) is endemic with frequent upsurges in"/>
   <result pre="disease in Sudan in 1973 showed that the seroprevalence of" exact="CHIKV" post="infection in Central Sudan was 13% [28]. Similar seroprevalences"/>
   <result pre="in the western region of the country documented much higher" exact="CHIKV" post="seroprevalence, up to 44% [29,35]. An epidemiological survey in"/>
   <result pre="(qRT-PCR) showed that 24% of pregnant women were infected with" exact="CHIKV" post="and the infections were associated with preterm delivery [44]."/>
   <result pre="study across the country reported a relatively low seroprevalence of" exact="CHIKV" post="in East and Central Sudan (1.8%) with 100% dengue"/>
   <result pre="CrisisGlob. J. Epidemiol. Public Health20141576110.12974/2313-0946.2014.01.02.4 32.YuillT.M.WoodallJ.P.BaekelandS.Latest outbreak news from ProMED-mail." exact="Yellow fever" post="outbreak—Darfur Sudan and ChadInt. J. Infect. Dis.201317e476e47810.1016/j.ijid.2013.03.009 33.MarkoffL.Yellow Fever"/>
   <result pre="Systematic ReviewPLoS Negl. Trop. Dis.201610e000519410.1371/journal.pntd.000519427926925 41.SeidahmedO.M.E.HassanS.A.SoghaierM.A.SiamH.A.M.AhmedF.T.A.ElkarsanyM.M.SulaimanS.M.Spatial and Temporal Patterns of" exact="Dengue" post="Transmission along a Red Sea Coastline: A Longitudinal Entomological"/>
   <result pre="Port Sudan CityPLoS Negl. Trop. Dis.20126e182110.1371/journal.pntd.000182123029582 42.HamidZ.HamidT.AlsedigK.AbdallahT.ElaagipA.AhmedA.KhalidF.Abdel HamidM.Molecular Investigation of" exact="Dengue" post="virus serotype 2 Circulation in Kassala State, SudanJpn. J."/>
   <result pre="of El-Gadarif state, SudanBMC Public Health20181892110.1186/s12889-018-5853-330053811 54.AhmedA.EldumaA.MagboulB.HigaziT.AliY.The First Outbreak of" exact="Dengue" post="Fever in Greater Darfur, Western SudanTrop. Med. Infect. Dis.201944310.3390/tropicalmed401004330823624"/>
   <result pre="reemerging mosquito-borne viral disease in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 59.DepoortereE.KavleJ.KeusK.ZellerH.MurriS.LegrosD.Outbreak of" exact="West Nile" post="virus causing severe neurological involvement in children, Nuba Mountains,"/>
   <result pre="Mountains, Sudan, 2002Trop. Med. Int. Health2004973073610.1111/j.1365-3156.2004.01253.x15189465 60.SoghaierM.A.AbdelgadirD.M.AbdelkhaligS.M.KafiH.ZarrougI.M.A.SallA.A.EldegaiM.H.ElagebR.M.OsmanM.M.KhogaliH.Evidence of pre-existing active" exact="Zika" post="virus circulation in Sudan prior to 2012BMC Res. Notes20181190610.1186/s13104-018-4027-930567583"/>
   <result pre="Indicates Vulnerability of Eastern and Central Sudan to Infection with" exact="Chikungunya" post="VirusVector Borne Zoonotic Dis.20161629029110.1089/vbz.2015.189726974266 62.collab: EMRO-WHO WHOWeekly Epidemiological Monitor:"/>
   <result pre="Chikungunya VirusVector Borne Zoonotic Dis.20161629029110.1089/vbz.2015.189726974266 62.collab: EMRO-WHO WHOWeekly Epidemiological Monitor:" exact="Chikungunya" post="in Sudan. Regional Office of the Eastern MediterraneanWeekly Epidemiol."/>
   <result pre="online: http://applications.emro.who.int/docs/epi/2018/Epi_Monitor_2018_11_39.pdf?ua=1(accessed on 12 October 2018) 63.collab: WHOEmergencies Preparedness, Response:" exact="Chikungunya" post="in SudanWHOGeneva, Switzerland2018Available online: http://www.who.int/csr/don/15-october-2018-chikungunya-sudan/en/(accessed on 23 November 2018)"/>
   <result pre="Organ.20179560760810.2471/BLT.16.18968828804174 Figure 1 Map of Sudan showing the prevalence of" exact="Yellow fever" post="virus infections (Yellow). Figure 2 Map of Sudan showing"/>
   <result pre="(Brown). Figure 3 Map of Sudan showing the prevalence of" exact="West Nile" post="virus infections (Green). Figure 4 Map of Sudan showing"/>
   <result pre="(Green). Figure 4 Map of Sudan showing the prevalence of" exact="Zika" post="virus infections (Grey). Figure 5 Map of Sudan showing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019470\results\search\tropicalVirus\results.xml">
   <result pre=": Review Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of" exact="Zika" post="Virus: A Review https://orcid.org/0000-0002-3779-4727da SilvaSeverino Jefferson Ribeiro1PardeeKeith2PenaLindomar1*[1], jeffersonbiotecviro@gmail.com[2], keith.pardee@utoronto.ca"/>
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The recent outbreak of" exact="Zika" post="virus (ZIKV) in the Americas and its devastating developmental"/>
   <result pre="Moreover, given the lack of antivirals or approved vaccines for" exact="ZIKV" post="infection, a POC diagnostic test is urgently needed for"/>
   <result pre="isothermal amplification (LAMP) is a compelling alternative to RT-qPCR for" exact="ZIKV" post="and other arboviruses. This low-cost molecular system can be"/>
   <result pre="LAMP assays can provide greater accessibility to much-needed diagnostics for" exact="ZIKV" post="infections, especially in developing countries where the ZIKV is"/>
   <result pre="diagnostics for ZIKV infections, especially in developing countries where the" exact="ZIKV" post="is now endemic. This review summarizes the different LAMP"/>
   <result pre="features, advantages, and limitations. diagnostic point-of-care loop-mediated isothermal amplification (LAMP)" exact="Zika" post="virus (ZIKV) 1. Introduction Zika virus (ZIKV) is a"/>
   <result pre="point-of-care loop-mediated isothermal amplification (LAMP) Zika virus (ZIKV) 1. Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne virus from the genus"/>
   <result pre="this genus include dengue virus (DENV), Japanese encephalitis virus (JEV)," exact="West Nile" post="virus (WNV), and yellow fever virus (YFV) [3]. Like"/>
   <result pre="and yellow fever virus (YFV) [3]. Like most flaviviruses, the" exact="ZIKV" post="is an enveloped virus with a capsid 50 nm"/>
   <result pre="host immune evasion [4,5]. First identified in 1947 in the" exact="Zika" post="Forest of Uganda, ZIKV infections in humans remained sporadic"/>
   <result pre="First identified in 1947 in the Zika Forest of Uganda," exact="ZIKV" post="infections in humans remained sporadic for 60 years, with"/>
   <result pre="with very few cases reported, until April 2007 when the" exact="ZIKV" post="caused an outbreak on Yap Island, Federated States of"/>
   <result pre="Yap Island, Federated States of Micronesia [6,7,8]. In 2013, the" exact="ZIKV" post="was identified in French Polynesia and spread rapidly across"/>
   <result pre="during those outbreaks, the link between Guillain–Barré syndrome (GBS) and" exact="ZIKV" post="was reported, raising concerns about the neurological tropism of"/>
   <result pre="the virus [12]. In May 2015, the first case of" exact="ZIKV" post="infection was reported in Brazil [13] and the virus"/>
   <result pre="defects, including microcephaly, in neonates born to mothers infected by" exact="ZIKV" post="during pregnancy [3,15,16]. ZIKV is transmitted mainly through the"/>
   <result pre="neonates born to mothers infected by ZIKV during pregnancy [3,15,16]." exact="ZIKV" post="is transmitted mainly through the bite of infected mosquitoes"/>
   <result pre="be involved in the transmission [17,18,19,20,21]. Additionally, other routes of" exact="ZIKV" post="transmission have been identified, including blood transfusions, transplacental, perinatal,"/>
   <result pre="identified, including blood transfusions, transplacental, perinatal, and sexual intercourse [22,23,24]." exact="ZIKV" post="infection usually causes a self-limiting and a mild illness,"/>
   <result pre="where there is a circulation of other arboviruses, such as" exact="DENV" post="and chikungunya (CHIKV), the clinical diagnosis of ZIKV infection"/>
   <result pre="such as DENV and chikungunya (CHIKV), the clinical diagnosis of" exact="ZIKV" post="infection becomes extremely difficult because of common symptoms. Therefore,"/>
   <result pre="rapid and reliable point-of-care (POC) diagnostic test for detection of" exact="ZIKV" post="is urgently required for control and prevention measures and"/>
   <result pre="the diagnostic capacity of ZIKV-affected, mainly in low-resource areas [27,28]." exact="ZIKV" post="infection is diagnosed in the laboratory by nucleic acid"/>
   <result pre="Currently, RT-qPCR is considered the gold standard method to detect" exact="ZIKV" post="from patient and mosquito samples [6,7,29]. Although RT-qPCR provides"/>
   <result pre="in the field [36]. Since the 2015 emergence of the" exact="ZIKV" post="in Brazil, many LAMP assays have been developed for"/>
   <result pre="development and application of LAMP methods for the diagnosis of" exact="ZIKV" post="and explore the next steps to bring this assay"/>
   <result pre="on lateral flow assays [38,39,44,46,53,57,58]. 3. Principles LAMP Platforms for" exact="ZIKV" post="Different LAMP platforms have been developed for ZIKV detection"/>
   <result pre="Platforms for ZIKV Different LAMP platforms have been developed for" exact="ZIKV" post="detection in both patient samples and arthropod vectors and"/>
   <result pre="one-step LAMP assays have been developed for the detection of" exact="ZIKV" post="[41,42,53]. Bst 2.0 DNA polymerase is an in silico"/>
   <result pre="Bst 2.0. The enzyme has been successfully used for rapid" exact="ZIKV" post="detection in both human and mosquito samples [40,53]. Bst"/>
   <result pre="of reaction inhibitors, which has enabled LAMP applications for the" exact="ZIKV" post="even without sample pre-treatment or RNA extraction [40,53]. These"/>
   <result pre="excellent candidate for POC platforms and the rapid detection of" exact="ZIKV" post="and other pathogens. OmniAmp is an alternate engineered DNA"/>
   <result pre="in LAMP assays but has yet to be exploited for" exact="ZIKV" post="detection [65]. In contrast, the two-step LAMP protocol needs"/>
   <result pre="2). The use of the two-step LAMP protocol to detect" exact="ZIKV" post="has been described by several groups [27,28,57,59]. However, the"/>
   <result pre="Wang et al. (2016) developed an RT-LAMP assay to detect" exact="ZIKV" post="using the commercially available Loopamp RNA Amplification Kit (Eiken"/>
   <result pre="system based on RT-LAMP capable of detecting ZIKV, DENV, and" exact="CHIKV" post="in human samples and mosquito homogenate [27]. Their assay"/>
   <result pre="and mosquito homogenate [27]. Their assay was able to detect" exact="ZIKV" post="directly in urine and plasma without RNA extraction or"/>
   <result pre="interest that may contain the target genome. The design of" exact="ZIKV" post="primers begins with performing multiple alignments of ZIKV and"/>
   <result pre="design of ZIKV primers begins with performing multiple alignments of" exact="ZIKV" post="and other arbovirus sequences to identify unique and conserved"/>
   <result pre="arbovirus sequences to identify unique and conserved regions within the" exact="ZIKV" post="genome that do not share homology with the related"/>
   <result pre="Designer Optigene (www.optigene.co.uk/lamp-designer/) or Premier Biosoft (http://www.premierbiosoft.com/isothermal/lamp.html). LAMP primers for" exact="ZIKV" post="have been successfully designed to target the genes encoding"/>
   <result pre="NS2A, NS4A, NS5, the capsid and envelope proteins of the" exact="ZIKV" post="genome [37,38,39,41,45,63]. In establishing a new LAMP diagnostic assay,"/>
   <result pre="al. (2016) in their work that optimized RT-LAMP for a" exact="ZIKV" post="lateral flow assay (LFA) using Bst 3.0 DNA polymerase"/>
   <result pre="dNTP, and the reaction time could provide detection of the" exact="ZIKV" post="RNA in 30 min without non-target amplification. In a"/>
   <result pre="combined with a paper microfluidic chip and smartphone to detect" exact="ZIKV" post="in only 15 min. Varying only reaction temperature, they"/>
   <result pre="min), they found that 10-min incubations were sufficient to detect" exact="ZIKV" post="from serum samples, whereas 20-min incubations resulted in false-positive"/>
   <result pre="designed to allow users to detect positive LAMP reactions. For" exact="ZIKV" post="alone, this includes colorimetric detection using fluorescent dyes, UV"/>
   <result pre="to visualize LAMP products in assays for the detection of" exact="ZIKV" post="[39]. Calcein dye is a metal ion binding fluorophore,"/>
   <result pre="This has been a popular method of detection for LAMP-based" exact="ZIKV" post="assays [27,39,40,42,44,53,64]. However, visualization of LAMP amplicons by gel"/>
   <result pre="Recently, turbidity-based LAMP was used to detect the presence of" exact="ZIKV" post="in serum samples [39,41]. In the case of the"/>
   <result pre="assay to real-time fluorescence has been used for detection of" exact="ZIKV" post="in several applications, including from patient and mosquito samples"/>
   <result pre="are critically required. Moreover, some studies reported the use of" exact="ZIKV" post="probes in the LAMP reaction, which limits the application"/>
   <result pre="pair with portable companion hardware like the smartphone for reading" exact="ZIKV" post="assay results [44,58,60]. Using this approach, Ganguli et al."/>
   <result pre="RT-LAMP smartphone-enabled assay for simultaneous detection of ZIKV, CHIKV, and" exact="DENV" post="from whole blood samples. They showed that this system"/>
   <result pre="chip with smartphone-based measurement to simultaneously detect ZIKV, DENV, and" exact="CHIKV" post="in blood, urine, and saliva. They used a system"/>
   <result pre="detect ZIKV. Using the pH change of productive LAMP reactions," exact="ZIKV" post="positive samples from urine and human plasma could be"/>
   <result pre="assay coupled with reverse dot blot analysis (RDB) to detect" exact="ZIKV" post="in human saliva. The system was configured as a"/>
   <result pre="also been used as a LAMP readout to detect synthetic" exact="ZIKV" post="oligonucleotides [38]. The system contains streptavidin-magnetic nanoparticles (streptavidin-MNPs) premixed"/>
   <result pre="to recognize 1 attomolar (aM: 10−18 moles per liter) synthetic" exact="ZIKV" post="oligonucleotide in 20% serum within 27 min and also"/>
   <result pre="(LFA) coupled with the LAMP method for end-point detection of" exact="ZIKV" post="[37,40]. LFA is a favored technique because it is"/>
   <result pre="detect as few as 5 plaque-forming units (PFU) of the" exact="ZIKV" post="in as little as 40 min [37]. In another"/>
   <result pre="Bst 3.0 DNA polymerase-based RT-LAMP with an LFA to detect" exact="ZIKV" post="[40]. This LFA LAMP platform contains an absorbent pad,"/>
   <result pre="this approach [34,86]. In the case of LAMP assays for" exact="ZIKV" post="detection, it is important that analytical specificity be assessed"/>
   <result pre="in the region. In the case of the most recent" exact="ZIKV" post="outbreak in Latin America, this would include the arboviruses"/>
   <result pre="ZIKV outbreak in Latin America, this would include the arboviruses" exact="DENV" post="1-4, CHIKV, and YFV [87,88,89,90,91]. High analytical specificity for"/>
   <result pre="America, this would include the arboviruses DENV 1-4, CHIKV, and" exact="YFV" post="[87,88,89,90,91]. High analytical specificity for LAMP-based ZIKV assays has"/>
   <result pre="1-4, CHIKV, and YFV [87,88,89,90,91]. High analytical specificity for LAMP-based" exact="ZIKV" post="assays has been reported in both mosquito and human"/>
   <result pre="virus (DENV 1-4), chikungunya virus (CHIKV), yellow fever virus (YFV)," exact="West Nile" post="virus (WNV), Saint Louis encephalitis (SLEV), Western equine encephalitis"/>
   <result pre="et al. (2018) developed a real-time fluorescence RT-LAMP assay for" exact="ZIKV" post="detection targeting the NS5 gene. In this study, the"/>
   <result pre="ATCC25922. The results showed excellent specificity for the detection of" exact="ZIKV" post="[57]. While exciting, this study evaluated analytical specificity only"/>
   <result pre="against arboviruses that cause similar symptoms to ZIKV. Moreover, the" exact="ZIKV" post="strain used was the historical MR766 ZIKV strain, which"/>
   <result pre="ZIKV. Moreover, the ZIKV strain used was the historical MR766" exact="ZIKV" post="strain, which is genetically very different from the contemporary"/>
   <result pre="strain, which is genetically very different from the contemporary epidemic" exact="ZIKV" post="strains. Several investigations have demonstrated that carry-over contamination and"/>
   <result pre="developed a highly specific RT-LAMP assay for the detection of" exact="ZIKV" post="in mosquito samples [53]. We evaluated the analytical specificity"/>
   <result pre="the analytical specificity with seven arboviruses circulating in Brazil, including" exact="ZIKV" post="(PE-243), DENV-1 (PE/97-42735), DENV 2 (PE/95-3808), DENV 3 (PE/02-95016),"/>
   <result pre="seven arboviruses circulating in Brazil, including ZIKV (PE-243), DENV-1 (PE/97-42735)," exact="DENV" post="2 (PE/95-3808), DENV 3 (PE/02-95016), DENV 4 (PE/10-0081), YFV"/>
   <result pre="in Brazil, including ZIKV (PE-243), DENV-1 (PE/97-42735), DENV 2 (PE/95-3808)," exact="DENV" post="3 (PE/02-95016), DENV 4 (PE/10-0081), YFV (17DD), and CHIKV"/>
   <result pre="ZIKV (PE-243), DENV-1 (PE/97-42735), DENV 2 (PE/95-3808), DENV 3 (PE/02-95016)," exact="DENV" post="4 (PE/10-0081), YFV (17DD), and CHIKV (PE2016-480). The study"/>
   <result pre="(PE/97-42735), DENV 2 (PE/95-3808), DENV 3 (PE/02-95016), DENV 4 (PE/10-0081)," exact="YFV" post="(17DD), and CHIKV (PE2016-480). The study shows that RT-LAMP"/>
   <result pre="(PE/95-3808), DENV 3 (PE/02-95016), DENV 4 (PE/10-0081), YFV (17DD), and" exact="CHIKV" post="(PE2016-480). The study shows that RT-LAMP is very specific"/>
   <result pre="(PE2016-480). The study shows that RT-LAMP is very specific for" exact="ZIKV" post="detection [53]. Taken together, these results demonstrate the high"/>
   <result pre="inexpensive, and accurate molecular detection tool for the detection of" exact="ZIKV" post="in arthropod vectors. 5. LAMP Sensitivity Similar to specificity,"/>
   <result pre="using ZIKV-spiked or RNA-spiked samples (Table 1) [27,28,37,38,39,40,41,42,44,53,57,58,59,60,61,62,63,64]. The top-performing" exact="ZIKV" post="RT-LAMP method could detect ZIKV RNA standard at as"/>
   <result pre="(Table 1) [27,28,37,38,39,40,41,42,44,53,57,58,59,60,61,62,63,64]. The top-performing ZIKV RT-LAMP method could detect" exact="ZIKV" post="RNA standard at as few as 0.02 PFU/test, using"/>
   <result pre="in vitro transcription. For assays that used RNA extracted from" exact="ZIKV" post="specimens, top-performing assays provided greater sensitivity than conventional PCR"/>
   <result pre="less sensitive than the RT-qPCR assay for the diagnosis of" exact="ZIKV" post="[28]. While some studies have found LAMP to have"/>
   <result pre="found LAMP to have lower or similar sensitivity for the" exact="ZIKV" post="when compared to RT-qPCR [28,39], others have found LAMP"/>
   <result pre="coworkers demonstrated that the RT-LAMP assay was able to detect" exact="ZIKV" post="RNA in serum and urine and showed sensitivity 10-fold"/>
   <result pre="have recently developed an RT-LAMP assay for the detection of" exact="ZIKV" post="in mosquito samples [53]. To calculate the analytical sensitivity"/>
   <result pre="of Aedes aegypti spiked with a 10-fold serial dilution of" exact="ZIKV" post="ranging from 105 to 10−7 PFU without RNA extraction"/>
   <result pre="ranging from 105 to 10−7 PFU without RNA extraction from" exact="ZIKV" post="spiked mosquito samples, with positive detection down to 10−5"/>
   <result pre="PFU. Additionally, our RT-LAMP assay was also able to detect" exact="ZIKV" post="in mosquito samples that had been previously assayed as"/>
   <result pre="sensitivity 10,000 times greater than RT-qPCR for the detection of" exact="ZIKV" post="in mosquito samples, thus corroborating previous studies demonstrating that"/>
   <result pre="Evaluation Using Clinical Samples The suitability of LAMP assays for" exact="ZIKV" post="detection in clinical samples has been evaluated in several"/>
   <result pre="were also assayed using RT-qPCR. The comparative analysis of the" exact="ZIKV" post="LAMP assays with RT-qPCR was based on several statistical"/>
   <result pre="of these studies, Kurosaki et al. (2017) evaluated of the" exact="ZIKV" post="RT-LAMP assay using 189 specimens (90 plasma/serum and 99"/>
   <result pre="In another study, Calvert et al. (2017) evaluated of the" exact="ZIKV" post="RT-LAMP assay with 178 clinical samples, including 94 serum"/>
   <result pre="and accuracy of 69.7 (95% CI 62.6%–75.9%) for detection of" exact="ZIKV" post="relative to RT-qPCR for diagnosis of ZIKV infection. The"/>
   <result pre="for detection of ZIKV relative to RT-qPCR for diagnosis of" exact="ZIKV" post="infection. The positive and negative predictive values were calculated"/>
   <result pre="evaluated the efficacy of the RT-LAMP for diagnosis of the" exact="ZIKV" post="in clinical samples and compared these results with RT-qPCR"/>
   <result pre="urine specimens, an RT-LAMP assay was able to detect the" exact="ZIKV" post="in 53.4% of the total number of samples. Interestingly,"/>
   <result pre="the total number of samples. Interestingly, this study showed that" exact="ZIKV" post="detection using saliva had a faster time to positivity"/>
   <result pre="compared to urine samples [61]. 7. LAMP for Detection of" exact="ZIKV" post="in Mosquito Samples Surveillance of ZIKV in mosquitoes is"/>
   <result pre="LAMP for Detection of ZIKV in Mosquito Samples Surveillance of" exact="ZIKV" post="in mosquitoes is an important measure for identifying potential"/>
   <result pre="[93]. LAMP has been evaluated for the detection of the" exact="ZIKV" post="in mosquito samples by many groups, including ourselves [27,41,42,53]."/>
   <result pre="a diagnostic tool based on RT-LAMP for the detection of" exact="ZIKV" post="in infected mosquito samples [27]. However, the need for"/>
   <result pre="assay is specific, sensitive, and robust for the detection of" exact="ZIKV" post="in experimentally infected Aedes aegypti [42]. Chotiwan and coworkers"/>
   <result pre="a LAMP assay for rapid detection of Asian- and African-lineage" exact="Zika" post="viruses without RNA extraction [41]. The authors demonstrated that"/>
   <result pre="Zika viruses without RNA extraction [41]. The authors demonstrated that" exact="ZIKV" post="RNA can be detected by the LAMP test using"/>
   <result pre="More recently, we developed a novel RT-LAMP assay to detect" exact="ZIKV" post="in mosquitoes samples from in Brazil [58]. In this"/>
   <result pre="RT-LAMP assay, specific and very sensitive for the detection of" exact="ZIKV" post="in experimentally and naturally infected mosquitoes (Aedes aegypti and"/>
   <result pre="the RT-LAMP assay relative to RT-qPCR for the detection of" exact="ZIKV" post="in mosquito samples were performed using 60 mosquito samples"/>
   <result pre="using 60 mosquito samples collected at the epicenter of the" exact="Zika" post="epidemic in Pernambuco state, Brazil [58]. The ZIKV RT-LAMP"/>
   <result pre="of the Zika epidemic in Pernambuco state, Brazil [58]. The" exact="ZIKV" post="RT-LAMP assay for detection of ZIKV in mosquito samples"/>
   <result pre="state, Brazil [58]. The ZIKV RT-LAMP assay for detection of" exact="ZIKV" post="in mosquito samples had a diagnostic sensitivity of 100%"/>
   <result pre="diagnostic specificity of 91.18 % (95% CI 76.32% to 98.14%)," exact="ZIKV" post="prevalence of 46.03% (95% CI 33.39% to 59.06%), positive"/>
   <result pre="scenarios. 8. Multiplexing Mosquito-borne viruses such as ZIKV, DENV, and" exact="CHIKV" post="have rapidly spread across the world, causing epidemics in"/>
   <result pre="been developed for the simultaneous detection of ZIKV, DENV, and" exact="CHIKV" post="[27,58,60]. Although these approaches were able to specifically differentiate"/>
   <result pre="1). 9. Clinical Application and Public Health Perspectives The current" exact="ZIKV" post="epidemic has highlighted key limitations for the POC diagnosis"/>
   <result pre="epidemic has highlighted key limitations for the POC diagnosis of" exact="ZIKV" post="and remains a significant unmet need in low-resource countries."/>
   <result pre="in low-resource countries. With the fact that ZIKV, DENV, and" exact="CHIKV" post="cause similar symptoms and co-circulate in many regions of"/>
   <result pre="not possible. Although there are reliable laboratory diagnostic methods for" exact="ZIKV" post="infection, there remains a need for lower-cost diagnostic platforms"/>
   <result pre="to be a rapid, easy, accurate, and inexpensive platform for" exact="ZIKV" post="diagnostics, especially in remote areas and developing countries which"/>
   <result pre="for POC applications, especially in low-resource settings. The LAMP for" exact="ZIKV" post="has the potential to provide diagnostic performance equal to,"/>
   <result pre="declare no conflict of interest. References References 1.HaddowA.D.SchuhA.J.YasudaC.Y.KasperM.R.HeangV.HuyR.GuzmanH.TeshR.B.WeaverS.C.Genetic characterization of" exact="Zika" post="virus strains: Geographic expansion of the Asian lineagePLoS Negl."/>
   <result pre="the Asian lineagePLoS Negl. Trop. Dis.20126e147710.1371/journal.pntd.000147722389730 2.FayeO.FreireC.C.IamarinoA.de OliveiraJ.V.DialloM.ZanottoP.M.SallA.A.Molecular evolution of" exact="Zika" post="virus during its emergence in the 20(th) centuryPLoS Negl."/>
   <result pre="Microbiol.19904464968810.1146/annurev.mi.44.100190.0032452174669 5.KunoG.ChangG.J.Full-length sequencing and genomic characterization of Bagaza, Kedougou, and" exact="Zika" post="virusesArch. Virol.200715268769610.1007/s00705-006-0903-z17195954 6.LanciottiR.S.KosoyO.L.LavenJ.J.VelezJ.O.LambertA.J.JohnsonA.J.StanfieldS.M.DuffyM.R.Genetic and serologic properties of Zika virus"/>
   <result pre="Kedougou, and Zika virusesArch. Virol.200715268769610.1007/s00705-006-0903-z17195954 6.LanciottiR.S.KosoyO.L.LavenJ.J.VelezJ.O.LambertA.J.JohnsonA.J.StanfieldS.M.DuffyM.R.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg."/>
   <result pre="and serological specificityTrans. R Soc. Trop. Med. Hyg.19524650952010.1016/0035-9203(52)90042-412995440 9.IoosS.MalletH.P.Leparc GoffartI.GauthierV.CardosoT.HeridaM.Current" exact="Zika" post="virus epidemiology and recent epidemicsMed. Mal. Infect.20144430230710.1016/j.medmal.2014.04.00825001879 10.MussoD.Zika Virus"/>
   <result pre="MelloL.M.de AlbuquerqueL.L.de BritoC.A.A.CordeiroM.T.PenaL.J.Lessons Learned at the Epicenter of Brazil’s Congenital" exact="Zika" post="Epidemic: Evidence From 87 Confirmed CasesClin. Infect. Dis. Off."/>
   <result pre="ONE20149e10944210.1371/journal.pone.010944225310102 18.GuoX.X.LiC.X.DengY.Q.XingD.LiuQ.M.WuQ.SunA.J.DongY.D.CaoW.C.QinC.F.et al.Culex pipiens quinquefasciatus: A potential vector to transmit" exact="Zika" post="virusEmerging Microbes Infect.20165e10210.1038/emi.2016.102 19.GuedesD.R.PaivaM.H.DonatoM.M.BarbosaP.P.KrokovskyL.RochaS.W.D.S.SaraivaK.CrespoM.M.RezendeT.M.WallauG.L.et al.Zika virus replication in the"/>
   <result pre="mosquito Culex quinquefasciatus in BrazilEmerg. Microbes Infect.20176e6910.1038/emi.2017.5928790458 20.Elizondo-QuirogaD.Medina-SánchezA.Sánchez-GonzálezJ.M.EckertK.A.Villalobos-SánchezE.Navarro-ZúñigaA.R.Sánchez-TejedaG.Correa-MoralesF.González-AcostaC.AriasC.F.et al.Author Correction:" exact="Zika" post="Virus in Salivary Glands of Five Different Species of"/>
   <result pre="Wild-Caught Mosquitoes from MexicoSci. Rep.20188788710.1038/s41598-018-25807-929760427 21.SmarttC.T.ShinD.KangS.TabachnickW.J.(Diptera: Culicidae) From Florida Transmitted" exact="Zika" post="VirusFront. Microbiol.2018976810.3389/fmicb.2018.0076829755428 22.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for Zika virus transmission through"/>
   <result pre="Culicidae) From Florida Transmitted Zika VirusFront. Microbiol.2018976810.3389/fmicb.2018.0076829755428 22.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
   <result pre="communicable disease bulletinEurosurveillance2014192076124739982 23.CunhaM.S.EspositoD.L.RoccoI.M.MaedaA.Y.VasamiF.G.NogueiraJ.S.de SouzaR.P.SuzukiA.Addas-CarvalhoM.Barjas-CastroM.E.L.et al.First Complete Genome Sequence of" exact="Zika" post="Virus (Flaviviridae, Flavivirus) from an Autochthonous Transmission in BrazilGenome"/>
   <result pre="Flavivirus) from an Autochthonous Transmission in BrazilGenome Announc.20164e00032-1610.1128/genomeA.00032-1626941134 24.HillsS.L.RussellK.HennesseyM.WilliamsC.OsterA.M.FischerM.MeadP.Transmission of" exact="Zika" post="Virus Through Sexual Contact with Travelers to Areas of"/>
   <result pre="newly emerging arbovirusLancet Infect. Dis.201616e119e12610.1016/S1473-3099(16)30010-X27282424 27.YarenO.AltoB.W.GangodkarP.V.RanadeS.R.PatilK.N.BradleyK.M.YangZ.PhadkeN.BennerS.A.Point of sampling detection of" exact="Zika" post="virus within a multiplexed kit capable of detecting dengue"/>
   <result pre="FilhoJ.L.YasudaJ.Development and evaluation of a rapid molecular diagnostic test for" exact="Zika" post="virus infection by reverse transcription loop-mediated isothermal amplificationSci. Rep.201771350310.1038/s41598-017-13836-929044149"/>
   <result pre="transcription loop-mediated isothermal amplificationSci. Rep.201771350310.1038/s41598-017-13836-929044149 29.FayeO.DialloD.DialloM.WeidmannM.SallA.A.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught mosquitoesVirol. J.20131031110.1186/1743-422X-10-31124148652 30.Abd El"/>
   <result pre="field-caught mosquitoesVirol. J.20131031110.1186/1743-422X-10-31124148652 30.Abd El WahedA.SanabaniS.S.FayeO.PessôaR.PatriotaJ.V.GiorgiR.R.PatelP.Böhlken-FascherS.LandtO.NiedrigM.et al.Rapid Molecular Detection of" exact="Zika" post="Virus in Acute-Phase Urine Samples Using the Recombinase Polymerase"/>
   <result pre="Polymerase Amplification AssayPLoS Curr.2017910.1371/currents.outbreaks.a7f1db2c7d66c3fc0ea0a774305d319e 31.NicoliniA.M.McCrackenK.E.YoonJ.Y.Future developments in biosensors for field-ready" exact="Zika" post="virus diagnosticsJ. Biol. Eng.201711710.1186/s13036-016-0046-z28127399 32.MeagherR.J.NegreteO.A.Van RompayK.K.Engineering Paper-Based Sensors for"/>
   <result pre="Zika virus diagnosticsJ. Biol. Eng.201711710.1186/s13036-016-0046-z28127399 32.MeagherR.J.NegreteO.A.Van RompayK.K.Engineering Paper-Based Sensors for" exact="Zika" post="VirusTrends Mol. Med.20162252953010.1016/j.molmed.2016.05.00927255410 33.FelixA.C.SouzaN.C.S.FigueiredoW.M.CostaA.A.InenamiM.da SilvaR.M.G.LeviJ.E.PannutiC.S.RomanoC.M.Cross reactivity of commercial anti-dengue"/>
   <result pre="SilvaR.M.G.LeviJ.E.PannutiC.S.RomanoC.M.Cross reactivity of commercial anti-dengue immunoassays in patients with acute" exact="Zika" post="virus infectionJ. Med. Virol.2017891477147910.1002/jmv.2478928229481 34.NotomiT.OkayamaH.MasubuchiH.YonekawaT.WatanabeK.AminoN.HaseT.Loop-mediated isothermal amplification of DNANucleic"/>
   <result pre="features, and future prospectsJ. Microbiol.2015531510.1007/s12275-015-4656-925557475 37.SongJ.MaukM.G.HackettB.A.CherryS.BauH.H.LiuC.Instrument-Free Point-of-Care Molecular Detection of" exact="Zika" post="VirusAnal. Chem.2016887289729410.1021/acs.analchem.6b0163227306491 38.TianB.QiuZ.MaJ.Zardán Gómez de la TorreT.JohanssonC.SvedlindhP.StrömbergM.Attomolar Zika virus"/>
   <result pre="Detection of Zika VirusAnal. Chem.2016887289729410.1021/acs.analchem.6b0163227306491 38.TianB.QiuZ.MaJ.Zardán Gómez de la TorreT.JohanssonC.SvedlindhP.StrömbergM.Attomolar" exact="Zika" post="virus oligonucleotide detection based on loop-mediated isothermal amplification and"/>
   <result pre="amplification and AC susceptometryBiosens. Bioelectron.20168642042510.1016/j.bios.2016.06.08527423039 39.WangX.YinF.BiY.ChengG.LiJ.HouL.LiY.YangB.LiuW.YangL.Rapid and sensitive detection of" exact="Zika" post="virus by reverse transcription loop-mediated isothermal amplificationJ. Virol Methods2016238869310.1016/j.jviromet.2016.10.01027793644"/>
   <result pre="amplificationJ. Virol Methods2016238869310.1016/j.jviromet.2016.10.01027793644 40.LeeD.ShinY.ChungS.HwangK.S.YoonD.S.LeeJ.H.Simple and Highly Sensitive Molecular Diagnosis of" exact="Zika" post="Virus by Lateral Flow AssaysAnal. Chem.201688122721227810.1021/acs.analchem.6b0346028193014 41.ChotiwanN.BrewsterC.D.MagalhaesT.Weger-LucarelliJ.DuggalN.K.RückertC.NguyenC.Garcia LunaS.M.FauverJ.R.AndreB.et al.Rapid"/>
   <result pre="41.ChotiwanN.BrewsterC.D.MagalhaesT.Weger-LucarelliJ.DuggalN.K.RückertC.NguyenC.Garcia LunaS.M.FauverJ.R.AndreB.et al.Rapid and specific detection of Asian- and African-lineage" exact="Zika" post="virusesSci. Transl. Med.20179eaag053810.1126/scitranslmed.aag053828469032 42.LambL.E.BartoloneS.N.TreeM.O.ConwayM.J.RossignolJ.SmithC.P.ChancellorM.B.Rapid Detection of Zika Virus in"/>
   <result pre="Asian- and African-lineage Zika virusesSci. Transl. Med.20179eaag053810.1126/scitranslmed.aag053828469032 42.LambL.E.BartoloneS.N.TreeM.O.ConwayM.J.RossignolJ.SmithC.P.ChancellorM.B.Rapid Detection of" exact="Zika" post="Virus in Urine Samples and Infected Mosquitos by Reverse"/>
   <result pre="Reverse Transcription-Loop-Mediated Isothermal AmplificationSci. Rep.20188380310.1038/s41598-018-22102-529491389 43.ZhaoJ.FengR.Sensitive and rapid detection of" exact="Zika" post="virus by loop-mediated isothermal amplificationVirus Genes201855435010.1007/s11262-018-1612-x30426316 44.KaarjK.AkarapipadP.YoonJ.Y.Simpler, Faster, and"/>
   <result pre="virus by loop-mediated isothermal amplificationVirus Genes201855435010.1007/s11262-018-1612-x30426316 44.KaarjK.AkarapipadP.YoonJ.Y.Simpler, Faster, and Sensitive" exact="Zika" post="Virus Assay Using Smartphone Detection of Loop-mediated Isothermal Amplification"/>
   <result pre="Rep.201881243810.1038/s41598-018-30797-930127503 45.BuiT.T.MoiM.L.MoritaK.HasebeF.Development of a universal and lineage-specific primer sets for" exact="Zika" post="virus (ZIKV) rapid detection in blood and urine samples"/>
   <result pre="the POCKIT™ Nucleic Acid AnalyzerJ. Virol. Methods2014207667210.1016/j.jviromet.2014.06.01624992669 50.LauY.L.LaiM.Y.TeohB.T.Abd-JamilJ.JohariJ.SamS.S.TanK.K.AbuBakarS.Colorimetric Detection of" exact="Dengue" post="by Single Tube Reverse-Transcription-Loop-Mediated Isothermal AmplificationPLoS ONE201510e013869410.1371/journal.pone.013869426384248 51.Lopez-JimenaB.BekaertM.BakheitM.FrischmannS.PatelP.Simon-LoriereE.LambrechtsL.DuongV.DussartP.HaroldG.et al.Development"/>
   <result pre="52.Lopez-JimenaB.WehnerS.HaroldG.BakheitM.FrischmannS.BekaertM.FayeO.SallA.A.WeidmannM.Development of a single-tube one-step RT-LAMP assay to detect the" exact="Chikungunya" post="virus genomePLoS Negl. Trop. Dis.201812e000644810.1371/journal.pntd.000644829813065 53.SilvaS.J.R.D.PaivaM.H.S.GuedesD.R.D.KrokovskyL.MeloF.L.SilvaM.A.L.D.SilvaA.D.AyresC.F.J.PenaL.J.Development and Validation of"/>
   <result pre="Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) for Rapid Detection of" exact="ZIKV" post="in Mosquito Samples from BrazilSci. Rep.20199449410.1038/s41598-019-40960-530872672 54.ChenH.W.WeissenbergerG.AtkinsE.ChaoC.C.SuputtamongkolY.ChingW.M.Highly Sensitive Loop-Mediated"/>
   <result pre="primersMol. Cell Probes20021622322910.1006/mcpr.2002.041512144774 57.GuoX.G.ZhouY.Z.LiQ.WangW.WenJ.Z.ZhengL.WangQ.Rapid and reliable diagnostic method to detect" exact="Zika" post="virus by real-time fluorescence reverse transcription loop-mediated isothermal amplificationAMB"/>
   <result pre="Zika, chikungunya, and dengue virusesSci. Rep.201774477810.1038/srep4477828317856 59.CalvertA.E.BiggerstaffB.J.TannerN.A.LauterbachM.LanciottiR.S.Rapid colorimetric detection of" exact="Zika" post="virus from serum and urine specimens by reverse transcription"/>
   <result pre="60.GanguliA.OrnobA.YuH.DamhorstG.L.ChenW.SunF.BhuiyaA.CunninghamB.T.BashirR.Hands-free smartphone-based diagnostics for simultaneous detection of Zika, Chikungunya, and" exact="Dengue" post="at point-of-careBiomed. Microdevices2017197310.1007/s10544-017-0209-928831630 61.CastroT.SabalzaM.BarberC.AbramsW.Da CostaA.C.De Pádua MilagresF.A.Braz-SilvaP.H.MalamudD.GallottiniM.Rapid diagnosis of"/>
   <result pre="Dengue at point-of-careBiomed. Microdevices2017197310.1007/s10544-017-0209-928831630 61.CastroT.SabalzaM.BarberC.AbramsW.Da CostaA.C.De Pádua MilagresF.A.Braz-SilvaP.H.MalamudD.GallottiniM.Rapid diagnosis of" exact="Zika" post="virus through saliva and urine by Loop-mediated isothermal amplification"/>
   <result pre="(LAMP)J. Oral Microbiol.201810151071210.1080/20002297.2018.151071230202506 62.BartoloneS.N.TreeM.O.ConwayM.J.ChancellorM.B.LambL.E.Reverse Transcription-Loop-mediated Isothermal Amplification (RT-LAMP) Assay for" exact="Zika" post="Virus and Housekeeping Genes in Urine, Serum, and Mosquito"/>
   <result pre="in Urine, Serum, and Mosquito SamplesJ. Vis. Exp.2018139e5843610.3791/58436 63.SabalzaM.YasminR.BarberC.A.CastroT.MalamudD.KimB.J.ZhuH.MontagnaR.A.AbramsW.R.Detection of" exact="Zika" post="virus using reverse-transcription LAMP coupled with reverse dot blot"/>
   <result pre="EstrelaP.F.de Melo MendesG.de OliveiraK.G.BailãA.M.de Almeida SoaresC.M.AssunçãoN.A.Mendes DuarteG.R.Ten-minute direct detection of" exact="Zika" post="virus in serum samples by RT-LAMPJ. Virol. Methods201911367510.1016/j.jviromet.2019.11367531170469 65.ChanderY.KoelblJ.PuckettJ.MoserM.J.KlingeleA.J.LilesM.R.CarriasA.MeadD.A.SchoenfeldT.W.A"/>
   <result pre="in Pernambuco, Brazil, Revealed a Cocirculation of Zika, Chikungunya, and" exact="Dengue" post="Virus Type 1Medicine201695e320110.1097/MD.000000000000320127015222 88.MagalhaesT.BragaC.CordeiroM.T.OliveiraA.L.S.CastanhaP.M.S.MacielA.P.R.AmancioN.M.L.GouveiaP.N.Peixoto-da-SilvaV.J.PeixotoT.F.L.et al.Zika virus displacement by a"/>
   <result pre="chikungunya outbreak in Recife, BrazilPLoS Negl. Trop. Dis.201711e000605510.1371/journal.pntd.000605529108009 89.CevallosV.PonceP.WaggonerJ.J.PinskyB.A.ColomaJ.QuirogaC.MoralesD.CárdenasM.J.Zika and" exact="Chikungunya" post="virus detection in naturally infected Aedes aegypti in EcuadorActa"/>
   <result pre="EcuadorActa Trop.2018177748010.1016/j.actatropica.2017.09.02928982578 90.Sánchez-CarbonelJ.Tantaléan-YépezD.Aguilar-LuisM.A.Silva-CasoW.WeilgP.Vásquez-AchayaF.CostaL.Martins-LunaJ.SandovalI.Del Valle-MendozaJ.Identification of infection by Chikungunya, Zika, and" exact="Dengue" post="in an area of the Peruvian coast. Molecular diagnosis"/>
   <result pre="uracil-DNA-glycosylase-supplemented loop-mediated isothermal amplification (UDG-LAMP)Chem. Commun.2014503747374910.1039/c4cc00540f 93.AyllónT.CamposR.M.BrasilP.MoroneF.C.CâmaraD.C.P.MeiraG.L.S.TannichE.YamamotoK.A.CarvalhoM.S.PedroR.S.et al.Early Evidence for" exact="Zika" post="Virus Circulation among Aedes aegypti Mosquitoes, Rio de Janeiro,"/>
   <result pre="LAMP modes of output. viruses-12-00019-t001_Table 1Table 1 LAMP platforms for" exact="Zika" post="virus (ZIKV) diagnostics. Procedure Samples ZIKV Strains Used Target"/>
   <result pre="1 LAMP platforms for Zika virus (ZIKV) diagnostics. Procedure Samples" exact="ZIKV" post="Strains Used Target Region of the Primers Analytical Sensitivity"/>
   <result pre="on lateral flow assay (LFA) Human blood spiked with RNA" exact="ZIKV" post="MR 766 Uganda (AY632535) Envelope Protein 10° ZIKV RNA"/>
   <result pre="with RNA ZIKV MR 766 Uganda (AY632535) Envelope Protein 10°" exact="ZIKV" post="RNA Copy No No [40] Development of a microfluidic"/>
   <result pre="the aid of leuco crystal violet (LCV) Saliva spiked with" exact="ZIKV" post="MEX 2-81 (Mosquito/2016/México) Envelope Protein 5 PFU Yes No"/>
   <result pre="with AC susceptometry Human serum spiked with synthetic oligonucleotides of" exact="ZIKV" post="Synthetic oligonucleotides of ZIKV NS5 1 aM No No"/>
   <result pre="serum spiked with synthetic oligonucleotides of ZIKV Synthetic oligonucleotides of" exact="ZIKV" post="NS5 1 aM No No [38] One-step RT-LAMP Detection:"/>
   <result pre="and UV light Saliva, urine, and serum experimentally infected with" exact="ZIKV" post="ZIKV_SMGC-1 China (KX266255) NS1 0.02 PFU/test Yes No [39]"/>
   <result pre="blood, plasma, saliva, urine, semen and Aedes mosquito spiked with" exact="ZIKV" post="Puerto Rico (PRVABC59), P6-740 (HQ234449), 41525 (KU955591) and MR"/>
   <result pre="Development of a Trioplex assay to detect ZIKV, DENV, and" exact="CHIKV" post="Detection: development of RT-LAMP protocol coupled with a smartphone"/>
   <result pre="with a smartphone for detecting fluorescence Human blood spiked with" exact="ZIKV" post="Puerto Rico (PRVABC59), NS1 1.56 PFU/mL Yes No [60]"/>
   <result pre="urine. In addition to human serum and urine spiked with" exact="ZIKV" post="PRABC59, 976 Uganda, ArD157995, P6-740, CPC-0740*, 41525-DAK* Envelope Protein"/>
   <result pre="Development of a Trioplex assay to detect ZIKV, DENV, and" exact="CHIKV" post="Detection: monitoring of fluorescence coupled to quenching of unincorporated"/>
   <result pre="reporters (QUASR) and smartphone Blood, urine, and saliva spiked with" exact="ZIKV" post="Puerto Rico (PRVABC59), Honduras (R103451), and Brazilian strain; NS5"/>
   <result pre="of a Trioplex kit trial to detect ZIKV, DENV, and" exact="CHIKV" post="Detection: monitoring of fluorescence coupled to RT-qPCR platform and"/>
   <result pre="naked eye Urine, saliva, plasma and Aedes mosquito spiked with" exact="ZIKV" post="Puerto Rico, (PRVABC59, KU501215.1) NS5 ~ 0.71 PFU equivalent"/>
   <result pre="and urine. In addition to saliva and urine spiked with" exact="ZIKV" post="(PRVABC59 – NR-50240) Capsid 2.2 × 103 RNA copies/mL"/>
   <result pre="in situ with a smartphone Plasma and urine spiked with" exact="ZIKV" post="Purified ZIKV particles NS5 1 copy/μL Yes No [44]"/>
   <result pre="with a smartphone Plasma and urine spiked with ZIKV Purified" exact="ZIKV" post="particles NS5 1 copy/μL Yes No [44] One-step RT-LAMP"/>
   <result pre="urine. In addition to urine and Aedes mosquito spiked with" exact="ZIKV" post="MR 766 Uganda (AY632535), MEX20 (ZK-HU 0165 P), Puerto"/>
   <result pre="of fluorescence and reverse dot-blot for detection Saliva spiked with" exact="ZIKV" post="Thailand (PLCal_ZV), Puerto Rican (NR-50244), Thailand (NR-50242), Florida (NR5024),"/>
   <result pre="the naked eye with SYBR Green I Serum spiked with" exact="ZIKV" post="and patient samples including human serum - 10−3 copies"/>
   <result pre="One-step RT-LAMP Detection: turbidity monitoring Serum and urine spiked with" exact="ZIKV" post="PRVABC59 (KX601168), MRS_OPY_Martinique_Pari_2015 (KU647676), H/PF/2013 (KJ776791), and MR766 (LC002520)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019608\results\search\tropicalVirus\results.xml">
   <result pre="virus (Rhabdoviridae), Equid herpesviruses (Herpesviridae), Borna disease virus (Bornaviridae) and" exact="West Nile" post="virus (Flaviviridae), as well as exotic viruses, will be"/>
   <result pre="be presented. encephalitis arbovirus rabies Equid herpesviruses Borna disease virus" exact="West Nile" post="virus horses 1. Introduction Neurological disorders represent an important"/>
   <result pre="as viruses are concerned, Rabies virus, Equid alphaherpesvirus 1 (EHV-1)," exact="West Nile" post="virus and related flaviviruses (Japanese Encephalitis virus, Saint-Louis Encephalitis"/>
   <result pre="during the horse clinical examination. Indeed, 14% to 38% of" exact="West Nile" post="disease diagnosed in Europe and 52% of equid herpesvirus"/>
   <result pre="been eradicated from Western Europe by successful vaccination campaigns, while" exact="West Nile" post="virus is a (re)emerging arthropod-borne virus that has recently"/>
   <result pre="virus (Rhabdoviridae), equid herpesviruses (Herpesviridae), Borna disease virus (Bornaviridae) and" exact="West Nile" post="virus (Flaviviridae), as well as exotic viruses. The most"/>
   <result pre="(Bornaviridae) and neurotropic flaviviruses transmitted by mosquitoes and ticks, e.g.," exact="West Nile," post="tick-borne encephalitis and Louping ill viruses (Flaviviridae). 2.1. Equid"/>
   <result pre="in controlling or preventing the disease [109]. 2.4. Enzootic Flaviviruses:" exact="West Nile" post="Virus, Tick-Borne Encephalitis Virus and Louping Ill Virus Three"/>
   <result pre="documented in horses suffering from meningoencephalitis are enzootic in Europe," exact="West Nile" post="virus (WNV), tick-borne encephalitis virus (TBEV) and Louping ill"/>
   <result pre="protein has been involved in virus neuroinvasiveness. Transmission and Epidemiology" exact="WNV" post="WNV is maintained and amplified in an enzootic cycle"/>
   <result pre="has been involved in virus neuroinvasiveness. Transmission and Epidemiology WNV" exact="WNV" post="is maintained and amplified in an enzootic cycle involving"/>
   <result pre="involving birds and mosquitoes from the Culex genus as vectors." exact="WNV" post="is transmitted to different animal species (mainly mammals but"/>
   <result pre="of infected mosquitoes. Horses and humans are highly susceptible to" exact="WNV" post="infection but are considered as dead-end hosts owing to"/>
   <result pre="neuroinvasive forms with meningitis, encephalitis or myelitis may occur [113,114]." exact="WNV" post="is the most widely distributed arbovirus that induces equine"/>
   <result pre="induces equine encephalitis (Figure 7). Over the last 15 years," exact="WNV" post="has been repeatedly reported in Europe with a high"/>
   <result pre="1960s [115]. After a silence of more than 30 years," exact="WNV" post="lineage 1 strains resurfaced in North Africa (in Morocco"/>
   <result pre="(Romania (1996), Italy (1998), Russia (1999) and France (2000)) [116,117,118]." exact="WNV" post="strikingly exemplified how fast and unpredictable flaviviruses can emerge"/>
   <result pre="and limited in time and space. Nevertheless, a revival of" exact="WNV" post="activity in Europe has been associated in particular with"/>
   <result pre="in particular with the introduction in 2004 of a new" exact="WNV" post="strain within lineage 2, most likely originating from Africa"/>
   <result pre="within lineage 2, most likely originating from Africa [120]. This" exact="WNV" post="lineage 2 was initially identified in Hungary and then"/>
   <result pre="including Greece in 2010 and Italy in 2011 [121]. Unprecedented" exact="WNV" post="transmission seasons in Europe were registered in 2010, 2012,"/>
   <result pre="France (13.5-fold) and Italy (10.9-fold). The number of European equine" exact="WNV" post="outbreaks doubled in 2018 (n = 285) in comparison"/>
   <result pre="doubled in 2018 (n = 285) in comparison with earlier" exact="WNV" post="transmission seasons (n = 97–191 in 2013–2017, with on"/>
   <result pre="was the reporting in 2018 for the first time of" exact="WNV" post="in northern Europe, with several bird species and two"/>
   <result pre="with several bird species and two horses found infected by" exact="WNV" post="lineage 2 in Germany [122]. In Australia, specific virus"/>
   <result pre="Australia, specific virus variants called Kunjin virus and classified into" exact="WNV" post="lineage 1b, recently caused unprecedented epizootics of neurological disease"/>
   <result pre="by infected mosquitoes, could have contributed to the phenomenon [123]." exact="WNV" post="neurovirulence and neuroinvasion are typically associated with sequence variations"/>
   <result pre="identified in virus strains that have been responsible for major" exact="WNV" post="outbreaks during the two last decades [125] and its"/>
   <result pre="last decades [125] and its role in the modulation of" exact="WNV" post="virulence and transmission is nowadays largely debated [126,127]. TBEV"/>
   <result pre="and Spain [140,141]. Pathogenesis and clinical disease: TBEV, LIV and" exact="WNV" post="induce severe neurological syndromes, through pathogenic mechanisms that are"/>
   <result pre="pathogenic mechanisms that are still largely unknown. The majority of" exact="WNV" post="and TBEV studies were done in vitro on transformed"/>
   <result pre="vivo on mouse experimental models [142]. The exact mechanism of" exact="WNV" post="and TBEV CNS invasion is unclear, but five models"/>
   <result pre="and/or axonal transport in the retrograde direction (mechanisms demonstrated for" exact="WNV" post="only) [147]. This latter axonal transport promotes entry into"/>
   <result pre="a limb. In an experimental model of infection of hamster," exact="WNV" post="was present 4–5 days after infection in multiple sites"/>
   <result pre="the spinal cord [148]. Neurons and astrocytes are infected with" exact="WNV" post="and TBEV [142,149,150]. Following neuronal cell death, inflammatory molecules"/>
   <result pre="cytotoxic action in the CNS [133,151]. An equine infection by" exact="WNV" post="can be suspected when the following symptoms are noticed:"/>
   <result pre="deficits, dysphagia or face paralysis [9]. During 2000 and 2004" exact="WNV" post="epizootics in Camargue, France, ataxia was the main clinical"/>
   <result pre="close and partially shared antigenicity with other flaviviruses such as" exact="WNV" post="and Japanese Encephalitis Virus (JEV) [136]. Encephalitis caused by"/>
   <result pre="sensitive real-time RT-PCR assays. Serology tests such as ELISA for" exact="WNV" post="and TBEV detection and hemagglutination inhibition assay for LIV"/>
   <result pre="in order to detect a recent infection (IgM ELISA for" exact="WNV" post="or an antibody titer kinetics). A virus neutralisation test,"/>
   <result pre="3 level laboratory allows the definitive identification of the flavivirus." exact="WNV" post="infection can also be diagnosed by RT-PCR on EDTA-blood"/>
   <result pre="on post-mortem. Samples must be shipped cold or frozen, as" exact="WNV" post="is very sensitive to thermal and chemical inactivation. Prevention"/>
   <result pre="have a European Marketing Authorization (Table 2). The Zoetis Equip" exact="WNV" post="vaccine is composed of the inactivated West Nile virus,"/>
   <result pre="The Zoetis Equip WNV vaccine is composed of the inactivated" exact="West Nile" post="virus, strain VM-2 New York 1999 combined with an"/>
   <result pre="The other two vaccines are recombinant and adjuvanted vaccines. Proteq" exact="West Nile" post="is composed of a canary poxvirus vector expressing the"/>
   <result pre="canary poxvirus vector expressing the prM and E genes of" exact="WNV" post="[157]. The canarypox vector performs an abortive replication cycle"/>
   <result pre="inserted gene product (transgene) is expressed [158]. Finally, the Equilis" exact="West Nile" post="vaccine from Intervet consists of the yellow fever virus"/>
   <result pre="17D vaccine strain where the prM and E genes of" exact="YFV" post="have been replaced by those of WNV. This recombinant"/>
   <result pre="MVEV induce similar clinical presentations to the ones reported with" exact="WNV" post="but mainly differ in their case fatality rate and"/>
   <result pre="Finally, SLEV appears as a recently re-emerging flavivirus. Subsequent to" exact="WNV" post="introduction in Northern America in 1999, probable virus competition"/>
   <result pre="in clinical presentation and cross-reactive diagnostic tools was given during" exact="WNV" post="introduction in the United States, when WNV was initially"/>
   <result pre="was given during WNV introduction in the United States, when" exact="WNV" post="was initially misdiagnosed with the closely related SLEV [183]."/>
   <result pre="invasive European mosquito species for equine encephalitis viruses, other than" exact="WNV" post="and JEV, has been unfrequently evaluated [191,192,193]. Consequently, identification"/>
   <result pre="disease in the horseCornell. Vet.1978681207618720 9.PorterR.S.LeblondA.LecollinetS.TritzP.CantileC.KutasiO.ZientaraS.PradierS.van GalenG.SpeybroekN.et al.Clinical diagnosis of" exact="West Nile" post="Fever in Equids by classification and regression tree (CART)"/>
   <result pre="DiseasesAvailable online: https://promedmail.org/(accessed on 15 December 2019) 17.collab: ECDCEpidemiological Update:" exact="West Nile" post="Virus Transmission Season in EuropeAvailable online: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-west-nile-virus-transmission-season-europe-2018(accessed on 28"/>
   <result pre="patterns and their consequences for the diagnosis and control of" exact="West Nile" post="diseaseInt. J. Environ. Res. Public Health2013106049608310.3390/ijerph1011604924225644 112.MelianE.B.HinzmanE.NagasakiT.FirthA.E.WillsN.M.NouwensA.S.BlitvichB.J.LeungJ.FunkA.AtkinsJ.F.et al.NS1’ of"/>
   <result pre="its distribution in EuropeRev. Sci. Tech.20123182984410.20506/rst.31.3.216723520737 114.GardnerI.A.WongS.J.FerraroG.L.BalasuriyaU.B.HullingerP.J.WilsonW.D.ShiP.Y.MacLachlanN.J.Incidence and effects of" exact="West Nile" post="virus infection in vaccinated and unvaccinated horses in CaliforniaVet."/>
   <result pre="N. Y. Acad. Sci.200195111712610.1111/j.1749-6632.2001.tb02690.x11797769 119.ChanceyC.GrinevA.VolkovaE.RiosM.The global ecology and epidemiology of" exact="West Nile" post="virusBioMed Res. Int.2015201537623010.1155/2015/37623025866777 120.BakonyiT.HubalekZ.RudolfI.NowotnyN.Novel flavivirus or new lineage of"/>
   <result pre="Nile virusBioMed Res. Int.2015201537623010.1155/2015/37623025866777 120.BakonyiT.HubalekZ.RudolfI.NowotnyN.Novel flavivirus or new lineage of" exact="West Nile" post="virus, central EuropeEmerg. Infect. Dis.20051122523110.3201/eid1102.04102815752439 121.Hernandez-TrianaL.M.JeffriesC.L.MansfieldK.L.CarnellG.FooksA.R.JohnsonN.Emergence of west nile"/>
   <result pre="spread of a mosquito-borne diseaseFront. Public Health2014227110.3389/fpubh.2014.0027125538937 122.MichelF.SiegM.FischerD.KellerM.EidenM.ReuschelM.SchmidtV.SchwehnR.RinderM.UrbaniakS.et al.Evidence for" exact="West Nile" post="Virus and Usutu Virus Infections in Wild and Resident"/>
   <result pre="123.Van den HurkA.F.Hall-MendelinS.WebbC.E.TanC.S.FrentiuF.D.ProwN.A.HallR.A.Role of enhanced vector transmission of a new" exact="West Nile" post="virus strain in an outbreak of equine disease in"/>
   <result pre="equine disease in Australia in 2011Parasites Vectors2014758610.1186/s13071-014-0586-325499981 124.KaiserJ.A.WangT.BarrettA.D.Virulence determinants of" exact="West Nile" post="virus: How can these be used for vaccine design?Future"/>
   <result pre="Virol.20171228329510.2217/fvl-2016-014128919920 125.LangevinS.A.BowenR.A.ReisenW.K.AndradeC.C.RameyW.N.MaharajP.D.AnishchenkoM.KenneyJ.L.DuggalN.K.RomoH.et al.Host competence and helicase activity differences exhibited by" exact="West Nile" post="viral variants expressing NS3-249 amino acid polymorphismsPLoS ONE20149e10080210.1371/journal.pone.010080224971589 126.BraultA.C.HuangC.Y.LangevinS.A.KinneyR.M.BowenR.A.RameyW.N.PanellaN.A.HolmesE.C.PowersA.M.MillerB.R.A"/>
   <result pre="expressing NS3-249 amino acid polymorphismsPLoS ONE20149e10080210.1371/journal.pone.010080224971589 126.BraultA.C.HuangC.Y.LangevinS.A.KinneyR.M.BowenR.A.RameyW.N.PanellaN.A.HolmesE.C.PowersA.M.MillerB.R.A single positively selected" exact="West Nile" post="viral mutation confers increased virogenesis in American crowsNat. Genet.2007391162116610.1038/ng209717694056"/>
   <result pre="American crowsNat. Genet.2007391162116610.1038/ng209717694056 127.DridiM.Van Den BergT.LecollinetS.LambrechtB.Evaluation of the pathogenicity of" exact="West Nile" post="virus (WNV) lineage 2 strains in a SPF chicken"/>
   <result pre="across the in vitro blood-brain barrierVirology200938542543310.1016/j.virol.2008.11.04719135695 144.WangP.DaiJ.BaiF.KongK.F.WongS.J.MontgomeryR.R.MadriJ.A.FikrigE.Matrix metalloproteinase 9 facilitates" exact="West Nile" post="virus entry into the brainJ. Virol.2008828978898510.1128/JVI.00314-0818632868 145.PalusM.VancovaM.SirmarovaJ.ElsterovaJ.PernerJ.RuzekD.Tick-borne encephalitis virus"/>
   <result pre="endothelial cells without compromising blood-brain barrier integrityVirology201750711012210.1016/j.virol.2017.04.01228432926 146.ChoH.DiamondM.S.Immune responses to" exact="West Nile" post="virus infection in the central nervous systemViruses201243812383010.3390/v412381223247502 147.SamuelM.A.WangH.SiddharthanV.MorreyJ.D.DiamondM.S.Axonal transport"/>
   <result pre="virus infection in the central nervous systemViruses201243812383010.3390/v412381223247502 147.SamuelM.A.WangH.SiddharthanV.MorreyJ.D.DiamondM.S.Axonal transport mediates" exact="West Nile" post="virus entry into the central nervous system and induces"/>
   <result pre="infection in the golden hamster (Mesocricetus auratus): A model for" exact="West Nile" post="encephalitisEmerg. Infect. Dis.2001771472110.3201/eid0704.01742011585537 149.PotokarM.JorgacevskiJ.ZorecR.Astrocytes in Flavivirus InfectionsInt. J. Mol."/>
   <result pre="virusJ. Gen. Virol.2014952411242610.1099/vir.0.068411-025000960 151.DonadieuE.LowenskiS.ServelyJ.L.LaloyE.LilinT.NowotnyN.RichardsonJ.ZientaraS.LecollinetS.CoulpierM.Comparison of the neuropathology induced by two" exact="West Nile" post="virus strainsPLoS ONE20138e8447310.1371/journal.pone.008447324367664 152.HydeJ.NettletonP.MarriottL.WilloughbyK.Louping ill in horsesVet. Rec.200716053210.1136/vr.160.15.53217435106 153.BeckC.LowenskiS.DurandB.BahuonC.ZientaraS.LecollinetS.Improved"/>
   <result pre="Rec.200716053210.1136/vr.160.15.53217435106 153.BeckC.LowenskiS.DurandB.BahuonC.ZientaraS.LecollinetS.Improved reliability of serological tools for the diagnosis of" exact="West Nile" post="fever in horses within EuropePLoS Negl. Trop. Dis.201711e000593610.1371/journal.pntd.000593628915240 154.ChaskopoulouA.L’AmbertG.PetricD.BelliniR.ZgombaM.GroenT.A.MarramaL.BicoutD.J.Ecology"/>
   <result pre="fever in horses within EuropePLoS Negl. Trop. Dis.201711e000593610.1371/journal.pntd.000593628915240 154.ChaskopoulouA.L’AmbertG.PetricD.BelliniR.ZgombaM.GroenT.A.MarramaL.BicoutD.J.Ecology of" exact="West Nile" post="virus across four European countries: Review of weather profiles,"/>
   <result pre="integrated animal-human-vector approachEuro Surveill.20172210.2807/1560-7917.ES.2017.22.18.3052628494844 156.European Medicines AgencyEPAR Product Information: Equip" exact="WNV" post="2015Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000137/WC500063683.pdf(accessed on 12 September 2019) 157.MinkeJ.M.SigerL.KaracaK.AustgenL.GordyP.BowenR.RenshawR.W.LoosmoreS.AudonnetJ.C.NordgrenB.Recombinant canarypoxvirus"/>
   <result pre="September 2019) 157.MinkeJ.M.SigerL.KaracaK.AustgenL.GordyP.BowenR.RenshawR.W.LoosmoreS.AudonnetJ.C.NordgrenB.Recombinant canarypoxvirus vaccine carrying the prM/E genes of" exact="West Nile" post="virus protects horses against a West Nile virus-mosquito challengeArch."/>
   <result pre="prM/E genes of West Nile virus protects horses against a" exact="West Nile" post="virus-mosquito challengeArch. Virol. Suppl.200418221230 158.El GarchH.MinkeJ.M.RehderJ.RichardS.Edlund ToulemondeC.DinicS.AndreoniC.AudonnetJ.C.NordgrenR.JuillardV.A West Nile"/>
   <result pre="a West Nile virus-mosquito challengeArch. Virol. Suppl.200418221230 158.El GarchH.MinkeJ.M.RehderJ.RichardS.Edlund ToulemondeC.DinicS.AndreoniC.AudonnetJ.C.NordgrenR.JuillardV.A" exact="West Nile" post="virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing"/>
   <result pre="in the horseVet. Immunol. Immunopathol.200812323023910.1016/j.vetimm.2008.02.00218372050 159.GuyB.GuirakhooF.BarbanV.HiggsS.MonathT.P.LangJ.Preclinical and clinical development of" exact="YFV" post="17D-based chimeric vaccines against dengue, West Nile and Japanese"/>
   <result pre="and clinical development of YFV 17D-based chimeric vaccines against dengue," exact="West Nile" post="and Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 160.DurandB.LecollinetS.BeckC.Martinez-LopezB.BalenghienT.ChevalierV.Identification of hotspots in the"/>
   <result pre="birds collected in 1997-2000 in Central ItalyZoonoses Public Health20186579880410.1111/zph.1250129974677 168.ReisenW.K.LothropH.D.WheelerS.S.KennsingtonM.GutierrezA.FangY.GarciaS.LothropB.Persistent" exact="West Nile" post="virus transmission and the apparent displacement St. Louis encephalitis"/>
   <result pre="virus in southeastern California, 2003–2006J. Med. Entomol.20084549450810.1603/0022-2585(2008)45[494:pwnvta]2.0.co;218533445 169.FangY.ReisenW.K.Previous infection with" exact="West Nile" post="or St. Louis encephalitis viruses provides cross protection during"/>
   <result pre="niches in EuropeParasites Vectors2016957310.1186/s13071-016-1853-227814747 191.VogelsC.B.GoertzG.P.PijlmanG.P.KoenraadtC.J.Vector competence of European mosquitoes for" exact="West Nile" post="virusEmerg. Microbes Infect.20176e9610.1038/emi.2017.8229116220 192.De WispelaereM.DespresP.ChoumetV.European Aedes albopictus and Culex"/>
   <result pre="for Japan encephalitis virus but are refractory to infection with" exact="West Nile" post="virusParasitol. Res.20141133195319910.1007/s00436-014-3983-924948103 Figure 1 Major viruses causing encephalitis in"/>
   <result pre="Rhabdoviridae, Flaviviridae, Bornaviridae and Togaviridae (adapted from ViralZone [7]). WNV:" exact="West Nile" post="virus; TBEV: Tick-Borne encephalitis virus; LIV: Louping ill virus;"/>
   <result pre="literature are depicted by dots (2014–2019). Figure 7 Distribution of" exact="WNV" post="outbreaks. Recent outbreaks in horses reported to the OIE"/>
   <result pre="prime and boosts performed every year or every 2 years." exact="WNV" post="Inactivated: EQUIP® WNV (Zoetis) Recombinant: EQUILIS® West Nile (MSD)"/>
   <result pre="performed every year or every 2 years. WNV Inactivated: EQUIP®" exact="WNV" post="(Zoetis) Recombinant: EQUILIS® West Nile (MSD) and PROTEQ® West"/>
   <result pre="every 2 years. WNV Inactivated: EQUIP® WNV (Zoetis) Recombinant: EQUILIS®" exact="West Nile" post="(MSD) and PROTEQ® West Nile (Boehringer Ingelheim) Good protection"/>
   <result pre="EQUIP® WNV (Zoetis) Recombinant: EQUILIS® West Nile (MSD) and PROTEQ®" exact="West Nile" post="(Boehringer Ingelheim) Good protection at the individual level provided"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020004\results\search\tropicalVirus\results.xml">
   <result pre="maternal–fetal barrier. Recent studies have confirmed the vertical transmission of" exact="Zika" post="virus (ZIKV), during which maternal infection with the virus"/>
   <result pre="These findings, in turn, highlight the ability of viruses like" exact="ZIKV" post="to develop strategies to invade and target placental cells"/>
   <result pre="its effect on the fetus and development of the congenital" exact="Zika" post="syndrome, Zika virus has emerged as the newest TORCH"/>
   <result pre="on the fetus and development of the congenital Zika syndrome," exact="Zika" post="virus has emerged as the newest TORCH agent [37]."/>
   <result pre="of birth defects during the recent epidemic has also emphasized" exact="ZIKV" post="as an important threat to public health in the"/>
   <result pre="as an important threat to public health in the Americas." exact="ZIKV" post="is a mosquito-borne flavivirus that can undergo vertical transmission"/>
   <result pre="abnormal central nervous system development [63,64]. Previous reports have confirmed" exact="ZIKV" post="RNA in the human fetal brain and amniotic fluid"/>
   <result pre="that primary human placental trophoblast cell lines are permissive to" exact="ZIKV" post="infection, whereas Schwartz, Rosenberg, and Quicke et al. confirmed"/>
   <result pre="Schwartz, Rosenberg, and Quicke et al. confirmed the presence of" exact="ZIKV" post="infection in HCs, in addition to hyperplasia of HCs"/>
   <result pre="Agaard et al. suggested that the receptors necessary to mediate" exact="ZIKV" post="entry are expressed during the differentiation process of placental"/>
   <result pre="process of placental trophoblasts to CTBs and STBs, and allow" exact="ZIKV" post="replication to occur in the trophoblasts [71]. These observations"/>
   <result pre="cells (NSCs), McGrath et al. also investigated the effects of" exact="ZIKV" post="infection on the neuronal differentiation of human NSCs (hNSCs)"/>
   <result pre="NSCs (hNSCs) [72,73]. Transcriptomic analysis revealed that certain strains of" exact="ZIKV" post="induce alterations in gene expression of hNSCs, such as"/>
   <result pre="and neural development. Also a member of the Flaviviridae family," exact="Dengue" post="virus (DENV) can also infect the fetus through vertical"/>
   <result pre="pigs are susceptible to infection by a contemporary strain of" exact="ZIKV" post="[98,99]. The similarities of trophoblast cell types between horses"/>
   <result pre="used to show that cytotrophoblasts are vulnerable to infection with" exact="ZIKV" post="strain MR766, whereas cytotrophoblasts cultured from full-term placental explants"/>
   <result pre="In Platt et al., neurotropic flaviviruses related to ZIKV, including" exact="West Nile" post="virus, were shown to be able not only to"/>
   <result pre="target cells? Perhaps we can learn from remarkable progress in" exact="ZIKV" post="research, which has provided significant insight into the role"/>
   <result pre="monocytes as the primary target for both African- and Asian-lineage" exact="ZIKV" post="infection from pregnant women [123]. Interestingly, there was differential"/>
   <result pre="in the monocytes of these pregnant women, in that African-lineage" exact="ZIKV" post="infection led to M1-skewed inflammation, whereas Asian-lineage ZIKV infection"/>
   <result pre="that African-lineage ZIKV infection led to M1-skewed inflammation, whereas Asian-lineage" exact="ZIKV" post="infection led to M2-skewed immunosuppression. Distinct roles of type"/>
   <result pre="type I vs. type III IFNs were also highlighted in" exact="ZIKV" post="research. Although the deficiency of IFN-αR in mice can"/>
   <result pre="the deficiency of IFN-αR in mice can lead to higher" exact="ZIKV" post="titers in the placentas of offspring ZIKV titers, while"/>
   <result pre="lead to higher ZIKV titers in the placentas of offspring" exact="ZIKV" post="titers, while exposure of midgestation human chorionic villous explants"/>
   <result pre="and autocrine manner to protect trophoblast and non-trophoblast cells from" exact="ZIKV" post="infection [68,126]. A recent report by Caine et al."/>
   <result pre="studies will be necessary to delineate the pathways by which" exact="ZIKV" post="accesses the fetal compartment, evades restriction by trophoblast-derived IFNλ1"/>
   <result pre="not reduce viral load [149]. 6. Conclusions The epidemics of" exact="ZIKV" post="and its clinical consequences during pregnancy raised awareness of"/>
   <result pre="in Rio de JaneiroN. Engl. J. Med.20163752321233410.1056/NEJMoa160241226943629 6.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.J.T.L.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–15: A retrospective"/>
   <result pre="Polynesia, 2013–15: A retrospective studyLancet20163872125213210.1016/S0140-6736(16)00651-626993883 7.DudleyD.M.VanK.R.CoffeyL.L.ArdeshirA.KeeslerR.I.Bliss-MoreauE.GrigsbyP.L.SteinbachR.J.HirschA.J.MacAllisterR.P.Miscarriage and stillbirth following maternal" exact="Zika" post="virus infection in nonhuman primatesNat. Med.2018241104110710.1038/s41591-018-0088-529967348 8.LeeJ.S.RomeroR.HanY.M.KimH.C.KimC.J.HongJ.-S.HuhD.Placenta-on-a-chip: A novel"/>
   <result pre="old and new agentsClin. Perinatol.19881572774410.1016/S0095-5108(18)30670-5 37.SchwartzD.A.The origins and emergence of" exact="Zika" post="virus, the newest TORCH infection: what’s old is new"/>
   <result pre="and the risk of microcephalyNew Engl. J. Med.20163751410.1056/NEJMp160536727222919 64.LeeJ.K.ShinO.S.Advances in" exact="Zika" post="virus–host cell interaction: Current knowledge and future perspectivesInt. J."/>
   <result pre="Obstet. Gynecol.2016476710.1002/uog.1583126731034 66.CalvetG.AguiarR.S.MeloA.S.SampaioS.A.De FilippisI.FabriA.AraujoE.S.de SequeiraP.C.de MendonçaM.C.de OliveiraL.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="III interferons produced by human placental trophoblasts confer protection against" exact="Zika" post="virus infectionCell Host Microbe20161970571210.1016/j.chom.2016.03.00827066743 69.SchwartzD.A.Viral infection, proliferation, and hyperplasia"/>
   <result pre="of inflammation characterize the placental pathology of fetuses with congenital" exact="Zika" post="virus infectionArch. Gynecol. Obstet.20172951361136810.1007/s00404-017-4361-528396992 70.RosenbergA.Z.YuW.HillD.A.ReyesC.A.SchwartzD.A.Placental pathology of Zika virus:"/>
   <result pre="with congenital Zika virus infectionArch. Gynecol. Obstet.20172951361136810.1007/s00404-017-4361-528396992 70.RosenbergA.Z.YuW.HillD.A.ReyesC.A.SchwartzD.A.Placental pathology of" exact="Zika" post="virus: Viral infection of the placenta induces villous stromal"/>
   <result pre="Pathol. Lab. Med.2016141434810.5858/arpa.2016-0401-OA27681334 71.AagaardK.M.LahonA.SuterM.A.AryaR.P.SeferovicM.D.VogtM.B.HuM.StossiF.ManciniM.A.HarrisR.A.Primary human placental trophoblasts are permissive for" exact="Zika" post="virus (ZIKV) replicationSci. Rep.201774138910.1038/srep4138928128342 72.HomemC.C.RepicM.KnoblichJ.A.Proliferation control in neural stem"/>
   <result pre="73.McGrathE.L.RossiS.L.GaoJ.WidenS.G.GrantA.C.DunnT.J.AzarS.R.RoundyC.M.XiongY.PrusakD.J.Differential responses of human fetal brain neural stem cells to" exact="Zika" post="virus infectionStem Cell Rep.2017871572710.1016/j.stemcr.2017.01.008 74.PouliotS.H.XiongX.HarvilleE.Paz-SoldanV.TomashekK.M.BreartG.BuekensP.Maternal dengue and pregnancy outcomes:"/>
   <result pre="infection in guinea pigsJ. Virol.1985554024092991565 98.KumarM.KrauseK.K.AzouzF.NakanoE.NerurkarV.R.A guinea pig model of" exact="Zika" post="virus infectionVirol. J.2017147510.1186/s12985-017-0750-428399888 99.KrauseK.K.AzouzF.ShinO.S.KumarM.Understanding the pathogenesis of Zika virus"/>
   <result pre="model of Zika virus infectionVirol. J.2017147510.1186/s12985-017-0750-428399888 99.KrauseK.K.AzouzF.ShinO.S.KumarM.Understanding the pathogenesis of" exact="Zika" post="virus infection using animal modelsImmune Netw.20171728729710.4110/in.2017.17.5.28729093650 100.CroyB.ChapeauC.Evaluation of the"/>
   <result pre="to probe nanoparticle exposure at the placental barrierToxicology20195410511310.1016/j.tiv.2018.08.01430248392 123.FooS.S.ChenW.ChanY.BowmanJ.W.ChangL.C.ChoiY.YooJ.S.GeJ.ChengG.BonninA.et al.Asian" exact="Zika" post="virus strains target CD14(+) blood monocytes and induce M2-skewed"/>
   <result pre="during pregnancyViral Immunol.20191076877510.1089/vim.2019.0076 125.YockeyL.J.JuradoK.A.AroraN.MilletA.RakibT.MilanoK.M.HastingsA.K.FikrigE.KongY.HorvathT.L.J.Type I interferons instigate fetal demise after" exact="Zika" post="virus infectionSci. Immunol.201831910.1126/sciimmunol.aao1680 126.CaineE.A.ScheafferS.M.AroraN.ZaitsevK.ArtyomovM.N.CoyneC.B.MoleyK.H.DiamondM.S.Interferon lambda protects the female reproductive"/>
   <result pre="infectionSci. Immunol.201831910.1126/sciimmunol.aao1680 126.CaineE.A.ScheafferS.M.AroraN.ZaitsevK.ArtyomovM.N.CoyneC.B.MoleyK.H.DiamondM.S.Interferon lambda protects the female reproductive tract against" exact="Zika" post="virus infectionNat. Commun.20191028010.1038/s41467-018-07993-230655513 127.LuoS.-S.IshibashiO.IshikawaG.IshikawaT.KatayamaA.MishimaT.TakizawaT.ShigiharaT.GotoT.IzumiA.Human villous trophoblasts express and secrete"/>
   <result pre="Coxsackievirus B Picornaviridae Humans Aerosols,fecal-oral route Miscarriage, stillbirth, fetal sepsis" exact="Zika" post="virus Flaviviridae Humans,monkeys Mosquito, sexual Miscarriage, microcephaly Dengue virus"/>
   <result pre="fetal sepsis Zika virus Flaviviridae Humans,monkeys Mosquito, sexual Miscarriage, microcephaly" exact="Dengue" post="virus Flaviviridae Humans Mosquito,breast milk Miscarriage, premature birth, stillbirth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020694\results\search\tropicalVirus\results.xml">
   <result pre="several viral vectors including papaya mosaic virus (PapMV) carrying M2e," exact="HPV" post="VLPs conjugated to the M2 protein, or VLPs derived"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020867\results\search\tropicalVirus\results.xml">
   <result pre="pmid: 31553384 doi: 10.5935/abc.20190187 : Case Report Myocarditis Following Recent" exact="Chikungunya" post="and Dengue Virus Coinfection: A Case Report http://orcid.org/0000-0002-8978-9903FariasLuís Arthur"/>
   <result pre="doi: 10.5935/abc.20190187 : Case Report Myocarditis Following Recent Chikungunya and" exact="Dengue" post="Virus Coinfection: A Case Report http://orcid.org/0000-0002-8978-9903FariasLuís Arthur Brasil Gadelha1BeserraFrancisca"/>
   <result pre="medium, provided the original work is properly cited. Myocarditis Coinfection" exact="Dengue" post="Chikungunya Virus Introduction Dengue virus (DENV) and chikungunya virus"/>
   <result pre="provided the original work is properly cited. Myocarditis Coinfection Dengue" exact="Chikungunya" post="Virus Introduction Dengue virus (DENV) and chikungunya virus (CHIKV)"/>
   <result pre="work is properly cited. Myocarditis Coinfection Dengue Chikungunya Virus Introduction" exact="Dengue" post="virus (DENV) and chikungunya virus (CHIKV) are arboviruses that"/>
   <result pre="that cause ongoing epidemics in several countries of Latin America." exact="DENV" post="belongs to the Flaviviridae family and CHIKV is an"/>
   <result pre="of Latin America. DENV belongs to the Flaviviridae family and" exact="CHIKV" post="is an alphavirus of the Togaviridae family. Both viruses"/>
   <result pre="febrile syndromes that can progress to severe or debilitating conditions.1,2" exact="DENV" post="infection has been endemic in Brazil since the 1980's."/>
   <result pre="infection has been endemic in Brazil since the 1980's. However," exact="CHIKV" post="is an emergent agent. Autochthonous transmission was first detected"/>
   <result pre="country.3 A total of 38,499 and 277,882 cases of suspected" exact="CHIKV" post="infection were reported by the national surveillance system in"/>
   <result pre="still unknown.5-7 There have been some reports of myopericarditis following" exact="DENV" post="and CHIKV infection, but this manifestation in coinfected patients"/>
   <result pre="There have been some reports of myopericarditis following DENV and" exact="CHIKV" post="infection, but this manifestation in coinfected patients is rare"/>
   <result pre="a young and immunocompetent man with myocarditis, following a recent" exact="DENV" post="and CHIKV coinfection. We discuss the clinical course and"/>
   <result pre="and immunocompetent man with myocarditis, following a recent DENV and" exact="CHIKV" post="coinfection. We discuss the clinical course and laboratory abnormalities"/>
   <result pre="being aware of this condition in developing countries endemic for" exact="DENV" post="and CHIKV. Case report The patient was a 28-year-old"/>
   <result pre="a patient with myocarditis and coinfection with dengue virus and" exact="Chikungunya" post="virus Characteristic Day 1 Day 2 Day 3 Day"/>
   <result pre="and found to be ELISA-IgM positive and ELISA-IgG positive for" exact="DENV" post="and ELISA-IgM positive for CHIKV. The DENV NS1 antigen"/>
   <result pre="ELISA-IgG positive for DENV and ELISA-IgM positive for CHIKV. The" exact="DENV" post="NS1 antigen test yielded a negative result. There was"/>
   <result pre="results during hospital stay. Discussion Typical clinical manifestations of acute" exact="CHIKV" post="infection are fever, headache, polyarthralgia/polyarthritis, myalgia, rash, and fatigue.11"/>
   <result pre="alterations to potentially lethal cardiac complications.6 The manifestations of acute" exact="DENV" post="infection are very similar to those of CHIKV, with"/>
   <result pre="with a lower prevalence for joint manifestations.15 Heart involvement in" exact="DENV" post="infection is not uncommon. Cardiac manifestations can vary widely,"/>
   <result pre="resulting in death.7 Arora et al.7 studying 120 patients with" exact="DENV" post="found 37.5% of patients with cardiac manifestation in the"/>
   <result pre="were cross-reactive to CHIKV.17 Although they share the same vector," exact="CHIKV" post="is part of the Togaviridae family, while DENV is"/>
   <result pre="same vector, CHIKV is part of the Togaviridae family, while" exact="DENV" post="is part of the Flaviviridae family. Heart disease associated"/>
   <result pre="IV hydrocortisone may be helpful to accomplish full recovery in" exact="DENV" post="myocarditis18 but there is yet no consensus about whether"/>
   <result pre="negative result. It is also important to note that the" exact="DENV" post="IgM may be positive from 139 up to 179"/>
   <result pre="at our center. Conclusion The case presented herein suggests that" exact="DENV" post="and CHIKV coinfection may result in myocarditis, which can"/>
   <result pre="center. Conclusion The case presented herein suggests that DENV and" exact="CHIKV" post="coinfection may result in myocarditis, which can be severe"/>
   <result pre="and the disease may be caused solely by either the" exact="DENV" post="or CHIKV virus. It is important to be aware"/>
   <result pre="disease may be caused solely by either the DENV or" exact="CHIKV" post="virus. It is important to be aware of this"/>
   <result pre="dengue virusesBMC Infectious Diseases3201616848426936191 6AlvarezMFBolívar-MejíaARodriguez-MoralesAJRamirez-VallejoECardiovascular involvement and manifestations of systemic" exact="Chikungunya" post="virus infection: A systematic reviewF1000Res2017639039028503297 7ShivanthanMNavinanMConstantineGRajapakseSCardiac involvement in dengue"/>
   <result pre="treatment - A ReviewMem Inst Oswaldo Cruz2017112852353128767976 12BrizziKNeurologic Manifestation of" exact="Chikungunya" post="VirusCurr Infect Dis Rep20171926628233188 13MahendradasPAvadhaniKShettyRChikungunya and the eye: a"/>
   <result pre="the eye: a reviewJ Ophthalmic Inflamm Infect201331353523514031 14BandyopadhyayDGhoshSKMucocutaneous manifestations of" exact="Chikungunya" post="feverIndian J Dermatol2010551646720418982 15SimmonsCPFarrarJJNguyenVVWillsBDengueN Engl J Med2012366151423143222494122 16AroraMPatilRSCardiac Manifestation"/>
   <result pre="feverIndian J Dermatol2010551646720418982 15SimmonsCPFarrarJJNguyenVVWillsBDengueN Engl J Med2012366151423143222494122 16AroraMPatilRSCardiac Manifestation in" exact="Dengue" post="FeverJ Assoc Physicians India20166474044 17KamYHPokKYEngKETanLKKaurSLeeWWet al.Sero-Prevalence and Cross-Reactivity of"/>
   <result pre="Dengue FeverJ Assoc Physicians India20166474044 17KamYHPokKYEngKETanLKKaurSLeeWWet al.Sero-Prevalence and Cross-Reactivity of" exact="Chikungunya" post="Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected PatientsPLoS Negl Trop"/>
   <result pre="recent Indian outbreakEur J Clin Microbiol Infect Dis201736112273227928756561 21PrinceHEMatudJLEstimation of" exact="Dengue" post="Virus IgM Persistence Using Regression AnalysisClin Vaccine Immunol201118122183218522030368"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7021315\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Physiology :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Immunology :"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Zika" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Proteins: Serum Proteins Impact of flavivirus vaccine-induced immunity on primary" exact="Zika" post="virus antibody response in humans Impact of prior flavivirus"/>
   <result pre="antibody response in humans Impact of prior flavivirus immunity on" exact="Zika" post="virus antibody response http://orcid.org/0000-0002-0222-9832MalafaStefanFormal analysisInvestigationMethodologyValidationVisualizationWriting – original draftWriting –"/>
   <result pre="provided the original author and source are credited.pntd.0008034.pdf Abstract Background" exact="Zika" post="virus has recently spread to South- and Central America,"/>
   <result pre="Since pre-existing cross-reactive immunity can potentially modulate antibody responses to" exact="Zika" post="virus infection and may affect the outcome of disease,"/>
   <result pre="virus-neutralizing and infection-enhancing activities of antibodies induced by a primary" exact="Zika" post="virus infection in flavivirus-naïve as well as yellow fever-"/>
   <result pre="and/or tick-borne encephalitis-vaccinated individuals. Methodology Antibodies in sera from convalescent" exact="Zika" post="patients with and without vaccine-induced immunity were assessed by"/>
   <result pre="without vaccine-induced immunity were assessed by ELISA with respect to" exact="Zika" post="virus-specificity and flavivirus cross-reactivity. Functional analyses included virus neutralization"/>
   <result pre="had a strong influence on the antibody response in primary" exact="Zika" post="virus infections, resulting in higher titers of broadly flavivirus"/>
   <result pre="of broadly flavivirus cross-reactive antibodies and slightly lower levels of" exact="Zika" post="virus-specific IgM. Antibody-dependent enhancement (ADE) of Zika virus was"/>
   <result pre="lower levels of Zika virus-specific IgM. Antibody-dependent enhancement (ADE) of" exact="Zika" post="virus was mediated by sub-neutralizing concentrations of specific IgG"/>
   <result pre="both neutralize and enhance infection of dengue virus but not" exact="Zika" post="virus, indicating a different exposure of conserved sequence elements"/>
   <result pre="In addition, our results highlight structural differences between strains of" exact="Zika" post="and dengue viruses that are used for analyzing infection-enhancement"/>
   <result pre="disease and vaccination efficacy. Author summary The explosive spread of" exact="Zika" post="virus, a flavivirus, to South- and Central America underscores"/>
   <result pre="America underscores the potential threat of newly emerging arthropod-borne viruses." exact="Zika" post="virus infection can cause congenital birth defects and neurological"/>
   <result pre="infections with other flaviviruses (e.g. dengue virus, which co-circulates in" exact="Zika" post="outbreak regions) or vaccinations (e.g. against yellow fever or"/>
   <result pre="of serum samples from flavivirus-naïve and vaccinated individuals after primary" exact="Zika" post="virus infections. Prior immunity led to a strong booster"/>
   <result pre="a strong booster of cross-reactive antibodies that did not neutralize" exact="Zika" post="virus. Importantly, we could also show that newly formed"/>
   <result pre="and its Supporting Information files. Introduction Epidemics of infections with" exact="Zika" post="virus, a mosquito-borne flavivirus, first emerged in Pacific islands"/>
   <result pre="in newborns after infection of pregnant women became apparent [3]." exact="Zika" post="virus is a close relative of other important human"/>
   <result pre="pathogenic flaviviruses like dengue (DEN) virus, yellow fever (YF) virus," exact="West Nile" post="(WN) virus, Japanese encephalitis virus, tick-borne encephalitis (TBE) virus"/>
   <result pre="tropical and sub-tropical regions around the world or dengue and" exact="Zika" post="viruses in South and Central America or Southeast Asia"/>
   <result pre="analyzed the antibody response in groups of individuals with recent" exact="Zika" post="virus infections that were either flavivirus-naïve or had previously"/>
   <result pre="such cryptic antigenic sites [19, 21]. Fig 1 Structure of" exact="Zika" post="virus and antigenic relationships of flaviviruses. (A) Zika virus"/>
   <result pre="Structure of Zika virus and antigenic relationships of flaviviruses. (A)" exact="Zika" post="virus particle (PDB: 6CO8, [22]). (B) Distance relationships between"/>
   <result pre="on amino acid sequence differences. (C) Ribbon diagram of the" exact="Zika" post="virus E dimer (side view) and (D) surface representation"/>
   <result pre="E dimer (side view) and (D) surface representation of the" exact="Zika" post="virus E dimer (top view). Color code: domain I"/>
   <result pre="for tick-borne encephalitis virus, AY640589 for yellow fever virus, DQ211652for" exact="West Nile" post="virus, D90194 for Japanese encephalitis virus, KJ776791 for Zika"/>
   <result pre="West Nile virus, D90194 for Japanese encephalitis virus, KJ776791 for" exact="Zika" post="virus, AF226687 for dengue 1 virus, DQ863638 for dengue"/>
   <result pre="vaccine-induced immunity on IgM and IgG profiles after recent primary" exact="Zika" post="virus infection. For this purpose, we analyzed samples from"/>
   <result pre="Zika virus infection. For this purpose, we analyzed samples from" exact="Zika" post="patients, who were either flavivirus naïve or had previously"/>
   <result pre="YF. We demonstrate that virus-specific IgM antibodies contribute substantially to" exact="Zika" post="virus neutralization in the early phase of infection and"/>
   <result pre="an important role in the prevention of IgG-mediated enhancement of" exact="Zika" post="virus infection of Fcγ receptor-positive cells. Importantly, the formation"/>
   <result pre="IgG antibodies, which caused ADE of dengue but not of" exact="Zika" post="virus infection in vitro. Our findings contribute to the"/>
   <result pre="of vaccines. Methods Ethics statement Human serum samples from 62" exact="Zika" post="patients were sent to the Center for Virology of"/>
   <result pre="from 62 patients who were diagnosed with an acute symptomatic" exact="Zika" post="virus infection after returning to Europe from Zika-endemic areas."/>
   <result pre="infection after returning to Europe from Zika-endemic areas. They developed" exact="Zika" post="virus-specific IgM and neutralizing antibodies, and 30 patients were"/>
   <result pre="Zika virus-specific IgM and neutralizing antibodies, and 30 patients were" exact="Zika" post="PCR positive (23 negative, 9 not tested). Samples from"/>
   <result pre="negative, 9 not tested). Samples from only two of these" exact="Zika" post="patients exhibited a low degree of broad flavivirus cross-reactivity"/>
   <result pre="strain NCBI Nucleotide NCBI Protein amino acids of E reference" exact="Zika" post="virus H/PF/2013 KJ776791 AHZ13508.1 1–408 [44] Rio Bravo virus"/>
   <result pre="1–393 [45] TBE virus Neudörfl U27495 AAA86870.1 1–400 [40, 43]" exact="Dengue" post="virus 2 16681 NC_001474.2 NP_056776.2 1–399 this study WN"/>
   <result pre="Technologies Inc.). Determination of the oligomeric state of the recombinant" exact="Zika" post="E protein Zika and WN virus E proteins were"/>
   <result pre="of the oligomeric state of the recombinant Zika E protein" exact="Zika" post="and WN virus E proteins were analyzed by rate"/>
   <result pre="as described previously [43, 47]. The monomer control for the" exact="Zika" post="virus E protein was prepared by incubation with 1%"/>
   <result pre="corresponding purified protein as a standard. Size-exclusion chromatography of the" exact="Zika" post="and WN virus E proteins was carried out with"/>
   <result pre="each ELISA plate. This control serum was obtained from a" exact="Zika" post="patient with YF and TBE pre-immunity and yielded similar"/>
   <result pre="(C8 and C10 –[44, 50], giving a positive reaction in" exact="Zika" post="and dengue ELISAs), the dengue-specific mab 4E11 [51], and"/>
   <result pre="in the TBE ELISA only). For cut-off determination of the" exact="Zika" post="and RB assays, we used 32 diagnostic serum samples"/>
   <result pre="negative controls at a 1:100 dilution plus 3 standard deviations." exact="Zika" post="IgG avidity ELISA Relative avidities of polyclonal serum samples"/>
   <result pre="ELISA Relative avidities of polyclonal serum samples were analyzed with" exact="Zika" post="virus E protein in the flavivirus IgG ELISA described"/>
   <result pre="was controlled using serum samples obtained early and late after" exact="Zika" post="virus infection (S2 Fig). Zika and RB IgM ELISA"/>
   <result pre="obtained early and late after Zika virus infection (S2 Fig)." exact="Zika" post="and RB IgM ELISA MaxiSorp microtiter plates (Nunc) were"/>
   <result pre="and Strep-Tactin-labeled HRP (IBA GmbH, Göttingen, Germany). For the quantitative" exact="Zika" post="IgM ELISA, a Zika virus post-infection serum sample (TBE-pre-vaccinated"/>
   <result pre="GmbH, Göttingen, Germany). For the quantitative Zika IgM ELISA, a" exact="Zika" post="virus post-infection serum sample (TBE-pre-vaccinated patient) was included as"/>
   <result pre="TBE and dengue neutralization tests (NTs) NTs were performed with" exact="Zika" post="virus strain H/PF/2013 (European virus archive), dengue virus serotype"/>
   <result pre="prM [56, 57] TBE virus IC3 TBE E DI [58]" exact="Zika" post="virus A1 flavivirus FL-specific [48] The assays were validated"/>
   <result pre="with neutralizing mabs specific for the different viruses, as follows:" exact="Zika" post="and dengue viruses were neutralized by the EDE-specific mabs"/>
   <result pre="corresponding to their activities reported in the literature [44, 50]." exact="Dengue" post="viruses were also tested with the dengue-specific mab 4E11"/>
   <result pre="Serial dilutions of heat-inactivated serum samples were pre-incubated with either" exact="Zika" post="virus or dengue virus serotype 2 (5,000–10,000 viral RNA"/>
   <result pre="and probes used in this study targeted the NS5 gene:" exact="Zika" post="virus: forward primer: ACAAGGGGAATTTGGAAAGGC; reverse primer: GAATCCAAGGGCTTCGAACTC; probe: FAM-AGCCGCGCCATCTGGTATATGTGG-TAMRA."/>
   <result pre="Zika virus: forward primer: ACAAGGGGAATTTGGAAAGGC; reverse primer: GAATCCAAGGGCTTCGAACTC; probe: FAM-AGCCGCGCCATCTGGTATATGTGG-TAMRA." exact="Dengue" post="virus 2: forward primer: CAGATGGAGGGAGAAGGAGTC; reverse primer: CGCCCTACTCTTGCTAACCA; probe:"/>
   <result pre="Scientific). A plasmid encoding part of the NS5 gene of" exact="Zika" post="virus or dengue virus 2 (synthesized by GeneArt/Thermo Fisher"/>
   <result pre="in the literature [61], and we observed no enhancement of" exact="Zika" post="virus under these conditions. As a negative control for"/>
   <result pre="the WN virus E protein [62]. Depletion of antibodies with" exact="Zika" post="or RB virus E protein For the depletion of"/>
   <result pre="Zika or RB virus E protein For the depletion of" exact="Zika" post="virus-specific or flavivirus broadly cross-reactive antibodies, 200 μg Zika"/>
   <result pre="of Zika virus-specific or flavivirus broadly cross-reactive antibodies, 200 μg" exact="Zika" post="or RB virus E protein were bound to Strep-Tactin"/>
   <result pre="and incubated for 10 min at RT. To deplete completely" exact="Zika" post="or RB virus-reactive antibodies a minimum of eight rounds"/>
   <result pre="verified by the flavivirus IgG ELISA (described above), using the" exact="Zika" post="virus E protein, and the presence of IgM in"/>
   <result pre="presence of IgM in the final eluate was confirmed by" exact="Zika" post="IgM ELISA (described above). IgM depletion 1 ml anti-IgM"/>
   <result pre="supernatant was subjected to control ELISAs. Depletion was verified by" exact="Zika" post="IgM ELISA (described above), and the presence of IgG"/>
   <result pre="confirmed by the flavivirus IgG ELISA (described above), using the" exact="Zika" post="virus E protein. Statistics Antibody titers that were less"/>
   <result pre="with urea as offset applying a GLM. Fold enhancement of" exact="Zika" post="and dengue virus infectivity between depleted and mock-depleted sera"/>
   <result pre="area under the log-dilution-log-fold-enhancement curves using GLM. Fold enhancement of" exact="Zika" post="virus between depleted and mock-depleted sera (using a single"/>
   <result pre="flavivirus immunity on the patterns of antibody responses in primary" exact="Zika" post="virus infections, we analyzed serum samples from laboratory-confirmed Zika"/>
   <result pre="primary Zika virus infections, we analyzed serum samples from laboratory-confirmed" exact="Zika" post="patients (travelers returning from Zika-endemic regions) with and without"/>
   <result pre="were randomly received for diagnostic purposes from travelers returning with" exact="Zika" post="virus infections, the groups were relatively heterogeneous with respect"/>
   <result pre="not been documented for the diagnostic samples used. 10.1371/journal.pntd.0008034.t003Table 3" exact="Zika" post="patients. flavivirus pre-immunity patientsn median age in years (range)"/>
   <result pre="multiple samples were available. Our analyses included the quantification of" exact="Zika" post="virus-specific and flavivirus cross-reactive IgM and IgG antibodies in"/>
   <result pre="as well as the determination of in vitro ADE of" exact="Zika" post="and dengue virus infections. Because these experiments required relatively"/>
   <result pre="pools. 10.1371/journal.pntd.0008034.t004Table 4 Serum samples from flavivirus naïve and pre-immune" exact="Zika" post="patients used for pools. flavivirus pre-immunity patientsna median age"/>
   <result pre="per patient was included in the pools. Characterization of the" exact="Zika" post="virus E dimer For the analysis of Zika virus-specific"/>
   <result pre="of the Zika virus E dimer For the analysis of" exact="Zika" post="virus-specific antibodies, we used a recombinant Zika virus E"/>
   <result pre="the analysis of Zika virus-specific antibodies, we used a recombinant" exact="Zika" post="virus E protein with a C-terminal strep-tag and lacking"/>
   <result pre="of E (E-dimer dependent epitope, EDE) [44]. In addition, the" exact="Zika" post="virus E protein was shown to have high affinity"/>
   <result pre="by Biolayer Interferometry [44]. The stable dimeric structure of the" exact="Zika" post="virus E protein in solution was verified by sedimentation"/>
   <result pre="crystals [54, 63, 64]. In addition, we analyzed whether our" exact="Zika" post="E dimer is recognized by the human EDE-specific mabs"/>
   <result pre="analyze the functional activity of polyclonal antibodies detected with the" exact="Zika" post="virus E dimer, we depleted three of the four"/>
   <result pre="Table 4 as well as four serum samples from individual" exact="Zika" post="patients (1 serum from each pool) with this protein."/>
   <result pre="more of NT activity was removed, indicating that the dimeric" exact="Zika" post="antigen allows the measurement of most of the functionally"/>
   <result pre="pools and individual sera (see Table 4) were tested in" exact="Zika" post="and Rio Bravo (RB) IgM as well as IgG"/>
   <result pre="Rio Bravo (RB) IgM as well as IgG ELISA, and" exact="Zika" post="NT. In all cases, the mean values of the"/>
   <result pre="the naïve and pre-immune pools would be even more pronounced." exact="Zika" post="IgG avidity could only be performed with the pools"/>
   <result pre="of individual sera. All four groups produced high amounts of" exact="Zika" post="virus-specific IgM antibodies, which were slightly higher in the"/>
   <result pre="flaviviruses (Fig 1B). In contrast to the IgM results, the" exact="Zika" post="virus-specific IgG response was significantly higher in all pre-vaccinated"/>
   <result pre="suggested by the higher relative avidities of these groups in" exact="Zika" post="IgG ELISA (Fig 2E), this pattern is consistent with"/>
   <result pre="booster response of IgG in the pre-vaccinated individuals. In the" exact="Zika" post="neutralization test (NT), however, no differences were found among"/>
   <result pre="cross-reactive antibodies did not contribute significantly to the neutralization of" exact="Zika" post="virus. Fig 2 Zika virus-specific and broadly cross-reactive antibody"/>
   <result pre="contribute significantly to the neutralization of Zika virus. Fig 2" exact="Zika" post="virus-specific and broadly cross-reactive antibody titers of four serum"/>
   <result pre="of individual sera are shown as red open circles. (A)" exact="Zika" post="virus IgM ELISA units, (B) Rio Bravo virus IgM"/>
   <result pre="Rio Bravo virus IgM ELISA absorbance values (cross-reactive antibodies), (C)" exact="Zika" post="virus IgG ELISA titers, (D) Rio Bravo virus IgG"/>
   <result pre="Rio Bravo virus IgG ELISA titers (cross-reactive antibodies), (E) relative" exact="Zika" post="virus IgG avidities (%), (F) Zika virus NT50 titers."/>
   <result pre="(cross-reactive antibodies), (E) relative Zika virus IgG avidities (%), (F)" exact="Zika" post="virus NT50 titers. The cut-off is indicated by a"/>
   <result pre="0.05; **, p &amp;lt; 0.01; ***, p &amp;lt; 0.001. ZIKV," exact="Zika" post="virus; RBV, Rio Bravo virus; naïve, flavivirus naïve serum"/>
   <result pre="and tick-borne encephalitis pre-vaccinated serum pool. Role of IgM in" exact="Zika" post="virus NT and ADE To obtain information about the"/>
   <result pre="GLM and Wald’s test as described in Methods. Fig 3" exact="Zika" post="virus neutralization NT50 titers by IgM after IgG depletion"/>
   <result pre="contrasts); *, p &amp;lt; 0.05; **, p &amp;lt; 0.01. ZIKV," exact="Zika" post="virus; naïve, flavivirus naïve serum pool; YF+, yellow fever"/>
   <result pre="extent the presence of neutralizing IgM antibodies could affect IgG-mediated" exact="Zika" post="virus ADE of infection. For this purpose, we determined"/>
   <result pre="Effect of IgM depletion from serum pools on ADE of" exact="Zika" post="virus infection. Serum pools were depleted with IgM agarose"/>
   <result pre="described in Methods. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of serially diluted (A) flavivirus-naïve"/>
   <result pre="line indicates no enhancement of infection. Comparison of fold-enhancement of" exact="Zika" post="virus infection in the presence of depleted and mock-depleted"/>
   <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; naïve, flavivirus naïve serum pool; YF+, yellow fever"/>
   <result pre="5 Effect of IgM and IgG depletion on ADE of" exact="Zika" post="virus infection. The four serum pools were depleted from"/>
   <result pre="described in Methods. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of a 1:1000 dilution of"/>
   <result pre="pre-vaccinated serum pool. Role of broadly flavivirus cross-reactive antibodies in" exact="Zika" post="virus NT and ADE Since the pre-immune groups had"/>
   <result pre="flavivirus cross-reactive antibodies (Fig 2D), we quantified their contribution to" exact="Zika" post="virus neutralization and enhancement by depletion of these antibodies"/>
   <result pre="this procedure (S8 Fig). Analysis of the depleted samples in" exact="Zika" post="IgG ELISA (Fig 6A) revealed that more than 60%"/>
   <result pre="6A) revealed that more than 60% of IgG reactivity were" exact="Zika" post="virus-specific in the naïve group, contrasting to only 5.8"/>
   <result pre="the naïve group. The data show that the newly synthesized" exact="Zika" post="virus-specific antibodies (i.e. those not removed by RB depletion)"/>
   <result pre="and 0.998). Depletion of cross-reactive antibodies had no influence on" exact="Zika" post="virus neutralization (Fig 6C)—consistent with the data displayed in"/>
   <result pre="displayed in Fig 2 - and did not significantly affect" exact="Zika" post="virus ADE (Fig 7A–7D). Fig 6 Effect of depletion"/>
   <result pre="antibodies from serum pools with Rio Bravo virus E on" exact="Zika" post="virus antibody titers. (A) Zika virus IgG ELISA titers,"/>
   <result pre="Rio Bravo virus E on Zika virus antibody titers. (A)" exact="Zika" post="virus IgG ELISA titers, (B) relative avidity of Zika"/>
   <result pre="(A) Zika virus IgG ELISA titers, (B) relative avidity of" exact="Zika" post="virus-specific IgG, and (C) Zika virus NT50 titers. Colored"/>
   <result pre="titers, (B) relative avidity of Zika virus-specific IgG, and (C)" exact="Zika" post="virus NT50 titers. Colored columns: mock depletion, empty columns:"/>
   <result pre="0.05; **, p &amp;lt; 0.01; ***, p &amp;lt; 0.001. ZIKV," exact="Zika" post="virus; mock dep, IgM and mock-depleted serum pool; RB"/>
   <result pre="serum pools with Rio Bravo virus E on ADE of" exact="Zika" post="virus infection. Fcγ receptor-positive K562 cells were infected with"/>
   <result pre="Zika virus infection. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of serially diluted (A) flavivirus-naïve"/>
   <result pre="line indicates no enhancement of infection. Comparison of fold-enhancement of" exact="Zika" post="virus infection in the presence of depleted and mock-depleted"/>
   <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; mock dep, IgM and mock-depleted serum pool; RB"/>
   <result pre="are more accessible in infectious dengue than in TBE and" exact="Zika" post="viruses (compare Fig 6C). This conclusion is also confirmed"/>
   <result pre="TBE and dengue virus neutralization. (A) TBE virus NT. (B)" exact="Dengue" post="virus NT. IgG-containing serum pools were further depleted with"/>
   <result pre="therefore also compared individual serum samples from naïve and pre-immune" exact="Zika" post="patients (Table 3), for which sufficient volumes were available,"/>
   <result pre="patients (Table 3), for which sufficient volumes were available, in" exact="Zika" post="IgM and IgG ELISAs, RB IgG ELISA, as well"/>
   <result pre="IgM and IgG ELISAs, RB IgG ELISA, as well as" exact="Zika" post="and dengue NTs. For this comparison and based on"/>
   <result pre="For this comparison and based on the small number of" exact="Zika" post="patients in the YF group, all samples from pre-vaccinated"/>
   <result pre="displayed in Figs 10 and 11. Fig 10 Quantification of" exact="Zika" post="virus-specific IgM and IgG antibodies and broadly cross-reactive IgG"/>
   <result pre="and broadly cross-reactive IgG antibodies using single serum samples from" exact="Zika" post="cases. (A) Zika virus IgM ELISA units, (B) Zika"/>
   <result pre="IgG antibodies using single serum samples from Zika cases. (A)" exact="Zika" post="virus IgM ELISA units, (B) Zika virus IgG ELISA"/>
   <result pre="from Zika cases. (A) Zika virus IgM ELISA units, (B)" exact="Zika" post="virus IgG ELISA titers, and (C) Rio Bravo virus"/>
   <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; RBV, Rio Bravo virus. Fig 11 Zika and"/>
   <result pre="graphs. ZIKV, Zika virus; RBV, Rio Bravo virus. Fig 11" exact="Zika" post="and dengue virus neutralization tests using single serum samples"/>
   <result pre="and dengue virus neutralization tests using single serum samples from" exact="Zika" post="cases. (A) Zika virus and (B) dengue virus NT50"/>
   <result pre="neutralization tests using single serum samples from Zika cases. (A)" exact="Zika" post="virus and (B) dengue virus NT50 titers from individual"/>
   <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; DENV1, dengue virus serotype 1. The distribution of"/>
   <result pre="two groups was much more pronounced in IgG ELISAs with" exact="Zika" post="and RB antigens (Fig 10B and 10C), with a"/>
   <result pre="booster response of broadly flavivirus cross-reactive antibodies. The pattern of" exact="Zika" post="virus NT appeared very similar with samples of the"/>
   <result pre="prior TBE and/or YF vaccination on antibody responses to primary" exact="Zika" post="virus infections and observed a strong anamnestic response in"/>
   <result pre="lower (Fig 6A). Since the magnitude of the newly formed" exact="Zika" post="virus-specific IgG response was similar in naïve and pre-vaccinated"/>
   <result pre="Consistent with this picture, broadly cross-reactive antibodies did not neutralize" exact="Zika" post="and TBE viruses to a significant extent (Figs 6C"/>
   <result pre="the FL epitope [19, 21]. The different properties of infectious" exact="Zika" post="and dengue viruses with respect to the exposure of"/>
   <result pre="albeit at sub-neutralizing concentrations [30]. Broadly cross-reactive antibodies boostered by" exact="Zika" post="virus in the TBE and YF pre-vaccinated individuals only"/>
   <result pre="TBE and YF pre-vaccinated individuals only enhanced dengue but not" exact="Zika" post="virus in our in vitro assays, consistent with a"/>
   <result pre="neutralization and strong ADE by cross-reactive antibodies, in contrast to" exact="Zika" post="virus) may be biased by the specific properties of"/>
   <result pre="the FL [65]. In our analyses we used a stable" exact="Zika" post="virus E dimer (S4 Fig) which has a native"/>
   <result pre="sera accounted for a maximum of ~ 10% of total" exact="Zika" post="virus NT activity (S5 Fig). Although Zika virus was"/>
   <result pre="10% of total Zika virus NT activity (S5 Fig). Although" exact="Zika" post="virus was not enhanced by broadly flavivirus cross-reactive antibodies"/>
   <result pre="study, infection enhancement of this virus was readily demonstrable with" exact="Zika" post="virus-specific antibodies at sub-neutralizing concentrations, consistent with the generally"/>
   <result pre="IgM antibodies was recently shown in a mouse study with" exact="Zika" post="virus, demonstrating that IgG-mediated ADE can be weakened by"/>
   <result pre="of the total neutralizing activity in our samples of primary" exact="Zika" post="virus infections, with a tendency of a lower contribution"/>
   <result pre="clearance early after infection, also deduced from animal studies with" exact="West Nile" post="virus and IgM-deficient mice [24]. It appears that the"/>
   <result pre="the specific situations analyzed in our study, the impairment of" exact="Zika" post="virus-specific IgM responses was not very strong but demonstrated"/>
   <result pre="primary infection with a distantly related flavivirus, in this case" exact="Zika" post="virus. The modulation observed, albeit with relatively small groups"/>
   <result pre="here for additional data file. S2 Fig Control of the" exact="Zika" post="IgG avidity ELISA with early and late Zika virus"/>
   <result pre="of the Zika IgG avidity ELISA with early and late" exact="Zika" post="virus post-infection serum samples. (A) Serum collected 3 weeks"/>
   <result pre="here for additional data file. S3 Fig Controls for the" exact="Zika" post="IgM ELISA. (A) Standard curve of the positive control"/>
   <result pre="(B) results of 32 negative control sera in ELISA with" exact="Zika" post="virus E protein. The cut-off is shown as dotted"/>
   <result pre="for additional data file. S4 Fig Analysis of the recombinant" exact="Zika" post="virus E protein used in this study. (A) Rate"/>
   <result pre="used in this study. (A) Rate zonal ultracentrifugation of untreated" exact="Zika" post="virus E protein (red solid line), and after SDS-treatment"/>
   <result pre="positions of monomers and dimers, respectively. (B) Size-exclusion chromatograms of" exact="Zika" post="virus E (upper panel) and the monomeric WN virus"/>
   <result pre="the monomeric WN virus E (lower panel). (C) ELISA with" exact="Zika" post="virus E protein and EDE-specific monoclonal antibodies (C8 and"/>
   <result pre="Click here for additional data file. S5 Fig Results of" exact="Zika" post="virus neutralization of samples before and after antibody depletion"/>
   <result pre="neutralization of samples before and after antibody depletion with the" exact="Zika" post="virus E dimer. (A) Serum pools. (B) Individual serum"/>
   <result pre="the range. Colored columns: mock depletion (mock dep), empty columns:" exact="Zika" post="virus E depletion (ZIKV dep). n.t., not tested, because"/>
   <result pre="(TIF) LINK Click here for additional data file. S6 Fig" exact="Zika" post="virus IgG and IgM ELISA after IgG depletion of"/>
   <result pre="depleted with protein G columns as described in Methods. (A)" exact="Zika" post="virus IgG ELISA showing more than 99% depletion of"/>
   <result pre="IgG ELISA showing more than 99% depletion of IgG. (B)" exact="Zika" post="virus IgM ELISA to control for loss of IgM"/>
   <result pre="(TIF) LINK Click here for additional data file. S7 Fig" exact="Zika" post="virus IgM and IgG ELISA after IgM depletion of"/>
   <result pre="depleted with anti-IgM agarose beads as described in Methods. (A)" exact="Zika" post="virus IgM ELISA showing more than 99% depletion of"/>
   <result pre="IgM ELISA showing more than 99% depletion of IgM. (B)" exact="Zika" post="virus IgG ELISA to control for loss of IgG"/>
   <result pre="the World Health Organization. 201610.2471/BLT.16.171082. 3PiersonTC, DiamondMS. The emergence of" exact="Zika" post="virus and its new clinical syndromes. Nature. 2018;560(7720):573–81. 10.1038/s41586-018-0446-y30158602"/>
   <result pre="Virology. 2. 6 edPhiladelphia: Lippincott Williams &amp;amp; Wilkins; 2013. 5HalsteadSB." exact="Dengue" post="antibody-dependent enhancement: knowns and unknowns. Microbiology Spectrum. 2014;2(6). 10.1128/microbiolspec.AID-0022-201426104444"/>
   <result pre="population at risk of dengue. Nature Microbiology. 201910.1038/s41564-019-0476-831182801 10MussoD, GublerDJ." exact="Zika" post="virus. Clin Microbiol Rev. 2016;29(3):487–524. Epub 03/30. 10.1128/CMR.00072-15 .27029595"/>
   <result pre="GuzmanH, AraujoTP, XiaoSY. Immunization with heterologous flaviviruses protective against fatal" exact="West Nile" post="encephalitis. Emerg Infect Dis. 2002;8(3):245–51. 10.3201/eid0803.01023811927020 17BarzonL, PercivalleE, PacentiM,"/>
   <result pre="BravoP, et al.Virus and antibody dynamics in travelers with acute" exact="Zika" post="virus infection. Clin Infect Dis. 201710.1093/cid/cix967 .29300893 18HasanSS, SevvanaM,"/>
   <result pre="Dis. 201710.1093/cid/cix967 .29300893 18HasanSS, SevvanaM, KuhnRJ, RossmannMG. Structural biology of" exact="Zika" post="virus and other flaviviruses. Nat Struct Mol Biol. 2018;25(1):13–20."/>
   <result pre="KloseT, BudaG, SunL, et al.Refinement and analysis of the mature" exact="Zika" post="virus cryo-EM structure at 3.1 Å resolution. Structure. 2018;26(9):1169–77.e3."/>
   <result pre="A critical role for induced IgM in the protection against" exact="West Nile" post="virus infection. J Exp Med. 2003;198(12):1853–62. 10.1084/jem.2003122314662909 25LibratyDH, NisalakA,"/>
   <result pre="against tick-borne encephalitis. Vaccine. 2010;28(16):2827–31. 10.1016/j.vaccine.2010.02.00120167301 28StaplesJE, MonathTP, GershmanMD, BarrettADT." exact="Yellow fever" post="vaccines. In: OrensteinWA, OffitPA, EdwardsKM, editors. Plotkin's Vaccines (Seventh"/>
   <result pre="Plotkin's Vaccines (Seventh Edition): Elsevier; 2018 p. 1181–265.e20. 29RichnerJM, DiamondMS." exact="Zika" post="virus vaccines: immune response, current status, and future challenges."/>
   <result pre="FremontDH, et al.The stoichiometry of antibody-mediated neutralization and enhancement of" exact="West Nile" post="virus infection. Cell host &amp;amp; microbe. 2007;1(2):135–45. 10.1016/j.chom.2007.03.002 .18005691"/>
   <result pre="10.1089/08828240376363546512725690 32BardinaSV, BunducP, TripathiS, DuehrJ, FrereJJ, BrownJA, et al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity. Science. 201710.1126/science.aal4365 .28360135"/>
   <result pre="on the dominance of virus-specific CD4 T cell epitopes in" exact="Zika" post="virus infection. Front Immunol. 2018;9:119610.3389/fimmu.2018.0119629899743 38MandlCW, HeinzFX, KunzC. Sequence"/>
   <result pre="HeinzFX. Immunodominance and functional activities of antibody responses to inactivated" exact="West Nile" post="virus and recombinant subunit vaccines in mice. Journal of"/>
   <result pre="al.Development of a humanized monoclonal antibody with therapeutic potential against" exact="West Nile" post="virus. Nature medicine. 2005;11(5):522–30. Epub 04/24. 10.1038/nm1240 .15852016 63NybakkenGE,"/>
   <result pre=".15852016 63NybakkenGE, NelsonCA, ChenBR, DiamondMS, FremontDH. Crystal structure of the" exact="West Nile" post="virus envelope glycoprotein. J Virol. 2006;80(23):11467–74. 10.1128/JVI.01125-0616987985 64KanaiR, KarK,"/>
   <result pre="64KanaiR, KarK, AnthonyK, GouldLH, LedizetM, FikrigE, et al.Crystal structure of" exact="West Nile" post="virus envelope glycoprotein reveals viral surface epitopes. J Virol."/>
   <result pre="et al.Zika virus-immune plasmas from symptomatic and asymptomatic individuals enhance" exact="Zika" post="pathogenesis in adult and pregnant mice. mBio. 2019;10(4):e00758–19. 10.1128/mBio.00758-1931266863"/>
   <result pre="1983;158(1):258–63. 10.1084/jem.158.1.2586864163 69BalakrishnanT, Bela-OngDB, TohYX, FlamandM, DeviS, KohMB, et al." exact="Dengue" post="virus activates polyreactive, natural IgG B cells after primary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7022353\results\search\tropicalVirus\results.xml">
   <result pre="International license.JVI.01127-19.pdf The emergence and reemergence of pathogens such as" exact="Zika" post="virus, chikungunya virus, and yellow fever virus have drawn"/>
   <result pre="approach. IMPORTANCE The emergence and reemergence of pathogens such as" exact="Zika" post="virus, chikungunya virus, and yellow fever virus have drawn"/>
   <result pre="a role. For example, mutations in the E1 protein of" exact="Chikungunya" post="virus affect its infectivity in different vector species (A226V"/>
   <result pre="GrubaughND, SomasekarS, ChiuCY, Muñoz-MedinaJE, et al.2017Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the Americas. Nature546:406–410. doi:10.1038/nature22401.28538727 64.QuickJ,"/>
   <result pre="AndersenKG, LomanNJ2017Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7031975\results\search\tropicalVirus\results.xml">
   <result pre="show that Venezuela has historically been an important source of" exact="DENV" post="dispersal in this region, even before the massive exodus"/>
   <result pre="population, suggesting already established paths of viral distribution. Like DENV," exact="CHIKV" post="was introduced into Ecuador at multiple time points in"/>
   <result pre="were associated with the Caribbean. Our findings indicated no direct" exact="CHIKV" post="connection between Ecuador, Colombia, and Venezuela as of 2015,"/>
   <result pre="between Ecuador, Colombia, and Venezuela as of 2015, suggesting that" exact="CHIKV" post="was, at this point, not following the paths of"/>
   <result pre="CHIKV was, at this point, not following the paths of" exact="DENV" post="spread. Conclusion Our results reveal that Ecuador is vulnerable"/>
   <result pre="healthcare for the vulnerable populations is of utmost importance. Keywords" exact="Dengue" post="Chikungunya Ecuador Venezuela Colombia Dissemination Funding http://dx.doi.org/10.13039/100014035Armed Forces Health"/>
   <result pre="for the vulnerable populations is of utmost importance. Keywords Dengue" exact="Chikungunya" post="Ecuador Venezuela Colombia Dissemination Funding http://dx.doi.org/10.13039/100014035Armed Forces Health Surveillance"/>
   <result pre="forms of dengue disease are on the rise [6, 7]." exact="Dengue" post="is not the only mosquito-borne disease to reemerge in"/>
   <result pre="not the only mosquito-borne disease to reemerge in the Americas." exact="Chikungunya" post="virus (CHIKV) has been suggested to have caused outbreaks"/>
   <result pre="long absence of the virus from this region [8, 9]." exact="CHIKV" post="reemerged in 2013 in the Caribbean and quickly spread"/>
   <result pre="and South America [10–12]. In Ecuador, the first cases of" exact="CHIKV" post="were reported at the end of 2014, and in"/>
   <result pre="of suspected dengue cases were confirmed to actually be acute" exact="CHIKV" post="infections (only 28% were confirmed to be acute DENV)"/>
   <result pre="the invasion of CHIKV, an arbovirus novel to the region," exact="Zika" post="virus (ZIKV), was identified in the Americas [13]. It"/>
   <result pre="in the country. In recent years, all three arboviruses (DENV," exact="CHIKV" post="and ZIKV) have co-circulated in Ecuador and its neighboring"/>
   <result pre="in infectious diseases such as malaria, measles, diphtheria, dengue, chikungunya," exact="Zika" post="and others [25, 26]. The massive human movement from"/>
   <result pre="in the harbor city of Machala revealed the first characterized" exact="CHIKV" post="outbreak in the country, as well all four serotypes"/>
   <result pre="2014–2015. In this study, we use the most prevalent Ecuadorian" exact="DENV" post="(DENV1 and DENV2) and CHIKV genomes from this time"/>
   <result pre="use the most prevalent Ecuadorian DENV (DENV1 and DENV2) and" exact="CHIKV" post="genomes from this time period to determine the origins"/>
   <result pre="area of Machala (Fig. 1). The sequenced genomes included two" exact="DENV" post="serotypes (1 and 2), that belonged to the genotype"/>
   <result pre="that belonged to the genotype V and Asian American, respectively." exact="CHIKV" post="genomes belonged to the Asian lineage, and are the"/>
   <result pre="to the Asian lineage, and are the first genomes of" exact="CHIKV" post="to be reported from the country of Ecuador (Additional"/>
   <result pre="cases of DENV1 and DENV2, and the two introductions of" exact="Chikungunya" post="(CHIKV-i-I, CHIKV-i-II); clinics are shown by ‘H’, with the"/>
   <result pre="consisting of ~ 300 genomes) and one E gene dataset per" exact="DENV" post="serotype were used in Bayesian analyses to investigate the"/>
   <result pre="between Brazil, Paraguay and also Bolivia. Several independent introductions of" exact="CHIKV" post="into Ecuador from the Caribbean/Central America CHIKV was circulating"/>
   <result pre="independent introductions of CHIKV into Ecuador from the Caribbean/Central America" exact="CHIKV" post="was circulating in Machala, Ecuador in 2015 (Additional file"/>
   <result pre="the Asian genotype MCC tree, indicating two independent introductions of" exact="CHIKV" post="into Ecuador (Fig. 3). Both introductions originated from the"/>
   <result pre="though the surveillance site was active in 2014, the first" exact="CHIKV" post="was sampled in March 2015, indicating a period of"/>
   <result pre="was sampled in March 2015, indicating a period of silent" exact="CHIKV" post="transmission in this region of 8 months (second introduction) to"/>
   <result pre="dispersed across the city, indicating simultaneous circulation of the two" exact="CHIKV" post="strains across the same area (Fig. 1). Interestingly, CHIKV"/>
   <result pre="two CHIKV strains across the same area (Fig. 1). Interestingly," exact="CHIKV" post="in Colombia was not closely related to either of"/>
   <result pre="in mid-2014 (2014.4; HPD: 2014.2–2014.6). Fig. 3 MCC tree of" exact="CHIKV" post="Asian lineage. Taxa from Ecuador are color coded in"/>
   <result pre="the text are noted next to the respective ancestor nodes" exact="CHIKV" post="genomes from Ecuador were screened for reported mutations that"/>
   <result pre="transmission and infection of the mosquito. As all Asian lineage" exact="CHIKV" post="strains, the viruses from Ecuador had the E1:A98T residue"/>
   <result pre="virus in Ae. aegypti, and has recently been observed in" exact="CHIKV" post="outbreaks in several regions of the world [30, 32]."/>
   <result pre="regions of the world [30, 32]. These results show that" exact="CHIKV" post="from Ecuador had not acquired all the mutations that"/>
   <result pre="to the main vector in Ecuador, Ae. aegypti. Table 1" exact="CHIKV" post="amino acid mutations associated with phenotype change in vector"/>
   <result pre="and DENV2 introductions into Ecuador, and the 2013/2014 DENV1 and" exact="CHIKV" post="introductions, both followed an increase of Colombian and Venezuelan"/>
   <result pre="of Venezuelan and Colombian citizens entering Ecuador. DENV1, DENV2 and" exact="CHIKV" post="introductions are noted as vertical lines. CHIKV lines are"/>
   <result pre="DENV1, DENV2 and CHIKV introductions are noted as vertical lines." exact="CHIKV" post="lines are black, and DENV lines are color coded"/>
   <result pre="are noted as vertical lines. CHIKV lines are black, and" exact="DENV" post="lines are color coded based on their country of"/>
   <result pre="color coded based on their country of origin association. b" exact="Dengue" post="incidence per 100,000 population in Colombia, Venezuela and Ecuador"/>
   <result pre="dengue infections to introductions of novel viruses - chikungunya and" exact="Zika" post="- and their sustained spread in the country. The"/>
   <result pre="Venezuela, with diseases such as malaria, measles, dengue, chikungunya and" exact="Zika" post="on the rise [35]. As the citizens are fleeing"/>
   <result pre="located along the Pan American Highway, near the Ecuador-Peru border." exact="DENV" post="is hyperendemic in Machala, and is transmitted by the"/>
   <result pre="Colombian and Venezuelan citizens in 2009 and 2012, respectively. Interestingly," exact="DENV" post="case count data indicate that both the 2011 and"/>
   <result pre="introductions into Ecuador were preceded by a sharp increase in" exact="DENV" post="cases in Colombia and Venezuela. This would indicate that"/>
   <result pre="Argentina, Nicaragua, Puerto Rico, Brazil and Ecuador, resulting in sustained" exact="DENV" post="spread in these countries [38–40]. The potential of dengue"/>
   <result pre="America continues to affect arboviral dispersal. Our analyses of the" exact="CHIKV" post="outbreak in Machala reveled that this arbovirus, like dengue,"/>
   <result pre="in 2014 and later that same year. Unlike dengue, however," exact="CHIKV" post="had been introduced from the Caribbean. CHIKV genomes from"/>
   <result pre="Unlike dengue, however, CHIKV had been introduced from the Caribbean." exact="CHIKV" post="genomes from Colombia showed no correlation to the genomes"/>
   <result pre="and were estimated introduced into this country from Martinique. Although" exact="CHIKV" post="is spreading in Venezuela, no full genomes were available"/>
   <result pre="infer the contribution of this country to the spread of" exact="CHIKV" post="in the region [42]. Previous E gene analyses from"/>
   <result pre="viral relationships, but did indicate a close connection to the" exact="CHIKV" post="genomes from the Caribbean [43]. Thus, these and our"/>
   <result pre="at least until 2015, there was no direct connection of" exact="CHIKV" post="strains between these countries. However, more recent findings suggest"/>
   <result pre="strains between these countries. However, more recent findings suggest that" exact="CHIKV" post="infections are found close to the country borders, suggesting"/>
   <result pre="infections are found close to the country borders, suggesting that" exact="CHIKV" post="might have started following the patterns of dengue spread"/>
   <result pre="vector, Ae. aegypti in South America, the possibility of direct" exact="CHIKV" post="dissemination between these countries of South America is real."/>
   <result pre="qualitative real-time reverse transcriptase RT-PCR assays for DENV1–4, CHIKV, and" exact="ZIKV" post="(diagnostic protocol described previously) [6]. RNA extracted from samples"/>
   <result pre="protocol described previously) [6]. RNA extracted from samples that were" exact="DENV" post="and CHIKV positive by RT-PCR were sent to WRAIR,"/>
   <result pre="previously) [6]. RNA extracted from samples that were DENV and" exact="CHIKV" post="positive by RT-PCR were sent to WRAIR, Viral Diseases"/>
   <result pre="produced using GADM shapefiles, in ArcGIS v 10.6.1 [47, 48]." exact="Dengue" post="case count data was retrieved from Pan American Health"/>
   <result pre="Here, extracted RNA was reverse transcribed and amplified utilizing serotype-specific" exact="DENV" post="(DENV1 or DENV2) primers (Additional file 7-8) or CHIKV"/>
   <result pre="serotype-specific DENV (DENV1 or DENV2) primers (Additional file 7-8) or" exact="CHIKV" post="specific primers (Additional file 9). Two approaches of generating"/>
   <result pre="of DENV1 and 1113 E genes of DENV2. All available" exact="CHIKV" post="full genomes were downloaded from the ViPR curated database"/>
   <result pre="genome alignment of the Asian lineage was constructed using all" exact="CHIKV" post="sequences except genomes without collection location or date, or"/>
   <result pre="analyses The best-fit models of evolution for DENV1, DENV2 and" exact="CHIKV" post="datasets were determined using jModelTest v2.1.7 and chosen based"/>
   <result pre="(ML) phylogenetic trees for each of the DENV1, DENV2 and" exact="CHIKV" post="datasets were inferred using Phyml v 4.9.1 [55] using"/>
   <result pre="determined by aLRT (approximate Likelihood Ratio Test). DENV1, DENV2 and" exact="CHIKV" post="reference alignments were further down sampled for Bayesian tree"/>
   <result pre="genome sampling skew, references were also down sampled for each" exact="DENV" post="serotype, such that no country contributed with more than"/>
   <result pre="than 65 genes (N = 515 for DENV1 and N = 505 for DENV2)." exact="CHIKV" post="full genome alignment for BEAST analyses consisted of 103"/>
   <result pre="Circuits of the Access Array (Fluidigm). LINK Additional file 9." exact="CHIKV" post="Specific Primer Pairs Used on the Integrated Fluidic Circuits"/>
   <result pre="Bayesian Evolutionary Analysis by Sampling Trees BIC Bayesian Information Criterion" exact="CHIKV" post="Chikungunya virus DENV Dengue virus ESS Effective Sample Size"/>
   <result pre="Evolutionary Analysis by Sampling Trees BIC Bayesian Information Criterion CHIKV" exact="Chikungunya" post="virus DENV Dengue virus ESS Effective Sample Size GTR + I + Γ"/>
   <result pre="by Sampling Trees BIC Bayesian Information Criterion CHIKV Chikungunya virus" exact="DENV" post="Dengue virus ESS Effective Sample Size GTR + I + Γ General Time"/>
   <result pre="Sampling Trees BIC Bayesian Information Criterion CHIKV Chikungunya virus DENV" exact="Dengue" post="virus ESS Effective Sample Size GTR + I + Γ General Time Reversible"/>
   <result pre="of the most recent common ancestor ViPR Virus Pathogen Resource" exact="ZIKV" post="Zika virus Publisher’s Note Springer Nature remains neutral with"/>
   <result pre="the most recent common ancestor ViPR Virus Pathogen Resource ZIKV" exact="Zika" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
   <result pre="Mortal Wkly Rep198938244194212498633 6.Stewart-IbarraAMRyanSJKennesonAKingCAAbbottMBarbachano-GuerreroAet al.The burden of dengue fever and" exact="Chikungunya" post="in southern coastal Ecuador: epidemiology, clinical presentation, and Phylogenetics"/>
   <result pre="novel epistatic mutations (E1:K211E and E2:V264A) in structural proteins of" exact="Chikungunya" post="virus enhance fitness in Aedes aegyptiVirology2016497596810.1016/j.virol.2016.06.02527423270 31.TsetsarkinKAWeaverSCSequential adaptive mutations"/>
   <result pre="Aedes aegyptiVirology2016497596810.1016/j.virol.2016.06.02527423270 31.TsetsarkinKAWeaverSCSequential adaptive mutations enhance efficient vector switching by" exact="Chikungunya" post="virus and its epidemic emergencePLoS Pathog2011712e100241210.1371/journal.ppat.100241222174678 32.Maljkovic BerryIEyaseFPollettSKonongoiSLJoyceMGFigueroaKet al.Global"/>
   <result pre="in 2012–2013Clin Microbiol Infect2015217713 e5713 e810.1016/j.cmi.2015.03.016 42.LizarazoEVincenti-GonzalezMGrilletMEBethencourtSDiazOOjedaNet al.Spatial dynamics of" exact="Chikungunya" post="virus, Venezuela, 2014Emerg Infect Dis201925467268010.3201/eid2504.17212130882314 43.CamachoDReyesJNegredoAHernandezLSanchez-SecoMComachGAsian genotype of Chikungunya"/>
   <result pre="of Chikungunya virus, Venezuela, 2014Emerg Infect Dis201925467268010.3201/eid2504.17212130882314 43.CamachoDReyesJNegredoAHernandezLSanchez-SecoMComachGAsian genotype of" exact="Chikungunya" post="virus circulating in Venezuela during 2014Acta Trop2017174889010.1016/j.actatropica.2017.06.02628690146 44.Carrillo-HernandezMYRuiz-SaenzJVillamizarLJGomez-RangelSYMartinez-GutierrezMCo-circulation and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7031979\results\search\tropicalVirus\results.xml">
   <result pre="VectorsParasites &amp;amp; Vectors1756-3305BioMed CentralLondon pmcid: 70319793966 doi: 10.1186/s13071-020-3966-x : Research" exact="Yellow fever" post="epizootics in non-human primates, Southeast and Northeast Brazil (2017"/>
   <result pre="stated in a credit line to the data. Abstract Background" exact="Yellow fever" post="(YF) is a severe, infectious, but non-communicable arboviral hemorrhagic"/>
   <result pre="to the sylvatic cycle. This study presents the monitoring of" exact="YFV" post="by real-time RT-PCR and the epidemiological findings related to"/>
   <result pre="and 2018. The samples were subjected to molecular diagnostics for" exact="YFV" post="detection using real-time reverse transcription polymerase chain reaction (rtRT-PCR)"/>
   <result pre="the role of Callithrix spp. in the transmission cycles of" exact="YFV" post="in Brazil. In particular, YFV transmission was observed in"/>
   <result pre="in the transmission cycles of YFV in Brazil. In particular," exact="YFV" post="transmission was observed in a region where viral circulation"/>
   <result pre="Brazil in previously considered &quot;YFV-free�? areas of the country. Keywords" exact="Yellow fever" post="Epizootics Non-human primates Molecular diagnosis Outbreak Funding Horizon 2020"/>
   <result pre="Estado do Rio de Janeiro E-26/2002.930/2016de FilippisAna M. Bispo Background" exact="Yellow fever" post="(YF) is an infectious disease that results in an"/>
   <result pre="Prerequisites for epidemic outbreaks include available reservoirs of infection with" exact="YFV" post="(such as non-human primates, NHPs) and high vector population"/>
   <result pre="spp. and Sabethes spp.) [1]. The primary wild hosts of" exact="YFV" post="are non-human primates in both Africa and the Americas."/>
   <result pre="2017, seven countries and territories in South America reported confirmed" exact="YFV" post="cases (Bolivia, Brazil, Colombia, Ecuador, French Guiana, Peru and"/>
   <result pre="regions was the highest observed in decades [9]. The 2016–2017" exact="YFV" post="epidemic in Brazil accounted for 1659 epizootics, 779 confirmed"/>
   <result pre="total of 4198 samples from 2099 NHPs were screened for" exact="YFV" post="detection by rtRT-PCR. Between January and December 2017, 1049"/>
   <result pre="in the last decades, virus circulation and NHP epizootics from" exact="YFV" post="were not detected in these areas except for MG,"/>
   <result pre="(BA), and Minas Gerais (MG) showing the with distribution of" exact="YFV" post="infected and non-infected non-human primates that tested positive and"/>
   <result pre="and non-infected non-human primates that tested positive and negative for" exact="YFV" post="infection. The infections were assessed by rtRT-PCR analysis for"/>
   <result pre="Espírito Santo; BA, Bahia The number of NHPs infected with" exact="YFV" post="in each state increased primarily from February to March,"/>
   <result pre="(Fig. 3). Fig. 3 Temporal distribution of confirmed cases of" exact="YFV" post="from 2017 to 2018. a Number of infected animals"/>
   <result pre="to October 2018. b Distribution of human cases confirmed for" exact="YFV" post="reported to SVS/MS, by symptom onset and classification from"/>
   <result pre="Brazilian Ministry of Health [10] Regarding the molecular detection of" exact="YFV" post="using rt-RT-PCR, Cq-values ranged between 6.42–35.26 (mean = 13.04,"/>
   <result pre="= 133, df = 2, P = 0.034). Fig. 4" exact="Yellow fever" post="RNA copies measured by quantification cycle threshold (Cq) values"/>
   <result pre="mostly under active surveillance, and only one animal positive for" exact="YFV" post="infection was detected in 2018. These results are consistent"/>
   <result pre="show a lower viral load, do not develop a fatal" exact="YFV" post="infection similar to that reported in humans, and can"/>
   <result pre="could be a risk factor for the re-emergence of urban" exact="YFV" post="epidemics in South America. Anthropophilic mosquitoes Aedes aegypti and"/>
   <result pre="and Aedes albopictus are highly susceptible to American and African" exact="YFV" post="strains [18]. Therefore, further studies are required to determine"/>
   <result pre="YF. The present NHP monitoring results expanded our knowledge of" exact="YFV" post="transmission in areas that have not been considered to"/>
   <result pre="of the renewal of NHP populations that are susceptible to" exact="YFV" post="infection [2]. In 2008–2009, epidemics in Rio Grande do"/>
   <result pre="Sul and São Paulo provided evidence of the expansion of" exact="YFV" post="transmission to the Southeast, which threatens densely populated areas"/>
   <result pre="and statistical analysis. The results showed that the presence of" exact="YFV" post="was associated with rain, altitude, diversity of NHP hosts,"/>
   <result pre="environmental aspects may influence different aspects of the transmission of" exact="YFV" post="[31]. We observed that approximately 10% of the NHPs"/>
   <result pre="epidemiology of diseases such as dengue, chikungunya, yellow fever and" exact="Zika" post="[24]. Unlike the DENV virus in the sylvatic cycle"/>
   <result pre="as dengue, chikungunya, yellow fever and Zika [24]. Unlike the" exact="DENV" post="virus in the sylvatic cycle in Southeast Asia and"/>
   <result pre="and Africa, which have different ecological and evolutionary lineages [32]," exact="YFV" post="in Brazil does not seem to present the same"/>
   <result pre="contribute to the death of these animals. Perhaps the low" exact="YFV" post="viremia alone cannot cause death of Callithrix spp. Considering"/>
   <result pre="to understand and prevent the urban and peri-urban transmission of" exact="YFV" post="in Brazil. Abbreviations YFV yellow fever virus NHP non-human"/>
   <result pre="the urban and peri-urban transmission of YFV in Brazil. Abbreviations" exact="YFV" post="yellow fever virus NHP non-human primate rtRT-PCR real-time reverse"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7033529\results\search\tropicalVirus\results.xml">
   <result pre="pmcid: 7033529S2215-017X(19)30622-8 doi: 10.1016/j.btre.2020.e00434e00434 : Research Article Optimization of recombinant" exact="Zika" post="virus NS1 protein secretion from HEK293 cells RoldánJulieta S.CassolaAlejandroCastilloDaniela"/>
   <result pre="article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Highlights •Stable recombinant" exact="ZIKV" post="NS1-His-expressing HEK293 cells were generated. •Rapamycin treatment followed by"/>
   <result pre="by serum starvation leads to a 29-fold increase in recombinant" exact="ZIKV" post="NS1 protein secretion. •The purified recombinant ZIKV NS1 hexamer"/>
   <result pre="increase in recombinant ZIKV NS1 protein secretion. •The purified recombinant" exact="ZIKV" post="NS1 hexamer is a reliable biological tool for clinical"/>
   <result pre="accurate and cost-effective diagnostic tests are urgently needed to detect" exact="Zika" post="virus (ZIKV) infection. Nonstructural 1 (NS1) glycoprotein is an"/>
   <result pre="medium. Purified rZNS1-His hexamer was recognized by anti-NS1 antibodies in" exact="ZIKV" post="patient's serum, and showed the ability to induce a"/>
   <result pre="be applied in the development of diagnostic tests to detect" exact="ZIKV" post="in infected patients during the acute phase. Keywords Zika"/>
   <result pre="detect ZIKV in infected patients during the acute phase. Keywords" exact="Zika" post="virus NS1 Recombinant protein Mammalian expression system 1 Introduction"/>
   <result pre="Zika virus NS1 Recombinant protein Mammalian expression system 1 Introduction" exact="Zika" post="virus (ZIKV), originally discovered in the Ziika forest of"/>
   <result pre="French Polynesia and the Pacific Islands in 2013 [4]. Thereafter," exact="ZIKV" post="spread throughout the South Pacific and eventually to the"/>
   <result pre="neurodevelopmental defects prompted the World Health Organization (WHO) to declare" exact="ZIKV" post="as a public health emergency of international concern on"/>
   <result pre="public health emergency of international concern on February 2016 [5]." exact="ZIKV" post="is primarily transmitted to humans from bites of infected"/>
   <result pre="been cases of sexual [8,9] and materno-fetal transmission [10]. Most" exact="ZIKV" post="infections are asymptomatic. Among symptomatic cases ―which develop 6–11"/>
   <result pre="rash, fever, arthralgia, conjunctivitis, edema and vomiting are reported [12]." exact="ZIKV" post="gained attention for its causal link to microcephaly in"/>
   <result pre="latter is an autoimmune disease that causes flaccid paralysis [16]." exact="ZIKV" post="is a member of the Flaviviridae family, which comprises"/>
   <result pre="which comprises other major global pathogens such as dengue virus," exact="West Nile" post="virus and yellow fever virus. Flavivirus encapsulate a positive-sense"/>
   <result pre="infected patients [29]. As with many other mosquito-borne flavivirus diseases," exact="ZIKV" post="epidemics usually occur in low resource populations, where Aedes"/>
   <result pre="diagnostic technique is urgently needed for the early detection of" exact="ZIKV" post="infected patients [29]. Considering the virus limited detection window"/>
   <result pre="that are being treated symptomatically and is critical in preventing" exact="ZIKV" post="propagation and in the control of future outbreaks. In"/>
   <result pre="is preferred for an accurate diagnosis [29]. Obtaining a functional" exact="ZIKV" post="hexameric NS1 protein for diagnosis is not trivial. Post-translational"/>
   <result pre="this study consisted of establishing a stable and optimized recombinant" exact="ZIKV" post="NS1 (rZNS1) expression system from HEK293 cells in order"/>
   <result pre="be used in the development of diagnostic tests to detect" exact="ZIKV" post="infection. Stable rZNS1-hexa-histidine (His)-expressing HEK293 cells were generated through"/>
   <result pre="increase. Purified rZNS1-His hexamer was recognized by anti-NS1 antibodies in" exact="ZIKV" post="patient's serum and showed the ability to induce a"/>
   <result pre="the development of improved diagnostic methods for the detection of" exact="ZIKV" post="in infected patients during the acute phase. 2 Materials"/>
   <result pre="Dot blot Equal amounts of cell supernatant, 10X supernatant, permeate," exact="ZIKV" post="stock, mock or rZNS1-His (250 ng) were spotted onto a"/>
   <result pre="F5 Multi-Mode microplate reader (Molecular Devices). 2.13 Stock virus growth" exact="ZIKV" post="inactivated stocks were a kind gift from Federico Giovannoni"/>
   <result pre="1.5 % FBS Minimum Essential Media (MEM) and infected with" exact="ZIKV" post="PRVABC59 Puerto Rico strain. Supernatants were collected at different"/>
   <result pre="Gutierrez&quot;. ZIKV-positive sera belong to individuals with positive diagnosis of" exact="ZIKV" post="infection. The serum samples had been codified upon collection"/>
   <result pre="the G protein of VSV, the sequence of MR 766" exact="ZIKV" post="isolate comprising amino acids 791–1142 that correspond to the"/>
   <result pre="the conformation of soluble NS1 secreted into the bloodstream of" exact="ZIKV" post="patients during the acute phase of the disease [29],"/>
   <result pre="indicated on the left. 3.4 rZNS1-His protein is recognized by" exact="ZIKV" post="infected patients sera and induces a humoral response in"/>
   <result pre="the produced rZNS1-His protein to develop diagnostic tests to detect" exact="ZIKV" post="infection, we first characterized the reactivity of anti-NS1 antibodies"/>
   <result pre="infection, we first characterized the reactivity of anti-NS1 antibodies in" exact="ZIKV" post="patient's serum towards rZNS1-His protein. iELISA assays were carried"/>
   <result pre="carried out with the sera of two patients with confirmed" exact="ZIKV" post="infection. Data showed that these sera contained IgG antibodies"/>
   <result pre="to rZNS1-His as expected. Next, we compared the reactivity of" exact="ZIKV" post="infected patient's serum against rZNS1-His or the native protein"/>
   <result pre="infected patient's serum against rZNS1-His or the native protein of" exact="ZIKV" post="Puerto Rico strain produced to the supernatant of ZIKV"/>
   <result pre="of ZIKV Puerto Rico strain produced to the supernatant of" exact="ZIKV" post="infected cells in a dot blot assay. The results"/>
   <result pre="cells in a dot blot assay. The results revealed that" exact="ZIKV" post="patient's serum reacted with rZNS1-His protein as well as"/>
   <result pre="well as with NS1 protein contained in the supernatant of" exact="ZIKV" post="infected cells (Fig. 4B). Control serum from a healthy"/>
   <result pre="ELISAs and lateral flow systems. Fig. 4 rZNS1-His reactivity with" exact="ZIKV" post="infected patients sera and immunogenicity in a mouse model."/>
   <result pre="Blot analysis with the indicated serum samples of rZNS1-His or" exact="ZIKV" post="stock obtained from C6/36 cells infected with ZIKV PRVABC59"/>
   <result pre="rZNS1-His or ZIKV stock obtained from C6/36 cells infected with" exact="ZIKV" post="PRVABC59 Puerto Rico strain. Mock-infected C6/36 cells supernatant was"/>
   <result pre="the curve represents mean ± SD of two sample replicates. 4 Discussion" exact="Zika" post="virus received little attention until 2015 outbreak in Brazil,"/>
   <result pre="epidemic ensued and congenital neurodevelopmental defects were associated with maternal" exact="ZIKV" post="infection [2]. Given that ZIKV NS1 hexameric glycoprotein is secreted"/>
   <result pre="defects were associated with maternal ZIKV infection [2]. Given that" exact="ZIKV" post="NS1 hexameric glycoprotein is secreted from the infected cells and"/>
   <result pre="[70]. In line with this, several studies have indicated that" exact="ZIKV" post="induces autophagy by triggering ER stress induction [[71], [72],"/>
   <result pre="treatment and serum deprivation can upregulate ―up to 29-fold― recombinant" exact="ZIKV" post="NS1 protein production in HEK293 cells, reaching protein yields"/>
   <result pre="ZNS1 hexamer is a reliable biological tool of great value for" exact="ZIKV" post="clinical diagnosis and surveillance purposes. CRediT authorship contribution statement"/>
   <result pre="(stegomyia) mosquitoesRev. Soc. Bras. Med. Trop.49201641026689277 7ChanJ.F.ChoiG.K.YipC.C.ChengV.C.YuenK.Y.Zika fever and congenital" exact="Zika" post="syndrome: an unexpected emerging arboviral diseaseJ. Infect.72201650752426940504 8VenturiG.ZammarchiL.FortunaC.RemoliM.E.BenedettiE.An autochthonous"/>
   <result pre="an unexpected emerging arboviral diseaseJ. Infect.72201650752426940504 8VenturiG.ZammarchiL.FortunaC.RemoliM.E.BenedettiE.An autochthonous case of" exact="Zika" post="due to possible sexual transmission, Florence, Italy, 2014Euro Surveill.2120163014826939607"/>
   <result pre="2016MMWR Morb. Mortal. Wkly. Rep.65201637237427078057 10BesnardM.LastereS.TeissierA.Cao-LormeauV.MussoD.Evidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Euro Surveill.192014"/>
   <result pre="2013 and February 2014Euro Surveill.192014 11LesslerJ.OttC.T.CarcelenA.C.KonikoffJ.M.WilliamsonJ.Times to key events in" exact="Zika" post="virus infection and implications for blood donation: a systematic"/>
   <result pre="a completed outbreakLancet Infect. Dis.182018e172e18229150310 13Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet38720161531153926948433 14BrasilP.PereiraJ.P.JrMoreiraM.E.Ribeiro"/>
   <result pre="as a diagnostic biomarkerAntiviral Res.98201319220823523765 30LesslerJ.ChaissonL.H.KucirkaL.M.BiQ.GrantzK.Assessing the global threat from" exact="Zika" post="virusScience3532016aaf8160 31BlitvichB.J.ScanlonD.ShiellB.J.MackenzieJ.S.PhamK.Determination of the intramolecular disulfide bond arrangement and"/>
   <result pre="293T cell linesJ. Virol. Methods1422007678017331594 56AlconS.TalarminA.DebruyneM.FalconarA.DeubelV.Enzyme-linked immunosorbent assay specific to" exact="Dengue" post="virus type 1 nonstructural protein NS1 reveals circulation of"/>
   <result pre="between nonstructural protein 1 detection and plasma virus load in" exact="Dengue" post="patientsAm. J. Trop. Med. Hyg.83201069669920810841 58ZhuJ.Mammalian cell protein expression"/>
   <result pre="in human umbilical vein endothelial cellsViruses102018 73ChiramelA.I.BestS.M.Role of autophagy in" exact="Zika" post="virus infection and pathogenesisVirus Res.2542018344028899653 74GrattonR.AgrelliA.TricaricoP.M.BrandaoL.CrovellaS.Autophagy in Zika Virus"/>
   <result pre="autophagy in Zika virus infection and pathogenesisVirus Res.2542018344028899653 74GrattonR.AgrelliA.TricaricoP.M.BrandaoL.CrovellaS.Autophagy in" exact="Zika" post="Virus Infection: A Possible Therapeutic Target to Counteract Viral"/>
   <result pre="for his help during lentiviral transduction sessions and for providing" exact="ZIKV" post="infected patients sera. The work described in this article"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7041325\results\search\tropicalVirus\results.xml">
   <result pre="such as dengue virus, chikungunya virus, yellow fever virus, and" exact="Zika" post="virus, was for a long time restricted by geographical,"/>
   <result pre="for example, dengue virus, chikungunya virus, yellow fever virus, and" exact="Zika" post="virus, which cause heavy health burden and economic losses"/>
   <result pre="four dengue virus serotypes, yellow fever virus, chikungunya virus, and" exact="Zika" post="virus and suggested to be potential vectors of Venezuelan"/>
   <result pre="including dengue, yellow fever, chikungunya, Rift Valley fever, Japanese encephalitis," exact="West Nile," post="and Sindbis viruses (Gubler and Rosen 1976, Savage et"/>
   <result pre="that Ae. albopictus has become a more effective vector for" exact="CHIKV" post="and is currently able to cause disease within a"/>
   <result pre="be responsible for the increased adaptability and improved transmission of" exact="CHIKV" post="by Ae. albopictus compared with Ae. aegypti (Tsetsarkin et"/>
   <result pre="demonstrate that Ae. albopictus and Ae. aegypti, when coinfected with" exact="DENV" post="and CHIKV, are able to replicate and disseminate both"/>
   <result pre="for example, the susceptibility of subpopulations from Ae. aegypti to" exact="DENV" post="serotype 2 (Failloux et al. 2002). This discovery may"/>
   <result pre="varying insecticide resistance levels, genetic markers, and vector competence for" exact="DENV" post="revealed the possibility of transmitting characteristics from one mosquito"/>
   <result pre="for example, chikungunya fever in Italy in 2007, outbreaks of" exact="West Nile" post="fever in the United States in 1999 and Greece"/>
   <result pre="the Black Sea region increases risk of chikungunya, dengue, and" exact="Zika" post="outbreaks in Europe. PLoS Negl Trop Dis2016; 10:e000466427115737 AlmeidaA,"/>
   <result pre="8:255–26524258900 DutraHLC, RochaMN, DiasFBS, MansurSB, et al.Wolbachia blocks currently circulating" exact="Zika" post="virus isolates in Brazilian Aedes aegypti mosquitoes. Cell Host"/>
   <result pre="et al.First detection of natural infection of Aedes aegypti with" exact="Zika" post="virus in Brazil and throughout South America. Mem Inst"/>
   <result pre="Salud Publica2006; 20:407–41517341332 HapuarachchiH, BandaraK, SumanadasaS, HapugodaM, et al.Re-emergence of" exact="Chikungunya" post="virus in South-east Asia: Virological evidence from Sri Lanka"/>
   <result pre="Dis2010; 4:e646 LanciottiR, RoehrigJ, DeubelV, SmithJ, et al.Origin of the" exact="West Nile" post="virus responsible for an outbreak of encephalitis in the"/>
   <result pre="VazeilleM, FaillouxABRecently introduced Aedes albopictus in Corsica is competent to" exact="Chikungunya" post="virus and in a lesser extent to dengue virus."/>
   <result pre="J Trop Med Hyg2004; 71:506–51315516650 PapaA, XanthopoulouK, GewehrS, MourelatosSDetection of" exact="West Nile" post="virus lineage 2 in mosquitoes during a human outbreak"/>
   <result pre="the potential of North American mosquitoes (Diptera: Culicidae) to transmit" exact="West Nile" post="virus. J Med Entomol2005; 42:57–6215691009 ValerioL, MariniF, BongiornoG, FacchinelliL,"/>
   <result pre="Stegomyia fasciata to Releasing Wolbachia pipientis: Australian Research on the" exact="Dengue" post="Virus Vector, Aedes aegypti, and Development of Novel Strategies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7044130\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.3389/fmicb.2020.00214 : Microbiology: Original Research The Mechanism of the" exact="Zika" post="Virus Crossing the Placental Barrier and the Blood-Brain Barrier"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Zika" post="virus (ZIKV) infection causes severe neurological symptoms in adults"/>
   <result pre="brain of microcephaly and meningoencephalitis patient. However, the mechanism of" exact="ZIKV" post="crossing the physiological barrier to the central nervous systems"/>
   <result pre="in vitro models of the physiological barriers. Results showed that" exact="ZIKV" post="could infect JEG-3 cells effectively and reduce the amounts"/>
   <result pre="the permeability of the barrier differentially changed in response to" exact="ZIKV" post="infection, allowing the virus particle to cross the host"/>
   <result pre="the virus particle to cross the host barrier. In contrast," exact="ZIKV" post="could infect hCMEC/D3 cells without disrupting the BBB barrier"/>
   <result pre="expression. Although no disruption to the BBB was observed during" exact="ZIKV" post="infection, ZIKV particles were released on the basal side"/>
   <result pre="no disruption to the BBB was observed during ZIKV infection," exact="ZIKV" post="particles were released on the basal side of the"/>
   <result pre="and infected underlying cells. In addition, we observed that fluorescence-labeled" exact="ZIKV" post="particles could cross the in vitro placenta barrier and"/>
   <result pre="low temperature or pharmacological inhibitors of endocytosis. In summary, the" exact="ZIKV" post="uses a cell-type specific paracellular pathway to cross the"/>
   <result pre="monolayer barrier by disrupting cellular tight junction. In addition, the" exact="ZIKV" post="can also cross both the placenta barrier and the"/>
   <result pre="into on the mechanism of the cellular barrier penetration of" exact="ZIKV" post="particles. Zika virus placental barrier blood-brain barrier tight junction"/>
   <result pre="the mechanism of the cellular barrier penetration of ZIKV particles." exact="Zika" post="virus placental barrier blood-brain barrier tight junction transcytosis single-virus"/>
   <result pre="ZO-1 Occludin fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction The" exact="Zika" post="virus (ZIKV), first isolated from the rhesus monkey in"/>
   <result pre="Flaviviridae family, which also include the dengue virus (DENV), the" exact="West Nile" post="virus (WNV), the Japanese encephalitis viruses (JEV) and the"/>
   <result pre="(JEV) and the yellow fever virus (YFV). Until 2015, most" exact="ZIKV" post="infections were deemed as a mild illness with some"/>
   <result pre="conjunctivitis (Petersen et al., 2016). However, based on recent epidemics," exact="ZIKV" post="infection in adult is associated with the Guillain-Barre’ syndrome"/>
   <result pre="al., 2016; Soares et al., 2016). Moreover, vertical transmission of" exact="ZIKV" post="from mother to fetus is linked to the elevating"/>
   <result pre="fetus is linked to the elevating incidences of the congenital" exact="Zika" post="syndrome on fetuses including microcephaly, congenital malformation, and fetal"/>
   <result pre="2018). For those infants born with a normal head, congenital" exact="ZIKV" post="infection may also cause developed postnatal-onset microcephaly, joint disorders,"/>
   <result pre="2018). These studies revealed a wide-spectrum of effects that congenital" exact="ZIKV" post="infection has on fetuses, strongly suggesting the importance of"/>
   <result pre="transmission. To reach the fetus brain from the infected mother," exact="ZIKV" post="needs to pass two major physiological barriers, the placenta"/>
   <result pre="recent studies reported that no barrier disruption was observed when" exact="ZIKV" post="gained access to the CNS (Papa et al., 2017;"/>
   <result pre="suggesting that the endocytic transport system is required for the" exact="ZIKV" post="to cross the BBB barrier. Given the existence of"/>
   <result pre="limit pathogen paracellular movement under the normal condition. However, the" exact="ZIKV" post="could be detected in the brains of microcephalic infants,"/>
   <result pre="detected in the brains of microcephalic infants, suggesting that the" exact="ZIKV" post="can penetrate the CNS in fetus (Calvet et al.,"/>
   <result pre="cytomegalovirus (CMV), the Human immunodeficiency virus type 1 (HIV-1), the" exact="West Nile" post="virus (WNV), the Japanese encephalitis virus (JEV), and herpes"/>
   <result pre="through the paracellular pathway but also through transcytosis. Although the" exact="ZIKV" post="is detected in both the amniotic fluid of pregnant"/>
   <result pre="single-virus tracking (SVT) approach to elucidate the mechanism that the" exact="ZIKV" post="employs to cross the placental and the BBB barriers."/>
   <result pre="penicillin/streptomycin. All cells were incubated at 37°C with 5% CO2." exact="ZIKV" post="Amplification The ZIKV strain PRVABC59 (2015 Puerto Rico strain,"/>
   <result pre="were incubated at 37°C with 5% CO2. ZIKV Amplification The" exact="ZIKV" post="strain PRVABC59 (2015 Puerto Rico strain, GenBank accession: KU501215)"/>
   <result pre="was propagated in Vero E6 cells. Cells were exposed to" exact="ZIKV" post="with multiplicity of infection (MOI) of 0.02 in a"/>
   <result pre="ZIKV-containing supernatant was stored at −80°C. Immunofluorescence Microscopy Imaging For" exact="ZIKV" post="infection assays, JEG-3 and hCMEC/D3 cells were seeded on"/>
   <result pre="by 0.1% Triton X-100 in PBS. The expression of the" exact="ZIKV" post="E protein was recognized by a 1:100 diluted rabbit"/>
   <result pre="vitro Transwell Barrier Assay To assess the ability of the" exact="ZIKV" post="crossing the barrier in vitro, the virus was added"/>
   <result pre="Transwell insert after the barrier cells were exposed to the" exact="ZIKV" post="for 24 h. The cells were seeded on the"/>
   <result pre="Reverse: 5′- CTCTAGGTGCCTGTTCGTAACGT-3′), Occludin (Forward: 5′- TCAGGGAATATCCACCTATCACTTCAG-3′; Reverse: 5′- CATCAGCAGCAGCCATGTACTCTTCAC-3′)," exact="ZIKV" post="E protein (Forward: 5′- AAGTACACATACCAAAACAAAGTGGT-3′; Reverse: 5′- TCCGCTCCCCCTTTGGTCTTG-3′), and"/>
   <result pre="at 95°C and 30 s at 60°C. Preparation of Fluorescence-Labeled" exact="ZIKV" post="Particles The procedure of virus labeling was performed as"/>
   <result pre="previously described with minor modifications (Chu et al., 2014, 2019)." exact="ZIKV" post="particles were pelleted from a ZIKV-containing supernatant by ultra-centrifugation"/>
   <result pre="and further concentrated by ultrafiltration spin columns (GE healthcare). Concentrated" exact="ZIKV" post="particles were labeled with Atto647N-NHS ester (Sigma-Aldrich), with maximum"/>
   <result pre="maximum emission at 664 nm. Briefly, 1 × 107pfu/ml of" exact="ZIKV" post="were mixed with 2 nmol of Atto 647N NHS"/>
   <result pre="at room temperature. The unincorporated dye was separated from fluorescence-labeled" exact="ZIKV" post="particles by a Sephadex G-25 column (GE Healthcare). The"/>
   <result pre="a Sephadex G-25 column (GE Healthcare). The fractions containing Atto647N-labeling" exact="ZIKV" post="were detected by a multimode microplate reader (TECAN 200/200Pro)"/>
   <result pre="PBS and were infected with 10-fold serial dilutions of the" exact="ZIKV" post="at 37°C with 5% CO2 for 2 h. Afterward,"/>
   <result pre="∗∗p &amp;lt; 0.01, ∗∗∗p &amp;lt; 0.001, ****p &amp;lt; 0.0001. Results" exact="ZIKV" post="Infects Both JEG-3 Cells and hCMEC/D3 Cells With No"/>
   <result pre="Effect on Cell Viability To investigate the mechanism of the" exact="ZIKV" post="crossing the placental barrier and the BBB, we infected"/>
   <result pre="et al., 2017). To first clarify the infectivity of the" exact="ZIKV" post="in JEG-3 and hCMEC/D3 cells, the viral envelop (E)"/>
   <result pre="anti-ZIKV E protein antibody at 24 h post-infection. Apparently, the" exact="ZIKV" post="E protein was detected in both cell lines in"/>
   <result pre="cells could be elevated as MOI increased (Figure 1B). The" exact="ZIKV" post="infected more than 80% cells at a MOI of"/>
   <result pre="post-infection (Figure 1C). FIGURE 1 The infectivity and virulence of" exact="ZIKV" post="in JEG-3 and hCMEC/D3 cells. (A) The immunofluorescence images"/>
   <result pre="in JEG-3 and hCMEC/D3 cells. (A) The immunofluorescence images of" exact="ZIKV" post="E protein revealed the population of ZIKV-infected cells in"/>
   <result pre="(MOI of 1 to 10) at 24 h post-infection. The" exact="ZIKV" post="E protein antibody was recognized by an Alex488-secondary antibody"/>
   <result pre="cells was quantified from (A). (C) JEG-3 cells were infected" exact="ZIKV" post="at MOI of 0.5 to 1, and hCMEC/D3 cells"/>
   <result pre="MOI of 0.5 to 1, and hCMEC/D3 cells were infected" exact="ZIKV" post="at MOI of 5 to 10 during 24 h."/>
   <result pre="of 5 to 10 during 24 h. The virulence of" exact="ZIKV" post="in JEG-3 and hCMEC/D3 was measured by a cell"/>
   <result pre="were obtained through t-tests. **p &amp;lt; 0.01; ***p &amp;lt; 0.001." exact="ZIKV" post="Crosses an In vitro Human Physiological Barrier Model Next,"/>
   <result pre="an in vitro Transwell barrier assay to investigate whether the" exact="ZIKV" post="can cross barrier cells. As shown in Figure 2A,"/>
   <result pre="plate containing pre-seed adherent Vero cells in the basal chamber." exact="ZIKV" post="was added on the top of the inserts at"/>
   <result pre="top of the inserts at a MOI of 0.5. If" exact="ZIKV" post="particles could cross barrier cells, they would exist in"/>
   <result pre="chamber and infect into Vero cells. The existence of the" exact="ZIKV" post="in Vero cells was detected by immunostaining using an"/>
   <result pre="anti-ZIKV E protein antibody. The results showed clearly that the" exact="ZIKV" post="E protein could be detected in Vero cells in"/>
   <result pre="as barrier cells (Figure 2B). These results indicated that the" exact="ZIKV" post="could cross the human physiological barrier cells. It is"/>
   <result pre="the human physiological barrier cells. It is possible for the" exact="ZIKV" post="to cross barrier cells by altering the permeability of"/>
   <result pre="added in the apical chamber after 24 h post-infection. If" exact="ZIKV" post="infection could alter cell permeability, the signal of FITC-dextran"/>
   <result pre="detected in the basal chamber. Compared with the mock group," exact="ZIKV" post="infection did increase FITC-dextran signal significantly when JEG-3 cells"/>
   <result pre="used as a positive control. These results suggested that the" exact="ZIKV" post="may cross the placenta barrier by changing the permeability"/>
   <result pre="changing the permeability of the barrier cells. In contrast, the" exact="ZIKV" post="crosses the BBB barrier cells but does not change"/>
   <result pre="barrier cells (Figures 2B,C), suggesting no barrier leakage when the" exact="ZIKV" post="crossed the BBB. FIGURE 2 ZIKV crossed in vitro"/>
   <result pre="barrier leakage when the ZIKV crossed the BBB. FIGURE 2" exact="ZIKV" post="crossed in vitro human physiological barriers. (A) A schematic"/>
   <result pre="in vitro barrier cells. (B) The immunofluorescence images of the" exact="ZIKV" post="E protein revealed ZIKV-infected Vero cells cultured in a"/>
   <result pre="barrier at MOI of 10 at 24 h post-infection. The" exact="ZIKV" post="E protein antibody was recognized by an Alex488-secondary antibody"/>
   <result pre="control. The permeability of an hCMEC/D3 barrier at 24 h" exact="ZIKV" post="post-infection was measured in (D). The error bars represent"/>
   <result pre="experiments. *p &amp;lt; 0.05; **p &amp;lt; 0.01; ****p &amp;lt; 0.0001." exact="ZIKV" post="Down-Regulated the Expression of Tight Junction Protein Through a"/>
   <result pre="Pathway Given that the leakage of FITC-dextran was increased by" exact="ZIKV" post="infection in the in vitro placenta barrier model but"/>
   <result pre="ZO-1 and occludin in JEG-3 cells in the presence of" exact="ZIKV" post="infection compared to that in the mock control group"/>
   <result pre="3B). To further confirm the disruption of tight junction by" exact="ZIKV" post="infection in JEG-3 cells, the distribution of ZO-1 and"/>
   <result pre="formed continuous seals between adjacent cells in the absence of" exact="ZIKV" post="infection (Figure 3C). In contrast, ZIKV infection disrupted the"/>
   <result pre="in the absence of ZIKV infection (Figure 3C). In contrast," exact="ZIKV" post="infection disrupted the continuity of occludin and ZO-1 in"/>
   <result pre="measuring the branch length of segments. The results demonstrated that" exact="ZIKV" post="infection declined the integrity of tight junction of JEG-3"/>
   <result pre="junction of JEG-3 cells (Figure 3C, right panel). FIGURE 3" exact="ZIKV" post="infection decreased expression of the tight junction protein ZO-1"/>
   <result pre="ZO-1 and Occludin were not affected in hCMEC/D3 cells with" exact="ZIKV" post="infection. The amount of ZO-1 and Occludin was normalized"/>
   <result pre="The distribution of ZO-1 and Occludin in JEG-3 cells with/without" exact="ZIKV" post="infection were imaged by confocal microscopy. The white arrows"/>
   <result pre="JEG-3 and hCMEC/D3 cells in the absence or presence of" exact="ZIKV" post="infection were determined by RT-qPCR. The results of RT-qPCR"/>
   <result pre="and occludin in both JEG-3 and hCMEC/D3 cells regardless of" exact="ZIKV" post="infection (Figures 4A,B). These data suggested that the down"/>
   <result pre="at the post-transcription level. To confirm this speculation, prior to" exact="ZIKV" post="infection, JEG-3 cells were treated individually by a series"/>
   <result pre="Figure 4C, the expression of ZO-1 and occludin repressed by" exact="ZIKV" post="infection could be notably rescued only by MG132, a"/>
   <result pre="of autophagosomes and lysosomes. Taken together, these results demonstrated that" exact="ZIKV" post="infection causes the leakage of the placenta barrier through"/>
   <result pre="cellular tight junction via the proteasomal degradation pathway. FIGURE 4" exact="ZIKV" post="infection decreased the accumulation of tight junction proteins through"/>
   <result pre="levels of ZO-1, Occludin and ZIKV-E in JEG-3 cells upon" exact="ZIKV" post="infection were quantified by RT-qPCR. Data were normalized by"/>
   <result pre="mRNA levels of ZO-1, Occludin and ZIKV-E in hCMEC/D3 upon" exact="ZIKV" post="infection are shown in (B). The error bars represent"/>
   <result pre="and Occludin in JEG-3 cells with various inhibitors treatments upon" exact="ZIKV" post="infection. The amount of ZO-1 and Occludin was normalized"/>
   <result pre="three independent experiments. *p &amp;lt; 0.05. Visualization of Transcytosis of" exact="ZIKV" post="It has been reported that transcytosis, a series action"/>
   <result pre="like to conduct a single-virus imaging analysis to investigate whether" exact="ZIKV" post="particle can also cross barriers cells by transcytosis in"/>
   <result pre="transcytosis in in vitro Transwell barrier models. To visualize single" exact="ZIKV" post="particles directly, ZIKV particles were labeled with a fluorescence"/>
   <result pre="vitro Transwell barrier models. To visualize single ZIKV particles directly," exact="ZIKV" post="particles were labeled with a fluorescence dye, atto647N, by"/>
   <result pre="the amino group of the viral envelope protein. The atto647N-labeled" exact="ZIKV" post="particles were purified through a Sephadex G-25 size-exclusion column."/>
   <result pre="6 to Fraction 10 (Figure 5A, solid squares) indicated atto647N-labeled" exact="ZIKV" post="particles (atto647N-ZIKV) because the diameter of a single ZIKV"/>
   <result pre="atto647N-labeled ZIKV particles (atto647N-ZIKV) because the diameter of a single" exact="ZIKV" post="particle is approximately 50 nm (Sirohi et al., 2016;"/>
   <result pre="detected within the same range of fractions from the Dye-free" exact="ZIKV" post="group (Figure 5A, solid triangles). These results confirmed a"/>
   <result pre="5A, solid triangles). These results confirmed a successful conjugation of" exact="ZIKV" post="particles with atto647N. The infectivity of atto647N-ZIKV particles was"/>
   <result pre="particles was then measured by a plaque assay. Both dye-free" exact="ZIKV" post="and atto647N-ZIKV presented similar virus titers, suggesting no significant"/>
   <result pre="atto647N-ZIKV presented similar virus titers, suggesting no significant influence on" exact="ZIKV" post="infectivity by the atto647N labeling procedure (Figure 5B). FIGURE"/>
   <result pre="the atto647N labeling procedure (Figure 5B). FIGURE 5 Detection of" exact="ZIKV" post="transcytosis. (A) Fluorescence intensity profiles of elution from a"/>
   <result pre="filtration (solid squares). No fluorescence signal was detected in Atto647N-free" exact="ZIKV" post="(solid triangles) within the same fraction layers. The 40"/>
   <result pre="were performed to determine the infectivity of the Atto647N-ZIKV. Dye-free" exact="ZIKV" post="was used as a control. Both virus samples were"/>
   <result pre="Transwell barrier assay, we would like to investigate whether the" exact="ZIKV" post="can penetrate a monolayer of barrier cells at 4°C"/>
   <result pre="4°C and 37°C (Figure 5D). These results implied that the" exact="ZIKV" post="can cross monolayers of either JEG-3 or hCMEC/D3 cells"/>
   <result pre="through a temperature-dependent transcytosis. To directly visualize the transcytosis of" exact="ZIKV" post="particle across a monolayer of barrier cells, we infected"/>
   <result pre="observed in hCMEC/D3 monolayers (Figure 6B). These results elucidated that" exact="ZIKV" post="particles might be directly transported across the monolayer of"/>
   <result pre="without undergoing the viral replication process. FIGURE 6 Visualization of" exact="ZIKV" post="transcytosis. The ZX images of confocal microscopy depicted the"/>
   <result pre="A), and cell membrane was stained by WGA488 (green) (A,B)." exact="ZIKV" post="Transport Can Be Blocked by Endocytosis and Microtubule Inhibitors"/>
   <result pre="vesicle-mediated endocytosis and macropinocytosis. To further examine endocytic pathways for" exact="ZIKV" post="entrance into barrier cells, we pretreated barrier cells with"/>
   <result pre="(Figure 7C), suggesting that endocytosis might be essential for the" exact="ZIKV" post="to cross the monolayer of barrier cells. In addition,"/>
   <result pre="ZIKV. To further quantify the effect of inhibitors on the" exact="ZIKV" post="crossing barrier cells, the titers of ZIKV isolated from"/>
   <result pre="inhibitors on the ZIKV crossing barrier cells, the titers of" exact="ZIKV" post="isolated from the basal chamber 3 h post-infection were"/>
   <result pre="suggested that transcytosis may be an important pathway for the" exact="ZIKV" post="to cross the placental barrier and the BBB. FIGURE"/>
   <result pre="to cross the placental barrier and the BBB. FIGURE 7" exact="ZIKV" post="transcytosis across JEG-3 and hCMEC/D3 barriers can be reduced"/>
   <result pre="Discussion In this study we investigated the pathways for the" exact="ZIKV" post="crossing the endothelial cell monolayer of both the placenta"/>
   <result pre="Using fluorescence-tagged dextran as an indicator, our results revealed that" exact="ZIKV" post="infection enhanced cellular permeability in JEG-3 cells but not"/>
   <result pre="cells but not in hCMEC/D3 cells. Moreover, in JEG-3 cells," exact="ZIKV" post="infection reduces the amount of tight junction proteins, ZO-1"/>
   <result pre="resulting in disruption of tight junction. In contrast, using fluorescence-labeled" exact="ZIKV" post="particles and pharmacological inhibitors of endocytosis, we demonstrated transcytosis"/>
   <result pre="endocytosis, we demonstrated transcytosis as an additional pathway for the" exact="ZIKV" post="crossing the monolayer of JEG-3 and hCMEC/D3. As summarized"/>
   <result pre="summarized in Figure 8, our current study elucidated that the" exact="ZIKV" post="uses a cell-type specific paracellular pathway to cross the"/>
   <result pre="monolayer barrier by disrupting cellular tight junction. In addition, the" exact="ZIKV" post="can also cross both the placenta barrier and the"/>
   <result pre="present study provides new insights on cellular barrier penetration of" exact="ZIKV" post="particles, which may facilitate the development of anti-ZIKV agents"/>
   <result pre="FIGURE 8 A schematic diagram depicts the mechanism of the" exact="ZIKV" post="crossing human physiological barriers. In the placenta barrier, ZIKV"/>
   <result pre="the ZIKV crossing human physiological barriers. In the placenta barrier," exact="ZIKV" post="infection can lead to disruption of tight junction that"/>
   <result pre="lead to disruption of tight junction that results in the" exact="ZIKV" post="crossing through the leakage of tight junction. In addition,"/>
   <result pre="crossing through the leakage of tight junction. In addition, the" exact="ZIKV" post="can also transport from the apical side to the"/>
   <result pre="the transcytosis pathway (top panel). In the blood-brain barrier, the" exact="ZIKV" post="can transport from the apical side to the basolateral"/>
   <result pre="(bottom panel). Several lines of evidence showed the existence of" exact="ZIKV" post="antigens in the chronic villi of a human placenta"/>
   <result pre="infant with microcephaly (Calvet et al., 2016), and isolation of" exact="ZIKV" post="RNA from placental tissue of mice infected with the"/>
   <result pre="ZIKV RNA from placental tissue of mice infected with the" exact="ZIKV" post="(Caine et al., 2018), suggesting that the ZIKV may"/>
   <result pre="with the ZIKV (Caine et al., 2018), suggesting that the" exact="ZIKV" post="may penetrate the placental barrier to infect the infant"/>
   <result pre="to infect the infant brain. Recent studies reported that the" exact="ZIKV" post="is able to infect and replicate in Hofbauer cells"/>
   <result pre="in cytotrophoblasts, suggesting a route of intrauterine transmission that the" exact="ZIKV" post="crosses the fetal compartment by directly infecting the placental"/>
   <result pre="et al., 2016). In this study, we revealed that the" exact="ZIKV" post="could cross the placenta barrier with both paracellular and"/>
   <result pre="respectively (Mateo et al., 2015). However, our data revealed that" exact="ZIKV" post="infection causes leakage of the placental barrier by disrupting"/>
   <result pre="al., 2016), our results proposed a paracellular pathway for the" exact="ZIKV" post="crossing the placental barrier by disrupting the cellular tight"/>
   <result pre="occludin. The activation mechanism of the proteasomal degradation pathway by" exact="ZIKV" post="infection remains to be further investigated. Using a SVT"/>
   <result pre="a SVT approach, we provided evidence to elucidate that the" exact="ZIKV" post="can cross the in vitro placenta model through transcytosis"/>
   <result pre="Story, 1997; Palmeira et al., 2012), Matthew al. showed that" exact="DENV" post="cross-reactive mAbs bound to the ZIKV undergo FcRn-mediated transcytosis"/>
   <result pre="Matthew al. showed that DENV cross-reactive mAbs bound to the" exact="ZIKV" post="undergo FcRn-mediated transcytosis across the placenta to productively infect"/>
   <result pre="macrophages (Zimmerman et al., 2018). In the current study, the" exact="ZIKV" post="crossing the placenta barrier cells was directly visualized by"/>
   <result pre="newly produced viral particles after replication. Moreover, the action of" exact="ZIKV" post="transcytosis could be inhibited by treatments with endocytosis inhibitors"/>
   <result pre="the paracellular pathway and the transcytosis pathway are utilized by" exact="ZIKV" post="to cross the placenta barrier (Figure 8, top panel)."/>
   <result pre="Further studies will be needed in order to illustrate how" exact="ZIKV" post="particles select a pathway to cross the placenta barrier"/>
   <result pre="placenta barrier and whether they require a specific receptor for" exact="ZIKV" post="to interact with. In addition to the placenta barrier,"/>
   <result pre="transcytosis (Mustafa et al., 2019). In the current study, the" exact="ZIKV" post="can cross brain endothelial cells and release of infectious"/>
   <result pre="7). This is in agreement with previous studies showing the" exact="ZIKV" post="crosses the BBB monolayer without the BBB barrier disruption"/>
   <result pre="permeability. Furthermore, although in vivo experiment models proposed that the" exact="ZIKV" post="crosses the BBB with no severe disruption, barrier breakdown"/>
   <result pre="at a later post-infection time (Papa et al., 2017). Because" exact="ZIKV" post="infection may recruit leukocyte to the brain and induce"/>
   <result pre="response rather than ZIKV-induced proteasomal degradation. Understanding the pathways for" exact="ZIKV" post="passing through physiological barriers, the placental barrier and the"/>
   <result pre="the BBB, furthers our understanding of the pathophysiology of the" exact="ZIKV" post="and provides a basis for developing anti-ZIKV drugs in"/>
   <result pre="in a paracellular pathway for the maternal-fetal transmission of the" exact="ZIKV" post="by disrupting tight junction proteins (Figures 2–4), it may"/>
   <result pre="evidence that transcytosis may be a common strategy for the" exact="ZIKV" post="to cross both the placental barrier and the BBB"/>
   <result pre="it may not be a good druggable target to treat" exact="ZIKV" post="infection. Therefore, further studies to reveal whether there is"/>
   <result pre="to reveal whether there is a specific interaction of the" exact="ZIKV" post="with the transcytosis machine will facilitate the development of"/>
   <result pre="(108DN01) to Y-HP. We are thankful to Taiwan CDC for" exact="Zika" post="virus (PRVABC59 strains). We also thank Dr. Janice Fon"/>
   <result pre="editing this article. References References AlimontiJ. B.Ribecco-LutkiewiczM.SodjaC.JezierskiA.StanimirovicD. B.LiuQ.et al. (2018)." exact="Zika" post="virus crosses an in vitro human blood brain barrier"/>
   <result pre="E.CalvetG. A.De SouzaR. V.et al. (2016). Guillain-Barre syndrome associated with" exact="Zika" post="virus infection.Lancet387:1482. BurtonG. J.FowdenA. L. (2015). The placenta: a"/>
   <result pre="S. O.SampaioS. A.De FilippisI.FabriA.et al. (2016). Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="al. (2014). Single-virus tracking approach to reveal the interaction of" exact="Dengue" post="virus with autophagy during the early stage of infection.J."/>
   <result pre="CordeiroM. T.PenaL. J.BritoC. A.GilL. H.MarquesE. T. (2016). Positive IgM for" exact="Zika" post="virus in the cerebrospinal fluid of 30 neonates with"/>
   <result pre="neonates with microcephaly in Brazil.Lancet3871811–1812. 10.1016/s0140-6736(16)30253-7 CoyneC. B.LazearH. M. (2016)." exact="Zika" post="virus - reigniting the TORCH.Nat. Rev. Microbiol.14707–715. 10.1038/nrmicro.2016.12527573577 DanemanR.PratA."/>
   <result pre="viral infections.Annu. Rev. Virol.1133–146. 10.1146/annurev-virology-031413-08552426958718 DickG. W.KitchenS. F.HaddowA. J. (1952)." exact="Zika" post="virus. i. isolations and serological specificity.Trans. R. Soc. Trop."/>
   <result pre="Trop. Med. Hyg.46509–520. 10.1016/0035-9203(52)90042-412995440 Dos SantosT.RodriguezA.AlmironM.SanhuezaA.RamonP.De OliveiraW. K.et al. (2016)." exact="Zika" post="virus and the guillain-barre syndrome - case series from"/>
   <result pre="Biophys. Acta1778660–669. 10.1016/j.bbamem.2007.07.01217854762 HoenB.SchaubB.FunkA. L.ArdillonV.BoullardM.CabieA.et al. (2018). Pregnancy outcomes after" exact="ZIKV" post="infection in french territories in the americas.N. Engl. J."/>
   <result pre="components.J. Cell Sci.128431–439. 10.1242/jcs.15940026046138 MittalR.NguyenD.DebsL. H.PatelA. P.LiuG.JhaveriV. M.et al. (2017)." exact="Zika" post="virus: an emerging global health threat.Front. Cell Infect. Microbiol.7:486."/>
   <result pre="global health threat.Front. Cell Infect. Microbiol.7:486. 10.3389/fcimb.2017.0048629276699 MlakarJ.KorvaM.TulN.PopovicM.Poljsak-PrijateljM.MrazJ.et al. (2016)." exact="Zika" post="virus associated with microcephaly.N. Engl. J. Med.374951–958. 10.1056/NEJMoa160065126862926 MoradG.CarmanC."/>
   <result pre="P.MeurenL. M.CoelhoS. V. A.LucasC. G. O.MustafaY. M.Lemos MatassoliF.et al. (2017)." exact="Zika" post="virus infects, activates, and crosses brain microvascular endothelial cells,"/>
   <result pre="barrier disruption.Front. Microbiol.8:2557. 10.3389/fmicb.2017.0255729312238 PetersenL. R.JamiesonD. J.PowersA. M.HoneinM. A. (2016)." exact="Zika" post="virus.N. Engl. J. Med.3741552–1563.27028561 QuickeK. M.BowenJ. R.JohnsonE. L.McdonaldC. E.MaH.O’NealJ."/>
   <result pre="J. Med.3741552–1563.27028561 QuickeK. M.BowenJ. R.JohnsonE. L.McdonaldC. E.MaH.O’NealJ. T.et al. (2016)." exact="Zika" post="virus infects human placental macrophages.Cell Host Microbe2083–90. 10.1016/j.chom.2016.05.01527247001 RoeK.KumarM.LumS.OrilloB.NerurkarV."/>
   <result pre="G.et al. (2016). The 3.8 A resolution cryo-EM structure of" exact="Zika" post="virus.Science352467–470. 10.1126/science.aaf531627033547 SoaresC. N.BrasilP.CarreraR. M.SequeiraP.De FilippisA. B.BorgesV. A.et al."/>
   <result pre="M.SequeiraP.De FilippisA. B.BorgesV. A.et al. (2016). Fatal encephalitis associated with" exact="Zika" post="virus infection in an adult.J. Clin. Virol.8363–65. 10.1016/j.jcv.2016.08.29727598870 StamatovicS."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7044319\results\search\tropicalVirus\results.xml">
   <result pre=": Article Complete Protection in Macaques Conferred by Purified Inactivated" exact="Zika" post="Vaccine: Defining a Correlate of Protection YoungGingerginger.young@takeda.com1BohningKelly J.1Zahralban-SteeleMelissa1HatherGreg2TadepalliSambasivarao3MickeyKristen4GodinC. Steven5SanisettySrisowmya1SonnbergStephanie1PatelHetal"/>
   <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract A critical global health need exists for a" exact="Zika" post="vaccine capable of mitigating the effects of future Zika"/>
   <result pre="a Zika vaccine capable of mitigating the effects of future" exact="Zika" post="epidemics. In this study we evaluated the antibody responses"/>
   <result pre="responses and efficacy of an aluminum hydroxide adjuvanted purified inactivated" exact="Zika" post="vaccine (PIZV) against challenge with Zika virus (ZIKV) strain"/>
   <result pre="hydroxide adjuvanted purified inactivated Zika vaccine (PIZV) against challenge with" exact="Zika" post="virus (ZIKV) strain PRVABC59. Indian rhesus macaques received two"/>
   <result pre="ranging from 0.016 µg − 10 µg and were subsequently challenged with" exact="ZIKV" post="six weeks or one year following the second immunization."/>
   <result pre="that was boosted by a second immunization. Complete protection against" exact="ZIKV" post="infection was achieved with the higher PIZV doses of"/>
   <result pre="Vaccines, Inc. Introduction In 2015 and 2016, large outbreaks of" exact="Zika" post="virus (ZIKV) occurred in the Americas. These outbreaks were"/>
   <result pre="of 7 infants born to pregnant women with laboratory confirmed" exact="Zika" post="in the US and US territories1. Incidence of ZIKV"/>
   <result pre="confirmed Zika in the US and US territories1. Incidence of" exact="ZIKV" post="infections subsequently declined in most of the Americas throughout"/>
   <result pre="Americas throughout 2017 and 20182. With the sporadic nature of" exact="ZIKV" post="outbreaks and a very low incidence of symptomatic disease"/>
   <result pre="in pregnant women demonstrate that the need for an effective" exact="Zika" post="vaccine remains. In such circumstances, alternative regulatory strategies such"/>
   <result pre="licensure3. Non-human primate studies have contributed to the development of" exact="ZIKV" post="vaccines by demonstrating protective efficacy and identifying biomarkers of"/>
   <result pre="that is reasonably likely to predict clinical benefit of several" exact="ZIKV" post="vaccines4,5. Indian rhesus macaques (Macaca mulatta) are susceptible to"/>
   <result pre="ZIKV vaccines4,5. Indian rhesus macaques (Macaca mulatta) are susceptible to" exact="ZIKV" post="infection and have been used extensively as a model"/>
   <result pre="been used extensively as a model to study efficacy of" exact="ZIKV" post="vaccines and pathogenesis of multiple ZIKV isolates6–10. ZIKV infection"/>
   <result pre="to study efficacy of ZIKV vaccines and pathogenesis of multiple" exact="ZIKV" post="isolates6–10. ZIKV infection can be performed by subcutaneous injection,"/>
   <result pre="efficacy of ZIKV vaccines and pathogenesis of multiple ZIKV isolates6–10." exact="ZIKV" post="infection can be performed by subcutaneous injection, which mimics"/>
   <result pre="via mosquito bite and causes consistent viremia11–15. The kinetics of" exact="ZIKV" post="infection are similar in rhesus macaques and humans where"/>
   <result pre="of infection and resolves within 10–14 days10,13,14. The purified inactivated" exact="Zika" post="vaccine (PIZV) has previously been evaluated in mouse models"/>
   <result pre="AG129 and CD1 mice and protected AG129 mice against lethal" exact="ZIKV" post="challenge16. In those studies, Baldwin et al. demonstrated that"/>
   <result pre="further evaluate immunogenicity and efficacy of PIZV, we conducted three" exact="ZIKV" post="challenge studies in rhesus macaques. In the first study,"/>
   <result pre="dose selection We conducted a challenge study to select a" exact="ZIKV" post="challenge dose that appropriately mimics human infection in Indian"/>
   <result pre="104 focus forming units (ffu; n = 2) or 105 ffu (n = 2)" exact="ZIKV" post="PRVABC59. Serum was collected daily for ZIKV RNA analysis"/>
   <result pre="105 ffu (n = 2) ZIKV PRVABC59. Serum was collected daily for" exact="ZIKV" post="RNA analysis by real-time quantitative RT-PCR (RT-qPCR), on days"/>
   <result pre="post-infection (dpi), and every other day from day 13–21 dpi." exact="Zika" post="viral RNA (vRNA) was detected above the assay lower"/>
   <result pre="of 4.8 and 5.0 log10 copies/mL, both on day 4." exact="Zika" post="vRNA was not detected above the assay LLOQ in"/>
   <result pre="vRNA per challenge dose and day post-challenge. Challenge Dose (ffu)" exact="Zika" post="vRNA (log10 copies/mL) Day 1 Day 2 Day 3"/>
   <result pre="UD UD UD 3.8 4.3 5.0 5.0 4.0 UD UD" exact="Zika" post="vRNA (log10 copies/mL) per day post-challenge for each individual"/>
   <result pre="vRNA (log10 copies/mL) per day post-challenge for each individual macaque." exact="Zika" post="vRNA for individual macaques was not quantified in the"/>
   <result pre="on day 71. Serum neutralizing antibodies were tested using a" exact="Zika" post="reporter virus particle (RVP) assay. All macaques were seronegative"/>
   <result pre="on day 1 and control macaques remained seronegative prior to" exact="ZIKV" post="challenge (Fig. 1). Twenty-eight days following the first vaccine"/>
   <result pre="(p = 0.037) compared to the 0.4 µg dose group. Titers prior to" exact="ZIKV" post="challenge on day 71 were slightly decreased compared to"/>
   <result pre="the level of neutralizing antibody was comparable to infection with" exact="ZIKV" post="challenge in the placebo group. The lack of anamnestic"/>
   <result pre="2, and 10 µg PIZV dose groups suggests that infection by" exact="ZIKV" post="challenge virus may have been prevented by vaccination. Figure"/>
   <result pre="vaccination. Figure 1 Neutralizing antibody titers following PIZV vaccination and" exact="ZIKV" post="challenge. Rhesus macaques were vaccinated on days 1 and"/>
   <result pre="days 1 and 29 and challenged on day 71. Individual" exact="Zika" post="RVP titers for each vaccine group on study day"/>
   <result pre="day 57 (28 days post-second dose), day 71 (prior to" exact="ZIKV" post="challenge), and day 101 (30 days post-ZIKV challenge). Mean"/>
   <result pre="anti-Zika IgG was detected in the control group prior to" exact="ZIKV" post="challenge. PIZV elicited dose-dependent anti-Zika IgG responses (Fig. 2)"/>
   <result pre="PIZV dose for all vaccinated groups (all p-values ≤0.001). Following" exact="ZIKV" post="challenge, the anti-Zika IgG responses increased significantly in the"/>
   <result pre="day 57 (28 days post-second dose), day 71 (prior to" exact="ZIKV" post="challenge), and day 101 (30 days post-ZIKV challenge). Mean"/>
   <result pre="shown for all groups and time points. PIZV protects against" exact="ZIKV" post="challenge Rhesus macaques were challenged subcutaneously on day 71"/>
   <result pre="the 0.4, 2, or 10 µg PIZV dose were protected against" exact="ZIKV" post="challenge, as no Zika vRNA could be quantified in"/>
   <result pre="10 µg PIZV dose were protected against ZIKV challenge, as no" exact="Zika" post="vRNA could be quantified in any of the macaques"/>
   <result pre="be quantified in any of the macaques in these groups." exact="Zika" post="vRNA was quantified in 3/6 macaques receiving the 0.08 µg"/>
   <result pre="macaques in the control group (Fig. 3). The peak post-challenge" exact="Zika" post="vRNA level decreased with increasing vaccine dose level. The"/>
   <result pre="vRNA level decreased with increasing vaccine dose level. The peak" exact="Zika" post="vRNA occurred on day 74 (3 days post-challenge), with"/>
   <result pre="challenge virus were seen throughout the studies. Figure 3 Post-challenge" exact="Zika" post="vRNA per group and study day. Zika vRNA (log10"/>
   <result pre="Figure 3 Post-challenge Zika vRNA per group and study day." exact="Zika" post="vRNA (log10 copies/mL) post-ZIKV challenge. Each line represents an"/>
   <result pre="(log10 copies/mL) post-ZIKV challenge. Each line represents an individual macaque." exact="Zika" post="vRNA levels below the LLOQ are plotted as half"/>
   <result pre="an anti-Zika IgG response which correlated with a reduction in" exact="ZIKV" post="vRNA post-challenge (Table 2). An immune correlate analysis was"/>
   <result pre="2). An immune correlate analysis was subsequently performed to correlate" exact="Zika" post="vRNA with neutralizing antibody titers (Fig. 4) and anti-Zika"/>
   <result pre="antibody titer of &amp;gt;3.02 log10 EC50, which conferred protection against" exact="ZIKV" post="serum viremia in Indian rhesus macaques. Due to overlap"/>
   <result pre="of protection. Table 2 Neutralizing antibody titers on day of" exact="ZIKV" post="challenge, Zika vRNA levels post-challenge. PIZV dose (µg) Mean"/>
   <result pre="Table 2 Neutralizing antibody titers on day of ZIKV challenge," exact="Zika" post="vRNA levels post-challenge. PIZV dose (µg) Mean neutralizing antibody"/>
   <result pre="neutralizing antibody titer (log10 EC50), day 71 Range of peak" exact="Zika" post="vRNA detection (log10 copies/mL) Percent macaques protected from ZIKV"/>
   <result pre="peak Zika vRNA detection (log10 copies/mL) Percent macaques protected from" exact="ZIKV" post="challenge 0 1.33 4.92–5.64 0 0.016 2.63 4.10–5.00 33"/>
   <result pre="post-ZIKV challenge (log10 copies/mL), and percent of macaques with quantifiable" exact="Zika" post="vRNA post-ZIKV challenge. All reported and analyzed data is"/>
   <result pre="of quantitation. Figure 4 Neutralizing antibody titers negatively correlate with" exact="Zika" post="vRNA peak value post-challenge. (a) Each point represents an"/>
   <result pre="and respective neutralizing antibody titer (log10 EC50) on day of" exact="ZIKV" post="challenge (day 71) and peak ZIKV vRNA concentration (log10"/>
   <result pre="EC50) on day of ZIKV challenge (day 71) and peak" exact="ZIKV" post="vRNA concentration (log10 copies/mL) post-ZIKV challenge. For each macaque,"/>
   <result pre="concentration (log10 copies/mL) post-ZIKV challenge. For each macaque, the maximum" exact="Zika" post="vRNA concentration observed over 10 days was plotted for"/>
   <result pre="vRNA concentration observed over 10 days was plotted for analysis." exact="Zika" post="vRNA levels below the LLOQ are plotted as half"/>
   <result pre="protection. Figure 5 Anti-Zika IgG antibody titers negatively correlate with" exact="Zika" post="vRNA post-challenge. (a) Each point represents an individual macaque."/>
   <result pre="Day 71 anti-Zika IgG and the peak vRNA concentration following" exact="ZIKV" post="challenge. Zika vRNA values below the LLOQ were replaced"/>
   <result pre="anti-Zika IgG and the peak vRNA concentration following ZIKV challenge." exact="Zika" post="vRNA values below the LLOQ were replaced by half"/>
   <result pre="PIZV on study days 1 and 29 and challenged with" exact="ZIKV" post="PRVABC59 on study day 371. Zika neutralizing antibody levels"/>
   <result pre="29 and challenged with ZIKV PRVABC59 on study day 371." exact="Zika" post="neutralizing antibody levels were measured every 28 days through"/>
   <result pre="through study day 365 (Fig. 6b). IgG titers increased following" exact="ZIKV" post="challenge. Figure 6 Long-term immunogenicity following PIZV vaccination. Both"/>
   <result pre="day 57 (28 days post-second dose), day 365 (prior to" exact="ZIKV" post="challenge), and day 401 (30 days post-ZIKV challenge). Each"/>
   <result pre="days post-ZIKV challenge). Each line represents an individual macaque. No" exact="Zika" post="vRNA was detected in serum from any of the"/>
   <result pre="was detected in serum from any of the macaques following" exact="ZIKV" post="challenge 1 year following the second dose. In addition,"/>
   <result pre="The combined results suggest that two doses of PIZV prevented" exact="ZIKV" post="infection 1 year post-vaccination. In conclusion, two 10 µg PIZV"/>
   <result pre="We demonstrated that PIZV elicits a dose-dependent response of both" exact="Zika" post="neutralizing and anti-Zika IgG antibodies. PIZV elicited neutralizing antibodies"/>
   <result pre="that persisted for at least 1 year and protected against" exact="ZIKV" post="challenge. Vaccinating with a broad range of PIZV dose"/>
   <result pre="both neutralizing and anti-Zika IgG antibody titers to protection against" exact="ZIKV" post="infection. We determined a neutralizing antibody correlate of protection"/>
   <result pre="using functional neutralizing antibodies as a correlate of protection for" exact="Zika" post="and other flaviviruses. Neutralizing antibodies directed against the envelope"/>
   <result pre="induction of ZIKV-specific neutralizing antibodies that conferred protection against live" exact="ZIKV" post="challenge in animal models6–8,16–22. These data support ZIKV E-specific"/>
   <result pre="against live ZIKV challenge in animal models6–8,16–22. These data support" exact="ZIKV" post="E-specific neutralizing antibodies as a mechanism of protection against"/>
   <result pre="ZIKV E-specific neutralizing antibodies as a mechanism of protection against" exact="ZIKV" post="infection. In flavivirus vaccine development, neutralizing antibody titers that"/>
   <result pre="RVP, and plaque reduction neutralization (PRNT). Studies of other candidate" exact="ZIKV" post="vaccines have demonstrated that a neutralizing antibody titer as"/>
   <result pre="of protection, it has been reported that passive transfer of" exact="Zika" post="neutralizing monoclonal antibodies or antisera from vaccinated humans and"/>
   <result pre="humans and animals to mice is sufficient to protect against" exact="ZIKV" post="challenge16,17,21,26. Adoptive transfer of serum from immunized mice fully"/>
   <result pre="provided marginal protection27 demonstrating that the mechanism of protection against" exact="ZIKV" post="infection is antibody mediated. While ZIKV exists as three"/>
   <result pre="mechanism of protection against ZIKV infection is antibody mediated. While" exact="ZIKV" post="exists as three genotypes (West African, East African and"/>
   <result pre="capable of eliciting antibodies that neutralize both African and Asian" exact="ZIKV" post="isolates in vitro16. Others have shown that the magnitude"/>
   <result pre="magnitude or duration of viremia in unvaccinated macaques challenged with" exact="ZIKV" post="isolates from Brazil or Puerto Rico is similar6, and"/>
   <result pre="and that vaccinated macaques are protected against challenge with heterologous" exact="ZIKV" post="strains13,21,30. Protection of animal models against heterologous challenge and"/>
   <result pre="challenge strain may be sufficient to show cross protection against" exact="ZIKV" post="strains from other lineages. Several groups have developed rhesus"/>
   <result pre="lineages. Several groups have developed rhesus macaque challenge models using" exact="Zika" post="strain PRVABC596,7,9,12,31 which is a well-documented and characterized isolate"/>
   <result pre="PIZV efficacy in mice16 to demonstrate efficacy in prevention of" exact="ZIKV" post="vRNA and to evaluate anamnestic antibody responses after ZIKV"/>
   <result pre="of ZIKV vRNA and to evaluate anamnestic antibody responses after" exact="ZIKV" post="challenge in non-human primates. We did not assess presence"/>
   <result pre="in tissues. Our working hypothesis is that prevention of serum" exact="ZIKV" post="vRNA may be a surrogate for prevention of the"/>
   <result pre="a surrogate for prevention of the most serious sequelae of" exact="ZIKV" post="infection in humans - fetal infection. By employing a"/>
   <result pre="By employing a PIZV dose titration study design and a" exact="ZIKV" post="RVP assay, we have established a minimum protective vaccine"/>
   <result pre="macaques and established a neutralizing antibody correlate of protection against" exact="ZIKV" post="challenge of 3.02 log10 EC50. Finally, we demonstrated that"/>
   <result pre="ZIKV challenge of 3.02 log10 EC50. Finally, we demonstrated that" exact="ZIKV" post="neutralizing antibodies persist and are capable of preventing ZIKV"/>
   <result pre="that ZIKV neutralizing antibodies persist and are capable of preventing" exact="ZIKV" post="infection for at least 1 year post-vaccination. In the"/>
   <result pre="challenge model may be important to support licensure of a" exact="Zika" post="vaccine3,5,32. Altogether, these data support neutralizing antibodies as an"/>
   <result pre="aluminum hydroxide adjuvanted whole purified inactivated virus vaccine based on" exact="ZIKV" post="strain PRVABC59 which was originally isolated from serum from"/>
   <result pre="from the control group was euthanized on the day of" exact="ZIKV" post="challenge due to reasons unrelated to the study, resulting"/>
   <result pre="the control group. Macaques were challenged subcutaneously with 104 ffu/0.5 mL" exact="ZIKV" post="PRVABC59 on study day 71. Serum samples were collected"/>
   <result pre="days 1, 29, 57, and 71, and 101, and for" exact="ZIKV" post="RNA on study days 71–80, and study day 84."/>
   <result pre="days 1 and 29 and challenged subcutaneously with 104 ffu/0.5 mL" exact="ZIKV" post="PRVABC59 on day 371. Serum samples were collected and"/>
   <result pre="monthly up to 1 year post-vaccination and 30 days following" exact="ZIKV" post="challenge (study day 401). To assess replication of Zika"/>
   <result pre="following ZIKV challenge (study day 401). To assess replication of" exact="Zika" post="vRNA following ZIKV challenge, serum samples were collected on"/>
   <result pre="(study day 401). To assess replication of Zika vRNA following" exact="ZIKV" post="challenge, serum samples were collected on study days 371–381,"/>
   <result pre="were collected on study days 371–381, and 385. Challenge virus" exact="Zika" post="virus Puerto Rico strain PRVABC59 was used for the"/>
   <result pre="magnetic beads coupled with Zika, Dengue, Yellow Fever, Japanese Encephalitis," exact="West Nile," post="Usutu, Saint Louis Encephalitis, and Chikungunya virus antigens. Serum"/>
   <result pre="Fever, Japanese Encephalitis, West Nile, Usutu, Saint Louis Encephalitis, and" exact="Chikungunya" post="virus antigens. Serum and beads were incubated on a"/>
   <result pre="cutoff criteria for seronegativity for all antigens. Neutralizing antibodies A" exact="Zika" post="RVP assay (Sonnberg et al., manuscript in preparation) was"/>
   <result pre="for study days 1, 29, 57, and 71 (prior to" exact="ZIKV" post="challenge) using a Luminex based anti-Zika IgG assay. Heat-inactivated"/>
   <result pre="purified RNA was evaluated in two separate RT-PCR assays. Primarily," exact="Zika" post="vRNA was detected and quantified using RT-qPCR with primers"/>
   <result pre="quantified using RT-qPCR with primers and probe specific to known" exact="ZIKV" post="genotypes as described in Lanciotti et al.33 and a"/>
   <result pre="et al.33 and a standard curve generated from synthetic reference" exact="Zika" post="vRNA (ATCC). A qualitative extraction control RT-PCR was also"/>
   <result pre="confirmed adequate nucleic acid extraction from serum samples independent of" exact="Zika" post="vRNA detection. The geometric mean, range of peak Zika"/>
   <result pre="of Zika vRNA detection. The geometric mean, range of peak" exact="Zika" post="vRNA detection, and the respective percentage of protected macaques"/>
   <result pre="protection The mean neutralizing antibody titers (log10 EC50) determined by" exact="Zika" post="RVP assay was computed for each dose group at"/>
   <result pre="computed for each dose group at day 71 (day of" exact="ZIKV" post="challenge). Zika vRNA copies/mL determined by RT-qPCR assay were"/>
   <result pre="each dose group at day 71 (day of ZIKV challenge)." exact="Zika" post="vRNA copies/mL determined by RT-qPCR assay were computed for"/>
   <result pre="Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital" exact="Zika" post="Virus Infection - U.S. Territories and Freely Associated States,"/>
   <result pre="Organization. PLISA Health Information Platform for the Americas: Cases of" exact="Zika" post="virus disease, by country or territory, http://www.paho.org/data/index.php/en/mnu-topics/zika/524-zika-weekly-en.html (Accessed 27Aug2019)."/>
   <result pre="http://www.paho.org/data/index.php/en/mnu-topics/zika/524-zika-weekly-en.html (Accessed 27Aug2019). 3.GruberMFet al.Clinical Development Strategies and Considerations for" exact="Zika" post="Vaccine LicensureJ. Infect. Dis.2017216S964S97010.1093/infdis/jix43329267913 4.PlotkinSACorrelates of protection induced by"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 6.AbbinkPet al.Protective efficacy of multiple vaccine platforms"/>
   <result pre="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 6.AbbinkPet al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysSci.20163531129113210.1126/science.aah6157 7.DowdKAet al.Rapid development of"/>
   <result pre="rhesus monkeysSci.20163531129113210.1126/science.aah6157 7.DowdKAet al.Rapid development of a DNA vaccine for" exact="Zika" post="virusSci.201635423724010.1126/science.aai9137 8.RichnerJMet al.Modified mRNA Vaccines Protect against Zika Virus"/>
   <result pre="vaccine for Zika virusSci.201635423724010.1126/science.aai9137 8.RichnerJMet al.Modified mRNA Vaccines Protect against" exact="Zika" post="Virus InfectionCell201716917610.1016/j.cell.2017.03.01628340344 9.RaynerJonathanKalkeriRajGoebelScottCaiZhaohuiGreenBrianLinShulingSnyderBethHagelinKimberlyWaltersKevinKoideFusatakaComparative Pathogenesis of Asian and African-Lineage Zika"/>
   <result pre="against Zika Virus InfectionCell201716917610.1016/j.cell.2017.03.01628340344 9.RaynerJonathanKalkeriRajGoebelScottCaiZhaohuiGreenBrianLinShulingSnyderBethHagelinKimberlyWaltersKevinKoideFusatakaComparative Pathogenesis of Asian and African-Lineage" exact="Zika" post="Virus in Indian Rhesus Macaque’s and Development of a"/>
   <result pre="Evaluation of New Drugs and VaccinesViruses201810522910.3390/v10050229 10.OsunaCEWhitneyJBNonhuman Primate Models of" exact="Zika" post="Virus Infection, Immunity, and Therapeutic DevelopmentJ. Infect. Dis.2017216S928S93410.1093/infdis/jix54029267926 11.NewmanCFriedrichTCO’ConnorDHMacaque"/>
   <result pre="Infection, Immunity, and Therapeutic DevelopmentJ. Infect. Dis.2017216S928S93410.1093/infdis/jix54029267926 11.NewmanCFriedrichTCO’ConnorDHMacaque monkeys in" exact="Zika" post="virus research: 1947-presentCurr. Opin. Virol.201725344010.1016/j.coviro.2017.06.01128750247 12.LiXFet al.Characterization of a"/>
   <result pre="Opin. Virol.201725344010.1016/j.coviro.2017.06.01128750247 12.LiXFet al.Characterization of a 2016 Clinical Isolate of" exact="Zika" post="Virus in Non-human PrimatesEBioMedicine20161217017710.1016/j.ebiom.2016.09.02227693104 13.AliotaMTet al.Heterologous Protection against Asian"/>
   <result pre="Zika Virus in Non-human PrimatesEBioMedicine20161217017710.1016/j.ebiom.2016.09.02227693104 13.AliotaMTet al.Heterologous Protection against Asian" exact="Zika" post="Virus Challenge in Rhesus MacaquesPLoS Negl. Trop. Dis.201610e000516810.1371/journal.pntd.000516827911897 14.DudleyDMet"/>
   <result pre="Negl. Trop. Dis.201610e000516810.1371/journal.pntd.000516827911897 14.DudleyDMet al.A rhesus macaque model of Asian-lineage" exact="Zika" post="virus infectionNat. Commun.201671220410.1038/ncomms1220427352279 15.HirschAJet al.Zika Virus infection of rhesus"/>
   <result pre="to viral persistence in multiple tissuesPLoS Pathog.201713e100621910.1371/journal.ppat.100621928278237 16.BaldwinWRet al.Purified Inactivated" exact="Zika" post="Vaccine Candidates Afford Protection against Lethal Challenge in MiceSci."/>
   <result pre="against Lethal Challenge in MiceSci. Rep.201881650910.1038/s41598-018-34735-730405178 17.SumathyKet al.Protective efficacy of" exact="Zika" post="vaccine in AG129 mouse modelSci. Rep.201774637510.1038/srep4637528401907 18.PardiNet al.Zika virus"/>
   <result pre="single low-dose nucleoside-modified mRNA vaccinationNat.201754324825110.1038/nature21428 19.MuthumaniKet al.In vivo protection against" exact="ZIKV" post="infection and pathogenesis through passive antibody transfer and active"/>
   <result pre="with a prMEnv DNA vaccineNPJ Vaccines201611602110.1038/npjvaccines.2016.2129263859 20.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNat.201653647447810.1038/nature18952 21.AbbinkPeterLaroccaRafael A.VisitsunthornKittiposBoydMichaelDe La BarreraRafael A.GromowskiGregory D.KirilovaMarinelaPetersonRebeccaLiZhenfengNanayakkaraOviniNityanandamRamyaMercadoNoe"/>
   <result pre="H.ThomasStephen J.MichaelNelson L.BarouchDan H.Durability and correlates of vaccine protection against" exact="Zika" post="virus in rhesus monkeysScience Translational Medicine20179420eaao416310.1126/scitranslmed.aao416329237759 22.EspinosaDet al.Passive Transfer"/>
   <result pre="Medicine20179420eaao416310.1126/scitranslmed.aao416329237759 22.EspinosaDet al.Passive Transfer of Immune Sera Induced by a" exact="Zika" post="Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika"/>
   <result pre="a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal" exact="Zika" post="Virus ChallengeEBioMedicine201827617010.1016/j.ebiom.2017.12.01029269041 23.HombachJSolomonTKuraneIJacobsonJWoodDReport on a WHO consultation on immunological"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="randomised, double-blind, placebo-controlled clinical trialsLancet201839156357110.1016/S0140-6736(17)33106-929217375 27.NazeraiLoulietaPravsgaard ChristensenJanRandrup ThomsenAllanA ‘Furry-Tale’ of" exact="Zika" post="Virus Infection: What Have We Learned from Animal Models?Viruses20191112910.3390/v11010029"/>
   <result pre="What Have We Learned from Animal Models?Viruses20191112910.3390/v11010029 28.LanciottiRSLambertAJHolodniyMSaavedraSSignor LdelCPhylogeny of" exact="Zika" post="Virus in Western Hemisphere, 2015Emerg. Infect. Dis.20162293393510.3201/eid2205.16006527088323 29.DowdKAet al.Broadly"/>
   <result pre="Western Hemisphere, 2015Emerg. Infect. Dis.20162293393510.3201/eid2205.16006527088323 29.DowdKAet al.Broadly Neutralizing Activity of" exact="Zika" post="Virus-Immune Sera Identifies a Single Viral SerotypeCell Rep.2016161485149110.1016/j.celrep.2016.07.04927481466 30.SariolCANogueiraMLVasilakisNA"/>
   <result pre="30.SariolCANogueiraMLVasilakisNA Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance" exact="Zika" post="Disease?Trends Microbiol.20182618619010.1016/j.tim.2017.10.00429122447 31.OsunaCEet al.Zika viral dynamics and shedding in"/>
   <result pre="Harbor Perspectives in Biology2017104a02890210.1101/cshperspect.a028902 33.LanciottiRSet al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7045448\results\search\tropicalVirus\results.xml">
   <result pre="mosquito-borne viral infections compared to south and eastern highland regions." exact="Yellow fever," post="chikungunya, dengue, Zika, Rift Valley fever, West Nile and"/>
   <result pre="highland regions. Yellow fever, chikungunya, dengue, Zika, Rift Valley fever," exact="West Nile" post="and O’nyong’nyong have been reported in the country. These"/>
   <result pre="viruses were found circulating in human, wildlife and domestic animals." exact="Yellow fever" post="and chikungunya outbreaks have been frequently reported. Aedes aegypti"/>
   <result pre="belonging to the genus Aedes are the major vectors of" exact="Chikungunya" post="(CHIKV), Dengue (DENV), Rift Valley fever (RVFV), Yellow fever"/>
   <result pre="the genus Aedes are the major vectors of Chikungunya (CHIKV)," exact="Dengue" post="(DENV), Rift Valley fever (RVFV), Yellow fever (YFV) and"/>
   <result pre="vectors of Chikungunya (CHIKV), Dengue (DENV), Rift Valley fever (RVFV)," exact="Yellow fever" post="(YFV) and Zika (ZIKV) [4]. These mosquito-borne viral diseases"/>
   <result pre="Dengue (DENV), Rift Valley fever (RVFV), Yellow fever (YFV) and" exact="Zika" post="(ZIKV) [4]. These mosquito-borne viral diseases are often misdiagnosed"/>
   <result pre="Kongo-Central in 1912 [7]. Thereafter a number of studies on" exact="YFV" post="and other mosquito-borne viral infections were carried out and"/>
   <result pre="1960 [8]. During the past two decades, repeated outbreaks of" exact="Chikungunya" post="and Yellow fever have been reported in DRC. During"/>
   <result pre="During the past two decades, repeated outbreaks of Chikungunya and" exact="Yellow fever" post="have been reported in DRC. During the same time,"/>
   <result pre="of public health importance such as DENV, ZIKV, RVFV and" exact="West Nile" post="virus (WNV) have also been recorded [9–11]. This review"/>
   <result pre="across the DRC. Among the Flaviviridae, four species, YFV, DENV," exact="ZIKV" post="and WNV, were recorded. Among the Alphaviridae, two species,"/>
   <result pre="ZIKV and WNV, were recorded. Among the Alphaviridae, two species," exact="CHIKV" post="and ONNV were reported. The recorded mosquito-borne viruses occurred"/>
   <result pre="during inter-epidemic periods. Most of the records were related to" exact="YFV" post="and CHIKV. A number of studies were carried during"/>
   <result pre="virus occurrence in between 1998 and 2018. Key: black rhombus," exact="West Nile" post="virus; purple triangle, chikungunya virus; red cross, dengue virus;"/>
   <result pre="purple triangle, chikungunya virus; red cross, dengue virus; black star," exact="Zika" post="virus; black line, borders of territories These viruses were"/>
   <result pre="studies reported co-occurrence or co-infections of mosquito-borne viruses. These included" exact="CHIKV" post="and YFV, CHIKV and DENV, YFV and DENV [9,"/>
   <result pre="or co-infections of mosquito-borne viruses. These included CHIKV and YFV," exact="CHIKV" post="and DENV, YFV and DENV [9, 10, 14–16]. Yellow"/>
   <result pre="mosquito-borne viruses. These included CHIKV and YFV, CHIKV and DENV," exact="YFV" post="and DENV [9, 10, 14–16]. Yellow fever virus The"/>
   <result pre="These included CHIKV and YFV, CHIKV and DENV, YFV and" exact="DENV" post="[9, 10, 14–16]. Yellow fever virus The first yellow"/>
   <result pre="YFV, CHIKV and DENV, YFV and DENV [9, 10, 14–16]." exact="Yellow fever" post="virus The first yellow fever outbreak in DRC was"/>
   <result pre="in 1912 at Matadi Beach [7]. Later in 1928, another" exact="YFV" post="outbreak occurred in the same area. This was the"/>
   <result pre="occurred in the same area. This was the first autochthonous" exact="YFV" post="outbreak in the DRC and it caused a mortality"/>
   <result pre="2004 [10]. In a demographic survey of 2013–2014, an overall" exact="YFV" post="prevalence of 31.5% among children was reported in DRC"/>
   <result pre="a single Province of Kongo-Centrale [23]. The autochthonous cases of" exact="YFV" post="have also been documented in the provinces of Bas-Uele,"/>
   <result pre="belongs to an endemic geographical area at high risk for" exact="YFV" post="transmission [24]. YFV transmission in DRC varies from one"/>
   <result pre="endemic geographical area at high risk for YFV transmission [24]." exact="YFV" post="transmission in DRC varies from one region to another"/>
   <result pre="region to another and within the region. The absence of" exact="YFV" post="circulation or lowest seroprevalence (&amp;lt; 5%) has been observed"/>
   <result pre="into Tanganyika, Haut-Lomami, Haut-Katanga, Lualaba) [25]. The highest seroprevalence of" exact="YFV" post="(≥ 30%) has been recorded from the savannah regions"/>
   <result pre="part of DRC [25, 26]. The identified territories with high" exact="YFV" post="transmission were Bosobolo and Mobayi-mbongo in the Province of"/>
   <result pre="provinces of the DRC, 1917–2018. Key: light pink, provinces with" exact="YFV" post="seroprevalence &amp;lt; 10%; dark pink: provinces with YFV seroprevalence"/>
   <result pre="provinces with YFV seroprevalence &amp;lt; 10%; dark pink: provinces with" exact="YFV" post="seroprevalence ranging between 10–20%; red, provinces with YFV seroprevalence"/>
   <result pre="provinces with YFV seroprevalence ranging between 10–20%; red, provinces with" exact="YFV" post="seroprevalence &amp;gt; 20%; white line: borders of provinces Chikungunya"/>
   <result pre="with YFV seroprevalence &amp;gt; 20%; white line: borders of provinces" exact="Chikungunya" post="The two first reported chikungunya cases in the DRC"/>
   <result pre="Bas-Uélé in Bondo territory [15]. Since then, no circulation of" exact="CHIKV" post="was documented in DRC until 1998 [11]. In 1998,"/>
   <result pre="In 1998, of 45 patients sampled during an outbreak of" exact="WNV" post="in Kisangani City in Tshopo Province of the north-eastern"/>
   <result pre="of the north-eastern region, 28.8% patients were found positive for" exact="CHIKV" post="immunoglobulin M (IgM) antibodies [11]. Kinshasa, the capital of"/>
   <result pre="municipality. More than half (57.9%) the samples tested positive for" exact="CHIKV" post="IgM antibodies and nine strains were isolated in C6/36"/>
   <result pre="2011, of the 453 sera screened, two positive cases of" exact="CHIKV" post="were detected by RT-PCR. One case was from Gemena"/>
   <result pre="patients tested negative for malaria in Kinshasa, the seroprevalence of" exact="CHIKV" post="was 9.6% and 5 samples were found positive for"/>
   <result pre="CHIKV was 9.6% and 5 samples were found positive for" exact="CHIKV" post="by RT-PCR [30]. Based on a genetic study, the"/>
   <result pre="RT-PCR [30]. Based on a genetic study, the isolates of" exact="CHIKV" post="that were found to circulate in DRC belonged to"/>
   <result pre="Province have been identified as potential hosts or reservoirs of" exact="CHIKV" post="by detecting the presence of antibodies from these species"/>
   <result pre="circulating in diverse animals and mosquitoes in DRC, 1960–2018 Animal/mosquito" exact="CHIKV" post="DENV YFV RVFV WNV ONNV Alphavirus Flavivirus Study location"/>
   <result pre="in diverse animals and mosquitoes in DRC, 1960–2018 Animal/mosquito CHIKV" exact="DENV" post="YFV RVFV WNV ONNV Alphavirus Flavivirus Study location Chimpanzee"/>
   <result pre="diverse animals and mosquitoes in DRC, 1960–2018 Animal/mosquito CHIKV DENV" exact="YFV" post="RVFV WNV ONNV Alphavirus Flavivirus Study location Chimpanzee +"/>
   <result pre="and mosquitoes in DRC, 1960–2018 Animal/mosquito CHIKV DENV YFV RVFV" exact="WNV" post="ONNV Alphavirus Flavivirus Study location Chimpanzee + + +"/>
   <result pre="spp. + Kinshasa [13] Key: +, screened positive for virus" exact="Dengue" post="Three serotypes of dengue virus (DENV-1, DENV-2 and DENV-3)"/>
   <result pre="to 8.8% [9, 11, 30]. In Kisangani of Tshopo Province," exact="DENV" post="was reported to co-circulate with CHIKV during the West"/>
   <result pre="Kisangani of Tshopo Province, DENV was reported to co-circulate with" exact="CHIKV" post="during the West Nile outbreak of 1998 [11]. In"/>
   <result pre="Province, DENV was reported to co-circulate with CHIKV during the" exact="West Nile" post="outbreak of 1998 [11]. In Kinshasa, co-occurrence of dengue"/>
   <result pre="and chikungunya was reported during the outbreak of 2012 [16]." exact="Dengue" post="occurrence has been reported from western (Kinshasa, Kongo central),"/>
   <result pre="and north-eastern regions (Tshopo, Haut-uélé, Bas-Uélé) (Table 4). Antibodies against" exact="DENV" post="have also been reported from chimpanzee in 1960 and"/>
   <result pre="of Aedes mosquitoes collected around Ndjili River in Kinshasa [13]." exact="Zika" post="Two studies on Zika were identified during the review."/>
   <result pre="around Ndjili River in Kinshasa [13]. Zika Two studies on" exact="Zika" post="were identified during the review. In the first study,"/>
   <result pre="of 453 archived sera collected country-wide from 2003–2011 that tested" exact="YFV" post="negative were also negative for ZIKV virus using RT-PCR"/>
   <result pre="from 2003–2011 that tested YFV negative were also negative for" exact="ZIKV" post="virus using RT-PCR [10]. The second study analysed 978"/>
   <result pre="during 2013–2014 showed that 34 samples (3.5%) were positive for" exact="Zika" post="antibodies using ELISA. However, of the 34 samples that"/>
   <result pre="that tested positive in ELISA, only one remained positive for" exact="ZIKV" post="by PRNT [9]. This positive case of Zika was"/>
   <result pre="positive for ZIKV by PRNT [9]. This positive case of" exact="Zika" post="was reported from the north-western part of DRC, from"/>
   <result pre="of DRC, from Sud-Ubangi Province bordering the Central African Republic." exact="West Nile" post="virus In the DRC, antibodies against WNV in humans"/>
   <result pre="African Republic. West Nile virus In the DRC, antibodies against" exact="WNV" post="in humans have been detected by virus neutralization tests,"/>
   <result pre="illness outbreak following heavy rainfall in Kisangani [11]. But no" exact="WNV" post="antibodies or RNA were detected in samples from Kinshasa"/>
   <result pre="detected in samples from Kinshasa collected during 1999–2000 during a" exact="CHIKV" post="outbreak [28]. The specific neutralizing antibodies against WNV in"/>
   <result pre="during a CHIKV outbreak [28]. The specific neutralizing antibodies against" exact="WNV" post="in Haut-Uelé Province have been detected in chimpanzee in"/>
   <result pre="Kinshasa in 2004, nine (30%) out of 20 horses were" exact="WNV" post="seropositive using ELISA and western blot analysis [38]. Afterwards,"/>
   <result pre="and western blot analysis [38]. Afterwards, a 12.5% seroprevalence of" exact="WNV" post="was reported in Kinshasa [39]. These observations provide evidence"/>
   <result pre="evidence of an animal role in the enzootic circulation of" exact="WNV" post="in the DRC. O’nyong’nyong virus O’nyong’nyong virus (ONNV) is"/>
   <result pre="the DRC. O’nyong’nyong virus O’nyong’nyong virus (ONNV) is a closer" exact="CHIKV" post="related alphavirus vectored mainly by the Anopheles mosquito. Its"/>
   <result pre="have been amplified with specific primers for CHIKV, ONNV, YFV," exact="WNV" post="or DENV [13]. In the Ango and Bondo territories"/>
   <result pre="amplified with specific primers for CHIKV, ONNV, YFV, WNV or" exact="DENV" post="[13]. In the Ango and Bondo territories from Bas-Uélé,"/>
   <result pre="spread of mosquito-borne virus outbreaks [11, 41]. For instance, the" exact="WNV" post="outbreak in Kisangani started at army camps where immigrated"/>
   <result pre="fever outbreaks [18]. In addition, significant rates of antibodies against" exact="YFV" post="have been detected among chimpanzee from savannah areas compared"/>
   <result pre="outbreaks or positive cases occurred during the rainy seasons. The" exact="West Nile" post="outbreak was preceded by heavy rainfall in Kisangani in"/>
   <result pre="change this general trend. Although, there is evidence of ZIKV," exact="DENV" post="and RVFV circulation in DRC, no epidemic has been"/>
   <result pre="One Health approaches with emphasis on integrated vector control. Abbreviations" exact="CHIKV" post="chikungunya virus DENV dengue virus RVFV Rift Valley fever"/>
   <result pre="with emphasis on integrated vector control. Abbreviations CHIKV chikungunya virus" exact="DENV" post="dengue virus RVFV Rift Valley fever virus YFV yellow"/>
   <result pre="chikungunya virus DENV dengue virus RVFV Rift Valley fever virus" exact="YFV" post="yellow fever virus WNV West Nile virus ZIKV Zika"/>
   <result pre="virus RVFV Rift Valley fever virus YFV yellow fever virus" exact="WNV" post="West Nile virus ZIKV Zika virus DRC Democratic Republic"/>
   <result pre="RVFV Rift Valley fever virus YFV yellow fever virus WNV" exact="West Nile" post="virus ZIKV Zika virus DRC Democratic Republic of the"/>
   <result pre="fever virus YFV yellow fever virus WNV West Nile virus" exact="ZIKV" post="Zika virus DRC Democratic Republic of the Congo ELISA"/>
   <result pre="virus YFV yellow fever virus WNV West Nile virus ZIKV" exact="Zika" post="virus DRC Democratic Republic of the Congo ELISA enzyme�?linked"/>
   <result pre="Infect Dis.20161618310.1186/s12879-016-1511-527112553 6.Carrillo-HernándezMYRuiz-SaenzJVillamizarLJGómez-RangelSYMartínez-GutierrezMCo-circulation and simultaneous co-infection of dengue, chikungunya, and" exact="Zika" post="viruses in patients with febrile syndrome at the Colombian-Venezuelan"/>
   <result pre="Republic of the CongoVector Borne Zoonotic Dis.20181836437010.1089/vbz.2017.217629768102 11.NurYAGroenJHeuvelmansHTuynmanWCopraCOsterhausADAn outbreak of" exact="West Nile" post="fever among migrants in Kisangani, Democratic Republic of CongoAm"/>
   <result pre="la fièvre jaune à GemenaAnn Soc Belge Méd Trop.19626859864 19.WHO." exact="Yellow fever" post="in the Democratic Republic of the Congo. Geneva: World"/>
   <result pre="World Health Organisation; 2010. http://www.who.int/csr/don/2010_07_19a/. Accessed 13 Nov 2018. 20.WHO." exact="Yellow fever" post="in the Democratic Republic of Congo. Geneva: World Health"/>
   <result pre="World Health Organisation; 2013. http://www.who.int/csr/don/2013_06_14_yellowfever/en/. Accessed 13 Nov 2018. 21.WHO." exact="Yellow fever" post="Democratic Republic of the Congo. Geneva: World Health Organisation;"/>
   <result pre="the CongoMed Trop Rev Corps Sante Colon.200363637638 29.BosscheVDCnopsLMeersmanKDomingoCGompelVAEsbroeckVMChikungunya virus and" exact="West Nile" post="virus infections imported into Belgium, 2007–2012Epidemiol Infect.20151432227223610.1017/S095026881400068524690286 30.Ido E,"/>
   <result pre="central AfricaTrans R Soc Trop Med Hyg.19423692010.1016/S0035-9203(42)90051-8 37.LucasseCFirst isolation of" exact="West Nile" post="virus in central AfricaBull Soc Path Ex196156156161 38.CabreOGrandadamMMariéJLGravierPPrangéASantinelliYet al.West"/>
   <result pre="in horses, sub-Saharan AfricaEmerg Infect Dis.2006121958196010.3201/eid1212.06004217326952 39.DavoustBLeparc-GoffartIDemoncheauxJPTineRDiarraMTrombiniGet al.Serologic surveillance for" exact="West Nile" post="virus in dogsAfrica. Emerg Infect Dis.2014201415141710.3201/eid2008.13069125061842 40.RwagumaELutwamaJSempalaSKiwanukaNKamugishaJOkwareSet al.Emergence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7046835\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.3389/fimmu.2020.00287 : Immunology: Perspective Role of T Cells in" exact="Chikungunya" post="Virus Infection and Utilizing Their Potential in Anti-Viral Immunity"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) is an arthropod-borne alphavirus that causes hallmark"/>
   <result pre="cells, are known to participate in the pathogenic role of" exact="CHIKV" post="immunopathology. The other T cell subsets, notably CD8+, NKT,"/>
   <result pre="these T cell subsets during acute and chronic phases of" exact="CHIKV" post="infection, and highlight gaps in the current literature. Importantly,"/>
   <result pre="Technology and Research10.13039/501100001348F00018 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) belongs to the Togaviridae family and is"/>
   <result pre="Symptoms usually manifest after 4–7 days of incubation period (3)." exact="CHIKV" post="infection has been shown by multiple studies to induce"/>
   <result pre="18). Host innate and adaptive immunity have multifaceted roles in" exact="CHIKV" post="infection. While innate immunity in response to CHIKV infection"/>
   <result pre="roles in CHIKV infection. While innate immunity in response to" exact="CHIKV" post="infection has been well-studied (3, 17, 30), the functions"/>
   <result pre="play significant roles in antiviral immunity, immunomodulation and pathology in" exact="CHIKV" post="infection (24, 28, 31, 32). A better comprehension of"/>
   <result pre="comprehension of the roles each T cell subset play during" exact="CHIKV" post="infection may aid in understanding how to control disease"/>
   <result pre="cells express CD69, CD107a, granzyme B, and perforin during acute" exact="CHIKV" post="infection (17, 33, 34), markers associated with T cell"/>
   <result pre="cell activation. Studies have identified putative CD8 epitopes within the" exact="CHIKV" post="genome in mice and humans (Figure 1) (35, 36)."/>
   <result pre="Despite the apparent abundance, only three HLA-A*0201 CD8 epitopes in" exact="CHIKV" post="6K protein were experimentally validated to trigger CD8 T"/>
   <result pre="different MHCs. Importantly, it remains unclear whether the recognition of" exact="CHIKV" post="epitopes by CD8+ T cells has a role to"/>
   <result pre="open up avenues to employ them as mediators in future" exact="CHIKV" post="vaccines. Figure 1 The list of conserved CD8 epitopes"/>
   <result pre="vaccines. Figure 1 The list of conserved CD8 epitopes in" exact="CHIKV" post="that was identified in silico by others and published"/>
   <result pre="were arranged according to the positions they occupy along the" exact="CHIKV" post="proteome. The immunogenicity scores are determined through the Immune"/>
   <result pre="CD8+ T cell numbers in the joints increased during acute" exact="CHIKV" post="infection. However, they do not protect against CHIKV-associated pathologies"/>
   <result pre="virus (RRV) (38) and Venezuela Equine Encephalomyelitis virus (VEEV) (39)." exact="CHIKV" post="RNA could be detected in the footpad of mice"/>
   <result pre="mice at up to 16 weeks post-challenge, suggesting that chronic" exact="CHIKV" post="infection could persist in the footpad (40). Persistent infection"/>
   <result pre="could persist in the footpad (40). Persistent infection indicates that" exact="CHIKV" post="epitopes could be continuously presented by antigen-presenting cells (APCs)"/>
   <result pre="incapable of eliminating infected cells (41, 42), resulting in perpetual" exact="CHIKV" post="infection. Indeed, the lower levels of CD8+ T cells"/>
   <result pre="of activated marker CD69 suggest an exhausted phenotype in chronic" exact="CHIKV" post="patients (33). In chronic viral (e.g., LCMV and HIV)"/>
   <result pre="a further immune shutdown and more persistent infection. Given that" exact="CHIKV" post="infection is shown to persist in infected mice and"/>
   <result pre="indicating that this is another potential avenue to treat chronic" exact="CHIKV" post="infection. CD4+ T Cells Activated CD4+ T cells have"/>
   <result pre="from exiting the lymphoid organs, also reduces joint pathology in" exact="CHIKV" post="infected mice. In addition, TCR−/− mice, which lack T"/>
   <result pre="T cells are also responsible for the chronic phase of" exact="CHIKV" post="infection. Pathogenic CHIKV-specific CD4+ T cells in CHIKV mouse"/>
   <result pre="phase of CHIKV infection. Pathogenic CHIKV-specific CD4+ T cells in" exact="CHIKV" post="mouse models express T-bet and secrete IFN-γ, markers that"/>
   <result pre="infection, the antiviral effects of IFN-γ are unable to block" exact="CHIKV" post="replication in virus-infected cells due to CHIKV interference with"/>
   <result pre="unable to block CHIKV replication in virus-infected cells due to" exact="CHIKV" post="interference with downstream JAK-STAT signaling (51). These CD4+ T"/>
   <result pre="in the joints of patients during the chronic phase of" exact="CHIKV" post="infection (34). Two CHIKV CD4+ epitopes have been identified"/>
   <result pre="patients during the chronic phase of CHIKV infection (34). Two" exact="CHIKV" post="CD4+ epitopes have been identified in mouse models thus"/>
   <result pre="far, with the cognate CD4+ T cells expressing IFN-γ during" exact="CHIKV" post="infection (32). Despite CD4+ T cells being a cause"/>
   <result pre="T cells being a cause of the pathogenic swelling accompanying" exact="CHIKV" post="infection, they are also crucial in orchestrating the formation"/>
   <result pre="molecules in the latter (52). Thus, when the APCs present" exact="CHIKV" post="epitopes to CD4+ T cells, they become anergic instead"/>
   <result pre="not affected by Tregs (52). Patients with acute and chronic" exact="CHIKV" post="infections were shown to have lower levels of Treg,"/>
   <result pre="Cells The impact of natural killer T (NKT) cells in" exact="CHIKV" post="infection is less well-understood. In patients, acute CHIKV infection"/>
   <result pre="cells in CHIKV infection is less well-understood. In patients, acute" exact="CHIKV" post="infection resulted in an increase of NKT cells in"/>
   <result pre="accumulate in the spleens of mice that are co-infected with" exact="CHIKV" post="and malaria parasites (48). This event is due to"/>
   <result pre="(56–58). Although this strategy of lymphocyte sequestration leads to decreased" exact="CHIKV" post="immunopathology (32, 49), it is not clear how much"/>
   <result pre="T cells are reported to play a protective role against" exact="CHIKV" post="infection (59). These cells do not affect CHIKV virus"/>
   <result pre="role against CHIKV infection (59). These cells do not affect" exact="CHIKV" post="virus replication in the joints. Instead, their absence is"/>
   <result pre="infiltration and result in tissue damage that is observed during" exact="CHIKV" post="infection. However, there is no information on the role"/>
   <result pre="no information on the role of γδ T cells in" exact="CHIKV" post="patients. Thus, the extent of protection these cells offer"/>
   <result pre="offer in human settings remains unclear. Mobilizing T Cells Against" exact="CHIKV" post="in Vaccine Design The roles that each subset of"/>
   <result pre="subset of T cells play in the joint swelling during" exact="CHIKV" post="infection is illustrated in Figure 2. Despite their participation"/>
   <result pre="infection is illustrated in Figure 2. Despite their participation in" exact="CHIKV" post="immunopathology, they have the potential to be included as"/>
   <result pre="neutralize the viruses (23, 28, 60–63). Furthermore, some of the" exact="CHIKV" post="vaccines have been demonstrated to protect against other alphaviruses,"/>
   <result pre="at the lower doses. However, vaccination with recombinant baculovirus expressing" exact="CHIKV" post="envelope proteins caused aged mice (&amp;gt;18 months old) to"/>
   <result pre="aged mice (&amp;gt;18 months old) to become more susceptible to" exact="CHIKV" post="infection (62), which was partly explained by the lower"/>
   <result pre="antibody titers in the aged mice. Although antigenic variations among" exact="CHIKV" post="isolates are not prevalent currently, subtle changes in the"/>
   <result pre="CHIKV isolates are not prevalent currently, subtle changes in the" exact="CHIKV" post="proteome was demonstrated to affect the neutralizing effect of"/>
   <result pre="results in reproductive-competent virus and yet abolishes antibody binding to" exact="CHIKV" post="epitopes may result in future pandemic outbreaks. Figure 2"/>
   <result pre="of the roles each T cell subset play during acute" exact="CHIKV" post="infection. (1) When CHIKV-infected mosquitoes transmit the virus to"/>
   <result pre="virus to its human host (or experimental infection in mice)," exact="CHIKV" post="infects the surrounding cells and creates pro-inflammatory milleu in"/>
   <result pre="cells to the infection site. (3) The APCs that engulfs" exact="CHIKV" post="antigens travel to lymphoid organs, present CHIKV epitopes to"/>
   <result pre="APCs that engulfs CHIKV antigens travel to lymphoid organs, present" exact="CHIKV" post="epitopes to CD4 and CD8 T cells and activate"/>
   <result pre="(81). Hence, the resulting skin TRMs generated can protect against" exact="CHIKV" post="infection from anywhere, regardless of where the virus-infected mosquitoes"/>
   <result pre="release the virus into the host. In the event where" exact="CHIKV" post="penetrates the skin barrier and infect the surrounding cells"/>
   <result pre="virus-infected cells before the disease is established (82, 83). Moreover," exact="CHIKV" post="exposure should further boost pre-existing anti-CHIKV immune response and"/>
   <result pre="memory T cells (79, 80). Over time, repeated exposure of" exact="CHIKV" post="should lead to further CHIKV-specific skin TRM accumulation all"/>
   <result pre="TRM accumulation all over the skin, with no establishment of" exact="CHIKV" post="pathology. The geographical range of mosquitoes that transmit the"/>
   <result pre="increase in the future due to climate change (84). Moreover," exact="CHIKV" post="shares some homology with other alphaviruses with the potential"/>
   <result pre="(85–89). This shift may ultimately lead to the spread of" exact="CHIKV" post="and other alphaviruses and cause future epidemics. However, as"/>
   <result pre="(90) and Powers et al. (91), the close homology between" exact="CHIKV" post="and other viruses within the family of alphaviruses suggest"/>
   <result pre="in the United States (92). Concluding Remarks The re-emergence of" exact="CHIKV" post="underscores the need for effective vaccine strategies to prevent"/>
   <result pre="the need for effective vaccine strategies to prevent further global" exact="CHIKV" post="dissemination. In immunological naïve individuals, CHIKV infection puts them"/>
   <result pre="to prevent further global CHIKV dissemination. In immunological naïve individuals," exact="CHIKV" post="infection puts them at risk of having their immune"/>
   <result pre="them at risk of having their immune system manipulated toward" exact="CHIKV" post="pathology and virus persistence. An optimal vaccine against CHIKV"/>
   <result pre="toward CHIKV pathology and virus persistence. An optimal vaccine against" exact="CHIKV" post="invokes not only humoral response, but more importantly, localized"/>
   <result pre="anti-CHIKV TRMs have the potential to react to more conserved" exact="CHIKV" post="epitopes (which may also be conserved in closely related"/>
   <result pre="of chikungunya virus. Nat Rev Microbiol. (2010) 8:491–500. 10.1038/nrmicro236820551973 4.StaplesEJBreimanRFPowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
   <result pre="re-emerging infectious disease. Clin Infect Dis. (2009) 49:942–8. 10.1086/60549619663604 5.NimmannityaSHalsteadSCohenSMargiottaM." exact="Dengue" post="and chikungunya virus infection in man in Thailand, 1962–1964."/>
   <result pre="Am J Trop Med Hygiene. (1969) 18:954–71. 10.4269/ajtmh.1969.18.9545355242 6.ThaikrueaLCharearnsookOReanphumkarnkitSDissomboonPPhonjanRRatchbudSet al.." exact="Chikungunya" post="in Thailand: a re-emerging disease?Southeast Asian J Trop Med"/>
   <result pre="2004. Am J Trop Med Hyg. (2008) 78:333–7. 10.4269/ajtmh.2008.78.33318256441 13.CoffeyLLFaillouxA-BWeaverSC." exact="Chikungunya" post="virus–vector interactions. Viruses. (2014) 6:4628–63. 10.3390/v611462825421891 14.PowersALogueC. Changing patterns"/>
   <result pre="colony-stimulating factor. J Infect Dis. (2011) 203:149–57. 10.1093/infdis/jiq04221288813 19.GardnerJAnrakuILeTTLarcherTMajorLRoquesPet al.." exact="Chikungunya" post="virus arthritis in adult wild-type mice. J Virol. (2010)"/>
   <result pre="adult wild-type mice. J Virol. (2010) 84:8021–32. 10.1128/JVI.02603-0920519386 20.LabadieKLarcherTJoubertCManniouiADelacheBBrochardPet al.." exact="Chikungunya" post="disease in nonhuman primates involves long-term viral persistence in"/>
   <result pre="T cell response and advancement of epitope based immunotherapy for" exact="CHIKV" post="infection. Infect Gene Evol. (2015) 31:118–26. 10.1016/j.meegid.2015.01.01725643869 36.WaheedYSafiSNajmiMAzizHImranM. Prediction"/>
   <result pre="in mice. Life Sci Alliance. (2019) 2:e201900298. 10.26508/lsa.20190029830665948 51.FrosJJLiuWProwNAGeertsemaCLigtenbergMVanlandinghamDLet al.." exact="Chikungunya" post="virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7047929\results\search\tropicalVirus\results.xml">
   <result pre="nM. The sensitivity found by optical sensor in contact with" exact="DENV" post="is 39.96° nM−1 (Omar et al., 2018). Figure 4"/>
   <result pre="16–21. Vinayagam et al. (2018) reported the recognition of serotype-specific" exact="DENV" post="employing multicolor triangular silver nanoparticles (TAg), which has the"/>
   <result pre="Paper-plastic microfluidic hybrid chip integrated with a lateral flow immunoassay" exact="Dengue" post="84.66 ng.mL−1 &amp;lt;2 min Spiked buffer Yuzon et al.,"/>
   <result pre="Yuzon et al., 2019 Trapezoidal SiNWs array fabricated by AFM-LAO" exact="Dengue" post="2.22 fM Real-time DNA Yusoh et al., 2019 Aptamer–gold"/>
   <result pre="gland extract Bosak et al., 2019 Acrylic-based genosensor (DNA biosensor)" exact="Dengue" post="(DEN-2) 1.21 × 10−16 M 30 min Blood Mazlan"/>
   <result pre="et al., 2019 Urine Saliva Gold nanoparticle-based lateral flow biosensor" exact="Dengue" post="0.01 μM 20 min Synthetic dengue-1 target Yrad et"/>
   <result pre="al., 2019 0.15 ng.mL−1 Serum Localized surface plasmon resonance immunosensors" exact="Dengue" post="(4 serotypes) 107 TCID50.mL−1 &amp;lt;5 min – Basso et"/>
   <result pre="et al., 2018 Two-dimensional MoS2 nanosheets-based disposable biosensor (electrochemical detection)" exact="Chikungunya" post="3.4 nmol.L−1 &amp;lt;60 min PBS serum Singhal et al.,"/>
   <result pre="al., 2018 Paper-based DNA biosensor using gold shell-coated magnetic nanocubes" exact="Chikungunya" post="0.1 nmol.L−1 – PBS serum Singhal et al., 2018"/>
   <result pre="pmol.L−1 5 min – Afsahi et al., 2018 Electrochemical immunosensor" exact="Dengue" post="0.3 ng.mL−1 – Serum Nawaz et al., 2018 Reverse-transcription"/>
   <result pre="tools with target-specific fluorescently tagged strand displaceable probes with RT-LAMP" exact="Dengue" post="~1.22 PFU equivalent viral RNAs 30 min Urine and"/>
   <result pre="Yaren et al., 2017 zika ~0.71 PFU equivalent viral RNAs" exact="Chikungunya" post="~38 copies of viral RNA Electrochemical stand with electrospun"/>
   <result pre="semi-conducting manganese (III) oxide (Mn2O3) nanofibers for DNA hybridization detection" exact="Dengue" post="120 × 10−21 mol.L−1 – Spiked serum Tripathy et"/>
   <result pre="– Spiked serum Tripathy et al., 2017 Electrochemical capacitive sensing" exact="Dengue" post="0.5 ng.mL−1 – Serum Cecchetto et al., 2017 zika"/>
   <result pre="Dengue 0.5 ng.mL−1 – Serum Cecchetto et al., 2017 zika" exact="Chikungunya" post="Coupling of reverse-transcription loop-mediated isothermal amplification (RT-LAMP) with the"/>
   <result pre="with the quenching of unincorporated amplification signal reporters (QUASR) technique" exact="Dengue" post="103.4 copies.μL−1 &amp;lt;40 min Blood, urine, and saliva Priye"/>
   <result pre="equivalent.mL−1(104-101 copies per rxn) 108-103 PFU.mL−1 7–15 min &amp;lt;40 min" exact="Chikungunya" post="Surface-enhanced Raman spectroscopy(SERS)-based sandwich immunoassays (LFA) zika (NS1) 0.72"/>
   <result pre="(NS1) 0.72 ng.mL−1 20 min Serum Sánchez-Purrà et al., 2017" exact="Dengue" post="7.67 ng.mL−1 Bead-based immunofluorescence assay on a microfluidic dielectrophoresis"/>
   <result pre="7.67 ng.mL−1 Bead-based immunofluorescence assay on a microfluidic dielectrophoresis platform" exact="Dengue" post="104 PFU.mL−1 5 min – Iswardy et al., 2017"/>
   <result pre="Iswardy et al., 2017 Optical caustic plasmonic light scattering sensor" exact="Dengue" post="50 pg.mL−1 15 min Serum García et al., 2017"/>
   <result pre="García et al., 2017 Carbon nanotube-based chemiresistor functionalized with heparin" exact="Yellow fever" post="8.4 × 102TCID50.mL−1 10 min – Wasik et al.,"/>
   <result pre="8.4 × 102TCID50.mL−1 10 min – Wasik et al., 2017" exact="Dengue" post="Multiplexed assay on a nanostructured plasmonic gold (pGOLD) platform"/>
   <result pre="et al., 2016 Lateral flow assay using multicolored silver nanoparticles" exact="Dengue" post="150 ng.mL−1 – Blood Yen et al., 2015 Carbon"/>
   <result pre="– Blood Yen et al., 2015 Carbon nanotube-ink printed electrode" exact="Dengue" post="12 ng.mL−1 – Serum Dias et al., 2013 Optical"/>
   <result pre="based on square-planar ethyl piperidine substituted nickel (II) salphen complex" exact="Dengue" post="0.2 mol.L−1 30–120 min Saliva and urine Ariffin et"/>
   <result pre="microvalves and micropumps for rapid DNA hybridization using shuttle flow" exact="Dengue" post="(4 serotypes) 100 pmol.L−1 90 s – Huang et"/>
   <result pre="DNA/RNA amplification, sample injection, and separation of nucleic acid products" exact="Dengue" post="– &amp;lt;5 min – Huang et al., 2010 Sensor-based"/>
   <result pre="al., 2010 Sensor-based microchip employing a magnetic bead bioassay platform" exact="Dengue" post="(antidengue virus IgG) 100 pg.mL−1 – – Aytur et"/>
   <result pre="A.et al.. (2018). Novel graphene-based biosensor for early detection of" exact="Zika" post="virus infection. Biosens. Bioelectron.100, 85–88. 10.1016/j.bios.2017.08.05128865242 AgnihotriA.Wazed AliS.DasA.AlagirusamyR. (2019)."/>
   <result pre="issues. Int. J. Environ. Res. Public Health16:3165. 10.3390/ijerph1617316531480254 AkahataW.UenoR. (2017)." exact="Zika" post="Virus Virus Like Particle. Available online at: https://patents.google.com/patent/WO2017150683A1/en (accessed"/>
   <result pre="10184–10206. 10.1007/s11356-017-9752-428755145 BenelliG.MehlhornH. (2016). Declining malaria, rising of dengue and" exact="Zika" post="virus: insights for mosquito vector control. Parasitol. Res.115, 1747–1754."/>
   <result pre="1139–1149. 10.5935/0103-5053.20160122 EboigbodinK. E.BrummerM.OjalehtoT.HoserM. (2016). Rapid molecular diagnostic test for" exact="Zika" post="virus with low demands on sample preparation and instrumentation."/>
   <result pre="of silver nanocrystals using Quisqualis indica: effectiveness on malaria and" exact="Zika" post="virus mosquito vectors, and impact on non-target aquatic organisms."/>
   <result pre="murex, an ancient Indian medicinal plant: histopathological effects on the" exact="Zika" post="virus vector Aedes aegypti and inhibition of biofilm-forming pathogenic"/>
   <result pre="of nanoformulated clothianidin. Environ. Sci.5, 882–889. 10.1039/C8EN00038G29755738 KaushikA.NairM. (2018). Rapid" exact="Zika" post="Virus Detection Using Nano-Enabled Electrochemical Sensing System. Available online"/>
   <result pre="(2019). Nitrogen-doped porous carbon-based fluorescence sensor for the detection of" exact="ZIKV" post="RNA sequences: fluorescence image analysis. Talanta205:120091. 10.1016/j.talanta.2019.06.09131450455 LiuS.LiuL.TanX.MengB. (2013)."/>
   <result pre="NicoliniA. M.McCrackenK. E.YoonJ.-Y. (2017a). Future developments in biosensors for field-ready" exact="Zika" post="virus diagnostics. J. Biol. Eng.11:7.28127399 NicoliniA. M.McCrackenK. E.YoonJ.-Y. (2017b)."/>
   <result pre="NicoliniA. M.McCrackenK. E.YoonJ.-Y. (2017b). Future developments in biosensors for field-ready" exact="Zika" post="virus diagnostics. J. Biol. Eng.11:7. 10.1186/s13036-016-0046-z28127399 OmarN. A. S.FenY."/>
   <result pre="disease diagnosis. ACS Infect. Dis.4, 1162–1178. 10.1021/acsinfecdis.8b0002329860830 PattersonJ.SammonM.GargM. (2016). Dengue," exact="Zika" post="and Chikungunya: emerging arboviruses in the new world. West."/>
   <result pre="lateral flow immunoassay platform for highly sensitive point-of-care detection of" exact="Zika" post="virus nonstructural protein 1. Anal. Chim. Acta1055, 140–147. 10.1016/j.aca.2018.12.04330782365"/>
   <result pre="Saf.121, 31–38. 10.1016/j.ecoenv.2015.07.00526184431 SabalzaM.YasminR.BarberC. A.CastroT.MalamudD.KimB. J.et al.. (2018). Detection of" exact="Zika" post="virus using reverse-transcription LAMP coupled with reverse dot blot"/>
   <result pre="(2017). Surface-enhanced raman spectroscopy-based sandwich immunoassays for multiplexed detection of" exact="Zika" post="and Dengue viral biomarkers. ACS Infect Dis.3, 767–776. 10.1021/acsinfecdis.7b0011028875696"/>
   <result pre="raman spectroscopy-based sandwich immunoassays for multiplexed detection of Zika and" exact="Dengue" post="viral biomarkers. ACS Infect Dis.3, 767–776. 10.1021/acsinfecdis.7b0011028875696 Schnell-InderstP.HungerT.Conrads-FrankA.ArvandiM.SiebertU. (2018)."/>
   <result pre="(accessed February 12, 2020). collab: Starpharma (2016). Starpharma|VivaGel® active against" exact="Zika" post="virus. Starpharma. Available online at: https://www.starpharma.com/news/281 (accessed December 31,"/>
   <result pre="nanoparticles: synthesis, antibacterial potential, toxicity and histopathological effects against the" exact="Zika" post="virus vector Aedes aegypti. J. Photochem. Photobiol.173, 404–411. 10.1016/j.jphotobiol.2017.06.00428654862"/>
   <result pre="TancharoenC.SukjeeW.ThepparitC.JaimipukT.AuewarakulP.ThitithanyanontA.et al.. (2019). Electrochemical biosensor based on surface imprinting for" exact="Zika" post="virus detection in serum. ACS Sens.4, 69–75. 10.1021/acssensors.8b0088530596236 TavaresM.da"/>
   <result pre="6, 2020). TianB.QiuZ.MaJ.Zardán Gómez de la TorreT.JohanssonC.SvedlindhP.et al.. (2016). Attomolar" exact="Zika" post="virus oligonucleotide detection based on loop-mediated isothermal amplification and"/>
   <result pre="Compositions and Cell-Based Methods for Monitoring the Activity of a" exact="Dengue" post="Virus Protease. Available online at: https://patents.google.com/patent/US10006077B2/en?oq=US10006077B2 (accessed November 14,"/>
   <result pre="R.PatilK. N.BradleyK. M.et al.. (2017). Point of sampling detection of" exact="Zika" post="virus within a multiplexed kit capable of detecting dengue"/>
   <result pre="A.AliasN. N. (2019). Trapezoidal SiNWs array fabricated by AFM-LAO for" exact="Dengue" post="virus DNA oligomer detection. Mater. Res. Express6:11500510.1088/2053-1591/ab3571 YuzonMa. K.KimJ.-H.KimS."/>
   <result pre="J.13, 277–287. 10.1007/s13206-019-3305-5 ZhangB.PinskyB. A.AnantaJ. S.ZhaoS.ArulkumarS.WanH.et al.. (2017). Diagnosis of" exact="Zika" post="virus infection on a nanotechnology platform. Nat. Med.23, 548–550."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7048371\results\search\tropicalVirus\results.xml">
   <result pre="and Bond, Verma, and co-workers,50 reported CG simulations of the" exact="Dengue" post="viral membrane (∼50 nm diameter, ∼1 million particles). In"/>
   <result pre="the Membrane in the Structure and Biophysical Robustness of the" exact="Dengue" post="Virion Envelope. Structure2016, 24, 375–382. 10.1016/j.str.2015.12.011.26833387 MarzinekJ. K.; HoldbrookD."/>
   <result pre="K.; HoldbrookD. A.; HuberR. G.; VermaC.; BondP. J.Pushing the Envelope:" exact="Dengue" post="Viral Membrane Coaxed into Shape by Molecular Simulations. Structure2016,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7052239\results\search\tropicalVirus\results.xml">
   <result pre="unfavorable conditions and may be implicated in dengue outbreaks. Since" exact="DENV" post="infection dynamics vary among wild-type viruses and vector populations,"/>
   <result pre="ecology Funding São Paulo Research Foundation (FAPESP)- Grant #2016/12140–0 Introduction" exact="Dengue" post="is considered the most serious re-emergent viral disease transmitted"/>
   <result pre="DENV5,10. The species has already been found naturally infected with" exact="DENV" post="in a pineapple plantation in Costa Rica11, but this"/>
   <result pre="as vertical transmission13,14. While in endemic areas the ability of" exact="DENV" post="to persist in the environment during periods that are"/>
   <result pre="indications that vertical transmission is an important maintenance mechanism for" exact="DENV" post="circulation during these periods15. Indeed, vertical transmission of this"/>
   <result pre="South America are the main continents where vertical transmission of" exact="DENV" post="in Ae. aegypti and Ae. albopictus under natural conditions"/>
   <result pre="locations. Investigation into the occurrence of natural vertical transmission of" exact="DENV" post="in Ae. aegypti and Ae. albopictus populations is therefore"/>
   <result pre="sought to investigate the occurrence of natural vertical transmission of" exact="DENV" post="in Ae. aegypti and Ae. albopictus mosquito populations in"/>
   <result pre="São Paulo. Results Mosquitoes To detect natural vertical transmission of" exact="DENV" post="in Ae. aegypti and Ae. albopictus during two seasons"/>
   <result pre="much discussion27,28. The first report of natural vertical transmission of" exact="DENV" post="in the Americas was described in specimens from Trinidad"/>
   <result pre="serotypes were also reported in Brazil18,34–36. Natural vertical transmission of" exact="DENV" post="in Ae. aegypti has been demonstrated in the states"/>
   <result pre="Janeiro43 and Amazonas44. Here, we report natural vertical transmission of" exact="DENV" post="in Ae. albopictus for the first time in the"/>
   <result pre="females of Ae. albopictus were able to transmit all four" exact="DENV" post="serotypes vertically to the offspring. The transmission rates varied"/>
   <result pre="to oral infection45. Similar results were found for a Brazilian" exact="DENV" post="strain and populations of Ae. aegypti and Ae. albopictus46,"/>
   <result pre="this species may be less relevant in the maintenance of" exact="DENV" post="during periods of low vector density45,47. Our results corroborate"/>
   <result pre="of Ae. albopictus when compared to Ae. aegypti24,25,48 which maintains" exact="DENV" post="circulation in areas with high concentrations of human beings"/>
   <result pre="and viruses make these parks high-risk areas for infection by" exact="DENV" post="and other arboviruses, raising the question of the relevance"/>
   <result pre="albopictus, such as its vector competence for dengue, yellow fever," exact="Zika" post="and chikungunya viruses in laboratory conditions46,62–64, our findings reinforce"/>
   <result pre="Study area To investigate the occurrence of vertical transmission of" exact="DENV" post="in female and male Ae. aegypti and Ae. albopictus"/>
   <result pre="amplification (semi-nested PCR) that allows simultaneous detection of the four" exact="DENV" post="serotypes by generating DNA products of unique sizes, which"/>
   <result pre="2 Amplification of viral genetic material. Oligonucleotides used to amplify" exact="DENV" post="serotypes. Primer Sequence (5′-3′) Position in the genome Amplified"/>
   <result pre="(60 °C, 30 s) and extension (72 °C, 1 min). RNA from the four" exact="DENV" post="serotypes and ultrapure water were used as positive and"/>
   <result pre="method using the Big Dye Terminator Sequencing Kit (ABI) and" exact="DENV" post="serotype specific primers (Table 2) in the ABI 3100"/>
   <result pre="3.Bennett, S. N. Taxonomy and evolutionary relationships of flaviviruses. in" exact="Dengue" post="and dengue hemorrhagic fever (eds. Gubler, D. J. &amp;amp;"/>
   <result pre="albopictus, and Culex quinquefasciatus (Diptera: Culicidae) as Potential Vectors of" exact="Zika" post="Virus in FloridaJ. Med. Entomol.201956101710.1093/jme/tjy14830165498 10.DegallierNet al.Aedes albopictus may"/>
   <result pre="in Southeastern Brazil and FloridaJ. Med. Entomol.20034078579410.1603/0022-2585-40.6.78514765654 27.KhinMMThanKATransovarial Transmission of" exact="Dengue" post="2 Virus by Aedes aegypti in NatureAm. J. Trop."/>
   <result pre="Trop. Med. Hyg.19833259059410.4269/ajtmh.1983.32.5906859404 28.WattsDMHarrisonBAPantuwatanaSKleinTABurkeDSFailure to Detect Natural Transovarial Transmission of" exact="Dengue" post="Viruses by Aedes aegypti and Aedes albopictus (Diptera: Culicidae)J."/>
   <result pre="albopictus (Diptera: Culicidae)J. Med. Entomol.19852226126510.1093/jmedent/22.3.2614009622 29.HullBTikasinghEde SouzaMMartinezRNatural Transovarial Transmission of" exact="Dengue" post="4 Virus in Aedes aegypti in TrinidadAm. J. Trop."/>
   <result pre="et al. Natural vertical infection by dengue virus serotype 4," exact="Zika" post="virus and Mayaro virus in Aedes (Stegomyia) aegypti and"/>
   <result pre="populations of Aedes aegyptiActa Trop.201717614014310.1016/j.actatropica.2017.07.01428743449 44.da CostaCFet al.Transovarial transmission of" exact="DENV" post="in Aedes aegypti in the Amazon basin: a local"/>
   <result pre="basin: a local model of xenomonitoringParasit. Vectors20171024910.1186/s13071-017-2194-528526066 45.RosenLShroyerDALienJCFreierJETeshRBTransovarial Transmission of" exact="Dengue" post="Viruses by Mosquitoes: Aedes albopictus and Aedes aegyptiAm. J."/>
   <result pre="no Estado de São PauloBol. epidemiol. paul.201292240 53.FaresRCGSouzaKPRAñezGRiosMEpidemiological Scenario of" exact="Dengue" post="in BrazilBiomed Res. Int.2015201511310.1155/2015/321873 54.GuWNovakRJShort report: detection probability of"/>
   <result pre="genetic markersMed. Vet. Entomol.20031719520410.1046/j.1365-2915.2003.00424.x12823837 57.GrunnillMBootsMHow Important is Vertical Transmission of" exact="Dengue" post="Viruses by Mosquitoes (Diptera: Culicidae)?J. Med. Entomol.20165311910.1093/jme/tjv16826545718 58.ThongrungkiatSManeekanPWasinpiyamongkolLPrummongkolSProspective field"/>
   <result pre="American Countries as a Crucial Factor in the Spread of" exact="Chikungunya" post="VirusJ. Virol.2014886294630610.1128/JVI.00370-1424672026 62.Chouin-CarneiroTet al.Differential Susceptibilities of Aedes aegypti and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7053713\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and Life Sciences : Evolutionary Biology"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Genetics: Molecular"/>
   <result pre="medium, provided the original author and source are credited.pntd.0008049.pdf Abstract" exact="Dengue" post="fever, a mosquito-borne viral disease in humans, has been"/>
   <result pre="18 of 21 cities of Guangdong. Phylogenetic analyses revealed that" exact="DENV" post="sequences did not form a single cluster, indicating that"/>
   <result pre="genome sequences were inconclusive. In this study, we sequenced 114" exact="DENV" post="complete genomes of DENV1-4 obtained from 2013 to 2017"/>
   <result pre="preparation of the manuscript. fig-count: table-count: page-count: Data Availability The" exact="DENV" post="genome sequences generated in this study were deposited in"/>
   <result pre="the NCBI GenBank database under the accession no. MN018285-MN018398. Introduction" exact="Dengue" post="fever was listed as a major threat to global"/>
   <result pre="the deaths resulting from dengue infection by 2020 (WHO, https://www.who.int/emergencies/ten-threats-to-global-health-in-2019)." exact="Dengue" post="infection is a mosquito-borne disease widely distributed in tropical"/>
   <result pre="Southeast Asia, Africa, Eastern Mediterranean, Americas, and Western Pacific [2]." exact="Dengue" post="fever is caused by dengue virus (DENV), belonging to"/>
   <result pre="classified into four serotypes (DENV1-4) [4, 5]. The genome of" exact="DENV" post="is a single-strand positive-sense RNA of approximately 11 kb,"/>
   <result pre="whether dengue outbreaks have become endemic in Guangdong. 10.1371/journal.pntd.0008049.t001Table 1" exact="Dengue" post="cases from 2013 to 2017 in Guangdong Province. Year"/>
   <result pre="2017 in Guangdong Province. Year 2013 2014 2015 2016 2017" exact="Dengue" post="cases 2894 45189 1683 544 1662 In the current"/>
   <result pre="patient's history of travelling was obtained through inquiry. Patients with" exact="DENV" post="who did not leave Guangdong within two weeks prior"/>
   <result pre="bodies were used to identify the serotype by indirect immunofluorescence." exact="DENV" post="positive samples were further used for viral isolation by"/>
   <result pre="instructions. One-step RT-PCR kit (TaKaRa, Japan) was used to amplify" exact="DENV" post="sequences according to the manufacturer’s protocols. PCR primer sequences"/>
   <result pre="sequences according to the manufacturer’s protocols. PCR primer sequences of" exact="DENV" post="are provided in S1 Table. Sanger sequencing (ABI 3730)"/>
   <result pre="S1 Table. Sanger sequencing (ABI 3730) was performed to obtain" exact="DENV" post="sequences after PCR products purification (Qiagen, Germany). Sequences assemblies"/>
   <result pre="23, and DENV-4 = 9). Each analyses dataset of four" exact="DENV" post="serotypes was composed of complete genome sequences in this"/>
   <result pre="DENV-4 genome sequences) were collected for subsequent analyses. All published" exact="DENV" post="complete genome accessions involved in this study are supplied"/>
   <result pre="Results Sequence characteristics in this study One hundred and fourteen" exact="DENV" post="complete genomes were sequenced in this study (DENV-1 ="/>
   <result pre="23, DENV-4 = 9). In contrast, there were 79 published" exact="DENV" post="genome sequences (DENV-1 = 55, DENV-2 = 17, DENV-3"/>
   <result pre="temporal distribution, there were 4, 17, 43, 31, and 19" exact="DENV" post="genome sequences from 2013 to 2017, respectively (Fig 1B)."/>
   <result pre="2:7 in DENV-4 (Fig 1B). Fig 1 Statistical information of" exact="DENV" post="genome sequences. (A) No. of DENV sequences both in"/>
   <result pre="1 Statistical information of DENV genome sequences. (A) No. of" exact="DENV" post="sequences both in the present study and those isolated"/>
   <result pre="system in China, http://bzdt.ch.mnr.gov.cn/). In geographical distribution, 75 of 114" exact="DENV" post="genome sequences were derived from five cities, Guangzhou, Shenzhen,"/>
   <result pre="Shenzhen and Foshan simultaneously included DENV1-4, and there were three" exact="DENV" post="serotype sequences distributed in Guangzhou, Dongguan, Zhongshan, Shantou, Jiangmen,"/>
   <result pre="in Guangzhou, Dongguan, Zhongshan, Shantou, Jiangmen, and Yangjiang. Only one" exact="DENV" post="serotype was derived from Zhanjiang, Zhuhai, Zhaoqing, Shanwei, Huizhou,"/>
   <result pre="(Fig 1C). Phylogenetic relationship To illuminate the phylogenetic relationship among" exact="DENV" post="genome sequences in this study, we conducted maximum likelihood"/>
   <result pre="infection were from Southeast and South Asian countries and most" exact="DENV" post="isolates were closet to those from Southeast and South"/>
   <result pre="in their ML trees (S1 and S2 Figs) and most" exact="DENV" post="isolates were closely related to those from Southeast and"/>
   <result pre="S2 Fig), which demonstrated that recombinant events took place in" exact="DENV" post="genomes. Evidence of viral recombination Recombination analyses of DENV"/>
   <result pre="in DENV genomes. Evidence of viral recombination Recombination analyses of" exact="DENV" post="genome CDS regions was performed using Recombination Detection Program"/>
   <result pre="2013 or 2014 (Fig 4B). Fig 4 Recombinant information of" exact="DENV" post="genomic coding regions. UTR sequences were excluded for recombinant"/>
   <result pre="the CDS regions of DENV1-4, only one genomic organization of" exact="DENV" post="is represented in the upper panel. In the lower"/>
   <result pre="(primary axis) and frequency (secondary axis) of recombinant event per" exact="DENV" post="gene. Every involved gene will be counted once if"/>
   <result pre="events. The number and frequency of recombinant event in each" exact="DENV" post="gene were further examined and the results showed that"/>
   <result pre="results showed that recombinant event occurred in every gene of" exact="DENV" post="genome except 2K (Fig 4A and 4C). The recombinant"/>
   <result pre="recombination signal was detected simultaneously in DENV1-4. For the four" exact="DENV" post="serotypes in this study, recombination signal was detected in"/>
   <result pre="We further made a statistical analyses of SNP distribution along" exact="DENV" post="genome within each subtype. The results showed that NS5"/>
   <result pre="then normalized. The normalized SNP represented an even distribution along" exact="DENV" post="genome and it was further compared with that of"/>
   <result pre="results showed that no significant difference was found in intra-serotype" exact="DENV" post="genes (Fig 5A, p &amp;gt; 0.01), which indicated that"/>
   <result pre="a similar rate. Fig 5 The normalized SNP distributions along" exact="DENV" post="genome. (A) Intra-subtype comparison of normalized SNP distributions along"/>
   <result pre="DENV genome. (A) Intra-subtype comparison of normalized SNP distributions along" exact="DENV" post="genomic regions. The normalized SNP are obtained by total"/>
   <result pre="mutation rate (Fig 5C). Discussion In some Southeast Asia countries," exact="Dengue" post="fever outbreaks had been endemic [24, 25]. However, whether"/>
   <result pre="recent years [26–28], while Wang and his colleagues believed that" exact="DENV" post="was an imported disease in Guangdong [29]. Compared to"/>
   <result pre="that is much more reliable about molecular epidemiological characteristics of" exact="DENV" post="in Guangdong in recent years. Genomic sequencing has played"/>
   <result pre="an important driver of viral evolution and adaption [34]. Numerous" exact="DENV" post="recombinant events have been identified in previous studies [26,"/>
   <result pre="that dengue disease is not endemic in Guangdong Province. Among" exact="DENV" post="genes, NS3 possessed the most recombinant events covering simultaneously"/>
   <result pre="in situ. Additionally, there were no obvious intra-serotype differences in" exact="DENV" post="genes, but more significant inter-subtype differences in non-structural genes"/>
   <result pre="in Guangdong is suitable for the multiplication of mosquitoes and" exact="DENV" post="transmission. Therefore, measures that are more effective for dengue"/>
   <result pre="Our investigation has provided further knowledge on the prevalence of" exact="DENV" post="in Guangdong and it is in favor with the"/>
   <result pre="for additional data file. S3 Fig The total SNPs among" exact="DENV" post="genome. (A) Total SNPs within UTR (green), non-synonymous (red)"/>
   <result pre="for additional data file. S2 Table GenBank accessions of published" exact="DENV" post="sequences in dataset. (PDF) LINK Click here for additional"/>
   <result pre="here for additional data file. S4 Table GenBank accessions of" exact="DENV" post="sequences in this study. (PDF) LINK Click here for"/>
   <result pre="diseases with significant public health impact caused by mosquito-borne flaviviruses:" exact="West Nile," post="Zika, dengue and yellow fever. Semin Diagn Pathol. 2019;"/>
   <result pre="10.1016/S1473-3099(16)00146-827091092 6KuhnRJ, ZhangW, MichaelGR, PletnevSV, CorverJ, LenchesE, et al.Structure of" exact="Dengue" post="Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Cell."/>
   <result pre="Flavivirus Organization, Maturation, and Fusion. Cell. 2002;108(5):717–725. 10.1016/s0092-8674(02)00660-811893341 7ChenB, LiuQY." exact="Dengue" post="fever in China. Lancet. 2015;385(9978):1621–2. 10.1016/S0140-6736(15)60793-025943817 8GutiérrezG, LionelG, MaríaP,"/>
   <result pre="of the Diagnostic Utility of the Traditional and Revised WHO" exact="Dengue" post="Case Definitions. PLoS Negl Trop Dis. 2013;7(8):e238510.1371/journal.pntd.000238523991237 9SunJ, LuL,"/>
   <result pre="Parasites &amp;amp; vectors. 2019;12(1):1710.1186/s13071-018-3281-y30621762 25MoorePR, van den HurkAF, MackenzieJS, PykeAT." exact="Dengue" post="viruses in Papua New Guinea: evidence of endemicity and"/>
   <result pre="JiangL, LuoL, FengH, LinP, et al.Evolutionary and phylodynamic analyses of" exact="Dengue" post="virus serotype I in Guangdong Province, China, between 1985"/>
   <result pre="2017;60(12):1–4. 10.1007/s11427-017-9252-y28058635 32KittichaiV, SriprapunM, KonklongP, ThonsanginN, ChompoosriJ, TawatsinA, et al.Double" exact="Dengue" post="Serotypes in Asymptomatic Populations Living in An Area of"/>
   <result pre="Asymptomatic Populations Living in An Area of Thailand Endemic for" exact="Dengue" post="Hemorrhagic Fever. Thai J Vet Med. 2015;45(2):205–12. 33LeeKS, LoS,"/>
   <result pre="of Ebola virus during 2014. Nat Microbiol. 2016;1(11):1615110.1038/nmicrobiol.2016.15127595345 41LazearHM, DiamondMS." exact="Zika" post="Virus: New Clinical Syndromes and Its Emergence in the"/>
   <result pre="the Western Hemisphere. J Virol. 2016;90(10):4864–75. 10.1128/JVI.00252-1626962217 42SutharMS, DiamondMS, GaleM." exact="West Nile" post="virus infection and immunity. Nat Rev Microbiol. 2013;11(2):115–128. 10.1038/nrmicro295023321534"/>
   <result pre="Nat Rev Microbiol. 2005;3(1):13–22. 10.1038/nrmicro106715608696 44DiamondMS, PiersonTC. Molecular Insight into" exact="Dengue" post="Virus Pathogenesis and Its Implications for Disease Control. Cell."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7055223\results\search\tropicalVirus\results.xml">
   <result pre="multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and" exact="Zika" post="Virus GargHimanshuHimanshu.garg@ttuhsc.eduMehmetoglu-GurbuzTugbaJoshiAnjalianjali.joshi@ttuhsc.edu[], 0000 0001 2179 3554grid.416992.1Center of Emphasis in"/>
   <result pre="an emerging threat as evident from the recent outbreak of" exact="Zika" post="virus (ZIKV) as well as repeated outbreaks of Chikungunya"/>
   <result pre="of Zika virus (ZIKV) as well as repeated outbreaks of" exact="Chikungunya" post="(CHIKV), Yellow fever (YFV) and Japanese encephalitis (JEV) virus"/>
   <result pre="virus (ZIKV) as well as repeated outbreaks of Chikungunya (CHIKV)," exact="Yellow fever" post="(YFV) and Japanese encephalitis (JEV) virus in different geographical"/>
   <result pre="host and vectors for these diseases1,2. Amongst these arboviral diseases," exact="Chikungunya" post="(CHIKV), Japanese Encephalitis (JEV), Yellow Fever (YFV) and Zika"/>
   <result pre="diseases, Chikungunya (CHIKV), Japanese Encephalitis (JEV), Yellow Fever (YFV) and" exact="Zika" post="virus (ZIKV) have expanded from isolated outbreaks in endemic"/>
   <result pre="burden on the healthcare system. The World Health Organization lists" exact="Dengue" post="virus (DENV) as the most common mosquito-borne viral disease"/>
   <result pre="(DENV) as the most common mosquito-borne viral disease with CHIKV," exact="YFV" post="and JEV as other arboviruses being endemic in various"/>
   <result pre="overlapping geographical regions; Aedes sp in the case of CHIKV," exact="YFV" post="and ZIKV and Culex sp in the case of"/>
   <result pre="regions; Aedes sp in the case of CHIKV, YFV and" exact="ZIKV" post="and Culex sp in the case of JEV2. Furthermore,"/>
   <result pre="vulnerable populations. Currently, a live attenuated virus (LAV) vaccine for" exact="YFV" post="and a LAV as well as a killed JEV"/>
   <result pre="including safety and availability. Similarly, a tetravalent LAV vaccine for" exact="Dengue" post="has recently been approved with limited success and much"/>
   <result pre="as vaccines12. Previously, we developed a VLP vaccine candidate for" exact="Zika" post="virus and found that the immunogenicity of Capsid protein"/>
   <result pre="different VLPs in desired concentrations into a single formulation15. The" exact="HPV" post="vaccine is one such example where VLPs from 9"/>
   <result pre="such example where VLPs from 9 closely related strains of" exact="HPV" post="are included to increase antigenic breadth and generate a"/>
   <result pre="to develop a safe and efficacious vaccine targeting CHIKV, JEV," exact="YFV" post="and ZIKV termed (CJaYZ vaccine). Stable cell lines secreting"/>
   <result pre="a safe and efficacious vaccine targeting CHIKV, JEV, YFV and" exact="ZIKV" post="termed (CJaYZ vaccine). Stable cell lines secreting Capsid protein"/>
   <result pre="study demonstrating the effectiveness of Capsid protein containing VLPs for" exact="YFV" post="and JEV as well as the first report demonstrating"/>
   <result pre="arboviruses. Results Synthetic gene constructs expressing structural proteins of YFV," exact="CHIKV" post="and JEV and generation of Capsid protein containing VLPs"/>
   <result pre="structural protein expression vectors for the above viruses. For ZIKV," exact="YFV" post="and JEV it included the CprME genes and for"/>
   <result pre="YFV and JEV it included the CprME genes and for" exact="CHIKV" post="the C-E3-E2-E1 genes. We have previously developed a VLP"/>
   <result pre="genes. We have previously developed a VLP based platform for" exact="Zika" post="Virus using a codon optimized synthetic gene construct13 and"/>
   <result pre="modifications. We developed a consensus sequence for CHIKV, JEV and" exact="YFV" post="to include the most representative circulating virus sequences in"/>
   <result pre="protein expression. As demonstrated in Fig. 1, CHIKV, JEV and" exact="YFV" post="constructs showed E expression upon transfection followed by fluorescence"/>
   <result pre="expression upon transfection followed by fluorescence microscopy. For, JEV and" exact="YFV" post="both E protein and Capsid protein expression was documented"/>
   <result pre="E protein expression could be detected as well (Fig. 1E)." exact="ZIKV" post="protein expression using a similar approach has been characterized"/>
   <result pre="approach has been characterized previously13,14. Figure 1 Characterization of JEV," exact="YFV" post="and CHKV protein expression and VLP release. (A) 293 T"/>
   <result pre="expression vector alone or the JEV CprME vector along with" exact="Zika" post="NS2B-3 expression plasmid. Culture supernatants were ultracentrifuged and analyzed"/>
   <result pre="expression by western blotting. (C) 293 T cells were transfected with" exact="YFV" post="CprME expression vector and analyzed for E protein and"/>
   <result pre="expression by immunofluorescence microscopy. (D) 293 T cells were transfected with" exact="YFV" post="CprME expression vector alone or the YFV CprME vector"/>
   <result pre="were transfected with YFV CprME expression vector alone or the" exact="YFV" post="CprME vector along with Zika NS2B-3 expression plasmid. Culture"/>
   <result pre="expression vector alone or the YFV CprME vector along with" exact="Zika" post="NS2B-3 expression plasmid. Culture supernatants were ultracentrifuged and analyzed"/>
   <result pre="the protease for cleavage and has been used previously for" exact="Zika" post="virus VLP production. We wanted to test whether JEV"/>
   <result pre="virus VLP production. We wanted to test whether JEV and" exact="YFV" post="CprME would be cleaved by the Zika NS2B3 protease."/>
   <result pre="whether JEV and YFV CprME would be cleaved by the" exact="Zika" post="NS2B3 protease. Cells were cotransfected with ZIKV NS2B3 with"/>
   <result pre="cleaved by the Zika NS2B3 protease. Cells were cotransfected with" exact="ZIKV" post="NS2B3 with either YFV or JEV CprME and the"/>
   <result pre="NS2B3 protease. Cells were cotransfected with ZIKV NS2B3 with either" exact="YFV" post="or JEV CprME and the supernatants were assayed for"/>
   <result pre="for VLP production. As demonstrated in Fig. 1B,D, JEV and" exact="YFV" post="constructs showed minimum VLP release into the supernatants in"/>
   <result pre="as detected by both E and CA antibodies. Moreover, both" exact="ZIKV" post="and WNV NS2B3 were efficient in cleaving ZIKV, YFV"/>
   <result pre="by both E and CA antibodies. Moreover, both ZIKV and" exact="WNV" post="NS2B3 were efficient in cleaving ZIKV, YFV and JEV"/>
   <result pre="both ZIKV and WNV NS2B3 were efficient in cleaving ZIKV," exact="YFV" post="and JEV CprME with comparable VLP release in the"/>
   <result pre="constructs show cellular expression of desired proteins and expression of" exact="Zika" post="NS2B3 with other flaviviral CprME can produce Capsid protein"/>
   <result pre="proteins (CprME) from a separate plasmid can complement a subgenomic" exact="WNV" post="replicon expressing a GFP reporter gene to generate RVPs."/>
   <result pre="has been shown to work well for different flaviviruses including" exact="WNV" post="and Zika13,21. We generated RVPs expressing JEV and YFV"/>
   <result pre="including WNV and Zika13,21. We generated RVPs expressing JEV and" exact="YFV" post="and ZIKV structural proteins and tested them for infectivity"/>
   <result pre="and Zika13,21. We generated RVPs expressing JEV and YFV and" exact="ZIKV" post="structural proteins and tested them for infectivity in Vero"/>
   <result pre="in Supplementary Figure 2A–C, Vero cells showed infection by JEV," exact="YFV" post="and ZIKV RVPs in a dose dependent manner. For"/>
   <result pre="Figure 2A–C, Vero cells showed infection by JEV, YFV and" exact="ZIKV" post="RVPs in a dose dependent manner. For CHIKV we"/>
   <result pre="YFV and ZIKV RVPs in a dose dependent manner. For" exact="CHIKV" post="we used a slightly different approach as it is"/>
   <result pre="Akahata et al.22, demonstrated that HIV reporter particles pseudotyped with" exact="CHIKV" post="Env generate a specific and sensitive RVP system that"/>
   <result pre="that can be used for neutralizing antibody detection. To develop" exact="CHIKV" post="RVPs, pcDNA3.1 vector expressing the Env region was co-transfected"/>
   <result pre="was co-transfected with HIV NL.LucR-E- vector to generate luciferase expressing" exact="CHIKV" post="pseudotyped RVPs. Once again, infection of Vero cells in"/>
   <result pre="of Vero cells in the presence of serial dilutions of" exact="CHIKV" post="RVPs showed a dose dependent luciferase signal (Supplementary Fig."/>
   <result pre="2D). Having developed RVP based infectivity assays for Zika, JEV," exact="YFV" post="and CHKV, we next asked if infection via RVPs"/>
   <result pre="a dose dependent manner. Moreover, no inhibition of JEV, YFV," exact="ZIKV" post="and CHIKV RVPs was seen in the presence of"/>
   <result pre="dependent manner. Moreover, no inhibition of JEV, YFV, ZIKV and" exact="CHIKV" post="RVPs was seen in the presence of matched control"/>
   <result pre="sera. Vero cells were infected with (A) JEV RVPs (B)" exact="YFV" post="RVPs (C) ZIKV RVPs or (D) CHIKV RVPs after"/>
   <result pre="were infected with (A) JEV RVPs (B) YFV RVPs (C)" exact="ZIKV" post="RVPs or (D) CHIKV RVPs after incubation with serial"/>
   <result pre="JEV RVPs (B) YFV RVPs (C) ZIKV RVPs or (D)" exact="CHIKV" post="RVPs after incubation with serial dilutions of virus specific"/>
   <result pre="mean ± SD of triplicate observations. Bicistronic vector expressing flaviviral CprME and" exact="Zika" post="NS2B3 produces Capsid protein containing VLPs The presence of"/>
   <result pre="immunogen and higher neutralizing antibody titers as seen in our" exact="Zika" post="VLP vaccine studies13,14. In order to produce CprME VLPs,"/>
   <result pre="lines. We have previously developed a biscistronic vector that co-expresses" exact="ZIKV" post="CprME and NS2B3 using an IRES sequence between the"/>
   <result pre="between the ORFs14. We used the same vector to replace" exact="Zika" post="CprME with either JEV or YFV CprME and tested"/>
   <result pre="same vector to replace Zika CprME with either JEV or" exact="YFV" post="CprME and tested them for VLP production. As demonstrated"/>
   <result pre="the bicistronic vectors resulted in robust production of JEV and" exact="YFV" post="VLPs in the supernatant that show incorporation of Capsid"/>
   <result pre="culture supernatants. Thus, a bicistronic vector expressing flaviviral CprME and" exact="Zika" post="NS2B3 robustly secretes Capsid protein containing VLPs into the"/>
   <result pre="lentiviral vector that included an IRES sequence followed by the" exact="Zika" post="NS2B-3 protease. 293 T cells were transfected with the JEV"/>
   <result pre="E protein and Capsid protein secretion via western blotting. (B)" exact="YFV" post="CprME was cloned into a lentiviral vector as above"/>
   <result pre="supernatants by western blotting for E and Capsid protein. (C)" exact="CHIKV" post="C-E3-E2-E1 genes were cloned into a lentiviral vector and"/>
   <result pre="Generation of stable cell lines producing ZIKV, YFV, JEV and" exact="CHIKV" post="VLPs Several successful VLP vaccines are currently in clinical"/>
   <result pre="up for commercial production. Using the bicistronic lentivirus vector expressing" exact="Zika" post="NS2B3 and flaviviral CprME’s, we generated stable cell lines"/>
   <result pre="generated stable cell lines that secrete high levels of JEV," exact="YFV" post="(Fig. 4A,B) and ZIKV VLPs14. For CHIKV, the lentivirus"/>
   <result pre="that secrete high levels of JEV, YFV (Fig. 4A,B) and" exact="ZIKV" post="VLPs14. For CHIKV, the lentivirus construct expressed the CE3E2E1"/>
   <result pre="by flow cytometry. Similarly, the YF9 clone was selected for" exact="YFV" post="(Fig. 4B) and CH3 clone for CHKV (Fig. 4C)"/>
   <result pre="CH3 clone for CHKV (Fig. 4C) for future analysis. The" exact="ZIKV" post="E2 cell line has been described and characterized before14."/>
   <result pre="find high VLP secreting single cell clones for JEV, YFV," exact="ZIKV" post="and CHIKV. These cell clones were used for VLP"/>
   <result pre="mice. Figure 4 Generation of stable cell lines secreting JEV," exact="YFV" post="and CHIKV VLPs. 293 T cells were transduced with (A)"/>
   <result pre="4 Generation of stable cell lines secreting JEV, YFV and" exact="CHIKV" post="VLPs. 293 T cells were transduced with (A) JEV (B)"/>
   <result pre="CHIKV VLPs. 293 T cells were transduced with (A) JEV (B)" exact="YFV" post="or (C) CHKV structural protein containing lentivirus particles. Transduced"/>
   <result pre="protein staining for the different single cell clones for JEV," exact="YFV" post="and CHIKV is shown on the right. Gel images"/>
   <result pre="for the different single cell clones for JEV, YFV and" exact="CHIKV" post="is shown on the right. Gel images were analyzed"/>
   <result pre="comparable VLP production for all four cell lines (JEV, CHIKV," exact="YFV" post="and ZIKV) as cells cultured in the presence of"/>
   <result pre="lines after long term culture. The morphology of JEV, CHIKV," exact="YFV" post="and ZIKV particles was consistent with that of virus"/>
   <result pre="long term culture. The morphology of JEV, CHIKV, YFV and" exact="ZIKV" post="particles was consistent with that of virus particles with"/>
   <result pre="with an average diameter of 40–50 nm or slightly larger for" exact="CHIKV" post="and densely staining membranes as demonstrated by electron microscopy"/>
   <result pre="combinations. We included a bivalent formulation that included JEV and" exact="CHIKV" post="VLPs as these two viruses are prevalent in Asia"/>
   <result pre="prevalent in Asia and a second bivalent group consisting of" exact="YFV" post="and CHIKV VLPs as these two viruses are endemic"/>
   <result pre="Asia and a second bivalent group consisting of YFV and" exact="CHIKV" post="VLPs as these two viruses are endemic in South"/>
   <result pre="EC50 values determined. Data for (A) JEV, (B) YFV, (C)" exact="ZIKV" post="and (D) CHIKV neutralization EC50 values from each mice"/>
   <result pre="Data for (A) JEV, (B) YFV, (C) ZIKV and (D)" exact="CHIKV" post="neutralization EC50 values from each mice are shown. All"/>
   <result pre="in immunized mice. For this, cell lysates form ZIKV, JEV," exact="YFV" post="and CHIKV VLP secreting stable cell lines were immunoprecipitated"/>
   <result pre="mice. For this, cell lysates form ZIKV, JEV, YFV and" exact="CHIKV" post="VLP secreting stable cell lines were immunoprecipitated with pooled"/>
   <result pre="Fig. 7A and consistent with the neutralizing antibody data, the" exact="CHIKV" post="monovalent VLP vaccine generated the strongest antibody titers followed"/>
   <result pre="combinations. This clearly demonstrates the presence of Capsid protein in" exact="CHIKV" post="VLPs and generation of an anti-Capsid immune response upon"/>
   <result pre="an anti-Capsid immune response upon immunization. For YFV, JEV and" exact="ZIKV" post="(Fig. 7B–D) again, specific E and prM antibodies were"/>
   <result pre="Overall, these data demonstrate the generation of specific YFV, JEV" exact="ZIKV" post="and CHIKV E, prM and Capsid antibodies upon immunization"/>
   <result pre="data demonstrate the generation of specific YFV, JEV ZIKV and" exact="CHIKV" post="E, prM and Capsid antibodies upon immunization with the"/>
   <result pre="cell lines for growth in suspension culture. (A) JEV, YFV," exact="ZIKV" post="and CHIKV stable cell lines were adapted to grow"/>
   <result pre="for growth in suspension culture. (A) JEV, YFV, ZIKV and" exact="CHIKV" post="stable cell lines were adapted to grow in suspension"/>
   <result pre="healthcare system25. The rise in arboviral outbreaks including CHIKV, JEV," exact="YFV" post="and more recently ZIKV is driven by multiple factors"/>
   <result pre="in arboviral outbreaks including CHIKV, JEV, YFV and more recently" exact="ZIKV" post="is driven by multiple factors including increased urbanization, increased"/>
   <result pre="an effective strategy in limiting outbreaks. Currently a JEV and" exact="YFV" post="vaccine is available in monovalent form29. Similarly a tetravalent"/>
   <result pre="is available in monovalent form29. Similarly a tetravalent vaccine for" exact="DENV" post="(DENV1-4) has recently been approved for use in individuals"/>
   <result pre="pregnant women. This is especially relevant in the case of" exact="ZIKV" post="vaccination where the target population is largely going to"/>
   <result pre="provides easy scale up and commercialization. A VLP vaccine against" exact="CHIKV" post="has shown efficacy in animal models and has now"/>
   <result pre="models and has now progressed to human trials22. Similarly a" exact="ZIKV" post="VLP vaccine has been tested in our lab in"/>
   <result pre="an additional antigen and better immunogenicity as evident from our" exact="Zika" post="studies13,14. Furthermore, previous studies on arboviral VLPs including CHIKV"/>
   <result pre="our Zika studies13,14. Furthermore, previous studies on arboviral VLPs including" exact="CHIKV" post="have been conducted in monovalent forms and there is"/>
   <result pre="towards determining whether a multivalent VLP formulation encompassing CHIKV, JEV," exact="YFV" post="and ZIKV would provide effective neutralizing response against all"/>
   <result pre="whether a multivalent VLP formulation encompassing CHIKV, JEV, YFV and" exact="ZIKV" post="would provide effective neutralizing response against all four viruses."/>
   <result pre="Virus (HPV) VLP vaccine is a 9 valent vaccine against" exact="HPV" post="types 6/11/16/18/31/33/45/52/58. Several studies have demonstrated the efficacy and"/>
   <result pre="group has developed a prME and CprME VLP vaccine against" exact="ZIKV" post="and demonstrated the superiority of Capsid protein containing VLP"/>
   <result pre="developed a strategy to generate Capsid protein containing VLPs for" exact="ZIKV" post="using a bicistronic vector that expresses the structural proteins"/>
   <result pre="that expresses the structural proteins CprME as well as the" exact="Zika" post="NS2B3 protease. This bicistronic vector helped us establish stable"/>
   <result pre="us establish stable cell lines that are high secretors of" exact="Zika" post="CprME VLPs14. In this study, we modified the bicistronic"/>
   <result pre="we modified the bicistronic vector by replacing CprME region of" exact="ZIKV" post="with that of YFV or JEV. Interestingly, ZIKV NS2B3"/>
   <result pre="vector by replacing CprME region of ZIKV with that of" exact="YFV" post="or JEV. Interestingly, ZIKV NS2B3 was effective at cleaving"/>
   <result pre="region of ZIKV with that of YFV or JEV. Interestingly," exact="ZIKV" post="NS2B3 was effective at cleaving C from prME for"/>
   <result pre="effective at cleaving C from prME for both JEV and" exact="YFV" post="allowing us to use the vector to establish stable"/>
   <result pre="Fisher) as per the manufacturer’s instructions. Antibodies for detection of" exact="Zika" post="Envelope (E) protein (GTX133314) and Capsid protein (GTX133317), JEV"/>
   <result pre="protein (GTX133317), JEV E protein (GTX125867) and Capsid protein (GTX634153)," exact="YFV" post="E protein (GTX134024) and Capsid protein (GTX134022) by western"/>
   <result pre="by western blotting were from GeneTex. For detection of ZIKV," exact="YFV" post="and JEV E protein by flow cytometry, the 4G2"/>
   <result pre="flow cytometry, the 4G2 antibody (MAB10216, Millipore) was used. For" exact="CHIKV" post="E1-E2 protein detection by flow cytometry and western blotting,"/>
   <result pre="blotting, the 6A11 clone was used from Novus Biologicals. JEV," exact="YFV" post="and ZIKV specific sera were kindly provided by BEI"/>
   <result pre="6A11 clone was used from Novus Biologicals. JEV, YFV and" exact="ZIKV" post="specific sera were kindly provided by BEI resources and"/>
   <result pre="specific sera were kindly provided by BEI resources and the" exact="CHIKV" post="specific sera was kindly provided by Centers for Disease"/>
   <result pre="was kindly provided by Centers for Disease Control. Plasmids The" exact="Zika" post="CprME vector has been described previously13. The WNV replicon"/>
   <result pre="Plasmids The Zika CprME vector has been described previously13. The" exact="WNV" post="replicon reporter plasmid Rep/GFP was kindly provided by Dr."/>
   <result pre="kindly provided by Dr. Ted Pierson (NIAID)21. Plasmid containing the" exact="WNV" post="NS2B3 accessory fusion protein expressing the active protease was"/>
   <result pre="was kindly provided by the AIDS reagent program. JEV and" exact="YFV" post="CprME regions were developed based on a consensus sequence"/>
   <result pre="synthetic genes were subcloned into pcDNA3.1+ expression vector. A codon optimized" exact="Zika" post="NS2B3 containing an HA Tag and IRES sequence was"/>
   <result pre="the lentiviral vector pLentiZikaCprME to generate pLentiZika CprME-IRES-NS2B314. To generate" exact="YFV" post="and JEV bicistronic constructs, the Zika CprME in the"/>
   <result pre="pLentiZika CprME-IRES-NS2B314. To generate YFV and JEV bicistronic constructs, the" exact="Zika" post="CprME in the pLentiZikaCprME vector was replaced with YFV"/>
   <result pre="the Zika CprME in the pLentiZikaCprME vector was replaced with" exact="YFV" post="and JEV CprME respectively. The NS2B-3 open reading frame"/>
   <result pre="to generate Zika-NS2B3. A similar approach was taken to generate" exact="CHIKV" post="structural protein (C-E3-E2-6K-E1) from a consensus sequence that was"/>
   <result pre="sequence that was further codon optimized and gene synthesized. The" exact="CHIKV" post="synthetic gene cassette was subcloned into pcDNA3.1+ vector as well"/>
   <result pre="subcloned into pcDNA3.1+ vector as well as pLenti6/V5 vector (Invitrogen). The" exact="CHIKV" post="E region (E3-E2-6K-E1) was PCR amplified from the synthetic"/>
   <result pre="construct and cloned into pCDNA3.1 TOPO vector to generate a" exact="CHIKV" post="E expression vector. Reporter virus particle assay Flaviviral Reporter"/>
   <result pre="generated as described previously13,35. Briefly, 239 T cells were transfected with" exact="WNV" post="Rep/GFP along with CprME plasmid from different flaviviruses (ZIKV,"/>
   <result pre="of GFP positive cells quantitated as described above. For the" exact="CHIKV" post="reporter virus assay, HIV reporter particles pseudotyped with CHIKV"/>
   <result pre="the CHIKV reporter virus assay, HIV reporter particles pseudotyped with" exact="CHIKV" post="E were used similar to the assay reported by"/>
   <result pre="the assay reported by Akahata et al.22. For this, the" exact="CHIKV" post="Envelope region (E3-E2-6K-E1) was PCR amplified from the synthetic"/>
   <result pre="and cloned into pCDNA 3.1 TOPO vector to generate a" exact="CHIKV" post="E expression vector. The HIV pNLLucR-E- vector that expresses"/>
   <result pre="minus the Env and includes a luciferase gene along with" exact="CHIKV" post="Env was used to generate luciferase expressing CHIKV pseudotyped"/>
   <result pre="along with CHIKV Env was used to generate luciferase expressing" exact="CHIKV" post="pseudotyped RVPs. Stable cell line generation Methods for the"/>
   <result pre="have been described previously13,14. Lentiviral vectors expressing ZIKV, JEV or" exact="YFV" post="CprME-IRES-NS2B-3 were packaged into lentiviral particles in 293 T cells"/>
   <result pre="Bulk selected cells were passaged 8–10 times and stained for" exact="ZIKV" post="E protein expression using monoclonal antibody MAB10216 (4G2, Millipore)"/>
   <result pre="further studies. The same strategy was used for generation of" exact="CHIKV" post="VLP secreting cell line. In this case the lentivirus"/>
   <result pre="secreting cell line. In this case the lentivirus expressed the" exact="CHIKV" post="structural proteins (C-E3-E2-6K-E1). The transduced 293 T cells were bulk"/>
   <result pre="cells were stained using E specific primary antibodies (4G2 or" exact="CHIKV" post="E Ab; 1:200 dilution) followed by Alexa 488 conjugated"/>
   <result pre="instructions. Cells were stained using the primary antibody 4G2 or" exact="CHIKV" post="E Ab at 1:500 dilution followed by secondary antibody"/>
   <result pre="and serum free media Stable cell lines secreting Zika, JEV," exact="YFV" post="and CHIKV VLPs were cultured in EX-CELL-293T serum free"/>
   <result pre="free media Stable cell lines secreting Zika, JEV, YFV and" exact="CHIKV" post="VLPs were cultured in EX-CELL-293T serum free media (Sigma)"/>
   <result pre="thank Dr. Ted Pierson (NIAID) for the sub-genomic GFP expressing" exact="WNV" post="replicon plasmids, Dr. Frank Scholle (NC State Univ.) for"/>
   <result pre="replicon plasmids, Dr. Frank Scholle (NC State Univ.) for the" exact="WNV" post="NS2B-3 protease plasmid, NIH AIDS Reagent Program for the"/>
   <result pre="Brandy Russell (CDC, Fort Collins, Colorado) for kindly providing the" exact="CHIKV" post="immune sera. We would also like to thank BEI"/>
   <result pre="would also like to thank BEI resources for the ZIKV," exact="YFV" post="and JEV immune sera and the TTUHSC-El Paso LARC"/>
   <result pre="Its Emergence in the Western HemisphereJournal of virology2016904864487510.1128/JVI.00252-1626962217 6.YactayoSStaplesJEMillotVCibrelusLRamon-PardoPEpidemiology of" exact="Chikungunya" post="in the AmericasThe Journal of infectious diseases2016214S441S44510.1093/infdis/jiw39027920170 7.SalimiHCainMDKleinRSEncephalitic Arboviruses:"/>
   <result pre="Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated" exact="Dengue" post="Vaccine (Dengvaxia): A Model Comparison StudyPLoS Med201613e100218110.1371/journal.pmed.100218127898668 12.WangJWRodenRBVirus-like particles"/>
   <result pre="Joshi, A. Development of Virus-Like-Particle Vaccine and Reporter Assay for" exact="Zika" post="Virus. Journal of virology91, 10.1128/JVI.00834-17 (2017). 14.GargHimanshuMehmetoglu-GurbuzTugbaRuddyGregory M.JoshiAnjaliCapsid containing"/>
   <result pre="10.1128/JVI.00834-17 (2017). 14.GargHimanshuMehmetoglu-GurbuzTugbaRuddyGregory M.JoshiAnjaliCapsid containing virus like particle vaccine against" exact="Zika" post="virus made from a stable cell lineVaccine201937487123713110.1016/j.vaccine.2019.09.09331607605 15.WongJasseyWangWangLiuLinVirus-Like Particle"/>
   <result pre="in the Flaviviridae FamilyVaccines20197412310.3390/vaccines7040123 16.PilsSJouraEAFrom the monovalent to the nine-valent" exact="HPV" post="vaccineClin Microbiol Infect20152182783310.1016/j.cmi.2015.05.00125980355 17.YamshchikovVFCompansRWFormation of the flavivirus envelope: role"/>
   <result pre="al.A rapid and quantitative assay for measuring antibody-mediated neutralization of" exact="West Nile" post="virus infectionVirology2006346536510.1016/j.virol.2005.10.03016325883 22.AkahataWet al.A virus-like particle vaccine for epidemic"/>
   <result pre="Nile virus infectionVirology2006346536510.1016/j.virol.2005.10.03016325883 22.AkahataWet al.A virus-like particle vaccine for epidemic" exact="Chikungunya" post="virus protects nonhuman primates against infectionNature medicine20101633433810.1038/nm.210520111039 23.MohsenMOZhaLCabral-MirandaGBachmannMFMajor findings"/>
   <result pre="Change and the Arboviruses: Lessons from the Evolution of the" exact="Dengue" post="and Yellow Fever VirusesAnnu Rev Virol2016312514510.1146/annurev-virology-110615-03563027482902 27.CollinsMHMetzSWProgress and Works"/>
   <result pre="particles as immunogensTrends in microbiology20031143844410.1016/S0966-842X(03)00208-713678860 32.JouraEBautistaO&amp;amp; Luxembourg, A. A 9-Valent" exact="HPV" post="Vaccine in WomenN Engl J Med20153722568256910.1056/NEJMc150435926107058 33.JouraEAet al.A 9-valent"/>
   <result pre="HPV Vaccine in WomenN Engl J Med20153722568256910.1056/NEJMc150435926107058 33.JouraEAet al.A 9-valent" exact="HPV" post="vaccine against infection and intraepithelial neoplasia in womenN Engl"/>
   <result pre="GirlsPediatr Infect Dis J20153499299810.1097/INF.000000000000077326090572 35.GargHLeeRTTekNOMaurer-StrohSJoshiAIdentification of conserved motifs in the" exact="West Nile" post="virus envelope essential for particle secretionBMC Microbiol20131319710.1186/1471-2180-13-19724007503 36.BrienJDLazearHMDiamondMSPropagation, quantification,"/>
   <result pre="for particle secretionBMC Microbiol20131319710.1186/1471-2180-13-19724007503 36.BrienJDLazearHMDiamondMSPropagation, quantification, detection, and storage of" exact="West Nile" post="virusCurrent protocols in microbiology20133115D 13 1115D 13 1810.1002/9780471729259.mc15d03s31"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7055907\results\search\tropicalVirus\results.xml">
   <result pre="RogerF. Epidemiological processes involved in the emergence of vector-borne diseases:" exact="West Nile" post="fever, Rift Valley fever, Japanese encephalitis and Crimean-Congo haemorrhagic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7057477\results\search\tropicalVirus\results.xml">
   <result pre="CentralLondon pmcid: 7057477115 doi: 10.1186/s40709-020-00115-4 : Review A review on" exact="Zika" post="virus outbreak, epidemiology, transmission and infection dynamics KazmiSyeda Sidra1AliWaqarwaqarali@bs.qau.edu.pk1BibiNousheen1NourozFaisal12[1],"/>
   <result pre="otherwise stated in a credit line to the data. Abstract" exact="Zika" post="virus (ZIKV) is a newly emergent relative of the"/>
   <result pre="of the Flaviviridae family and linked to dengue (DENV) and" exact="Chikungunya" post="(CHIVKV). ZIKV is one of the rising pathogens promptly"/>
   <result pre="Flaviviridae family and linked to dengue (DENV) and Chikungunya (CHIVKV)." exact="ZIKV" post="is one of the rising pathogens promptly surpassing geographical"/>
   <result pre="is one of the rising pathogens promptly surpassing geographical borders." exact="ZIKV" post="infection was characterized by mild disease with fever, headache,"/>
   <result pre="in fetus and new-borns in Brazil have been related to" exact="ZIKV" post="infection, raising serious worldwide public health concerns. ZIKV is"/>
   <result pre="related to ZIKV infection, raising serious worldwide public health concerns." exact="ZIKV" post="is transmitted by the bite of infected female mosquitoes"/>
   <result pre="we extensively described the current understanding of the effects of" exact="ZIKV" post="on heath, clinical manifestation, diagnosis and treatment options based"/>
   <result pre="on modern, alternative and complementary medicines regarding the disease. Keywords" exact="Zika" post="virus Aedes mosquito Epidemiology Guillain–Barré syndrome Microcephaly Treatment Introduction"/>
   <result pre="Guillain–Barré syndrome Microcephaly Treatment Introduction Among the family of viruses," exact="Zika" post="virus (ZIKV) is an emerging evolving virus on the"/>
   <result pre="initially reported from Uganda in 1940s [1, 2]. Transmission of" exact="ZIKV" post="is related to the two other imperative arbo-viruses including"/>
   <result pre="the blood of a sentinel rhesus macaque placed in the" exact="Zika" post="Forest of Uganda [4, 5]. ZIKV stayed relatively silent"/>
   <result pre="macaque placed in the Zika Forest of Uganda [4, 5]." exact="ZIKV" post="stayed relatively silent for almost 70 years and all"/>
   <result pre="Islands to Brazil [6]. Recently it was identified that the" exact="ZIKV" post="strain found in the Americas had escalated to Angola"/>
   <result pre="above mentioned studies endorse overview of mosquito-borne transmission of the" exact="ZIKV" post="strain from the Americas into continental Africa. World Health"/>
   <result pre="international concern as a result of global alarm created by" exact="ZIKV" post="by becoming first foremost infectious disease coupled with defects"/>
   <result pre="than a half of century [10]. History and epidemiology of" exact="ZIKV" post="ZIKV is a member of family Flaviviridae and spread"/>
   <result pre="a half of century [10]. History and epidemiology of ZIKV" exact="ZIKV" post="is a member of family Flaviviridae and spread through"/>
   <result pre="family include arboviruses, dengue virus and Japanese encephalitis viruses [11]." exact="ZIKV" post="antibodies were also detected in animal species, especially non-human"/>
   <result pre="were also detected in animal species, especially non-human primates [12]." exact="ZIKV" post="was also isolated from several mosquito species in Africa"/>
   <result pre="aegypti [13] and Aedes albopictus, respectively [14]. Studies reported that" exact="ZIKV" post="has three main lineages, two from Africa and one"/>
   <result pre="strain as its own lineage. Epidemiology studies revealed distribution of" exact="ZIKV" post="in half of the north African continent, Vietnam, Malaysia,"/>
   <result pre="during a study indicating the presence of neutralizing antibodies to" exact="ZIKV" post="in sera [25]. Only few cases of infection in"/>
   <result pre="infection in human were reported before 2007 when outbreak of" exact="ZIKV" post="infection in humans occurred in Yap, Federated States of"/>
   <result pre="Pacific region [26]. In French Polynesia the largest epidemic of" exact="ZIKV" post="occurred during 2013 to 2014 and extended to New"/>
   <result pre="Vanuatu, Easter Island, Solomon Islands and other Pacific Islands [5]." exact="ZIKV" post="transmission is known in 55 countries and territories. However,"/>
   <result pre="affected with local infection [27]. Fig. 1 Chronological time-line of" exact="ZIKV" post="epidemic from 1947–2016 Molecular biology and virology Flaviviridae family"/>
   <result pre="encephalitis, visceral involvement and hemorrhagic fever [29]. The length of" exact="ZIKV" post="genome is 10,794 kb, comprising a positive sense single-stranded"/>
   <result pre="folding patterns are present in the 39 NCR of the" exact="ZIKV" post="genome [30]. These nucleotides and folding patterns may involve"/>
   <result pre="and genome stabilization [31]. Fig. 2 The genome organization of" exact="ZIKV" post="All identified structures of flaviviruses vary on the basis"/>
   <result pre="that is composed of two dissimilar proteins having 180 copies." exact="ZIKV" post="varies from other flaviviruses bulges by glycosylation spot on"/>
   <result pre="protein at this spot. Surrounding residues and glycosylation site on" exact="ZIKV" post="may be responsible for attachment of virus to human"/>
   <result pre="infect. If the function of glycosylation spot is analogous to" exact="DENV" post="(attachment to the cells receptor of human body) it"/>
   <result pre="be targeted by an antiviral compound [32]. Incubation period for" exact="ZIKV" post="disease is around 2–7 days [33], with symptoms like"/>
   <result pre="disturbances, photophobia, cough malaise, back pain, aphthous ulcers and sweating." exact="ZIKV" post="infection can be misdiagnosed with other arboviruses and bacterial"/>
   <result pre="with other arboviruses and bacterial infections as not explicit to" exact="ZIKV" post="infection, especially in prevalent areas. In French Polynesia serious"/>
   <result pre="was increased to 20-fold during the epidemic [35]. Transmission of" exact="ZIKV" post="ZIKV vector-borne transmission Aedes aegypti, Aedes polynesiensis and Aedes"/>
   <result pre="increased to 20-fold during the epidemic [35]. Transmission of ZIKV" exact="ZIKV" post="vector-borne transmission Aedes aegypti, Aedes polynesiensis and Aedes albopictus"/>
   <result pre="albopictus are the potential vectors responsible for the transmission of" exact="ZIKV" post="infection by biting. Aedes aegypti is the foremost vector"/>
   <result pre="infection by biting. Aedes aegypti is the foremost vector of" exact="DENV" post="and CHIKV. Aedes polynesiensis is the main vector responsible"/>
   <result pre="Polynesia these species of mosquitoes were collected and tested for" exact="ZIKV" post="infection by RT-PCR and only one Aedes aegypti mosquito"/>
   <result pre="RT-PCR and only one Aedes aegypti mosquito was confirmed having" exact="ZIKV" post="RNA; experimental investigations showed the French Polynesian strain of"/>
   <result pre="Polynesian strain of Aedes aegypti can replicate the French Polynesian" exact="ZIKV" post="strain (Additional file 1: Figure S1) [36]. Altogether, 61"/>
   <result pre="conventional competent Aedes aegypti vectors but have not yet documented" exact="ZIKV" post="transmission [37]. Thus, risk of ZIKV spread to other"/>
   <result pre="have not yet documented ZIKV transmission [37]. Thus, risk of" exact="ZIKV" post="spread to other countries is still likely. Might be"/>
   <result pre="was also reported in all areas with prior reports of" exact="ZIKV" post="transmission. Altogether in the African lineage eight mosquitoes were"/>
   <result pre="only mosquito isolated in the Asian lineage (Malaysia/1966). In 2007," exact="ZIKV" post="was identified in patients infected with Aedes aldopictus mosquitoes"/>
   <result pre="that cause Micronesia outbreak [38]. Later on, in 2013, the" exact="ZIKV" post="spread out to French Polynesia, with consequent extent to"/>
   <result pre="Aedes aegypti is considered as the utmost common vector for" exact="DENV" post="[41]. Later on in 2006, Chouin-Carneiro reported that the"/>
   <result pre="and Aedes albopictus which found to be poor transmitters of" exact="ZIKV" post="results in continuous divergence of the Asian lineage [42]."/>
   <result pre="Indeed, while Aedes is widely accepted as the vector for" exact="ZIKV" post="[1, 43, 44], Guedes et al. has revealed that"/>
   <result pre="ZIKV [1, 43, 44], Guedes et al. has revealed that" exact="ZIKV" post="can infect and replicate in the salivary glands, midgut,"/>
   <result pre="Altogether this work suggests that the transmission vector range for" exact="ZIKV" post="may be larger than foreseen (although still a debatable"/>
   <result pre="debatable topic demanding more exploration). Non-vector-borne transmission Non-vector-borne transmission of" exact="ZIKV" post="infection can be caused during labor (mother to child),"/>
   <result pre="(Fig. 3). Fig. 3 Schematic diagram representing the transmission of" exact="ZIKV" post="Antibodies against ZIKV were detected by Serosurvey studies in"/>
   <result pre="3 Schematic diagram representing the transmission of ZIKV Antibodies against" exact="ZIKV" post="were detected by Serosurvey studies in goats, rodents (Meriones"/>
   <result pre="These studies suggest that there is no clear association between" exact="ZIKV" post="and a specific species of animal [36]. In humans,"/>
   <result pre="viral infection may also refer to sexual contact [5]. High" exact="ZIKV" post="RNA load has detected in breast milk, so transmission"/>
   <result pre="breast milk, so transmission is possible by breast feeding and" exact="ZIKV" post="can also be transmitted by blood transfusions [46] as"/>
   <result pre="reported on December 2015 in Brazil, the first case of" exact="ZIKV" post="blood transfusion transmission [47]. ZIKV is adopted to transmit"/>
   <result pre="Brazil, the first case of ZIKV blood transfusion transmission [47]." exact="ZIKV" post="is adopted to transmit by enzootic and sub Urban"/>
   <result pre="non-vector borne transmission of ZIKV. Fig. 4 Transmission cycle of" exact="ZIKV" post="Pathophysiology and diagnosis In the beginning, ZIKV infection was"/>
   <result pre="Transmission cycle of ZIKV Pathophysiology and diagnosis In the beginning," exact="ZIKV" post="infection was misdiagnosed with dengue infection. Virus isolation and"/>
   <result pre="serological methods are carried out for laboratory diagnosis examination for" exact="ZIKV" post="(Table 1) [48]. Virus isolation needs several days (i.e."/>
   <result pre="serological methods [15]. Cell culture may be utilized to isolate" exact="ZIKV" post="[5] but specialized laboratories are required to practice it"/>
   <result pre="16]. Reverse transcription PCR (RT-PCR) is used for confirmation of" exact="ZIKV" post="infections whereas IgM against ZIKV can be detected by"/>
   <result pre="is used for confirmation of ZIKV infections whereas IgM against" exact="ZIKV" post="can be detected by ELISA [48]. RT-PCR is time"/>
   <result pre="is time saving, specific and sensitive in order to detect" exact="ZIKV" post="in serum or cell culture [15]. Molecular detection of"/>
   <result pre="ZIKV in serum or cell culture [15]. Molecular detection of" exact="ZIKV" post="was increased when saliva was used at the acute"/>
   <result pre="children and neonates as blood is difficult to collect [5]." exact="ZIKV" post="fever diagnosis from PAHO is shown in Fig. 5."/>
   <result pre="diagnosis from PAHO is shown in Fig. 5. RT-PCR for" exact="ZIKV" post="is done on blood or saliva sample. Sequencing is"/>
   <result pre="Sequencing is performed if the results of RT-PCR are positive." exact="ZIKV" post="IgM serology comprises detection by immunofluorescence or ELISA, with"/>
   <result pre="are equivocal or positive [36]. Table 1 Differential diagnosis of" exact="ZIKV" post="infection includes various viral diseases with similar signs and"/>
   <result pre="includes various viral diseases with similar signs and symptoms as" exact="ZIKV" post="infection [49] No Viral diseases Similarities with Zika virus"/>
   <result pre="symptoms as ZIKV infection [49] No Viral diseases Similarities with" exact="Zika" post="virus Dissimilarities with Zika virus Diagnostic test 1 Dengue"/>
   <result pre="[49] No Viral diseases Similarities with Zika virus Dissimilarities with" exact="Zika" post="virus Diagnostic test 1 Dengue fever High fever, severe"/>
   <result pre="with Zika virus Dissimilarities with Zika virus Diagnostic test 1" exact="Dengue" post="fever High fever, severe muscle pain, and headache and"/>
   <result pre="be associated with hemorrhage Not associated with conjunctivitis Serology 2" exact="Chikungunya" post="High fever and intense joint pain affecting the hands,"/>
   <result pre="lymphadenopathy Not associated with conjunctivitis, coryza is not present in" exact="ZIKV" post="infection Serology 5 Measles Fever, cough, conjunctivitis, and lymphadenitis."/>
   <result pre="generalized rash Sore throat and coryza are not present in" exact="ZIKV" post="infection Serology 6 Leptospirosis Fever, rigors, myalgia, conjunctival suffusion,"/>
   <result pre="Leptospirosis Fever, rigors, myalgia, conjunctival suffusion, headache, arthralgia Distinguished from" exact="ZIKV" post="infection by the presence of jaundice Serology 7 Malaria"/>
   <result pre="smear and polymerase chain reaction Fig. 5 Flow scheme for" exact="ZIKV" post="fever diagnosis [73, 74] Neurological complications of ZIKV infection"/>
   <result pre="scheme for ZIKV fever diagnosis [73, 74] Neurological complications of" exact="ZIKV" post="infection Guillain–Barré syndrome and cases of other neurologic manifestations"/>
   <result pre="other neurologic manifestations appears in Brazil and French Polynesia throughout" exact="ZIKV" post="epidemics, even though it is self-limiting [50, 51]. A"/>
   <result pre="is a possible relation between fetal deformities and infection with" exact="ZIKV" post="in pregnancy, as the incidences of microcephaly cases among"/>
   <result pre="neonates have amplified by a factor of about 20 [51]." exact="ZIKV" post="infection in fetus can be identified by Ultrasound in"/>
   <result pre="after birth and 30 of these were associated to congenital" exact="ZIKV" post="infection [53]. It has been published from the Paraíba"/>
   <result pre="It has been published from the Paraíba State recently that" exact="ZIKV" post="infection was detected in newborns having severe congenital CNS"/>
   <result pre="with intertwined relation between congenital CNS malformations during pregnancy and" exact="ZIKV" post="infection [54]. Risk of Guillain–Barré syndrome Guillain–Barré syndrome (GBS)"/>
   <result pre="(GBS) is one of the new complications and manifestations of" exact="ZIKV" post="infection [34]. GBS is a serious and life threatening"/>
   <result pre="respiratory failure characterized by progressive muscular weakness [55]. Outbreak of" exact="ZIKV" post="in French Polynesia four years ago added it to"/>
   <result pre="GBS. Sufficient intravenous (IV) immunoglobulin (Ig) treatment for patients with" exact="ZIKV" post="related GBS should be applied [57]. Increased verification of"/>
   <result pre="related GBS should be applied [57]. Increased verification of a" exact="ZIKV" post="infection based on laboratory results and GBS prevalence have"/>
   <result pre="period from December 2015 to March 2016 [53]. Treatment of" exact="ZIKV" post="In ZIKV infection, individuals should have adequate water intake,"/>
   <result pre="December 2015 to March 2016 [53]. Treatment of ZIKV In" exact="ZIKV" post="infection, individuals should have adequate water intake, ample rest"/>
   <result pre="no specific medications or vaccine available to treat or prevent" exact="ZIKV" post="infections until now; only medications for symptomatic relief can"/>
   <result pre="medical condition [54]. Homeopathy is a worthy treatment option in" exact="ZIKV" post="infection as it proved to be effective in Japanese"/>
   <result pre="encephalitis virus which is included in the same genus like" exact="Zika" post="virus [33]. Treatment with belladonna efficaciously reduced the severity"/>
   <result pre="diseases and illnesses [62]. Fig. 6 Schematic representation of possible" exact="ZIKV" post="treatment Eupatorium is a naturally occurring pharmaceutical homeopathic compound"/>
   <result pre="naturally occurring pharmaceutical homeopathic compound effective against the symptoms of" exact="ZIKV" post="disease, so it can be utilized as prophylactic treatment"/>
   <result pre="disease, so it can be utilized as prophylactic treatment against" exact="ZIKV" post="infection [63]. Eupatorium perfoliatum, Rhustox and Atropa belladonna are"/>
   <result pre="belladonna are the homeopathic prescriptions that may be utilized for" exact="ZIKV" post="infection treatment. These medicinal agents are effective against the"/>
   <result pre="treatment. These medicinal agents are effective against the symptoms of" exact="ZIKV" post="infection [64]. During epidemics homeopathic pharmaceuticals are more effective"/>
   <result pre="these ayurvedic plants so they might also be effective for" exact="ZIKV" post="[33]. Beside homeopathic and ayurveda medicines, engineering approaches were"/>
   <result pre="directed towards resolving symptoms and not the actual infection; however," exact="ZIKV" post="treatments and vaccines are in development. In 2016, WHO"/>
   <result pre="all publicly affirmed commercial, government and academic-led projects focused at" exact="ZIKV" post="interventions, together with vaccines [69]. The list encompasses numerous"/>
   <result pre="71]. Suggested workflow for prompt discovery of drug counter to" exact="ZIKV" post="is presented in Fig. 7; whole process is proposed"/>
   <result pre="trial and if getting optimistic results, manufacturing the drug against" exact="ZIKV" post="by scale up process, advertising and dissemination of drug"/>
   <result pre="drug [72]. Fig. 7 Proposed workflow for drug development against" exact="ZIKV" post="Prevention and control of ZIKV Most precarious threats for"/>
   <result pre="workflow for drug development against ZIKV Prevention and control of" exact="ZIKV" post="Most precarious threats for ZIKV infection are mosquitoes including"/>
   <result pre="ZIKV Prevention and control of ZIKV Most precarious threats for" exact="ZIKV" post="infection are mosquitoes including their reproducing localities. Their encounter"/>
   <result pre="mosquitoes containing active ingredients Tetramethrin and Cypermethrin [75]. Tests against" exact="ZIKV" post="infection should be performed before blood transfusions to prevent"/>
   <result pre="related transmission. Pregnancy must be avoided in the high risk" exact="ZIKV" post="infection prone areas before complete eradication or extra care"/>
   <result pre="extra care must be exercised as microcephaly is associated with" exact="ZIKV" post="infection [76]. Besides, different vector control strategies for averting"/>
   <result pre="ZIKV infection [76]. Besides, different vector control strategies for averting" exact="Zika" post="virus spread can be employed. Subjugation of mosquito population"/>
   <result pre="on honeydew, fruit, and nectar [77]. Hence, the spread of" exact="ZIKV" post="can be encountered by utilizing these species. Aedes species"/>
   <result pre="it worldwide. At present there is no vaccine available for" exact="ZIKV" post="infection. Vaccines against flaviviral infections available for use of"/>
   <result pre="vector borne infections must be followed in order to prevent" exact="ZIKV" post="infection, as well as avoiding mosquito bite and control"/>
   <result pre="vector is the only available options. Animal models of the" exact="ZIKV" post="disease are immediately required not only for exhibiting the"/>
   <result pre="virus on host’s immunity and reproductive health throughout the life." exact="ZIKV" post="infection is increasing dramatically, so it is the need"/>
   <result pre="lethal infection and to constrain its future entrance as well." exact="ZIKV" post="specific rapid molecular diagnosis should be done urgently in"/>
   <result pre="of broad spectrum clinical consequences that are resulting from fetal" exact="ZIKV" post="infection and the environmental influences that effect their emergence."/>
   <result pre="effective medications and the vaccines to shield humans counter to" exact="ZIKV" post="disease. Supplementary information LINK Additional file 1: Figure S1:"/>
   <result pre="Hyg201610.4269/ajtmh.15-086626903610 4.PetersenLRJamiesonDJPowersAMHoneinMAZika virusN Eng J Med20163741552156310.1056/NEJMra1602113 5.MussoDRocheCRobinENhanTTeissierACao-LormeauV-MPotential sexual transmission of" exact="Zika" post="virusEmerg Infect Dis20152135936110.3201/eid2102.14136325625872 6.FauciASMorensDMZika virus in the Americas—yet another"/>
   <result pre="Med201637460160410.1056/NEJMp160029726761185 7.World Health Organization Regional Office for Africa. Microcephaly—suspected congenital" exact="Zika" post="syndrome, Angola. Weekly bulletin on outbreaks and other emergencies;"/>
   <result pre="Accessible at: https://apps.who.int/iris/bitstream/handle/10665/259557/OEW48- 2504122017.pdf?sequence = 1. 8.SassettiMZé-ZéLFrancoJCunhaJDGomesAToméAet al.First case of confirmed congenital" exact="Zika" post="syndrome in continental AfricaTrans R Soc Trop Med Hyg201811245846210.1093/trstmh/try07430053235"/>
   <result pre="AfricaTrans R Soc Trop Med Hyg201811245846210.1093/trstmh/try07430053235 9.HillSCVasconcelosJNetoZJandondoDZé-ZeLAguiarRSet al.Emergence of the" exact="Zika" post="virus Asian lineage in Angola: an outbreak investigationLancet Inf"/>
   <result pre="public health emergency of international concernJAMA �?eurol.20167313951396 11.HamelRDejarnacOWichitSEkchariyawatPNeyretALuplertlopNet al.Biology of" exact="Zika" post="virus infection in human skin cellsJ Virol2015898880889610.1128/JVI.00354-1526085147 12.KiryaBGOkiaNOA yellow"/>
   <result pre="in human skin cellsJ Virol2015898880889610.1128/JVI.00354-1526085147 12.KiryaBGOkiaNOA yellow fever epizootic in" exact="Zika" post="Forest, Uganda, during 1972: part 2: Monkey serologyTrans R"/>
   <result pre="2: Monkey serologyTrans R Soc Trop Med Hyg19777130030310.1016/0035-9203(77)90104-3413216 13.MarchetteNJGarciaRRudnickAIsolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm J Trop"/>
   <result pre="Aedes albopictus?PLoS Negl Trop Dis.20148e268110.1371/journal.pntd.000268124516683 15.FayeOFayeODialloDDialloMWeidmannMSallAAQuantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught mosquitoesVirol J.201320131031110.1186/1743-422X-10-311 16.LanciottiRSKosoyOLLavenJJVelezJOLambertAJJohnsonAJet al.Genetic"/>
   <result pre="with field-caught mosquitoesVirol J.201320131031110.1186/1743-422X-10-311 16.LanciottiRSKosoyOLLavenJJVelezJOLambertAJJohnsonAJet al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg"/>
   <result pre="State, Micronesia, 2007Emerg Infect Dis2008141232123910.3201/eid1408.08028718680646 17.FayeOFreireCCMIamarinoAFayeOde OliveiraJVCDialloMet al.Molecular evolution of" exact="Zika" post="virus during its emergence in the 20th centuryPLoS Negl"/>
   <result pre="the 20th centuryPLoS Negl Trop Dis.20148e263610.1371/journal.pntd.000263624421913 18.HaddowADSchuhAJYasudaCYKasperMRHeangVHuyRet al.Genetic characterization of" exact="Zika" post="virus strains: geographic expansion of the Asian lineagePLoS Negl"/>
   <result pre="BahiaBrazil. Emerg Infect Dis.2015211885188610.3201/eid2110.15084726401719 21.ZanlucaCMeloVCMosimannALSantosGISantosCNLuzKFirst report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem Inst Oswaldo Cruz201511056957210.1590/0074-0276015019226061233 22.WongsurawatTAthipanyasilpNJenjaroenpunPJunSRKaewnapanBWassenaarTMet al.Case of"/>
   <result pre="22.WongsurawatTAthipanyasilpNJenjaroenpunPJunSRKaewnapanBWassenaarTMet al.Case of microcephaly after congenital infection with Asian lineage" exact="Zika" post="virusThailand. Emerg Infect Dis.201810.3201/eid2409.18041629985788 23.LanPTQuangLCHuongVTQThuongNVHungPCHuongTTLNet al.Fetal Zika virus infection"/>
   <result pre="with Asian lineage Zika virusThailand. Emerg Infect Dis.201810.3201/eid2409.18041629985788 23.LanPTQuangLCHuongVTQThuongNVHungPCHuongTTLNet al.Fetal" exact="Zika" post="virus infection in VietnamPLOS Curr.201710.1371/currents.outbreaks.1c8f631e0ef8cd7777d639eba48647fa29188136 24.OlsonJGKsiazekTGSuhandimanTZika virus, a cause"/>
   <result pre="spread of a mosquito-borne virusBull World Health Organ20169467568610.2471/BLT.16.17108227708473 26.GourinatCAO’ConnorOCalvezEGoarantCDupont-RouzeyrolMDetection of" exact="Zika" post="Virus in UrineEmerg Infect Dis201521848610.3201/eid2101.14089425530324 27.World Health Organization (2016)"/>
   <result pre="Zika Virus in UrineEmerg Infect Dis201521848610.3201/eid2101.14089425530324 27.World Health Organization (2016)" exact="Zika" post="virus: Fact sheet http://www.who.int/mediacentre/factsheets/zika/en/. Accessed 3 Feb 2016. 28.WongSSPoonRWWongSCZika"/>
   <result pre="flavivirusJ Virol199872738310.1128/JVI.72.1.73-83.19989420202 31.LindenbachBDRiceCMMolecular biology of flavivirusesAdv Virus Res200359236110.1016/S0065-3527(03)59002-914696326 32.Purdue University." exact="Zika" post="virus structure revealed a critical advance in the development"/>
   <result pre="and treatmentVirusDisease.20162711111510.1007/s13337-016-0307-y27366760 34.FontesMBZika virus-related hypertensive iridocyclitisArq Bras Oftalmol.2016796310.5935/0004-2749.2016002026840174 35.MussoDNhanTXEmergence of" exact="Zika" post="VirusClin Microbiol.201541000222 36.MussoDGublerDJZika VirusClin Microbiol Rev20162948752410.1128/CMR.00072-1527029595 37.World Health Organization."/>
   <result pre="37.World Health Organization. Countries and territories with current or previous" exact="Zika" post="virustransmission. Updated July 2019. https://www.who.int/emergencies/diseases/zika/countries-with-zika-and-vectors-table.pdf. 38.DuffyMRChenT-HHancockTWPowersAMKoolJLLanciottiRSet al.Zika virus outbreak"/>
   <result pre="in OceaniaWestern Pac Surveill Response J.2013481010.5365/wpsar.2013.4.2.00324015365 40.MussoDNillesEJCao-LormeauVMRapid spread of emerging" exact="Zika" post="virus in the Pacific areaClin Microbiol Infect201420O595O59610.1111/1469-0691.1270724909208 41.Lourenco-de-OliveiraRRuaAVVezzaniDWillatGVazeilleMMoussonLet al.Aedes"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="VirusPLoS Negl Trop Dis.201610e000454310.1371/journal.pntd.000454326938868 43.HayesEBZika virus outside AfricaEmerg Infect"/>
   <result pre="virus outside AfricaEmerg Infect Dis2009151347135010.3201/eid1509.09044219788800 44.BerthetNNakounéEKamgangBSelekonBDescorps-DeclèreSGessainAet al.Molecular characterization of three" exact="Zika" post="flaviviruses obtained from sylvatic mosquitoes in the Central African"/>
   <result pre="quinquefasciatus in BrazilEmerg Microbes Infect.20176e6910.1038/emi.2017.5928790458 46.BesnardMLastèreSTeissierACao-LormeauVMussoDEvidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Euro Surveill2014192075110.2807/1560-7917.ES2014.19.13.2075124721538"/>
   <result pre="December 2013 and February 2014Euro Surveill2014192075110.2807/1560-7917.ES2014.19.13.2075124721538 47.ProMED-mail. 23 December 2015." exact="Zika" post="virus—Americas, Atlantic Ocean. ProMED-mail archive no. 20151223.3886435. http://www.promedmail.org. Accessed"/>
   <result pre="and seroepidemiological investigations in Oyo StateJ Hyg19798321321910.1017/S0022172400025997489960 49.LaBeaud AD. 2016." exact="ZIKV" post="infection: an overview. http://www.uptodate.com/contents/zika-virus-infection-an-overview. 50.IoosSMalletHPLeparc GoffartIGauthierVCardosoTHeridaMCurrent Zika virus epidemiology"/>
   <result pre="49.LaBeaud AD. 2016. ZIKV infection: an overview. http://www.uptodate.com/contents/zika-virus-infection-an-overview. 50.IoosSMalletHPLeparc GoffartIGauthierVCardosoTHeridaMCurrent" exact="Zika" post="virus epidemiology and recent epidemicsMed Mal Infect.20144430230710.1016/j.medmal.2014.04.00825001879 51.Rapid risk"/>
   <result pre="virus epidemiology and recent epidemicsMed Mal Infect.20144430230710.1016/j.medmal.2014.04.00825001879 51.Rapid risk assessment:" exact="Zika" post="virus epidemic in the Americas: potential association with microcephaly"/>
   <result pre="Organization (PAHO). 2016. Epidemiological Update Neurological syndrome, congenital anomalies, and" exact="Zika" post="virus infection. http://www.paho.org/hq/index.php?option=com_docman&amp;amp;task=doc_view&amp;amp;Itemid=270&amp;amp;gid=32879&amp;amp;lang=en. 54.European Centre for Disease Prevention and"/>
   <result pre="54.European Centre for Disease Prevention and Control. Rapid risk assessment:" exact="ZIKV" post="infection outbreak, Brazil and the Pacific region. 25 May"/>
   <result pre="55.PithadiaABKakadiaNGuillain–Barré syndrome (GBS)Pharmacol Rep.20106222023210.1016/S1734-1140(10)70261-920508277 56.Cao-LormeauVMBlakeAMonsSLastèreSRocheCVanhomwegenJet al.Guillain–Barré syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 57.MalkkiHZika"/>
   <result pre="Research CollaborationJ Herb Pharmacother.20044619010.1080/J157v04n04_0615927926 63.CalvetGAguiarRSMeloASOSampaioSAde FilippisIFabriAet al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="medicinal plant—a reviewJ Med Plants Stud.201423247 68.JackmanJACostaVVParkSRealALCParkJHCardozoPLet al.Therapeutic treatment of" exact="Zika" post="virus infection using a brain-penetrating antiviral peptideNature Mater.20181797197710.1038/s41563-018-0194-230349030 69.QuanquinNWangLChengGPotential"/>
   <result pre="a brain-penetrating antiviral peptideNature Mater.20181797197710.1038/s41563-018-0194-230349030 69.QuanquinNWangLChengGPotential for treatment and a" exact="Zika" post="virus vaccineCurr Opin Pediatr20172911412110.1097/MOP.000000000000044127906864 70.FernandezEDiamondMSVaccination strategies against Zika virusCurr"/>
   <result pre="and a Zika virus vaccineCurr Opin Pediatr20172911412110.1097/MOP.000000000000044127906864 70.FernandezEDiamondMSVaccination strategies against" exact="Zika" post="virusCurr Opin Virol.201723596710.1016/j.coviro.2017.03.00628432975 71.AbbinkPStephensonKEBarouchDHZika virus vaccinesNat Rev Microbiol20181659460010.1038/s41579-018-0039-729921914 72.EkinsSMietchenDCoffeeMStrattonTPFreundlichJSFreitas-JuniorLet"/>
   <result pre="virus vaccinesNat Rev Microbiol20181659460010.1038/s41579-018-0039-729921914 72.EkinsSMietchenDCoffeeMStrattonTPFreundlichJSFreitas-JuniorLet al.Open drug discovery for the" exact="Zika" post="virusF1000Res2016515010.12688/f1000research.8013.127134728 73.Pan American Health Organization. 2015. Zika virus (ZIKV)"/>
   <result pre="discovery for the Zika virusF1000Res2016515010.12688/f1000research.8013.127134728 73.Pan American Health Organization. 2015." exact="Zika" post="virus (ZIKV) surveillance in the Americas: interim guidance for"/>
   <result pre="DC.http://www.paho.org/hq/index.php?option=com_docman&amp;amp;task=doc_view&amp;amp;gid=30176&amp;amp;Itemid=270. 74.OrganizationPan American HealthEpidemiological alert. Neurological syndrome, congenital malformations, and" exact="Zika" post="virus infections. Implications for public health in the Americas2015WashingtonPan"/>
   <result pre="public health and reproductive research: what history tells us about" exact="Zika" post="virusJ Assist Reprod Genet20163343944010.1007/s10815-016-0687-326943916 77.BenelliGJeffriesCLWalkerTBiological control of mosquito vectors:"/>
   <result pre="Q.20163615017510.1080/01652176.2016.118833327158761 79.RossiSLTeshRBAzarSRMuruatoAEHanleyKAAugusteAJet al.Characterization of a novel murine model to study" exact="Zika" post="virusAm J Trop Med Hyg2016941362136910.4269/ajtmh.16-011127022155 80.McGrathELRossiSLGaoJWidenSGGrantACDunnTJet al.Differential responses of"/>
   <result pre="al.Differential responses of human fetal brain neural stem cells to" exact="Zika" post="virus infectionStem Cell Reports.2017871572710.1016/j.stemcr.2017.01.00828216147"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7058363\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Microbiology :"/>
   <result pre="Medical microbiology : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Medicine and health sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="number of arboviruses, including eastern equine encephalitis, Jamestown Canyon, and" exact="West Nile" post="that pose an annual threat to human and animal"/>
   <result pre="arbovirus detections among sites. Overall, the avian host arboviruses, mainly" exact="West Nile" post="and eastern equine encephalitis, displayed the most specific associations"/>
   <result pre="considerable morbidity and mortality in the United States (U.S.) [1]." exact="West Nile" post="virus (WNV) remains the leading cause of locally acquired"/>
   <result pre="potential for introduction and local transmission of dengue, chikungunya, and" exact="Zika" post="viruses, all of which currently circulate in tropical U.S."/>
   <result pre="of specific arboviral infections have yielded mixed results. In the" exact="WNV" post="system, research in Chicago, Illinois, U.S. did not find"/>
   <result pre="find a direct relationship between indices of mosquito diversity and" exact="WNV" post="infection rates in Culex spp. mosquitoes [18], and a"/>
   <result pre="[18], and a study in Atlanta, Georgia, U.S. concluded that" exact="WNV" post="infections in non-Culex mosquito species likely represent events of"/>
   <result pre="than functional contributions to arboviral transmission [19]. Outside of the" exact="WNV" post="system (which is arguably the most-studied zoonotic arbovirus in"/>
   <result pre="eastern half of the state, but with the introduction of" exact="WNV" post="in North America and detection of the virus in"/>
   <result pre="mosquitoes) with 3,640 pools (1.71%) testing positive for an arbovirus." exact="West Nile" post="virus was the most commonly isolated arbovirus (58.7% of"/>
   <result pre="the most commonly isolated arbovirus (58.7% of all positive samples):" exact="WNV" post="was also isolated in all 18 years of surveillance,"/>
   <result pre="of the surveillance network’s inception which was to monitor for" exact="WNV" post="and EEEV, which are most common in developed (WNV)"/>
   <result pre="of avian arboviruses were distinct from vectors of mammalian arboviruses," exact="WNV" post="vectors were distinct from EEEV and HJV vectors, univoltine"/>
   <result pre="for EEEV and HJV (Cs. melanura), TVTV (Ae. trivittatus), and" exact="WNV" post="(Cx. pipiens) as shown by the total number of"/>
   <result pre="vectors. Our methods also found a significant odds ratio of" exact="WNV" post="detection for the mammal-biting species Aedes stimulans, though this"/>
   <result pre="artifact of the GLMM’s structure and the unusual timing/prevalence of" exact="WNV" post="detections in this species at a particular site in"/>
   <result pre="S1 Fig). Fig 4 Epidemic curves for the avian arboviruses:" exact="West Nile" post="virus (A), eastern equine encephalitis virus (B), and Highlands"/>
   <result pre="the strongest spatial and habitat associations among the seven arboviruses." exact="West Nile" post="virus was more common in the southwestern region of"/>
   <result pre="&amp;gt; 0.2). Fig 6 Risk maps for the avian arboviruses:" exact="West Nile" post="virus (A), eastern equine encephalitis virus (B), and Highlands"/>
   <result pre="health in the region, our results support previous findings that" exact="WNV" post="and EEEV associate with discrete habitats which are in"/>
   <result pre="analyses confirm that Cx. pipiens is the primary vector of" exact="WNV" post="[36] and Cs. melanura is the primary vector of"/>
   <result pre="Though all three species shared a statistical association with WNV," exact="WNV" post="infections in these species were most frequently detected during"/>
   <result pre="We additionally encourage greater scrutiny of similar overwintering/amplification predictions for" exact="WNV" post="and other avian arboviruses [45]. The broad detection of"/>
   <result pre="integration of vector control programs could improve the control of" exact="WNV" post="and EEEV. However, we caution that the successes and"/>
   <result pre="estimates from a binomial-error generalized linear mixed effects model for" exact="West Nile" post="virus detection (1—infected, 0—uninfected) in mosquito samples collected in"/>
   <result pre="J Med. 2013;368(18):1670–3. Epub 2013/05/03. 10.1056/NEJMp1213696 .23635048 4LaDeauSL, KilpatrickAM, MarraPP." exact="West Nile" post="virus emergence and large-scale declines of North American bird"/>
   <result pre=".17507930 5GeorgeTL, HarriganRJ, LaMannaJA, DeSanteDF, SaraccoJF, SmithTB. Persistent impacts of" exact="West Nile" post="virus on North American bird populations. Proc Natl Acad"/>
   <result pre="GriffinI, BinghamAM, StanekD, FischerM, WhiteS, et al.Local Mosquito-Borne Transmission of" exact="Zika" post="Virus—Miami-Dade and Broward Counties, Florida, June-August 2016. MMWR Morb"/>
   <result pre="the potential of north American mosquitoes (Diptera: Culicidae) to transmit" exact="West Nile" post="Virus. Journal of medical entomology. 2005;42(1):57–62. Epub 2005/02/05. 10.1093/jmedent/42.1.57"/>
   <result pre="9Centers for Disease Control and Prevention. Mosquito species in which" exact="West Nile" post="virus has been detected, United States, 1999–2016 2018. Available"/>
   <result pre="the vectorial capacity of multiple vectors to observed patterns of" exact="West Nile" post="virus transmission. Journal of Applied Ecology. 2019;56(4):956–65. 10.1111/1365-2664.13322 20AndreadisTG,"/>
   <result pre=".9615549 24AndersonJF, AndreadisTG, VossbrinckCR, TirrellS, WakemEM, FrenchRA, et al.Isolation of" exact="West Nile" post="virus from mosquitoes, crows, and a Cooper's hawk in"/>
   <result pre="of Culex pipiens complex mosquitoes to transmission and persistence of" exact="West Nile" post="virus in North America. Journal of the American Mosquito"/>
   <result pre="38KwanJL, KluhS, ReisenWK. Antecedent avian immunity limits tangential transmission of" exact="West Nile" post="virus to humans. PloS one. 2012;7(3):e34127 Epub 2012/03/30. 10.1371/journal.pone.003412722457819"/>
   <result pre="39WimberlyMC, LamsalA, GiacomoP, ChuangTW. Regional variation of climatic influences on" exact="West Nile" post="virus outbreaks in the United States. The American journal"/>
   <result pre="vexans and Culiseta melanura (Diptera: Culicidae) and its implication for" exact="West Nile" post="virus transmission in Connecticut, U.S.A. Journal of medical entomology."/>
   <result pre="ArmstrongPM, AndersonJF, VossbrinckCR. Host feeding patterns of Culex mosquitoes and" exact="West Nile" post="virus transmission, northeastern United States. Emerg Infect Dis. 2006;12(3):468–74."/>
   <result pre="(Diptera: Culicidae) Populations in Catch Basins and Its Impact on" exact="West Nile" post="Virus Transmission in Urban Parks in Atlanta, GA. Journal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7058646\results\search\tropicalVirus\results.xml">
   <result pre="at random from patients from eight provinces. The presence of" exact="DENV" post="IgM and CHIKV IgM was examined by enzyme-linked immunosorbent"/>
   <result pre="patients from eight provinces. The presence of DENV IgM and" exact="CHIKV" post="IgM was examined by enzyme-linked immunosorbent assay. Of the"/>
   <result pre="enzyme-linked immunosorbent assay. Of the 1306 sera tested, 210 were" exact="CHIKV" post="seropositive and 82 were dengue seropositive. Statistical analysis demonstrated"/>
   <result pre="dengue seropositive. Statistical analysis demonstrated a significant increase in the" exact="CHIKV" post="IgM antibody seropositivity rate in Kerman (OR = 2.07,"/>
   <result pre="(OR = 1.77, 95% CI: 1.06–2.93; P = 0.027). The" exact="DENV" post="and CHIKV seropositivity rate in summer is higher than"/>
   <result pre="1.77, 95% CI: 1.06–2.93; P = 0.027). The DENV and" exact="CHIKV" post="seropositivity rate in summer is higher than in other"/>
   <result pre="other seasons (P &amp;lt; 0.01). Our seropositive samples suggest possible" exact="CHIKV" post="and DENV infection in Iran. It is likely that"/>
   <result pre="(P &amp;lt; 0.01). Our seropositive samples suggest possible CHIKV and" exact="DENV" post="infection in Iran. It is likely that these viruses"/>
   <result pre="the Flaviviridae family with four closely related but antigenically different" exact="DENV" post="serotypes 1–4 [8]. It is responsible for about 400"/>
   <result pre="or mild dengue fever to dengue haemorrhagic fever [9]. Currently," exact="DENV" post="infection is a major health threat and the most"/>
   <result pre="in both the tropics and subtropical regions [10, 11]. The" exact="CHIKV" post="and DENV transmission between humans occurs through different Aedes"/>
   <result pre="the tropics and subtropical regions [10, 11]. The CHIKV and" exact="DENV" post="transmission between humans occurs through different Aedes species including"/>
   <result pre="distributed throughout the world [4, 12]. Signs of disease in" exact="CHIKV" post="and DENV infections are associated with arthralgia, fever, rash"/>
   <result pre="the world [4, 12]. Signs of disease in CHIKV and" exact="DENV" post="infections are associated with arthralgia, fever, rash and also"/>
   <result pre="headache, nausea and fatigue [4]. In Iran, the epidemiology of" exact="DENV" post="and CHIKV remains poorly understood. Iran is a country"/>
   <result pre="and fatigue [4]. In Iran, the epidemiology of DENV and" exact="CHIKV" post="remains poorly understood. Iran is a country located in"/>
   <result pre="and Iraq, countries where epidemics and endemics of arboviruses including" exact="CHIKV" post="and DENV have occurred [13, 14]. Therefore, Iran is"/>
   <result pre="countries where epidemics and endemics of arboviruses including CHIKV and" exact="DENV" post="have occurred [13, 14]. Therefore, Iran is strategically placed"/>
   <result pre="°C) minimum temperature [24]. Enzyme-linked immunosorbent assay The presence of" exact="DENV" post="IgM and CHIKV IgM were examined by a commercial"/>
   <result pre="[24]. Enzyme-linked immunosorbent assay The presence of DENV IgM and" exact="CHIKV" post="IgM were examined by a commercial Semiquantitative IgM ELISA"/>
   <result pre="from 1306 patients from eight provinces were tested. The overall" exact="CHIKV" post="and DENV IgM seropositivity was 16.07% (210/1306) and 6.27%"/>
   <result pre="patients from eight provinces were tested. The overall CHIKV and" exact="DENV" post="IgM seropositivity was 16.07% (210/1306) and 6.27% (82/1306) respectively."/>
   <result pre="Khorasan-e-Jonubi. Logistic regression analysis showed a significant increase in the" exact="CHIKV" post="IgM antibody seropositivity rate in Kerman (OR = 2.07,"/>
   <result pre="CI: 1.06–2.93; P = 0.027). Fig. 1. Map showing the" exact="CHIKV" post="Seropositivity rate in study areas in Iran, 2017. Fig."/>
   <result pre="study areas in Iran, 2017. Fig. 2. Map showing the" exact="DENV" post="Seropositivity rate in study areas in Iran, 2017. The"/>
   <result pre="the dengue positive cases belonged to infants (7.9%). Although the" exact="CHIKV" post="seropositivity rate was higher in infants, CHIKV seropositivity was"/>
   <result pre="(7.9%). Although the CHIKV seropositivity rate was higher in infants," exact="CHIKV" post="seropositivity was not statistically significant based on the age"/>
   <result pre="101/605 (16.69%) in the female group were positive for anti-IgM" exact="CHIKV" post="antibodies and 33/701 (4.07%) in the male group and"/>
   <result pre="49/605 (8.09%) in the female group were positive for anti-IgM" exact="DENV" post="antibodies. The highest dengue seropositivity rate was seen in"/>
   <result pre="0.01). Discussion The seropositive cases in our study reveal possible" exact="CHIKV" post="and DENV infection in Iran. As mentioned before, among"/>
   <result pre="The seropositive cases in our study reveal possible CHIKV and" exact="DENV" post="infection in Iran. As mentioned before, among the studied"/>
   <result pre="provinces, Kerman and Fars had a significant increase in the" exact="CHIKV" post="seropositivity rate in comparison with other provinces. Kerman and"/>
   <result pre="fever have been reported. So, it could be suggested that" exact="CHIKV" post="has possibly been imported through travellers to this neighbouring"/>
   <result pre="in 2005–2006, there is no report of autochthonous transmission of" exact="DENV" post="from these countries so far [27]. Despite the fact"/>
   <result pre="Sea region [30], that may pose risk for spread of" exact="DENV" post="from Pakistan to Iran or Afghanistan [19]. With this"/>
   <result pre="[19]. With this regard, a significant difference in the high" exact="CHIKV" post="and dengue seropositivity rate in summer was observed (P"/>
   <result pre="[20]. Even though in our study, the presence of the" exact="CHIKV" post="IgM antibody is not associated with gender, on the"/>
   <result pre="particularly that of Flaviviruses, with other viral infections such as" exact="West Nile" post="Virus, which had been previously reported in Iran was"/>
   <result pre="suggest that there has been an exposure to DENGV and" exact="CHIKV" post="by a local population in Iran. This is an"/>
   <result pre="exposure of the population to the presence of dengue and" exact="CHIKV" post="in Iran. Acknowledgement The Research reported in this publication"/>
   <result pre="Asia. Journal of Vector Borne Diseases50, 77.23995308 4.AfzalMFet al. (2015)" exact="Chikungunya" post="fever among children presenting with nonspecific febrile illness during"/>
   <result pre="aegypti and Ae. albopictus. eLife4, e08347.26126267 13.AmarasingheA and LetsonGW (2012)" exact="Dengue" post="in the Middle East: a neglected, emerging disease of"/>
   <result pre="and Infectious Disease11, 166–169.23194952 21.PouriayevaliMHet al. (2019) Imported cases of" exact="Chikungunya" post="virus in Iran. BMC Infectious Diseases19, 1004.31775718 22.AskarianMet al."/>
   <result pre="(Accessed 27 May 2019). 25.VairoFet al. (2018) The surveillance of" exact="CHIKV" post="in a temperate climate: challenges and possible solutions from"/>
   <result pre="Lazio Region, Italy. Viruses10, 501. 26.GhasemzadehI, DalakiM and SafariR (2016)" exact="Dengue" post="fever in Iran. A case report. Acta Medica Mediterranea32,"/>
   <result pre="A case report. Acta Medica Mediterranea32, 2025–2027. 27.HumphreyJMet al. (2016)" exact="Dengue" post="in the Middle East and North Africa: a systematic"/>
   <result pre="PLoS Neglected Tropical Diseases10, e0005194.27926925 28.ChiaP-Y, NgMM-L and ChuJJH (2010)" exact="Chikungunya" post="fever: a review of a re-emerging mosquito-borne infectious disease"/>
   <result pre="Available at http://go.worldbank.org/Y88FI6V7R0 (Accessed 2 May 2019). 30.MalikMRet al. (2014)" exact="Chikungunya" post="outbreak in Al-Hudaydah, Yemen, 2011: epidemiological characterization and key"/>
   <result pre="Journal of Clinical Virology45, 218–222.19487157 35.Trravassos da RosaAet al. (2000)" exact="Dengue" post="epidemic in Belém, Pará, Brazil, 1996–97. Emerging Infectious Diseases6,"/>
   <result pre="Brazil, 1996–97. Emerging Infectious Diseases6, 298–301.10827121 36.García-RiveraEJ and Rigau-PérezJG (2003)" exact="Dengue" post="severity in the elderly in Puerto Rico. Revista Panamericana"/>
   <result pre="Rico. Revista Panamericana de Salud Pública13, 362–368.12880516 37.GuzmanMGet al. (1984)" exact="Dengue" post="haemorrhagic fever in Cuba. I. Serological confirmation of clinical"/>
   <result pre="Medicine and Hygiene78, 235–238.6464113 38.ZiyaeyanMet al. (2018) Widespread circulation of" exact="West Nile" post="virus, but not Zika virus in southern Iran. PLoS"/>
   <result pre="al. (2018) Widespread circulation of West Nile virus, but not" exact="Zika" post="virus in southern Iran. PLoS Neglected Tropical Diseases12, e0007022.30557321"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7059383\results\search\tropicalVirus\results.xml">
   <result pre="equipment RVF Rift valley fever VHF Viral haemorrhagic fever YF" exact="Yellow fever" post="Publisher’s Note Springer Nature remains neutral with regard to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7059726\results\search\tropicalVirus\results.xml">
   <result pre="populationJ Med Virol2016882078208410.1002/jmv.2457227155288 133.MounceBCPoirierEZPassoniGSimon-LoriereECesaroTProtMStaplefordKAMoratorioGSakuntabhaiALevraudJPVignuzziMInterferon-induced Spermidine-Spermine Acetyltransferase and polyamine depletion restrict" exact="Zika" post="and Chikungunya virusesCell Host Microbe20162016717710.1016/j.chom.2016.06.01127427208 134.YeungAWTerentisACKingNJThomasSRRole of indoleamine 2,3-dioxygenase"/>
   <result pre="Virol2016882078208410.1002/jmv.2457227155288 133.MounceBCPoirierEZPassoniGSimon-LoriereECesaroTProtMStaplefordKAMoratorioGSakuntabhaiALevraudJPVignuzziMInterferon-induced Spermidine-Spermine Acetyltransferase and polyamine depletion restrict Zika and" exact="Chikungunya" post="virusesCell Host Microbe20162016717710.1016/j.chom.2016.06.01127427208 134.YeungAWTerentisACKingNJThomasSRRole of indoleamine 2,3-dioxygenase in health"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7064921\results\search\tropicalVirus\results.xml">
   <result pre="This review summarizes the role of cell�?mediated immune responses in" exact="CHIKV" post="pathogenesis, with a specific focus on pro�?inflammatory Th1 responses"/>
   <result pre="specific focus on pro�?inflammatory Th1 responses in the development of" exact="CHIKV" post="joint inflammation. Furthermore, due to the explosive nature of"/>
   <result pre="will also discuss the potential impact of malaria co�?infections on" exact="CHIKV" post="pathogenesis and their relevance in alphavirus control programs in"/>
   <result pre="but recent reports have suggested that serious clinical forms of" exact="CHIKV" post="disease could compromise brain tissues leading to permanent neurological"/>
   <result pre="damage.8, 9, 10, 11 Among the arthritogenic alphaviruses, research on" exact="CHIKV" post="was the most extensive owing to the global epidemics"/>
   <result pre="of host immune responses in the development of alphavirus arthritides." exact="CHIKV" post="infections trigger a strong immune response characterized by the"/>
   <result pre="chronic forms of arthritis remains elusive. The striking similarities between" exact="CHIKV" post="arthritic disease and rheumatoid arthritis (RA) at the transcriptomic"/>
   <result pre="DEVELOPMENT OF CHIKV�?INDUCED INFLAMMATION 2.1 Pro�?inflammatory immune mediators induced upon" exact="CHIKV" post="infection Inflammatory cytokines such as IFNγ, IFNα, IL�?2, IL�?2R,"/>
   <result pre="responses during the acute phase of disease. Transcriptomics analysis in" exact="CHIKV" post="mouse models revealed overlapping pro�?inflammatory gene expression signatures with"/>
   <result pre="with acute CHIKF and RA. It has been shown that" exact="CHIKV" post="infection triggers strong IFNγ�?producing CD4+ T cell responses (Th1).13"/>
   <result pre="patients.18, 34 In line with this observation, mouse studies of" exact="CHIKV" post="and RRV suggested that the monocytes/macrophages subset represents an"/>
   <result pre="results indicate that monocytes and macrophages might contribute to the" exact="CHIKV" post="inflammatory pathology, a separate study suggested that infection in"/>
   <result pre="inflamed tissues is believed to play an important role in" exact="CHIKV" post="pathology by exerting direct antiviral activity through cytotoxic mechanisms"/>
   <result pre="in CHIKV�?induced inflammation The hypothetical function of T cells during" exact="CHIKV" post="infection was initially postulated based on their proliferation and"/>
   <result pre="IFNγ thus suggesting the engagement of Th1�?biased immune responses upon" exact="CHIKV" post="infection.18 In further support of these observations, immune profiling"/>
   <result pre="immune profiling of peripheral blood of patients from the Gabonese" exact="CHIKV" post="outbreak of 200746 revealed a strong early activation and"/>
   <result pre="T cells abolished the major peak of joint swelling during" exact="CHIKV" post="infection with no impact on viral tropism, demonstrating the"/>
   <result pre="that this process is mediated by virus�?specific CD4+ T cells.49" exact="CHIKV" post="proteome�?wide screening assays identified nsP1�?P4�?2 (145�?162 aa, non�?structural protein"/>
   <result pre="Next, adoptively transferred CHIKV�?specific CD8+ T cells induced upon live�?attenuated" exact="CHIKV" post="vaccination failed to control CHIKV infection in mice.52 Although"/>
   <result pre="T cells induced upon live�?attenuated CHIKV vaccination failed to control" exact="CHIKV" post="infection in mice.52 Although CD8+ T cells have been"/>
   <result pre="been linked to protection against RRV48 and SINV,47 findings in" exact="CHIKV" post="suggest that CD8+ T cells play different roles in"/>
   <result pre="infections. 2.5 Th1 cytokines and CD4+ T cells interplay during" exact="CHIKV" post="infection IFNγ is the main effector cytokine produced by"/>
   <result pre="of mononuclear cells to the site of the infection.60, 61" exact="CHIKV" post="infection in the absence of IFNγ has provided inconclusive"/>
   <result pre="alphaviruses.62 This is partially corroborated by a recent work63 where" exact="CHIKV" post="infection of IFNγ−/− mice led to higher viremia but"/>
   <result pre="due to differential pathogenicity derived from the use of distinct" exact="CHIKV" post="isolates: SGP11 in Ref. [49, 51] and LR2006�?OPY1 in"/>
   <result pre="recent studies have suggested that CD4+ T cells might mediate" exact="CHIKV" post="arthritic disease through the secretion of proteins other than"/>
   <result pre="3.0 Generic License. http://smart.servier.com/ 3 CO�?INFECTION WITH PLASMODIUM PARASITES MODULATES" exact="CHIKV" post="PATHOLOGIES The CHIKV outbreaks in Asia, the Indian Ocean"/>
   <result pre="http://smart.servier.com/ 3 CO�?INFECTION WITH PLASMODIUM PARASITES MODULATES CHIKV PATHOLOGIES The" exact="CHIKV" post="outbreaks in Asia, the Indian Ocean islands and its"/>
   <result pre="developing economies.12, 72, 73, 74, 75 Importantly, the expansion of" exact="CHIKV" post="distribution and the establishment of local transmission hotspots in"/>
   <result pre="diseases. A number of epidemiological studies have reported co�?infections of" exact="CHIKV" post="with pathogens such as Zika virus (ZIKV), dengue virus"/>
   <result pre="studies have reported co�?infections of CHIKV with pathogens such as" exact="Zika" post="virus (ZIKV), dengue virus (DENV), and malaria parasites in"/>
   <result pre="African malaria cohorts86, 87, 88, 89 suggested the presence of" exact="CHIKV" post="infections. Furthermore, the highly pro�?inflammatory profiles of both diseases—including"/>
   <result pre="acute P. vivax from Thailand suggested both pre�?exposure and ongoing" exact="CHIKV" post="infection.90 CHIKV�?Plasmodium co�?infections are therefore not only restricted to"/>
   <result pre="areas of co�?circulation in Asia and Latin America. Moreover, although" exact="CHIKV" post="and Plasmodium parasites are known to be vectored by"/>
   <result pre="These reports suggest an increasing likelihood of concurrent co�?infections by" exact="CHIKV" post="and Plasmodium in endemic areas. There are well�?established rodent"/>
   <result pre="ideal to study co�?infections with CHIKV. 3.2 Immune modulation of" exact="CHIKV" post="innate responses by Plasmodium co�?infections Immunosuppression has been well�?documented"/>
   <result pre="malaria strains for 4 days followed by subsequent inoculation with" exact="CHIKV" post="(early sequential co�?infection) or concurrent CHIKV�?Plasmodium co�?infection markedly reduced"/>
   <result pre="the chemokine network in infected tissues. Figure 2 Regulation of" exact="CHIKV" post="immune responses by malaria infections. Murine malaria infections lead"/>
   <result pre="antiviral affects of INFγ induced by pre�?existing malaria infections limit" exact="CHIKV" post="replication and dissemination resulting in reduced viremia. Moreover, suppression"/>
   <result pre="viremia only in animals pre�?infected with malaria (4 days prior" exact="CHIKV" post="inoculation) suggested that immune mediators produced upon parasite infection"/>
   <result pre="upon parasite infection could be responsible for the control of" exact="CHIKV" post="dissemination. Human and mouse studies have reported early induction"/>
   <result pre="antiviral role of this cytokine has been also proposed during" exact="CHIKV" post="infections.51, 63 In the context of sequential Plasmodium�?CHIKV co�?infection,"/>
   <result pre="could exert an antiviral activity through the priming of primary" exact="CHIKV" post="targets such as fibroblasts, myocytes, endothelial cells, and macrophages"/>
   <result pre="at the site of infection. Plasmodium inoculation during an ongoing" exact="CHIKV" post="infection modified the outcome of murine malaria. Co�?infection in"/>
   <result pre="the outcome of murine malaria. Co�?infection in mice pre�?infected with" exact="CHIKV" post="for 4 days with either PbA or Py17x did"/>
   <result pre="the development of footpad swelling or viremia. In contrast, ongoing" exact="CHIKV" post="infection exacerbated Plasmodium�?induced pathology by increasing the parasite load"/>
   <result pre="The availability of type I interferon induced by a pre�?existing" exact="CHIKV" post="infection16, 17 might be responsible of the increase in"/>
   <result pre="re�?challenge of recovered animals previously infected with either malaria or" exact="CHIKV" post="with their respective heterologous pathogen did not affect the"/>
   <result pre="of any of their individual pathologies.119 3.3 Immune modulation of" exact="CHIKV" post="T cell responses by Plasmodium co�?infections Interestingly, the marked"/>
   <result pre="potential of DCs, and other APCs, at the site of" exact="CHIKV" post="inoculation remains to be explored. Impaired expansion and early"/>
   <result pre="and not CCR5 is functionally important for CD4+ T cell�?mediated" exact="CHIKV" post="inflammation and that CXCR3�?mediated chemotaxis was impaired during co�?infection.119"/>
   <result pre="malaria infections remain to be explored. 3.4 Immune modulation of" exact="CHIKV" post="B cell responses by Plasmodium co�?infections B cell immune"/>
   <result pre="known to play a pivotal role in the control of" exact="CHIKV" post="infection. Lum et al152 reported that CHIKV infection in"/>
   <result pre="the control of CHIKV infection. Lum et al152 reported that" exact="CHIKV" post="infection in mice lacking functional B cells resulted in"/>
   <result pre="animals119 (Figure 2). Although the precise mechanisms governing impairment of" exact="CHIKV" post="antibody responses upon malaria co�?infection are still unknown, the"/>
   <result pre="REMARKS The unique protective effects exerted by Plasmodium infections against" exact="CHIKV" post="pathologies might have relevant implications in the control of"/>
   <result pre="antiviral or antimalarial treatment. At the epidemiological level, co�?infections by" exact="CHIKV" post="and Plasmodium parasites can be underestimated in human populations"/>
   <result pre="of malaria which can result in the development of asymptomatic" exact="CHIKV" post="infections without compromised joints. The absence of alphavirus screening"/>
   <result pre="cases might also contribute to a higher burden of asymptomatic" exact="CHIKV" post="carriers.87 On the other hand, reduced viremia upon co�?infection"/>
   <result pre="On the other hand, reduced viremia upon co�?infection could impact" exact="CHIKV" post="transmission dynamics by reducing the number of successfully infected"/>
   <result pre="TanabeELL, SantosEC, et al. Cellular and molecular immune response to" exact="Chikungunya" post="virus infection. Front Cell Infect Microbiol. 2018;8:345.30364124 5PowersAM, BraultAC,"/>
   <result pre="alphaviruses. Reumatol Clin. 2018;14(2):97�?105.28365217 7ZaidA, GerardinP, TaylorA, MostafaviH, MalvyD, MahalingamS." exact="Chikungunya" post="arthritis: implications of acute and chronic inflammation mechanisms on"/>
   <result pre="Rheumatol. 2018;70(4):484�?495.29287308 8DaginawalaHatimF, ChandakNitinH, KashyapRajpalS, et al. Neurological complications of" exact="Chikungunya" post="virus infection. Neurol India. 2009;57(2):177�?180.19439849 9MahtoSK, GuptaPK, SinghA, MeenaRC."/>
   <result pre="Care Med. 2018;22(4):306�?308.29743772 10BarrKL, KhanE, FarooqiJQ, et al. Evidence of" exact="Chikungunya" post="virus disease in pakistan since 2015 with patients demonstrating"/>
   <result pre="system. Front Public Health. 2018;6:186.30042937 11SaPKO, NunesMDM, LeiteIR, et al." exact="Chikungunya" post="virus infection with severe neurologic manifestations: report of four"/>
   <result pre="Int J Infect Dis. 2017;58:69�?76.28288924 13GardnerJ, AnrakuI, LeTT, et al." exact="Chikungunya" post="virus arthritis in adult wild�?type mice. J Virol. 2010;84(16):8021�?8032.20519386"/>
   <result pre="of current in vivo mouse models for the study of" exact="Chikungunya" post="virus pathogenesis. Med Sci (Basel). 2015;3(3):64�?77.29083392 15NgLF, ChowA, SunYJ,"/>
   <result pre="SunYJ, et al. IL�?1beta, IL�?6, and RANTES as biomarkers of" exact="Chikungunya" post="severity. PLoS ONE. 2009;4(1):e4261.19156204 16TeoTH, HerZ, TanJJ, et al."/>
   <result pre="2009;4(1):e4261.19156204 16TeoTH, HerZ, TanJJ, et al. Caribbean and La Reunion" exact="Chikungunya" post="virus isolates differ in their capacity to induce proinflammatory"/>
   <result pre="A systematic meta�?analysis of immune signatures in patients with acute" exact="Chikungunya" post="virus infection. J Infect Dis. 2015;211(12):1925�?1935.25635123 18HoarauJJ, Jaffar BandjeeM�?C,"/>
   <result pre="Krejbich TrototP, et al. Persistent chronic inflammation and infection by" exact="Chikungunya" post="arthritogenic alphavirus in spite of a robust host immune"/>
   <result pre="2010;184(10):5914�?5927.20404278 19HerZ, TengTS, TanJJL, et al. Loss of TLR3 aggravates" exact="CHIKV" post="replication and pathology due to an altered virus�?specific neutralizing"/>
   <result pre="2015;7(1):24�?41.25452586 20NakayaHI, GardnerJ, PooYS, MajorL, PulendranB, SuhrbierA. Gene profiling of" exact="Chikungunya" post="virus arthritis in a mouse model reveals significant overlap"/>
   <result pre="RiviereJ�?P, et al. Human muscle satellite cells as targets of" exact="Chikungunya" post="virus infection. PLoS ONE. 2007;2(6):e527.17565380 35LidburyB, RulliN, SuhrbierA, et"/>
   <result pre="WauquierN, et al. Unconventional repertoire profile is imprinted during acute" exact="Chikungunya" post="infection for natural killer cells polarization toward cytotoxicity. PLoS"/>
   <result pre="46WauquierN, BecquartP, NkogheD, PadillaC, Ndjoyi�?MbiguinoA, LeroyEM. The acute phase of" exact="Chikungunya" post="virus infection in humans is associated with strong innate"/>
   <result pre="50KamYW, LumFM, TeoTH, et al. Early neutralizing IgG response to" exact="Chikungunya" post="virus in infected patients targets a dominant linear epitope"/>
   <result pre="et al. A pathogenic role for CD4+ T cells during" exact="Chikungunya" post="virus infection in mice. J Immunol. 2013;190(1):259�?269.23209328 52ChuH, DasSC,"/>
   <result pre="of adaptive immunity to CHIKV/IRES a novel candidate vaccine against" exact="Chikungunya" post="in the A129 mouse model. Vaccine. 2013;31(33):3353�?3360.23727003 53AbbasAK, MurphyKM,"/>
   <result pre="Virol. 2016;16:143�?150.26986235 70TsetsarkinKA, VanlandinghamDL, McGeeCE, HiggsS. A single mutation in" exact="Chikungunya" post="virus affects vector specificity and epidemic potential. PLoS Pathog."/>
   <result pre="Pathog. 2007;3(12):e201.18069894 71SchuffeneckerI, ItemanI, MichaultA, et al. Genome microevolution of" exact="Chikungunya" post="viruses causing the Indian Ocean outbreak. PLoS Med. 2006;3(7):e263.16700631"/>
   <result pre="Infect Ecol Epidemiol. 2015;5:29853.26689654 73PanningM, GrywnaK, van EsbroeckM, EmmerichP, DrostenC." exact="Chikungunya" post="fever in travelers returning to Europe from the Indian"/>
   <result pre="Indian Ocean region, 2006. Emerg Infect Dis. 2008;14(3):416�?422.18325256 74ChenLH, WilsonME." exact="Dengue" post="and Chikungunya infections in travelers. Curr Opin Infect Dis."/>
   <result pre="region, 2006. Emerg Infect Dis. 2008;14(3):416�?422.18325256 74ChenLH, WilsonME. Dengue and" exact="Chikungunya" post="infections in travelers. Curr Opin Infect Dis. 2010;23(5):438�?444.20581669 75JohanssonMA,"/>
   <result pre="2010;23(5):438�?444.20581669 75JohanssonMA, PowersAM, PesikN, CohenNJ, StaplesJE. Nowcasting the spread of" exact="Chikungunya" post="virus in the Americas. PLoS ONE. 2014;9(8):e104915.25111394 76SalamN, MustafaS,"/>
   <result pre="Infect Dis. 2015;21(5):908�?909.25898147 78KinimiE, ShayoMJ, PatrickBN, et al. Evidence of" exact="Chikungunya" post="virus infection among febrile patients seeking healthcare in selected"/>
   <result pre="Dis. 2018;74:41�?46.30100535 81Villamil�?GómezWE, Rodríguez�?MoralesAJ, Uribe�?GarcíaAM, et al. Zika, Dengue, and" exact="Chikungunya" post="co�?infection in a pregnant woman from Colombia. Int J"/>
   <result pre="2016;51:135�?138.27497951 82Furuya�?KanamoriL, LiangS, MilinovichG, et al. Co�?distribution and co�?infection of" exact="Chikungunya" post="and dengue viruses. BMC Infect Dis. 2016;16:84.26936191 83KaurM, SinghK,"/>
   <result pre="Infect Dis. 2016;16:84.26936191 83KaurM, SinghK, SidhuSK, et al. Coinfection of" exact="Chikungunya" post="and Dengue viruses: a serological study from North Western"/>
   <result pre="2016;16:84.26936191 83KaurM, SinghK, SidhuSK, et al. Coinfection of Chikungunya and" exact="Dengue" post="viruses: a serological study from North Western region of"/>
   <result pre="Za Zhi. 2018;30(3):158�?164.30069124 85WaggonerJ, BrichardJ, MutukuF, et al. Malaria and" exact="Chikungunya" post="detected using molecular diagnostics among febrile kenyan children. Open"/>
   <result pre="HisamuddinM, et al. Concurrent infection with plasmodium vivax and the" exact="Dengue" post="and Chikungunya viruses in a paediatric patient from New"/>
   <result pre="al. Concurrent infection with plasmodium vivax and the Dengue and" exact="Chikungunya" post="viruses in a paediatric patient from New Delhi, India"/>
   <result pre="Intervirology. 2017;60(1–2):48�?52.28910810 90TeoTH. Host Immune modulation during Malaria Parasites and" exact="Chikungunya" post="virus coinfection in experimental models. Singapore: National University of"/>
   <result pre="Singapore;2015. 91YadavP, GokhaleMD, BardePV, SinghDK, MishraAC, MouryaDT. Experimental transmission of" exact="Chikungunya" post="virus by Anopheles stephensi mosquitoes. Acta Virol. 2003;47(1):45�?47.12828344 92DialloD,"/>
   <result pre="2003;47(1):45�?47.12828344 92DialloD, SallAA, BuenemannM, et al. Landscape ecology of sylvatic" exact="Chikungunya" post="virus and mosquito vectors in southeastern Senegal. PLoS Negl"/>
   <result pre="NgLF. An essential role of antibodies in the control of" exact="Chikungunya" post="virus infection. J Immunol. 2013;190(12):6295�?6302.23670192 153Ryg�?CornejoV, IoannidisL, LyA, et"/>
   <result pre="Pathog Glob Health. 2017;111(6):271�?275.28829253 155PowersAM, BraultAC, TeshRB, WeaverSC. Re�?emergence of" exact="Chikungunya" post="and O'nyong�?nyong viruses: evidence for distinct geographical lineages and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7065052\results\search\tropicalVirus\results.xml">
   <result pre="experiences of pregnant women in accessing healthcare services during the" exact="Zika" post="virus epidemic in Villavicencio, Colombia, 2015–2016 gomez ET AL."/>
   <result pre="Colombia. Email: ja.ocampo@uniandes.edu.co epub: 2020-1-1ppub: 2020-1148Suppl 210.1002/ijgo.v148.s2Building opportunities during the" exact="Zika" post="epidemic in the Americas: The case for strengthening research"/>
   <result pre="conducted in Villavicencio. Six women who had been diagnosed with" exact="Zika" post="virus infection during their pregnancies and whose fetus had"/>
   <result pre="the provision of healthcare services to pregnant women during the" exact="Zika" post="epidemic. Policy makers need to utilize the results from"/>
   <result pre="perinatal health. Access Colombia Experience Healthcare services Pregnant women Qualitative" exact="Zika" post="virus Funding HRP, TDR, WHO fig-count: table-count: page-count: word-count:"/>
   <result pre="table-count: page-count: word-count: 1 INTRODUCTION A year after the 2015" exact="Zika" post="virus outbreak in Latin America, the World Health Organization"/>
   <result pre="the World Health Organization (WHO) recognized a causal relationship between" exact="Zika" post="virus infection during pregnancy and the development of newborn"/>
   <result pre="3 Before this outbreak, the known signs and symptoms of" exact="Zika" post="virus infection had only included mild fever, malaise, headache,"/>
   <result pre="rash.4 Although there were reports of Guillain�?Barré syndrome associated with" exact="Zika" post="virus,5 no deaths had been reported.6 Given the neurologic"/>
   <result pre="been reported.6 Given the neurologic sequelae in newborns associated with" exact="Zika" post="virus infection during pregnancy, the high direct and indirect"/>
   <result pre="microcephaly management and consequences,7 and the risk of future outbreaks," exact="Zika" post="virus has since been considered a public health priority.8"/>
   <result pre="December 29, 2016, there were 177 614 confirmed cases of" exact="Zika" post="virus infection and 2525 confirmed congenital syndromes associated with"/>
   <result pre="with it.9 In Colombia, there were 6363 confirmed cases of" exact="Zika" post="virus infection in pregnant women since the beginning of"/>
   <result pre="there were 318 cases of newborn microcephaly attributed to pregnancy�?related" exact="Zika" post="virus infection during the epidemic phase of the virus"/>
   <result pre="in Colombia that registered the most confirmed cases of pregnancy�?related" exact="Zika" post="virus infections (8.7%), behind Norte de Santander (16.8%), Valle"/>
   <result pre="health interventions that would aim to prevent the consequences of" exact="Zika" post="virus infection, particularly in pregnant women and women of"/>
   <result pre="pregnant women and women of childbearing age at risk of" exact="Zika" post="virus infection.14 This document was intended to give healthcare"/>
   <result pre="and confirmed cases to mitigate the consequences of exposure to" exact="Zika" post="virus during pregnancy. Despite the existence of these national"/>
   <result pre="February 2016, additional confirmed cases of pregnant women infected with" exact="Zika" post="virus and newborns afflicted with microcephaly arose after this"/>
   <result pre="health outcomes and some determinants of health.15, 16 Specifically for" exact="Zika" post="virus, factors that can affect the prevention, diagnosis, and"/>
   <result pre="include poor vector control strategies, poor sanitation, knowledge gaps in" exact="Zika" post="transmission and its health consequences, lack of strategies for"/>
   <result pre="healthcare services from the perspective of pregnant women infected with" exact="Zika" post="virus. Recognizing and understanding the experiences of women in"/>
   <result pre="the experiences of women in accessing health care during the" exact="Zika" post="virus outbreak will help improve the guidelines and their"/>
   <result pre="experiences in accessing healthcare services of pregnant women diagnosed with" exact="Zika" post="virus whose newborns had microcephaly. 2 MATERIALS AND METHODS"/>
   <result pre="semistructured interviews of pregnant or recently pregnant women infected with" exact="Zika" post="virus. The study was a subcomponent of a larger"/>
   <result pre="system response and clinical approaches to pregnant women affected by" exact="Zika" post="virus in two municipalities of Colombia. Study participants were"/>
   <result pre="records. A total of 12 cases of microcephaly associated with" exact="Zika" post="virus infection in the mother during the perinatal period"/>
   <result pre="services, as well as knowledge about prevention and transmission of" exact="Zika" post="virus, counseling on voluntary termination of pregnancy, pregnancy outcomes,"/>
   <result pre="in the national management guidelines for women suspected to have" exact="Zika" post="virus infection. Besides the previously described deductive approach, the"/>
   <result pre="as a planned pregnancy.21 Three main themes were identified: (1)" exact="Zika" post="virus knowledge; (2) availability of healthcare resources and timely"/>
   <result pre="and (3) out�?of�?pocket payments for access to healthcare services. 3.1" exact="Zika" post="virus knowledge 3.1.1 What did women know about Zika"/>
   <result pre="3.1 Zika virus knowledge 3.1.1 What did women know about" exact="Zika" post="virus and the epidemic in their town? By the"/>
   <result pre="of pregnancy, all women reported having a basic knowledge of" exact="Zika" post="virus infection such as signs and symptoms, transmission, prevention"/>
   <result pre="fetus. All participants knew mosquitoes transmitted the virus and that" exact="Zika" post="could cause a disease. When asked about other ways"/>
   <result pre="manifestations. One of the participants referred that the symptoms of" exact="Zika" post="virus infection were similar to those of the Chikungunya"/>
   <result pre="of Zika virus infection were similar to those of the" exact="Chikungunya" post="virus. Women talked about how to reduce the risk"/>
   <result pre="virus. Women talked about how to reduce the risk of" exact="Zika" post="virus infection. Strategies included using insect repellent and bed"/>
   <result pre="to reduce the risk of the fetus being affected by" exact="Zika" post="virus. All women understood that Zika virus infection during"/>
   <result pre="fetus being affected by Zika virus. All women understood that" exact="Zika" post="virus infection during pregnancy could have consequences for the"/>
   <result pre="the baby. All participants knew they were at risk of" exact="Zika" post="virus infection in their municipality given the geographic characteristics"/>
   <result pre="epidemic situation. 3.1.2 Where did the participants obtain information on" exact="Zika" post="virus? All women revealed that they acquired most of"/>
   <result pre="women revealed that they acquired most of the information about" exact="Zika" post="virus from the news, other media, family members, and"/>
   <result pre="or gynecologists, five women did not receive any information regarding" exact="Zika" post="virus risks, modes of transmission, or the risks of"/>
   <result pre="physicians when they thought they had been infected by the" exact="Zika" post="virus. I was almost five months pregnant, and then"/>
   <result pre="baby was already formed. Participant 3, age 23 Right now" exact="Zika" post="is trending. In a few months another disease will"/>
   <result pre="access to specialists. All women who were suspected of having" exact="Zika" post="virus infection during pregnancy underwent blood tests to confirm"/>
   <result pre="results that had been performed to confirm or rule out" exact="Zika" post="virus infection. Some women mentioned that they had pursued"/>
   <result pre="ultrasounds during pregnancy. 4 DISCUSSION All participants knew something about" exact="Zika" post="virus; however, there were some important knowledge gaps, especially"/>
   <result pre="some important knowledge gaps, especially surrounding the asymptomatic course of" exact="Zika" post="virus. This viral infection is asymptomatic in up to"/>
   <result pre="provided by the Colombian MoH that healthcare providers should share" exact="Zika" post="virus information with women at risk of infection,14 only"/>
   <result pre="at risk. This is critical given that the association between" exact="Zika" post="virus infection in pregnant women and neurologic consequences for"/>
   <result pre="to focus on health professionals’ knowledge and communication strategies about" exact="Zika" post="virus, and how patient education is being disseminated. Despite"/>
   <result pre="by nurses or general practitioners for women suspected to have" exact="Zika" post="virus infection during their pregnancy. According to national guidelines,"/>
   <result pre="to healthcare services for newborns with suspected microcephaly associated with" exact="Zika" post="virus was difficult for most of the women interviewed"/>
   <result pre="the clinical management of congenital anomalies of fetuses exposed to" exact="Zika" post="virus during pregnancy, a thorough and comprehensive follow�?up is"/>
   <result pre="recommendations from the study, health policies to address and mitigate" exact="Zika" post="virus infection must consider the particularities of the virus"/>
   <result pre="prenatal checkup counseling on aspects such as the effects of" exact="Zika" post="virus infection, different methods used for prevention, diagnosis, and"/>
   <result pre="management and treatment of pregnant women and children affected by" exact="Zika" post="virus are accurately implemented and followed. One way to"/>
   <result pre="conclusion, access to healthcare services by pregnant women with suspected" exact="Zika" post="virus infection whose fetuses had suspected or confirmed microcephaly"/>
   <result pre="influenced by high levels of knowledge of basic information about" exact="Zika" post="virus and negatively influenced by poor provision of timely"/>
   <result pre="that explores access to healthcare services for women affected by" exact="Zika" post="virus. Understanding the population's needs and priorities, and identifying"/>
   <result pre="for her support and assistance. References REFERENCES 1RodriguezLC. Microcephaly and" exact="Zika" post="virus infection. Lancet. 2016;387:2070–2072.26993880 2RasmussenSA, JamiesonDJ, HoneinMA, PetersenLR. Zika"/>
   <result pre="and Zika virus infection. Lancet. 2016;387:2070–2072.26993880 2RasmussenSA, JamiesonDJ, HoneinMA, PetersenLR." exact="Zika" post="virus and birth defects—reviewing the evidence for causality. N"/>
   <result pre="2016;374:1981–1987.27074377 3collab: Centers for Disease Control and Prevention . Congenital" exact="Zika" post="Syndrome &amp;amp; Other Birth Defects. [CDC Website]. https://www.cdc.gov/pregnancy/zika/testing-follow-up/zika-syndrome-birth-defects.html. Published"/>
   <result pre="Accessed August 18, 2018. 4PosenHJ, KeystoneJS, GubbayJB, MorrisSK. Epidemiology of" exact="Zika" post="virus, 1947–2007. BMJ Glob Health. 2016;1:1–11. 5OehlerE, WatrinL, LarreP,"/>
   <result pre="1947–2007. BMJ Glob Health. 2016;1:1–11. 5OehlerE, WatrinL, LarreP, et al." exact="Zika" post="virus infection complicated by Guillain�?Barré syndrome – case report,"/>
   <result pre="report, French Polynesia, December 2013. Euro Surveill. 2014;19:7–9. 6FauciAS, MorensDM." exact="Zika" post="virus in the Americas—yet another arbovirus threat. N Engl"/>
   <result pre="Red Crescent Societies . A Socio�?economic Impact Assessment of the" exact="Zika" post="Virus in Latin America and the Caribbean: with a"/>
   <result pre="Suriname. 2017http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/a-socio-economic-impact-assessment-of-the-zika-virus-in-latin-am.html. Accessed Ausgust 18, 2018. 8SharmaS, TandelK, DashPK, ParidaM." exact="Zika" post="virus: A public health threat. J Med Virol. 2017;89:1693–1699.28369961"/>
   <result pre="J Med Virol. 2017;89:1693–1699.28369961 9collab: Pan American Health Organization ." exact="Zika" post="Cumulative Cases – 29�?December2016 [PAHO website] https://www.paho.org/hq/index.php?option=com_content%26view=article%26id=12390:zika-cumulative-cases%26Itemid=42090%26lang=en. Accessed August"/>
   <result pre="Accessed August 26, 2018. 12Tolosa PérezN. Public Health Surveillance Protocol:" exact="Zika" post="Virus Disease. National Institute of Health, Ministry of Health"/>
   <result pre="Ministry of Health and Social Protection . Response Plan against" exact="Zika" post="Virus Fever. Bogota: MINSALUD; 2016https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/plan-respuesta-fiebre-zika-colombia.pdf. Accessed August 15, 2018"/>
   <result pre="Guidelines for the Clinical Approach of Pregnant Women Exposed to" exact="Zika" post="virus in Colombia. Bogota: MINSALUD; 2016https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-provionales-abordaje-clinico-gestantes-expuestas-zika-colombia.pdf. Accessed August 15,"/>
   <result pre="Challenges, opportunities and insights. J Urban Health. 2007;84(Suppl.1):65–74. 16CarabalíJM, HendrickxD." exact="Dengue" post="and health care access: The role of social determinants"/>
   <result pre="implications. Int J Environ Res Public Health. 2018;15:E96.29315224 18SharmaA, LalSK." exact="Zika" post="virus: Transmission, detection, control, and prevention. Front Microbiol. 2017;8:1–14.28197127"/>
   <result pre="reproductive health knowledge, attitudes and practices in relation to the" exact="Zika" post="virus outbreak in northeast Brazil. PLoS Negl Trop Dis."/>
   <result pre="Public Health. 2016:1–111. 22HabyMM, PinartM, EliasV, ReveizL. Prevalence of asymptomatic" exact="Zika" post="virus infection: A systematic review. Bull World Health Organ."/>
   <result pre="Pan American Health Organisation . Neurological syndrome, congenital malformations, and" exact="Zika" post="virus infection. Implications for public health in the Americas."/>
   <result pre="17, 2018. 26Schuler�?FacciniL, RibeiroEM, FeitosaIML, et al. Possible association between" exact="Zika" post="virus infection and microcephaly—Brazil, 2015. MMWR Morb Mortal Wkly"/>
   <result pre="Morb Mortal Wkly Rep. 2016;65:59–62.26820244 27collab: World Health Organization ." exact="Zika" post="virus status report: Neurological syndrome and congenital anomalies. [WHO"/>
   <result pre="August 19, 2018. 28NunesML, CarliniCR, MarinowicD, et al. Microcephaly and" exact="Zika" post="virus: A clinical and epidemiological analysis of the current"/>
   <result pre="World Health Organization . Pregnancy management in the context of" exact="Zika" post="virus infection. [WHO website]. Published 2016http://www.who.int/csr/resources/publications/zika/pregnancy-management/en/. Accessed August 19,"/>
   <result pre="Published 2016http://www.who.int/csr/resources/publications/zika/pregnancy-management/en/. Accessed August 19, 2018. 30RasmussenSA, JamiesonDJ, HoneinMA, PetersenLR." exact="Zika" post="virus and birth defects—reviewing the evidence for causality. N"/>
   <result pre="N Engl J Med. 2016;374:1981–1987.27074377 31collab: World Health Organization ." exact="Zika" post="virus infection – Brazil and Colombia. [WHO website]. 2015http://www.who.int/csr/don/21-October-2015-zika/en/."/>
   <result pre="website]. 2015http://www.who.int/csr/don/21-October-2015-zika/en/. Accessed August 16, 2018. 32PetersenLR, JamiesonDJ, PowersAM, HoneinMA." exact="Zika" post="virus. N Engl J Med. 2016;374:1552–1563.27028561 33Vargas LorenzoI. Barriers"/>
   <result pre="Comprenhensive Clinical Management of Congenital Anomalies With Fetuses Exposed to" exact="Zika" post="Virus During Gestation of Patients in Colombia, Vol 1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7065065\results\search\tropicalVirus\results.xml">
   <result pre="Brazil. Email: jussara.angelo@ensp.fiocruz.br epub: 2020-1-1ppub: 2020-1148Suppl 210.1002/ijgo.v148.s2Building opportunities during the" exact="Zika" post="epidemic in the Americas: The case for strengthening research"/>
   <result pre="inflammatory polyneuropathies from 2015 to 2017. The extent to which" exact="Zika" post="virus symptoms explained GBS hospitalizations was evaluated using a"/>
   <result pre="A/H1N1 in 2009, dengue virus type 4 in 2013, and" exact="Zika" post="virus in 2015. Of 50 patients hospitalized, 14 (28.0%)"/>
   <result pre="the disorder has also been associated with dengue virus and" exact="Zika" post="virus.3 During the Zika virus epidemic in Rio de"/>
   <result pre="been associated with dengue virus and Zika virus.3 During the" exact="Zika" post="virus epidemic in Rio de Janeiro, Brazil, during the"/>
   <result pre="not been a baseline of GBS cases prior to the" exact="Zika" post="virus epidemic to provide a comparison with GBS rates"/>
   <result pre="included GBS, to time series of influenza, dengue virus, and" exact="Zika" post="virus in the state of Rio de Janeiro, Brazil."/>
   <result pre="1 and 2). We analyzed data on dengue virus and" exact="Zika" post="virus from Brazil's notifiable diseases database (Sistema de Agravos"/>
   <result pre="diseases database (Sistema de Agravos de Notificação [SINAN], in Portuguese)." exact="Zika" post="virus cases are only available in SINAN beginning in"/>
   <result pre="which cases of GBS could be explained by cases of" exact="Zika" post="virus and Zika + dengue virus. We used the"/>
   <result pre="GBS could be explained by cases of Zika virus and" exact="Zika" post="+ dengue virus. We used the hhh4 model for"/>
   <result pre="the model, we tabulated the number of cases of GBS," exact="Zika" post="virus, and dengue virus per month in Rio de"/>
   <result pre="on the population of i, cases of dengue virus and" exact="Zika" post="virus in month t, the number of GBS cases"/>
   <result pre="of time to reflect seasonal variation in GBS incidence. Since" exact="Zika" post="virus and dengue virus have similar clinical presentations such"/>
   <result pre="presentations such as febrile illness and rash,7 we pooled the" exact="Zika" post="+ dengue virus cases into the category arbovirus cases."/>
   <result pre="the category arbovirus cases. We also analyzed clinical cases of" exact="Zika" post="virus separately from the Zika + dengue virus cases."/>
   <result pre="also analyzed clinical cases of Zika virus separately from the" exact="Zika" post="+ dengue virus cases. While the analysis of syndromic"/>
   <result pre="de Janeiro because this area had the highest incidence of" exact="Zika" post="virus in the state in 2016 (Fig. 2, supporting"/>
   <result pre="the patient had a lab test for chikungunya, dengue, or" exact="Zika" post="virus. 3 RESULTS From 1997 to 2017, 1593 cases"/>
   <result pre="virus type 410; and in 2015 with the arrival of" exact="Zika" post="virus (n=326) (Fig. 3). Figure 3 Time series of"/>
   <result pre="variation in GBS incidence with 15% fewer cases during winter." exact="Zika" post="virus cases were a significant variable for explaining cases"/>
   <result pre="S3). The data were compatible with the null hypothesis that" exact="Zika" post="virus cases provided a good fit to the GBS"/>
   <result pre="P=0.403). As noted above, due to the difficulty of distinguishing" exact="Zika" post="virus from dengue virus, we also pooled the data"/>
   <result pre="S4). When we compared the goodness of fit of the" exact="Zika" post="virus and Zika + dengue virus models, the former"/>
   <result pre="compared the goodness of fit of the Zika virus and" exact="Zika" post="+ dengue virus models, the former had lower errors"/>
   <result pre="GBS from 1997 to 2017 coincided with the introduction of" exact="Zika" post="virus in 2015–2016 (Fig. 3). A predictive model based"/>
   <result pre="virus in 2015–2016 (Fig. 3). A predictive model based on" exact="Zika" post="virus cases explains the temporal pattern of GBS cases"/>
   <result pre="pattern of GBS cases better than a model based on" exact="Zika" post="+ dengue virus (Fig. 4). An example is the"/>
   <result pre="of Rio de Janeiro (Fig. 4B). The model based on" exact="Zika" post="virus predicts a major increase in GBS cases, while"/>
   <result pre="major increase in GBS cases, while the model based on" exact="Zika" post="+ dengue virus predicts a smaller increase. Dengue virus"/>
   <result pre="based on Zika + dengue virus predicts a smaller increase." exact="Dengue" post="virus did not improve the predictive accuracy of the"/>
   <result pre="cases were reported during this period. The fit of the" exact="Zika" post="virus model to the GBS cases is poorer for"/>
   <result pre="the city of Rio de Janeiro (Fig. 4B). Figure 4" exact="Zika" post="cases predict cases of GBS. (A) Rio de Janeiro"/>
   <result pre="II. The goodness of fit of the model based on" exact="Zika" post="+ dengue virus is lower than that of the"/>
   <result pre="Zika + dengue virus is lower than that of the" exact="Zika" post="virus only model. For both models, accuracy is higher"/>
   <result pre="immunoglobulin. Of the 14 cases with inflammatory polyneuropathy and arboviruses," exact="Zika" post="virus infection was confirmed by reverse transcriptase polymerase chain"/>
   <result pre="H1N1 in 2009, dengue virus type 4 in 2013, and" exact="Zika" post="virus in 2015. In 2009, a novel reassortant influenza"/>
   <result pre="an association between arboviruses and neuropathies in Brazil during the" exact="Zika" post="virus epidemic.4, 13, 14, 15 The rates of rash,"/>
   <result pre="HIV seropositive, use corticosteroids, have alcoholism, and have a silent" exact="Zika" post="virus infection, as up to 60% of cases are"/>
   <result pre="may have represented cases of Campylobacter, Cytomegalovirus, or influenza. The" exact="Zika" post="virus epidemic in Brazil is unique in that Brazil"/>
   <result pre="simultaneous transmission of four medically important arboviruses: chikungunya, dengue virus," exact="Zika" post="virus, and yellow fever virus. All four can cause"/>
   <result pre="complications including GBS.19, 20 Distinguishing between chikungunya, dengue virus, and" exact="Zika" post="virus is difficult because of similar signs and symptoms"/>
   <result pre="the analysis of syndromic surveillance, we pooled suspected cases of" exact="Zika" post="virus and dengue virus into the category of arboviruses."/>
   <result pre="into the category of arboviruses. Nevertheless, the model based on" exact="Zika" post="alone explained GBS cases better than the model based"/>
   <result pre="alone explained GBS cases better than the model based on" exact="Zika" post="+ dengue virus (arboviruses). Adding dengue virus to the"/>
   <result pre="Aedes mosquitos in these areas. Chart review indicated that suspected" exact="Zika" post="virus cases were seldom confirmed by laboratory exams. To"/>
   <result pre="arbovirus, but cannot determine whether it was chikungunya, dengue, or" exact="Zika" post="virus. Differential diagnosis of Flavivirus species is complicated because"/>
   <result pre="is complicated because commercial tests for dengue virus cross�?react to" exact="Zika" post="virus antibodies and vice versa.23, 24 The present study"/>
   <result pre="of Rio de Janeiro, which had a high incidence of" exact="Zika" post="virus, it is unknown whether our conclusions apply to"/>
   <result pre="modeling to test the hypothesis that an emerging virus, namely" exact="Zika" post="virus, could explain cases of GBS in the population"/>
   <result pre="of GBS across the state. Further, the model consisting of" exact="Zika" post="virus alone outperformed the model with all arboviruses, which"/>
   <result pre="authors have no conflicts of interest. Supporting information Figure S1." exact="Zika" post="virus incidence in the state of Rio de Janeiro"/>
   <result pre="library SURVEILLANCE in R.6 Table S3. hhh4 model based on" exact="Zika" post="virus cases in the state of Rio de Janeiro,"/>
   <result pre="in bold indicate P&amp;lt;0.05. Table S4. hhh4 model based on" exact="Zika" post="+ dengue virus in the state of Rio de"/>
   <result pre="2014;10:469–482.25023340 3RozéB, NajioullahF, FergéJ�?L, et al. Guillain�?Barré syndrome associated with" exact="Zika" post="virus infection in martinique in 2016: A prospective study."/>
   <result pre="Medialdea�?CarreraR, et al. The spectrum of neurological disease associated with" exact="Zika" post="and chikungunya viruses in adults in Rio de Janeiro,"/>
   <result pre="Stat Softw. 2017;77:1–55. 7BragaJU, BressanC, DalviAPR, et al. Accuracy of" exact="Zika" post="virus disease case definition during simultaneous Dengue and Chikungunya"/>
   <result pre="al. Accuracy of Zika virus disease case definition during simultaneous" exact="Dengue" post="and Chikungunya epidemics. PLoS ONE. 2017;12:e0179725.28650987 8MartynCN, HughesRA. Epidemiology"/>
   <result pre="of Zika virus disease case definition during simultaneous Dengue and" exact="Chikungunya" post="epidemics. PLoS ONE. 2017;12:e0179725.28650987 8MartynCN, HughesRA. Epidemiology of peripheral"/>
   <result pre="viral analysis. PLoS ONE. 2010;5:e14158.21152402 10HeringerM, SouzaTMA, LimaMDRQ, et al." exact="Dengue" post="type 4 in Rio de Janeiro, Brazil: Case characterization"/>
   <result pre="al. Guillain�?Barre syndrome and other neurological manifestations possibly related to" exact="Zika" post="virus infection in municipalities from Bahia, Brazil, 2015. Epidemiol"/>
   <result pre="Krow�?LucalER, et al. Increased rates of Guillain�?Barré syndrome associated with" exact="Zika" post="virus outbreak in the Salvador metropolitan area, Brazil. PLoS"/>
   <result pre="al. Guillain�?Barre syndrome in patients with a recent history of" exact="Zika" post="in Cucuta, Colombia: A descriptive case series of 19"/>
   <result pre="and clinical characteristics of Guillain�?Barre syndrome before the introduction of" exact="Zika" post="virus in Puerto Rico. J Neurol Sci. 2017;377:102–106.28477675 18HabyMM,"/>
   <result pre="Neurol Sci. 2017;377:102–106.28477675 18HabyMM, PinartM, EliasV, ReveizL. Prevalence of asymptomatic" exact="Zika" post="virus infection: A systematic review. Bull World Health Organ."/>
   <result pre="Neurol. 2013;12:906–919.23948177 20ChandakNH, KashyapRS, KabraD, et al. Neurological complications of" exact="Chikungunya" post="virus infection. Neurol India. 2009;57:177–180.19439849 21MussoD, GublerDJ. Zika virus."/>
   <result pre="complications of Chikungunya virus infection. Neurol India. 2009;57:177–180.19439849 21MussoD, GublerDJ." exact="Zika" post="virus. Clin Microbiol Rev. 2016;29:487–524.27029595 22FullerTL, CalvetG, Genaro EstevamC,"/>
   <result pre="EstevamC, et al. Behavioral, climatic, and environmental risk factors for" exact="Zika" post="and Chikungunya virus infections in Rio de Janeiro, Brazil,"/>
   <result pre="al. Behavioral, climatic, and environmental risk factors for Zika and" exact="Chikungunya" post="virus infections in Rio de Janeiro, Brazil, 2015�?16. PLoS"/>
   <result pre="commercial IgM and IgG enzyme�?linked immunoassays (ELISAs) for diagnosis of" exact="Zika" post="virus infection. Virol J. 2018;15:108.30005683 24FelixAC, SouzaNCS, FigueiredoWM, et"/>
   <result pre="Cross reactivity of commercial anti�?dengue immunoassays in patients with acute" exact="Zika" post="virus infection. J Med Virol. 2017;89:1477–1479.28229481 25van LeeuwenN, LingsmaHF,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7066069\results\search\tropicalVirus\results.xml">
   <result pre="Research Liposomal Delivery of the RNA Genome of a Live-Attenuated" exact="Chikungunya" post="Virus Vaccine Candidate Provides Local, but Not Systemic Protection"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) is the causative pathogen of chikungunya fever,"/>
   <result pre="progress to chronic arthritis. Our previous studies have identified the" exact="CHIKV" post="live-attenuated vaccine candidate CHIKV-NoLS. Like most live-attenuated vaccines, attenuated"/>
   <result pre="viremia and disease signs representative of this lethal model of" exact="CHIKV" post="infection, demonstrating de novo vaccine particle production in vivo."/>
   <result pre="of liposome-delivered CHIKV-NoLS RNA did not provide systemic protection from" exact="CHIKV" post="wild-type (WT) challenge but was found to promote an"/>
   <result pre="of CHIKV-WT-challenged mice. These results support previous studies that suggest" exact="CHIKV" post="is vulnerable to antibody-mediated enhancement of disease. Further studies"/>
   <result pre="of Primary Industries10.13039/100010000 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="fever is a mosquito-borne viral disease caused by the"/>
   <result pre="a mosquito-borne viral disease caused by the chikungunya virus (CHIKV)." exact="CHIKV" post="is a positive-sense single-stranded RNA (+ssRNA) virus and has"/>
   <result pre="2005–2006) and India (3–4 million estimated cases in 2005–2011) (1–3)." exact="CHIKV" post="has recently become established in the Americas, infecting over"/>
   <result pre="just 2 years (4). The majority of individuals infected with" exact="CHIKV" post="develop disease (5, 6). Symptoms of chikungunya disease are"/>
   <result pre="lasting several weeks to years (7). This chronic form of" exact="CHIKV" post="disease contributes considerably to disease burden. Atypical presentations associated"/>
   <result pre="disease contributes considerably to disease burden. Atypical presentations associated with" exact="CHIKV" post="infection include hepatitis, Guillain-Barré syndrome, myocarditis, retinitis, and nephritis"/>
   <result pre="nephritis (8). Increases in mortality have been described in several" exact="CHIKV" post="epidemics with most deaths occurring in neonates, patients with"/>
   <result pre="available. Our previous studies report the development of a live-attenuated" exact="CHIKV" post="vaccine candidate CHIKV-NoLS (12, 13). Mutating the nucleolar localization"/>
   <result pre="CHIKV-NoLS (12, 13). Mutating the nucleolar localization sequence (NoLS) of" exact="CHIKV" post="capsid protein, replacing 10 wild-type (WT) amino acids with"/>
   <result pre="of mice with one dose of CAF01-delivered CHIKV-NoLS RNA produced" exact="CHIKV" post="neutralizing antibodies and provided regional protection from disease following"/>
   <result pre="CHIKV neutralizing antibodies and provided regional protection from disease following" exact="CHIKV" post="challenge. This study provides the basis for developing CAF01-mediated"/>
   <result pre="RNA as a vaccine strategy. Further characterization of the live-attenuated" exact="CHIKV" post="vaccine candidate CHIKV-NoLS demonstrates the high degree of attenuation"/>
   <result pre="foot. The immunologically competent C57BL/6 mouse footpad model of acute" exact="CHIKV" post="disease recapitulates the arthritis, tenosynovitis, and myositis associated with"/>
   <result pre="0.05 was considered to be significant. Results CAF01 Delivers Replication-Competent" exact="CHIKV" post="RNA in vitro To overcome potential production limits for"/>
   <result pre="RNA in vitro To overcome potential production limits for our" exact="CHIKV" post="vaccine candidate (CHIKV-NoLS), we developed a liposomal approach to"/>
   <result pre="infection (Figure 1B). Cells transfected with RNA alone showed no" exact="CHIKV" post="infectivity and no signs of cytopathic effect (tested up"/>
   <result pre="transfection). Results demonstrate that CAF01 is able to deliver replication-competent" exact="CHIKV" post="RNA in vitro. Cell transfected with CHIKV-WT CAF01 began"/>
   <result pre="transfection (data not shown). To examine the productive replication of" exact="CHIKV" post="following CHIKV-WT CAF01 transfection, growth kinetics were analyzed by"/>
   <result pre="by plaque assay. CHIKV-WT CAF01 transfected cells produced live infectious" exact="CHIKV" post="with increasing titer to 53 h post transfection (Figure"/>
   <result pre="CHIKV-WT RNA showed signs of cytopathic effect and produced high" exact="CHIKV" post="titers earlier than cells transfected with CHIKV-WT CAF01. Cells"/>
   <result pre="(Figure 2A). Results suggest CAF01 is able to deliver replication-competent" exact="CHIKV" post="RNA in vivo to produce viable infectious CHIKV particles."/>
   <result pre="deliver replication-competent CHIKV RNA in vivo to produce viable infectious" exact="CHIKV" post="particles. Figure 2 Inoculation with CHIKV-NoLS CAF01 elicits de"/>
   <result pre="Signs but Recover From Infection As a lethal model of" exact="CHIKV" post="infection, the attenuation of CHIKV-NoLS CAF01 was tested in"/>
   <result pre="Mice Survive CHIKV-WT Challenge and Are Protected From Development of" exact="CHIKV" post="Disease As CHIKV-NoLS CAF01-inoculated AG129 mice survived, AG129 mice"/>
   <result pre="performed by non-parametric Mann–Whitney t-test. CHIKV-NoLS CAF01 Inoculation Protects Against" exact="CHIKV" post="Disease in the Ipsilateral Foot of C57BL/6 Mice Challenged"/>
   <result pre="5A–C). Results suggest that CHIKV-NoLS immunization provides systemic protection from" exact="CHIKV" post="challenge after one dose. All mice inoculated with either"/>
   <result pre="challenge (Figures 5A–C). Figure 5 CHIKV-NoLS CAF01 inoculation protects against" exact="CHIKV" post="disease in the ipsilateral foot of C57BL/6 mice upon"/>
   <result pre="CHIKV-NoLS CAF01 immunization provides local but not systemic protection from" exact="CHIKV" post="challenge. Cellular Infiltration in Challenged C57BL/6 Mice To further"/>
   <result pre="feet of CHIKV-NoLS RNA-inoculated mice compared to mock-infected controls following" exact="CHIKV" post="challenge (Figures 6B,C). For both activated neutrophils and inflammatory"/>
   <result pre="CHIKV-WT-inoculated group, which was protected from development of swelling upon" exact="CHIKV" post="challenge. This suggests that activated neutrophils and inflammatory monocytes"/>
   <result pre="groups compared to unchallenged controls also emphasizes their involvement in" exact="CHIKV" post="disease. Together, these data suggest that cellular infiltrates, particularly"/>
   <result pre="inflammatory monocytes, are involved in the early onset of severe" exact="CHIKV" post="disease in CHIKV-NoLS RNA-challenged mice. Figure 6 Cellular infiltration"/>
   <result pre="challenged with CHIKV. Antibody Response in CHIKV-NoLS CAF01-Inoculated C57BL/6 Mice" exact="CHIKV" post="vaccine studies in mice and non-human primates indicate that"/>
   <result pre="site (21). Interestingly, CHIKV-NoLS CAF01-inoculated C57BL/6 mice, although protected from" exact="CHIKV" post="disease when challenged at the site of inoculation, did"/>
   <result pre="the site of inoculation, did not develop systemic protection from" exact="CHIKV" post="challenge. In fact, an early onset of severe disease"/>
   <result pre="mice. This enhancement of inflammation has been observed in previous" exact="CHIKV" post="vaccination strategies and likened to a phenomenon known as"/>
   <result pre="of CHIKV-specific antibodies, demonstrating the role of antibody-mediated enhancement during" exact="CHIKV" post="infection and pathogenesis (30). With significantly low levels of"/>
   <result pre="mechanisms, in addition to neutralizing antibodies, mediate local protection from" exact="CHIKV" post="disease in mice. Further studies are ongoing to evaluate"/>
   <result pre="2005-2006. Am J Trop Med Hyg. (2007) 77:727–31. 10.4269/ajtmh.2007.77.72717978079 3.BeesoonSFunkhouserEKoteaNSpielmanARobichtRM." exact="Chikungunya" post="fever, Mauritius, 2006. Emerg Infect Dis. (2008) 14:337–8. 10.3201/eid1402.07102418258136"/>
   <result pre="2006. Emerg Infect Dis. (2008) 14:337–8. 10.3201/eid1402.07102418258136 4.Van BortelWDorleansFRosineJBlateauARoussetDMatheusSet al.." exact="Chikungunya" post="outbreak in the Caribbean region, December 2013 to March"/>
   <result pre="chikungunya virus infection. Lancet Infect Dis. (2008) 8:2–3. 10.1016/S1473-3099(07)70294-318156079 6.SimonFJavelleEOliverMLeparc-GoffartIMarimoutouC." exact="Chikungunya" post="virus infection. Curr Infect Dis Rep. (2011) 13:218–28. 10.1007/s11908-011-0180-121465340"/>
   <result pre="chikungunya epidemic of 2014. Epidemiol Infect. (2018) 146:2059–65. 10.1017/S095026881800231530152293 10.StaplesJEBreimanRFPowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
   <result pre="by Foroderm. Vaccine. (2015) 33:5172–80. 10.1016/j.vaccine.2015.07.09926296498 29.HallengardDKakoulidouMLullaAKummererBMJohanssonDXMutsoMet al.. Novel attenuated" exact="Chikungunya" post="vaccine candidates elicit protective immunity in C57BL/6 mice. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7067377\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Social Sciences : Sociology : Communications :"/>
   <result pre="on collective attention in the United States during the 2016" exact="Zika" post="epidemic News exposure and collective attention during epidemics http://orcid.org/0000-0001-7246-2341TizzoniMicheleConceptualizationData"/>
   <result pre="the Internet Archive—to quantify population-scale information seeking about the 2016" exact="Zika" post="virus epidemic in the U.S., explicitly linking such behavioural"/>
   <result pre="study the dynamics of collective attention received by the 2016" exact="Zika" post="epidemic in the USA and its interplay with the"/>
   <result pre="of US states and cities. We measure the attention to" exact="Zika" post="through geo-localized Wikipedia page view data, and we compare"/>
   <result pre="page view data, and we compare it with mentions of" exact="Zika" post="in US news outlets and TV shows. We also"/>
   <result pre="collective attention received by the outbreak with the incidence of" exact="Zika" post="reported by the US Centers for Disease Control and"/>
   <result pre="on spatio-temporally resolved accesses to Wikipedia pages on the 2015-2016" exact="Zika" post="virus (ZIKV) epidemic, regarded as a proxy for collective"/>
   <result pre="and on their relation to media coverage of the epidemic." exact="ZIKV" post="is a RNA virus from the Flaviviridae family which"/>
   <result pre="serious and sometimes fatal neurological defects in neonates born to" exact="ZIKV" post="infected women. In particular, following the association between ZIKV"/>
   <result pre="to ZIKV infected women. In particular, following the association between" exact="ZIKV" post="and a cluster of microcephaly cases in Brazil [10],"/>
   <result pre="in Brazil [10], the World Health Organization (WHO) declared the" exact="ZIKV" post="epidemic a Public Health Emergency of International Concern (PHEIC)"/>
   <result pre="the PHEIC to be over [12]. As of March 2017," exact="ZIKV" post="has spread worldwide to 79 countries where there has"/>
   <result pre="the American continent with 47 countries or territories reporting local" exact="ZIKV" post="transmission, due to the extensive presence of Aedes mosquitoes"/>
   <result pre="all the region’s countries [13]. In such epidemiological context, the" exact="ZIKV" post="epidemic has posed peculiar communication challenges to the public"/>
   <result pre="the 2016 Summer Olympics [13–15]. The communication challenges posed by" exact="ZIKV" post="are well exemplified in a manual released in 2017"/>
   <result pre="on how to deal with the complex communication challenges of" exact="ZIKV" post="and mosquito borne disease outbreaks in general. Among the"/>
   <result pre="more is learned about the outbreak and scientific knowledge about" exact="Zika" post="virus and its complications evolve. Public polls conducted in"/>
   <result pre="in the United States evidenced the lack of knowledge about" exact="ZIKV" post="in the general population and more specifically in groups"/>
   <result pre="knowledge of it in the affected areas make the 2016" exact="ZIKV" post="epidemic an ideal case study to characterize collective attention"/>
   <result pre="of public attention in the United States, during the 2016" exact="ZIKV" post="epidemic. Accesses to Wikipedia pages represent a signal of"/>
   <result pre="spatial patterns of pageviews in relation to the timeline of" exact="ZIKV" post="incidence reported by the US Centers for Disease Control"/>
   <result pre="Prevention (CDC), and in relation to the coverage of the" exact="ZIKV" post="epidemic by local and national media sources. In particular,"/>
   <result pre="sources. In particular, we focused on news coverage of the" exact="ZIKV" post="epidemic by online media and television in 2016, available"/>
   <result pre="news coverage Public attention and media coverage of the 2016" exact="ZIKV" post="epidemic showed a distinct and synchronous temporal pattern, as"/>
   <result pre="epidemic (Fig 1B) and in the Web news coverage of" exact="Zika" post="(Fig 1C). The three time series are indeed highly"/>
   <result pre="Fig 1 Attention, media coverage and disease incidence of the" exact="Zika" post="virus in the USA in 2016. (A) Daily Wikipedia"/>
   <result pre="the USA in 2016. (A) Daily Wikipedia pageview counts of" exact="Zika" post="related pages. B, Daily mentions of the word &quot;Zika�?"/>
   <result pre="extracted from the GDELT project. D, Weekly incidence of the" exact="Zika" post="virus reported by the CDC. Originally reported case counts"/>
   <result pre="is very similar to the one displayed by mentions of" exact="Zika" post="in media outlets, the temporal profile of the disease"/>
   <result pre="disease incidence is qualitatively very different. The number of new" exact="ZIKV" post="cases in the United States reported by the CDC"/>
   <result pre="2016 was also characterized by the first reports of local" exact="ZIKV" post="transmission in Florida and in Texas, events that were"/>
   <result pre="increased news coverage of Zika. However, the surge of reported" exact="ZIKV" post="cases in the United States did not result in"/>
   <result pre="the TV coverage of the epidemic and the mentions of" exact="Zika" post="on the Web, the attention patterns at State level"/>
   <result pre="and the name of the state, and to the local" exact="ZIKV" post="incidence profiles. Attention profiles in each state were generally"/>
   <result pre="the country (see S3 Table in the Supporting Information). Interestingly," exact="ZIKV" post="incidence in each state could explain such geographic variations"/>
   <result pre="the Supporting Information. On the other hand, Web news covering" exact="Zika" post="in each state were positively correlated with the local"/>
   <result pre="50 states ranked by degree of correlation between news and" exact="ZIKV" post="incidence, and between news and attention, showed a negative"/>
   <result pre="to the national one and less correlated with the local" exact="ZIKV" post="epidemiology. It is natural to ask whether correlations between"/>
   <result pre="resolutions. To answer this question, we examined the attention to" exact="ZIKV" post="in 788 cities of the United States with a"/>
   <result pre="Zika-related articles only, we identified locations where the attention to" exact="ZIKV" post="was higher than expected. As shown in Fig 3A,"/>
   <result pre="in the Northeast. On the contrary, the lowest attention to" exact="ZIKV" post="was observed in cities in California, and in the"/>
   <result pre="population higher than 40,000, where the volume of attention to" exact="ZIKV" post="related pages was higher (panel A) or lower (panel"/>
   <result pre="negative (panel D) difference in their pageview rankings, based on" exact="ZIKV" post="related pages and the full Wikipedia. The labels on"/>
   <result pre="assess the mutual relationships between news coverage, Wikipedia pageviews and" exact="Zika" post="incidence, we turn to a Vector Autoregression (VAR) model,"/>
   <result pre="89.23, df = 2, p &amp;lt; 10−6). To include the" exact="ZIKV" post="incidence timeline in our analysis, we build another VAR"/>
   <result pre="weekly time series: Zika-related pageviews, TV mentions, Web news and" exact="ZIKV" post="incidence. For this model we identify the optimal time"/>
   <result pre="pageviews and the other variables is supported (p &amp;lt; 10−3)." exact="ZIKV" post="incidence, instead, does not Granger-cause the other time series"/>
   <result pre="at daily and weekly scale. On the contrary, the epidemiological" exact="ZIKV" post="curve does not show to have a predictive power"/>
   <result pre="estimates [30]. These states are also those where the epidemic" exact="ZIKV" post="activity in 2016 was the highest. In S7 Table,"/>
   <result pre="all states with the only exception of Alaska, where no" exact="ZIKV" post="cases were reported in 2016. We train the model"/>
   <result pre="media signals, taken independently, are already quite informative of the" exact="Zika" post="population-rescaled pageview time series: using exclusively TV close captions"/>
   <result pre="regression informed only by the epidemiological signal, that is the" exact="ZIKV" post="incidence in each state. As shown in Table 1,"/>
   <result pre="shown in Table 1, first row, the predictive performance of" exact="ZIKV" post="incidence is generally poor with R2 = −0.398, r"/>
   <result pre="model comparison. Features R2 Pearson r Spearman �? AIC Δi" exact="ZIKV" post="-0.398 (0.032) -0.032 (0.030) 0.1515 (0.055) -917.21 131.35 TV"/>
   <result pre="dynamics of Wikipedia pageviews in the United States during the" exact="ZIKV" post="2016 epidemic was highly predictable, even at state level,"/>
   <result pre="on the volume of national and international news sources mentioning" exact="Zika" post="and the United States. Collective attention to the ZIKV"/>
   <result pre="mentioning Zika and the United States. Collective attention to the" exact="ZIKV" post="outbreak thus seems to have been mainly driven by"/>
   <result pre="by the disease transmission dynamics, although the epidemic profile of" exact="ZIKV" post="infections varied significantly from state to state and the"/>
   <result pre="hand, the temporal dynamics of Wikipedia pageviews during the 2016" exact="ZIKV" post="epidemic showed a nonlinear dependence with media coverage: the"/>
   <result pre="the volume of media coverage is feasible. During the 2016" exact="ZIKV" post="outbreak, different aspects of the epidemic, and the risks"/>
   <result pre="expected that news did not necessarily follow the number of" exact="ZIKV" post="cases, such result highlight the limitations of several behavioral"/>
   <result pre="made by journalists regarding newsworthiness of specific aspects related to" exact="ZIKV" post="infection affected the level of knowledge and familiarity in"/>
   <result pre="in the US population [39]. Also, the media narrative around" exact="ZIKV" post="evolved over time, as found in a recent study"/>
   <result pre="recent study by Yotam Ophir [40]. The content of the" exact="ZIKV" post="news coverage shifted from focusing on scientific themes, at"/>
   <result pre="data streams to measure the global reaction to the 2015-2016" exact="ZIKV" post="outbreaks in different countries. Similarly, we did not find"/>
   <result pre="significant correlation between the viewership of Wikipedia pages and the" exact="ZIKV" post="incidence data in the U.S. The correlation between ZIKV"/>
   <result pre="the ZIKV incidence data in the U.S. The correlation between" exact="ZIKV" post="incidence and media coverage was also mild, and varied"/>
   <result pre="to announcements by the CDC at the beginning of the" exact="Zika" post="outbreak was highlighted by a recent study by Southwell"/>
   <result pre="to all epidemic outbreaks. Indeed, the peculiar characteristics of the" exact="ZIKV" post="infection, such as its association to mild symptoms and"/>
   <result pre="meaning of risk. Individual perception of risk during the 2016" exact="ZIKV" post="outbreak has probably decreased quickly, after it became clear"/>
   <result pre="course of a chikungunya outbreak, another vector-borne disease similar to" exact="ZIKV" post="[46]. From the point of view of media coverage,"/>
   <result pre="of view of media coverage, the fact that most of" exact="ZIKV" post="cases were asymptomatic, may have reduced newsworthiness, as media"/>
   <result pre="They were, by far, the most accessed pages among all" exact="Zika" post="related articles in the English Wikipedia, with the &quot;Zika"/>
   <result pre="in our study report the number of news items citing" exact="Zika" post="that appeared each day in 2016. Multiple mentions of"/>
   <result pre="including multiple mentions of the word in the same program." exact="Zika" post="case notification data Incidence data of the Zika virus"/>
   <result pre="same program. Zika case notification data Incidence data of the" exact="Zika" post="virus in the United States was collected from the"/>
   <result pre="(https://github.com/cdcepi/zika). The CDC epidemiological reports provide the cumulative number of" exact="Zika" post="cases by State, starting from February 24, 2016. Additional"/>
   <result pre="× 1 for weekly time series (with the addition of" exact="ZIKV" post="incidence). L is the lag order and u assigns"/>
   <result pre="= ZIKVs(w), where ZIKVs(w) is the weekly number of reported" exact="ZIKV" post="cases in state s. To take into account the"/>
   <result pre="S2 Table Correlations between Wikipedia pageviews, the Web news mentioning" exact="Zika" post="and TV close captions in 2016. The table reports"/>
   <result pre="for the Wikipedia page view counts, the Web news mentioning" exact="Zika" post="and the TV close captions at national level. All"/>
   <result pre="file. S3 Table Correlations between Wikipedia pageviews and news mentioning" exact="Zika" post="by state. All states are ranked by Pearson’s r"/>
   <result pre="additional data file. S4 Table Correlations between Wikipedia pageviews and" exact="ZIKV" post="incidence by state. All states are ranked by Pearson’s"/>
   <result pre="for additional data file. S5 Table Correlations between news mentioning" exact="Zika" post="and ZIKV incidence by state. All states are ranked"/>
   <result pre="data file. S5 Table Correlations between news mentioning Zika and" exact="ZIKV" post="incidence by state. All states are ranked by Pearson’s"/>
   <result pre="KucirkaLM, BiQ, GrantzK, SaljeH, et al.Assessing the global threat from" exact="Zika" post="virus. Science. 2016;353(6300):aaf816010.1126/science.aaf816027417495 10MlakarJ, KorvaM, TulN, PopovićM, Poljšak-PrijateljM, MrazJ,"/>
   <result pre="International Health Regulations (2005) regarding microcephaly, other neurological disorders and" exact="Zika" post="virus; 2016. Available from: http://www.who.int/mediacentre/news/statements/2016/zika-fifth-ec/en/. 13MaloneRW, HomanJ, CallahanMV, Glasspool-MaloneJ,"/>
   <result pre="2016;10(3):e000453010.1371/journal.pntd.000453026934531 14FergusonNM, CucunubáZM, DorigattiI, Nedjati-GilaniGL, DonnellyCA, BasáñezMG, et al.Countering the" exact="Zika" post="epidemic in Latin America. Science. 2016;353(6297):353–354. 10.1126/science.aag021927417493 15ZhangQ, SunK,"/>
   <result pre="15ZhangQ, SunK, ChinazziM, y PionttiAP, DeanNE, RojasDP, et al.Spread of" exact="Zika" post="virus in the Americas. Proceedings of the National Academy"/>
   <result pre="Sciences. 2017;114(22):E4334–E4343. 10.1073/pnas.1620161114 16World Health Organization Regional Office for Europe." exact="Zika" post="virus and emerging mosquito—borne diseases: The European emergency risk"/>
   <result pre="of Public Health. Many U.S. families considering pregnancy don’t know" exact="Zika" post="facts; 2016. Available from: https://www.hsph.harvard.edu/news/press-releases/zika-virus-awareness-pregnant-women/. 18ShihTJ, WijayaR, BrossardD. Media"/>
   <result pre="10.1177/1750698013490590 26ShachamE, NelsonEJ, HoftDF, SchootmanM, GarzaA. Potential High-Risk Areas for" exact="Zika" post="Virus Transmission in the Contiguous United States. American journal"/>
   <result pre="Royal Society open science. 2016;3(10):16046010.1098/rsos.16046027853560 39OphirY, JamiesonKH. The Effects of" exact="Zika" post="Virus Risk Coverage on Familiarity, Knowledge and Behavior in"/>
   <result pre="BarberisI, MartiniM, et al.Global reaction to the recent outbreaks of" exact="Zika" post="virus: Insights from a Big Data analysis. PloS one."/>
   <result pre="Data analysis. PloS one. 2017;12(9):e018526310.1371/journal.pone.018526328934352 44SouthwellBG, DolinaS, Jimenez-MagdalenoK, SquiersLB, KellyBJ." exact="Zika" post="virus–related news coverage and online behavior, United States, Guatemala,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7067471\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences: Epidemiology : Biology"/>
   <result pre="Areas: Rural Areas First report of Aedes albopictus infected by" exact="Dengue" post="and Zika virus in a rural outbreak in Brazil"/>
   <result pre="Areas First report of Aedes albopictus infected by Dengue and" exact="Zika" post="virus in a rural outbreak in Brazil Dengue and"/>
   <result pre="Dengue and Zika virus in a rural outbreak in Brazil" exact="Dengue" post="and Zika in Aedes albopictus in Brazil Ricas RezendeHelderConceptualizationInvestigationWriting"/>
   <result pre="Zika virus in a rural outbreak in Brazil Dengue and" exact="Zika" post="in Aedes albopictus in Brazil Ricas RezendeHelderConceptualizationInvestigationWriting – review"/>
   <result pre="the original author and source are credited.pone.0229847.pdf Abstract In Brazil," exact="Dengue" post="(DENV) and Zika (ZIKV) viruses are reported as being"/>
   <result pre="and source are credited.pone.0229847.pdf Abstract In Brazil, Dengue (DENV) and" exact="Zika" post="(ZIKV) viruses are reported as being transmitted exclusively by"/>
   <result pre="This is the first report of A. albopictus infected by" exact="DENV" post="and ZIKV during an outbreak in a rural area"/>
   <result pre="the first report of A. albopictus infected by DENV and" exact="ZIKV" post="during an outbreak in a rural area in Brazil,"/>
   <result pre="manuscript and in GenBank under the accession number MN567709. Introduction" exact="Dengue" post="virus (DENV) and Zika virus (ZIKV) are etiological agents"/>
   <result pre="under the accession number MN567709. Introduction Dengue virus (DENV) and" exact="Zika" post="virus (ZIKV) are etiological agents of reemerging and emerging"/>
   <result pre="infected mosquitoes of the Aedes genus (Stegomya subgenus) [2]. Consequently," exact="DENV" post="and ZIKV present an epidemiological overlap, with occurrence influenced"/>
   <result pre="of the Aedes genus (Stegomya subgenus) [2]. Consequently, DENV and" exact="ZIKV" post="present an epidemiological overlap, with occurrence influenced by similar"/>
   <result pre="[3]. In 2019, more than 100 countries were endemic for" exact="DENV" post="and 87 had evidence of autochthonous transmission of ZIKV"/>
   <result pre="for DENV and 87 had evidence of autochthonous transmission of" exact="ZIKV" post="[4]. Brazil is currently the nation with the highest"/>
   <result pre="Brazil is currently the nation with the highest report of" exact="DENV" post="[5] and ZIKV infections in the world [4]. There,"/>
   <result pre="the nation with the highest report of DENV [5] and" exact="ZIKV" post="infections in the world [4]. There, Aedes aegypti is"/>
   <result pre="to this environment [7]. Aedes albopictus was never associated with" exact="DENV" post="and ZIKV transmission in Brazil, despite its recognition as"/>
   <result pre="environment [7]. Aedes albopictus was never associated with DENV and" exact="ZIKV" post="transmission in Brazil, despite its recognition as a competent"/>
   <result pre="Brazil [13, 27]. There, 73,998-suspected cases and 37 deaths by" exact="DENV" post="infection were reported in 2019 until the 39° epidemiological"/>
   <result pre="2019 until the 39° epidemiological week, and 1,055 registers of" exact="ZIKV" post="were made in the same period [28]. The introduction"/>
   <result pre="2019, an outbreak of dengue-like illness with 20-suspected cases of" exact="DENV" post="infection was reported in a rural area of Linhares"/>
   <result pre="reports of exanthematous febrile illness. Four cases were tested for" exact="DENV" post="infection by the public health authority: one was positive"/>
   <result pre="Molecular tests for arboviruses detection were made through Real-Time PCR." exact="Dengue" post="detection was made according to Huhtano et al. (2010)"/>
   <result pre="and probes serotype-specific described by Callahan et al. (2001) [32]." exact="Zika" post="RNA detection was done using the protocol developed by"/>
   <result pre="PCR The extracted RNAs that were positive for DENV-1 and" exact="ZIKV" post="were submitted to whole-genome amplification using a tiling, multiplex"/>
   <result pre="from Primal Scheme using as input the &quot;ZikaAsian�? scheme for" exact="ZIKV" post="(https://github.com/zibraproject) and the one described by Quick et al."/>
   <result pre="all identified as A. (Stegomyia) albopictus (Skuse, 1894) and females." exact="ZIKV" post="was amplified in the subsample 2f (subsample f of"/>
   <result pre="Virus Ct 2f 27 March 2019 8:30 am– 10:30 am" exact="ZIKV" post="35 3i 27 March 2019 2:30 pm– 4:00 pm"/>
   <result pre="ZIKV 35 3i 27 March 2019 2:30 pm– 4:00 pm" exact="DENV" post="23.7 Fourteen reads of the ZIKV gene were amplified"/>
   <result pre="2:30 pm– 4:00 pm DENV 23.7 Fourteen reads of the" exact="ZIKV" post="gene were amplified and sequenced, resulting in a consensus"/>
   <result pre="consensus sequence with 401 nucleotides, and 98.8% similarity with the" exact="ZIKV" post="genome. Due to the low sequence coverage, phylogenetic analysis"/>
   <result pre="study is the first to report A. albopictus infected by" exact="DENV" post="and ZIKV during an outbreak of a dengue-like illness"/>
   <result pre="the first to report A. albopictus infected by DENV and" exact="ZIKV" post="during an outbreak of a dengue-like illness in a"/>
   <result pre="typical of urban settings. Despite a tendency of expansion of" exact="DENV" post="to the countryside, all the explanations for this phenomenon"/>
   <result pre="of A. aegypti in smaller cities [39]. Differential diagnosis between" exact="DENV" post="and ZIKV infections is challenging due to their similar"/>
   <result pre="aegypti in smaller cities [39]. Differential diagnosis between DENV and" exact="ZIKV" post="infections is challenging due to their similar signs and"/>
   <result pre="an exanthematous febrile illness and four had laboratory confirmation for" exact="DENV" post="infection. One infection by DENV-1 was identified, and the"/>
   <result pre="in A. albopictus. Despite the absence of confirmed cases of" exact="ZIKV" post="infection in humans, six human cases of febrile illness"/>
   <result pre="of febrile illness were considered to be not caused by" exact="DENV" post="and could have plausibly been a result of ZIKV"/>
   <result pre="by DENV and could have plausibly been a result of" exact="ZIKV" post="infection or diseases with similar symptoms, such as those"/>
   <result pre="fever and yellow fever. A subsample of mosquitoes infected by" exact="ZIKV" post="was engorged, indicating the potential involvement of A. albopictus"/>
   <result pre="the sylvatic environment. Despite the lack of molecular detection of" exact="ZIKV" post="or other arboviruses in the studied human cases, the"/>
   <result pre="identified field-collected immature forms of A. albopictus infected by all" exact="DENV" post="serotypes [6, 17, 19, 45–47], and by ZIKV [48]."/>
   <result pre="by all DENV serotypes [6, 17, 19, 45–47], and by" exact="ZIKV" post="[48]. Despite the variation on the vector competence of"/>
   <result pre="in Brazil. A possible scenario of A. albopictus involvement in" exact="DENV" post="and ZIKV transmission in Brazil imposes a concern on"/>
   <result pre="A possible scenario of A. albopictus involvement in DENV and" exact="ZIKV" post="transmission in Brazil imposes a concern on the transmission"/>
   <result pre="the broad distribution with ecological plasticity, a possible &quot;ruralization�? of" exact="DENV" post="and ZIKV may impose additional challenges for the control"/>
   <result pre="distribution with ecological plasticity, a possible &quot;ruralization�? of DENV and" exact="ZIKV" post="may impose additional challenges for the control of these"/>
   <result pre="was not possible to identify if the mosquitoes positive for" exact="DENV" post="and ZIKV were collected in intradomicile, peridomicile, or in"/>
   <result pre="possible to identify if the mosquitoes positive for DENV and" exact="ZIKV" post="were collected in intradomicile, peridomicile, or in the cocoa"/>
   <result pre="Dzul-ManzanillaF, Gomez-DantésH, Pavia-RuzN, HladishTJ, LenhartA, et al.Spatio-temporal coherence of Dengue," exact="Chikungunya" post="and Zika outbreaks in Merida, Mexico.PLoS Negl Trop Dis."/>
   <result pre="Pavia-RuzN, HladishTJ, LenhartA, et al.Spatio-temporal coherence of Dengue, Chikungunya and" exact="Zika" post="outbreaks in Merida, Mexico.PLoS Negl Trop Dis. 2018;12: e000629810.1371/journal.pntd.000629829543910"/>
   <result pre="Mexico.PLoS Negl Trop Dis. 2018;12: e000629810.1371/journal.pntd.000629829543910 4collab: World Health Organization." exact="Zika" post="epidemiology update. Geneva: World Health Organization; 2019. 5BezerraJMT, AraújoRGP,"/>
   <result pre="SouzaKPR, FigueiredoLB, ResendeMC. Natural vertical transmission by Stegomyia albopicta as" exact="Dengue" post="vector in Brazil.Braz J Biol. 2009;69: 123–127. 10.1590/s1519-6984200900010001519347154 18Ceretti-JuniorW,"/>
   <result pre="Aedes aegypti and Aedes albopictus in an endemic area of" exact="Dengue" post="in Brazil.Rev Inst Med Trop Sao Paulo. 2019;61: e1810.1590/S1678-994620196101830970109"/>
   <result pre="31HuhtamoE, HasuE, UzcáteguiNY, ErraE, NikkariS, KanteleA, et al.Early diagnosis of" exact="Dengue" post="in travelers: Comparison of a novel Real-Time RT-PCR, NS1"/>
   <result pre="serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for" exact="Dengue" post="virus.J Clin Virol. 2001;39: 4119–4124. 33LanciottiRS, KosoyOL, LavenJJ, VelezJO,"/>
   <result pre="LavenJJ, VelezJO, LambertAJ, JohnsonAJ, et al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007."/>
   <result pre="of a multiplex Real-Time RT-PCR assay for simultaneous detection of" exact="Dengue" post="and Chikungunya viruses. Arch Virol. 2015;160: 323–327. 10.1007/s00705-014-2217-x25233940 35collab:"/>
   <result pre="multiplex Real-Time RT-PCR assay for simultaneous detection of Dengue and" exact="Chikungunya" post="viruses. Arch Virol. 2015;160: 323–327. 10.1007/s00705-014-2217-x25233940 35collab: World Health"/>
   <result pre="et al.Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples.Nat Protoc."/>
   <result pre="CalvezE, Chouin-CarneiroT, DialloD, FaillouxA-B. An overview of mosquito vectors of" exact="Zika" post="virus. Microbes Infect. 2018;20: 646e60.29481868 42CarneiroAR, CruzACR, VallinotoM, MeloDV,"/>
   <result pre="42CarneiroAR, CruzACR, VallinotoM, MeloDV, RamosRTJ, MedeirosDBA, et al.Molecular characterisation of" exact="Dengue" post="virus type 1 reveals lineage replacement during circulation in"/>
   <result pre="Cruz. 2012;107: 805–812. 10.1590/s0074-0276201200060001622990972 43Ramos-CastañedaJ, SantosFB, Martínez-VegaR, AraujoJMG, JointG, SartiE." exact="Dengue" post="in Latin America: Systematic review of molecular epidemiological trends.PLoS"/>
   <result pre="1716010.1038/s41598-018-35622-x30464188 45SerufoJC, OcaHMd, TavaresVA, SouzaAM, RosaRV, JamalMC, et al.Isolation of" exact="Dengue" post="virus type 1 from larvae of Aedes albopictus in"/>
   <result pre="46FigueiredoMLG, GomesAC, AmarillaAA, LeandroAS, OrricoAS, AraujoRF, et al.Mosquitoes infected with" exact="Dengue" post="viruses in Brazil.Virol J. 2010;7: 15210.1186/1743-422X-7-15220624314 47PessanhaJEM, CaiaffaWT, CecilioAB,"/>
   <result pre="StennTMS, ChenT-Y, TeixeiraMG, QueirozEP, Souza Dos SantosL, et al.Evidence of" exact="Zika" post="virus RNA fragments in Aedes albopictus (Diptera: Culicidae) field-collected"/>
   <result pre="vector competency of Aedes albopictus populations from the Americas for" exact="Zika" post="virus. Am J Trop Med Hyg. 2017;97: 330–339. 10.4269/ajtmh.16-096928829735"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7068348\results\search\tropicalVirus\results.xml">
   <result pre="threshold effect vector index negative binomial regression model 1. Introduction" exact="Dengue" post="fever is a mosquito-borne communicable disease transmitted through the"/>
   <result pre="distributed and rapidly spreading mosquito-borne viral disease in the world." exact="Dengue" post="fever has been now reported in over 124 countries"/>
   <result pre="and regions in the world, with an estimated 390 million" exact="DENV" post="infections and 250,000 deaths occurring worldwide each year [1,2,3]."/>
   <result pre="the BI dengue vector index in Taiwan. 2. Background to" exact="Dengue" post="Fever 2.1. Dengue Fever in Taiwan Dengue fever is"/>
   <result pre="vector index in Taiwan. 2. Background to Dengue Fever 2.1." exact="Dengue" post="Fever in Taiwan Dengue fever is geographically distributed in"/>
   <result pre="2. Background to Dengue Fever 2.1. Dengue Fever in Taiwan" exact="Dengue" post="fever is geographically distributed in tropical and subtropical regions."/>
   <result pre="years compared with the period from 2006 to 2012. 2.2." exact="Dengue" post="and Climate Change Climate change is likely to expand"/>
   <result pre="optimal temperature for transmission of dengue fever is 21.6–32.9 °C." exact="Dengue" post="cases started to increase when the temperature exceeded 21.6"/>
   <result pre="future [15,16]. 3. Estimating the Threshold Effects of Temperature on" exact="Dengue" post="Vector Index 3.1. Dataset The panel dataset covered the"/>
   <result pre="population density. Below is a brief description of the dataset:" exact="Dengue" post="case surveillance data: In Taiwan, dengue fever is classified"/>
   <result pre="30.2 °C. 4. Estimating the Relationship between Entomological Index and" exact="Dengue" post="Cases Because the number of confirmed cases of dengue"/>
   <result pre="IPS Test PP-Fisher Chi-Sq. Breteau Index (BI) −47.58*** −54.06*** 131.73***" exact="Dengue" post="Cases (DF) −28.81*** −48.65*** 118.41*** Average Temperature (Temp) −2.49**"/>
   <result pre="1Table 1 Descriptive statistics of variables used in analyses Region" exact="Dengue" post="Fever (Cases) BI Temperature ( ℃ ) Humidity (%)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7068796\results\search\tropicalVirus\results.xml">
   <result pre="antigens of the hepatitis B virus (22) and of the" exact="HPV" post="L1-derived virus-like particles (23) that compose the HPV vaccine,"/>
   <result pre="of the HPV L1-derived virus-like particles (23) that compose the" exact="HPV" post="vaccine, which only started to be used in 2010"/>
   <result pre="or not, and to recombinant vaccines against hepatitis B and" exact="HPV" post="and other organisms. The Delay in the Development of"/>
   <result pre="vaccine development: an overview. Pediatr Res. (2004) 55:347–56. 10.1203/01.PDR.0000106317.36875.6A14630981 19.BarrettADT." exact="Yellow fever" post="live attenuated vaccine: a very successful live attenuated vaccine"/>
   <result pre="surface antigen particles in yeast. Nature. (1982) 298:347–50. 10.1038/298347a07045698 23.GuptaGGlueckRPatelPR." exact="HPV" post="vaccines: global perspectives. Hum Vaccines Immunother. (2017) 13:1421–4. 10.1080/21645515.2017.128930128362244"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7069648\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Research and Analysis Methods : Database and"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and Life Sciences : Molecular Biology"/>
   <result pre="of Indian origin in acute febrile patients in rural Kenya" exact="Dengue" post="virus type 2 of Indian origin in rural Kenya"/>
   <result pre="medium, provided the original author and source are credited.pntd.0008099.pdf Abstract" exact="Dengue" post="virus (DENV) has caused recent outbreaks in coastal cities"/>
   <result pre="of Kenya is largely unknown. We investigated the role of" exact="DENV" post="infection as a cause of acute febrile disease in"/>
   <result pre="Kibera, Nairobi (n = 233). The samples were studied for" exact="DENV" post="IgM, IgG, NS1 antigen and flaviviral RNA. IgG seroprevalence"/>
   <result pre="characteristics and future risks of dengue in Kenya. Author summary" exact="Dengue" post="virus (DENV) is an emerging mosquito-borne global health threat"/>
   <result pre="of symptoms from febrile illness to haemorrhagic fever. Information of" exact="DENV" post="in Africa is limited and fragmented. In Kenya, dengue"/>
   <result pre="that have experienced recent outbreaks. We investigated the role of" exact="DENV" post="infection as a cause of acute febrile disease in"/>
   <result pre="to better understanding of the epidemiological situation and origins of" exact="DENV" post="in Kenya. Funding Academy of FinlandVapalahtiOlli http://dx.doi.org/10.13039/100008376Helsingin ja Uudenmaan"/>
   <result pre="important mosquito-borne human pathogens such as the yellow fever, Zika," exact="West Nile" post="and dengue viruses, all found in Africa [1]. Dengue"/>
   <result pre="West Nile and dengue viruses, all found in Africa [1]." exact="Dengue" post="viruses (DENV-1 to 4) have a significant impact on"/>
   <result pre="demonstrating sustained DENV-2 circulation in Kenya. The other serotypes of" exact="DENV" post="have also been reported in Kenya, however the sequence"/>
   <result pre="and Kisumu, Western Kenya in 2014–2015, with all the four" exact="DENV" post="serotypes detected by using DENV typing RT-PCR [14]. The"/>
   <result pre="2014–2015, with all the four DENV serotypes detected by using" exact="DENV" post="typing RT-PCR [14]. The main vector of DENV Aedes"/>
   <result pre="by using DENV typing RT-PCR [14]. The main vector of" exact="DENV" post="Aedes (Stegomyia) aegypti is known to be present in"/>
   <result pre="and the coastal region of Kenya [15–18]. Sylvatic cycles of" exact="DENV" post="are known to exist in Western Africa [19]. These"/>
   <result pre="and the environmental factors would likely allow sylvatic cycles of" exact="DENV" post="as well [20]. Detection of dengue or other flaviviral"/>
   <result pre="aim of this study was to determine the role of" exact="DENV" post="infection (and potentially other flaviviruses) in acute febrile patients"/>
   <result pre="and rural areas of Kenya. We investigated the role of" exact="DENV" post="infection as a cause of acute febrile disease in"/>
   <result pre="(Meridian Bioscience, Cincinnati, USA) prior to IgM IFA testing. Known" exact="DENV" post="IgG and IgM positive samples were used as positive"/>
   <result pre="Cypress, USA). Samples that were found to be positive in" exact="DENV" post="IgM EIA, IgG IFA or viral RNA screening were"/>
   <result pre="screening were additionally tested for dengue NS1 antigen using Platelia" exact="Dengue" post="NS1 Ag test (BIORAD). If there was enough sample"/>
   <result pre="Ag test (BIORAD). If there was enough sample volume left," exact="DENV" post="IgG IFA positive samples were further tested for anti-Zika"/>
   <result pre="commercial ELISA test (Euroimmun, Luebeck, Germany), and samples positive for" exact="DENV" post="IgM IFA were tested for anti-ZIKV IgM using an"/>
   <result pre="values of the model. Results Patient characteristics and associations with" exact="DENV" post="marker positivity A total of 560 samples (sera or"/>
   <result pre="patients (Table 1). According to Fisher’s exact test (S1 Table)," exact="DENV" post="marker positivity was significantly more common in Taita-Taveta compared"/>
   <result pre="found (Table 2). 10.1371/journal.pntd.0008099.t002Table 2 Best logistic regression models for" exact="DENV" post="in the whole study group (Taita Taveta and Nairobi"/>
   <result pre="9.1% (51/560) of samples were found to be positive in" exact="DENV" post="IgG IFA and 3.9% (3/76) of IgM IFA positive"/>
   <result pre="screening dilution due to a lack of sample volume. In" exact="ZIKV" post="antibody tests, 1/51 and 1/57 were found to be"/>
   <result pre="tests, 1/51 and 1/57 were found to be positive for" exact="ZIKV" post="IgG and IgM, respectively. Acute DENV infection was documented"/>
   <result pre="to be positive for ZIKV IgG and IgM, respectively. Acute" exact="DENV" post="infection was documented by molecular methods in five patients"/>
   <result pre="collected in May 2016 and one in June 2016. The" exact="DENV" post="NS1 antigen assay was positive in three of the"/>
   <result pre="(IFA)titre IgM (IFA) IgM EIA dengue Pan- flavi virus RT-PCR" exact="DENV" post="NS1 Ag Virus isolation Sequence confirmation 76 Wundanyi16-May-2016 Nairobi"/>
   <result pre="fever *** available from the authors upon request; DENV-2 =" exact="Dengue" post="virus type 2 In addition to these five confirmed"/>
   <result pre="EIA (Capture DXSelect, Focus Diagnostics) result. The patients positive for" exact="DENV" post="IgG only (6.4%) were considered to have old flaviviral"/>
   <result pre="2014–2015). Discussion Neither of our study areas had documented previous" exact="DENV" post="outbreaks. Dengue outbreaks have occurred previously mainly in the"/>
   <result pre="Neither of our study areas had documented previous DENV outbreaks." exact="Dengue" post="outbreaks have occurred previously mainly in the coastal area"/>
   <result pre="was available for rural Taita–Taveta County regarding flavivirus seroprevalence or" exact="DENV" post="transmission. The flavivirus IgG seroprevalence in Taita–Taveta was found"/>
   <result pre="in Taita–Taveta were probably more likely to be exposed to" exact="DENV" post="or other flaviviruses during their life, than the younger"/>
   <result pre="is known to be endemic, in addition to DENV, to" exact="West Nile" post="virus, yellow fever virus (YFV) and Wesselsbron virus [5]."/>
   <result pre="Nile virus, yellow fever virus (YFV) and Wesselsbron virus [5]." exact="YFV" post="vaccination status of the patients was not known, but"/>
   <result pre="specificities via neutralization assays was not attempted. Notably, only two" exact="DENV" post="seropositive patients were found to be positive also for"/>
   <result pre="DENV seropositive patients were found to be positive also for" exact="ZIKV" post="NS1 specific antibodies: one for IgG and one for"/>
   <result pre="of these patients reported recent travel to western Kenya where" exact="ZIKV" post="neutralizing antibodies have been previously detected [7]. The reason"/>
   <result pre="The reason for the high number of patients positive for" exact="DENV" post="IgM IFA but negative in all other tests (n"/>
   <result pre="patients [45], the used diagnostic methods should have detected acute" exact="DENV" post="or other flaviviral infections. The statistical analyses of questionnaire"/>
   <result pre="further evidence of the occurrence of the local transmission of" exact="DENV" post="in Taita–Taveta. The sequence analysis was restricted due to"/>
   <result pre="sequence analysis was restricted due to the limited amount of" exact="DENV" post="sequence data obtained in this study, and available in"/>
   <result pre="Kenya and the neighbouring countries. In this study, a single" exact="DENV" post="serotype (DENV-2) and genotype (Cosmopolitan) was detected. Our sequence"/>
   <result pre="once. Globalization has probably facilitated the introduction of the Indian" exact="DENV" post="to Kenya, as Kenya along with other African countries"/>
   <result pre="for trade and travel [47], and India is hyperendemic for" exact="DENV" post="[48]. To conclude, we detected unnoticed DENV-2 transmission outside"/>
   <result pre="outside epidemics and previously known endemic regions in rural Kenya." exact="Dengue" post="was not a common cause of acute febrile disease"/>
   <result pre="England). 2008;371(9611):500–9. Epub 2008/02/12. 10.1016/s0140-6736(08)60238-x .18262042 2AmarasingheA, KuritskJN, LetsonGW, MargolisHS." exact="Dengue" post="virus infection in Africa. Emerging infectious diseases. 2011;17(8):1349–54. Epub"/>
   <result pre="surveillance and seroprevalence studies: protocol of field studies of the" exact="Dengue" post="Vaccine Initiative. BMJ open. 2018;8(1):e017673 Epub 2018/01/24. 10.1136/bmjopen-2017-01767329358421 4MeaseLE,"/>
   <result pre="NgoiJM, de LaurentZR, GitongaJ, CottenM, et al.Complete Genome Sequences of" exact="Dengue" post="Virus Type 2 Strains from Kilifi, Kenya. Microbiology resource"/>
   <result pre="10.1128/mra.01566-1830701251 11GathiiK, NyatayaJN, MutaiBK, AwindaG, WaitumbiJN. Complete Coding Sequences of" exact="Dengue" post="Virus Type 2 Strains from Febrile Patients Seen in"/>
   <result pre="Patients Seen in Malindi District Hospital, Kenya, during the 2017" exact="Dengue" post="Fever Outbreak. Genome announcements. 2018;6(15). Epub 2018/04/14. 10.1128/genomeA.00076-1829650565 12ObonyoM,"/>
   <result pre="Epub 2018/04/14. 10.1128/genomeA.00076-1829650565 12ObonyoM, FidhowA, OfulaV. Investigation of laboratory confirmed" exact="Dengue" post="outbreak in North-eastern Kenya, 2011. PloS one. 2018;13(6):e0198556 Epub"/>
   <result pre="2016/11/07. 10.1186/s12985-016-0641-027814732 14VuDM, MutaiN, HeathCJ, VululeJM, MutukuFM, NdengaBA, et al.Unrecognized" exact="Dengue" post="Virus Infections in Children, Western Kenya, 2014–2015. Emerging infectious"/>
   <result pre="tropical diseases. 2016;10(10):e0004981 Epub 2016/10/27. 10.1371/journal.pntd.000498127783626 16AghaSB, TchouassiDP, BastosADS, SangR." exact="Dengue" post="and yellow fever virus vectors: seasonal abundance, diversity and"/>
   <result pre="et al.Seroprevalence of Infections with Dengue, Rift Valley Fever and" exact="Chikungunya" post="Viruses in Kenya, 2007. PloS one. 2015;10(7):e0132645 Epub 2015/07/16."/>
   <result pre="Epub 2009/12/08. 10.1016/j.jcv.2009.11.001 .19963435 27ErraEO, KorhonenEM, VoutilainenL, HuhtamoE, VapalahtiO, KanteleA." exact="Dengue" post="in travelers: kinetics of viremia and NS1 antigenemia and"/>
   <result pre="2015/04/30. 10.1371/journal.pntd.000373325923210 45MullerDA, DepelsenaireAC, YoungPR. Clinical and Laboratory Diagnosis of" exact="Dengue" post="Virus Infection. The Journal of infectious diseases. 2017;215(suppl_2):S89–s95. Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077230\results\search\tropicalVirus\results.xml">
   <result pre="a rising frequency of emerging viral infections, e.g., SARS [4]," exact="Zika" post="[5], or a more recent Coronavirus 2019-nCoV outbreak [6]."/>
   <result pre="which is critical during outbreaks of viral infections, such as" exact="Zika" post="virus [55] or Ebola virus [56], when fast unbiased"/>
   <result pre="(EBV) [86], 0.0003% for Lassa virus [87] and 0.3% for" exact="Zika" post="virus [88]. Considering that metagenomics focuses on relative quantities"/>
   <result pre="Olympics in 2010 [128] and epidemics of Ebola [56] and" exact="Zika" post="diseases [129]. Sequencing of long (2.5–3.0 kb) amplified fragments"/>
   <result pre="genomes yielded complete genome sequences for the influenza virus [133]," exact="Dengue" post="virus [134] and HCV [135]. This approach proves apt"/>
   <result pre="It has also been successfully used for rapid investigation of" exact="Dengue" post="virus outbreak in Angola [188] and Ebola epidemic in"/>
   <result pre="Biol.20141551910.1186/s13059-014-0519-725403361 88.CalvetG.AguiarR.S.MeloA.S.O.SampaioS.A.de FilippisI.FabriA.AraujoE.S.M.de SequeiraP.C.de MendonçaM.C.L.de OliveiraL.et al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="RoutesJ. Infect. Dis.20152121574157810.1093/infdis/jiv27126153409 129.SinghR.K.DhamaK.KarthikK.TiwariR.KhandiaR.MunjalA.IqbalH.M.N.MalikY.S.Bueno-MaríR.Advances in Diagnosis, Surveillance, and Monitoring of" exact="Zika" post="Virus: An UpdateFront. Microbiol.20188267710.3389/fmicb.2017.0267729403448 130.CottenM.PetrovaV.PhanM.V.T.RabaaM.A.WatsonS.J.OngS.H.KellamP.BakerS.Deep Sequencing of Norovirus Genomes"/>
   <result pre="between 2009 and 2013J. Virol.2015899920993110.1128/JVI.00840-1526202246 134.ParameswaranP.CharleboisP.TellezY.NunezA.RyanE.M.MalboeufC.M.LevinJ.Z.LennonN.J.BalmasedaA.HarrisE.et al.Genome-Wide Patterns of Intrahuman" exact="Dengue" post="Virus Diversity Reveal Associations with Viral Phylogenetic Clade and"/>
   <result pre="clinical samplesEurosurveillance20182310.2807/1560-7917.ES.2018.23.50.180022830563591 180.FariaN.R.QuickJ.ClaroI.M.ThézéJ.de JesusJ.G.GiovanettiM.KraemerM.U.G.HillS.C.BlackA.da CostaA.C.et al.Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the AmericasNature201754640641010.1038/nature2240128538727 181.BatovskaJ.LynchS.E.RodoniB.C.SawbridgeT.I.CoganN.O.Metagenomic arbovirus detection"/>
   <result pre="VasconcelosJ.N.GranjaB.G.ThézéJ.JandondoD.NetoZ.MirandelaM.dos Santos SebastiãoC.CândidoA.L.M.ClementeC.et al.Early Genomic Detection of Cosmopolitan Genotype of" exact="Dengue" post="Virus Serotype 2, Angola, 2018Emerg. Infect. Dis.20192578478710.3201/eid2504.18095830882320 189.Check HaydenE.Pint-sized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077231\results\search\tropicalVirus\results.xml">
   <result pre="of arboviral infections differ around the world. The mosquito-borne arboviruses," exact="Yellow fever" post="virus (YFV), dengue virus (DENV), Zika virus (ZIKV), West"/>
   <result pre="The mosquito-borne arboviruses, Yellow fever virus (YFV), dengue virus (DENV)," exact="Zika" post="virus (ZIKV), West Nile virus (WNV), and chikungunya virus"/>
   <result pre="Yellow fever virus (YFV), dengue virus (DENV), Zika virus (ZIKV)," exact="West Nile" post="virus (WNV), and chikungunya virus (CHIKV), are globally distributed,"/>
   <result pre="the four major Aedes transmitted arboviruses: YFV, DENV, ZIKV, and" exact="CHIKV" post="[6]. Although these estimates may affect policy and help"/>
   <result pre="recording the lowest numbers. For example, with the exception of" exact="YFV" post="outbreaks in the past, which are currently under control"/>
   <result pre="Park. Finally, since the sample collection period overlapped with the" exact="DENV" post="outbreaks in Cote d’Ivoire in 2015 and in Burkina"/>
   <result pre="2016, this study gives an idea of the status of" exact="DENV" post="in Ghana during the outbreak and reports on the"/>
   <result pre="the outbreak and reports on the first mutual interaction between" exact="DENV" post="and a double-stranded RNA (dsRNA) virus. 2. Materials and"/>
   <result pre="and Culex mosquito pools were screened for DENV, CHIKV, or" exact="WNV" post="by RT-PCR. Screening was carried out using the PrimeScript"/>
   <result pre="RT-PCR Kit ver. 2 (Takara Bio) and the species-specific primers" exact="DENV" post="(D1: 5’-TCAATATGCTGAAACGCGCGAGAAACCG-3’ and D2: 5’-TTGCACCAACAGTCAATGTCTTCAGGTTC-3’); CHIKV (Chik10294s, 5’-ACG CAA"/>
   <result pre="and the species-specific primers DENV (D1: 5’-TCAATATGCTGAAACGCGCGAGAAACCG-3’ and D2: 5’-TTGCACCAACAGTCAATGTCTTCAGGTTC-3’);" exact="CHIKV" post="(Chik10294s, 5’-ACG CAA TTG AGC GAA GCA CAT-3’ and"/>
   <result pre="5’-AAA TTG TCC TGG TCT TCC TG-3’ for CHIKV); and" exact="WNV" post="(WNNY514, 5’-CGG CGC CTT CAT ACA CW-3’ and WNNY904,"/>
   <result pre="in the colony as well as the dissemination rate. 2.12." exact="DENV" post="Superinfection in C6/36 Cells Persistently Infected with AaTV A"/>
   <result pre="28 °C/5% CO2 overnight. The cells were inoculated with the" exact="Dengue" post="virus serotype 1 (DENV-1; D1/Hu/Saitama/NIID100/2014) with a multiplicity of"/>
   <result pre="Malaria Research and Reference Reagent Resource Center) cell line. 3.4." exact="DENV" post="Superinfection in C6/36 Cells Persistently Infected with AaTV In"/>
   <result pre="Aedes hirsutus, which has been implicated as a vector of" exact="ZIKV" post="[56], is an example of the diversity of possible"/>
   <result pre="[57,58]. Although sample collection for this study overlapped with the" exact="DENV" post="outbreaks in Cote d’Ivoire and Burkina Faso in 2015"/>
   <result pre="were residents of the Greater Accra region, raising concerns about" exact="DENV" post="transmission in the region [53,54]. However, it is necessary"/>
   <result pre="Crosse virus, an orthobunyavirus, as well as flaviviruses such as" exact="ZIKV" post="and DENV in vitro [60]. Furthermore, although CFAV was"/>
   <result pre="an orthobunyavirus, as well as flaviviruses such as ZIKV and" exact="DENV" post="in vitro [60]. Furthermore, although CFAV was initially reported"/>
   <result pre="by PCLV, and recent reports indicate that CFAV interferes with" exact="DENV" post="dissemination in vivo [11,60,61]. These reports show the importance"/>
   <result pre="arboviruses: Why today?One Health2017411310.1016/j.onehlt.2017.06.00128785601 4.ChanceyC.GrinevA.VolkovaE.RiosM.The Global Ecology and Epidemiology of" exact="West Nile" post="VirusBiomed. Res. Int.2015201537623010.1155/2015/37623025866777 5.LiangG.GaoX.GouldE.A.Factors responsible for the emergence of"/>
   <result pre="Keys for the Identification of Mosquitoes (Diptera: Culicidae) Associated with" exact="Dengue" post="Virus TransmissionZootaxa200458916010.11646/zootaxa.589.1.1 17.RudbeckL.DissingJ.Rapid, Simple Alkaline Extraction of Human Genomic"/>
   <result pre="virus in East AsiaArch. Virol.20141592675268510.1007/s00705-014-2117-024906523 22.LanciottiR.S.CalisherC.H.GublerD.J.ChangG.J.VorndamA.V.Rapid Detection and Typing of" exact="Dengue" post="Viruses from Clinical Samples by Using Reverse Transcriptase-Polymerase Chain"/>
   <result pre="d’Ivoire to Japan, June 2017Emerg. Infect. Dis.2017231758176010.3201/eid2310.171132 53.AmoakoN.DuoduS.DennisF.E.BonneyJ.H.K.AsanteK.P.AmehJ.MosiL.HayashiT.AgbosuE.E.PrattD.et al.Detection of" exact="Dengue" post="Virus among Children with Suspected Malaria, Accra, GhanaEmerg. Infect."/>
   <result pre="northern regionsGhana Med. J.20064013714110.4314/gmj.v40i3.5526917496987 56.ThamH.BalasubramaniamV.OoiM.K.ChewM.Viral Determinants and Vector Competence of" exact="Zika" post="Virus TransmissionFront. Microbiol.20189104010.3389/fmicb.2018.0104029875751 57.BennettK.L.LintonY.M.ShijaF.KaddumukasaM.DjouakaR.MisinzoG.LutwamaJ.HuangY.M.MitchellL.B.RichardsM.et al.Molecular Differentiation of the African"/>
   <result pre="Figure 14 Effect of AaTV infection in C6/36 cells on" exact="DENV" post="growth. (A) DENV-1 growth curve [multiplicity of infection (MOI)"/>
   <result pre="0.01] (B) DENV-1 growth curve (MOI = 1). Controls were" exact="DENV" post="infection on naïve C6/36 cells. Statistical significance was done"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077299\results\search\tropicalVirus\results.xml">
   <result pre="virus, HIV; Porcine epidemic diarrhea virus, PEDV; Rabies virus, RABV;" exact="West Nile" post="virus, WNV) infections or toxins (e.g., ricin and shiga"/>
   <result pre="Secretory IgASci. Rep.201774584310.1038/srep4584328368034 42.LaiH.EngleM.FuchsA.KellerT.JohnsonS.GorlatovS.DiamondM.S.ChenQ.Monoclonal antibody produced in plants efficiently treats" exact="West Nile" post="virus infection in miceProc. Natl. Acad. Sci. USA20101072419242410.1073/pnas.091450310720133644 43.RattanapisitK.SrijangwadA.ChuanasaT.SukrongS.TantituvanontA.MasonH.S.NilubolD.PhoolcharoenW.Rapid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077306\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.3390/v12020196viruses-12-00196 : Article Changes in the Transmission Dynamic of" exact="Chikungunya" post="Virus in Southeastern Senegal SowAbdourahmane123*NikolayBirgit456FayeOumar1CauchemezSimon456CanoJorge7DialloMawlouth8FayeOusmane1SadioBakary1NdiayeOumar1https://orcid.org/0000-0001-8016-8556WeaverScott C.9DiaAnta T.2SallAmadou Alpha1MalvyDenis3[1], Oumar.faye@pasteur.snOusmane.Faye@pasteur.snBakary.Sadio@pasteur.snOumar.Ndiaye@pasteur.snAmadou.Sall@pasteur.sn[2],"/>
   <result pre="anti-CHIKV IgG antibodies by ELISA. We investigated the association of" exact="CHIKV" post="seroprevalence with environmental variables using logistic regression analysis and"/>
   <result pre="individuals sampled during the survey tested positive for CHIKV-specific IgG." exact="CHIKV" post="seroprevalence was significantly higher in populations living close to"/>
   <result pre="increase of the risk of human exposition in the region." exact="Chikungunya" post="spatial autocorrelation environmental risk gold mining Senegal 1. Introduction"/>
   <result pre="Chikungunya spatial autocorrelation environmental risk gold mining Senegal 1. Introduction" exact="Chikungunya" post="virus (CHIKV) is a mosquito–borne alphavirus that belongs to"/>
   <result pre="an epidemic in the Newala district of Tanzania [2,3]. Acute" exact="CHIKV" post="infection in humans can cause a flu-like syndrome associated"/>
   <result pre="with a rash and severe arthralgia [4,5,6,7,8]. In sub-Saharan Africa," exact="CHIKV" post="is maintained in a sylvatic cycle involving non-human primates"/>
   <result pre="among humans living in rural areas [9,13,14]. In urban areas," exact="CHIKV" post="is transmitted among humans by Aedes aegypti and Aedes"/>
   <result pre="albopictus mosquitoes [15]. Since the outbreak in Tanzania in 1952," exact="CHIKV" post="outbreaks have been reported in Africa, Asia, and Latin"/>
   <result pre="and Latin America between the 1960s and 2000s [16]. Recently," exact="CHIKV" post="was recognized as an emerging arbovirus with an important"/>
   <result pre="among travelers from India in 2006 [18,19,20,21]. The spread of" exact="CHIKV" post="in Europe and parts of Asia was attributed to"/>
   <result pre="transportation, and the global movement of viremic individuals [22,23,24], emphasizing" exact="CHIKV" post="as a re-emerging threat to global public health. In"/>
   <result pre="as a re-emerging threat to global public health. In Senegal," exact="CHIKV" post="was first isolated from a bat in 1962 [25,26],"/>
   <result pre="the border of Guinea, in southeastern Senegal. In this area," exact="CHIKV" post="was repeatedly isolated from Aedes furcifer, Aedes luteocephalus, and"/>
   <result pre="Aedes furcifer, Aedes luteocephalus, and Aedes taylori [9,29,30,31,32]. Amplifications of" exact="CHIKV" post="have been detected at approximately 5-year intervals. This interval"/>
   <result pre="susceptible vertebrate hosts, mainly nonhuman primates [6]. In 2009, a" exact="CHIKV" post="zoonotic amplification occurred in the Kedougou region, detected in"/>
   <result pre="Ae. luteocephalus (5 pools) [33]. Despite active sylvatic circulation of" exact="CHIKV" post="in the Kedougou region, limited information is available about"/>
   <result pre="on Microplate ELISA 96-well Maxisorp. After a coating step with" exact="CHIKV" post="mouse hyperimmune ascitic fluid, followed by CHIKV antigen capture,"/>
   <result pre="coating step with CHIKV mouse hyperimmune ascitic fluid, followed by" exact="CHIKV" post="antigen capture, samples were added, and specific antibody-antigen complexes"/>
   <result pre="and demographic datasets was used to explore potential drivers of" exact="CHIKV" post="outbreaks in the study area. From the Moderate Resolution"/>
   <result pre="2.3.3. Environmental Risk Factors We first investigated the association of" exact="CHIKV" post="seroprevalence with environmental variables by univariable logistic regression analysis,"/>
   <result pre="implemented in Winbugs [40]. 3. Results 3.1. Serological Investigation for" exact="CHIKV" post="IgG in 2012 In total, 998 individuals living in"/>
   <result pre="were male. Fifty-four percent of individuals (51%–57%) were positive for" exact="CHIKV" post="IgG. Seroprevalence did not vary significantly by sex (males"/>
   <result pre="age-group (p = 0.485) (Figure 2). 3.2. Spatial Variation in" exact="CHIKV" post="IgG Seroprevalence Seroprevalence against CHIKV varied among villages and"/>
   <result pre="2). 3.2. Spatial Variation in CHIKV IgG Seroprevalence Seroprevalence against" exact="CHIKV" post="varied among villages and rural communities in the study"/>
   <result pre="Table A1 in Appendix A show that in univariate analysis," exact="CHIKV" post="seroprevalence was significantly higher in populations living in areas"/>
   <result pre="are the main sites of traditional gold mining), seroprevalence against" exact="CHIKV" post="peaked among adults; in particular, it was significantly higher"/>
   <result pre="that over 50% of studied individuals had a history of" exact="CHIKV" post="infection. Seroprevalence was homogeneously distributed over all age ranges,"/>
   <result pre="suggesting a simultaneous and recent exposure of the population to" exact="CHIKV" post="circulation. Distinctly, continuous endemic circulation of CHIKV within this"/>
   <result pre="the population to CHIKV circulation. Distinctly, continuous endemic circulation of" exact="CHIKV" post="within this population would have led to a significant"/>
   <result pre="significant age pattern with increasing seroprevalence by age. Seroprevalence against" exact="CHIKV" post="was highest in remote areas with low population density."/>
   <result pre="in those areas were 1.24 times more likely exposed to" exact="CHIKV" post="than those living in areas with a high population"/>
   <result pre="with a high population density. This can be explained by" exact="CHIKV" post="transmission through spillover via sylvatic mosquitoes, such as Ae."/>
   <result pre="Although overall seroprevalence was low in the Bandafassi rural community," exact="CHIKV" post="seroprevalence was significantly higher in gold mining sites where"/>
   <result pre="villages harboring such gold mining sites were most affected by" exact="CHIKV" post="[43]. A similar pattern was also observed during the"/>
   <result pre="CHIKV [43]. A similar pattern was also observed during the" exact="CHIKV" post="outbreak in 2015, where confirmed cases in the Saraya"/>
   <result pre="to the forest galleries, may increase exposure of humans to" exact="CHIKV" post="through spillover from the enzootic cycle. Moreover, environmental changes"/>
   <result pre="larval sites [43]. However, to better understand the distribution of" exact="CHIKV" post="infection in the region, other potential risk factors that"/>
   <result pre="was found to be high (&amp;gt;50%). This finding suggests either" exact="CHIKV" post="circulation, with many mild or asymptomatic infections, which has"/>
   <result pre="districts, which have more robust surveillance. The elevated exposure to" exact="CHIKV" post="among human populations living in the rural Kedougou area"/>
   <result pre="act as hotspots for the emergence and dissemination of new" exact="CHIKV" post="strains. Given the abundance of CHIKV vectors in the"/>
   <result pre="and dissemination of new CHIKV strains. Given the abundance of" exact="CHIKV" post="vectors in the Kedougou region, the weakness of surveillance"/>
   <result pre="is needed to prevent the establishment of a domestic, human-amplified" exact="CHIKV" post="transmission cycle, and the potential global spread of newly"/>
   <result pre="virus strains. Finally, due to the potential serologic cross-reactivity between" exact="CHIKV" post="and alphaviruses, such as the o’nyong-nyong virus (ONNV), further"/>
   <result pre="mosquito pools collected in the Kedougou region, suggests that the" exact="CHIKV" post="seroprevalence that we measure does not represent cross-reactions. Acknowledgments"/>
   <result pre="A viruses-12-00196-t0A1_Table A1Table A1 Univariable analysis of the association between" exact="CHIKV" post="seroprevalence and environmental variables using 3km buffers around villages."/>
   <result pre="km2 (log-transformed) 0.73 (0.64; 0.81) &amp;lt;0.001 1337 viruses-12-00196-t0A3_Table A3Table A3" exact="CHIKV" post="seroprevalence by sex and age group in villages where"/>
   <result pre="50% Subtotal 10 50 20% Figure A1 (A) Semivariogram of" exact="CHIKV" post="village prevalence and (B) village random effects adjusting for"/>
   <result pre="unusual disease: The chikungunya epidemicSemin. Pediatr. Infect. Dis.2006179910410.1053/j.spid.2006.04.00916822471 9.DialloM.ThonnonJ.TraoreL.M.FontenilleD.Vectors of" exact="Chikungunya" post="virus in Senegal: Current data and transmission cyclesAm. J."/>
   <result pre="migrationParasitVectors201033510.1186/1756-3305-3-35 16.DevauxC.A.Emerging and re-emerging viruses: A global challenge illustrated by" exact="Chikungunya" post="virus outbreaksWorld J. Virol.20121112210.5501/wjv.v1.i1.1124175207 17.WeaverS.C.ReisenW.K.Present and Future Arboviral ThreatsAntiviral"/>
   <result pre="Concepts, structure, and extensibilityStat. Comput.20001032533710.1023/A:1008929526011 41.DialloD.SallA.A.BuenemannM.ChenR.FayeO.DiagneC.T.T.FayeO.BaY.DiaI.WattsD.et al.Landscape Ecology of Sylvatic" exact="Chikungunya" post="Virus and mosquito Vectors in Southeastern SenegalPLoS Negl. Trop."/>
   <result pre="online: http://www.worldpop.org.uk/(accessed on 15 September 2016) 43.SowA.FayeO.DialloD.ChenR.FayeO.DiagneC.T.T.NdiayeY.SenghorC.S.Abdourahmane FayeA.DiopO.M.et al.Re-emergence of" exact="Yellow fever" post="in Kedougou, Southeastern Senegal in 2010–2011Int. J. Sc. Res.201710.1016/j.ijid.2014.03.878"/>
   <result pre="intervals. viruses-12-00196-t001_Table 1Table 1 Univariable analysis of the association between" exact="CHIKV" post="seroprevalence and environmental variables. The models were adjusted for"/>
   <result pre="criterion. viruses-12-00196-t002_Table 2Table 2 Multivariable analysis of the association between" exact="CHIKV" post="seroprevalence and environmental variables. The models were adjusted for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077324\results\search\tropicalVirus\results.xml">
   <result pre="Metabolic Activity in a Mouse Model of Infection with the" exact="Chikungunya" post="Virus East/Central/South African Genotype Ngwe TunMya Myat1MuthugalaRohitha1https://orcid.org/0000-0002-1384-8030Kyaw KyawAung12ShimadaSatoshi12MoritaKouichi12HayasakaDaisuke13*[1], myamyat@tm.nagasaki-u.ac.jprohithavm@yahoo.comkanomkrok77@gmail.commoritak@nagasaki-u.ac.jp[2],"/>
   <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Epidemics of the" exact="Chikungunya" post="virus (CHIKV) from 2004 onwards were caused by the"/>
   <result pre="explained. In this study, we examined the pathogenic potential of" exact="CHIKV" post="ECSA genotype M-30 (M-30) by comparing it with that"/>
   <result pre="virus proliferation, anti-type-II IFN response and metabolic activity in the" exact="CHIKV" post="ECSA virus in mice. CHIKV ECSA IFN-γ mouse model"/>
   <result pre="and metabolic activity in the CHIKV ECSA virus in mice." exact="CHIKV" post="ECSA IFN-γ mouse model viral pathogenesis 1. Introduction Chikungunya"/>
   <result pre="mice. CHIKV ECSA IFN-γ mouse model viral pathogenesis 1. Introduction" exact="Chikungunya" post="virus (CHIKV) belongs to the genus Alphavirus (family Togaviridae)"/>
   <result pre="mosquitoes such as Aedes aegypti and Aedes albopictus [1]. The" exact="CHIKV" post="genome is a single-stranded, positive-sense RNA virus with a"/>
   <result pre="composed of nonstructural proteins (5′-nsP1-nsP2-nsP3-nsP4) and structural proteins (C-E3-E2-6K-E1-3′) [3]." exact="CHIKV" post="strains are clustered into three distinct genotypes: West African,"/>
   <result pre="(ECSA) and Asian [4]. Historically, it has been recognized that" exact="CHIKV" post="infection causes similar clinical symptoms to dengue fever: fever,"/>
   <result pre="dengue fever: fever, rash and arthritis. During 2005 and 2006," exact="Chikungunya" post="fever emerged as a serious epidemic in India [5]."/>
   <result pre="been fully explained. Langsjoen et al., 2018 reported that Asian/American" exact="CHIKV" post="strains are less virulent than those in the Asian,"/>
   <result pre="study, we examined and compared the pathogenic potential of the" exact="CHIKV" post="ECSA genotype of the M-30 infection by comparing it"/>
   <result pre="mouse model. 2. Materials and Methods 2.1. Virus and Cells" exact="CHIKV" post="M-30 (KF 590566.1) was isolated from the acute serum"/>
   <result pre="cells were grown at 28 °C. Stock viruses of the" exact="CHIKV" post="M-30 and S-27 strains were prepared in C6/36 cells."/>
   <result pre="strains were prepared in C6/36 cells. All experiments using live" exact="CHIKV" post="were performed in a biosafety level 3 laboratory at"/>
   <result pre="Cytokines Using Real-Time Polymerase Chain Reaction As discussed above, following" exact="CHIKV" post="infection, the mice were sacrificed and their spleens and"/>
   <result pre="Map Kit Serum samples were collected from mice infected with" exact="CHIKV" post="(102 FFU) and from mock-infected mice at 5 days"/>
   <result pre="diseases. 4. Discussion In this study, we demonstrated that the" exact="CHIKV" post="ECSA genotype M-30 has a higher pathogenetic potential than"/>
   <result pre="induce atypical metabolic activity. Therefore, our established mouse model of" exact="CHIKV" post="infections may provide a novel concept of the pathogenic"/>
   <result pre="of viruses and their spread [26]. Similarly to other alphaviruses," exact="CHIKV" post="replication caused a dramatic shutoff of host gene expression,"/>
   <result pre="responses played a critical role in preventing lethal infections of" exact="CHIKV" post="because IFN responses of deficient A129 and AG129 mice"/>
   <result pre="in identifying the viral factors against type-II IFN responses in" exact="CHIKV" post="infections in vivo. Further studies, such as in vitro"/>
   <result pre="provide useful information to help elucidate the pathogenic mechanism of" exact="CHIKV" post="infections. In conclusion, our observations raise the concern that"/>
   <result pre="5.KaurP.PonniahM.MurhekarM.V.RamachandranV.RamachandranR.RajuH.K.PerumalV.MishraA.C.GupteM.D.Chikungunya outbreak, South India, 2006Emerg. Infect. Dis.2008141623162510.3201/eid1410.07056918826830 6.SergonK.NjugunaC.KalaniR.OfulaV.OnyangoC.KonongoiL.S.BednoS.BurkeH.DumillaA.M.KondeJ.et al.Seroprevalence of" exact="Chikungunya" post="virus (CHIKV) infection on Lamu Island, Kenya, October 2004Am."/>
   <result pre="study on La Reunion Island, 2005–2009Neurology2016869410210.1212/WNL.000000000000223426609145 8.RamfulD.CarbonnierM.PasquetM.BouhmaniB.GhazouaniJ.NoormahomedT.BeullierG.AttaliT.SamperizS.FourmaintrauxA.et al.Mother-to-child transmission of" exact="Chikungunya" post="virus infectionPediatric Infect. Dis. J.20072681181510.1097/INF.0b013e3180616d4f 9.LangsjoenR.M.HallerS.L.RoyC.J.Vinet-OliphantH.BergrenN.A.ErasmusJ.H.LivengoodJ.A.PowellT.D.WeaverS.C.RossiS.L.Chikungunya Virus Strains Show"/>
   <result pre="mediated innate immune response in mice brain following infection with" exact="Chikungunya" post="virusVirus Res.201418919420510.1016/j.virusres.2014.05.01024905288 15.ChiamC.W.ChanY.F.OngK.C.WongK.T.SamI.C.Neurovirulence comparison of chikungunya virus isolates of"/>
   <result pre="mouse neuronal cells following infection with novel ECSA genotype of" exact="Chikungunya" post="virus with and without E1:A226V mutationInfect. Genet. Evol. J."/>
   <result pre="Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.20132039640610.1016/j.meegid.2013.09.030 25.VazeilleM.MoutaillerS.CoudrierD.RousseauxC.KhunH.HuerreM.ThiriaJ.DehecqJ.S.FontenilleD.SchuffeneckerI.et al.Two" exact="Chikungunya" post="isolates from the outbreak of La Reunion (Indian Ocean)"/>
   <result pre="and low titer 102 PFU (D–F) of M-30 and S-27" exact="CHIKV" post="strains. The error bars represent the standard deviations. The"/>
   <result pre="and low titer 102 PFU (D–F) of M-30 and S-27" exact="CHIKV" post="strains. The error bars represent the standard deviations. The"/>
   <result pre="subcutaneous infection with high titer 105 PFU M-30 and S-27" exact="CHIKV" post="strains. The asterisks show significant differences by one-way ANOVA"/>
   <result pre="subcutaneous infection with 102 PFU of the M-30 and S-27" exact="CHIKV" post="strains. The asterisks show significant differences by the Mann–Whitney"/>
   <result pre="subcutaneous infection with 102 PFU of the M-30 and S-27" exact="CHIKV" post="strains. Figure 6 mRNA levels of IFN-γ, IL-6, IL-10,"/>
   <result pre="after subcutaneous infection with 102 PFU of M-30 and S-27" exact="CHIKV" post="strains. The asterisks show significant differences by the Kruskal–Wallis"/>
   <result pre="after subcutaneous infection with 102 PFU of M-30 and S-27" exact="CHIKV" post="strains. The asterisks show significant differences by the Kruskal–Wallis"/>
   <result pre="after subcutaneous infection with 102 PFU of M-30 and S-27" exact="CHIKV" post="strains. The asterisks show significant differences by the Kruskal–Wallis"/>
   <result pre="after subcutaneous infection with 102 PFU of M-30 and S-27" exact="CHIKV" post="strains. Asterisks show significant differences by Kruskal-Wallis test (*)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077838\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : People and Places : Population Groupings :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Physiology :"/>
   <result pre="Assessment of diagnostic and analytic performance of the SD Bioline" exact="Dengue" post="Duo test for dengue virus (DENV) infections in an"/>
   <result pre="Lao People's Democratic Republic) Performance evaluation of the SD Bioline" exact="Dengue" post="Duo test BlessmannJörgConceptualizationData curationFormal analysisInvestigationSupervisionWriting – review &amp;amp; editing1WinkelmannYvonneInvestigationWriting"/>
   <result pre="92 acute phase serum samples from patients with a PCR-confirmed" exact="DENV" post="infection collected in Lao People’s Democratic Republic (Lao PDR)"/>
   <result pre="in 2013 and 2015 were analyzed with the SD Bioline" exact="Dengue" post="Duo test. A subset of 74 samples was additionally"/>
   <result pre="additionally tested with the Platelia NS1 antigen test, the Panbio" exact="DENV" post="μ-capture ELISA and the Panbio DENV IgG ELISA. IgM"/>
   <result pre="antigen test, the Panbio DENV μ-capture ELISA and the Panbio" exact="DENV" post="IgG ELISA. IgM seroconversion was assayed using follow-up samples"/>
   <result pre="acute phase serum samples tested positive in the SD Bioline" exact="Dengue" post="Duo NS1, IgM, and IgG test, respectively. Diagnostic sensitivity"/>
   <result pre="and IgG test, respectively. Diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 test strongly correlated with viral load, decreased"/>
   <result pre="presence of high anti-DENV IgG antibody titers resulting from secondary" exact="DENV" post="infection. While a good concordance (Cohen’s kappa 0.78) was"/>
   <result pre="concordance (Cohen’s kappa 0.78) was found between the SD Bioline" exact="Dengue" post="Duo NS1 test and the Platelia NS1 antigen ELISA,"/>
   <result pre="and the Platelia NS1 antigen ELISA, both the SD Bioline" exact="Dengue" post="Duo IgM and IgG test displayed a significantly lower"/>
   <result pre="sensitivity than the corresponding ELISA tests. Conclusions/significance The SD Bioline" exact="Dengue" post="Duo test is a valuable tool for diagnosis of"/>
   <result pre="Dengue Duo test is a valuable tool for diagnosis of" exact="DENV" post="infections especially when analyzing early acute phase samples with"/>
   <result pre="previously unaffected areas [1]. Transmission of the four genetically distinct" exact="DENV" post="serotypes mainly occurs by the bite of infected Aedes"/>
   <result pre="warning signs�? and &quot;severe dengue infection�? [6]. Laboratory diagnostics of" exact="DENV" post="infection can be based on the detection of the"/>
   <result pre="presence of DENV-specific IgG antibodies indicates a prior exposure to" exact="DENV" post="[6]. Although infection with one DENV serotype confers lifelong"/>
   <result pre="a prior exposure to DENV [6]. Although infection with one" exact="DENV" post="serotype confers lifelong homotypic immunity, heterotypic cross-protection is timely"/>
   <result pre="typhus, leptospirosis), parasitic (e.g. malaria) or viral (e.g. chikungunya fever," exact="Zika" post="fever, influenza, measles) pathogens is necessary [1,6]. Thereby, an"/>
   <result pre="settings, lateral flow based point-of-care tests (as the SD Bioline" exact="Dengue" post="Duo test) may be the only option to investigate"/>
   <result pre="this rapid test using sera from patients with a PCR-confirmed" exact="DENV" post="infection from an endemic region in Southeast Asia (Savannakhet"/>
   <result pre="fever core multiplex real-time PCR (FastTrack Diagnostics) and/or SD Bioline" exact="Dengue" post="Duo test (NS1, IgM, IgG) (Alere/Abott)) of acute phase"/>
   <result pre="shipped on dry ice to BNITM (Hamburg/Germany) for further analysis." exact="DENV" post="diagnostic testing In addition to the on-site analysis, the"/>
   <result pre="diagnostic tests were performed according to the manufacturers’ instructions: RealStar®" exact="Dengue" post="RT-PCR Kit 1.0 (Altona Diagnostics), RealStar® Dengue Type RT-PCR"/>
   <result pre="manufacturers’ instructions: RealStar® Dengue RT-PCR Kit 1.0 (Altona Diagnostics), RealStar®" exact="Dengue" post="Type RT-PCR Kit 1.0 (Altona Diagnostics), PLATELIA™ Dengue NS1"/>
   <result pre="Diagnostics), RealStar® Dengue Type RT-PCR Kit 1.0 (Altona Diagnostics), PLATELIA™" exact="Dengue" post="NS1 Ag ELISA (Bio-Rad), Panbio® Dengue IgM Capture ELISA"/>
   <result pre="1.0 (Altona Diagnostics), PLATELIA™ Dengue NS1 Ag ELISA (Bio-Rad), Panbio®" exact="Dengue" post="IgM Capture ELISA (Alere/Abbott), Panbio® Dengue IgG Indirect ELISA"/>
   <result pre="Ag ELISA (Bio-Rad), Panbio® Dengue IgM Capture ELISA (Alere/Abbott), Panbio®" exact="Dengue" post="IgG Indirect ELISA (Alere/Abbott). For the DENV IgG indirect"/>
   <result pre="ELISA (Alere/Abbott), Panbio® Dengue IgG Indirect ELISA (Alere/Abbott). For the" exact="DENV" post="IgG indirect immunofluorescence test (IIFT), Vero cells infected with"/>
   <result pre="DENV IgG indirect immunofluorescence test (IIFT), Vero cells infected with" exact="DENV" post="serotype 2 were plated on glass slides and fixed"/>
   <result pre="PDR patients and 35/454 (8%) of Colombia patients, an acute" exact="DENV" post="infection was confirmed by the RealStar® Dengue RT-PCR Kit"/>
   <result pre="patients, an acute DENV infection was confirmed by the RealStar®" exact="Dengue" post="RT-PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany). For 92"/>
   <result pre="respectively, a complete dataset comprising conclusive PCR-based serotyping, SD Bioline" exact="Dengue" post="Duo Rapid test results and DENV IgG IIFT results"/>
   <result pre="PCR-based serotyping, SD Bioline Dengue Duo Rapid test results and" exact="DENV" post="IgG IIFT results was available; only samples from those"/>
   <result pre="from those patients were included in the analysis. SD Bioline" exact="Dengue" post="Duo NS1 test using samples after immune complex dissociation"/>
   <result pre="was applied to the sample well of the SD Bioline" exact="Dengue" post="Duo NS1 test. For comparison, 50 μl serum were"/>
   <result pre="were applied to the sample well of the SD Bioline" exact="Dengue" post="Duo NS1 test. According to the manufacturer’s instruction, all"/>
   <result pre="Cohen’s kappa [12]. Results Diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 antigen test depends on viral load and"/>
   <result pre="symptoms) from 92 Lao patients (Table 1) with a PCR-confirmed" exact="DENV" post="infection were analyzed using the SD Bioline Dengue Duo"/>
   <result pre="a PCR-confirmed DENV infection were analyzed using the SD Bioline" exact="Dengue" post="Duo rapid test (Fig 1). Overall, 53/92 samples (57.6%)"/>
   <result pre="were detected (Fig 1C) indicating a high incidence of secondary" exact="DENV" post="infections. Overall, 68.5% of samples tested positive in the"/>
   <result pre="collective (n = 26) of DF patients with a PCR-confirmed" exact="DENV" post="infection collected 2014 in an endemic region in South"/>
   <result pre="South America (Valledupar/Colombia [13–15]) (S1 Fig). Fig 1 SD Bioline" exact="Dengue" post="Duo test results. Acute phase serum samples from 92"/>
   <result pre="Acute phase serum samples from 92 patients with a PCR-confirmed" exact="DENV" post="infection were analyzed with the SD Bioline Dengue Duo"/>
   <result pre="a PCR-confirmed DENV infection were analyzed with the SD Bioline" exact="Dengue" post="Duo NS1 (A,D), IgM (B, D) and IgG test"/>
   <result pre="per μl for PLT. Diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo test does not differ between DENV serotypes 2"/>
   <result pre="the SD Bioline Dengue Duo test does not differ between" exact="DENV" post="serotypes 2 and 3 and does not correlate with"/>
   <result pre="PLT counts No correlation was observed between the main two" exact="DENV" post="serotypes represented in the patient collective (DENV2 and DENV3)"/>
   <result pre="the diagnostic sensitivity of either component of the SD Bioline" exact="Dengue" post="test (S2 Fig). Furthermore, the percentage of SD Bioline"/>
   <result pre="Dengue test (S2 Fig). Furthermore, the percentage of SD Bioline" exact="Dengue" post="Duo NS1 positivity did not differ significantly between patients"/>
   <result pre="values, respectively (S3 Fig). Diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 rapid test depends on anti-DENV IgG status"/>
   <result pre="were categorized according to the results of the BNITM in-house" exact="DENV" post="IgG IIFT (Fig 2A). While NS1 antigen was detected"/>
   <result pre="2A). While NS1 antigen was detected by the SD Bioline" exact="Dengue" post="Duo NS1 antigen rapid test in 95.8% of the"/>
   <result pre="Duo NS1 antigen rapid test in 95.8% of the 24" exact="DENV" post="IgG IIFT negative samples (Fig 2B), only 44.1% of"/>
   <result pre="IIFT negative samples (Fig 2B), only 44.1% of the 68" exact="DENV" post="IgG IIFT positive samples (Fig 2C) generated a positive"/>
   <result pre="a positive result in this test. Fig 2 SD Bioline" exact="Dengue" post="Duo NS1 test results stratified according to anti-DENV IgG"/>
   <result pre="Acute phase serum samples from 92 patients with a PCR-confirmed" exact="DENV" post="infection were categorized according to their anti-DENV IgG status"/>
   <result pre="categorized according to their anti-DENV IgG status as defined by" exact="DENV" post="IgG IIFT. (A) Tabular representation of subgroup characteristics. Ct:"/>
   <result pre="Ct: threshold cycle, dpo: days post onset of symptoms. (B)" exact="DENV" post="IgG IIFT negative samples (N = 24), (C) DENV"/>
   <result pre="(B) DENV IgG IIFT negative samples (N = 24), (C)" exact="DENV" post="IgG IIFT positive samples (N = 68). Samples were"/>
   <result pre="post onset of symptoms. Ct values were similar for the" exact="DENV" post="IgG IIFT negative and positive samples in this subgroup"/>
   <result pre="samples in this subgroup (p = 0.2892), nevertheless, all 9" exact="DENV" post="IgG IIFT negative samples were tested positive in the"/>
   <result pre="IIFT negative samples were tested positive in the SD Bioline" exact="Dengue" post="Duo NS1 rapid test (Fig 2B) while only 50%"/>
   <result pre="NS1 rapid test (Fig 2B) while only 50% (13/26) of" exact="DENV" post="IgG IIFT positive samples generated a positive result in"/>
   <result pre="samples, were found to be incompatible with the SD Bioline" exact="Dengue" post="Duo NS1 antigen test (S4 Fig). Comparison of rapid"/>
   <result pre="antigen test, Panbio μ-capture ELISA, Panbio IgG ELISA) and in-house" exact="DENV" post="IgG IIFT To compare the performance of the SD"/>
   <result pre="IgG IIFT To compare the performance of the SD Bioline" exact="Dengue" post="Duo test with conventional ELISA testing, 74 of the"/>
   <result pre="While a good concordance was observed between the SD Bioline" exact="Dengue" post="Duo NS1 test and the Platelia NS1 Antigen ELISA"/>
   <result pre="respectively, also generated a positive result in the SD Bioline" exact="Dengue" post="Duo IgM/IgG test (Fig 3C and 3D). Similarly, only"/>
   <result pre="agreement (Cohen’s kappa 0.42) was found between the SD Bioline" exact="Dengue" post="Duo IgG test and the DENV IgG IIFT (Fig"/>
   <result pre="between the SD Bioline Dengue Duo IgG test and the" exact="DENV" post="IgG IIFT (Fig 3E) while the DENV IgG IIFT"/>
   <result pre="test and the DENV IgG IIFT (Fig 3E) while the" exact="DENV" post="IgG IIFT and the Panbio IgG ELISA were in"/>
   <result pre="Fig, Cohen’s kappa 0.75). Fig 3 Comparison of SD Bioline" exact="Dengue" post="Duo test results with ELISA results and DENV IgG"/>
   <result pre="SD Bioline Dengue Duo test results with ELISA results and" exact="DENV" post="IgG IIFT. A subset of 74 acute phase serum"/>
   <result pre="analyzed with the Platelia NS1 Antigen ELISA (B), the Panbio" exact="DENV" post="μ-capture ELISA (C) and the Panbio DENV IgG ELISA"/>
   <result pre="(B), the Panbio DENV μ-capture ELISA (C) and the Panbio" exact="DENV" post="IgG ELISA (D). Open/filled circles represent negative/positive results obtained"/>
   <result pre="circles represent negative/positive results obtained with the corresponding SD Bioline" exact="Dengue" post="Duo tests. Shaded areas represent index values rated as"/>
   <result pre="IgM seroconversion in DF patients as analyzed by SD Bioline" exact="Dengue" post="Duo IgM rapid test and Panbio μ-capture ELISA For"/>
   <result pre="IgM ELISA, only 22/35 (62.9%) of samples were detected as" exact="DENV" post="IgM positive in the SD Bioline Dengue Duo IgM"/>
   <result pre="were detected as DENV IgM positive in the SD Bioline" exact="Dengue" post="Duo IgM test (Fig 4B). A significant difference was"/>
   <result pre="were detectable in the S2 sample by the SD Bioline" exact="Dengue" post="Duo IgM test in 11/11 (100.0%) of patients with"/>
   <result pre="Duo IgM test in 11/11 (100.0%) of patients with an" exact="DENV" post="IgG IIFT negative S1 sample (Fig 4C), but only"/>
   <result pre="4C), but only in 11/24 (45.8%) of patients with an" exact="DENV" post="IgG IIFT IgG positive S1 sample (Fig 4D). Fig"/>
   <result pre="Fig 4 Seroconversion in DF patients detected by SD Bioline" exact="Dengue" post="Duo IgM test and Panbio μ-capture ELISA. For 35"/>
   <result pre="Open/filled circles represent samples tested negative/positive in the SD Bioline" exact="Dengue" post="Duo IgM test. Shaded areas represent index values rated"/>
   <result pre="respective manufacturer’s recommendations. (C) Subset of sample pairs with a" exact="DENV" post="IgG IIFT negative S1 sample, (D) Subset of sample"/>
   <result pre="negative S1 sample, (D) Subset of sample pairs with a" exact="DENV" post="IgG IIFT positive S1 sample. (E) Tabular summary of"/>
   <result pre="Hospital in 2013–2015 (Table 2, S6 Fig). The SD Bioline" exact="Dengue" post="Duo NS1/IgM tests and the Platelia NS1 ELISA showed"/>
   <result pre="μ-capture ELISA detected isolated IgM in 6 (12.8%) of 47" exact="DENV" post="RT-PCR negative patients not classified as presumptive DF. 10.1371/journal.pone.0230337.t002Table"/>
   <result pre="classified as presumptive DF. 10.1371/journal.pone.0230337.t002Table 2 Specificity of SD Bioline" exact="Dengue" post="Duo NS1 (NS1 RT), Platelia NS1 Antigen ELISA (NS1"/>
   <result pre="(NS1 RT), Platelia NS1 Antigen ELISA (NS1 ELISA), SD Bioline" exact="Dengue" post="Duo IgM (IgM RT), and Panbio DENV μ-capture ELISA"/>
   <result pre="ELISA), SD Bioline Dengue Duo IgM (IgM RT), and Panbio" exact="DENV" post="μ-capture ELISA (IgM ELISA). category N n (%) pos"/>
   <result pre="IgM ELISA Malaria 22 0 (0.0) nt 0 (0.0) nt" exact="Chikungunya" post="fever 1 0 (0.0) nt 0 (0.0) nt Rickettsia"/>
   <result pre="work, we describe the diagnostic performance of the SD Bioline" exact="Dengue" post="Duo rapid test in comparison to commercial ELISA kits"/>
   <result pre="Duo rapid test in comparison to commercial ELISA kits (PLATELIA™" exact="Dengue" post="NS1 Ag ELISA, Panbio® Dengue IgM Capture ELISA, Panbio®"/>
   <result pre="to commercial ELISA kits (PLATELIA™ Dengue NS1 Ag ELISA, Panbio®" exact="Dengue" post="IgM Capture ELISA, Panbio® Dengue IgG Indirect ELISA) and"/>
   <result pre="Dengue NS1 Ag ELISA, Panbio® Dengue IgM Capture ELISA, Panbio®" exact="Dengue" post="IgG Indirect ELISA) and an in-house DENV IgG IIFT"/>
   <result pre="Capture ELISA, Panbio® Dengue IgG Indirect ELISA) and an in-house" exact="DENV" post="IgG IIFT in an endemic setting (Savannakhet province, Lao"/>
   <result pre="DF outbreak in southern Lao PDR [9], no co-infections with" exact="CHIKV" post="were observed in the DF patients enrolled in our"/>
   <result pre="patients admitted to Savannakhet Provincial Hospital was found to be" exact="CHIKV" post="PCR-positive. Interestingly, this patient reported to have recently returned"/>
   <result pre="a travel to Champasak province. Collected before the first autochthonous" exact="ZIKV" post="case in Lao PDR had been reported to the"/>
   <result pre="WHO in 2016 [24], samples were not tested on-site for" exact="ZIKV" post="(co-)infection. A retrospective analysis of acute phase serum samples"/>
   <result pre="Laotian patients with suspected dengue fever revealed the presence of" exact="ZIKV" post="in 18 (1.3%) of 1353 tested samples [24]. Thus,"/>
   <result pre="ZIKV in 18 (1.3%) of 1353 tested samples [24]. Thus," exact="ZIKV" post="(co-)infections cannot be ruled out completely, but their abundance"/>
   <result pre="only in two out of 99 patients with an assignable" exact="DENV" post="serotype and no DENV4 cases were seen in 2013."/>
   <result pre="4 post onset of symptoms) from patients with a PCR-confirmed" exact="DENV" post="infection revealed an overall diagnostic sensitivity of the SD"/>
   <result pre="infection revealed an overall diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 test of 57.6%. NS1 positivity strongly correlated"/>
   <result pre="a study employing samples from Brazil [29]. IgG antibodies recognizing" exact="DENV" post="antigens were detectable by the in-house DENV IgG IIFT"/>
   <result pre="IgG antibodies recognizing DENV antigens were detectable by the in-house" exact="DENV" post="IgG IIFT in 74% (68/92) of acute phase serum"/>
   <result pre="serum samples (Fig 2) indicating a high percentage of secondary" exact="DENV" post="infections in the Lao PDR study collective [6]. In"/>
   <result pre="observed a significantly reduced diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 test in secondary DENV infections. By stratifying"/>
   <result pre="of the SD Bioline Dengue Duo NS1 test in secondary" exact="DENV" post="infections. By stratifying the samples according to viral load"/>
   <result pre="IgG antibodies on the diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 test could be shown. Thus, the low"/>
   <result pre="testing in patients of our study collective with a detectable" exact="DENV" post="IgG antibody titer in the acute phase sample is"/>
   <result pre="a variety of different disease conditions including HIV infection [20–22]," exact="West Nile" post="fever [18], and Dengue fever [10,16,17,19,23]. Nevertheless, the DENV"/>
   <result pre="conditions including HIV infection [20–22], West Nile fever [18], and" exact="Dengue" post="fever [10,16,17,19,23]. Nevertheless, the DENV IgG assays applied in"/>
   <result pre="West Nile fever [18], and Dengue fever [10,16,17,19,23]. Nevertheless, the" exact="DENV" post="IgG assays applied in this work either employ native"/>
   <result pre="particles displaying all antigens (DENV IgG IIFT) or a recombinant" exact="DENV" post="envelope protein E (SD Bioline Dengue Duo IgG rapid"/>
   <result pre="IIFT) or a recombinant DENV envelope protein E (SD Bioline" exact="Dengue" post="Duo IgG rapid test); the antigen used in the"/>
   <result pre="Duo IgG rapid test); the antigen used in the Panbio" exact="DENV" post="Indirect IgG ELISA has not been specified in the"/>
   <result pre="to an overall increase of the diagnostic sensitivity of an" exact="DENV" post="NS1 antigen capture ELISA developed by Shen et al."/>
   <result pre="this apparent methodical incompatibility: 1) Acid treatment may (partially) denature" exact="DENV" post="NS1, preventing efficient binding of monoclonal antibodies recognizing conformational"/>
   <result pre="was observed between the diagnostic sensitivities of the SD Bioline" exact="Dengue" post="Duo NS1 for the two main DENV serotypes (DENV2,"/>
   <result pre="the SD Bioline Dengue Duo NS1 for the two main" exact="DENV" post="serotypes (DENV2, DENV3) represented in our study collective. In"/>
   <result pre="observed a significantly lower diagnostic sensitivity of both the PLATELIA™" exact="Dengue" post="NS1 Ag ELISA and an NS1 lateral flow rapid"/>
   <result pre="respectively [26]. A lower diagnostic sensitivity of the SD Bioline" exact="Dengue" post="Duo NS1 test for DENV2 and DENV4 in comparison"/>
   <result pre="blood cell and platelet counts are more frequently observed in" exact="DENV" post="infection than in other febrile diseases [3]. While an"/>
   <result pre="Sri Lankan patients [36], no significant difference in SD Bioline" exact="Dengue" post="Duo NS1 positivity was detected between acute phase patient"/>
   <result pre="respective lower reference values in our study. The SD Bioline" exact="Dengue" post="Duo rapid test results for NS1 antigen and IgM/IgG"/>
   <result pre="sample panel originating from French Guiana [37], the SD Bioline" exact="Dengue" post="Duo NS1 test results were in good concordance with"/>
   <result pre="NS1 test results were in good concordance with the PLATELIA™" exact="Dengue" post="NS1 Ag ELISA. In contrast, significantly fewer samples were"/>
   <result pre="fewer samples were classified as positive in the SD Bioline" exact="Dengue" post="Duo IgM test than in the Panbio® Dengue IgM"/>
   <result pre="SD Bioline Dengue Duo IgM test than in the Panbio®" exact="Dengue" post="IgM Capture ELISA, resulting in low Cohen’s kappa value"/>
   <result pre="(Cohen’s kappa = 0.53) was found between the SD Bioline" exact="Dengue" post="Duo IgM test and another commercial DENV IgM ELISA"/>
   <result pre="the SD Bioline Dengue Duo IgM test and another commercial" exact="DENV" post="IgM ELISA (Dengue Fever IgM Capture DxSelect™, Focus Diagnostics)"/>
   <result pre="et al. [37]. The analytical sensitivity of the SD Bioline" exact="Dengue" post="Duo IgM test was found to be particularly low"/>
   <result pre="found to be particularly low in comparison to the Panbio" exact="DENV" post="IgM capture ELISA when serum samples from patients with"/>
   <result pre="commented on in the Instructions For Use. The SD Bioline" exact="Dengue" post="Duo IgG test preferentially detected samples with a DENV"/>
   <result pre="Bioline Dengue Duo IgG test preferentially detected samples with a" exact="DENV" post="IgG IIFT titer &amp;gt; 1:2,000 (Fig 3, S5 Fig)"/>
   <result pre="S5 Fig) Therefore, a positive result of the SD Bioline" exact="Dengue" post="Duo IgG test in an acute phase sample is"/>
   <result pre="an acute phase sample is strongly indicative of a secondary" exact="DENV" post="infection. Although a good agreement (Cohen’s kappa = 0.75)"/>
   <result pre="agreement (Cohen’s kappa = 0.75) was found between the in-house" exact="DENV" post="IgG IIFT and the Panbio DENV IgG ELISA, seven"/>
   <result pre="found between the in-house DENV IgG IIFT and the Panbio" exact="DENV" post="IgG ELISA, seven samples generating a weak to medium"/>
   <result pre="to medium high signal in the ELISA were classified as" exact="DENV" post="IgG negative by the in-house DENV IgG IIFT. This"/>
   <result pre="ELISA were classified as DENV IgG negative by the in-house" exact="DENV" post="IgG IIFT. This divergence may either be caused by"/>
   <result pre="obtained for the majority of tested samples with the Panbio" exact="DENV" post="IgG ELISA indicating a saturation of the obtained signals."/>
   <result pre="to be high (&amp;gt; 97%) for both the SD Bioline" exact="Dengue" post="Duo NS1 and the SD Bioline Dengue Duo IgM"/>
   <result pre="the SD Bioline Dengue Duo NS1 and the SD Bioline" exact="Dengue" post="Duo IgM test when testing samples from Laotian patients"/>
   <result pre="typhus and spotted fever. As reported previously [42], the Panbio" exact="DENV" post="μ-capture ELISA showed a higher false positive rate than"/>
   <result pre="case number and the strong bias to the two major" exact="DENV" post="serotypes (DENV2, DENV3) found in the southern part of"/>
   <result pre="DF are endemic, patients should be tested for malaria and" exact="DENV" post="NS1 positivity as early as possible post onset of"/>
   <result pre="days of illness. Even at a high rate of secondary" exact="DENV" post="infections, early application of the fairly inexpensive NS1 rapid"/>
   <result pre="test will quickly identify the majority of DF cases. Only" exact="DENV" post="NS1 negative sera from patients not suffering from malaria"/>
   <result pre="Click here for additional data file. S1 Fig SD Bioline" exact="Dengue" post="Duo test results (Colombia DF patients). Acute phase serum"/>
   <result pre="phase serum samples from 26 patients (A) with a PCR-confirmed" exact="DENV" post="infection were analyzed with the SD Bioline Dengue Duo"/>
   <result pre="a PCR-confirmed DENV infection were analyzed with the SD Bioline" exact="Dengue" post="Duo NS1 (B), IgM (C) and IgG test (D)."/>
   <result pre="post onset of symptoms) and Ct value in the RealStar" exact="Dengue" post="RT-PCR. Dashed lines indicate Ct-value categories low (Ct ≤"/>
   <result pre="Open/filled circles represent samples tested negative/positive in the SD Bioline" exact="Dengue" post="Duo test. (E) Filled circles represent samples tested positive"/>
   <result pre="Click here for additional data file. S2 Fig SD Bioline" exact="Dengue" post="Duo NS1 test results stratified according to DENV serotype"/>
   <result pre="SD Bioline Dengue Duo NS1 test results stratified according to" exact="DENV" post="serotype (Lao PDR DF patients). Acute phase serum samples"/>
   <result pre="(N = 12, M—P) were analyzed with the SD Bioline" exact="Dengue" post="Duo NS1, IgM, and IgG test. Samples were stratified"/>
   <result pre="post onset of symptoms) and Ct value in the RealStar" exact="Dengue" post="RT-PCR. Dashed lines indicate Ct-value categories low (Ct ≤"/>
   <result pre="Open/filled circles represent samples tested negative/positive in the SD Bioline" exact="Dengue" post="Duo test. (Q) Tabular representation and statistical analysis of"/>
   <result pre="representation and statistical analysis of subgroup characteristics and SD Bioline" exact="Dengue" post="Duo test results; ns: not significant. (PDF) LINK Click"/>
   <result pre="Click here for additional data file. S3 Fig SD Bioline" exact="Dengue" post="Duo NS1 test results do not correlate with WBC"/>
   <result pre="acute phase serum samples from 92 patients with a PCR-confirmed" exact="DENV" post="infection. Dashed lines indicate reference values. Open/filled circles represent"/>
   <result pre="Open/filled circles represent samples tested negative/positive in the SD Bioline" exact="Dengue" post="Duo NS1 test. (C) Tabular summary of results. Statistical"/>
   <result pre="complex dissociation methods are not compatible with the SD Bioline" exact="Dengue" post="Duo NS1 antigen test. Serum samples with a high,"/>
   <result pre="a high, medium, or low signal in the SD Bioline" exact="Dengue" post="Duo NS1 test (A) were subjected to immune complex"/>
   <result pre="Click here for additional data file. S5 Fig Comparison of" exact="DENV" post="IgG IIFT and Panbio IgG ELISA results. 74 acute"/>
   <result pre="74 acute phase serum samples were analyzed with the in-house" exact="DENV" post="IgG IIFT and the Panbio DENV IgG ELISA. (A)"/>
   <result pre="analyzed with the in-house DENV IgG IIFT and the Panbio" exact="DENV" post="IgG ELISA. (A) Open/grey/black circles represent DENV IIFT negative/positive"/>
   <result pre="and the Panbio DENV IgG ELISA. (A) Open/grey/black circles represent" exact="DENV" post="IIFT negative/positive (low titer: &amp;lt; 1:2,000, high titer: ≥"/>
   <result pre="from patients with a confirmed diagnosis of malaria or presumptive" exact="DENV" post="infection are indicated by filled circles and red diamonds,"/>
   <result pre="Dos SantosF, Martinez-VegaR, Galvao de AraujoJM, JointG, et al. (2017)" exact="Dengue" post="in Latin America: Systematic Review of Molecular Epidemiological Trends."/>
   <result pre="(2008) Defining the levels of secreted non-structural protein NS1 after" exact="West Nile" post="virus infection in cell culture and mice. J Med"/>
   <result pre="detection sensitivity of the nonstructural-1 glycoprotein in patients infected with" exact="DENV" post="type-4. J Virol Methods204: 105–108. 10.1016/j.jviromet.2014.02.03124747585 20NishanianP, HuskinsKR, StehnS,"/>
   <result pre="Infect50: 167–174. 10.1016/j.jmii.2015.05.00826260863 24LimSK, LimJK, YoonIK (2017) An Update on" exact="Zika" post="Virus in Asia. Infect Chemother49: 91–100. 10.3947/ic.2017.49.2.9128681575 25KhampapongpaneB, LewisHC,"/>
   <result pre="Validation and reliability of the rapid diagnostic test 'SD Bioeasy" exact="Dengue" post="Duo' for dengue diagnosis in Brazil: a phase III"/>
   <result pre="e317110.1371/journal.pntd.000317125330157 31MullerDA, DepelsenaireAC, YoungPR (2017) Clinical and Laboratory Diagnosis of" exact="Dengue" post="Virus Infection. J Infect Dis215: S89–S95. 10.1093/infdis/jiw64928403441 32DejnirattisaiW, JumnainsongA,"/>
   <result pre="233–239. 10.1007/s00430-011-0195-021533786 36ParanavitaneSA, GomesL, KamaladasaA, AdikariTN, WickramasingheN, et al. (2014)" exact="Dengue" post="NS1 antigen as a marker of severe clinical disease."/>
   <result pre="NacherM, et al. (2017) Prospective evaluation of the SD BIOLINE" exact="Dengue" post="Duo rapid test during a dengue virus epidemic. Eur"/>
   <result pre="Lab Immunol10: 622–630. 10.1128/CDLI.10.4.622-630.200312853395 40WangSM, SekaranSD (2010) Early diagnosis of" exact="Dengue" post="infection using a commercial Dengue Duo rapid test kit"/>
   <result pre="SekaranSD (2010) Early diagnosis of Dengue infection using a commercial" exact="Dengue" post="Duo rapid test kit for the detection of NS1,"/>
   <result pre="TavaresAS, PaploskiIAD, et al. (2019) Accuracy of the SD BIOLINE" exact="Dengue" post="Duo for rapid point-of-care diagnosis of dengue. PLoS One14:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077839\results\search\tropicalVirus\results.xml">
   <result pre="Jiangsu, China, 2010 [21] Serum collection non-HFMD inpatients non-HFMD inpatients" exact="Dengue" post="inpatients Healthy children in schools non-HFMD patients Healthy children"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077840\results\search\tropicalVirus\results.xml">
   <result pre="10.1128/JCM.40.1.1-4.200211773083 2ChanE., et al.Using Web Search Query Data to Monitor" exact="Dengue" post="Epidemics: A New Model for Neglected Tropical Disease Surveillance."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7080275\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="sub-clinical infections on the most populated island, Tahiti. Author summary" exact="Dengue" post="virus is the most significant arthropod-borne virus infecting man."/>
   <result pre="become a more general URL for full data availability. Introduction" exact="Dengue" post="is caused by any of four antigenically distinct dengue"/>
   <result pre="and DENV-4, which are transmitted by Aedes (Ae.) mosquito species." exact="Dengue" post="has become a major international public health concern and"/>
   <result pre="[1–4]. More than 3.5 billion people are at risk of" exact="DENV" post="infection and it has been estimated that there are"/>
   <result pre="and it has been estimated that there are 390 million" exact="DENV" post="infections every year [5]. Understanding the spatio-temporal dynamics of"/>
   <result pre="infection, chains of transmission and quantifying the force of infection." exact="Dengue" post="epidemics occur intermittently, driven by climate suitability impacting mosquito"/>
   <result pre="a changing human background. Coupled with difficulties in differentiating among" exact="DENV" post="serotypes using serological methods and the high but variable"/>
   <result pre="as to whether French Polynesia is effectively a meta-population whereby" exact="DENV" post="is maintained by island-hopping or whether there is a"/>
   <result pre="infection on the main island of Tahiti that subsequently feeds" exact="DENV" post="into the smaller islands. We provide here the first"/>
   <result pre="Polynesia showing the five administrative subdivisions and associated islands. [12]." exact="Dengue" post="case data Institut Louis Malardé (ILM) is a local"/>
   <result pre="mosquitoes with the serum from suspected cases (1979–1980); isolation of" exact="DENV" post="on C6/36 mosquito cell culture (1984–2005); IgM ELISA (from"/>
   <result pre="of a dengue-incident month across all islands and according to" exact="DENV" post="serotype is shown in Fig 3. Until 2013, DENV"/>
   <result pre="to DENV serotype is shown in Fig 3. Until 2013," exact="DENV" post="circulation was monotypic with very few occasions of co-circulation"/>
   <result pre="the zero month absence point on the Y-axis. However, because" exact="DENV" post="is mosquito-borne and can persist in the infected mosquito"/>
   <result pre="per island. Island size being clearly a limiting factor for" exact="DENV" post="persistence, we then addressed two population size dependent phenomena:"/>
   <result pre="duration of viral transmission within the island. The probability of" exact="DENV" post="establishing itself for at least two consecutive dengue incident"/>
   <result pre="size, the number of cases in the first month and" exact="DENV" post="serotype. We first assumed that at least two consecutive"/>
   <result pre="with population size, but to a lesser extent (lower OR)." exact="DENV" post="serotype (DENV-1, -2, -3, -4, or mixed -1 and"/>
   <result pre="was not found to be associated with the probability of" exact="DENV" post="transmission during two consecutive months (Wald χ24 = 7.62,"/>
   <result pre="a function of population size, cumulative number of cases and" exact="DENV" post="serotype. Local transmission was presumed to have stopped when"/>
   <result pre="(RR = 2.49, 95%CI 2.13–2.91, P&amp;lt;0.001) (S4 and S5 Figs)." exact="DENV" post="circulation was also longer for DENV-1 as compared to"/>
   <result pre="is useful, based on classical concepts of synchrony and persistence." exact="Dengue" post="incidence was largely asynchronous across subdivisions, but partially synchronous"/>
   <result pre="[23–26], except for French Polynesia. Epidemic recrudescence of a persisting" exact="DENV" post="occurred in 2006, with the same viral strain as"/>
   <result pre="the 2001 epidemic. How in French Polynesia, whatever the serotype," exact="DENV" post="circulation can persist between epidemics for several months with"/>
   <result pre="epidemic occurring in the outlying islands. The long-term persistence of" exact="DENV" post="during inter-epidemic periods is remarkable and suggests that the"/>
   <result pre="(TIF) LINK Click here for additional data file. S1 Table" exact="Dengue" post="circulation within islands. Population size is the mid-term value"/>
   <result pre="to complete the dengue database. References References 1GublerD, KunoG, editors." exact="Dengue" post="and Dengue Hemorrhagic Fever. Wallingford: CAB International; 1997. 2LambrechtsL,"/>
   <result pre="the dengue database. References References 1GublerD, KunoG, editors. Dengue and" exact="Dengue" post="Hemorrhagic Fever. Wallingford: CAB International; 1997. 2LambrechtsL, ScottTW, GublerDJ."/>
   <result pre="Tropical Medicine and Hygiene2007; 77(5 suppl): 129. 24ChungueE, DeparisX, MurgueB." exact="Dengue" post="In French Polynesia: Major Features, Surveillance, Molecular Epidemiology And"/>
   <result pre="French Polynesia: Major Features, Surveillance, Molecular Epidemiology And Current Situation." exact="Dengue" post="Bulletin1998; 22: 74–93. 25LiDS, LiuW, GuigonA, MostynC, GrantR, AaskovJ."/>
   <result pre="26Cao-LormeauV-M, RocheC, AubryM, TeissierA, LastereS, DaudensE, et al.Recent Emergence of" exact="Dengue" post="Virus Serotype 4 in French Polynesia Results from Multiple"/>
   <result pre="Islands. PLoS ONE2011; 6(12): e2955510.1371/journal.pone.002955522216313 27DesclouxE, Cao-LormeauVM, RocheC, De LamballerieX." exact="Dengue" post="1 diversity and microevolution, French Polynesia 2001–2006: connection with"/>
   <result pre="e000592610.1371/journal.pntd.000592628953902 30AubryM, TeissierA, HuartM, VanhomwegenJ, MapotoekeM, Mariteragi-HelleT, et al.Seroprevalence of" exact="Dengue" post="and Chikungunya Virus Antibodies, French Polynesia, 2014–2015. Emerg Infect"/>
   <result pre="TeissierA, HuartM, VanhomwegenJ, MapotoekeM, Mariteragi-HelleT, et al.Seroprevalence of Dengue and" exact="Chikungunya" post="Virus Antibodies, French Polynesia, 2014–2015. Emerg Infect Dis2018; 24(3):"/>
   <result pre="CarvalhoMS, CruzOG, Magalhães MdeA, et al.Spatial Evaluation and Modeling of" exact="Dengue" post="Seroprevalence and Vector Density in Rio de Janeiro, Brazil."/>
   <result pre="MassadE, AlonsoWJ, et al.Spatio-Temporal Tracking and Phylodynamics of an Urban" exact="Dengue" post="3 Outbreak in São Paulo, Brazil. PLoS Negl Trop"/>
   <result pre="36Vazquez-ProkopecGM, KitronU, MontgomeryB, HorneP, RitchieSA. Quantifying the Spatial Dimension of" exact="Dengue" post="Virus Epidemic Spread within a Tropical Urban Environment. PLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7081911\results\search\tropicalVirus\results.xml">
   <result pre="100 cases have required hospitalization or even intensive care, exceeding" exact="West Nile" post="virus in numbers of pediatric neuroinvasive arboviral infection (13)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7083784\results\search\tropicalVirus\results.xml">
   <result pre="diseases for instance Rift Valley fever, malaria, dengue fever, and" exact="West Nile" post="fever in endemic areas may occur (Okaka and Odhiambo,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7089401\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Microbiology :"/>
   <result pre="Medical microbiology : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Medicine and health sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Molecular biology"/>
   <result pre="are credited.pntd.0008166.pdf Abstract Flaviviruses such as yellow fever, dengue or" exact="Zika" post="viruses are responsible for significant human and veterinary diseases"/>
   <result pre="and two chimeric viruses generated as hybrids between BgV and" exact="West Nile" post="virus, we demonstrated that BgV host-restriction occurred post-cell entry."/>
   <result pre="mutant viruses were injected into immunocompetent mice, alongside BgV and" exact="West Nile" post="virus chimeras, infection and neurovirulence were enhanced as determined"/>
   <result pre="include flaviviruses such as yellow fever virus, dengue virus and" exact="Zika" post="virus, which continue to cause disease worldwide. Some of"/>
   <result pre="human pathogens and cause large scale epidemics. Recent examples include" exact="Zika" post="and yellow fever viruses, which have caused large epidemics"/>
   <result pre="examples of large-scale epidemics caused by under-studied flaviviruses such as" exact="Zika" post="virus [4]. The emergence of flaviviruses as pathogens may"/>
   <result pre="detected in their saliva after incubation, and could interfere with" exact="West Nile" post="virus (WNV) and Murray Valley encephalitis virus replication in"/>
   <result pre="(WNV) and Murray Valley encephalitis virus replication in vitro and" exact="WNV" post="transmission in vivo [13]. Since this host-restricted virus was"/>
   <result pre="BgV infectious clone and two chimeric viruses between BgV and" exact="WNV" post="to investigate which BgV genes might be responsible for"/>
   <result pre="vertebrate cell lines were inoculated in triplicates with BgV and" exact="WNV" post="at MOI 1 for 1h 30min, the inoculum removed"/>
   <result pre="and p = 0.0254 at 48h) and so did the" exact="WNV" post="infectious clone-derived virus compare to the WNV isolate (p"/>
   <result pre="so did the WNV infectious clone-derived virus compare to the" exact="WNV" post="isolate (p = 0.0101 at 24h). Aside from these"/>
   <result pre="sequence and WNVKUN prME: BgV/WNV-prME and the reverse chimera with" exact="WNV" post="backbone sequence and BgV prME: WNV/BgV-prME. B. Replication kinetics"/>
   <result pre="others to evaluate the host-range of arthropod-borne viruses such as" exact="Zika" post="virus or chikungunya virus [19, 20]. We show that"/>
   <result pre="flavivirus, Rabensburg virus (RabV), which is a divergent strain of" exact="WNV" post="[28, 29]. RabV failed to replicate in Vero, BHK,"/>
   <result pre="been shown that a single amino acid change occurring in" exact="WNV" post="NS4B (C102S) resulted in restricted replication in Vero cells"/>
   <result pre="addition, another report described a mutation in the C-terminus of" exact="WNV" post="NS4B (E249G) which attenuated the virus as manifested by"/>
   <result pre="as causing lower morbidity and mortality in vivo [33]. While" exact="WNV" post="NS4B is a few amino acids longer than BgV"/>
   <result pre="NS4A/2K cleavage site (see Fig 3C) led to drastically impaired" exact="WNV" post="replication and virion production [34]. The BgV NS4A C-terminal"/>
   <result pre="realistic. This dose was similar to the one used for" exact="Zika" post="virus in other host-restriction studies in these animals [48]."/>
   <result pre="organization. Viruses. 2015;7(4):1927–59. Epub 2015/04/14. 10.3390/v704192725866904 2AliotaMT, KramerLD. Replication of" exact="West Nile" post="virus, Rabensburg lineage in mammalian cells is restricted by"/>
   <result pre="virus is transmitted horizontally by Culex mosquitoes and interferes with" exact="West Nile" post="virus replication in vitro and transmission in vivo. PLOS"/>
   <result pre="2017/06/09. 10.1038/s41598-017-03120-128592864 18ProwNA, SetohYX, BironRM, SesterDP, KimKS, Hobson-PetersJ, et al.The" exact="West Nile" post="virus-like flavivirus Koutango is highly virulent in mice due"/>
   <result pre="HartwigAE, BowenRA. Reptiles and Amphibians as Potential Reservoir Hosts of" exact="Chikungunya" post="Virus. The American journal of tropical medicine and hygiene."/>
   <result pre="the Potential Role of North American Animals as Hosts for" exact="Zika" post="Virus. Vector Borne Zoonotic Dis. 2017;17(3):161–4. Epub 2017/02/02. 10.1089/vbz.2016.2099"/>
   <result pre="RNase L plays a role in the antiviral response to" exact="West Nile" post="virus. J Virol. 2006;80(6):2987–99. Epub 2006/02/28. 10.1128/JVI.80.6.2987-2999.200616501108 22SamuelMA, WhitbyK,"/>
   <result pre="et al.PKR and RNase L contribute to protection against lethal" exact="West Nile" post="Virus infection by controlling early viral spread in the"/>
   <result pre="IFN-independent activation of a subset of interferon stimulated genes in" exact="West Nile" post="virus Eg101-infected mouse cells. Virology. 2012;425(2):82–94. 10.1016/j.virol.2012.01.006 PMC3288888. 22305622"/>
   <result pre="28BakonyiT, HubalekZ, RudolfI, NowotnyN. Novel flavivirus or new lineage of" exact="West Nile" post="virus, central Europe. Emerging infectious diseases. 2005;11(2):225–31. Epub 2005/03/09."/>
   <result pre="(Diptera: Culicidae) surveillance for arboviruses in an area endemic for" exact="West Nile" post="(Lineage Rabensburg) and Tahyna viruses in Central Europe. J"/>
   <result pre="KramerLD. Characterization of Rabensburg virus, a flavivirus closely related to" exact="West Nile" post="virus of the Japanese encephalitis antigenic group. PLoS One."/>
   <result pre="single amino acid substitution in the central portion of the" exact="West Nile" post="virus NS4B protein confers a highly attenuated phenotype in"/>
   <result pre="ZhouY, Muñoz-JordánJL, García-SastreA, et al.A mouse cell-adapted NS4B mutation attenuates" exact="West Nile" post="virus RNA synthesis. Virology. 2007;361(1):229–41. Epub 2006/12/18. 10.1016/j.virol.2006.11.012 .17178141"/>
   <result pre="Epub 2006/12/18. 10.1016/j.virol.2006.11.012 .17178141 34AmbroseRL, MackenzieJM. A conserved peptide in" exact="West Nile" post="virus NS4A protein contributes to proteolytic processing and is"/>
   <result pre="J Virol. 2003;77(14):7804–13. Epub 2003/06/28. 10.1128/JVI.77.14.7804-7813.200312829820 44HenchalEA, GentryMK, McCownJM, BrandtWE." exact="Dengue" post="virus-specific and flavivirus group determinants identified with monoclonal antibodies"/>
   <result pre="HartwigAE, BowenRA. Reptiles and Amphibians as Potential Reservoir Hosts of" exact="Chikungunya" post="Virus. Am J Trop Med Hyg. 2018;98(3):841–4. Epub 2018/01/10."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7092853\results\search\tropicalVirus\results.xml">
   <result pre="Communications0006-291X1090-2104Elsevier Inc. pmcid: 7092853S0006-291X(19)32332-0 doi: 10.1016/j.bbrc.2019.12.012 : Article Cephalotaxine inhibits" exact="Zika" post="infection by impeding viral replication and stability LaiZheng-ZongabcHoYi-Jungde∗∗LuJeng-Weijengweilu@gmail.comf∗[a], [b],"/>
   <result pre="long as the COVID-19 resource centre remains active. Abstract The" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus that has reemerged"/>
   <result pre="an alkaloid isolated from Cephalotaxus drupacea, was effective in inhibiting" exact="ZIKV" post="activity in vitro (i.e., in Vero and A549 cell"/>
   <result pre="decrease in viral replication. Specifically, CET was found to decrease" exact="ZIKV" post="RNA and viral protein expression, inhibit ZIKV replication, and"/>
   <result pre="found to decrease ZIKV RNA and viral protein expression, inhibit" exact="ZIKV" post="replication, and inhibit ZIKV mRNA/protein production. We also determined"/>
   <result pre="RNA and viral protein expression, inhibit ZIKV replication, and inhibit" exact="ZIKV" post="mRNA/protein production. We also determined that CET is effective"/>
   <result pre="could be an effective lead compound in the treatment of" exact="ZIKV" post="and also suggest that further investigation and development of"/>
   <result pre="to a new class of anti-Flavivirus medications. Highlights •CET against" exact="ZIKV" post="infection via inhibiting replication and stability. •CET was identified"/>
   <result pre="and stability. •CET was identified as a potent inhibitor of" exact="ZIKV" post="infection. •CET as a candidate compound for potential ZIKV"/>
   <result pre="of ZIKV infection. •CET as a candidate compound for potential" exact="ZIKV" post="treatment. Keywords Antiviral Cephalotaxine Viral production Replication Dengue virus"/>
   <result pre="for potential ZIKV treatment. Keywords Antiviral Cephalotaxine Viral production Replication" exact="Dengue" post="virus Zika virus 1 Introduction The Zika virus (ZIKV)"/>
   <result pre="ZIKV treatment. Keywords Antiviral Cephalotaxine Viral production Replication Dengue virus" exact="Zika" post="virus 1 Introduction The Zika virus (ZIKV) is a"/>
   <result pre="Viral production Replication Dengue virus Zika virus 1 Introduction The" exact="Zika" post="virus (ZIKV) is a mosquito-borne, enveloped RNA virus that"/>
   <result pre="family (a family to which the Hepatitis C virus (HCV]," exact="Dengue" post="virus (DENV], West Nile virus (WNV], Yellow fever virus"/>
   <result pre="to which the Hepatitis C virus (HCV], Dengue virus (DENV]," exact="West Nile" post="virus (WNV], Yellow fever virus [YFV], and Japanese encephalitis"/>
   <result pre="C virus (HCV], Dengue virus (DENV], West Nile virus (WNV]," exact="Yellow fever" post="virus [YFV], and Japanese encephalitis virus [JEV] also belong.)"/>
   <result pre="fever virus [YFV], and Japanese encephalitis virus [JEV] also belong.)" exact="ZIKV" post="was first isolated from rhesus monkeys near the Zika"/>
   <result pre="belong.) ZIKV was first isolated from rhesus monkeys near the" exact="Zika" post="Forest in Uganda in 1947 [1,2]. The viral genome"/>
   <result pre="Forest in Uganda in 1947 [1,2]. The viral genome of" exact="ZIKV" post="encodes a polyprotein which consists of a capsid, a"/>
   <result pre="NS3, NS4A, NS4 B, and NS5 [3]. In recent years," exact="ZIKV" post="infection has become a serious and escalating threat to"/>
   <result pre="a serious and escalating threat to global health. For example," exact="ZIKV" post="spread rapidly in 2015 in at least 33 regions"/>
   <result pre="between 0.5 and 1.5 million people [[4], [5], [6], [7]]." exact="ZIKV" post="infection has been associated with several neurological complications, such"/>
   <result pre="which affected Brazil and other Central and South American countries," exact="ZIKV" post="infection was only considered to lead only to a"/>
   <result pre="as well as neurological and ocular abnormalities. In some cases," exact="ZIKV" post="during pregnancy can even led to perinatal death [10]."/>
   <result pre="ZIKV during pregnancy can even led to perinatal death [10]." exact="ZIKV" post="is also known to cause a benign febrile illness"/>
   <result pre="which are similar to those of other arbovirus infections, including" exact="DENV" post="and the chikungunya virus (CHIKV). Specifically, these symptoms include"/>
   <result pre="headaches, vomiting and jaundice [11]. Other clinical symptoms typical of" exact="ZIKV" post="infection include fever, headaches, joint pain, conjunctivitis, and macular"/>
   <result pre="[12]. In February 2016, the World Health Organization (WHO) declared" exact="ZIKV" post="to be a Public Health Emergency of International Concern"/>
   <result pre="Health Emergency of International Concern (PHEIC) [13]. Strategies of fighting" exact="ZIKV" post="infection include the development of vaccines and the screening"/>
   <result pre="of the viral life cycle [14]. Unfortunately, no approved antiviral" exact="ZIKV" post="agents are currently available. There is thus an urgent"/>
   <result pre="urgent need to develop safe and effective antiviral agents against" exact="ZIKV" post="and to elucidate their mechanisms. Doing so should help"/>
   <result pre="treatment of other diseases, including some cancers [18]. HT inhibits" exact="CHIKV" post="replication by down-regulating viral protein expression, while HHT shows"/>
   <result pre="that CET (1) disrupts the viral life cycle by preventing" exact="ZIKV" post="from replicating and (2) exhibits virucidal activity against ZIKV."/>
   <result pre="ATCC® CCL-185™) cells, as these cells are more permissive to" exact="ZIKV" post="(PRAVABC59, ATCC® VR-1843™) replication. Both Vero and A549 cells"/>
   <result pre="concentrations of CET, and 400 foci forming units (FFUs) of" exact="ZIKV" post="were added to the cells. Following incubation for another"/>
   <result pre="titers contained therein were determined using IFA. Relative quantifications of" exact="ZIKV" post="RNA in Vero cells were determined using quantitative reverse"/>
   <result pre="co-treatment group, CET was added at the initial point of" exact="ZIKV" post="infection. (3) For the post-treatment group, CET was added"/>
   <result pre="infection. (3) For the post-treatment group, CET was added after" exact="ZIKV" post="infection. (4) For the pre-treatment group, CET was added"/>
   <result pre="For the pre-treatment group, CET was added 3 h before" exact="ZIKV" post="infection. Following ZIKV infection, Vero cells in all treatment"/>
   <result pre="group, CET was added 3 h before ZIKV infection. Following" exact="ZIKV" post="infection, Vero cells in all treatment groups were incubated"/>
   <result pre="The cell-free anti-ZIKV activity of CET was investigated by incubating" exact="ZIKV" post="suspensions containing 5 × 104 FFU with indicated concentrations"/>
   <result pre="considered significant [[22], [23], [24]]. 3 Results 3.1 CET inhibited" exact="ZIKV" post="infection Earlier research found that CET was able to"/>
   <result pre="seeded in 12-well plates overnight and were then infected with" exact="ZIKV" post="at 1500 FFU per well. After 48 h of"/>
   <result pre="1500 FFU per well. After 48 h of incubation with" exact="ZIKV" post="and indicated concentrations of CET, cells were fixed and"/>
   <result pre="demonstrated that CET from 20 to 100 μM significantly inhibited" exact="ZIKV" post="infection in a dose-dependent manner (Fig. 1 A, B,"/>
   <result pre="(Fig. 1 A, B, and 1C). Fig. 1 CET inhibited" exact="ZIKV" post="infection. The inhibition of CET in ZIKV-infected Vero cells"/>
   <result pre="Statistical significance was determined via a t-test compared with the" exact="ZIKV" post="group: * indicates p &amp;lt; 0.05; ** indicates p"/>
   <result pre="0.01; and *** indicates p &amp;lt; 0.001. 3.2 CET inhibited" exact="ZIKV" post="production The viability of CET-treated Vero cells was determined"/>
   <result pre="measuring viral RNA levels, protein expression, and viral titers. (B)" exact="ZIKV" post="RNA levels were analyzed by qRT-PCR. (C) ZIKV protein"/>
   <result pre="titers. (B) ZIKV RNA levels were analyzed by qRT-PCR. (C)" exact="ZIKV" post="protein expression was detected by Western blotting. (D) Virus"/>
   <result pre="Statistical significance was determined via a t-test compared with the" exact="ZIKV" post="group: * indicates p &amp;lt; 0.05; ** indicates p"/>
   <result pre="were seeded in 12-well plates overnight, infected with 400 FFU" exact="ZIKV" post="per well, and incubated with indicated concentrations of CET"/>
   <result pre="assays were employed. Results of qRT-PCR showed that CET inhibited" exact="ZIKV" post="infection in a dose-dependent manner (Fig. 2B). In particular,"/>
   <result pre="100 μM CET was found to suppress approximately 98% of" exact="ZIKV" post="RNA production. Furthermore, Vero cells infected with 1000 FFU"/>
   <result pre="ZIKV RNA production. Furthermore, Vero cells infected with 1000 FFU" exact="ZIKV" post="per well under indicated dosages of CET for 48"/>
   <result pre="48 h incubation. Results of Western blotting analysis revealed that" exact="ZIKV" post="protein expression was significantly reduced under CET treatment (Fig."/>
   <result pre="of FFU assays revealed that CET is able to decrease" exact="ZIKV" post="progeny yield in a dose-dependent manner (Fig. 2D). Taken"/>
   <result pre="the above evidence indicates that CET is effective in suppressing" exact="ZIKV" post="propagation. 3.3 CET may affect ZIKV RNA replication and"/>
   <result pre="is effective in suppressing ZIKV propagation. 3.3 CET may affect" exact="ZIKV" post="RNA replication and stability Our data indicated that CET"/>
   <result pre="stability Our data indicated that CET is able to inhibit" exact="ZIKV" post="infection by decreasing viral RNA, protein, and progeny yield."/>
   <result pre="groups. (Cells in all groups were infected with 8000 FFU" exact="ZIKV" post="per well for 1 h) Following the end of"/>
   <result pre="analysis revealed that CET likely affects the late stage of" exact="ZIKV" post="infection (Fig. 3 A and B), which means that"/>
   <result pre="likely occur after virus entry. To investigate CET inhibition after" exact="ZIKV" post="entry, Vero cells were infected with ZIKV, washed with"/>
   <result pre="the post-treatment group were administered 40 or 80 μM CET," exact="ZIKV" post="RNA levels were significantly reduced (Fig. 3C). FFU assays"/>
   <result pre="in which cells were incubated with supernatant containing 50,000 FFU" exact="ZIKV" post="with or without 40 μM CET at room temperature"/>
   <result pre="(B) virus progeny production. The effects of administering CET after" exact="ZIKV" post="infection (i.e., the post-treatment group) as revealed by (C)"/>
   <result pre="Statistical significance was determined via a t-test compared with the" exact="ZIKV" post="group: * indicates p &amp;lt; 0.05, ** indicates p"/>
   <result pre="*** indicates p &amp;lt; 0.001. 4 Discussion The outbreak of" exact="ZIKV" post="in Brazil in 2015 was one of most uncontrollable"/>
   <result pre="most uncontrollable epidemics that the world has experienced. Since then," exact="ZIKV" post="has become a flavivirus of great medical concern. Nonetheless,"/>
   <result pre="and effective clinical compounds is critical for the treatment of" exact="ZIKV" post="patients and for the control of ZIKV outbreaks [25,26]."/>
   <result pre="the treatment of ZIKV patients and for the control of" exact="ZIKV" post="outbreaks [25,26]. CET and its derived ester compounds (such"/>
   <result pre="ester derivatives have inhibitory effects against HBV [16], VZV and" exact="CHIKV" post="[19,21]. However, this is the first study to demonstrate"/>
   <result pre="this is the first study to demonstrate that CET inhibits" exact="ZIKV" post="infection. Specifically, results of IFA revealed that CET treatment"/>
   <result pre="Moreover, HT has been found to limit the replication of" exact="CHIKV" post="by inhibiting large ribosomal subunits and subsequently down-regulating the"/>
   <result pre="addition assay showed that CET affected the late stage of" exact="ZIKV" post="infection (Fig. 3A and B). We further sought to"/>
   <result pre="sought to determine the possible mechanism by which CET influences" exact="ZIKV" post="RNA replication. Previous research which investigated VZV determined that"/>
   <result pre="which suggest that the primary mechanism by which CET inhibited" exact="ZIKV" post="involved viral replication, not virus release. However, the time"/>
   <result pre="summary, our data indicate that CET is able to inhibit" exact="ZIKV" post="infection by affecting both viral replication and viral stability."/>
   <result pre="four different dengue virus serotypes and found that CET reduced" exact="DENV" post="RNA levels in a Vero cell model, in which"/>
   <result pre="the further study of CET as a candidate compound for" exact="ZIKV" post="treatment. Declaration of Competing Interest None. References References 1DickG.W.KitchenS.F.HaddowA.J.Zika"/>
   <result pre="serological specificityTrans. R. Soc. Trop. Med. Hyg.46195250952012995440 2EspanoE.NamJ.H.SongE.J.SongD.LeeC.K.KimJ.K.Lipophilic statins inhibit" exact="Zika" post="virus production in Vero cellsSci. Rep.920191146131391514 3KunoG.ChangG.J.Full-length sequencing and"/>
   <result pre="Rep.920191146131391514 3KunoG.ChangG.J.Full-length sequencing and genomic characterization of Bagaza, Kedougou, and" exact="Zika" post="virusesArch. Virol.152200768769617195954 4PetersenL.R.JamiesonD.J.PowersA.M.HoneinM.A.Zika virusN. Engl. J. Med.37420161552156327028561 5HennesseyM.FischerM.StaplesJ.E.Zika virus"/>
   <result pre="2016MMWR Morb. Mortal. Wkly. Rep.652016555826820163 6TeixeiraM.G.Costa MdaC.de OliveiraW.K.NunesM.L.RodriguesL.C.The epidemic of" exact="Zika" post="virus-related microcephaly in Brazil: detection, control, etiology, and future"/>
   <result pre="early epidemiological and genetic findingsScience352201634534927013429 8LeeJ.L.LoeM.W.C.LeeR.C.H.ChuJ.J.H.Antiviral activity of pinocembrin against" exact="Zika" post="virus replicationAntivir. Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of congenital Zika disease depend"/>
   <result pre="of pinocembrin against Zika virus replicationAntivir. Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of congenital" exact="Zika" post="disease depend on timing of infection and maternal-fetal interferon"/>
   <result pre="Epidemiol. Rec.912016738126897760 14BatistaM.N.BragaA.C.S.CamposG.R.F.SouzaM.M.MatosR.P.A.LopesT.Z.CandidoN.M.LimaM.L.D.MachadoF.C.AndradeS.T.Q.BittarC.NogueiraM.L.CarneiroB.M.MariuttiR.B.ArniR.K.CalmonM.F.RahalP.Natural products isolated from oriental medicinal herbs inactivate" exact="Zika" post="virusViruses112019 15LuS.WangJ.Homoharringtonine and omacetaxine for myeloid hematological malignanciesJ. Hematol."/>
   <result pre="agent of chikungunya virus through multiple mechanismsAntivir. Res.159201813414230300716 23HoY.J.LuJ.W.HuangY.L.LaiZ.Z.Palmatine inhibits" exact="Zika" post="virus infection by disrupting virus binding, entry, and stabilityBiochem."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7093544\results\search\tropicalVirus\results.xml">
   <result pre="strain and collected at each time point was tested against" exact="CHIKV" post="(Sup. Table 2). PRNT50 values revealed that the MAYV/IRES"/>
   <result pre="disease. There is a potential risk that MAYV may follow" exact="CHIKV" post="to cause large urban epidemics31–36, especially since new lineages"/>
   <result pre="common hallmarks of MF40,41. As for other arboviruses, such as" exact="Zika" post="and Dengue42,43, resistance of adult mice to alphavirus infection"/>
   <result pre="have shown significant hypernociception in response to mechanical stimulation upon" exact="Dengue" post="virus infection49. Accordingly, we and others50 have demonstrated that"/>
   <result pre="been identified in experimental models of alphavirus infections such as" exact="CHIKV" post="and RRV viruses. In patients with CHIKV, imaging studies"/>
   <result pre="with constant quantities of wt MAYV (1 × 106 PFU/mL) or with" exact="CHIKV" post="strains (1 × 105 PFU/mL) and then incubated for 1 hour at"/>
   <result pre="strain and collected at each time point was tested against" exact="CHIKV" post="(Sup. Table 2). PRNT50 values revealed that the MAYV/IRES"/>
   <result pre="supported by the National Institute of Science and Technology in" exact="Dengue" post="and Host-microorganism Interaction (INCT dengue), which is a program"/>
   <result pre="candidate for mayaro FeverPLoS Negl. Trop. Dis.20148e296910.1371/journal.pntd.000296925101995 26.WebbEMet al.Effects of" exact="Chikungunya" post="virus immunity on Mayaro virus disease and epidemic potentialSci."/>
   <result pre="an IRES-based attenuation and host range alteration mechanismPLoS Pathog.20117e100214210.1371/journal.ppat.100214221829348 31.HotezPJMurrayKODengue," exact="West Nile" post="virus, chikungunya, Zika-and now Mayaro?PLoS Negl. Trop. Dis.201711e000546210.1371/journal.pntd.000546228859086 32.EspositoDLAFonsecaBWill"/>
   <result pre="virus infection and diseaseAntivir. Res.200880879310.1016/j.antiviral.2008.06.01018619493 43.LazearHMet al.A Mouse Model of" exact="Zika" post="Virus PathogenesisCell host microbe20161972073010.1016/j.chom.2016.03.01027066744 44.da Silva CaetanoCCet al.Mayaro Virus"/>
   <result pre="Hyg.201010439239910.1016/j.trstmh.2010.01.01120171708 52.GoupilBAet al.Novel Lesions of Bones and Joints Associated with" exact="Chikungunya" post="Virus Infection in Two Mouse Models of Disease: New"/>
   <result pre="Recovery Phase of Mayaro Virus InfectionEmerg. Infect. Dis.20162275075210.3201/eid2204.15150226981875 55.NgLFPImmunopathology of" exact="Chikungunya" post="Virus Infection: Lessons Learned from Patients and Animal ModelsAnnu."/>
   <result pre="testingVaccine2015337051706010.1016/j.vaccine.2015.09.11226478201 65.RossiSLet al.Characterization of a Novel Murine Model to Study" exact="Zika" post="VirusAm. J. tropical Med. Hyg.2016941362136910.4269/ajtmh.16-0111 66.MeierKCGardnerCLKhoretonenkoMVKlimstraWBRymanKDA mouse model for"/>
   <result pre="al.Subversion of early innate antiviral responses during antibody-dependent enhancement of" exact="Dengue" post="virus infection induces severe disease in immunocompetent miceMed. Microbiol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7094556\results\search\tropicalVirus\results.xml">
   <result pre="Medical Education and Research pmcid: 7094556S0025-6196(19)30483-5 doi: 10.1016/j.mayocp.2019.05.016 : Article" exact="Zika" post="Vaccine Development: Current Status PolandGregory A.MDpoland.gregory@mayo.edu∗OvsyannikovaInna G.PhDKennedyRichard B.PhD[], ∗Correspondence:"/>
   <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Zika" post="virus outbreaks have been explosive and unpredictable and have"/>
   <result pre="the world needs safe and effective vaccines to protect against" exact="Zika" post="virus infection. Whether such vaccines can be developed through"/>
   <result pre="mRNA, messenger RNA prM, premembrane/membrane WHO, World Health Organization ZIKV," exact="Zika" post="virus While discovered in 1947, Zika virus (ZIKV) remained"/>
   <result pre="World Health Organization ZIKV, Zika virus While discovered in 1947," exact="Zika" post="virus (ZIKV) remained unimportant and unnoticed until the Yap"/>
   <result pre="the world has had to play &quot;catch-up�? by rapidly investigating" exact="ZIKV" post="immunology, pathophysiology, and its short- and long-term effects, as"/>
   <result pre="also at risk. Travelers from endemic areas can also introduce" exact="ZIKV" post="into the new territories.4, 5, 6 This scenario begs"/>
   <result pre="9, 10, 11 The current unpredictability and lack of future" exact="ZIKV" post="outbreaks is a major impediment to creating effective public"/>
   <result pre="In this review, we will briefly summarize current knowledge about" exact="ZIKV" post="and outbreaks, while primarily focusing on issues related to"/>
   <result pre="ZIKV and outbreaks, while primarily focusing on issues related to" exact="Zika" post="vaccine development and the current status of these efforts."/>
   <result pre="Finally, we provide a &quot;look ahead�? regarding the future of" exact="Zika" post="vaccine development. Zika Disease/Outbreaks Zika virus was first isolated"/>
   <result pre="a &quot;look ahead�? regarding the future of Zika vaccine development." exact="Zika" post="Disease/Outbreaks Zika virus was first isolated in Uganda in"/>
   <result pre="ahead�? regarding the future of Zika vaccine development. Zika Disease/Outbreaks" exact="Zika" post="virus was first isolated in Uganda in 1947 in"/>
   <result pre="in the infection of three-quarters of the approximately 270,000 residents,13" exact="ZIKV" post="infections remained limited to periodic cases or small-scale epidemics."/>
   <result pre="cases of congenital malformations and other neurologic disorders linked to" exact="ZIKV" post="infection (in French Polynesia and Brazil), ZIKV has spread"/>
   <result pre="disorders linked to ZIKV infection (in French Polynesia and Brazil)," exact="ZIKV" post="has spread to many countries in South America, Central"/>
   <result pre="(GBS), and other neurologic conditions associated with the appearance of" exact="ZIKV" post="in the Americas. On November 18, 2016, the WHO"/>
   <result pre="that nearly 400 million individuals can be potentially infected with" exact="ZIKV" post="annually (similar to dengue virus [DENV] infection and burden),14"/>
   <result pre="aegypti, Aedes albopictus, Aedes polynesiensis, and Aedes hensilli) associated with" exact="ZIKV" post="transmission is widespread. A recent study estimates that 22.7"/>
   <result pre="the Aedes mosquito vectors, setting the stage for possible year-round" exact="ZIKV" post="transmission.15 Local transmission has already occurred in US territories"/>
   <result pre="the Caribbean and Pacific regions, demonstrating the unexpected ability of" exact="ZIKV" post="to quickly spread to nonepidemic regions. Countries with a"/>
   <result pre="spread to nonepidemic regions. Countries with a documented presence of" exact="ZIKV" post="(as of March 2018) are shown in Figure A"/>
   <result pre="are shown in Figure B. Figure Countries at risk for" exact="Zika" post="virus infection. A, The world map shows locations with"/>
   <result pre="virus infection. A, The world map shows locations with known" exact="Zika" post="virus presence in dark green (current as of March"/>
   <result pre="Prevention.16 B, Countries suitable for Aedes aegypti and Aedes albopictus." exact="Zika" post="virus infection typically causes no or mild clinical symptoms"/>
   <result pre="have significant similarities with DENV-like disease. The incubation period of" exact="ZIKV" post="is not clear but is likely to range from"/>
   <result pre="to range from 3 to 12 days.18 Only 18% of" exact="ZIKV" post="infection cases are reported to be symptomatic, and many"/>
   <result pre="have been infected with ZIKV.13 Strong evidence now indicates that" exact="ZIKV" post="infection can cause severe fetal neurologic malformations, including microcephaly"/>
   <result pre="malformations, including microcephaly or fetal death (referred to as congenital" exact="Zika" post="syndrome).19, 20 The most severe spectrum of Zika syndrome"/>
   <result pre="as congenital Zika syndrome).19, 20 The most severe spectrum of" exact="Zika" post="syndrome pathology occurs in the unborn, including musculoskeletal, ocular,"/>
   <result pre="unborn, including musculoskeletal, ocular, craniofacial, genitourinary, pulmonary, and other abnormalities.21" exact="Zika" post="virus has also been linked to an increased incidence"/>
   <result pre="occurs predominantly in older adults.23 Since the beginning of the" exact="ZIKV" post="epidemic in French Polynesia in 2013, the incidence of"/>
   <result pre="most affected country, with estimates of 1.5 million cases of" exact="ZIKV" post="infection reported since the outbreak began.26 In 2015, the"/>
   <result pre="of GBS in Brazil in comparison with the prior year.27" exact="Zika" post="virus is transmitted by Aedes genus mosquito bites; however,"/>
   <result pre="males and mother to child transmission, have been well documented.28" exact="Zika" post="virus has been detected in bodily fluids (eg, semen,"/>
   <result pre="the longest reported period from symptom onset to detection of" exact="ZIKV" post="RNA was 9 months following infection in semen from"/>
   <result pre="from the largest cohort study to date revealed that infectious" exact="ZIKV" post="RNA shedding in semen declines during the first 3"/>
   <result pre="symptom onset.29 Notably, a recently developed synthetic DNA vaccine encoding" exact="ZIKV" post="premembrane/membrane (prM) and envelope (E) proteins entirely protected mice"/>
   <result pre="New research using pregnant rhesus macaques revealed long-standing persistence of" exact="ZIKV" post="in both maternal and fetal tissues, enhanced maternal and"/>
   <result pre="effects are different or more severe among immunocompromised persons. Given" exact="ZIKV" post="pathogenesis and cell and tissue tropism, there is an"/>
   <result pre="and tissue tropism, there is an urgent need to develop" exact="Zika" post="vaccines that have the potential to protect the public—especially"/>
   <result pre="potential to protect the public—especially pregnant women and their fetuses—from" exact="ZIKV" post="infection.32 Zika Virus Zika is an emerging, mosquito-borne, enveloped,"/>
   <result pre="protect the public—especially pregnant women and their fetuses—from ZIKV infection.32" exact="Zika" post="Virus Zika is an emerging, mosquito-borne, enveloped, nonsegmented, 10-kilobase,"/>
   <result pre="public—especially pregnant women and their fetuses—from ZIKV infection.32 Zika Virus" exact="Zika" post="is an emerging, mosquito-borne, enveloped, nonsegmented, 10-kilobase, single-stranded, positive-sense"/>
   <result pre="RNA flavivirus of global significance. Three main genetic lineages of" exact="ZIKV" post="(2 from Africa [African I and African II lineages]"/>
   <result pre="to the areas around Africa and Asia by the 2000s;" exact="ZIKV" post="then evolved into 2 distinct lineages with differential pathogenesis—African"/>
   <result pre="immune interferon (IFN) regulatory factors via NS1, NS4B, and NS5" exact="ZIKV" post="nonstructural proteins while African lineage strains have not, demonstrating"/>
   <result pre="and molecular responses between Asian and African lineages.39, 41 The" exact="Zika" post="genome is analogous to that of other Flaviviridae RNA"/>
   <result pre="of other Flaviviridae RNA viruses (ie, yellow fever, Japanese encephalitis," exact="West Nile," post="tick-borne encephalitis, and dengue type 1-4 viruses) and encodes"/>
   <result pre="is cleaved by furin protein to generate mature infectious virions." exact="Zika" post="virus E protein is the main surface protein that"/>
   <result pre="are engaged in virus propagation. Robust adaptive immune responses to" exact="ZIKV" post="E, NS1, NS3, NS4B, and NS5 proteins such as"/>
   <result pre="and T-cell responses have been detected in animal models of" exact="ZIKV" post="infection, which indicates that vaccination may protect against ZIKV"/>
   <result pre="of ZIKV infection, which indicates that vaccination may protect against" exact="ZIKV" post="disease.43, 44, 45, 46 Issues in Vaccine Development The"/>
   <result pre="45, 46 Issues in Vaccine Development The ideal vaccine against" exact="Zika" post="would require a single dose, be capable of being"/>
   <result pre="multiple vulnerable populations, the uncertain effects of prior immunity to" exact="ZIKV" post="or other flaviviruses (ie, DENV), and the lack of"/>
   <result pre="Tolerable reactogenicity and acceptable safety profile Efficacy Demonstrated prevention of" exact="ZIKV" post="illness Meets an established surrogate of immunity in animal"/>
   <result pre="= intramuscular; SC = subcutaneous; WHO = World Health Organization;" exact="ZIKV" post="= Zika virus. Data from the World Health Organization.47"/>
   <result pre="SC = subcutaneous; WHO = World Health Organization; ZIKV =" exact="Zika" post="virus. Data from the World Health Organization.47 Zika Immunology"/>
   <result pre="ZIKV = Zika virus. Data from the World Health Organization.47" exact="Zika" post="Immunology Both type I and type III IFNs are"/>
   <result pre="I and type III IFNs are produced in response to" exact="ZIKV" post="infection and can limit viral replication.50 Zika virus proteins"/>
   <result pre="in response to ZIKV infection and can limit viral replication.50" exact="Zika" post="virus proteins can actively inhibit the IFN response during"/>
   <result pre="for vaccine candidates. Many of the animal models used for" exact="ZIKV" post="work have defects in innate immune pathways; therefore, results"/>
   <result pre="diagnostic tests in areas where diseases such as dengue fever," exact="West Nile" post="virus, and yellow fever are endemic. In these geographic"/>
   <result pre="must be considered during the development and deployment of a" exact="ZIKV" post="vaccine.60 Monoclonal antibody treatment protects mice against infection,61 and"/>
   <result pre="not know if ADE could also be an issue for" exact="ZIKV" post="vaccines as it has been in the use of"/>
   <result pre="ZIKV vaccines as it has been in the use of" exact="DENV" post="vaccines; (2) vaccine responses are likely to be quite"/>
   <result pre="quite different in individuals who have no prior exposure to" exact="Zika" post="or other flaviviruses compared with those with preexisting immunity,"/>
   <result pre="and (3) it is likely that optimal humoral responses to" exact="ZIKV" post="will require T-cell help, and a solitary focus on"/>
   <result pre="titers as the only immunologic end point may be counterproductive." exact="Dengue" post="virus infection also serves as a good model of"/>
   <result pre="of cellular immunity to ZIKV. Robust T-cell responses develop after" exact="DENV" post="infection, with CD4+ T-cell responses targeting the C, E,"/>
   <result pre="In a mouse model, both vaginal and subcutaneous infection with" exact="ZIKV" post="led to the proliferation of virus-specific T cells.67 Adoptive"/>
   <result pre="humoral and cellular immunity. Vaccine Indications and Target Audience Although" exact="Zika" post="infection typically causes no or self-limited symptoms, more severe"/>
   <result pre="those who are immunocompromised. Given the destructive fetal effects of" exact="Zika" post="infection and the need to protect unborn children, it"/>
   <result pre="and under what conditions should pregnant women be included in" exact="Zika" post="vaccine trials, given the unknown possible effects on the"/>
   <result pre="tools (ie, antibodies and sequence information) available. Mouse models of" exact="ZIKV" post="infection are relatively common, and a number of strains"/>
   <result pre="number of strains have been used to examine aspects of" exact="ZIKV" post="disease.69 Zika virus has variable replication efficiency in wild-type"/>
   <result pre="strains have been used to examine aspects of ZIKV disease.69" exact="Zika" post="virus has variable replication efficiency in wild-type mouse strains"/>
   <result pre="in Swiss Jim Lambert (SJL) mice.70 Although immune responses to" exact="ZIKV" post="have been detected in a large number of larger"/>
   <result pre="lions, sheep), nonhuman primates are the model of choice for" exact="ZIKV" post="research. Rhesus and cynomolgus macaques are most commonly used."/>
   <result pre="more restrictive animal model.72 It should be noted that different" exact="ZIKV" post="strains induce different symptoms in different animals, suggesting that"/>
   <result pre="strain-dependent. The nonhuman primate studies have provided important insights into" exact="ZIKV" post="immunity, as well as efficacy testing for developmental vaccines."/>
   <result pre="will continue to be useful platforms for testing and evaluating" exact="ZIKV" post="vaccines. Current Status of Vaccine Development The recent outbreaks"/>
   <result pre="vaccines. Current Status of Vaccine Development The recent outbreaks of" exact="ZIKV" post="in the Pacific and South America significantly heightened public"/>
   <result pre="Pacific and South America significantly heightened public health awareness of" exact="Zika" post="as well as increased research interest in Zika virology,"/>
   <result pre="awareness of Zika as well as increased research interest in" exact="Zika" post="virology, pathology, epidemiology, and immunology. In March 2016, the"/>
   <result pre="epidemiology, and immunology. In March 2016, the WHO reported 18" exact="ZIKV" post="vaccine programs, and the number may have grown since"/>
   <result pre="will highlight a few of the vaccine approaches. Table 2" exact="Zika" post="Vaccines in Development Institute/company Status Vaccine(s) platform(s) Inovio Pharmaceuticals,"/>
   <result pre="1 clinical trials DNA vaccineLive VSV recombinant (early R&amp;amp;D)Live attenuated" exact="ZIKV" post="(early R&amp;amp;D) WRAIR/Sanofi Pasteur Limited In phase 1 clinical"/>
   <result pre="Purified inactivated virusYF17DD chimeraVLPDNA US CDC Early-stage research VLP expressing" exact="ZIKV" post="DNALive adenovirus recombinant CureVac AG Early-stage research Thermostabile mRNA-based"/>
   <result pre="Clinic Vaccine Research Group Early-stage research Naturally processed and HLA-presented" exact="ZIKV" post="peptides packaged with biodegradable nanoparticles Moderna, Inc Early-stage research"/>
   <result pre="stomatitis virus; WRAIR = Walter Reed Army Institute of Research;" exact="ZIKV" post="= Zika virus. The Walter Reed Army Institute of"/>
   <result pre="WRAIR = Walter Reed Army Institute of Research; ZIKV =" exact="Zika" post="virus. The Walter Reed Army Institute of Research has"/>
   <result pre="transfer into mice significantly reduced or eliminated viral titers following" exact="ZIKV" post="challenge.74 Adverse effects were reported by 84% of recipients"/>
   <result pre="adults (NCT03611946). This vaccine is constructed on the backbone of" exact="DENV" post="serotype 4 and expresses ZIKV surface proteins. The virus"/>
   <result pre="constructed on the backbone of DENV serotype 4 and expresses" exact="ZIKV" post="surface proteins. The virus vector has been attenuated through"/>
   <result pre="modified to remove epitopes in regions known to contribute to" exact="DENV" post="ADE.77 Uridines have also been replaced with 1-methylpseudouridine in"/>
   <result pre="or without the booster immunization) were protected against a lethal" exact="ZIKV" post="challenge. A lower vaccine dose (2 ug) resulted in"/>
   <result pre="Mice were pretreated with IFNAR-blocking antibody and then challenged with" exact="ZIKV" post="(Dakar 41519). Unimmunized mice developed high levels of viremia,"/>
   <result pre="prM and E proteins of a French Polynesian strain of" exact="ZIKV" post="(H/PF/2013). It is currently undergoing a phase 2 clinical"/>
   <result pre="the prM and E proteins of the H/PF/2013 strain of" exact="ZIKV" post="(NCT02840487).78, 79 Animal studies demonstrated that these vaccine candidates"/>
   <result pre="the IXIARO Japanese encephalitis vaccine. After 2016, the number of" exact="ZIKV" post="cases has decreased to the point that phase 3"/>
   <result pre="advantages that would be ideally suited for use as a" exact="ZIKV" post="vaccine: inexpensive to manufacture, safe for universal administration, no"/>
   <result pre="and a Look Ahead We believe that safe and effective" exact="Zika" post="vaccines can be developed and approved; however, major concerns"/>
   <result pre="be developed and approved; however, major concerns exist. First, because" exact="Zika" post="outbreaks have essentially ceased and are unpredictable, it is"/>
   <result pre="given current realities, it is likely that more than one" exact="Zika" post="vaccine type may need to be developed. For example,"/>
   <result pre="immunity. Third, more research is necessary to determine what the" exact="Zika" post="infection outcomes of interest are that we want vaccine"/>
   <result pre="are that we want vaccine to prevent. Is it GBS?" exact="Zika" post="congenital conditions? Latent infection and persistence in gonadal organs?"/>
   <result pre="insights in immunology have combined to accelerate vaccine development against" exact="Zika" post="virus. Multiple vaccine candidates are already in preclinical through"/>
   <result pre="studies of efficacy. This is remarkable given the fact that" exact="Zika" post="virus went relatively unnoticed until the large outbreaks in"/>
   <result pre="is likely that in the private sector, the costs of" exact="Zika" post="vaccine development cannot be recouped due to the relative"/>
   <result pre="authorities. In the meantime, limited history thus far suggests that" exact="ZIKV" post="outbreaks can strike and abate relatively rapidly, with limited"/>
   <result pre="further mutational divergence of strains and the development of new" exact="Zika" post="clades that may require more than a monotypic vaccine"/>
   <result pre="and well-being of the globe requires a safe and effective" exact="Zika" post="vaccine. For couples of childbearing age desiring to have"/>
   <result pre="of childbearing age desiring to have children, the prospect of" exact="Zika" post="infection is terrifying. Maternal infections can and do lead"/>
   <result pre="among us—the yet unborn—depends on our efforts. References References 1LoweR.BarcellosC.BrasilP.The" exact="Zika" post="virus epidemic in Brazil: from discovery to future implicationsInt"/>
   <result pre="Control and PreventionZika virus: statistics and mapshttps://www.cdc.gov/zika/reporting/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fzika%2Freporting%2Fcase-counts.html 4LederK.GrobuschM.P.GautretP.GeoSentinel Surveillance Network." exact="Zika" post="beyond the Americas: travelers as sentinels of Zika virus"/>
   <result pre="Surveillance Network. Zika beyond the Americas: travelers as sentinels of" exact="Zika" post="virus transmission; a GeoSentinel analysis, 2012 to 2016PLoS One12102017e018568928973011"/>
   <result pre="GeoSentinel analysis, 2012 to 2016PLoS One12102017e018568928973011 5HamerD.H.BarbreK.A.ChenL.H.GeoSentinel Surveillance Network. Travel-associated" exact="Zika" post="virus disease acquired in the Americas through February 2016:"/>
   <result pre="6Wilder-SmithA.ChangC.R.LeongW.Y.Zika in travellers 1947-2017: a systematic reviewJ Trav Med2512018 7WattsA.G.HuberC.BogochIIBradyO.J.KraemerM.U.G.KhanK.Potential" exact="Zika" post="virus spread within and beyond IndiaJ Trav Med2512018 8HamerD.H.ChenL.H.Zika"/>
   <result pre="other African settingsTrans R Soc Trop Med Hyg11111201752752929394415 10BogochI.I.BradyO.J.KraemerM.U.G.Potential for" exact="Zika" post="virus introduction and transmission in resource-limited countries in Africa"/>
   <result pre="11RocklövJ.QuamM.B.SudreB.Assessing seasonal risks for the introduction and mosquito-borne spread of" exact="Zika" post="virus in EuropeEBioMedicine9201625025627344225 12DickG.W.KitchenS.F.HaddowA.J.Zika virus, I: Isolations and serological"/>
   <result pre="distribution and burden of dengueNature4967446201350450723563266 15BogochIIBradyO.J.KraemerM.U.G.Anticipating the international spread of" exact="Zika" post="virus from BrazilLancet38710016201633533626777915 16collab: Centers for Disease Control and"/>
   <result pre="Engl J Med. 2016;375(5):498]N Engl J Med375120161427222919 20PanchaudA.StojanovM.AmmerdorfferA.VougaM.BaudD.Emerging role of" exact="Zika" post="virus in adverse fetal and neonatal outcomesClin Microbiol Rev293201665969427281741"/>
   <result pre="we knowArch Pathol Lab Med14112017263227636525 22BarbiL.CoelhoA.V.C.AlencarL.C.A.CrovellaS.Prevalence of Guillain-Barré syndrome among" exact="Zika" post="virus infected cases: a systematic review and meta-analysisBraz J"/>
   <result pre="French Polynesia, December 2013Euro Surveill1992014 25Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barré syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet3871002720161531153926948433 26World"/>
   <result pre="OrganizationGuillain-Barré syndrome – Brazilhttps://www.who.int/csr/don/8-february-2016-gbs-brazil/en/Published February 8, 2016 28GrischottF.PuhanM.HatzC.SchlagenhaufP.Non-vector-borne transmission of" exact="Zika" post="virus: a systematic reviewTravel Med Infect Dis144201631333027425793 29MeadP.S.DuggalN.K.HookS.A.Zika virus"/>
   <result pre="infected menN Engl J Med3781520181377138529641964 30GriffinB.D.MuthumaniK.WarnerB.M.DNA vaccination protects mice against" exact="Zika" post="virus-induced damage to the testesNat Commun820171574328589934 31HirschA.J.RobertsV.H.J.GrigsbyP.L.Zika virus infection"/>
   <result pre="causes placental dysfunction and immunopathologyNat Commun91201826329343712 32PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect Dis1872018e211e21929396004 33ShenS.ShiJ.WangJ.Phylogenetic analysis revealed the central roles"/>
   <result pre="two African countries in the evolution and worldwide spread of" exact="Zika" post="virusVirol Sin312201611813027129451 34LanciottiR.S.LambertA.J.HolodniyM.SaavedraS.Signor LdelC.Phylogeny of Zika virus in Western"/>
   <result pre="and worldwide spread of Zika virusVirol Sin312201611813027129451 34LanciottiR.S.LambertA.J.HolodniyM.SaavedraS.Signor LdelC.Phylogeny of" exact="Zika" post="virus in Western Hemisphere, 2015Emerg Infect Dis225201693393527088323 35TognarelliJ.UlloaS.VillagraE.A report"/>
   <result pre="Hemisphere, 2015Emerg Infect Dis225201693393527088323 35TognarelliJ.UlloaS.VillagraE.A report on the outbreak of" exact="Zika" post="virus on Easter Island, South Pacific, 2014Arch Virol1613201666566826611910 36FauciA.S.MorensD.M.Zika"/>
   <result pre="Americas—yet another arbovirus threatN Engl J Med3747201660160426761185 37SmithD.R.SpragueT.R.HollidgeB.S.African and Asian" exact="Zika" post="virus isolates display phenotypic differences both in vitro and"/>
   <result pre="Americas: early epidemiological and genetic findingsScience3526283201634534927013429 39BeaverJ.T.LelutiuN.HabibR.SkountzouI.Evolution of two major" exact="Zika" post="virus lineages: implications for pathology, immune response, and vaccine"/>
   <result pre="and vaccine developmentFront Immunol92018164030072993 40WangL.ZhaoH.OlivaS.M.ZhuH.Modeling the transmission and control of" exact="Zika" post="in BrazilSci Rep712017772128798323 41MladinichM.C.SchwedesJ.MackowE.R.Zika virus persistently infects and is"/>
   <result pre="type I interferon signalingCell Host Microbe196201688289027212660 43WinklerC.W.MyersL.M.WoodsT.A.Adaptive immune responses to" exact="Zika" post="virus are important for controlling virus infection and preventing"/>
   <result pre="and testesJ Immunol198920173526353528330900 44PardyR.D.RajahM.M.CondottaS.A.TaylorN.G.SaganS.M.RicherM.J.Analysis of the T cell response to" exact="Zika" post="virus and identification of a novel CD8+ T cell"/>
   <result pre="virus protection by a single low-dose nucleoside-modified mRNA vaccinationNature5437644201724825128151488 46BraultA.C.DomiA.McDonaldE.M.A" exact="Zika" post="vaccine targeting NS1 protein protects immunocompetent adult mice in"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine376201986386830639461 49Wilder-SmithA.VanniceK.DurbinA.Zika vaccines and therapeutics: landscape analysis and"/>
   <result pre="landscape analysis and challenges aheadBMC Med16120188429871628 50LazearH.M.GoveroJ.SmithA.M.A mouse model of" exact="Zika" post="virus pathogenesisCell Host Microbe195201672073027066744 51BowenJ.R.ZimmermanM.G.SutharM.S.Taking the defensive: immune control"/>
   <result pre="virus pathogenesisCell Host Microbe195201672073027066744 51BowenJ.R.ZimmermanM.G.SutharM.S.Taking the defensive: immune control of" exact="Zika" post="virus infectionVirus Res2542018212628867493 52MartinotA.J.AbbinkP.AfacanO.Fetal neuropathology in Zika virus-infected pregnant"/>
   <result pre="immune control of Zika virus infectionVirus Res2542018212628867493 52MartinotA.J.AbbinkP.AfacanO.Fetal neuropathology in" exact="Zika" post="virus-infected pregnant female rhesus monkeysCell1735201811111122.e1029606355 53MohrE.L.BlockL.N.NewmanC.M.Ocular and uteroplacental pathology"/>
   <result pre="53MohrE.L.BlockL.N.NewmanC.M.Ocular and uteroplacental pathology in a macaque pregnancy with congenital" exact="Zika" post="virus infectionPLoS One1312018e019061729381706 54KumarM.KrauseK.K.AzouzF.NakanoE.NerurkarV.R.A guinea pig model of Zika"/>
   <result pre="congenital Zika virus infectionPLoS One1312018e019061729381706 54KumarM.KrauseK.K.AzouzF.NakanoE.NerurkarV.R.A guinea pig model of" exact="Zika" post="virus infectionVirol J14120177528399888 55GoodfellowF.T.TeslaB.SimchickG.Zika virus induced mortality and microcephaly"/>
   <result pre="and microcephaly in chicken embryosStem Cells Dev252220161691169727627457 56ShahS.K.KimmelmanJ.LyerlyA.Ethical considerations for" exact="Zika" post="virus human challenge trials: report and recommendationshttps://www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeStudiesReport2017.pdfPublished February 2017"/>
   <result pre="challenge trials: report and recommendationshttps://www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeStudiesReport2017.pdfPublished February 2017 57DaiL.SongJ.LuX.Structures of the" exact="Zika" post="virus envelope protein and its complex with a flavivirus"/>
   <result pre="flavivirus broadly protective antibodyCell Host Microbe195201669670427158114 58SapparapuG.FernandezE.KoseN.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature5407633201644344727819683 59PriyamvadaL.QuickeK.M.HudsonW.H.Human antibody"/>
   <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virusProc Natl Acad Sci U S A1132820167852785727354515 60Rodriguez-MoralesA.J.Villamil-GómezW.E.Franco-ParedesC.The arboviral"/>
   <result pre="disease caused by co-circulation and co-infection of dengue, chikungunya and" exact="Zika" post="in the AmericasTravel Med Infect Dis143201617717927224471 61ZhaoH.FernandezE.DowdK.A.Structural basis of"/>
   <result pre="Zika in the AmericasTravel Med Infect Dis143201617717927224471 61ZhaoH.FernandezE.DowdK.A.Structural basis of" exact="Zika" post="virus-specific antibody protectionCell166420161016102727475895 62LaroccaR.A.AbbinkP.PeronJ.P.Vaccine protection against Zika virus from"/>
   <result pre="61ZhaoH.FernandezE.DowdK.A.Structural basis of Zika virus-specific antibody protectionCell166420161016102727475895 62LaroccaR.A.AbbinkP.PeronJ.P.Vaccine protection against" exact="Zika" post="virus from BrazilNature5367617201647447827355570 63WeiskopfD.AngeloM.A.de AzeredoE.L.Comprehensive analysis of dengue virus-specific"/>
   <result pre="Acad Sci U S A110222013E2046E205323580623 64RothC.DelgadoF.G.Simon-LorièreE.SakuntabhaiA.Immune responses to dengue and" exact="Zika" post="viruses—guidance for T cell vaccine developmentInt J Environ Res"/>
   <result pre="Health1522018385 65GrifoniA.PhamJ.SidneyJ.Prior dengue virus exposure shapes T cell immunity to" exact="Zika" post="virus in humansJ Virol91242017 66TurtleL.BaliT.BuxtonG.Human T cell responses to"/>
   <result pre="diseaseJ Exp Med213720161331135227242166 67ScottJ.M.LebrattiT.J.RichnerJ.M.Cellular and humoral immunity protect against vaginal" exact="Zika" post="virus infection in miceJ Virol9272018 68collab: Ethics Working Group"/>
   <result pre="virus infection in miceJ Virol9272018 68collab: Ethics Working Group on" exact="ZIKV" post="Research &amp;amp; PregnancyPregnant Women &amp;amp; the Zika Virus Vaccine"/>
   <result pre="Working Group on ZIKV Research &amp;amp; PregnancyPregnant Women &amp;amp; the" exact="Zika" post="Virus Vaccine Research Agenda: Ethics Guidance on Priorities, Inclusion,"/>
   <result pre="Priorities, Inclusion, and Evidence Generationhttp://guidance.zikapregnancyethics.org/wp-content/uploads/2017/08/Full+Guidance-Pregnant-Women-the-Zika-Virus-Vaccine-Research-Agenda_optimized.pdfPublished June 2017 69BradleyM.P.NagamineC.M.Animal models of" exact="Zika" post="virusComp Med673201724225228662753 70CugolaF.R.FernandesI.R.RussoF.B.The Brazilian Zika virus strain causes birth"/>
   <result pre="June 2017 69BradleyM.P.NagamineC.M.Animal models of Zika virusComp Med673201724225228662753 70CugolaF.R.FernandesI.R.RussoF.B.The Brazilian" exact="Zika" post="virus strain causes birth defects in experimental modelsNature5347606201626727127279226 71JoguetG.MansuyJ.M.MatusaliG.Effect"/>
   <result pre="strain causes birth defects in experimental modelsNature5347606201626727127279226 71JoguetG.MansuyJ.M.MatusaliG.Effect of acute" exact="Zika" post="virus infection on sperm and virus clearance in body"/>
   <result pre="Virol182016646927093699 73AbbinkP.LaroccaR.A.De La BarreraR.A.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience353630420161129113227492477 74ModjarradK.LinL.GeorgeS.L.Preliminary aggregate safety and"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="regionAm J Trop Med Hyg655200140541311716091 77RichnerJ.M.HimansuS.DowdK.A.Modified mRNA vaccines protect against" exact="Zika" post="virus infection[published correction appears in Cell. 2017;169(1):176]Cell1686201711141125.e1028222903 78GaudinskiM.R.HouserK.V.MorabitoK.M.VRC 319"/>
   <result pre="VRC 320 Study Teams. Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
   <result pre="1 clinical trialsLancet39110120201855256229217376 79DowdK.A.KoS.Y.MorabitoK.M.Rapid development of a DNA vaccine for" exact="Zika" post="virusScience3546309201623724027708058 80Emergent BioSolutions and Valneva report positive phase 1"/>
   <result pre="positive phase 1 results for their vaccine candidate against the" exact="Zika" post="virus. GlobeNewswire websitehttp://globenewswire.com/news-release/2018/11/19/1654097/0/en/Emergent-BioSolutions-and-Valneva-Report-Positive-Phase-1-Results-for-Their-Vaccine-Candidate-Against-the-Zika-Virus.html?culture=en-us2018Published November 19, 2018 81GruberM.F.FarizoK.M.PrattR.D.Clinical development strategies"/>
   <result pre="websitehttp://globenewswire.com/news-release/2018/11/19/1654097/0/en/Emergent-BioSolutions-and-Valneva-Report-Positive-Phase-1-Results-for-Their-Vaccine-Candidate-Against-the-Zika-Virus.html?culture=en-us2018Published November 19, 2018 81GruberM.F.FarizoK.M.PrattR.D.Clinical development strategies and considerations for" exact="Zika" post="vaccine licensureJ Infect Dis216suppl 102017S964S97029267913 Supplemental Online Material Supplemental"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7100368\results\search\tropicalVirus\results.xml">
   <result pre="Media S.A. pmcid: 7100368 doi: 10.3389/fmicb.2020.00362 : Microbiology: Review Defeat" exact="Dengue" post="and Zika Viruses With a One-Two Punch of Vaccine"/>
   <result pre="pmcid: 7100368 doi: 10.3389/fmicb.2020.00362 : Microbiology: Review Defeat Dengue and" exact="Zika" post="Viruses With a One-Two Punch of Vaccine and Vector"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Dengue" post="virus (DENV) and Zika virus (ZIKV) are two mosquito-borne"/>
   <result pre="not comply with these terms. Abstract Dengue virus (DENV) and" exact="Zika" post="virus (ZIKV) are two mosquito-borne flaviviruses afflicting nearly half"/>
   <result pre="be manifested as hemorrhagic fever and hemorrhagic shock syndrome, and" exact="ZIKV" post="infection has been linked to increased incidence of peripheral"/>
   <result pre="these infectious diseases are either non-satisfactory or entirely lacking. Because" exact="DENV" post="and ZIKV have much similarities in genomic and structural"/>
   <result pre="diseases are either non-satisfactory or entirely lacking. Because DENV and" exact="ZIKV" post="have much similarities in genomic and structural features, almost"/>
   <result pre="countermeasures against both. Here, we review the existing knowledge on" exact="DENV" post="and ZIKV regarding epidemiology, molecular virology, protective immunity and"/>
   <result pre="both. Here, we review the existing knowledge on DENV and" exact="ZIKV" post="regarding epidemiology, molecular virology, protective immunity and vaccine development,"/>
   <result pre="vaccine and vector blockade to overcome antibody-dependent enhancement and defeat" exact="Dengue" post="and Zika viruses. dengue virus Zika virus epidemiology virology"/>
   <result pre="vector blockade to overcome antibody-dependent enhancement and defeat Dengue and" exact="Zika" post="viruses. dengue virus Zika virus epidemiology virology protective immunity"/>
   <result pre="antibody-dependent enhancement and defeat Dengue and Zika viruses. dengue virus" exact="Zika" post="virus epidemiology virology protective immunity vaccine mosquitoes Funding National"/>
   <result pre="Shanghai Municipality10.13039/501100003399 fig-count: table-count: equation-count: ref-count: page-count: word-count: Epidemiology of" exact="Dengue" post="Virus and Zika Virus Dengue virus (DENV) is the"/>
   <result pre="table-count: equation-count: ref-count: page-count: word-count: Epidemiology of Dengue Virus and" exact="Zika" post="Virus Dengue virus (DENV) is the most prevalent mosquito-borne"/>
   <result pre="ref-count: page-count: word-count: Epidemiology of Dengue Virus and Zika Virus" exact="Dengue" post="virus (DENV) is the most prevalent mosquito-borne flavivirus that"/>
   <result pre="population in 128 countries and regions (Brady et al., 2012)." exact="Zika" post="virus (ZIKV) is another virus that has caught public"/>
   <result pre="during 2014–2016 (Baud et al., 2017). The transmitting vectors of" exact="DENV" post="and ZIKV are Aedes mosquitoes, mainly A. aegypti and"/>
   <result pre="(Baud et al., 2017). The transmitting vectors of DENV and" exact="ZIKV" post="are Aedes mosquitoes, mainly A. aegypti and A. albopictus"/>
   <result pre="but also have features that are distinct from each other." exact="Dengue" post="viruses are antigenically classified into four serotypes that originate"/>
   <result pre="(mostly children) progress to more severe forms of dengue disease," exact="Dengue" post="Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS), in"/>
   <result pre="severe forms of dengue disease, Dengue Hemorrhagic Fever (DHF) and" exact="Dengue" post="Shock Syndrome (DSS), in which plasma leakage and hemorrhagic"/>
   <result pre="al., 1984; Guzman et al., 2013; Katzelnick et al., 2017)." exact="Dengue" post="like disease has been a public health problem for"/>
   <result pre="the only licensed vaccine is far from satisfactory. In comparison," exact="Zika" post="virus emerged more recently as a public health concern."/>
   <result pre="recently as a public health concern. The historical documents of" exact="Zika" post="virus started as its first isolation from a monkey"/>
   <result pre="virus started as its first isolation from a monkey in" exact="Zika" post="forest of Uganda in 1947 (Dick et al., 1952)."/>
   <result pre="(Duffy et al., 2009; Grard et al., 2014). Symptoms of" exact="ZIKV" post="infection including fever, arthralgia, rash and conjunctivitis were presented"/>
   <result pre="was observed for the first time to be associated with" exact="Zika" post="virus infection, implicating the neurotropic feature of Zika virus"/>
   <result pre="associated with Zika virus infection, implicating the neurotropic feature of" exact="Zika" post="virus (Musso et al., 2018); additionally, detection of viral"/>
   <result pre="were also documented during this outbreak. Nevertheless, the threat of" exact="Zika" post="virus was not recognized until 2015–2016 when it caused"/>
   <result pre="from northeast region of Brazil (Faria et al., 2017), where" exact="Zika" post="virus infected 63% peoples in Salvador. The virus spread"/>
   <result pre="and pacific islands (Baud et al., 2017). In Europe, travel-associated" exact="ZIKV" post="cases were reported in most EU (European Union) countries"/>
   <result pre="the Caribbean (Spiteri et al., 2017). During the Brazil outbreak," exact="ZIKV" post="has been suspected to persistently replicate in multiple organs"/>
   <result pre="babies (Weaver et al., 2016). Soon after, the association between" exact="Zika" post="virus infection and microcephaly was confirmed by extensive studies"/>
   <result pre="2017; Szaba et al., 2018). Furthermore, in vivo replication of" exact="ZIKV" post="in neuron, placenta and fetus was also verified by"/>
   <result pre="Mlakar et al., 2016). Since early 2016, WHO has declared" exact="Zika" post="virus disease as a public health emergency of global"/>
   <result pre="health emergency of global concern. It should be noted that" exact="ZIKV" post="and DENV spread through the same Aedes mosquito vectors"/>
   <result pre="of global concern. It should be noted that ZIKV and" exact="DENV" post="spread through the same Aedes mosquito vectors in overlapping"/>
   <result pre="and genomic structures should be of value. Virological Features of" exact="Dengue" post="Virus and Zika Virus Both Dengue virus and Zika"/>
   <result pre="should be of value. Virological Features of Dengue Virus and" exact="Zika" post="Virus Both Dengue virus and Zika virus belong to"/>
   <result pre="value. Virological Features of Dengue Virus and Zika Virus Both" exact="Dengue" post="virus and Zika virus belong to the genus of"/>
   <result pre="of Dengue Virus and Zika Virus Both Dengue virus and" exact="Zika" post="virus belong to the genus of flavivirus in the"/>
   <result pre="NS2A, NS2B, NS3, NS4A, NS5). Generally, the sequence homology between" exact="DENV" post="and ZIKV polyprotein is 55–56%, whereas the homology among"/>
   <result pre="NS3, NS4A, NS5). Generally, the sequence homology between DENV and" exact="ZIKV" post="polyprotein is 55–56%, whereas the homology among four serotype"/>
   <result pre="infected cells form the major architecture of viral particles of" exact="ZIKV" post="and DENV, whereas the non-structural proteins (except for NS1)"/>
   <result pre="recent study at 9 Å resolution showed structure of immature" exact="Zika" post="virus and demonstrated that there was a regular but"/>
   <result pre="capsid inside the membrane, implying a dynamical morphological alteration during" exact="Zika" post="virus maturation (Prasad et al., 2017). Despite minor differences,"/>
   <result pre="(Prasad et al., 2017). Despite minor differences, the structures of" exact="DENV" post="and ZIKV are generally similar. A noted difference exists"/>
   <result pre="al., 2017). Despite minor differences, the structures of DENV and" exact="ZIKV" post="are generally similar. A noted difference exists in a"/>
   <result pre="exists in a region surrounding glycosylation site at Asn154 of" exact="ZIKV" post="envelope protein and Asn153 of DENV envelope protein, these"/>
   <result pre="site at Asn154 of ZIKV envelope protein and Asn153 of" exact="DENV" post="envelope protein, these sites may influence virus transmission and"/>
   <result pre="surface. Functionally, in contrast to the mature virus, the immature" exact="DENV" post="and ZIKV are non-infectious, however, such immature virus particle"/>
   <result pre="in contrast to the mature virus, the immature DENV and" exact="ZIKV" post="are non-infectious, however, such immature virus particle can also"/>
   <result pre="et al., 2017; Bailey et al., 2018). Cell Tropism of" exact="Dengue" post="Virus and Zika Virus Transmission of DENV and ZIKV"/>
   <result pre="Bailey et al., 2018). Cell Tropism of Dengue Virus and" exact="Zika" post="Virus Transmission of DENV and ZIKV are mainly mediated"/>
   <result pre="Cell Tropism of Dengue Virus and Zika Virus Transmission of" exact="DENV" post="and ZIKV are mainly mediated by Aedes mosquitoes. When"/>
   <result pre="of Dengue Virus and Zika Virus Transmission of DENV and" exact="ZIKV" post="are mainly mediated by Aedes mosquitoes. When human is"/>
   <result pre="monocyte was the principle target cell among PBMCs for both" exact="DENV" post="and ZIKV infection, as well as the main mediators"/>
   <result pre="the principle target cell among PBMCs for both DENV and" exact="ZIKV" post="infection, as well as the main mediators for ADE"/>
   <result pre="circulating CD14 + monocytes were the primary cellular targets of" exact="ZIKV" post="infection in PBMCs (Foo et al., 2017; Michlmayr et"/>
   <result pre="disseminate through the circulatory and lymphatic system, dengue virus and" exact="Zika" post="virus spread to different tissues and organs. Dengue virus"/>
   <result pre="virus and Zika virus spread to different tissues and organs." exact="Dengue" post="virus infects primary vascular endothelial cells, splenic macrophage and"/>
   <result pre="2007; Dalrymple and Mackow, 2012). In contrast, besides these tissues," exact="Zika" post="virus also replicates in uterus and many immune privileged"/>
   <result pre="neuropathology, congenital disorders, and damages to reproductive organs. So far," exact="Zika" post="virus has been found to infect a wide range"/>
   <result pre="and Diamond, 2017; Qian et al., 2017). Several investigations indicated" exact="Zika" post="virus infects endothelial cells, the key component of blood"/>
   <result pre="tissue barriers, a fact that may help to explain how" exact="Zika" post="virus crosses blood brain barrier and placental barrier (Liu"/>
   <result pre="al., 2017). However, it is still controversial as to whether" exact="Zika" post="virus infection alters endothelial barrier integrity. A recent study"/>
   <result pre="infection alters endothelial barrier integrity. A recent study showed that" exact="ZIKV" post="infection of human umbilical vein endothelial cells (HUVECs) increased"/>
   <result pre="et al., 2019), whereas some other studies have demonstrated that" exact="Zika" post="virus directionally infected polarized epithelial cells from apical side"/>
   <result pre="of cell monolayer integrity (Tamhankar and Patterson, 2019). Understanding of" exact="ZIKV" post="cell tropism and dissemination across blood tissue barriers will"/>
   <result pre="dissemination across blood tissue barriers will help to better elucidate" exact="Zika" post="pathology, and provide opportunity for the development of efficient"/>
   <result pre="tissue tropism should also been considered during development of prophylactic" exact="ZIKV" post="vaccine. Its criteria for protective efficacies need to include"/>
   <result pre="Shan et al., 2017; Zou et al., 2018). Different from" exact="DENV" post="vaccine candidates, ZIKV vaccine might have to elicit higher"/>
   <result pre="2017; Zou et al., 2018). Different from DENV vaccine candidates," exact="ZIKV" post="vaccine might have to elicit higher level of immune"/>
   <result pre="studies of the incidence of fetal microcephaly in women received" exact="ZIKV" post="vaccine are also necessary in clinical trials. The Benefits"/>
   <result pre="clinical trials. The Benefits and Limitations of the Only Licensed" exact="Dengue" post="Vaccine With effort that lasted two decades, the first"/>
   <result pre="itself. Last but not the least, whether the emergence of" exact="Zika" post="virus in DENV endemic regions and prior ZIKV immunity"/>
   <result pre="not the least, whether the emergence of Zika virus in" exact="DENV" post="endemic regions and prior ZIKV immunity in vaccine recipients"/>
   <result pre="emergence of Zika virus in DENV endemic regions and prior" exact="ZIKV" post="immunity in vaccine recipients will affect the efficacy of"/>
   <result pre="unknown, and whether vaccination by Dengvaxia will enhance or prevent" exact="Zika" post="virus infection is also uncertain. As co-circulation of two"/>
   <result pre="uncertain. As co-circulation of two viruses and complicated interference between" exact="Dengue" post="and Zika virus-specific immunity have already been observed (Bardina"/>
   <result pre="co-circulation of two viruses and complicated interference between Dengue and" exact="Zika" post="virus-specific immunity have already been observed (Bardina et al.,"/>
   <result pre="al., 2019), it is worthwhile taking the probable influence of" exact="ZIKV" post="into consideration during dengue vaccine development. Therefore, either the"/>
   <result pre="new vaccines must be applied judiciously in epidemic regions. Other" exact="Dengue" post="and Zika Vaccines Currently in Clinical Trials Other Dengue"/>
   <result pre="must be applied judiciously in epidemic regions. Other Dengue and" exact="Zika" post="Vaccines Currently in Clinical Trials Other Dengue Vaccines in"/>
   <result pre="Other Dengue and Zika Vaccines Currently in Clinical Trials Other" exact="Dengue" post="Vaccines in Clinical Trials Besides the approved dengue vaccine"/>
   <result pre="protein vaccine, and one DNA vaccine (Table 1). TABLE 1" exact="Dengue" post="vaccines in clinical trials. Name Vaccine type Immunogen Developer"/>
   <result pre="on the backbone of attenuated DENV-4 NIAID/Butantan Institute Phase III" exact="DENV" post="subunit V180 Subunit protein Ectodomain (N-terminal 80%) of envelope"/>
   <result pre="antibody and provide protection against challenge with multiple serotypes of" exact="DENV" post="in murine and non-human primate models (Clements et al.,"/>
   <result pre="al., 2012), much of its results have not been published." exact="Zika" post="Vaccines in Clinical Trials In contrast to Dengue vaccines,"/>
   <result pre="been published. Zika Vaccines in Clinical Trials In contrast to" exact="Dengue" post="vaccines, Zika vaccines have only been developed recently since"/>
   <result pre="Zika Vaccines in Clinical Trials In contrast to Dengue vaccines," exact="Zika" post="vaccines have only been developed recently since the large"/>
   <result pre="Zika vaccines have only been developed recently since the large" exact="ZIKV" post="outbreaks in 2015–2016. Multiple candidates are under development simultaneously,"/>
   <result pre="II clinical trials will be discussed (Table 2). TABLE 2" exact="Zika" post="vaccines in clinical trials. Name Vaccine type Immunogen Developers"/>
   <result pre="injection &amp;amp; electroporation GeneOne life science Inc./Inovio Pharmaceuticals Phase I" exact="ZIKV" post="purified inactivated vaccine (ZPIV) Inactivated vaccine Formalin-inactivated whole virus"/>
   <result pre="Valneva Australia GmbH Phase I rZIKV/D4delta30 Chimeric live attenuated vaccine" exact="ZIKV" post="prM and E genes inserted to DEN4delta30 NIAID Phase"/>
   <result pre="genes inserted to DEN4delta30 NIAID Phase I MV-ZIKA Viral vector" exact="ZIKV" post="prM and E genges inserted to measles virus vector"/>
   <result pre="prM and E ModernaTX, Inc. Phase I The most advanced" exact="Zika" post="vaccine candidates is a DNA vaccine containing Zika virus"/>
   <result pre="most advanced Zika vaccine candidates is a DNA vaccine containing" exact="Zika" post="virus prM and E genes (VRC5283) that is being"/>
   <result pre="DNA vaccine GLS-5700 (developed by GeneOne/Inovio) containing consensus sequences of" exact="ZIKV" post="prM and E genes, delivered via intradermal injection followed"/>
   <result pre="from vaccine recipients protected 92% immune deficient mice from lethal" exact="ZIKV" post="challenge (Tebas et al., 2017). The development of inactivated"/>
   <result pre="ZIKV challenge (Tebas et al., 2017). The development of inactivated" exact="Zika" post="vaccine was started soon after the ZIKV outbreaks. There"/>
   <result pre="development of inactivated Zika vaccine was started soon after the" exact="ZIKV" post="outbreaks. There are currently two purified inactivated Zika vaccine"/>
   <result pre="after the ZIKV outbreaks. There are currently two purified inactivated" exact="Zika" post="vaccine candidates in Phase I clinical trials, they were"/>
   <result pre="IgG from vaccine recipients to mice prior to challenge with" exact="ZIKV" post="led to reduced viremia in mice, indicating its potential"/>
   <result pre="a similar strategy for DENV-2 vaccine TV003/TV005, recombinant live attenuated" exact="Zika" post="vaccine has been constructed with the backbone of attenuated"/>
   <result pre="I clinical trial, and might be tested in combination with" exact="DENV" post="vaccine TV005 in the future (ID: NCT03611946) (Durbin and"/>
   <result pre="Measles vaccine virus has also been adapted to construct chimeric" exact="ZIKV" post="vaccine. One of such vaccine, MV-ZIKA, has been developed"/>
   <result pre="lipid nanoparticle-encapsulated modified mRNA has also been used to develop" exact="Zika" post="vaccine. An mRNA that contains prM-E genes of ZIKV"/>
   <result pre="develop Zika vaccine. An mRNA that contains prM-E genes of" exact="ZIKV" post="and optimized 5′ and 3′ untranslated sequences with type-1"/>
   <result pre="high titers (∼1/100,000) of neutralizing antibodies, and conferred protection against" exact="ZIKV" post="challenge in mice (Richner et al., 2017a). An mRNA-based"/>
   <result pre="Phase I clinical trial (ID: NCT03014089). Besides, other forms of" exact="ZIKV" post="vaccine, such as protein based subunit vaccine (Medina et"/>
   <result pre="et al., 2019; Slon-Campos et al., 2019) and live attenuated" exact="Zika" post="vaccines (Richner et al., 2017b; Xie et al., 2018;"/>
   <result pre="at the pre-clinical stage. Considering the cross-reactivity and ADE between" exact="ZIKV" post="and DENV, newly developed ZIKV vaccine should also be"/>
   <result pre="the cross-reactivity and ADE between ZIKV and DENV, newly developed" exact="ZIKV" post="vaccine should also be tested for DENV enhancement activity."/>
   <result pre="DENV, newly developed ZIKV vaccine should also be tested for" exact="DENV" post="enhancement activity. This additional requirement will likely to be"/>
   <result pre="requirement will likely to be a huge obstacle for both" exact="ZIKV" post="and DENV vaccines. Protective Immunity Against Dengue and Zika"/>
   <result pre="likely to be a huge obstacle for both ZIKV and" exact="DENV" post="vaccines. Protective Immunity Against Dengue and Zika Viruses Protective"/>
   <result pre="obstacle for both ZIKV and DENV vaccines. Protective Immunity Against" exact="Dengue" post="and Zika Viruses Protective Antibody Response Although various antibodies"/>
   <result pre="both ZIKV and DENV vaccines. Protective Immunity Against Dengue and" exact="Zika" post="Viruses Protective Antibody Response Although various antibodies targeting different"/>
   <result pre="indicated that E domain III was the predominant targets for" exact="DENV" post="neutralizing antibodies, and antibodies to this region are mainly"/>
   <result pre="III specific neutralizing antibodies only constitute a small proportion of" exact="DENV" post="antibody repertoire. Mapping antibody epitope using recombinant envelope proteins,"/>
   <result pre="Rouvinski et al., 2015). On the contrary, the importance of" exact="ZIKV" post="EDIII specific antibodies has been shown directly in some"/>
   <result pre="neutralization (Stettler et al., 2016). Additionally, using two cohorts of" exact="ZIKV" post="infected individuals from Mexico and Brazil, it was revealed"/>
   <result pre="the levels of antibodies specific for the lateral ridge of" exact="ZIKV" post="E domain III were positively correlated with sera neutralization"/>
   <result pre="quaternary epitopes formed between E domains II and III of" exact="Zika" post="virus were demonstrated to be both protective and therapeutic"/>
   <result pre="al., 2016; Hasan et al., 2017; Collins et al., 2019)." exact="DENV" post="and ZIKV show high level of structure homology between"/>
   <result pre="Hasan et al., 2017; Collins et al., 2019). DENV and" exact="ZIKV" post="show high level of structure homology between their envelope"/>
   <result pre="EDE1 antibodies, one subset of EDE antibodies originally isolated from" exact="DENV" post="patients, has been shown to potently neutralize Zika virus"/>
   <result pre="isolated from DENV patients, has been shown to potently neutralize" exact="Zika" post="virus in vitro and provides protection against lethal challenge"/>
   <result pre="virus in vitro and provides protection against lethal challenge of" exact="Zika" post="virus in mice. These antibodies recognize a conserved conformational"/>
   <result pre="antibodies that have broader footprints covering N153 glycosylation site of" exact="DENV" post="E proteins, these antibodies can also cross-neutralize ZIKV at"/>
   <result pre="site of DENV E proteins, these antibodies can also cross-neutralize" exact="ZIKV" post="at high concentrations (Fernandez et al., 2017; Abbink et"/>
   <result pre="al., 2017; Abbink et al., 2018; Figure 1A). In contrast," exact="ZIKV" post="neutralization antibodies targeting quaternary epitopes identified so far, such"/>
   <result pre="and EDE2 were isolated mainly from patients of acute secondary" exact="DENV" post="infection, whereas A9E and G9E were isolated from DENV"/>
   <result pre="secondary DENV infection, whereas A9E and G9E were isolated from" exact="DENV" post="naïve ZIKV patients at 6 months after the onset"/>
   <result pre="infection, whereas A9E and G9E were isolated from DENV naïve" exact="ZIKV" post="patients at 6 months after the onset of illness."/>
   <result pre="Rouvinski et al. (2017). Collectively, neutralization antibodies to dengue or" exact="Zika" post="viruses are mainly constituted of type specific EDIII antibodies,"/>
   <result pre="in vitro studies have already demonstrated that most antibodies to" exact="DENV" post="or ZIKV prM and E proteins have the potential"/>
   <result pre="studies have already demonstrated that most antibodies to DENV or" exact="ZIKV" post="prM and E proteins have the potential to enhance"/>
   <result pre="al., 2010; de Alwis et al., 2014). Further investigation on" exact="Zika" post="and dengue monoclonal antibodies indicates that antibody concentrations that"/>
   <result pre="to in vitro studies using human samples, ADE of heterotypic" exact="DENV" post="infection has been more stringently demonstrated in mouse models."/>
   <result pre="has been more stringently demonstrated in mouse models. Administering heterotypic" exact="DENV" post="immune sera or viral-specific monoclonal antibodies to AG129 immune"/>
   <result pre="(Zellweger et al., 2010). Consistently, clinical evidence of ADE in" exact="DENV" post="infection has been reported previously. Infants born to dengue"/>
   <result pre="6–9 months of age, due to the decay of maternal-derived" exact="DENV" post="antibodies (Halstead, 2003). Further, the increased risk of hospitalization"/>
   <result pre="(Katzelnick et al., 2017). More significantly, a cross-serocomplex ADE between" exact="ZIKV" post="and DENV has also been reproduced in mouse model."/>
   <result pre="al., 2017). More significantly, a cross-serocomplex ADE between ZIKV and" exact="DENV" post="has also been reproduced in mouse model. DENV and"/>
   <result pre="ZIKV and DENV has also been reproduced in mouse model." exact="DENV" post="and WNV immune sera were both found to enhance"/>
   <result pre="DENV has also been reproduced in mouse model. DENV and" exact="WNV" post="immune sera were both found to enhance Zika virus"/>
   <result pre="DENV and WNV immune sera were both found to enhance" exact="Zika" post="virus infection in mice (Bardina et al., 2017). Also,"/>
   <result pre="accelerated fetal resorption (Leborgne et al., 2019). Reciprocally, maternally acquired" exact="Zika" post="virus antibodies also enhanced dengue disease severity in mice"/>
   <result pre="are not as clear. Two studies did not show enhanced" exact="Zika" post="virus infection in macaques that were infected by DENV"/>
   <result pre="enhanced Zika virus infection in macaques that were infected by" exact="DENV" post="either 420 days or 2.8 years before experiments (McCracken"/>
   <result pre="should be noted that the interval between primary and secondary" exact="DENV" post="infections is critical for disease severity, and DENV ADE"/>
   <result pre="and secondary DENV infections is critical for disease severity, and" exact="DENV" post="ADE in human has only occurred within a relatively"/>
   <result pre="has only occurred within a relatively narrow range of pre-existing" exact="DENV" post="antibody concentration (Katzelnick et al., 2017). In dengue infected"/>
   <result pre="usually 12 months or longer, but unknown for enhancement of" exact="Zika" post="virus infection. Limited data from a long-term cohort study"/>
   <result pre="long-term cohort study in Brazil before and after the 2015" exact="ZIKV" post="outbreak have found that the pre-existing DENV NS1 specific"/>
   <result pre="after the 2015 ZIKV outbreak have found that the pre-existing" exact="DENV" post="NS1 specific IgG3 antibody within 4–6 months of infection"/>
   <result pre="of infection was positively associated with the risk of subsequent" exact="ZIKV" post="infection, but high titer of total IgG to DENV"/>
   <result pre="subsequent ZIKV infection, but high titer of total IgG to" exact="DENV" post="was associated with protection against the acquisition of ZIKV"/>
   <result pre="to DENV was associated with protection against the acquisition of" exact="ZIKV" post="infection (Rodriguez-Barraquer et al., 2019). Our previous study using"/>
   <result pre="convalescent dengue patients also revealed that stronger cross-serocomplex ADE of" exact="ZIKV" post="infection in PBMC appeared more often in sera obtained"/>
   <result pre="appeared more often in sera obtained within 3 months of" exact="DENV" post="infection (Li et al., 2018). These results are supportive"/>
   <result pre="two infections are important factors for determining cross-serocomplex enhancement between" exact="ZIKV" post="and DENV. Collectively, ADE is now considered to be"/>
   <result pre="development. Despite the impact of prior cross-serocomplex immunity for subsequent" exact="ZIKV" post="or DENV infections are clinically unknown, candidate vaccines that"/>
   <result pre="the impact of prior cross-serocomplex immunity for subsequent ZIKV or" exact="DENV" post="infections are clinically unknown, candidate vaccines that provide protection"/>
   <result pre="development. T Cell Responses Aside from the double-edged antibody responses," exact="DENV" post="and ZIKV infections also elicit strong T cell responses"/>
   <result pre="Cell Responses Aside from the double-edged antibody responses, DENV and" exact="ZIKV" post="infections also elicit strong T cell responses of dubious"/>
   <result pre="al., 2010). A subsequent human cohort study further illustrated that" exact="DENV" post="specific CD8 + T cell responses played protective roles"/>
   <result pre="specific CD8 + T cell responses played protective roles against" exact="DENV" post="infection in an HLA-linked manner (Weiskopf et al., 2013)."/>
   <result pre="full scope of T cell responses toward conserved epitopes. Similarly," exact="ZIKV" post="specific CD8 + T cells were also first showed"/>
   <result pre="Ngono et al., 2017; Huang et al., 2017), and human" exact="ZIKV" post="CD8 + T cells were revealed to have cytotoxic"/>
   <result pre="its antiviral cytotoxicity might be associated with neurological pathology in" exact="ZIKV" post="infection, the pre-existence of specific CD8 + T cells"/>
   <result pre="disease (Huang et al., 2017; Jurado et al., 2018). Whether" exact="ZIKV" post="CD4 + T cell responses are necessary for virus"/>
   <result pre="peptide immunization have been demonstrated to protect host from subsequent" exact="ZIKV" post="infection (Hassert et al., 2018; Elong Ngono et al.,"/>
   <result pre="2019). In one cohort study conducted in dengue endemic countries," exact="ZIKV" post="specific CD8 + T cell epitopes were found to"/>
   <result pre="al., 2017b). Cross-reactive T cell responses were often observed between" exact="DENV" post="and ZIKV, because of their homology at amino acid"/>
   <result pre="and ZIKV, because of their homology at amino acid level." exact="DENV" post="specific memory CD8 + T cells could cross-react with"/>
   <result pre="DENV specific memory CD8 + T cells could cross-react with" exact="Zika" post="virus and protected mice from subsequent lethal ZIKV challenge"/>
   <result pre="cross-react with Zika virus and protected mice from subsequent lethal" exact="ZIKV" post="challenge (Wen et al., 2017a). Adoptive transfer of DENV"/>
   <result pre="lethal ZIKV challenge (Wen et al., 2017a). Adoptive transfer of" exact="DENV" post="CD8 + T cells to pregnant mice inhibited Zika"/>
   <result pre="of DENV CD8 + T cells to pregnant mice inhibited" exact="Zika" post="virus replication in placenta and increased the survival of"/>
   <result pre="increased the survival of fetus (Regla-Nava et al., 2018). In" exact="DENV" post="convalescent patients, memory CD4 + and CD8 + T"/>
   <result pre="+ T cells could be activated by peptides derived from" exact="ZIKV" post="capsid and NS3 proteins, and the activated CD8 +"/>
   <result pre="proteins, and the activated CD8 + T cells could kill" exact="ZIKV" post="infected cells in vitro (Lim et al., 2018). Nevertheless,"/>
   <result pre="the cross-reactive CD4 + T cells are few, evidence for" exact="ZIKV" post="specific memory T cells cross-react with DENV antigens is"/>
   <result pre="few, evidence for ZIKV specific memory T cells cross-react with" exact="DENV" post="antigens is still lacking. All above demonstrate that T"/>
   <result pre="is an important element of adaptive immunity toward dengue and" exact="Zika" post="virus, and T cell component should be considered in"/>
   <result pre="the existing knowledge of vaccine immunology and protective immunity to" exact="DENV" post="and ZIKV, it is predicted that an ideal dengue"/>
   <result pre="and ZIKV, it is predicted that an ideal dengue or" exact="Zika" post="vaccine should induce both humoral and cellular immune response"/>
   <result pre="response to ensure full protection. Universal B Cell Vaccines for" exact="DENV" post="and ZIKV Previous investigation on dengue and Zika vaccine"/>
   <result pre="ensure full protection. Universal B Cell Vaccines for DENV and" exact="ZIKV" post="Previous investigation on dengue and Zika vaccine mainly focused"/>
   <result pre="Vaccines for DENV and ZIKV Previous investigation on dengue and" exact="Zika" post="vaccine mainly focused on the B cell immunity, aiming"/>
   <result pre="Because of the complex interaction among antibody responses to four" exact="DENV" post="serotypes and ZIKV, an ideal dengue vaccine should elicit"/>
   <result pre="broadly neutralizing antibodies that cross-react with all serotypes of viruses." exact="Zika" post="vaccines developed independently need to be able to trigger"/>
   <result pre="the antibody responses elicited by intact or recombinant dengue or" exact="Zika" post="viruses still maintain the dual functions of neutralization and"/>
   <result pre="strains. Epitopes on &quot;pr�? peptides are probably exposed on immature" exact="ZIKV" post="virus surface and elicit abundant ADE inducing antibodies, similar"/>
   <result pre="elicit abundant ADE inducing antibodies, similar to what happened in" exact="DENV" post="infected patients. The same issue must be dealt with"/>
   <result pre="selection and quality control. In most subunit candidate vaccines of" exact="DENV" post="and ZIKV, soluble EDIII or E80 as antigens were"/>
   <result pre="Figure 1B). Consistently, in a recent study, the covalently stabilized" exact="ZIKV" post="E dimer has successfully elicited protective antibody responses against"/>
   <result pre="ZIKV E dimer has successfully elicited protective antibody responses against" exact="ZIKV" post="infection in mice, without causing cross-reactivity to dengue viruses"/>
   <result pre="mice, without causing cross-reactivity to dengue viruses or ADE of" exact="DENV" post="(Slon-Campos et al., 2019). Currently, both Zika EDIII and"/>
   <result pre="or ADE of DENV (Slon-Campos et al., 2019). Currently, both" exact="Zika" post="EDIII and Dengue tetravalent EDIII vaccines are under development."/>
   <result pre="DENV (Slon-Campos et al., 2019). Currently, both Zika EDIII and" exact="Dengue" post="tetravalent EDIII vaccines are under development. The EDIII component"/>
   <result pre="vivo protection varies among four serotypes of dengue viruses or" exact="Zika" post="virus, to adjust the balance among immune responses in"/>
   <result pre="E80, further incorporation of consensus E80 monomers derived from both" exact="DENV" post="and ZIKV to a stabilized dimer might help to"/>
   <result pre="incorporation of consensus E80 monomers derived from both DENV and" exact="ZIKV" post="to a stabilized dimer might help to present most"/>
   <result pre="cell memory response is another essential aim for dengue or" exact="Zika" post="vaccine. In clinical trial of CYD-TDV, GMT of antibody"/>
   <result pre="we should be able to construct a universal dengue and" exact="Zika" post="B cell vaccine. Furthermore, with suitable heterologous vaccines in"/>
   <result pre="responses that have limited ADE effect. T Cell Vaccines for" exact="DENV" post="and ZIKV In contrast to the extensive attention on"/>
   <result pre="have limited ADE effect. T Cell Vaccines for DENV and" exact="ZIKV" post="In contrast to the extensive attention on B cell"/>
   <result pre="experienced than dengue naïve vaccine recipients. As a chimera of" exact="Dengue" post="virus and YF-17D vaccine, CYD-TDV mainly elicited YFV specific"/>
   <result pre="chimera of Dengue virus and YF-17D vaccine, CYD-TDV mainly elicited" exact="YFV" post="specific T cell responses through YFV non-structural proteins, of"/>
   <result pre="vaccine, CYD-TDV mainly elicited YFV specific T cell responses through" exact="YFV" post="non-structural proteins, of which reactivity to dengue virus was"/>
   <result pre="infection, dengue specific memory T cell responses were boosted by" exact="YFV" post="cross-reactive epitopes in seropositive recipients and contributed to protection."/>
   <result pre="is complementary to traditional B cell vaccines for defense against" exact="DENV" post="and ZIKV. Distinct from B cell epitopes, T cell"/>
   <result pre="restricted. Some HLA-linked protective epitopes have already been identified for" exact="DENV" post="and ZIKV, it is worthwhile to study epitope distribution"/>
   <result pre="in a study of immunogenicity and protection efficacy of multiepitope" exact="DENV" post="NS3 DNA vaccine in Balb/c mice, and it demonstrated"/>
   <result pre="T cell responses. TAK-003 and TV003 containing non-structural proteins of" exact="DENV" post="have been shown to elicit both antibody responses and"/>
   <result pre="to induce protective T cell immunity toward four serotypes of" exact="DENV" post="and ZIKV simultaneously, and whether cross-reactive T cell responses"/>
   <result pre="protective T cell immunity toward four serotypes of DENV and" exact="ZIKV" post="simultaneously, and whether cross-reactive T cell responses could be"/>
   <result pre="we propose an improvement of the strategy for dengue and" exact="Zika" post="virus vaccine development by inclusion of T cell epitopes"/>
   <result pre="effect in vivo. Vector Blockade Through NS1 Antibodies As both" exact="DENV" post="and ZIKV are transmitted through Aedes mosquitoes, countermeasures that"/>
   <result pre="vivo. Vector Blockade Through NS1 Antibodies As both DENV and" exact="ZIKV" post="are transmitted through Aedes mosquitoes, countermeasures that block the"/>
   <result pre="blood meal. Furthermore, we demonstrated that NS1 antigenemia also determined" exact="ZIKV" post="infectivity in mosquitoes. Specifically, comparing with ZIKV Asian strains"/>
   <result pre="antigenemia also determined ZIKV infectivity in mosquitoes. Specifically, comparing with" exact="ZIKV" post="Asian strains that were isolated before recent outbreaks, contemporary"/>
   <result pre="enhanced infectivity in mosquitoes. This mechanism helps to explain how" exact="ZIKV" post="of Asian lineage acquired the ability to rapidly spread"/>
   <result pre="host pathology, some of which are completely opposite. Previously, soluble" exact="DENV" post="NS1 was found to contribute directly to vascular leakage"/>
   <result pre="al., 2017). Further study on DENV, WNV, YFV, JEV, and" exact="ZIKV" post="revealed that the effect of NS1 on cell permeability"/>
   <result pre="patterns for different viruses (Puerta-Guardo et al., 2019). In addition," exact="DENV" post="NS1 also facilitates viral immune evasion through inhibiting complement"/>
   <result pre="initiate complement dependent cytotoxicity (CDC). Recent investigations show that transferring" exact="ZIKV" post="NS1 antibodies from human or vaccinated mice to IFN"/>
   <result pre="apoptosis of endothelial cells, and thus leading to pathology in" exact="DENV" post="infections (Falconar, 1997; Lin et al., 2005; Cheng et"/>
   <result pre="in human vaccine might offer a better chance for defeating" exact="DENV" post="and ZIKV epidemics. Special Concerns in the Development of"/>
   <result pre="vaccine might offer a better chance for defeating DENV and" exact="ZIKV" post="epidemics. Special Concerns in the Development of ZIKV and"/>
   <result pre="DENV and ZIKV epidemics. Special Concerns in the Development of" exact="ZIKV" post="and DENV Vaccines Because ZIKV and DENV have different"/>
   <result pre="ZIKV epidemics. Special Concerns in the Development of ZIKV and" exact="DENV" post="Vaccines Because ZIKV and DENV have different pathogenic characteristics"/>
   <result pre="Concerns in the Development of ZIKV and DENV Vaccines Because" exact="ZIKV" post="and DENV have different pathogenic characteristics and tropism, special"/>
   <result pre="the Development of ZIKV and DENV Vaccines Because ZIKV and" exact="DENV" post="have different pathogenic characteristics and tropism, special issues should"/>
   <result pre="the development of vaccines to these viruses, especially for prophylactic" exact="ZIKV" post="vaccines which are currently under development by several research"/>
   <result pre="and to reduce mortality in lethal infection murine models. However," exact="ZIKV" post="has the ability to infect and replicate in reproductive"/>
   <result pre="Prisant et al., 2016; Miner and Diamond, 2017). Therefore, during" exact="ZIKV" post="vaccine development, specified criteria for protective efficacies should include"/>
   <result pre="and decreased damages to reproductive systems. In contrast, evaluation of" exact="DENV" post="vaccine in disease models mainly includes blockage of vascular"/>
   <result pre="dengue, and hospitalization were the three major parameters to evaluate" exact="DENV" post="vaccine candidates (Hadinegoro et al., 2015; Biswal et al.,"/>
   <result pre="In addition to these three parameters, for the evaluation of" exact="ZIKV" post="vaccine, other parameters might have to be included, such"/>
   <result pre="syndrome, fetal brain development abnormality). To fulfill the criteria above," exact="ZIKV" post="vaccine strategy should also be modified, since the characteristics"/>
   <result pre="weaker T cell responses were elicited by a live attenuated" exact="ZIKV" post="vaccine during pregnancy, comparing to that in non-pregnant mice."/>
   <result pre="required to protect pregnant mice and block vertical transmission of" exact="ZIKV" post="(Shan et al., 2019). Such evidence warrants a vaccine"/>
   <result pre="better approaches to defeat dengue viruses. The sudden outbreaks of" exact="Zika" post="virus has brought additional difficulties to solve the dengue"/>
   <result pre="additional difficulties to solve the dengue problem, because the pre-existing" exact="ZIKV" post="antibodies have the potential to enhance DENV infection, and"/>
   <result pre="because the pre-existing ZIKV antibodies have the potential to enhance" exact="DENV" post="infection, and antibodies elicited by dengue vaccines also have"/>
   <result pre="elicited by dengue vaccines also have the potential to augment" exact="ZIKV" post="infection. However, as for any other scientific challenges before,"/>
   <result pre="any other scientific challenges before, the large global outbreak of" exact="ZIKV" post="has brought in extensive investigations on flavivirus virology, immunology,"/>
   <result pre="approaches are necessary. FIGURE 3 Urban cycle of dengue and" exact="Zika" post="virus transmission can be blocked at multiple steps by"/>
   <result pre="multiple steps by vaccine elicited immune responses. Both dengue and" exact="Zika" post="viruses are transmitted between human through mosquitoes in urban"/>
   <result pre="T cells can be activated by infected cells that present" exact="DENV" post="or ZIKV peptides in the context of MHC-I molecules,"/>
   <result pre="can be activated by infected cells that present DENV or" exact="ZIKV" post="peptides in the context of MHC-I molecules, and activated"/>
   <result pre="existing knowledge on epidemiology, molecular virology, and vaccine development of" exact="DENV" post="and ZIKV; and updated our understanding on protective immunity"/>
   <result pre="and ZIKV; and updated our understanding on protective immunity against" exact="DENV" post="and ZIKV. We have also discussed recent discoveries on"/>
   <result pre="a potential one-two punch strategy that overcomes ADE and defeats" exact="Dengue" post="and Zika viruses through a combination of vaccines and"/>
   <result pre="one-two punch strategy that overcomes ADE and defeats Dengue and" exact="Zika" post="viruses through a combination of vaccines and vector blockade."/>
   <result pre="(2018). Therapeutic and protective efficacy of a dengue antibody against" exact="Zika" post="infection in rhesus monkeys.Nat. Med.24721–723. 10.1038/s41591-018-0056-029867228 AvirutnanP.FuchsA.HauhartR. E.SomnukeP.YounS.DiamondM. S.et"/>
   <result pre="(2019). Antibodies elicited by an ns1-based vaccine protect mice against" exact="Zika" post="Virus.MBio10e2861–e2818. 10.1128/mBio.02861-1830940710 BaileyM. J.DuehrJ.DulinH.BroeckerF.BrownJ. A.ArumemiF. O.et al. (2018). Human"/>
   <result pre="10.1128/mBio.02861-1830940710 BaileyM. J.DuehrJ.DulinH.BroeckerF.BrownJ. A.ArumemiF. O.et al. (2018). Human antibodies targeting" exact="Zika" post="virus NS1 provide protection against disease in a mouse"/>
   <result pre="Commun.9:4560. 10.1038/s41467-018-07008-030385750 BardinaS. V.BunducP.TripathiS.DuehrJ.FrereJ. J.BrownJ. A.et al. (2017). Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity.Science356175–180. 10.1126/science.aal436528360135 BarnettR. (2017)."/>
   <result pre="(2016). Infection dynamics in a traveller with persistent shedding of" exact="Zika" post="virus RNA in semen for six months after returning"/>
   <result pre="2016.Euro Surveill21:30316. 10.2807/1560-7917.ES.2016.21.32.3031627542178 BaudD.GublerD. J.SchaubB.LanteriM. C.MussoD. (2017). An update on" exact="Zika" post="virus infection.Lancet3902099–2109. 10.1016/S0140-6736(17)31450-228647173 BeattyP. R.Puerta-GuardoH.KillingbeckS. S.GlasnerD. R.HopkinsK.HarrisE. (2015). Dengue"/>
   <result pre="on Zika virus infection.Lancet3902099–2109. 10.1016/S0140-6736(17)31450-228647173 BeattyP. R.Puerta-GuardoH.KillingbeckS. S.GlasnerD. R.HopkinsK.HarrisE. (2015)." exact="Dengue" post="virus NS1 triggers endothelial permeability and vascular leak that"/>
   <result pre="L.SimmonsC. P.MacagnoA.SimonelliL.QuyenN. T.et al. (2010). The human immune response to" exact="Dengue" post="virus is dominated by highly cross-reactive antibodies endowed with"/>
   <result pre="mice.J. Virol.759731–9740. 10.1128/JVI.75.20.9731-9740.200111559806 BlaneyJEJr.SatheN. S.GoddardL.HansonC. T.RomeroT. A.HanleyK. A.et al. (2008)." exact="Dengue" post="virus type 3 vaccine candidates generated by introduction of"/>
   <result pre="J. Trop. Med. Hyg.7274–81. 10.4269/ajtmh.2005.72.7415728870 CamposG. S.BandeiraA. C.SardiS. I. (2015)." exact="Zika" post="virus outbreak. Bahia, Brazil.Emerg. Infect. Dis.211885–1886. 10.3201/eid2110.15084726401719 CapedingM. R.TranN."/>
   <result pre="phase 3, randomised, observer-masked, placebo-controlled trial.Lancet3841358–1365. 10.1016/S0140-6736(14)61060-625018116 CareyD. E. (1971)." exact="Chikungunya" post="and dengue: a case of mistaken identity?J. Hist. Med."/>
   <result pre="on platelets and inhibit platelet aggregation.Mol. Immunol.47398–406. 10.1016/j.molimm.2009.08.03319822367 ClarkeT. (2002)." exact="Dengue" post="virus: break-bone fever.Nature416672–674. 10.1038/416672a11961522 ClementsD. E.CollerB. A.LiebermanM. M.OgataS.WangG.HaradaK. E.et"/>
   <result pre="A.Gimblet-OchiengC.LiouG. A.JadiR. S.MetzS. W.et al. (2019). Human antibody response to" exact="Zika" post="targets type-specific quaternary structure epitopes.JCI Insight4:e123588. 10.1172/jci.insight.12458830996133 CostaS. M.YorioA."/>
   <result pre="USA.Vaccine315047–5054. 10.1016/j.vaccine.2013.08.08824021313 de AlwisR.WilliamsK. L.SchmidM. A.LaiC. Y.PatelB.SmithS. A.et al. (2014)." exact="Dengue" post="viruses are enhanced by distinct populations of serotype cross-reactive"/>
   <result pre="enhance dengue virus infection in humans.Science328745–748. 10.1126/science.118518120448183 DejnirattisaiW.SupasaP.WongwiwatW.RouvinskiA.Barba-SpaethG.DuangchindaT.et al. (2016)." exact="Dengue" post="virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika"/>
   <result pre="with dengue virus.Nat. Immunol.16170–177. 10.1038/ni.305825501631 DickG. W.KitchenS. F.HaddowA. J. (1952)." exact="Zika" post="virus. I. Isolations and serological specificity.Trans. R Soc. Trop."/>
   <result pre="10.1073/pnas.101086710720837518 DuffyM. R.ChenT. H.HancockW. T.PowersA. M.KoolJ. L.LanciottiR. S.et al. (2009)." exact="Zika" post="virus outbreak on Yap Island. Federated States of Micronesia.N."/>
   <result pre="children with dengue.J. Immunol.1847281–7287. 10.4049/jimmunol.090326220483770 DurbinA.Wilder-SmithA. (2017). An update on" exact="Zika" post="vaccine developments.Expert Rev. Vaccines16781–787. 10.1080/14760584.2017.134530928633549 DurbinA. P.KirkpatrickB. D.PierceK. K.ElwoodD.LarssonC."/>
   <result pre="and role of the CD8(+) T cell response during primary" exact="Zika" post="Virus Infection in Mice.Cell Host Microbe2135–46. 10.1016/j.chom.2016.12.01028081442 Elong NgonoA.YoungM."/>
   <result pre="CD4+ T cells promote humoral immunity and viral control during" exact="Zika" post="virus infection.PLoS Pathog.15:e1007474. 10.1371/journal.ppat.100747430677097 FalconarA. K. (1997). The dengue"/>
   <result pre="M.ThezeJ.de JesusJ. G.GiovanettiM.et al. (2017). Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the Americas.Nature546406–410. 10.1038/nature2240128538727 FatimaK.SyedN. I."/>
   <result pre="to the dengue virus E-dimer epitope have therapeutic activity against" exact="Zika" post="virus infection.Nat. Immunol.181261–1269. 10.1038/ni.384928945244 FooS. S.ChenW.ChanY.BowmanJ. W.ChangL. C.ChoiY.et al."/>
   <result pre="infection.Nat. Immunol.181261–1269. 10.1038/ni.384928945244 FooS. S.ChenW.ChanY.BowmanJ. W.ChangL. C.ChoiY.et al. (2017). Asian" exact="Zika" post="virus strains target CD14(+) blood monocytes and induce M2-skewed"/>
   <result pre="in mice.Cell Host Microbe24, 743.E5–750.e5. 10.1016/j.chom.2018.09.01530439343 GaucherD.TherrienR.KettafN.AngermannB. R.BoucherG.Filali-MouhimA.et al. (2008)." exact="Yellow fever" post="vaccine induces integrated multilineage and polyfunctional immune responses.J. Exp."/>
   <result pre="M.HuZ.YamshchikovG.RothwellR. S.et al. (2018). Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
   <result pre="Clinical Trial.J. Infect. Dis.2121032–1041. 10.1093/infdis/jiv17925791116 GlasnerD. R.RatnasiriK.Puerta-GuardoH.EspinosaD. A.BeattyP. R.HarrisE. (2017)." exact="Dengue" post="virus NS1 cytokine-independent vascular leak is dependent on endothelial"/>
   <result pre="endothelial glycocalyx components.PLoS Pathog.13:e1006673. 10.1371/journal.ppat.100667329121099 GoveroJ.EsakkyP.ScheafferS. M.FernandezE.DruryA.PlattD. J.et al. (2016)." exact="Zika" post="virus infection damages the testes in mice.Nature540438–442. 10.1038/nature2055627798603 GovindarajanD.MeschinoS.GuanL.ClementsD."/>
   <result pre="efficacy in nonhuman primates.Vaccine334105–4116. 10.1016/j.vaccine.2015.06.06726144900 GrardG.CaronM.MomboI. M.NkogheD.Mboui OndoS.JiolleD.et al. (2014)." exact="Zika" post="virus in Gabon (Central Africa)–2007: a new threat from"/>
   <result pre="GriffinB. D.MuthumaniK.WarnerB. M.MajerA.HaganM.AudetJ.et al. (2017). DNA vaccination protects mice against" exact="Zika" post="virus-induced damage to the testes.Nat. Commun.8:15743. 10.1038/ncomms1574328589934 GrifoniA.AngeloM. A.LopezB.O’RourkeP."/>
   <result pre="(2017b). Prior dengue virus exposure shapes T Cell Immunity to" exact="Zika" post="Virus in Humans.J. Virol.91:e01469-17. 10.1128/JVI.01469-1728978707 GrifoniA.Costa-RamosP.PhamJ.TianY.RosalesS. L.SeumoisG.et al. (2018)."/>
   <result pre="edge: transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of" exact="Zika" post="Virus-Specific CD8(+) T Cells.J. Immunol.2013487–3491. 10.4049/jimmunol.180109030413672 GublerD. J. (1987)."/>
   <result pre="Zika Virus-Specific CD8(+) T Cells.J. Immunol.2013487–3491. 10.4049/jimmunol.180109030413672 GublerD. J. (1987)." exact="Dengue" post="and dengue hemorrhagic fever in the Americas.P R Health"/>
   <result pre="of dengue viruses.Adv. Virus Res.60421–467. 10.1016/s0065-3527(03)60011-414689700 HalsteadS. B.DansL. F. (2019)." exact="Dengue" post="infection and advances in dengue vaccines for children.Lancet Child"/>
   <result pre="Hyg.32154–156. 10.4269/ajtmh.1983.32.1546824120 HasanS. S.MillerA.SapparapuG.FernandezE.KloseT.LongF.et al. (2017). A human antibody against" exact="Zika" post="virus crosslinks the E protein to prevent infection.Nat. Commun.8:14722."/>
   <result pre="E.DiPaoloR. J.BrienJ. D.PintoA. K. (2018). CD4+T cells mediate protection against" exact="Zika" post="associated severe disease in a mouse model of infection.PLoS"/>
   <result pre="(2017). CD8(+) T Cell Immune Response in Immunocompetent Mice during" exact="Zika" post="Virus Infection.J. Virol.91e900–e917. 10.1128/JVI.00900-1728835502 JessieK.FongM. Y.DeviS.LamS. K.WongK. T. (2004)."/>
   <result pre="Transcriptome profiling reveals Pro-Inflammatory cytokines and matrix metalloproteinase activation in" exact="Zika" post="Virus infected human umbilical vein endothelial cells.Front. Pharmacol.10:642. 10.3389/fphar.2019.0064231249527"/>
   <result pre="cells.Front. Pharmacol.10:642. 10.3389/fphar.2019.0064231249527 KhaiboullinaS. F.RibeiroF. M.UppalT.MartynovaE. V.RizvanovA. A.VermaS. C. (2019)." exact="Zika" post="virus transmission through blood tissue barriers.Front. Microbiol.10:1465. 10.3389/fmicb.2019.0146531333605 KirkpatrickB."/>
   <result pre="in duchenne muscular dystrophy patients.Cell Immunol.342:103780. 10.1016/j.cellimm.2018.03.00429571923 LiC.XuD.YeQ.HongS.JiangY.LiuX.et al. (2016)." exact="Zika" post="virus disrupts neural progenitor development and leads to microcephaly"/>
   <result pre="and function of human monoclonal antibodies contribute to enhancement of" exact="Zika" post="virus infectivity in vitro.Sci. China Life Sci.601396–1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et"/>
   <result pre="infectivity in vitro.Sci. China Life Sci.601396–1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et al. (2018)." exact="Dengue" post="immune sera enhance Zika virus infection in human peripheral"/>
   <result pre="Life Sci.601396–1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et al. (2018). Dengue immune sera enhance" exact="Zika" post="virus infection in human peripheral blood monocytes through Fc"/>
   <result pre="monocytes through Fc gamma receptors.PLoS One13:e0200478. 10.1371/journal.pone.020047830044839 LiangH.YangR.LiuZ.LiM.LiuH.JinX. (2018). Recombinant" exact="Zika" post="virus envelope protein elicited protective immunity against Zika virus"/>
   <result pre="(2018). Recombinant Zika virus envelope protein elicited protective immunity against" exact="Zika" post="virus in immunocompetent mice.PLoS One13:e0194860. 10.1371/journal.pone.019486029590178 LimM. Q.KumaranE. A."/>
   <result pre="function of dengue capsid and NS3-specific memory T Cells Toward" exact="Zika" post="Virus.Front. Immunol.9:2225. 10.3389/fimmu.2018.0222530327651 Limon-FloresA. Y.Perez-TapiaM.Estrada-GarciaI.VaughanG.Escobar-GutierrezA.Calderon-AmadorJ.et al. (2005). Dengue virus"/>
   <result pre="Cells Toward Zika Virus.Front. Immunol.9:2225. 10.3389/fimmu.2018.0222530327651 Limon-FloresA. Y.Perez-TapiaM.Estrada-GarciaI.VaughanG.Escobar-GutierrezA.Calderon-AmadorJ.et al. (2005)." exact="Dengue" post="virus inoculation to human skin explants: an effective approach"/>
   <result pre="transgenic mice.PLoS One12:e0184207. 10.1371/journal.pone.018420728863168 LiuY.LiuJ.DuS.ShanC.NieK.ZhangR.et al. (2017). Evolutionary enhancement of" exact="Zika" post="virus infectivity in Aedes aegypti mosquitoes.Nature545482–486. 10.1038/nature2236528514450 LiuI. J.ChiuC."/>
   <result pre="T. (2016). AXL-Mediated Productive Infection of Human Endothelial Cells by" exact="Zika" post="Virus.Circ. Res.1191183–1189. 10.1161/CIRCRESAHA.116.30986627650556 LokS. M.KostyuchenkoV.NybakkenG. E.HoldawayH. A.BattistiA. J.Sukupolvi-PettyS.et al."/>
   <result pre="of surface glycoproteins.Nat. Struct. Mol. Biol.15312–317. 10.1038/nsmb.138218264114 MaW.LiS.MaS.JiaL.ZhangF.ZhangY.et al. (2016)." exact="Zika" post="virus causes testis damage and leads to male infertility"/>
   <result pre="(2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis," exact="West Nile" post="and dengue viruses.Nat. Med.10(Suppl.), S98–S109. 10.1038/nm114415577938 ManoffS. B.SausserM.Falk RussellA.MartinJ.RadleyD.HyattD.et"/>
   <result pre="in flavivirus-naive adults.Hum. Vaccin Immunother.152195–2204. 10.1080/21645515.2018.154652330427741 MansuyJ. M.DutertreM.MengelleC.FourcadeC.MarchouB.DelobelP.et al. (2016)." exact="Zika" post="virus: high infectious viral load in semen, a new"/>
   <result pre="(1999). Infection of primary cultures of human Kupffer cells by" exact="Dengue" post="virus: no viral progeny synthesis, but cytokine production is"/>
   <result pre="RamosA. M.DaviH. P.IgleziasS. D.KanamuraC. T.et al. (2016). Pathology of congenital" exact="Zika" post="syndrome in Brazil: a case series.Lancet388898–904. 10.1016/S0140-6736(16)30883-227372395 McCrackenM. K.GromowskiG."/>
   <result pre="La BarreraR.et al. (2017). Impact of prior flavivirus immunity on" exact="Zika" post="virus infection in rhesus macaques.PLoS Pathog.13:e1006487. 10.1371/journal.ppat.100648728771605 McGeeC. E.TsetsarkinK.VanlandinghamD."/>
   <result pre="MetzS. W.ThomasA.BrackbillA.ForsbergJ.MileyM. J.LopezC. A.et al. (2019). Oligomeric state of the" exact="ZIKV" post="E protein defines protective immune responses.Nat. Commun.10:4606. 10.1038/s41467-019-12677-631601808 MichlmayrD.AndradeP.GonzalezK.BalmasedaA.HarrisE."/>
   <result pre="10.1038/s41467-019-12677-631601808 MichlmayrD.AndradeP.GonzalezK.BalmasedaA.HarrisE. (2017). CD14(+)CD16(+) monocytes are the main target of" exact="Zika" post="virus infection in peripheral blood mononuclear cells in a"/>
   <result pre="paediatric study in Nicaragua.Nat. Microbiol.21462–1470. 10.1038/s41564-017-0035-028970482 MinerJ. J.DiamondM. S. (2017)." exact="Zika" post="virus pathogenesis and tissue tropism.Cell Host Microbe21134–142. 10.1016/j.chom.2017.01.00428182948 MitragotriS."/>
   <result pre="liquid jet injectors.Nat. Rev. Drug Discov.5543–548. 10.1038/nrd207616816837 MlakarJ.KorvaM.TulN.PopovicM.Poljsak-PrijateljM.MrazJ.et al. (2016)." exact="Zika" post="virus associated with microcephaly.N. Engl. J. Med374951–958. 10.1056/NEJMoa160065126862926 ModhiranN.WattersonD.MullerD."/>
   <result pre="Engl. J. Med374951–958. 10.1056/NEJMoa160065126862926 ModhiranN.WattersonD.MullerD. A.PanettaA. K.SesterD. P.LiuL.et al. (2015)." exact="Dengue" post="virus NS1 protein activates cells via Toll-like receptor 4"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="randomised, double-blind, placebo-controlled clinical trials.Lancet391563–571. 10.1016/S0140-6736(17)33106-929217375 MussoD.BossinH.MalletH. P.BesnardM.BroultJ.BaudouinL.et al. (2018)." exact="Zika" post="virus in French Polynesia 2013-14: anatomy of a completed"/>
   <result pre="the maternal-fetal interface.Science3361317–1321. 10.1126/science.122003022679098 NettoE. M.Moreira-SotoA.PedrosoC.HoserC.FunkS.KucharskiA. J.et al. (2017). High" exact="Zika" post="virus seroprevalence in salvador, northeastern brazil limits the potential"/>
   <result pre="Disease.Bull. Hist Med.90193–221. 10.1353/bhm.2016.004127374846 PantojaP.Perez-GuzmanE. X.RodriguezI. V.WhiteL. J.GonzalezO.SerranoC.et al. (2017)." exact="Zika" post="virus pathogenesis in rhesus macaques is unaffected by pre-existing"/>
   <result pre="P.MeurenL. M.CoelhoS. V. A.LucasC. G. O.MustafaY. M.Lemos MatassoliF.et al. (2017)." exact="Zika" post="Virus infects, activates, and crosses brain microvascular endothelial cells,"/>
   <result pre="al. (2007). The stoichiometry of antibody-mediated neutralization and enhancement of" exact="West Nile" post="virus infection.Cell Host Microbe1135–145. 10.1016/j.chom.2007.03.00218005691 PorterK. R.EwingD.ChenL.WuS. J.HayesC. G.FerrariM.et"/>
   <result pre="10.1016/j.vaccine.2011.10.08522085548 PrasadV. M.MillerA. S.KloseT.SirohiD.BudaG.JiangW.et al. (2017). Structure of the immature" exact="Zika" post="virus at 9 A resolution.Nat. Struct. Mol. Biol.24184–186. 10.1038/nsmb.335228067914"/>
   <result pre="A resolution.Nat. Struct. Mol. Biol.24184–186. 10.1038/nsmb.335228067914 PrisantN.BujanL.BenichouH.HayotP. H.PaviliL.LurelS.et al. (2016)." exact="Zika" post="virus in the female genital tract.Lancet Infect Dis.161000–1001. 10.1016/S1473-3099(16)30193-1"/>
   <result pre="10.1016/j.celrep.2019.01.03630726741 QianX.NguyenH. N.JacobF.SongH.MingG. L. (2017). Using brain organoids to understand" exact="Zika" post="virus-induced microcephaly.Development144952–957. 10.1242/dev.14070728292840 QuickeK. M.BowenJ. R.JohnsonE. L.McDonaldC. E.MaH.O’NealJ. T.et"/>
   <result pre="microcephaly.Development144952–957. 10.1242/dev.14070728292840 QuickeK. M.BowenJ. R.JohnsonE. L.McDonaldC. E.MaH.O’NealJ. T.et al. (2016)." exact="Zika" post="Virus Infects Human Placental Macrophages.Cell Host Microbe2083–90. 10.1016/j.chom.2016.05.01527247001 Regla-NavaJ."/>
   <result pre="Regla-NavaJ. A.Elong NgonoA.ViramontesK. M.HuynhA. T.WangY. T.NguyenA. T.et al. (2018). Cross-reactive" exact="Dengue" post="virus-specific CD8(+) T cells protect against Zika virus during"/>
   <result pre="al. (2018). Cross-reactive Dengue virus-specific CD8(+) T cells protect against" exact="Zika" post="virus during pregnancy.Nat. Commun.9:3042. 10.1038/s41467-018-05458-030072692 RichnerJ. M.HimansuS.DowdK. A.ButlerS. L.SalazarV.FoxJ."/>
   <result pre="A.ButlerS. L.SalazarV.FoxJ. M.et al. (2017a). Modified mRNA vaccines protect against" exact="Zika" post="Virus Infection.Cell169:176. 10.1016/j.cell.2017.03.01628340344 RichnerJ. M.JaggerB. W.ShanC.FontesC. R.DowdK. A.CaoB.et al."/>
   <result pre="M.JaggerB. W.ShanC.FontesC. R.DowdK. A.CaoB.et al. (2017b). Vaccine mediated protection against" exact="Zika" post="virus-induced congenital disease.Cell170273.e12–283.e12. 10.1016/j.cell.2017.06.04028708997 RivinoL.TanA. T.ChiaA.KumaranE. A.GrotenbregG. M.MacAryP. A.et"/>
   <result pre="S.SacramentoG. A.et al. (2019). Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region.Science363607–610. 10.1126/science.aav661830733412 RothmanA."/>
   <result pre="is hierarchical.Mol. Immunol.113115–119. 10.1016/j.molimm.2018.08.01130146122 Sanchez-San MartinC.LiT.BouquetJ.StreithorstJ.YuG.ParanjpeA.et al. (2018). Differentiation enhances" exact="Zika" post="virus infection of neuronal brain cells.Sci. Rep.8:14543. 10.1038/s41598-018-32400-730266962 SangkawibhaN.RojanasuphotS.AhandrikS.ViriyapongseS.JatanasenS.SalitulV.et"/>
   <result pre="10.1093/oxfordjournals.aje.a1139326496446 SapparapuG.FernandezE.KoseN.BinC.FoxJ. M.BombardiR. G.et al. (2016). Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in mice.Nature540443–447. 10.1038/nature2056427819683 ShanC.MuruatoA."/>
   <result pre="D.MedeirosD. B. A.et al. (2017). A single-dose live-attenuated vaccine prevents" exact="Zika" post="virus pregnancy transmission and testis damage.Nat. Commun.8:676. 10.1038/s41467-017-00737-828939807 ShanC.XieX.LuoH.MuruatoA."/>
   <result pre="ShanC.XieX.LuoH.MuruatoA. E.LiuY.WakamiyaM.et al. (2019). Maternal vaccination and protective immunity against" exact="Zika" post="virus vertical transmission.Nat. Commun.10:5677. 10.1038/s41467-019-13589-131831806 SharmaM.GlasnerD. R.WatkinsH.Puerta-GuardoH.KassaY.EganM. A.et al."/>
   <result pre="G.et al. (2016). The 3.8 A resolution cryo-EM structure of" exact="Zika" post="virus.Science352467–470. 10.1126/science.aaf531627033547 Slon-CamposJ. L.DejnirattisaiW.JaggerB. W.Lopez-CamachoC.WongwiwatW.DurnellL. A.et al. (2019). A"/>
   <result pre="virus.Science352467–470. 10.1126/science.aaf531627033547 Slon-CamposJ. L.DejnirattisaiW.JaggerB. W.Lopez-CamachoC.WongwiwatW.DurnellL. A.et al. (2019). A protective" exact="Zika" post="virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement"/>
   <result pre="antibody-dependent enhancement of dengue infection.Nat. Immunol.201291–1298. 10.1038/s41590-019-0477-z31477918 SpiteriG.SudreB.SeptfonsA.BeauteJ.collab: The European," exact="Zika" post="Surveillanceet al. (2017). Surveillance of Zika virus infection in"/>
   <result pre="10.1038/s41590-019-0477-z31477918 SpiteriG.SudreB.SeptfonsA.BeauteJ.collab: The European, Zika Surveillanceet al. (2017). Surveillance of" exact="Zika" post="virus infection in the EU/EEA, June 2015 to January"/>
   <result pre="al. (2016). Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infection.Science353823–826. 10.1126/science.aaf850527417494 SunJ.LiM.WangY.HaoP.JinX. (2017). Elaboration of tetravalent antibody"/>
   <result pre="envelope sequence.Vaccine356308–6320. 10.1016/j.vaccine.2017.09.06328987441 SzabaF. M.TigheM.KummerL. W.LanzerK. G.WardJ. M.LanthierP.et al. (2018)." exact="Zika" post="virus infection in immunocompetent pregnant mice causes fetal damage"/>
   <result pre="Pathog.14:e1006994. 10.1371/journal.ppat.100699429634758 TamhankarM.PattersonJ. L. (2019). Directional entry and release of" exact="Zika" post="virus from polarized epithelial cells.Virol. J.16:99. 10.1186/s12985-019-1200-231395061 TebasP.RobertsC. C.MuthumaniK.ReuschelE."/>
   <result pre="dengue vaccines.Vaccine363411–3417. 10.1016/j.vaccine.2018.02.06229525283 VermillionM. S.LeiJ.ShabiY.BaxterV. K.CrillyN. P.McLaneM.et al. (2017). Intrauterine" exact="Zika" post="virus infection of pregnant immunocompetent mice models transplacental transmission"/>
   <result pre="mice.Front. Microbiol.10:1113. 10.3389/fmicb.2019.0111331134046 WeaverS. C.CostaF.Garcia-BlancoM. A.KoA. I.RibeiroG. S.SaadeG.et al. (2016)." exact="Zika" post="virus: History, emergence, biology, and prospects for control.Antiviral. Res.13069–80."/>
   <result pre="infection.J. Virol.8811383–11394. 10.1128/JVI.01108-1425056881 WenJ.Elong NgonoA.Regla-NavaJ. A.KimK.GormanM. J.DiamondM. S.et al. (2017a)." exact="Dengue" post="virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika"/>
   <result pre="(2017a). Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent" exact="Zika" post="virus challenge.Nat. Commun.8:1459. 10.1038/s41467-017-01669-z29129917 WenJ.TangW. W.SheetsN.EllisonJ.SetteA.KimK.et al. (2017b). Identification"/>
   <result pre="virus challenge.Nat. Commun.8:1459. 10.1038/s41467-017-01669-z29129917 WenJ.TangW. W.SheetsN.EllisonJ.SetteA.KimK.et al. (2017b). Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
   <result pre="mosquitoes, mice, and rhesus monkeys.Vaccine214307–4316. 10.1016/s0264-410x(03)00488-214505913 Wilder-SmithA.VanniceK.DurbinA.HombachJ.ThomasS. J.ThevarjanI.et al. (2018)." exact="Zika" post="vaccines and therapeutics: landscape analysis and challenges ahead.BMC Med.16:84."/>
   <result pre="Control: New Edition.Geneva: WHO. collab: World Health Organization [WHO] (2017)." exact="Dengue" post="vaccine: WHO position paper, July 2016 - recommendations.Vaccine351200–1201. 10.1016/j.vaccine.2016.10.07028185744"/>
   <result pre="10.1073/pnas.130633311023686453 ZouJ.XieX.LuoH.ShanC.MuruatoA. E.WeaverS. C.et al. (2018). A single-dose plasmid-launched live-attenuated" exact="Zika" post="vaccine induces protective immunity.EBioMedicine3692–102. 10.1016/j.ebiom.2018.08.05630201444"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7100975\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Tropical Diseases"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and Life Sciences : Anatomy :"/>
   <result pre="review &amp;amp; editing8911http://orcid.org/0000-0003-0117-3061CabiéAndréConceptualizationProject administrationSupervisionWriting – review &amp;amp; editing346collab: the Chronic" exact="Chikungunya" post="working group of University Medical Center of Martinique¶[1], INSERM,"/>
   <result pre="that no competing interests exist. ¶ Members of the Chronic" exact="Chikungunya" post="working group of University Medical Center of Martinique are"/>
   <result pre="findings A total of 193 patients who tested positive for" exact="CHIKV" post="RNA via qRT-PCR underwent clinical investigations in the acute"/>
   <result pre="risk chronic chikungunya disorders. Trial registration clinicaltrials.gov (NCT01099852). Author summary" exact="Chikungunya" post="is a tropical, mosquito-borne virus that has been re-emerging"/>
   <result pre="97261 Fort-de-France, Martinique, France. Contact: Cedric CONTARET; email: cedric.contaret@chu-fortdefrance.fr. Introduction" exact="Chikungunya" post="virus (CHIKV) is a re-emerging alphavirus transmitted to humans"/>
   <result pre="Italy, where the first European outbreak occurred in 2007 [11,12]." exact="CHIKV" post="is known to target human epithelial and endothelial cells,"/>
   <result pre="the predictive factors of severe dengue. Following the introduction of" exact="CHIKV" post="in Martinique, the inclusion criteria of the DAG study"/>
   <result pre="the DAG-2 cohort was extended to other arboviruses (including the" exact="Zika" post="virus), and was renamed &quot;the CARBO cohort.�? This study"/>
   <result pre="in the departments most likely to receive patients infected with" exact="CHIKV" post="(the emergency department and the department of infectious diseases)."/>
   <result pre="age, ability to sign informed consent, blood sample positive for" exact="CHIKV" post="RNA via qRT-PCR, and onset of symptoms (headache, arthralgia,"/>
   <result pre="of rheumatologists, one of whom was a member of the" exact="CHIKV" post="patient care team. Patients with CCA were managed in"/>
   <result pre="transaminases) were performed upon a blood sample testing positive for" exact="CHIKV" post="RNA via qRT-PCR (RealStar Chikungunya RT-PCR kit 1.0—Altona Diagnostics,"/>
   <result pre="blood sample testing positive for CHIKV RNA via qRT-PCR (RealStar" exact="Chikungunya" post="RT-PCR kit 1.0—Altona Diagnostics, Hamburg, Germany). A biological bank"/>
   <result pre="the study (54 patients were excluded: 51 tested negative for" exact="CHIKV" post="RNA via qRT-PCR, 2 were not tested for CHIKV"/>
   <result pre="for CHIKV RNA via qRT-PCR, 2 were not tested for" exact="CHIKV" post="RNA due to a temporary technical problem in the"/>
   <result pre="0.07** Asthma 167 2 (2.50) 5 (5.75) 3.25 [-2.72;9.22] 0.4**" exact="Dengue" post="167 4 (5.00) 2 (2.30) -2.70[-8.42;3.02] 0.4** Hemoglobinopathy 167"/>
   <result pre="cartilage can be restored after rehydration with physiological salt solution." exact="CHIKV" post="has been shown to damage cartilage [61] and synovial"/>
   <result pre="hypothesis we have formulated: dehydration during the acute phase of" exact="CHIKV" post="infection is a cause of CCA. Indeed, we did"/>
   <result pre="viremia through serum concentration, as some studies have reported higher" exact="CHIKV" post="plasma viral loads in CCA patients [62,63]. However, we"/>
   <result pre="and severity at presentation [41,42,64]. However, no autoimmune markers for" exact="CHIKV" post="have been highlighted in observational studies [34]. In other"/>
   <result pre="phase. These 2 conditions, which are highly specific to symptomatic" exact="CHIKV" post="infection, have not yet been identified as risk factors"/>
   <result pre="in cooperation with a rheumatologist or a rehabilitation physician [80]." exact="Chikungunya" post="disease and especially CCA with relapsing sequela have been"/>
   <result pre="hypothesis opens up new avenues for prevention and research in" exact="CHIKV" post="pathways. Supporting information S1 Fig EuroQol 5 Dimensions (EQ5D)"/>
   <result pre="Arianne Dorval for editorial assistance as well as the Chronic" exact="Chikungunya" post="working group at the University Medical Center of Martinique"/>
   <result pre="of Aedes albopictus and Aedes aegypti in the emergence of" exact="Dengue" post="and Chikungunya in central Africa.Vector Borne Zoonotic Dis Larchmt"/>
   <result pre="albopictus and Aedes aegypti in the emergence of Dengue and" exact="Chikungunya" post="in central Africa.Vector Borne Zoonotic Dis Larchmt N. 2010;"/>
   <result pre="2PastorinoB, Muyembe-TamfumJJ, BessaudM, TockF, TolouH, DurandJP, et al.Epidemic resurgence of" exact="Chikungunya" post="virus in Democratic Republic of the Congo: identification of"/>
   <result pre="Senegal and Cape Verde Archipelago for West African Lineages of" exact="Chikungunya" post="Virus.Am J Trop Med Hyg. 2014; 91(3): 635–41. 10.4269/ajtmh.13-062725002293"/>
   <result pre="15(1): 3–13. 5VazeilleM, MoutaillerS, CoudrierD, RousseauxC, KhunH, HuerreM, et al.Two" exact="Chikungunya" post="isolates from the outbreak of La Reunion (Indian Ocean)"/>
   <result pre="8VijayakumarKP, Nair AnishTS, GeorgeB, LawrenceT, MuthukkuttySC, RamachandranR. Clinical Profile of" exact="Chikungunya" post="Patients during the Epidemic of 2007 in Kerala, India.J"/>
   <result pre="e262010.1371/journal.pntd.000262024587454 10CamachoD, ReyesJ, NegredoA, HernándezL, Sánchez-SecoM, ComachG. Asian genotype of" exact="Chikungunya" post="virus circulating in Venezuela during 2014. Acta Trop. 2017;"/>
   <result pre="temperate region. The Lancet. 2007; 370(9602): 1840–6. 12HorcadaML, Díaz-CalderónC, GarridoL." exact="Chikungunya" post="fever. Rheumatic manifestations of an emerging disease in Europe.Reumatol"/>
   <result pre="AfonsoPV, MoulyV, et al.Human muscle satellite cells as targets of" exact="Chikungunya" post="virus infection.PloS One. 2007; 2(6): e52710.1371/journal.pone.000052717565380 17KashyapRS, MoreyS, BhullarS,"/>
   <result pre="Receptor-Induced Cytokine Profiles in the Blood and Cerebrospinal Fluid of" exact="Chikungunya" post="Patients. Neuroimmunomodulation. 2014; 21(6): 338–46. 10.1159/00035824024776821 18ArpinoC, CuratoloP, RezzaG."/>
   <result pre="Chikungunya Patients. Neuroimmunomodulation. 2014; 21(6): 338–46. 10.1159/00035824024776821 18ArpinoC, CuratoloP, RezzaG." exact="Chikungunya" post="and the nervous system: what we do and do"/>
   <result pre="19ChandakNH, KashyapRS, KabraD, KarandikarP, SahaSS, MoreySH, et al.Neurological complications of" exact="Chikungunya" post="virus infection.Neurol India. 2009; 57(2): 177–80. 10.4103/0028-3886.5128919439849 20BankAM, BatraA,"/>
   <result pre="GoubeP, BazillioR. [Acute neurologic and sensorial disorders in dengue and" exact="Chikungunya" post="fever]. Bull Société Pathol Exot Ses Fil. 1971; 64(1):"/>
   <result pre="NicolettiL, MaguranoF, et al.A fatal case of encephalitis associated with" exact="Chikungunya" post="virus infection. Scand J Infect Dis. 2008; 40(11–12): 995–6."/>
   <result pre="public health.Med Pregl. 2015; 68(3–4): 122–5. 10.2298/mpns1504122h26214992 28SimonF, PauleP, OliverM." exact="Chikungunya" post="virus-induced myopericarditis: toward an increase of dilated cardiomyopathy in"/>
   <result pre="51(7): 1315–22. 36RamachandranV, MalaisamyM, PonnaiahM, KaliaperuamlK, VadivooS, GupteMD. Impact of" exact="Chikungunya" post="on health related quality of life Chennai, South India.PloS"/>
   <result pre="AndradeDC, JeanS, ClavelouP, DallelR, BouhassiraD. Chronic pain associated with the" exact="Chikungunya" post="Fever: long lasting burden of an acute illness. BMC"/>
   <result pre="165–72. 10.1016/j.jinf.2012.04.00522522292 40SissokoD, MalvyD, EzzedineK, RenaultP, MoscettiF, LedransM, et al.Post-epidemic" exact="Chikungunya" post="disease on Reunion Island: course of rheumatic manifestations and"/>
   <result pre="e38910.1371/journal.pntd.000038919274071 41GérardinP, FianuA, MichaultA, MussardC, BoussaïdK, RollotO, et al.Predictors of" exact="Chikungunya" post="rheumatism: a prognostic survey ancillary to the TELECHIK cohort"/>
   <result pre="17]. [Internet]. Available from: http://www.ars.martinique.sante.fr/fileadmin/MARTINIQUE/Actualites/Autres_actu/2015/fin_epidemie_CHIK/PE_Antilles_2015-2_Chik.pdf 46ChopraA, AnuradhaV, GhorpadeR, SalujaM. Acute" exact="Chikungunya" post="and persistent musculoskeletal pain following the 2006 Indian epidemic:"/>
   <result pre="842–50. 10.1017/S095026881100130021767452 47RamachandranV, KaurP, KanagasabaiK, VadivooS, MurhekarM. Persistent arthralgia among" exact="Chikungunya" post="patients and associated risk factors in Chennai, South India.J"/>
   <result pre="BinaT, PaulBJ. Disability with Persistent Pain Following an Epidemic of" exact="Chikungunya" post="in Rural South India. J Rheumatol. 2016; 43(2): 440–4."/>
   <result pre="BoothroydDB, MitchellG, et al.The Identification of Risk Factors for Chronic" exact="Chikungunya" post="Arthralgia in Grenada, WestIndies: A Cross-Sectional Cohort Study.Open Forum"/>
   <result pre="WongS-C, KwekDJC, et al.Active Infection of Human Blood Monocytes by" exact="Chikungunya" post="Virus Triggers an Innate Immune Response. J Immunol. 2010;184(10):"/>
   <result pre="DasT, Li-Pat-YuenG, DassaB, et al.Persistent Chronic Inflammation and Infection by" exact="Chikungunya" post="Arthritogenic Alphavirus in Spite of a Robust Host Immune"/>
   <result pre="HerZ, OngEKS, ChenJ, DimatatacF, KwekDJC, et al.Persistent Arthralgia Induced by" exact="Chikungunya" post="Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage"/>
   <result pre="149–57. 10.1093/infdis/jiq04221288813 64SissokoD, MalvyD, EzzedineK, RenaultP, MoscettiF, LedransM, et al.Post-epidemic" exact="Chikungunya" post="disease on Reunion Island: course of rheumatic manifestations and"/>
   <result pre="CombeB. A report of 21 cases of rheumatoid arthritis following" exact="Chikungunya" post="fever. A mean follow-up of two years. Joint Bone"/>
   <result pre="10.1016/j.jbspin.2009.08.00519945329 66MinerJJ, Aw-YeangH-X, FoxJM, TaffnerS, MalkovaON, OhST, et al.Brief Report:" exact="Chikungunya" post="viral arthritis in the United States: A mimic of"/>
   <result pre="21(3): 530–2. 10.3201/eid2103.14139725695499 68Arroyo-�?vilaM, ViláLM. Rheumatic Manifestations in Patients with" exact="Chikungunya" post="Infection.P R Health Sci J.2015; 34(2): 71–7. 26061056 69FoissacM,"/>
   <result pre="530–2. 10.3201/eid2103.14139725695499 70EconomopoulouA, DominguezM, HelynckB, SissokoD, WichmannO, QuenelP, et al.Atypical" exact="Chikungunya" post="virus infections: clinical manifestations, mortality and risk factors for"/>
   <result pre="WongS-C, KwekDJC, et al.Active Infection of Human Blood Monocytes by" exact="Chikungunya" post="Virus Triggers an Innate Immune Response. J Immunol. 2010;"/>
   <result pre="in a naïve group of individuals 15 months following a" exact="Chikungunya" post="viral epidemic in south India: a population based observational"/>
   <result pre="J Clin Pract.2011; 65(12): 1306–12. 10.1111/j.1742-1241.2011.02792.x22093538 75SeijoA. [Tenosynovitis associated to" exact="Chikungunya" post="virus (CHKV) infection: a response].Medicina (Mex).2015; 75(2): 130. 76Yağcı"/>
   <result pre="75(2): 130. 76Yağcı ÇağlayıkD, UyarY, KorukluoğluG, ErtekM, UnalS. [An imported" exact="Chikungunya" post="fever case from New Delhi, India to Ankara, Turkey:"/>
   <result pre="122–8. 77ParolaP, SimonF, OliverM. Tenosynovitis and Vascular Disorders Associated with" exact="Chikungunya" post="Virus–Related Rheumatism. Clin Infect Dis. 2007; 45(6): 801–2. 78Chikungunya."/>
   <result pre="[cited 2015 Mar 28] [Internet]. Available from: http://www.ars.martinique.sante.fr/fileadmin/MARTINIQUE/Actualites/Autres_actu/2014 80VijayanV, SukumaranS." exact="Chikungunya" post="Virus Disease: An Emerging Challenge for the Rheumatologist.J Clin"/>
   <result pre="203–11. 81SoumahoroM-K, GérardinP, BoëlleP-Y, PerrauJ, FianuA, PouchotJ, et al.Impact of" exact="Chikungunya" post="virus infection on health status and quality of life:"/>
   <result pre="4(11): e780010.1371/journal.pone.000780019911058 82BhatiaMS, GautamP, JhanjeeA. Psychiatric Morbidity in Patients with" exact="Chikungunya" post="Fever: First Report from India.J Clin Diagn Res JCDR.2015;"/>
   <result pre="Res JCDR.2015; 9(10):VC01–VC03. 10.7860/JCDR/2015/14569.658626557595 83WadhwaniGG. Homeopathic drug therapy Homeopathy in" exact="Chikungunya" post="Fever and Post-Chikungunya Chronic Arthritis: an observational study.Homeopathy. 2013;"/>
   <result pre="2013; 102(3): 193–8. 10.1016/j.homp.2013.02.00123870379 84AbdelnabiR, NeytsJ, DelangL. Antiviral Strategies Against" exact="Chikungunya" post="Virus.Methods Mol Biol Clifton NJ. 2016; 1426: 243–53. 85YaseenHM,"/>
   <result pre="15: 24910.1186/1471-2474-15-24925059583 86SoumahoroM-K, BoelleP-Y, GaüzereB-A, AtsouK, PelatC, LambertB, et al.The" exact="Chikungunya" post="epidemic on La Réunion Island in 2005–2006: a cost-of-illness"/>
   <result pre="MalmontetT, FournetB, CésaireR, FanonJL, DraméM. Do Two Screening Tools for" exact="Chikungunya" post="Virus Infection that were Developed among Younger Population Work"/>
   <result pre="BartholetS, GazeuseY, BrousteY, NajioullahF, KanagaratnamL, CésaireR, FanonJL, DraméM. Misdiagnosis of" exact="Chikungunya" post="Virus Infection: Comparison of Old and Younger Adults.J Am"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7101102\results\search\tropicalVirus\results.xml">
   <result pre="Since 2014, nondengue arbovirus infections increased; until 2016, chikungunya and" exact="Zika" post="were most common. Imported arbovirus infections (mostly dengue) were"/>
   <result pre="infections (mostly dengue) were frequently diagnosed, although increased chikungunya and" exact="Zika" post="virus infections coincided with their introduction and spread in"/>
   <result pre="age, some despite receipt of pretravel advice. Keywords: dengue chikungunya" exact="Zika" post="travel immigration viruses Spain arboviruses vector-borne infections In recent"/>
   <result pre="recent decades, pathogenic flaviviruses (yellow fever virus, dengue [DENV], and" exact="Zika" post="[ZIKV]) and the alphavirus chikungunya (CHIKV) have become the"/>
   <result pre="nonstructural (NS) 1 antigen detection for DENV. A diagnosis of" exact="ZIKV" post="infection based on positive IgM required a finding of"/>
   <result pre="infection based on positive IgM required a finding of negative" exact="DENV" post="IgM and vice versa or confirmation with a neutralization"/>
   <result pre="68 (22.1) 11 (52.4) 230 (46.7) Etiologic virus, no. &amp;lt;0.001" exact="Dengue" post="14 93 9 340 Chikungunya 8 162 7 103"/>
   <result pre="(46.7) Etiologic virus, no. &amp;lt;0.001 Dengue 14 93 9 340" exact="Chikungunya" post="8 162 7 103 Zika 1 53 5 50"/>
   <result pre="Dengue 14 93 9 340 Chikungunya 8 162 7 103" exact="Zika" post="1 53 5 50 Region, no. (%)† &amp;lt;0.001 Sub-Saharan"/>
   <result pre="2014, cases of non-DENV arbovirus infection reported in +Redivi increased;" exact="CHIKV" post="and ZIKV were the most common arbovirus infections until"/>
   <result pre="of non-DENV arbovirus infection reported in +Redivi increased; CHIKV and" exact="ZIKV" post="were the most common arbovirus infections until 2016 (Figure)."/>
   <result pre="arbovirus infections until 2016 (Figure). During the peak of the" exact="ZIKV" post="outbreak (mainly December 2015–November 2016), there were 226 cases"/>
   <result pre="of arbovirus infections compared with total number of infections registered." exact="Dengue" post="A total of 456 (53%) DENV monoinfections were recorded;"/>
   <result pre="number of infections registered. Dengue A total of 456 (53%)" exact="DENV" post="monoinfections were recorded; the proportion of infected women (262"/>
   <result pre="South America (66.7%) and Southeast Asia (33.3%); none were immunosuppressed." exact="Chikungunya" post="A total of 280 (32.5%) CHIKV monoinfections were recorded;"/>
   <result pre="(33.3%); none were immunosuppressed. Chikungunya A total of 280 (32.5%)" exact="CHIKV" post="monoinfections were recorded; the proportion of women (198 women,"/>
   <result pre="only 23 (16.9%) had received pretravel advice. Among patients with" exact="CHIKV" post="infection, 2 had a previous diagnosis of HIV infection"/>
   <result pre="diagnosis of HIV infection and 2 were immunosuppressed (unspecified cause)." exact="Zika" post="A total of 109 (12.7%) ZIKV monoinfections were recorded;"/>
   <result pre="were immunosuppressed (unspecified cause). Zika A total of 109 (12.7%)" exact="ZIKV" post="monoinfections were recorded; the proportion of women (66 women,"/>
   <result pre="No cases in pregnant women were recorded. Among patients with" exact="ZIKV" post="infection, 1 had a previous diagnosis of HIV infection"/>
   <result pre="&amp;gt;1 arbovirus (some probable co-infections with positive serology results for" exact="DENV" post="and ZIKV were also registered, but these cases could"/>
   <result pre="(some probable co-infections with positive serology results for DENV and" exact="ZIKV" post="were also registered, but these cases could not be"/>
   <result pre="were also registered, but these cases could not be confirmed)." exact="DENV" post="and ZIKV co-infection occurred in 10 patients and DENV"/>
   <result pre="registered, but these cases could not be confirmed). DENV and" exact="ZIKV" post="co-infection occurred in 10 patients and DENV and CHIKV"/>
   <result pre="confirmed). DENV and ZIKV co-infection occurred in 10 patients and" exact="DENV" post="and CHIKV co-infection in 4. Two patients were co-infected"/>
   <result pre="and ZIKV co-infection occurred in 10 patients and DENV and" exact="CHIKV" post="co-infection in 4. Two patients were co-infected with CHIKV"/>
   <result pre="and CHIKV co-infection in 4. Two patients were co-infected with" exact="CHIKV" post="and ZIKV. Most patients were travelers (9/16, 56.3%) or"/>
   <result pre="reflect recent acute (nonviremic) infections. Among VFR immigrants, infection with" exact="DENV" post="was relatively less frequent than infection with other arboviruses;"/>
   <result pre="hypothetical protected state if these patients had already experienced multiple" exact="DENV" post="infections before immigration. On the other hand, some of"/>
   <result pre="group may have resulted from waning or incomplete immunity to" exact="DENV" post="because homotypic reinfections, as well as poor in vitro"/>
   <result pre="although in recent years, and coinciding with the introduction of" exact="CHIKV" post="and ZIKV in the Western Hemisphere, increased infections caused"/>
   <result pre="recent years, and coinciding with the introduction of CHIKV and" exact="ZIKV" post="in the Western Hemisphere, increased infections caused by CHIKV"/>
   <result pre="and ZIKV in the Western Hemisphere, increased infections caused by" exact="CHIKV" post="and ZIKV have been registered. In our study, CHIKV"/>
   <result pre="in the Western Hemisphere, increased infections caused by CHIKV and" exact="ZIKV" post="have been registered. In our study, CHIKV accounted for"/>
   <result pre="by CHIKV and ZIKV have been registered. In our study," exact="CHIKV" post="accounted for most of the arbovirus infections diagnosed during"/>
   <result pre="for most of the arbovirus infections diagnosed during 2015, and" exact="ZIKV" post="caused most of the arbovirus infections diagnosed during 2016,"/>
   <result pre="a key risk factor associated with severe arthralgia caused by" exact="CHIKV" post="infection (11–13). However, these findings are not consistent; other"/>
   <result pre="studies describing complicated infections have found that among patients with" exact="CHIKV" post="infection admitted to an intensive care unit, the greater"/>
   <result pre="pretravel advice), an issue of concern given the association of" exact="ZIKV" post="and possibly DENV infection with increased risk for congenital"/>
   <result pre="issue of concern given the association of ZIKV and possibly" exact="DENV" post="infection with increased risk for congenital malformations (16,17). Although"/>
   <result pre="for congenital malformations (16,17). Although we found no records of" exact="ZIKV" post="infections in pregnant women, cases of congenital ZIKV infection"/>
   <result pre="records of ZIKV infections in pregnant women, cases of congenital" exact="ZIKV" post="infection have been reported in Spain (18). Available data"/>
   <result pre="(all dengue) occurred in immunosuppressed patients. According to published data," exact="CHIKV" post="in solid organ transplant recipients seems to have a"/>
   <result pre="a benign course and favorable outcome (19,20), whereas data for" exact="DENV" post="in these patients are less clear. Case descriptions report"/>
   <result pre="with dengue (21–23). A recent report of DENV, ZIKV, and" exact="CHIKV" post="infections diagnosed in hematopoietic stem cell transplant recipients and"/>
   <result pre="recipients and oncohematologic patients found prolonged viremia in those with" exact="DENV" post="and viruria in those with ZIKV; the most common"/>
   <result pre="outcomes and even atypical presentations: a fatal pseudotumoral form of" exact="ZIKV" post="meningoencephalitis in a heart transplant recipient has been reported"/>
   <result pre="(20,26,27). In a study of 43 HIV-positive patients with confirmed" exact="ZIKV" post="infection, no hospitalizations, complications, or deaths were found, and"/>
   <result pre="cell counts and HIV viral load did not differ after" exact="ZIKV" post="infection (28). Regarding arbovirus infections in patients immunosuppressed for"/>
   <result pre="and transmission by the same species of DENV, ZIKV, and" exact="CHIKV" post="vector during the main outbreak periods in Latin America"/>
   <result pre="to investigate patients with acute undifferentiated febrile illness during the" exact="CHIKV" post="outbreak in Haiti found that ≈10% of the children"/>
   <result pre="outbreak in Haiti found that ≈10% of the children with" exact="CHIKV" post="infection during the study period were infected with another"/>
   <result pre="disease. In some cases, cross-reactions between antibodies to the flaviviruses" exact="DENV" post="and ZIKV may have posed a diagnostic challenge (neutralization"/>
   <result pre="some cases, cross-reactions between antibodies to the flaviviruses DENV and" exact="ZIKV" post="may have posed a diagnostic challenge (neutralization assays were"/>
   <result pre="Recent yellow fever vaccination may yield false-positive IgM results for" exact="DENV" post="and ZIKV, but most of these infections in this"/>
   <result pre="are established, as illustrated by the recent diagnosis of autochthonous" exact="DENV" post="and CHIKV infections in several southern European countries such"/>
   <result pre="as illustrated by the recent diagnosis of autochthonous DENV and" exact="CHIKV" post="infections in several southern European countries such as France,"/>
   <result pre="from Barcelona (2,33). In 2019, an additional case of autochthonous" exact="DENV" post="was diagnosed in Catalonia (34). The virus was probably"/>
   <result pre="in mainland Spain. Ae. aegypti mosquitoes, the main vector for" exact="DENV" post="transmission, have been introduced in areas of Europe, are"/>
   <result pre="Canary Islands were reported (2). Recently, probable sexual transmission of" exact="DENV" post="in an area without documented presence of mosquito vectors"/>
   <result pre="diagnostic tests to detect specific antigens such as the NS1" exact="DENV" post="antigen. Early detection of imported infections in viremic patients"/>
   <result pre="in areas where competent vectors are established. The number of" exact="ZIKV" post="infections in women of childbearing age, despite these women"/>
   <result pre="even several months after travel (36). Although sexual transmission of" exact="DENV" post="seems to be a rare route of transmission and"/>
   <result pre="extremely low, clinicians should consider this possibility for patients with" exact="DENV" post="and no compatible travel history and should advise patients"/>
   <result pre="and no compatible travel history and should advise patients with" exact="DENV" post="that the risk for transmission via this route may"/>
   <result pre="International Health Regulations (2005) regarding microcephaly, other neurological disorders and" exact="Zika" post="virus [cited 2018 Dec 26]. https://www.who.int/en/news-room/detail/18-11-2016-fifth-meeting-of-the-emergency-committee-under-the-international-health-regulations-(2005)-regarding-microcephaly-other-neurological-disorders-and-zika-virus 4. LederK, GrobuschMP,"/>
   <result pre="GautretP, ChenLH, KuhnS, LimPL, et al.; collab: GeoSentinel Surveillance Network." exact="Zika" post="beyond the Americas: Travelers as sentinels of Zika virus"/>
   <result pre="Surveillance Network. Zika beyond the Americas: Travelers as sentinels of" exact="Zika" post="virus transmission. A GeoSentinel analysis, 2012 to 2016.PLoS One."/>
   <result pre="Dis. 2018;24:178–80. 10.3201/eid2401.17160529076806 7. HamerDH, ChenLH, LibmanM, GrobuschMP, EspositoDH. Travel-associated" exact="Zika" post="virus disease.Ann Intern Med. 2017;166:913–4. 10.7326/L17-019528630988 8. WaggonerJJ, BalmasedaA,"/>
   <result pre="associated with severe arthralgia in acute and chronic phases of" exact="Chikungunya" post="virus infection.Exp Ther Med. 2018;15:2634–42.29467856 13. LozierM, AdamsL, FeboMF,"/>
   <result pre="13. LozierM, AdamsL, FeboMF, Torres-AponteJ, Bello-PaganM, RyffKR, et al.Incidence of" exact="Zika" post="virus disease by age and sex—Puerto Rico, November 1,"/>
   <result pre="15. VougaM, ChiuYC, PomarL, de MeyerSV, MasmejanS, GentonB, et al.Dengue," exact="Zika" post="and chikungunya during pregnancy: pre- and post-travel advice and"/>
   <result pre="management.J Travel Med. 2019;26:taz077. 10.1093/jtm/taz07731616923 16. RasmussenSA, JamiesonDJ, HoneinMA, PetersenLR." exact="Zika" post="virus and birth defects—reviewing the evidence for causality.N Engl"/>
   <result pre="18. SulleiroE, RandoA, AlejoI, SuyA, GonceA, RodóC, et al.Screening for" exact="Zika" post="virus infection in 1057 potentially exposed pregnant women, Catalonia"/>
   <result pre="Dis. 2019;29:69–71. 10.1016/j.tmaid.2019.03.00630885699 19. RossoF, RodríguezS, CedanoJA, MoraBL, MoncadaPA, VelezJD." exact="Chikungunya" post="in solid organ transplant recipients, a case series and"/>
   <result pre="2018;20:e12978. 10.1111/tid.1297830120808 20. Dalla GasperinaD, BalsamoML, GaravagliaSD, RovidaF, BaldantiF, GrossiPA." exact="Chikungunya" post="infection in a human immunodeficiency virus-infected kidney transplant recipient"/>
   <result pre="Dominican Republic.Transpl Infect Dis. 2015;17:876–9. 10.1111/tid.1245326771689 21. WeerakkodyRM, PatrickJA, SheriffMH." exact="Dengue" post="fever in renal transplant patients: a systematic review of"/>
   <result pre="Proc. 2017;92:460–6. 10.1016/j.mayocp.2016.12.01928259231 26. Delgado-EncisoI, Espinoza-GómezF, Ochoa-JiménezR, Valle-ReyesS, VásquezC, López-LemusUA." exact="Dengue" post="infection in a human immunodeficiency virus-1 positive patient chronically"/>
   <result pre="FilippisAM, MendonçaMC, SequeiraPC, SiqueiraAM, VelosoVG, et al.First detection of autochthonous" exact="Zika" post="virus transmission in a HIV-infected patient in Rio de"/>
   <result pre="AnjosRO, SantosVC, GonçalvesTSF, et al.Concomitant transmission of dengue, chikungunya and" exact="Zika" post="viruses in Brazil: clinical and epidemiological findings from surveillance"/>
   <result pre="NormanFF, ChamorroS, VázquezA, Sánchez-SecoMP, Pérez-MolinaJA, Monge-MailloB, et al.Sequential chikungunya and" exact="Zika" post="virus infections in a traveler from Honduras.Am J Trop"/>
   <result pre="guidance for preconception counseling and prevention of sexual transmission of" exact="Zika" post="virus for men with possible Zika virus exposure—United States,"/>
   <result pre="of sexual transmission of Zika virus for men with possible" exact="Zika" post="virus exposure—United States, August 2018.MMWR Morb Mortal Wkly Rep."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7101119\results\search\tropicalVirus\results.xml">
   <result pre="pmid: 3204395918-1739 doi: 10.3201/eid2604.181739 : Research: Research: Comprehensive Profiling of" exact="Zika" post="Virus Risk with Natural and Artificial Mitigating Strategies, United"/>
   <result pre="Natural and Artificial Mitigating Strategies, United States Comprehensive Profiling of" exact="Zika" post="Virus Risk with Natural and Artificial Mitigating Strategies, United"/>
   <result pre="Risk with Natural and Artificial Mitigating Strategies, United States Profiling" exact="Zika" post="Virus Risk, United States MinaMichael J.1GutermanL. Beryl1AllenKristen E.OmerSaad B.[],"/>
   <result pre="St, Buffalo, NY 14203, USA; email: lberylguterman@gmail.com ppub: 2020-4264700710 Abstract" exact="Zika" post="virus is transitioning to become a long-term public health"/>
   <result pre="We developed a stochastic epidemiologic model to profile risk for" exact="Zika" post="virus emergence, including trimester-specific fetal risk across time, in"/>
   <result pre="should serve as a critical resource for resource allocation. Keywords:" exact="Zika" post="transmission control viruses United States mosquitoborne diseases vector-borne infections"/>
   <result pre="viruses United States mosquitoborne diseases vector-borne infections viruses risk profiling" exact="Zika" post="virus is a flavivirus spread by Aedes mosquitoes that"/>
   <result pre="an esoteric threat to human health (1). However, the recent" exact="Zika" post="epidemic, which erupted in South America in 2015 and"/>
   <result pre="classified a global emergency by the World Health Organization (WHO)," exact="Zika" post="virus emergence and transmission continues globally, and WHO warns"/>
   <result pre="virus emergence and transmission continues globally, and WHO warns that" exact="Zika" post="virus is set to remain as a long-term public"/>
   <result pre="public health challenge (3). Given the critical importance of preventing" exact="Zika" post="virus infections, especially during pregnancy, transmission anywhere requires that"/>
   <result pre="entirely susceptible populations. Numerous models for the potential emergence of" exact="Zika" post="virus in the United States focus largely on the"/>
   <result pre="the year are more limited. Here we present a stochastic" exact="Zika" post="virus compartment model that considers the overlap of vector"/>
   <result pre="Rico. The model was used to profile the risk for" exact="Zika" post="virus transmission, assuming an initial introduction into each county,"/>
   <result pre="under varying control measures. We tested 3 approaches to controlling" exact="Zika" post="virus transmission and assessed their utility in preventing or"/>
   <result pre="virus transmission and assessed their utility in preventing or abrogating" exact="Zika" post="virus transmission. These approaches include reducing human–vector contact (i.e.,"/>
   <result pre="once herd-immunity thresholds are achieved (11). Methods We modeled county-level" exact="Zika" post="virus transmission using a coupled 2-system stochastic human–mosquito differential"/>
   <result pre="(12) describing the ecologic extent of the major vectors of" exact="Zika" post="virus, Ae. aegypti and Ae. albopictus mosquitoes, with dynamic"/>
   <result pre="virus, Ae. aegypti and Ae. albopictus mosquitoes, with dynamic temperature-dependent" exact="Zika" post="virus and Aedes life-stage models, local climate data, and"/>
   <result pre="information, including population and monthly birth cohort data. We simulated" exact="Zika" post="virus transmission given a single importation (index case) into"/>
   <result pre="fitting nonlinear models to county-level monthly birth data, trimester-specific fetal" exact="Zika" post="virus exposures. To remain relevant to local, state, and"/>
   <result pre="Table 1; Appendix Figure 1). Given the novelty of the" exact="Zika" post="virus as a major human pathogen, relatively limited information"/>
   <result pre="flavivirus that shares the same mosquito vector host system as" exact="Zika" post="virus. Such a strategy is commonly used in modeling"/>
   <result pre="is commonly used in modeling for emerging pathogens, including other" exact="Zika" post="virus transmission models (7,14). Trimester-Specific Pregnancies and Exposure Calculations"/>
   <result pre="transmission models (7,14). Trimester-Specific Pregnancies and Exposure Calculations Infection with" exact="Zika" post="virus is most concerning during pregnancy, where maternal infection"/>
   <result pre="(15). These defects appear to be most strongly associated with" exact="Zika" post="virus infection during the first and second trimesters (16,17)."/>
   <result pre="reported or published estimated incidence and case counts for known" exact="Zika" post="that have arisen from local transmission in the United"/>
   <result pre="against the respective simulated data. In addition, given similarities between" exact="Zika" post="virus and dengue virus, such as common transmission vectors"/>
   <result pre="used 2 resources to derive estimates of monthly and cumulative" exact="Zika" post="virus incidence across Puerto Rico’s 8 health regions. Official"/>
   <result pre="validation (Appendix). Results Across the United States, when an infectious" exact="Zika" post="virus–infected person was introduced during peak Aedes abundance for"/>
   <result pre="(Figure 1, panel A; Appendix Figures 4–6). Figure 1 County-level" exact="Zika" post="virus risk profiling, United States including Puerto Rico. A)"/>
   <result pre="duration of outbreaks. Shown is the median monthly incidence of" exact="Zika" post="virus infections from August index cases. E) Total number"/>
   <result pre="F; Appendix Figure 13). These findings are consistent with previous" exact="Zika" post="epidemics among island populations, where seropositivity reached 50%–70% (24,25)."/>
   <result pre="and 3% sustained through the second and third winters, respectively." exact="Zika" post="Virus Infections during Pregnancy We found that natural seasonality"/>
   <result pre="of first- and second-trimester pregnancies that are out-of-phase with peak" exact="Zika" post="virus infections in the model (Figure 2, panel A)"/>
   <result pre="Our model indicates that birth seasonality alone reduced risk for" exact="Zika" post="virus exposure during first- (versus second- and third-) trimester"/>
   <result pre="risk 0.89 [95% CI 0.80–0.99]; p = 0.012). Figure 2" exact="Zika" post="virus infections during pregnancy and effects of natural birth"/>
   <result pre="States and Texas are plotted against the simulated and standardized" exact="Zika" post="epidemic curves for each county and for every month"/>
   <result pre="generalized additive model fit to the county-level data. B, C)" exact="Zika" post="virus exposure risk ratio and 95% CI during (B)"/>
   <result pre="to the baseline incidence (Figure 3, panel C). Figure 3" exact="Zika" post="prevention and control strategies, United States. For each county"/>
   <result pre="panels G–I). This finding is consistent with an R0 for" exact="Zika" post="virus of 3–4, based on the simple but robust"/>
   <result pre="estimates (26,27). Model Validation We validated the model against known" exact="Zika" post="outbreaks in the United States including Puerto Rico since"/>
   <result pre="0.980; p&amp;lt;0.001; Figure 4, panel A). In Miami-Dade County, where" exact="Zika" post="virus transmitted locally in 2016, the model estimated a"/>
   <result pre="reported by CDC (20,28,29). In Brownsville County, Texas, where local" exact="Zika" post="virus transmission was detected during October–December 2016 and infected"/>
   <result pre="of 4 cases (IQR 1–8). Figure 4 Model validation for" exact="Zika" post="virus infection cases reported or estimated and simulated for"/>
   <result pre="addition, these counties might serve as optimal US settings for" exact="Zika" post="vaccine efficacy trials. Zika outbreaks are likely to be"/>
   <result pre="serve as optimal US settings for Zika vaccine efficacy trials." exact="Zika" post="outbreaks are likely to be highly restricted by both"/>
   <result pre="uninterrupted transmission. These findings are also consistent with CDC’s reported" exact="Zika" post="virus disease trends among travelers for 2016 and 2017,"/>
   <result pre="addition, planned seasonal conception (based on birth seasonality and local" exact="Zika" post="virus transmission data) is a viable intervention to pursue"/>
   <result pre="transmission data) is a viable intervention to pursue while maternal" exact="Zika" post="virus vaccine and risk profiles, as they relate to"/>
   <result pre="in 2016. Previous estimates by Ellington et al. (29) using" exact="Zika" post="case data projected that ≈7,800 exposures in pregnancy would"/>
   <result pre="the proposed model might influence county level risk profiles for" exact="Zika" post="virus transmission. For areas with a high level of"/>
   <result pre="For areas with a high level of travel-associated imports of" exact="Zika" post="virus cases, such as cities with cruise ship ports"/>
   <result pre="certain parameters (e.g., incubation period and period of infectiousness of" exact="Zika" post="virus infection) and transmission pathways (e.g., sexual transmission of"/>
   <result pre="Zika virus infection) and transmission pathways (e.g., sexual transmission of" exact="Zika" post="virus) are not fully understood and might contribute to"/>
   <result pre="not fully understood and might contribute to elevated risk for" exact="Zika" post="epidemics (36,37). Zika virus transmission is expected to persist"/>
   <result pre="and might contribute to elevated risk for Zika epidemics (36,37)." exact="Zika" post="virus transmission is expected to persist as a long-term"/>
   <result pre="entirely susceptible population, with risk for transmission. As long as" exact="Zika" post="virus circulates anywhere, the continued importation into the United"/>
   <result pre="local, state, and national resources aimed at preventing and controlling" exact="Zika" post="virus transmission and should provide critical information to inform"/>
   <result pre="future vaccination efforts. Appendix Additional information about comprehensive profiling of" exact="Zika" post="virus risk with natural and artificial mitigating strategies, United"/>
   <result pre="MJ, Guterman LB, Allen KE, Omer SB. Comprehensive profiling of" exact="Zika" post="virus risk with natural and artificial mitigating strategies, United"/>
   <result pre="develop and implement vaccine programs. References References 1. FauciAS, MorensDM." exact="Zika" post="virus in the Americas—yet another arbovirus threat.N Engl J"/>
   <result pre="J Med. 2016;374:601–4. 10.1056/NEJMp160029726761185 2. JohanssonMA, Mier-y-Teran-RomeroL, ReefhuisJ, GilboaSM, HillsSL." exact="Zika" post="and the risk of microcephaly.N Engl J Med. 2016;375:1–4."/>
   <result pre="2016;375:1–4. 10.1056/NEJMp160536727222919 3. collab: World Health Organization. WHO response to" exact="Zika" post="virus [cited 2017 Feb 7]. http://www.who.int/emergencies/zika-virus 4. RasmussenSA, JamiesonDJ,"/>
   <result pre="[cited 2017 Feb 7]. http://www.who.int/emergencies/zika-virus 4. RasmussenSA, JamiesonDJ, HoneinMA, PetersenLR." exact="Zika" post="virus and birth defects—reviewing the evidence for causality.N Engl"/>
   <result pre="MajorCG, MayshackM, MedinaN, MatosD, RyffKR, et al.Guillain-Barré syndrome during ongoing" exact="Zika" post="virus transmission—Puerto Rico, January 1–July 31, 2016.MMWR Morb Mortal"/>
   <result pre="BradyOJ, PigottDM, ShearerFM, WeissDJ, et al.Mapping global environmental suitability for" exact="Zika" post="virus.eLife. 2016;5:e15272. 10.7554/eLife.1527227090089 7. BogochII, BradyOJ, KraemerMUG, GermanM, CreatoreMI,"/>
   <result pre="KraemerMUG, GermanM, CreatoreMI, KulkarniMA, et al.Anticipating the international spread of" exact="Zika" post="virus from Brazil.Lancet. 2016;387:335–6. 10.1016/S0140-6736(16)00080-526777915 8. collab: Centers for"/>
   <result pre="Pastore-PionttiA, ChinazziM, MistryD, DeanNE, et al.Quantifying the risk of local" exact="Zika" post="virus transmission in the contiguous US during the 2015-2016"/>
   <result pre="Zika virus transmission in the contiguous US during the 2015-2016" exact="ZIKV" post="epidemic.BMC Med. 2018;16:195. 10.1186/s12916-018-1185-530336778 10. CastroLA, FoxSJ, ChenX, LiuK,"/>
   <result pre="10. CastroLA, FoxSJ, ChenX, LiuK, BellanSE, DimitrovNB, et al.Assessing real-time" exact="Zika" post="risk in the United States.BMC Infect Dis. 2017;17:284. 10.1186/s12879-017-2394-928468671"/>
   <result pre="10.1063/1.274529917581038 14. PerkinsTA, SirajAS, RuktanonchaiCW, KraemerMUG, TatemAJ. Model-based projections of" exact="Zika" post="virus infections in childbearing women in the Americas.Nat Microbiol."/>
   <result pre="10.1038/nmicrobiol.2016.12627562260 15. PachecoO, BeltránM, NelsonCA, ValenciaD, TolosaN, FarrSL, et al." exact="Zika" post="virus disease in Colombia—preliminary report. N Engl J Med."/>
   <result pre="JaenischT, RosenbergerKD, BritoC, BradyO, BrasilP, MarquesET. Risk of microcephaly after" exact="Zika" post="virus infection in Brazil, 2015 to 2016.Bull World Health"/>
   <result pre="Health Organ. 2017;95:191–8. 10.2471/BLT.16.17860828250532 17. GérardinP, Cao-LormeauV-M, MussoD, DesprèsP, BesnardM." exact="Zika" post="rash and increased risk of congenital brain abnormalities.Lancet. 2017;389:151–2."/>
   <result pre="AlamriYS, RabhanFS, AlabdullahAA, AlsanieNA, AlmarshadFA, et al.Overview of dengue and" exact="Zika" post="virus similarity, what can we learn from the Saudi"/>
   <result pre="Health Sci (Qassim). 2018;12:77–82.29623022 19. McNeilDG, FernandezM. Local transmission of" exact="Zika" post="virus is reported in Texas. The New York Times."/>
   <result pre="2017 Apr 28]. https://www.nytimes.com/2016/11/28/health/zika-case-texas.html 20. collab: Florida Department of Health." exact="Zika" post="virus [cited2017 Apr 28]. http://www.floridahealth.gov/diseases-and-conditions/zika-virus 21. RadkeEG, GregoryCJ, KintzigerKW,"/>
   <result pre="West, Florida, USA, 2009.Emerg Infect Dis. 2012;18:135–7. 10.3201/eid1801.11013022257471 22. ReyJR." exact="Dengue" post="in Florida (USA).Insects. 2014;5:991–1000. 10.3390/insects504099126462955 23. ChevalierMS, BiggerstaffBJ, BasavarajuSV,"/>
   <result pre="Climent-PerisC, et al.Use of blood donor screening data to estimate" exact="Zika" post="virus incidence, Puerto Rico, April–August 2016.Emerg Infect Dis. 2017;23:790–5."/>
   <result pre="24. CauchemezS, BesnardM, BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013-15: a retrospective"/>
   <result pre="MubayiA, Romero-VivasCME. Estimate of the reproduction number of the 2015" exact="Zika" post="virus outbreak in Barranquilla, Colombia, and estimation of the"/>
   <result pre="FergusonNM, CucunubáZM, DorigattiI, Nedjati-GilaniGL, DonnellyCA, BasáñezM-G, et al.EPIDEMIOLOGY. Countering the" exact="Zika" post="epidemic in Latin America.Science. 2016;353:353–4. 10.1126/science.aag021927417493 28. collab: Puerto"/>
   <result pre="Puerto Rico Department of Health. Weekly report on arboviral diseases," exact="Zika" post="report by municipalities [in Spanish] [cited 2016 Dec 19]."/>
   <result pre="Perez-PadillaJ, et al.Estimating the number of pregnant women infected with" exact="Zika" post="virus and expected infants with microcephaly following the Zika"/>
   <result pre="with Zika virus and expected infants with microcephaly following the" exact="Zika" post="virus outbreak in Puerto Rico, 2016.JAMA Pediatr. 2016;170:940–5. 10.1001/jamapediatrics.2016.297427544075"/>
   <result pre="32. HallV, WalkerWL, LindseyNP, LehmanJA, KolsinJ, LandryK, et al.Update: noncongenital" exact="Zika" post="virus disease cases—50 U.S. States and the District of"/>
   <result pre="2018;67:265–9. 10.15585/mmwr.mm6709a129518067 33. HayJA, NouvelletP, DonnellyCA, RileyS. Potential inconsistencies in" exact="Zika" post="surveillance data and our understanding of risk during pregnancy.PLoS"/>
   <result pre="during pregnancy.PLoS Negl Trop Dis. 2018;12:e0006991. 10.1371/journal.pntd.000699130532143 34. MartinezME. Preventing" exact="Zika" post="virus infection during pregnancy using a seasonal window of"/>
   <result pre="DudasG, TanAL, GangavarapuK, et al.Genomic epidemiology reveals multiple introductions of" exact="Zika" post="virus into the United States.Nature. 2017;546:401–5. 10.1038/nature2240028538723 36. LesslerJ,"/>
   <result pre="CarcelenAC, KonikoffJM, WilliamsonJ, BiQ, et al.Times to key events in" exact="Zika" post="virus infection and implications for blood donation: a systematic"/>
   <result pre="CounotteMJ, KimCR, WangJ, BernsteinK, DealCD, BroutetNJN, et al.Sexual transmission of" exact="Zika" post="virus and other flaviviruses: A living systematic review.PLoS Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7101124\results\search\tropicalVirus\results.xml">
   <result pre="Letter: Research Letter: Detection of Rocio Virus SPH 34675 during" exact="Dengue" post="Epidemics, Brazil, 2011–2013 Detection of Rocio Virus SPH 34675"/>
   <result pre="Epidemics, Brazil, 2011–2013 Detection of Rocio Virus SPH 34675 during" exact="Dengue" post="Epidemics, Brazil, 2011–2013 Detection of Rocio Virus SPH 34675"/>
   <result pre="Epidemics, Brazil, 2011–2013 Detection of Rocio Virus SPH 34675 during" exact="Dengue" post="Epidemics, Brazil, 2011–2013 SaivishMarielena V.da CostaVivaldo G.RodriguesRoger L.FéresValéria C.R.Montoya-DiazEduardoMoreliMarcos"/>
   <result pre="infection. During the outbreak, the city reported ≈88,000 cases of" exact="DENV" post="infection (6). Of the 647 samples screened for DENV"/>
   <result pre="of DENV infection (6). Of the 647 samples screened for" exact="DENV" post="by use of serologic and molecular methods, 121 were"/>
   <result pre="encephalitis virus; TBEV, tick-borne encephalitis virus; USUV, Usutu virus; WNV," exact="West Nile" post="virus; YFV, yellow fever virus; ZIKV, Zika virus. The"/>
   <result pre="virus; WNV, West Nile virus; YFV, yellow fever virus; ZIKV," exact="Zika" post="virus. The 2 ROCV-positive samples were from a 33-year-old"/>
   <result pre="KeaseySL, PughCL, JensenSMR, SmithJL, HontzRD, DurbinAP, et al.Antibody responses to" exact="Zika" post="virus infections in environments of flavivirus endemicity.Clin Vaccine Immunol."/>
   <result pre="JulianoR, VelezJ, NogueiraRMR, KomarN. Serological evidence of widespread circulation of" exact="West Nile" post="virus and other flaviviruses in equines of the Pantanal,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7102570\results\search\tropicalVirus\results.xml">
   <result pre="in Patients With Severe InfluenzaNCT03394209https://clinicaltrials.gov/ct2/show/NCT033942092018 Cardona-OspinaJ.A.Henao-SanMartinV.Paniz-MondolfiA.E.Rodriguez-MoralesA.J.Mortality and fatality due to" exact="Chikungunya" post="virus infection in ColombiaJournal of Clinical Virology702015141526305812 CarolineA.L.PowellD.S.BethelL.M.OuryT.D.ReedD.S.HartmanA.L.Broad spectrum"/>
   <result pre="treatment of argentine hemorrhagic feverAntiviral Research23199423318141590 Escribano-RomeroE.Jiménez de OyaN.DomingoE.SaizJ.C.Extinction of" exact="West Nile" post="virus by favipiravir through lethal mutagenesisAntimicrobial Agents and Chemotherapy61112017"/>
   <result pre="virusIntervirology2919883013102852653 MorreyJ.D.TaroB.S.SiddharthanV.WangH.SmeeD.F.ChristensenA.J.FurutaY.Efficacy of orally administered T-705 pyrazine analog on lethal" exact="West Nile" post="virus infection in rodentsAntiviral Research80200837737918762216 NaesensL.GuddatL.W.KeoughD.T.van KuilenburgA.B.MeijerJ.Vande VoordeJ.BalzariniJ.Role of"/>
   <result pre="endonuclease inhibitor baloxavir marboxilScientific Reports82018963329941893 PhilpottD.C.E.NolanM.S.EvertN.MayesB.HesalroadD.FonkenE.MurrayK.O.Acute and delayed deaths after" exact="West Nile" post="virus infection, Texas, USA, 2002-2012Emerging Infectious Diseases252019256264 PomfretE.A.PomposelliJ.J.JenkinsR.L.Live donor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7102768\results\search\tropicalVirus\results.xml">
   <result pre="in mammalian hosts, in both H5N1 and H3N2 subtypes. [67]" exact="West Nile" post="Virus (WNV) NS3 T249P A single change (Thr→Pro) in"/>
   <result pre="amino acids 627K or 627E/701NPLoS Pathog52009e1000252 68BraultA.C.HuangC.Y.H.LangevinS.A.KinneyR.M.BowenR.A.RameyW.N.PanellaN.A.HolmesE.C.PowersA.M.MillerB.R.A single positively selected" exact="West Nile" post="viral mutation confers increased virogenesis in American crowsNat Genet3920071162116617694056"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7106000\results\search\tropicalVirus\results.xml">
   <result pre="by S. calcitrans may include equine infectious anaemia virus (EIAV)," exact="West Nile" post="fever virus (WNFV), Rift Valley fever virus (RVFV), lumpy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7106487\results\search\tropicalVirus\results.xml">
   <result pre="Communication: Communications Design, Synthesis and Discovery of N,N’�?Carbazoyl�?aryl�?urea Inhibitors of" exact="Zika" post="NS5 Methyltransferase and Virus Replication SpizzichinoSharon12MattediGiulio1LauderKate1ValleCoralie3AouadiWahibaDr.3CanardBrunoDr.3DecrolyEtienneDr.3KapteinSuzanne J. F.Dr.4NeytsJohanProf.4GrahamCarl1SuleZakary1BarlowDavid J.Dr.1SilvestriRomanoProf.2CastagnoloDanieleDr.http://orcid.org/0000-0002-7517-57321daniele.castagnolo@kcl.ac.uk[1],"/>
   <result pre="work is properly cited.file:CMDC-15-385.pdf Abstract Abstract The recent outbreaks of" exact="Zika" post="virus (ZIKV) infection worldwide make the discovery of novel"/>
   <result pre="priority. This work describes the identification of novel inhibitors of" exact="ZIKV" post="through a structure�?based virtual screening approach using the ZIKV"/>
   <result pre="of ZIKV through a structure�?based virtual screening approach using the" exact="ZIKV" post="NS5�?MTase. A novel series of molecules with a carbazoyl�?aryl�?urea"/>
   <result pre="library of analogues has been synthesized. The new compounds inhibit" exact="ZIKV" post="MTase with IC50 between 23–48 μM. In addition, carbazoyl�?aryl�?ureas also"/>
   <result pre="IC50 between 23–48 μM. In addition, carbazoyl�?aryl�?ureas also proved to inhibit" exact="ZIKV" post="replication activity at micromolar concentration. Novel antivirals targeting ZIKA"/>
   <result pre="concentration. Novel antivirals targeting ZIKA virus: The recent outbreaks of" exact="Zika" post="virus (ZIKV) worldwide make the discovery of novel antivirals"/>
   <result pre="series of carbazoyl�?urea derivatives that are able to inhibit the" exact="ZIKV" post="NS5�?MTase as well as ZIKV replication at micromolar concentration."/>
   <result pre="are able to inhibit the ZIKV NS5�?MTase as well as" exact="ZIKV" post="replication at micromolar concentration. Zika flavivirus methyltransferase antiviral agents"/>
   <result pre="ZIKV NS5�?MTase as well as ZIKV replication at micromolar concentration." exact="Zika" post="flavivirus methyltransferase antiviral agents urea Funding European program H2020"/>
   <result pre="D. J. Barlow, R. Silvestri, D. Castagnolo, ChemMedChem2020, 15, 385." exact="Zika" post="virus (ZIKV)1, 2 is a single positive�?strand RNA mosquito�?borne"/>
   <result pre="Flavivirus and it causes mild�?severe diseases in humans and animals." exact="ZIKV" post="is closely related to Dengue virus (DENV), and just"/>
   <result pre="diseases in humans and animals. ZIKV is closely related to" exact="Dengue" post="virus (DENV), and just like DENV, is mainly transmitted"/>
   <result pre="infected Aedes species mosquitoes (Ae. aegypti and Ae. albopictus).3 However," exact="ZIKV" post="can also be transmitted between humans through contact with"/>
   <result pre="by mother�?to�?fetus transmission during the pregnancy.6 While global epidemics of" exact="DENV" post="have spread over the past few decades causing more"/>
   <result pre="past few decades causing more than 20,000 demises per year," exact="ZIKV" post="infections have emerged as a major public health concern"/>
   <result pre="However, following the recent outbreaks in the Americas in 2015," exact="ZIKV" post="was declared by the World Health Organization (WHO) as"/>
   <result pre="of International Concern (PHEIC) and the first case of sexually�?transmitted" exact="ZIKV" post="was reported in USA in 2008. While ZIKV infections"/>
   <result pre="of sexually�?transmitted ZIKV was reported in USA in 2008. While" exact="ZIKV" post="infections generally cause a mild fever, headache, malaise, skin"/>
   <result pre="outbreaks, as well as the increasing number of cases of" exact="ZIKV" post="infections worldwide, have raised the attention of pharmaceutical industries"/>
   <result pre="of efficient treatments against these diseases. Although a vaccine against" exact="DENV" post="has recently been commercialized (DENGVAXIA®),6 there is as yet"/>
   <result pre="been commercialized (DENGVAXIA®),6 there is as yet no vaccine against" exact="ZIKV" post="available. In addition, there are no drugs available to"/>
   <result pre="addition, there are no drugs available to treat or prevent" exact="ZIKV" post="infections, especially in the event of an outbreak. A"/>
   <result pre="number of early�?phase discovery studies have identified few inhibitors of" exact="DENV" post="and ZIKV replication,7, 8, 9, 10, 11, 12, 13,"/>
   <result pre="early�?phase discovery studies have identified few inhibitors of DENV and" exact="ZIKV" post="replication,7, 8, 9, 10, 11, 12, 13, 14, 15"/>
   <result pre="such as 1–5 (Figure 1), have been designed to target the" exact="DENV" post="viral proteins NS3 (protease domain,16 helicase domain,17 and full�?length"/>
   <result pre="RNA�?dependent RNA polymerase (RdRp).20 The NS3 and NS5 proteins of" exact="DENV" post="and ZIKV show a high degree of homology, and"/>
   <result pre="polymerase (RdRp).20 The NS3 and NS5 proteins of DENV and" exact="ZIKV" post="show a high degree of homology, and their crystal"/>
   <result pre="their crystal structures have recently been determined.21, 22, 23 While" exact="DENV" post="NS5�?polymerase has been investigated by a number of research"/>
   <result pre="antivirals, there has been very little work carried out on" exact="DENV" post="and ZIKV NS5�?MTase.18, 23, 24 The NS5�?MTase is responsible"/>
   <result pre="has been very little work carried out on DENV and" exact="ZIKV" post="NS5�?MTase.18, 23, 24 The NS5�?MTase is responsible for maturation"/>
   <result pre="anti�?DENV, antivirals.24 Figure 1 Examples of small molecules active against" exact="DENV" post="and/or ZIKV, and overview of this work. Herein, a"/>
   <result pre="virtual screening on a set of chemical libraries using the" exact="ZIKV" post="NS5�?MTase was performed, with the aim to identify structurally"/>
   <result pre="to identify structurally novel flaviviruses inhibitors. The structure of the" exact="ZIKV" post="NS5 MTase was built by homology modelling using SWISS�?MODEL28,"/>
   <result pre="urea 6 was thus evaluated in enzymatic inhibition assays against" exact="ZIKV" post="NS5�?MTase, showing an IC50 of 35 μM (Table 1). A similar"/>
   <result pre="IC50 of 38 μM was observed when 6 was assayed against" exact="DENV" post="NS5�?MTase. Due to the novelty of the structure when"/>
   <result pre="favorable binding pose of the hit compound 6 in the" exact="ZIKV" post="NS5�?MTase binding pocket. The urea spacer connects the carbazole"/>
   <result pre="with the protein. The high sequence and structural identity between" exact="ZIKV" post="and DENV NS5�?MTases led to the identical binding of"/>
   <result pre="protein. The high sequence and structural identity between ZIKV and" exact="DENV" post="NS5�?MTases led to the identical binding of compound 6"/>
   <result pre="11 and 21 against host and flavivirus MTases. Compd hRNMT" exact="ZIKV" post="NS5�?MTase DENV NS5�?MTase IC50 [μM] 6 13.9±0.7 35±5 38±6.7"/>
   <result pre="21 against host and flavivirus MTases. Compd hRNMT ZIKV NS5�?MTase" exact="DENV" post="NS5�?MTase IC50 [μM] 6 13.9±0.7 35±5 38±6.7 9a ≈122"/>
   <result pre="Verlag GmbH &amp;amp; Co. KGaA, Figure 2 a) SAM bound" exact="ZIKV" post="NS5 MTase in PDB 5M5B.23 b) Docking of compound"/>
   <result pre="MTase in PDB 5M5B.23 b) Docking of compound 6 in" exact="ZIKV" post="NS5 MTase. The carbazole pocket is accommodated in the"/>
   <result pre="of the binding pocket. c) Docking of compound 6 in" exact="DENV" post="NS5�?MTase (PDB 5E9Q).24 Next, a library of analogues of"/>
   <result pre="viral and the human MTases (NS5 and hRNMT). However, both" exact="ZIKV" post="and DENV NS5�?MTase possess a hydrophobic pocket located near"/>
   <result pre="the human MTases (NS5 and hRNMT). However, both ZIKV and" exact="DENV" post="NS5�?MTase possess a hydrophobic pocket located near the exocyclic"/>
   <result pre="of SAM,18 which is absent in the hRNMT. In the" exact="ZIKV" post="MTase, the region is defined by the amino acids"/>
   <result pre="residues F133, I147, G148, E149, R160, and V164 in the" exact="DENV" post="MTase. We anticipated that the absence of this hydrophobic"/>
   <result pre="to hRNTM (PDB 5E8J).30 b) Docking of compound 21 b in" exact="ZIKV" post="NS5 MTase. The ethyl spacer on the carbazole nitrogen"/>
   <result pre="recombinant MTases. All compounds were initially screened at 50 μM against" exact="ZIKV" post="NS5�?MTase and hRNMT as well as against DENV NS5�?MTase"/>
   <result pre="50 μM against ZIKV NS5�?MTase and hRNMT as well as against" exact="DENV" post="NS5�?MTase due to its similarity with ZIKV protein. The"/>
   <result pre="well as against DENV NS5�?MTase due to its similarity with" exact="ZIKV" post="protein. The SAM mimetic sinefungin was included as control."/>
   <result pre="9 a, 9 d, 21 b, 21 c, 21 e and 21 f showed inhibition of" exact="ZIKV" post="NS5�?MTase higher than ∼30 %. The compound 21 e and 21 f"/>
   <result pre="compound 21 e and 21 f showed the more potent reduction of" exact="ZIKV" post="NS5�?MTase activity of ∼70 %. Conversely the compounds 15 and"/>
   <result pre="and those of series 11 and 14 barely inhibited the" exact="ZIKV" post="MTase. Interestingly compound 6 and those of the series"/>
   <result pre="of the series 9 showed a similar inhibition profile on" exact="DENV" post="NS5�?MTase, but the compounds of series 21 barely inhibit"/>
   <result pre="NS5�?MTase, but the compounds of series 21 barely inhibit the" exact="DENV" post="MTase suggesting some specificity of this family. A dose�?response"/>
   <result pre="did not affect the inhibitory activity of the compound against" exact="ZIKV" post="MTase, whilst it proved to be detrimental for inhibiting"/>
   <result pre="MTase, whilst it proved to be detrimental for inhibiting the" exact="DENV" post="MTase. Similarly, the replacement of the electron withdrawing nitro"/>
   <result pre="9 f) negatively affected the compound's inhibitory activity mainly against the" exact="ZIKV" post="MTase. The different activity of compounds 6 and 9"/>
   <result pre="compounds. Derivatives 21 c, 21 e and 21 f showed good activity against" exact="ZIKV" post="MTase at concentrations similar to 6 (IC50=23–48 μM). It is"/>
   <result pre="of all the derivatives synthesized in this work to inhibit" exact="ZIKV" post="replication was assessed. Results of the most active compounds,"/>
   <result pre="activity against ZIKV. Table 2 EC50 and CC50 values against" exact="ZIKV" post="of the most active compounds of the library. Compd"/>
   <result pre="ZIKV of the most active compounds of the library. Compd" exact="ZIKV" post="EC50 [μM] CC50 [μM] 6 &amp;gt;3.99 3.99 9a &amp;gt;50"/>
   <result pre="21b 12.5 20 21d 25 100 21f &amp;gt;20 20 Compd" exact="DENV" post="EC50 [μM] CC50 [μM] 15 9.75 20 (C) Wiley�?VCH"/>
   <result pre="MTase activity. This could explain the very poor inhibition of" exact="ZIKV" post="replication in the cell�?based assay, as the 2′�?O methylation"/>
   <result pre="showed some MTase inhibitory activity, also exhibited antiviral activity against" exact="ZIKV" post="in the cell�?based assay (EC50=4.78 μM). Interestingly, derivative 15,31 which"/>
   <result pre="Interestingly, derivative 15,31 which did not show any activity against" exact="ZIKV" post="NS5�?MTase, was able to inhibit ZIKV replication with an"/>
   <result pre="show any activity against ZIKV NS5�?MTase, was able to inhibit" exact="ZIKV" post="replication with an EC50 of 1.67 μM. It is plausible"/>
   <result pre="an EC50 of 1.67 μM. It is plausible that 15 inhibits" exact="ZIKV" post="replication via a different mode of action than via"/>
   <result pre="treated cells. Interestingly, compound 15 also showed some activity against" exact="DENV" post="(EC50=9.75 μM), even if the antiviral activity is clearly linked"/>
   <result pre="(CC50=20 μM). Finally, compound 21 b which showed no enhanced activity against" exact="ZIKV" post="MTases, proved to inhibit ZIKV replication at good concentration"/>
   <result pre="showed no enhanced activity against ZIKV MTases, proved to inhibit" exact="ZIKV" post="replication at good concentration (EC50=12.5 μM). However, compound 21 b showed"/>
   <result pre="assay as well as 21 f which was found active on" exact="ZIKV" post="MTase instead. This could suggest that these compounds might"/>
   <result pre="virus replication. Interestingly, compound 21 d, which showed poor inhibition of" exact="ZIKV" post="MTase, inhibits ZIKV with good EC50=25 μM and no toxicity"/>
   <result pre="compound 21 d, which showed poor inhibition of ZIKV MTase, inhibits" exact="ZIKV" post="with good EC50=25 μM and no toxicity (CC50=100 μM). In summary,"/>
   <result pre="screening protocol on a set of chemical libraries using the" exact="ZIKV" post="NS5�?MTase was performed leading to the identification of a"/>
   <result pre="Compounds 6 and 21 c, 21 e, 21 f showed inhibitory activity against" exact="ZIKV" post="MTase as well as the related DENV MTase. Conversely,"/>
   <result pre="inhibitory activity against ZIKV MTase as well as the related" exact="DENV" post="MTase. Conversely, the urea derivative 15 showed an antiviral"/>
   <result pre="Conversely, the urea derivative 15 showed an antiviral effect against" exact="ZIKV" post="with EC50 of 1.67 μM, despite its poor inhibitory activity"/>
   <result pre="Med.2016, 374, 1552–1563.27028561 3European Centre for Disease Prevention and Control," exact="Zika" post="Virus disease. https://ecdc.europa.eu/en/zika-virus-disease 4A.Hajra, D.Bandyopadhyay, L. R.Bhadra, S.Ball, S."/>
   <result pre="28When the work was carried out, the 3D structure of" exact="ZIKV" post="NS5-MTase was not elucidated yet. Thus, a homology model"/>
   <result pre="not elucidated yet. Thus, a homology model based on the" exact="DENV" post="NS5 MTase was built. The homology model was then"/>
   <result pre="homology model was then compared to the 3D structure of" exact="ZIKV" post="NS5MTase once it was released, showing full similarity. 29A.Waterhouse,"/>
   <result pre="44, 10423–10436.27422871 31Compound 15 did not show any effect on" exact="DENV" post="MTase and poorly inhibited the ZIKV MTase (25 % of"/>
   <result pre="show any effect on DENV MTase and poorly inhibited the" exact="ZIKV" post="MTase (25 % of inhibition). For this reason, the IC50"/>
   <result pre="of inhibition). For this reason, the IC50 of 15 against" exact="ZIKV" post="MTase was not determined."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7108131\results\search\tropicalVirus\results.xml">
   <result pre="the wrong CFR. Therapeutic trials for the prevention of congenital" exact="Zika" post="syndrome will be hindered by the absence of consistently"/>
   <result pre="DunningJ, HorbyPWClinical trials of therapeutics for the prevention of congenital" exact="Zika" post="virus disease: challenges and potential solutions. Ann Intern Med2017;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7108492\results\search\tropicalVirus\results.xml">
   <result pre="disease; Rift Valley fever; severe fever with thrombocytopenia syndrome; and" exact="Zika" post="virus. The revised list, as of February 2018 (12),"/>
   <result pre="and henipaviral diseases (priority list); Rift Valley fever (priority list);" exact="Zika" post="virus (priority list); Disease X (priority list); arenaviral hemorrhagic"/>
   <result pre="cattle and other domesticated livestock that also infects humans (30)." exact="Chikungunya" post="infection can lead to substantial morbidity; patients can experience"/>
   <result pre="development of drugs for biodefense. Drug Dev Res.2007;68(4):183–185. 22.Themis Bioscience." exact="Chikungunya" post="vaccine study in previously exposed adults. https://clinicaltrials.gov/ct2/show/NCT03807843. Updated July"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7109116\results\search\tropicalVirus\results.xml">
   <result pre="cases.113,114 Recently, GBS has been associated with arboviruses infections, like" exact="Zika" post="virus and chikungunya, but the mechanisms are still debated.49"/>
   <result pre="Zika virus and chikungunya, but the mechanisms are still debated.49" exact="Zika" post="virus (ZIKV) has caused recent outbreaks in Latin America,"/>
   <result pre="against ZIKV. Nico et al. reported anti-GD3 antibodies in acute" exact="ZIKV" post="infections.119 Baskar and colleagues showed anti-GM1 antibodies in 50%"/>
   <result pre="showed that only a fraction of patients with GBS after" exact="ZIKV" post="had AGAs, and their sera (anti-GA1 and GD1a) displayed"/>
   <result pre="their sera (anti-GA1 and GD1a) displayed no antibody competition between" exact="ZIKV" post="proteins and GA1, a.k.a. asialo GM1.116 In addition to"/>
   <result pre="other arbovirus infections have been associated with GBS, like dengue," exact="West Nile" post="and chikungunya with sporadic reports in the literature. Case"/>
   <result pre="who were born with microcephaly and laboratory evidence of congenital" exact="Zika" post="virus infection during the 2015 Zika virus outbreak—Brazil, 2017Mmwr."/>
   <result pre="laboratory evidence of congenital Zika virus infection during the 2015" exact="Zika" post="virus outbreak—Brazil, 2017Mmwr. Morb. Mortal. Wkly. Rep.2017661347135110.15585/mmwr.mm6649a229240727 116.Cao-LormeauVMet al.Guillain-Barré"/>
   <result pre="Morb. Mortal. Wkly. Rep.2017661347135110.15585/mmwr.mm6649a229240727 116.Cao-LormeauVMet al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 117.AnayaJMet"/>
   <result pre="119.NicoDet al.Prevalence of IgG autoantibodies against GD3 Ganglioside in acute" exact="Zika" post="virus infectionFront. Med.201852510.3389/fmed.2018.00025 120.Baskar, D., Amalnath, D., Mandal, J.,"/>
   <result pre="D., Mandal, J., Dhodapkar, R. &amp;amp; Vanathi, K. Antibodies to" exact="Zika" post="virus, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7109256\results\search\tropicalVirus\results.xml">
   <result pre="complement resistance to these pathogenic microbes. Its interaction with soluble" exact="West Nile" post="virus NS1 protein has also been described (31). Furthermore,"/>
   <result pre="Further examples of viral regulation of complement includes binding of" exact="West Nile" post="virus non-structural protein (NS1) to factor H, or association"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7109593\results\search\tropicalVirus\results.xml">
   <result pre="or naturally acquired (re-)emerging arboviral infections such as dengue, chikungunya," exact="West Nile," post="tick-borne encephalitis and Zika virus infection have demonstrated atypical"/>
   <result pre="infections such as dengue, chikungunya, West Nile, tick-borne encephalitis and" exact="Zika" post="virus infection have demonstrated atypical or more complicated clinical"/>
   <result pre="trends are likely to continue in future years. For example," exact="West Nile" post="virus (WNV), one of the most widely distributed arboviruses"/>
   <result pre="reported, including previously virus-free regions[7]. In addition, geographical distribution of" exact="Zika" post="virus (ZIKV) has steadily expanded. In 2015 and 2016,"/>
   <result pre="In the USA and US Territories, 5168 and 36512 symptomatic" exact="ZIKV" post="disease cases were reported in 2016[8]. Hepatitis E virus"/>
   <result pre="encephalitis Few data: Meningoencephalitis ELISA (IgM, IgG); VNT; RT-PCR [4,63,65]" exact="Zika" post="virus Asymptomatic infection to severe neurological disorders Infectious complications"/>
   <result pre="complications and graft rejection ELISA (IgM, IgG); VNT; RT-PCR [4,69-71]" exact="Chikungunya" post="virus Mild febrile illness and polyarthralgia, rarely meningoencephalitis, myocarditis"/>
   <result pre="impact on graft function ELISA (IgM, IgG); VNT; RT-PCR [4,74,75,77,79,80]" exact="Dengue" post="virus Asymptomatic infection to severe fatal illness More commonly"/>
   <result pre="graft rejection ELISA (IgM, IgG); VNT; NS1 antigen; RT-PCR [4,82,84-86]" exact="West Nile" post="virus Asymptomatic infection, mild febrile disease, neuroinvasive disease (elderly)"/>
   <result pre="One patient recovered fully; the other patient had residual dysarthria[65]." exact="ZIKV" post="ZIKV is an emerging mosquito-borne flavivirus. Before the large"/>
   <result pre="patient recovered fully; the other patient had residual dysarthria[65]. ZIKV" exact="ZIKV" post="is an emerging mosquito-borne flavivirus. Before the large outbreak"/>
   <result pre="is an emerging mosquito-borne flavivirus. Before the large outbreak of" exact="ZIKV" post="infection on Yap Island (Federated States of Micronesia), only"/>
   <result pre="cases were reported in Africa and Asia, but in 2007" exact="ZIKV" post="emerged as an important human pathogen[66,67]. Human infections mainly"/>
   <result pre="(Ae. aegypti and Ae. albopictus), however, non-vector borne transmission of" exact="ZIKV" post="such as sexual and transplacental transmission was also reported[68]."/>
   <result pre="and transplacental transmission was also reported[68]. Although symptoms associated with" exact="ZIKV" post="infection are generally mild and the majority of infected"/>
   <result pre="the majority of infected persons do not develop any symptoms," exact="ZIKV" post="is also associated with severe neurological disorders, mainly Guillain-Barré"/>
   <result pre="with severe neurological disorders, mainly Guillain-Barré syndrome. Diagnostic testing for" exact="ZIKV" post="infection can be accomplished using molecular and serologic methods[69,70]."/>
   <result pre="be accomplished using molecular and serologic methods[69,70]. Case reports describing" exact="ZIKV" post="infection in transplant patients are limited. In 2015 and"/>
   <result pre="infection in transplant patients are limited. In 2015 and 2016," exact="ZIKV" post="infection was confirmed among 129 kidney transplants and 58"/>
   <result pre="it was not possible to assess the potential impact of" exact="ZIKV" post="in the immunosuppressed SOT recipients, including infectious complications and"/>
   <result pre="Therefore, further studies are needed to evaluate the impact of" exact="ZIKV" post="infection in this population group. Chikungunya virus Chikungunya virus"/>
   <result pre="evaluate the impact of ZIKV infection in this population group." exact="Chikungunya" post="virus Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus."/>
   <result pre="impact of ZIKV infection in this population group. Chikungunya virus" exact="Chikungunya" post="virus (CHIKV) is an emerging mosquito-borne alphavirus. Since 2004,"/>
   <result pre="Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus. Since 2004," exact="CHIKV" post="caused several large outbreaks in Africa, the Indian Ocean"/>
   <result pre="and hepatic failure[74,75]. Laboratory diagnosis is accomplished by detection of" exact="CHIKV" post="RNA and/or detection of IgM and IgG antibodies[72]. Few"/>
   <result pre="IgG antibodies[72]. Few data exist regarding the clinical characteristics of" exact="CHIKV" post="infections in the transplant population[76-79]. In one case series"/>
   <result pre="one case series of SOT recipients from Colombia with confirmed" exact="CHIKV" post="infection, most patients had a benign clinical course with"/>
   <result pre="complications[77]. Another Brazilian study showed similar results. SOT recipients with" exact="CHIKV" post="infection seem to have a clinical presentation and course"/>
   <result pre="the transplant community must be reminded that the risk of" exact="CHIKV" post="infection should be considered in deceased organ donor candidates"/>
   <result pre="organ donor candidates recently returned from travel to endemic areas[76]." exact="Dengue" post="virus Dengue virus (DENV) is a mosquito-borne flavivirus widely"/>
   <result pre="candidates recently returned from travel to endemic areas[76]. Dengue virus" exact="Dengue" post="virus (DENV) is a mosquito-borne flavivirus widely distributed in"/>
   <result pre="the bite of Ae. aegypti and Ae. albopictus mosquitoes. Non-vectorial" exact="DENV" post="transmission through SOT can also occur[81]. The clinical presentations"/>
   <result pre="transmission through SOT can also occur[81]. The clinical presentations of" exact="DENV" post="infection range from asymptomatic to severe illness with fatal"/>
   <result pre="can be obtained by virus isolation, detection of NS1 antigen," exact="DENV" post="RNA or specific IgM and IgG antibodies[83]. SOT recipients"/>
   <result pre="cases were also reported[84-86]. A Thai study analyzed outcomes of" exact="DENV" post="infection in a large cohort of kidney transplant recipients."/>
   <result pre="Colombian study on retrospective case series of SOT recipients with" exact="DENV" post="infection showed that regarding the clinical course, 75% of"/>
   <result pre="In contrast, a study from India showed that early post-transplant" exact="DENV" post="infection appears to be severe and associated with more"/>
   <result pre="kidney transplant recipients[89]. There have been limited descriptions of possible" exact="DENV" post="transmission through SOT, of which the majority are classified"/>
   <result pre="are classified as possible transmission due to the lack of" exact="DENV" post="RNA confirmation in the donor[81,90,91]. A case of DENV"/>
   <result pre="of DENV RNA confirmation in the donor[81,90,91]. A case of" exact="DENV" post="transmission from donor to the recipient after liver transplantation"/>
   <result pre="hyperbilirubinemia, suggesting that the liver could be more susceptible to" exact="DENV" post="or is generally more compromised in transplant recipients[81,91,92]. A"/>
   <result pre="from India presented the first report on the detection of" exact="DENV" post="in the donor cornea indicating the risk of iatrogenic"/>
   <result pre="DENV in the donor cornea indicating the risk of iatrogenic" exact="DENV" post="transmission through corneal transplantation[93]. To avoid DENV transmission by"/>
   <result pre="risk of iatrogenic DENV transmission through corneal transplantation[93]. To avoid" exact="DENV" post="transmission by organ or tissue transplantation, the donors should"/>
   <result pre="tissue transplantation, the donors should be screened in endemic areas." exact="WNV" post="WNV is one of the most widely distributed emerging"/>
   <result pre="transplantation, the donors should be screened in endemic areas. WNV" exact="WNV" post="is one of the most widely distributed emerging mosquito-borne"/>
   <result pre="of Culex mosquitoes[94]. Approximately 80% of immunocompetent individuals infected with" exact="WNV" post="remain asymptomatic while 20% develop mild febrile disease (WNV"/>
   <result pre="(meningitis, encephalitis, myelitis)[95]. Diagnosis is confirmed by the detection of" exact="WNV" post="IgM and IgG antibodies in serum/CSF with confirmation by"/>
   <result pre="by virus neutralization test in samples with cross-reactive antibodies[96]. Since" exact="WNV" post="IgM antibodies may persist up to 500 d in"/>
   <result pre="to 500 d in some patients, IgG avidity differentiates current/recent" exact="WNV" post="infection from persistent IgM seropositivity from the previous WNV"/>
   <result pre="current/recent WNV infection from persistent IgM seropositivity from the previous" exact="WNV" post="transmission season[97]. WNV RNA can be detected in blood,"/>
   <result pre="from persistent IgM seropositivity from the previous WNV transmission season[97]." exact="WNV" post="RNA can be detected in blood, CSF and urine"/>
   <result pre="using RT-PCR, but molecular methods are less sensitive than serology[98]." exact="WNV" post="has been identified as a cause of both donor-derived"/>
   <result pre="identified as a cause of both donor-derived and post-transplant infection[99]." exact="WNV" post="transmission by organ transplantation was first reported in 2002[100]."/>
   <result pre="Thereafter, there are many reports on donor-derived or naturally acquired" exact="WNV" post="infection in the adult transplant population[101-108]. Although WNV infection"/>
   <result pre="naturally acquired WNV infection in the adult transplant population[101-108]. Although" exact="WNV" post="infection is associated with higher mortality in the transplant"/>
   <result pre="mortality in the transplant patients[105,108,109] there are some reports on" exact="WNV" post="in SOT recipients with a complete recovery as well"/>
   <result pre="recovery as well as asymptomatic infections[108,110]. Few reports describing post-transplant" exact="WNV" post="neuroinvasive disease in pediatric patients showed a complete recovery"/>
   <result pre="complete recovery in all patients[104,111,112]. In the light of the" exact="WNV" post="(re-) emergence, clinicians should be aware that SOT recipients"/>
   <result pre="should be aware that SOT recipients could be exposed to" exact="WNV" post="via multiple sources. Therefore, WNV should be included in"/>
   <result pre="recipients could be exposed to WNV via multiple sources. Therefore," exact="WNV" post="should be included in the differential diagnosis in all"/>
   <result pre="Since many of USUV cases remain underdiagnosed or misdiagnosed as" exact="WNV" post="due to similar clinical symptoms and serological cross-reactivity, clinicians"/>
   <result pre="Washington: ASM Press, 2017 5Vilibic-CavlekTSavicVPetrovicTToplakIBarbicLPetricDTabainIHrnjakovic-CvjetkovicIBogdanicMKlobucarAMrzljakAStevanovicVDinjar-KujundzicPRadmanicLMonacoFListesESaviniGEmerging Trends in the Epidemiology of" exact="West Nile" post="and Usutu Virus Infections in Southern EuropeFront Vet Sci2019643731867347"/>
   <result pre="in Southern EuropeFront Vet Sci2019643731867347 6CampJVNowotnyNThe knowns and unknowns of" exact="West Nile" post="virus in Europe: what did we learn from the"/>
   <result pre="for Disease Prevention and Control (ECDC)Historical Data by Year -" exact="West Nile" post="Fever Seasonal Surveillance 2018Available from: https://ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/historical 8collab: Centers for"/>
   <result pre="Public Health201948203130847308 68Rodriguez-MoralesAJBandeiraACFranco-ParedesCThe expanding spectrum of modes of transmission of" exact="Zika" post="virus: a global concernAnn Clin Microbiol Antimicrob2016151326939897 69collab: European"/>
   <result pre="European Centre for Disease Prevention and Control (ECDC)Laboratory tests for" exact="Zika" post="virus diagnosticAvailable from: https://www.ecdc.europa.eu/en/publications-data/laboratory-tests-zika-virus-diagnostic 70WrightJKCastellaniLLecceCKhatibABontaMBoggildAKZika Virus-Associated Aseptic Meningitis and"/>
   <result pre="Clin North Am2019331003102531668189 73GanesanVKDuanBReidSPChikungunya Virus: Pathophysiology, Mechanism, and ModelingViruses20179 74EconomopoulouADominguezMHelynckBSissokoDWichmannOQuenelPGermonneauPQuatresousIAtypical" exact="Chikungunya" post="virus infections: clinical manifestations, mortality and risk factors for"/>
   <result pre="Management of Dengue/DHF/DSSTrop Med Health2011398387 83MullerDADepelsenaireACYoungPRClinical and Laboratory Diagnosis of" exact="Dengue" post="Virus InfectionJ Infect Dis2017215S89S9528403441 84NasimAAnisSBaqiSAkhtarSFBaig-AnsariNClinical presentation and outcome of"/>
   <result pre="Soc Trop Med Hyg201911343143631034049 93JananiMKDurgadeviPPadmapriyaJMalathiJKulandaiLTRao MadhavanHNFirst Report on Detection of" exact="Dengue" post="Virus in the Donor CorneaCornea2018371586158930272614 94ZannoliSSambriVWest Nile Virus and"/>
   <result pre="in Europe: Epidemiology and ImplicationsMicroorganisms20197 95SejvarJJClinical manifestations and outcomes of" exact="West Nile" post="virus infectionViruses2014660662324509812 96Di GennaroALorussoACasacciaCConteAMonacoFSaviniGSerum neutralization assay can efficiently replace"/>
   <result pre="replace plaque reduction neutralization test for detection and quantitation of" exact="West Nile" post="virus antibodies in human and animal serum samplesClin Vaccine"/>
   <result pre="97Vilibic-CavlekTKristoficBSavicVKolaricBBarbicLTabainIPericLSabadiDMiklausicBPotocnik-HunjadiTZemberSStevanovicVListesESaviniGDiagnostic significance of immunoglobulin G avidity in symptomatic and asymptomatic" exact="West Nile" post="virus infectionRev Soc Bras Med Trop20185159159530304263 98ZanoniFAlfieriCMoroniGPasseriniPRegaliaAMeneghiniMMessaPDelayed Diagnosis of"/>
   <result pre="Nile virus infectionRev Soc Bras Med Trop20185159159530304263 98ZanoniFAlfieriCMoroniGPasseriniPRegaliaAMeneghiniMMessaPDelayed Diagnosis of" exact="West Nile" post="Virus Infection in a Kidney Transplant Patient Due to"/>
   <result pre="Clinical Transplantation2018110.6002/ect.2018.0107 99AnesiJASilveiraFPcollab: AST Infectious Diseases Community of PracticeArenaviruses and" exact="West Nile" post="Virus in solid organ transplant recipients: Guidelines from the"/>
   <result pre="Society of Transplantation Infectious Diseases Community of PracticeClin Transplant201933e1357631022306 100IwamotoMJerniganDBGuaschATrepkaMJBlackmoreCGHellingerWCPhamSMZakiSLanciottiRSLance-ParkerSEDiazGranadosCAWinquistAGPerlinoCAWiersmaSHillyerKLGoodmanJLMarfinAAChamberlandMEPetersenLRcollab:" exact="West Nile" post="Virus in Transplant Recipients Investigation TeamTransmission of West Nile"/>
   <result pre="100IwamotoMJerniganDBGuaschATrepkaMJBlackmoreCGHellingerWCPhamSMZakiSLanciottiRSLance-ParkerSEDiazGranadosCAWinquistAGPerlinoCAWiersmaSHillyerKLGoodmanJLMarfinAAChamberlandMEPetersenLRcollab: West Nile Virus in Transplant Recipients Investigation TeamTransmission of" exact="West Nile" post="virus from an organ donor to four transplant recipientsN"/>
   <result pre="two chronically immunosuppressed renal transplant recipientsAm J Transplant200331312131514510707 102Kleinschmidt-DeMastersBKMarderBALeviMELairdSPMcNuttJTEscottEJEversonGTTylerKLNaturally acquired" exact="West Nile" post="virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and"/>
   <result pre="reportJ Heart Lung Transplant20052462162315896763 106JainNFiskDSotirMKehlKSWest Nile encephalitis, status epilepticus and" exact="West Nile" post="pneumonia in a renal transplant patientTranspl Int20072080080317630998 107InojosaWOScottonPGFuserRGiobbiaMPaolinAMarescaMCBrunelloANascimbenESorbaraCRigoliRBertiRGajoGBGiomettoBWest Nile"/>
   <result pre="Italy: a case report and implications for pre-procurement screeningInfection20124055756222544764 108WinstonDJVikramHRRabeIBDhillonGMulliganDHongJCBusuttilRWNowickiMJMoneTCivenRTecleSATrivediKKHocevarSNcollab:" exact="West Nile" post="Virus Transplant-Associated Transmission Investigation TeamDonor-derived West Nile virus infection"/>
   <result pre="pre-procurement screeningInfection20124055756222544764 108WinstonDJVikramHRRabeIBDhillonGMulliganDHongJCBusuttilRWNowickiMJMoneTCivenRTecleSATrivediKKHocevarSNcollab: West Nile Virus Transplant-Associated Transmission Investigation TeamDonor-derived" exact="West Nile" post="virus infection in solid organ transplant recipients: report of"/>
   <result pre="cases and review of clinical, diagnostic, and therapeutic featuresTransplantation20149788188924827763 109DongEMorrisKSodhiGChangDCzerLChungJZabnerRRaastadKKlapperEKobashigawaJNurokMNeuroinvasive" exact="West Nile" post="Virus Post-Heart Transplantation: A Case ReportTransplant Proc2018504057406130577314 110RabeIBSchwartzBSFarnonECJosephsonSAWebberABRobertsJPde MattosAMGallayBJvan"/>
   <result pre="Virus Post-Heart Transplantation: A Case ReportTransplant Proc2018504057406130577314 110RabeIBSchwartzBSFarnonECJosephsonSAWebberABRobertsJPde MattosAMGallayBJvan SlyckSMessengerSLYenCJBlochEMDrewCPFischerMGlaserCAcollab:" exact="WNV" post="Transplant Investigation TeamFatal transplant-associated west nile virus encephalitis and"/>
   <result pre="virus encephalitis and public health investigation-california, 2010Transplantation20139646346823823653 111FranciscoAMGlaserCFrykmanEColeBCheungMMeyersHGinsbergMDeckertAJeanCJinaduBA2004 California pediatric" exact="West Nile" post="virus case seriesPediatr Infect Dis J200625818416395112 112LambertSLAvilesDVehaskariVMAshoorIFSevere West Nile"/>
   <result pre="pediatric West Nile virus case seriesPediatr Infect Dis J200625818416395112 112LambertSLAvilesDVehaskariVMAshoorIFSevere" exact="West Nile" post="virus meningoencephalitis in a pediatric renal transplant recipient: successful"/>
   <result pre="Italy, 1996Emerg Infect Dis20131927427723347844 114Vilibic-CavlekTKaicBBarbicLPem-NovoselISlavic-VrzicVLesnikarVKurecic-FilipovicSBabic-ErcegAListesEStevanovicVGjenero-MarganISaviniGFirst evidence of simultaneous occurrence of" exact="West Nile" post="virus and Usutu virus neuroinvasive disease in humans in"/>
   <result pre="clinical and laboratory featuresJ Neurovirol201521929725361698 116Vilibic-CavlekTSavicVSabadiDPericLBarbicLKlobucarAMiklausicBTabainISantiniMVuceljaMDvorskiEButiganTKolaric-SvibenGPotocnik-HunjadiTBalenovicMBogdanicMAndricZStevanovicVCapakKBalicevicMListesESaviniGPrevalence and molecular epidemiology of" exact="West Nile" post="and Usutu virus infections in Croatia in the &quot;One"/>
   <result pre="infection, Italy, August-September 2009Euro Surveill200914 119NagyAMezeiENagyOBakonyiTCsonkaNKaposiMKoroknaiASzomorKRigóZMolnárZDánielisz�?, Takács MExtraordinary increase in" exact="West Nile" post="virus cases and first confirmed human Usutu virus infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7112921\results\search\tropicalVirus\results.xml">
   <result pre="SmedleyR.C.PattersonJ.S.MillerR.MasseyJ.P.WiseA.G.MaesR.K.WuP.KaneeneJ.B.KiupelM.Sensitivity and specificity of monoclonal and polyclonal immunohistochemical staining for" exact="West Nile" post="virus in various organs from American crows (Corvus brachyrhynchos)BMC"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7117767\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Aedes albopictus (Diptera: Culicidae) from Central Africa are susceptible to" exact="Zika" post="virus infection Risk of Zika in Central Africa http://orcid.org/0000-0002-8883-4557KamgangBasileConceptualizationData"/>
   <result pre="Central Africa are susceptible to Zika virus infection Risk of" exact="Zika" post="in Central Africa http://orcid.org/0000-0002-8883-4557KamgangBasileConceptualizationData curationFormal analysisFunding acquisitionInvestigationMethodologyWriting – original"/>
   <result pre="medium, provided the original author and source are credited.pntd.0008163.pdf Abstract" exact="Zika" post="virus (ZIKV) is a Flavivirus (Flaviviridae) transmitted to humans"/>
   <result pre="Aedes mosquitoes. Aedes aegypti is the primary epidemic vector of" exact="ZIKV" post="and Ae. albopictus, the secondary one. However, the epidemiological"/>
   <result pre="ecological settings in Central Africa were experimentally infected with a" exact="ZIKV" post="strain isolated in West Africa. Mosquitoes were analysed at"/>
   <result pre="Both Ae. aegypti and Ae. albopictus were able to transmit" exact="ZIKV" post="but with higher overall transmission efficiency for Ae. aegypti"/>
   <result pre="both Ae. aegypti and Ae. albopictus are able to transmit" exact="ZIKV" post="and may intervene as active Zika vectors in Central"/>
   <result pre="are able to transmit ZIKV and may intervene as active" exact="Zika" post="vectors in Central Africa. These findings could contribute to"/>
   <result pre="contribute to a better understanding of the epidemiological transmission of" exact="ZIKV" post="in Central Africa and develop suitable strategy to prevent"/>
   <result pre="in Central Africa and develop suitable strategy to prevent major" exact="ZIKV" post="outbreaks in this region. Author summary Zika virus (ZIKV),"/>
   <result pre="to prevent major ZIKV outbreaks in this region. Author summary" exact="Zika" post="virus (ZIKV), isolated for the first time in Uganda"/>
   <result pre="in different ecological settings in Central Africa to transmit a" exact="ZIKV" post="strain isolated in West Africa. Analysis showed that both"/>
   <result pre="both Ae. aegypti and Ae. albopictus are able to transmit" exact="ZIKV" post="but with higher overall transmission efficiency for Ae. aegypti"/>
   <result pre="in Central Africa, Ae. aegypti is more competent to transmit" exact="ZIKV" post="than Ae. albopictus although parameters such as the feeding"/>
   <result pre="contribute to a better understanding of the epidemiological transmission of" exact="ZIKV" post="in Central Africa and develop suitable strategy to prevent"/>
   <result pre="in Central Africa and develop suitable strategy to prevent major" exact="ZIKV" post="outbreaks in this region. Funding http://dx.doi.org/10.13039/100004440Wellcome Trust 204862/Z/16/Zhttp://orcid.org/0000-0002-8883-4557KamgangBasile European"/>
   <result pre="Data Availability All relevant data are within the manuscript. Introduction" exact="Zika" post="virus (ZIKV) is a recently emerged, mosquito-borne virus belonging"/>
   <result pre="Flavivirus genus isolated initially from a sentinel monkey, at the" exact="Zika" post="forest in Uganda in 1947 [1]. For decades, only"/>
   <result pre="Uganda in 1947 [1]. For decades, only sporadic circulation of" exact="ZIKV" post="was documented in Africa and South East Asia [2]"/>
   <result pre="and territories in the Americas [9]. During the same period," exact="ZIKV" post="transmission was reported in some African countries such as"/>
   <result pre="Bissau [11], and Angola [12]. Because of the association of" exact="ZIKV" post="with microcephaly [13], Guillain-Barré syndrome [14], and myelitis [15],"/>
   <result pre="ZIKV with microcephaly [13], Guillain-Barré syndrome [14], and myelitis [15]," exact="ZIKV" post="was declared as a Public Health emergency of International"/>
   <result pre="a Public Health emergency of International concern in 2016 [16]." exact="ZIKV" post="can be transmitted by sexual intercourse, blood transfusion, and"/>
   <result pre="supplant the resident species Ae. aegypti [22–25]. Interestingly, the first" exact="ZIKV" post="strain isolated from Ae. albopictus was in Gabon (Central"/>
   <result pre="[26], highlighting the potential role of this species as a" exact="ZIKV" post="vector in the region. In contrast, Ae. aegypti has"/>
   <result pre="contrast, Ae. aegypti has never been found naturally infected with" exact="ZIKV" post="in the Central African region. However, from a study"/>
   <result pre="region. However, from a study with blood donors showing that" exact="ZIKV" post="is circulating in Cameroon, nearly 5–10% of people from"/>
   <result pre="5–10% of people from six towns have been exposed to" exact="ZIKV" post="infections [27]. The vector competence of natural Aedes populations"/>
   <result pre="level of vector competence varies according to mosquito populations and" exact="ZIKV" post="strains [28–31]. To fill this gap, we assessed the"/>
   <result pre="and Ae. albopictus populations from Central Africa to transmit a" exact="ZIKV" post="strain isolated in West Africa. Methods Ethics statement This"/>
   <result pre="Fig 1 Map of Cameroon vegetation showing the sampling sites." exact="Zika" post="virus strain used The ZIKV strain (Ae. taylori-tc/SEN/1984/41662-DAK) was"/>
   <result pre="vegetation showing the sampling sites. Zika virus strain used The" exact="ZIKV" post="strain (Ae. taylori-tc/SEN/1984/41662-DAK) was isolated in December 1984 from"/>
   <result pre="cells expressed in pfu (plaque-forming units)/mL. Challenged of mosquitoes with" exact="ZIKV" post="For each population, six batches of 60, 7–10 day-old"/>
   <result pre="or Ae. albopictus (four populations) were more likely to sustain" exact="ZIKV" post="outbreak in Central Africa, the ability of the virus"/>
   <result pre="were examined at 14 and 21 dpe as well as" exact="ZIKV" post="particles secreted in saliva (only at 21 dpe) (Figs"/>
   <result pre="Ae. albopictus were highly susceptible to infection and dissemination with" exact="ZIKV" post="(Fig 2A), and at 21 dpe, all four populations"/>
   <result pre="Ae. albopictus (42%) (Fisher’s exact test: P = 0.02). Overall," exact="ZIKV" post="titres were significantly higher in Ae. aegypti compared to"/>
   <result pre="Brazzaville population. While in Ae. albopictus, no significant variation of" exact="ZIKV" post="titres was observed (Chi-squared test: χ2 = 2.65, df"/>
   <result pre="df = 3, P = 0.44) (Fig 4). Fig 4" exact="Zika" post="virus titres in saliva of Ae. aegypti and Ae."/>
   <result pre="viral load in each population. Discussion The first evidence of" exact="ZIKV" post="circulation was reported in Africa [1]. In Central Africa,"/>
   <result pre="ZIKV circulation was reported in Africa [1]. In Central Africa," exact="ZIKV" post="circulation in human populations was confirmed in Cameroon, Central"/>
   <result pre="blood donors were ZIKV-positive [27]. In Central Africa, exposure to" exact="ZIKV" post="has also been confirmed in animals, monkeys and bats"/>
   <result pre="also been confirmed in animals, monkeys and bats [18], and" exact="ZIKV" post="was detected in two mosquito species in CAR (Ae."/>
   <result pre="[26]. Up to now, no data on vector competence to" exact="ZIKV" post="is available for mosquitoes from Central Africa. In this"/>
   <result pre="in different ecological settings in Central Africa to transmit a" exact="ZIKV" post="strain isolated from sylvatic mosquitoes, Ae. africanus, collected in"/>
   <result pre="africanus, collected in Dakar in 1984. We demonstrated that this" exact="ZIKV" post="strain was able to replicate, disseminate, and be secreted"/>
   <result pre="and Ae. albopictus. The results of these experiments indicate that" exact="ZIKV" post="could be transmitted during blood feeding. Our analysis showed"/>
   <result pre="both species which is in agreement with previous experiments using" exact="ZIKV" post="from the African lineage [36–39]. Disseminated infection and transmission"/>
   <result pre="varied among mosquito populations [28, 30]. Overall, transmission efficiency and" exact="ZIKV" post="titre in saliva were significantly higher in Ae. aegypti"/>
   <result pre="Ae. albopictus corroborating the main role of Ae. aegypti in" exact="ZIKV" post="transmission compared to Ae. albopictus [40, 41]. Nevertheless, lower"/>
   <result pre="Ae. albopictus [40, 41]. Nevertheless, lower transmission rates and saliva" exact="ZIKV" post="titres in Ae. aegypti were found for two populations"/>
   <result pre="modulate arbovirus transmission [44–46]. In addition, refractoriness of mosquito to" exact="ZIKV" post="can also be caused by mosquito immune responses since"/>
   <result pre="species, Ae. aegypti. However, both are suspected to contribute to" exact="ZIKV" post="transmission. Interestingly, Ae. albopictus collected in Gabon (Central Africa)"/>
   <result pre="2007 during concurrent chikungunya/dengue outbreak was found naturally infected with" exact="ZIKV" post="[26]. Level of transmission rates reported in both Aedes"/>
   <result pre="help to determine the epidemiological role of each species in" exact="ZIKV" post="transmission. In addition, as our results showed that the"/>
   <result pre="region, should be further explored to determine their impact on" exact="ZIKV" post="transmission. These findings highlight the urgent need to plan"/>
   <result pre="to plan a vector surveillance program and control methods against" exact="Zika" post="vectors in the region in order to prevent future"/>
   <result pre="collaboration during the field works. References References 1DickGW, KitchenSF, HaddowAJ." exact="Zika" post="virus. I. Isolations and serological specificity. Transactions of the"/>
   <result pre="2HaddowAD, SchuhAJ, YasudaCY, KasperMR, HeangV, HuyR, et al.Genetic characterization of" exact="Zika" post="virus strains: geographic expansion of the Asian lineage. PLoS"/>
   <result pre="FreireCC, IamarinoA, FayeO, de OliveiraJV, DialloM, et al.Molecular evolution of" exact="Zika" post="virus during its emergence in the 20(th) century. PLoS"/>
   <result pre="Neglected Tropical Diseases. 2014;8(1):e263610.1371/journal.pntd.0002636 .24421913 4MarchetteNJ, GarciaR, RudnickA. Isolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in Malaysia. The American"/>
   <result pre="2014;20(6):1085–6. 10.3201/eid2006.140138 .24856001 7MussoD, NillesEJ, Cao-LormeauVM. Rapid spread of emerging" exact="Zika" post="virus in the Pacific area. Clinical microbiology and infection:"/>
   <result pre="LagosJ, AguayoC, FasceR, et al.A report on the outbreak of" exact="Zika" post="virus on Easter Island, South Pacific, 2014. Archives of"/>
   <result pre="2014. Archives of Virology. 2016;161(3):665–8. 10.1007/s00705-015-2695-5 .26611910 9HennesseyM, FischerM, StaplesJE." exact="Zika" post="virus spreads to new areas—region of the Americas, May"/>
   <result pre="MonteiroM, ValdezT, Monteiro RodriguesJ, PybusO, Rodrigues FariaN. Epidemiology of the" exact="Zika" post="virus outbreak in the Cabo Verde islands, West Africa."/>
   <result pre=".29394415 13CauchemezS, BesnardM, BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–15: a retrospective"/>
   <result pre="MonsS, LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control study. Lancet."/>
   <result pre="HerrmannC, PoullainP, TranTH, DeschampsN, MathonG, et al.Acute myelitis due to" exact="Zika" post="virus infection. Lancet. 2016 Epub 2016/03/08. 10.1016/S0140-6736(16)00644-9 .26946926 16WHO."/>
   <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="virus and observed increase in neurological disorders and neonatal"/>
   <result pre="neonatal malformations. World Health Organization 2016; http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/. (1): 17SharmaA, LalSK." exact="Zika" post="virus: transmission, detection, control, and prevention. Frontiers in Microbiology."/>
   <result pre="CalvezE, Chouin-CarneiroT, DialloD, FaillouxAB. An overview of mosquito vectors of" exact="Zika" post="virus. Microbes and Infection. 201810.1016/j.micinf.2018.01.006 .29481868 19DialloD, SallAA, DiagneCT,"/>
   <result pre="27GakeB, VernetMA, Leparc-GoffartI, DrexlerJF, GouldEA, GallianP, et al.Low seroprevalence of" exact="Zika" post="virus in Cameroonian blood donors. The Brazilian Journal of"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="virus. PLoS Neglected Tropical Diseases. 2016;10(3):e000454310.1371/journal.pntd.0004543 .26938868 29JupilleH, SeixasG,"/>
   <result pre="Neglected Tropical Diseases. 2016;10(3):e000454310.1371/journal.pntd.0004543 .26938868 29JupilleH, SeixasG, MoussonL, SousaCA, FaillouxAB." exact="Zika" post="virus, a new threat for Europe?PLoS Neglected Tropical Diseases."/>
   <result pre="vector competency of Aedes albopictus populations from the Americas for" exact="Zika" post="virus. The American Journal of Tropical Medicine and Hygiene."/>
   <result pre="et al.Experimental studies of susceptibility of Italian Aedes albopictus to" exact="Zika" post="virus. Euro surveillance: bulletin Europeen sur les maladies transmissibles"/>
   <result pre="LamballerieX, NougairedeA. Simple reverse genetics systems for Asian and African" exact="Zika" post="viruses. Scientific Reports. 2016;6:3938410.1038/srep39384 .27991555 34DubrulleM, MoussonL, MoutaillerS, VazeilleM,"/>
   <result pre="viruses. Scientific Reports. 2016;6:3938410.1038/srep39384 .27991555 34DubrulleM, MoussonL, MoutaillerS, VazeilleM, FaillouxAB." exact="Chikungunya" post="virus and Aedes mosquitoes: saliva is infectious as soon"/>
   <result pre="RoussetD, FayeO, RichardV, et al.Differential transmission of Asian and African" exact="Zika" post="virus lineages by Aedes aegypti from New Caledonia. Emerging"/>
   <result pre="LealG, YunR, et al.Variation in Aedes aegypti mosquito competence for" exact="Zika" post="virus transmission. Emerging Infectious Diseases. 2017;23(4):625–32. 10.3201/eid2304.161484 .28287375 38HeryL,"/>
   <result pre="BoullisA, DelannayC, Vega-RuaA. Transmission potential of African, Asian and American" exact="Zika" post="virus strains by Aedes aegypti and Culex quinquefasciatus from"/>
   <result pre="Aedes aegypti and Aedes albopictus for an epidemic strain of" exact="Zika" post="virus. PLoS Neglected Tropical Diseases. 2019;13(4):e000728110.1371/journal.pntd.0007281 .30946747 41DucheminJB, MeePT,"/>
   <result pre="Tropical Diseases. 2019;13(4):e000728110.1371/journal.pntd.0007281 .30946747 41DucheminJB, MeePT, LynchSE, VedururuR, TrinidadL, ParadkarP." exact="Zika" post="vector transmission risk in temperate Australia: a vector competence"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7118414\results\search\tropicalVirus\results.xml">
   <result pre=": Original Paper Global transmission and evolutionary dynamics of the" exact="Chikungunya" post="virus DeebaF.1HaiderM. S. H.1AhmedA.23https://orcid.org/0000-0001-8944-318XTazeenA.1FaizanM. I.1SalamN.4HussainT.2AlameryS. F.2https://orcid.org/0000-0002-6359-0760ParveenS.1[1], Centre for Interdisciplinary"/>
   <result pre="in any medium, provided the original work is properly cited.S0950268820000497a.pdf" exact="Chikungunya" post="virus (CHIKV) is a re-emerging pathogen of global importance."/>
   <result pre="the world. We describe transmission dynamics and genetic characterisation of" exact="CHIKV" post="across the globe during the last 65 years from"/>
   <result pre="65 years from 1952 to 2017. The evolutionary pattern of" exact="CHIKV" post="was analysed using the E1 protein gene through phylogenetic,"/>
   <result pre="evolutionary rate of 2.78 × 10−4 substitutions/site/year. Genetic characterisation of" exact="CHIKV" post="strains was carried out in terms of variable sites,"/>
   <result pre="The present study augments global epidemiological and population dynamics of" exact="CHIKV" post="warranting undertaking of appropriate control measures. The identification of"/>
   <result pre="strategies against this re-emerging viral pathogen. Key words Bayesian analysis" exact="Chikungunya" post="virus docking entropy networking phylogenetics selection pressure fig-count: table-count:"/>
   <result pre="entropy networking phylogenetics selection pressure fig-count: table-count: ref-count: page-count: Introduction" exact="Chikungunya" post="fever is caused by Chikungunya virus (CHIKV), an arboviral"/>
   <result pre="fig-count: table-count: ref-count: page-count: Introduction Chikungunya fever is caused by" exact="Chikungunya" post="virus (CHIKV), an arboviral pathogen that has caused numerous"/>
   <result pre="numerous outbreaks across the globe. It has been suggested that" exact="CHIKV" post="probably originated in the Central/East Africa probably around 300–500"/>
   <result pre="Central/East Africa probably around 300–500 years ago [1, 2]. Phylogenetically," exact="CHIKV" post="consists of three separate clades namely (i) The ‘West"/>
   <result pre="(ii) ‘Asian’ and (iii) ‘East Central South African’ (ECSA) [3]." exact="CHIKV" post="has now been recognised as a global pathogen due"/>
   <result pre="in a wide geographical range [3]. Increased global travel from" exact="CHIKV" post="endemic regions has been the major cause of dispersal"/>
   <result pre="the virus to non-endemic regions of the Americas and Europe." exact="CHIKV" post="has succeeded to maintain its mosquito–human life cycle causing"/>
   <result pre="the situation stands today, there is no local transmission of" exact="CHIKV" post="in the USA currently. The virus has adapted itself"/>
   <result pre="to previously unexposed populations [5, 6]. The genomic analyses of" exact="CHIKV" post="sequences reported from India during the 2009–2010 outbreak revealed"/>
   <result pre="of the virus to locally available vector populations [7, 8]." exact="CHIKV" post="is currently circulating in around 100 countries worldwide as"/>
   <result pre="world map showing the distribution of different lineages of the" exact="Chikungunya" post="virus. Regions with the evidence of well-established CHIKV circulation"/>
   <result pre="of the Chikungunya virus. Regions with the evidence of well-established" exact="CHIKV" post="circulation are circled whereas imported cases of CHIKV are"/>
   <result pre="of well-established CHIKV circulation are circled whereas imported cases of" exact="CHIKV" post="are denoted by stars in the map. (The map"/>
   <result pre="the infection. We undertook global distribution and evolutionary analysis of" exact="CHIKV" post="using phylogenetic, networking and Bayesian methods. This also included"/>
   <result pre="if there is a set pattern of the emergence of" exact="Chikungunya" post="fever in different geographical regions. This information can be"/>
   <result pre="information can be useful for the prevention and control of" exact="CHIKV" post="outbreaks globally. Transmission and evolutionary analysis of the virus"/>
   <result pre="virus will help elucidate host–pathogen dynamics during the course of" exact="CHIKV" post="infections in humans. Materials and methods DNA sequences The"/>
   <result pre="till March 2019) of the partial E1 protein gene of" exact="CHIKV" post="were downloaded after an extensive search in GenBank. The"/>
   <result pre="The complete E1 sequence of the S27 prototype strain of" exact="CHIKV" post="(AF369024) was used for the analysis. The IEDB (Immune"/>
   <result pre="recent past. Fig. 2. The ML phylogenetic tree of the" exact="Chikungunya" post="virus. The tree was generated by 1000 bootstrap values"/>
   <result pre="are shown at nodes. Further, the analysis of the global" exact="CHIKV" post="sequences suggested interesting clustering pattern of the sequences, i.e."/>
   <result pre="(Fig. 3, Supplementary Fig. S2 and Table S1). All the" exact="CHIKV" post="strains formed a network that is illustrated in panels"/>
   <result pre="illustrated in panels a, b and c. Panel ‘a’ contains" exact="CHIKV" post="strains reported from Tanzania in 1952 (first reported strain)"/>
   <result pre="strains. Fig. 3. The phylogenetic Network showing clusters of the" exact="Chikungunya" post="virus sequences from different geographical regions. The network shows"/>
   <result pre="geographical regions. The network shows the pattern of emergence of" exact="CHIKV" post="related to the first isolated strains. The size of"/>
   <result pre="African Republic reported during 1952–56 (ECSA genotype). The recently circulating" exact="CHIKV" post="in countries like India, Bhutan, Vietnam, Cambodia, Myanmar, Thailand,"/>
   <result pre="such as Indonesia, Malaysia, Philippines and Thailand. Several recently reported" exact="CHIKV" post="strains (2012–17) from Brazil, Mexico, Puerto Rico, Columbia, Guatemala,"/>
   <result pre="of the sequences as described earlier by phylogenetic analysis. The" exact="CHIKV" post="was calculated to be originated around 491 years ago"/>
   <result pre="respectively. Fig. 4. The MCMC Bayesian tree generated using different" exact="Chikungunya" post="virus strains from various parts of the world. The"/>
   <result pre="5) [30]. The plot showed almost a constant phase of" exact="CHIKV" post="infection till 2000 and then a slight decrease. Following"/>
   <result pre="plot shows viral population vs. time of circulation of the" exact="Chikungunya" post="virus strains from India. Shannon entropy analysis The Shannon"/>
   <result pre="1. Selection pressure analysis of the E1 gene of the" exact="Chikungunya" post="virus. The details of positively selected sites under different"/>
   <result pre="31 potential epitopes were shortlisted in the E1 protein of" exact="CHIKV" post="and were analysed in subsequent steps. Three peptides (YPFMWGGAY,"/>
   <result pre="The potential epitopes for MHC-II in the E1 protein of" exact="CHIKV" post="were initially predicted in IEDB peptide binding to MHC-II"/>
   <result pre="of the potential epitopes of the E1 protein of the" exact="Chikungunya" post="virus with MHCI/II alleles. The images a, b and"/>
   <result pre="83, LYS 111, GLN 34, GLU 36, ARG 39 Discussion" exact="CHIKV" post="has been described from different geographical regions including autochthonous"/>
   <result pre="A few reports also relate to the evolutionary divergence of" exact="CHIKV" post="in different parts of the world [1, 2, 31]."/>
   <result pre="different parts of the world [1, 2, 31]. Outbreaks of" exact="Chikungunya" post="fever across the globe, spread of infection across a"/>
   <result pre="of the world. We evaluated the transmission dynamics of the" exact="CHIKV" post="across the globe using phylogenetic, Network and Bayesian analysis"/>
   <result pre="sites, entropy, selection pressure and epitope mapping. The evidence of" exact="CHIKV" post="occurrence in different geographical regions was reported as early"/>
   <result pre="Gujarat in 1824–25 [32]. Our data also supported that the" exact="CHIKV" post="infection in humans originated around 491 years ago (1526)."/>
   <result pre="is similar to the reports that described the origin of" exact="CHIKV" post="to be of 300–500 years age [1, 2]. The"/>
   <result pre="the central, East and South African regions. Later on, the" exact="CHIKV" post="diverged from these initial strains and were transmitted to"/>
   <result pre="gene [2]. The phylogenetic and Bayesian analyses of the global" exact="CHIKV" post="sequences revealed interesting clustering of the sequences. Both the"/>
   <result pre="suggested a similar branching pattern thereby delineating the spread of" exact="CHIKV" post="in different geographic regions. The ECSA strains formed three"/>
   <result pre="Network analysis revealed that in the West African region, Nigerian" exact="CHIKV" post="strain further diverged to Senegal and Cote D'ivoire [2,"/>
   <result pre="Mexico and French Polynesia [9, 38–40]. The Asian genotype of" exact="CHIKV" post="was reported to have caused epidemics in many Asian"/>
   <result pre="strains in the Asian countries were initiated during 2004 [41]." exact="CHIKV" post="initially circulated in major parts of Africa till 2004."/>
   <result pre="subsequently to other Asian countries [42]. This progressive spread of" exact="CHIKV" post="initiated an explosive epidemic that affected millions of inhabitants"/>
   <result pre="from Angola to the USA [9]. These branching patterns of" exact="CHIKV" post="strains across the globe based on the E1 gene"/>
   <result pre="and consistent evolution. A detailed genetic characterisation of the global" exact="CHIKV" post="strains was done using the variable sites, selection pressure"/>
   <result pre="described in the crystal structure of the structural polyproteins of" exact="CHIKV" post="[50]. The T-cell epitopes induce long-lasting cell-mediated innate immune"/>
   <result pre="viral pathogen. Conclusions The reconstruction of the geographic distribution of" exact="CHIKV" post="suggested a distinctive branching pattern owing to gradual alterations"/>
   <result pre="associated with travel cases and its autochthonous transmission. Co-circulation of" exact="CHIKV" post="with other arthropod-borne viruses like Dengue and Zika in"/>
   <result pre="autochthonous transmission. Co-circulation of CHIKV with other arthropod-borne viruses like" exact="Dengue" post="and Zika in many regions has been reported from"/>
   <result pre="Co-circulation of CHIKV with other arthropod-borne viruses like Dengue and" exact="Zika" post="in many regions has been reported from different geographical"/>
   <result pre="particularly in underdeveloped countries, can complicate the accurate reporting of" exact="CHIKV" post="infections. Therefore, a comprehensive surveillance of all the arthropod-borne"/>
   <result pre="References 1.CherianSSet al. (2009) Evolutionary rates and timescale comparison of" exact="Chikungunya" post="viruses inferred from the whole genome/E1 gene with special"/>
   <result pre="various evolutionary rates. Journal of Virology84, 6497–6504.20410280 3.DeebaFet al. (2016)" exact="Chikungunya" post="virus: recent advances in epidemiology, host pathogen interaction and"/>
   <result pre="vaccine strategies. Pathogens and Disease74, ftv119.26657109 4.EvansD and MeiresJL (2016)" exact="Chikungunya" post="virus: a rising health risk in the United States"/>
   <result pre="Practitioners12, 289–298. 5.NgLC and HapuarachchiHC (2010) Tracing the path of" exact="Chikungunya" post="virus – evolution and adaptation. Infection, Genetics and Evolution10,"/>
   <result pre="Euro Surveillance21, 30234. 7.SumathyK and EllaKM (2012) Genetic diversity of" exact="Chikungunya" post="virus, India 2006–2010: evolutionary dynamics and serotype analyses. Journal"/>
   <result pre="vex010.28480053 9.NunesMRTet al. (2015) Emergence and potential for spread of" exact="Chikungunya" post="virus in Brazil. BMC Medicine13, 102.25976325 10.MachadoLCet al. (2019)"/>
   <result pre="vaccine: in silico approach for the epitope-based peptide vaccine against" exact="Zika" post="virus envelope glycoprotein. Immunology149, 386–399.27485738 27.HoofIet al. (2009) NetMHCpan,"/>
   <result pre="al.(2017) Potential entry inhibitors of the envelope protein (E2) of" exact="Chikungunya" post="virus: in silico structural modeling, docking and molecular dynamic"/>
   <result pre="genome tracking of East, Central and South African genotype of" exact="Chikungunya" post="virus in South-east Asia between 2006 and 2009. Asian"/>
   <result pre="2009. Asian Pacific Journal of Tropical Medicine4, 535–540.21803304 32.CareyDE (1971)" exact="Chikungunya" post="and dengue: a case of mistaken identity?Journal of the"/>
   <result pre="Journal of Tropical Medicine and Hygiene72, 616–621.15891138 34.NimmannityaSet al. (1969)" exact="Dengue" post="and chikungunya virus infection in man in Thailand, 1962–64."/>
   <result pre="Journal of Tropical Medicine and Hygiene18, 954–971.5355242 35.LamSet al. (2001)" exact="Chikungunya" post="infection – an emerging disease in Malaysia. Southeast Asian"/>
   <result pre="Southeast Asian J Trop Medical Health32, 447–451. 36.Dupont-RouzeyrolMet al. (2012)" exact="Chikungunya" post="virus and the mosquito vector Aedes aegypti in New"/>
   <result pre="1036–1041.23167500 37.LanciottiRS and ValadereAM (2014) Transcontinental movement of Asian genotype" exact="Chikungunya" post="virus. Emerging Infectious Diseases20, 1400–1402.25076384 38.AubryMet al. (2015) Chikungunya"/>
   <result pre="genotype Chikungunya virus. Emerging Infectious Diseases20, 1400–1402.25076384 38.AubryMet al. (2015)" exact="Chikungunya" post="outbreak, French Polynesia, 2014. Emerging Infectious Diseases21, 724.25811534 39.ChiuCYet"/>
   <result pre="cases. Genome Announcements3, e00300–15.25953170 41.ArankalleVAet al. (2007) Genetic divergence of" exact="Chikungunya" post="viruses in India (1963–2006) with special reference to the"/>
   <result pre="epidemic potential. PLoS Pathogens3, e201.18069894 44.StaplesJE, BreimanRF and PowersAM (2009)" exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
   <result pre="Number 8—August 2009-Emerging Infectious Disease journal-CDC. 46.DuongV (2012) Reemergence of" exact="Chikungunya" post="Virus in Cambodia-Volume 18, Number 12—December 2012-Emerging Infectious Disease"/>
   <result pre="Cambodia-Volume 18, Number 12—December 2012-Emerging Infectious Disease journal-CDC. 47.WangchukS (2013)" exact="Chikungunya" post="Fever Outbreak, Bhutan, 2012-Volume 19, Number 10—October 2013-Emerging Infectious"/>
   <result pre="19, Number 10—October 2013-Emerging Infectious Disease journal-CDC. 48.LuXet al. (2014)" exact="Chikungunya" post="emergency in China: microevolution and genetic analysis for a"/>
   <result pre="ECSA genotype with replacement of K211E in E1 gene of" exact="Chikungunya" post="virus in Delhi from 2010 to 2014. Asian Pacific"/>
   <result pre="of Tropical Disease6, 564–566. 50.VossJEet al. (2010) Glycoprotein organization of" exact="Chikungunya" post="virus particles revealed by X-ray crystallography. Nature468, 709–712.21124458 51.ChiouS-Set"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7122809\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Women's Health"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and life sciences : Organisms :"/>
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus ZIKA Virus infection in pregnant women in French"/>
   <result pre="in pregnant women in French Guiana: More precarious-more at risk" exact="Zika" post="and precariousness HalletEdouardData curationFormal analysisWriting – original draftWriting –"/>
   <result pre="populations living in precarious neighborhoods were more at risk for" exact="Chikungunya" post="CHIKV than those living in more privileged areas. The"/>
   <result pre="living in precarious neighborhoods were more at risk for Chikungunya" exact="CHIKV" post="than those living in more privileged areas. The objective"/>
   <result pre="of the present study was to test the hypothesis that" exact="Zika" post="virus (ZIKV) infection was more frequent in precarious pregnant"/>
   <result pre="A multicentric cross-sectional study was conducted in Cayenne hospital including" exact="ZIKV" post="pregnant women with serological or molecular proof of ZIKV"/>
   <result pre="including ZIKV pregnant women with serological or molecular proof of" exact="ZIKV" post="during their pregnancy between January and December 2016. Health"/>
   <result pre="6654 women were included. Among them 1509 (22,7%) had confirmed" exact="ZIKV" post="infection. Most women were precarious (2275/3439) but the proportion"/>
   <result pre="and undocumented status were associated with a higher prevalence of" exact="ZIKV" post="during pregnancy (adjusted prevalence ratio = 1.59 (95%CI ="/>
   <result pre="p&amp;lt;0.0001), respectively. Conclusions These results illustrate that in French Guiana" exact="ZIKV" post="transmission disproportionately affected the socially vulnerable pregnant women, presumably"/>
   <result pre="living in precarious neighborhoods were more at risk for chikungunya" exact="CHIKV" post="than those living in more privileged areas. The objective"/>
   <result pre="of the present study was to test the hypothesis that" exact="Zika" post="virus (ZIKV) infection was more frequent in precarious pregnant"/>
   <result pre="health insurance status. A multicenter cross-sectional study was conducted including" exact="ZIKV" post="pregnant women with serological or molecular proof of ZIKV"/>
   <result pre="including ZIKV pregnant women with serological or molecular proof of" exact="ZIKV" post="during their pregnancy between January and December 2016. Health"/>
   <result pre="6654 women were included. Among them, 1509 (22,7%) had confirmed" exact="ZIKV" post="infection. The majority of women were precarious, but the"/>
   <result pre="and undocumented status were associated with a higher prevalence of" exact="ZIKV" post="acquisition during pregnancy. The present results illustrate that in"/>
   <result pre="The present results illustrate that in French Guiana, as elsewhere," exact="ZIKV" post="transmission disproportionately affected the socially vulnerable pregnant women, presumably"/>
   <result pre="populations were more likely to have been immunized during previous" exact="DENV" post="epidemics because of greater vector densities and transmission in"/>
   <result pre="suggested a possible link between poverty and the risk of" exact="Zika" post="virus -related microcephaly[5]. This epidemic spread to neighboring French"/>
   <result pre="In order to deal with the important proportion of asymptomatic" exact="Zika" post="virus (ZIKV) infections [6] and a risk of delayed"/>
   <result pre="risk of delayed access to medical care in poor populations,[7,8]" exact="ZIKV" post="serology was recommended at each trimester for all seronegative"/>
   <result pre="provided a representative picture of the spectrum of disease of" exact="ZIKV" post="infection in pregnant women and mapped the intensity of"/>
   <result pre="women. However, the serological surveillance at each trimester during the" exact="ZIKV" post="outbreak in 2016 allowed us to test whether the"/>
   <result pre="whether the poorest pregnant women were more likely to acquire" exact="ZIKV" post="than more socioeconomically privileged women. The objective of the"/>
   <result pre="of the study was thus to compare the prevalence of" exact="ZIKV" post="contact in FG for pregnant women according to their"/>
   <result pre="official declaration of the end of the outbreak. Women without" exact="ZIKV" post="serology were excluded. We also included women with positive"/>
   <result pre="information. Women without health insurance can receive free care (including" exact="ZIKV" post="screening) at the hospital after receiving a &quot;PASS�? voucher"/>
   <result pre="fetal structural abnormalities. Placenta and amniotic liquid were assayed for" exact="ZIKV" post="RNA by real time RT-PCR using the Lanciotti method[10],"/>
   <result pre="by real time RT-PCR using the Lanciotti method[10], the RealStar" exact="ZIKV" post="RT-PCR kit, or ELISA serology. Analyses were realized by"/>
   <result pre="French law. More specifically, in the emergency context of the" exact="Zika" post="epidemic it was part of the health authorities’ epidemiologic"/>
   <result pre="2475/3439. The proportion of precarious women was significantly greater in" exact="ZIKV" post="confirmed 728/906 (80.4%) than the ZIKV negatives 1747/2533 (69.0%),"/>
   <result pre="was significantly greater in ZIKV confirmed 728/906 (80.4%) than the" exact="ZIKV" post="negatives 1747/2533 (69.0%), p&amp;lt;0.0001. Among precarious, irregular immigrants seemed"/>
   <result pre="APR = 1.59) were associated with a significant increase of" exact="ZIKV" post="prevalence adjusted for residence location (Table 2). 10.1371/journal.pntd.0008193.t002Table 2"/>
   <result pre="10.1371/journal.pntd.0008193.t002Table 2 Crude and adjusted prevalence ratios (Poisson regression) for" exact="ZIKV" post="infection in pregnant women in French Guiana in 2016."/>
   <result pre="infection in pregnant women in French Guiana in 2016. Confirmed" exact="ZIKV" post="(n = 906) Negative ZIKV (n = 2533) PR"/>
   <result pre="French Guiana in 2016. Confirmed ZIKV (n = 906) Negative" exact="ZIKV" post="(n = 2533) PR (95% CI) p aPR(95% CI)"/>
   <result pre="problems. Relationship between social aspects and seropositivity to ZIKV, to" exact="DENV" post="(p&amp;lt;1012)[13], and to CHIKV (p&amp;lt;1015) [14] suggests a complex"/>
   <result pre="aspects and seropositivity to ZIKV, to DENV (p&amp;lt;1012)[13], and to" exact="CHIKV" post="(p&amp;lt;1015) [14] suggests a complex interplay between individual factors"/>
   <result pre="vector-control by specifically targeting such areas. In conclusion, during the" exact="ZIKV" post="epidemic in French Guiana, precarious pregnant women and women"/>
   <result pre="living in Western French Guiana were significantly more affected by" exact="ZIKV" post="than non-precarious women and women living in Central coastal"/>
   <result pre="CruzOG, Magalhães M deAFM, et al.Spatial evaluation and modeling of" exact="Dengue" post="seroprevalence and vector density in Rio de Janeiro, Brazil."/>
   <result pre="BonnefoyC, HurpeauB, NacherM, DjossouF, et al.Poverty and Arbovirus Outbreaks: When" exact="Chikungunya" post="Virus Hits More Precarious Populations Than Dengue Virus in"/>
   <result pre="Arbovirus Outbreaks: When Chikungunya Virus Hits More Precarious Populations Than" exact="Dengue" post="Virus in French Guiana. Open Forum Infect Dis. 2017;4:"/>
   <result pre="infections and spectrum of disease among pregnant women infected by" exact="Zika" post="virus: systematic monitoring in French Guiana, 2016. Euro Surveill."/>
   <result pre="LavenJJ, VelezJO, LambertAJ, JohnsonAJ, et al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007."/>
   <result pre="Emergence of a New Arbovirus: Implications for the Control of" exact="Chikungunya" post="Virus in French Guiana. PLoS Negl Trop Dis. 2016;10:"/>
   <result pre="e000623910.1371/journal.pntd.000623929513667 15DiderichsenF, Augusto LG daS, PerezB. Understanding social inequalities in" exact="Zika" post="infection and its consequences: A model of pathways and"/>
   <result pre="et al.Environmental and Social Change Drive the Explosive Emergence of" exact="Zika" post="Virus in the Americas. PLoS Negl Trop Dis. 2017;11:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7122823\results\search\tropicalVirus\results.xml">
   <result pre="but Not for Recall T Cell Responses following an Attenuated" exact="West Nile" post="Virus Infection. PerlmanS, editor. J Virol. 2017;9110.1128/JVI.02097-1628077630 35LukeJM, SimonGG,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7124917\results\search\tropicalVirus\results.xml">
   <result pre="7124917 pmid: 32043443tpmd190732 doi: 10.4269/ajtmh.19-0732 : Articles Entomological Investigation Detects" exact="Dengue" post="Virus Type 1 in Aedes (Stegomyia) albopictus (Skuse) during"/>
   <result pre="*Address correspondence to Ryan R. Hemme, Entomology and Ecology Activity," exact="Dengue" post="Branch, Centers for Disease Control and Prevention, 1324 Calle"/>
   <result pre="Stephanie Martinez-Conde, and Ryan R. Hemme, Entomology and Ecology Team," exact="Dengue" post="Branch, Centers for Disease Control and Prevention, San Juan,"/>
   <result pre="Munoz-Jordan, and Freddy A. Medina, Surveillance and Research Laboratory Team," exact="Dengue" post="Branch, Centers for Disease Control and Prevention, San Juan,"/>
   <result pre="Vector Control Branch, Hilo, HI, E-mail: bernard.asuncion@doh.hawaii.gov. Stephen H. Waterman," exact="Dengue" post="Branch, Centers for Disease Control and Prevention, San Juan,"/>
   <result pre="15 containing Ae. albopictus were positive for the presence of" exact="DENV" post="type 1 RNA. No virus was detected in pools"/>
   <result pre="and 2014. This is the first report of detection of" exact="DENV" post="in Ae. albopictus from Hawaii. page-count: Note: Supplemental table"/>
   <result pre="from Hawaii. page-count: Note: Supplemental table appears at www.ajtmh.org. INTRODUCTION" exact="Dengue" post="is a vector-borne disease caused by four types of"/>
   <result pre="caused by DENV-1, was the first identified autochthonous transmission of" exact="DENV" post="in the state in 56 years.7 Entomological surveys at"/>
   <result pre="aegypti on Hawaii Island.7 No DENV-positive mosquito pools were detected.7" exact="Dengue" post="epidemics vectored by Ae. albopictus are less common than"/>
   <result pre="and sylvan areas within 800 m of clusters of laboratory-confirmed" exact="DENV" post="cases (Tables 1 and 2). Rock Bottom was relatively"/>
   <result pre="pools tested, pools positive for dengue virus (DENV) RNA, and" exact="DENV" post="infection rates from three sampling sites in Hawaii Island"/>
   <result pre="albopictus Number of pools tested (average size) DENV-positive pools (%)" exact="DENV" post="infection rate per 1,000 (95% CI) Sampling site AGO"/>
   <result pre="varied in use of CO2 were placed in areas where" exact="DENV" post="or the presence of Ae. aegypti was suspected, and"/>
   <result pre="at −20°C until they could be shipped to the CDC" exact="Dengue" post="Branch where they were stored at −80°C until tested"/>
   <result pre="screened 185 pools of female mosquitoes for the presence of" exact="DENV" post="RNA of which 135 were Ae. albopictus, 38 were"/>
   <result pre="icon were derived from human hosts. DISCUSSION During the 2015–16" exact="DENV" post="outbreak on Hawaii Island, Ae. albopictus was found at"/>
   <result pre="that Ae. albopictus was the primary vector responsible for transmitting" exact="DENV" post="on Hawaii Island during the 2015–16 outbreak. This is"/>
   <result pre="2015–16 outbreak. This is the first entomological investigation to detect" exact="DENV" post="in Ae. albopictus in the state of Hawaii, confirming"/>
   <result pre="albopictus in the state of Hawaii, confirming its importance in" exact="DENV" post="transmission on the islands of Hawaii. We are unable"/>
   <result pre="viral RNA, as those collected in neighborhoods where no recent" exact="DENV" post="cases were reported would have been less likely to"/>
   <result pre="separate virus introductions (Figure 2). It has been suggested that" exact="DENV" post="outbreaks transmitted by Ae. albopictus are less explosive and"/>
   <result pre="materials LINK Acknowledgments: We would like to thank the Hawaii" exact="Dengue" post="Response Team for all their efforts in completing this"/>
   <result pre="in completing this investigation and Jose Ruiz-Valcarcel at the CDC" exact="Dengue" post="Branch for his help on the manuscript. References REFERENCES"/>
   <result pre="the 21(st) century. Trop Med Health39: 3–11. 3.JohnstonDVirayMUshirodaJWhelenACSciulliRGoseRLeeRHondaEParkSY; collab: Hawaii" exact="Dengue" post="Response Team, 2016Notes from the field: outbreak of locally"/>
   <result pre="history and resurgence as a global health problem. GublerDJKuniG, eds." exact="Dengue" post="and Dengue Hemorrhagic fever. London, United Kingdom: CAB International,"/>
   <result pre="resurgence as a global health problem. GublerDJKuniG, eds. Dengue and" exact="Dengue" post="Hemorrhagic fever. London, United Kingdom: CAB International, 1–22. 7.EfflerPVet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7125191\results\search\tropicalVirus\results.xml">
   <result pre="small-world type13. Similarly, transmission networks of viruses such as the" exact="West Nile" post="virus, which are transmitted in short-range by mosquitos and"/>
   <result pre="the National Academy of Sciences2000971114910.1073/pnas.200327197 14.SuleWFet al.Epidemiology and ecology of" exact="West Nile" post="virus in sub-Saharan AfricaParasites &amp;amp; Vectors20181141410.1186/s13071-018-2998-y30005653 15.DuffySWhy are RNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7128525\results\search\tropicalVirus\results.xml">
   <result pre="illness include novel strains of influenza, Ebola virus, Marburg virus," exact="Dengue" post="virus, AIDS, and tuberculosis between pastoralists and their livestock"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7140399\results\search\tropicalVirus\results.xml">
   <result pre="human embryonal development, such as that recently reflected by the" exact="Zika" post="virus (ZIKV), can be characterized. Here, we discuss human"/>
   <result pre="can be characterized. Here, we discuss human cytomegalovirus (HCMV) and" exact="ZIKV" post="in comparison to RV as viruses with well-known congenital"/>
   <result pre="development interferon placenta blastocyst iPSC pluripotent stem cells organoid cytomegalovirus" exact="Zika" post="virus rubella virus congenital virus infection 1. New Perspectives"/>
   <result pre="This was revealed by a mouse model for the congenital" exact="Zika" post="virus (ZIKV) infection based on the heterozygous knock-out of"/>
   <result pre="to their homozygous (IFNAR-/-) counterparts, the placental damage caused by" exact="ZIKV" post="infection was reduced. Moreover, these heterozygote (IFNAR-/+) pups were"/>
   <result pre="by the constant threat posed by emerging viruses. The recent" exact="ZIKV" post="outbreak has shown how even a virus that has"/>
   <result pre="alpha-inducible protein 6, which are induced in placenta explants upon" exact="ZIKV" post="infection [8]. Originally, they were identified as top ranked"/>
   <result pre="cells of mid-gestation [9] and full-term placentas [10] refractory to" exact="ZIKV" post="infection. This emphasizes the contributory role of the IFN"/>
   <result pre="[17]. There is also a wealth of literature available for" exact="ZIKV" post="transplacental passage. Multiple studies were performed on mid- and"/>
   <result pre="and 2 [18]. In their study, Tan et al. analyzed" exact="ZIKV" post="infection at the stage of pre- and peri-implantation blastocysts"/>
   <result pre="[18]. Ex vivo infection of mouse and human blastocysts with" exact="ZIKV" post="revealed viral replication in TE cells, which was further"/>
   <result pre="hESC-derived TE cells to ZIKV. Furthermore, mice were infected with" exact="ZIKV" post="at embryonal day (E) 2.5 and E3.5 before implantation"/>
   <result pre="onwards. Experimental proof is provided for in utero transmission of" exact="ZIKV" post="before formation of the placenta is initiated and even"/>
   <result pre="and differences of the congenital infections caused by HCMV and" exact="ZIKV" post="as opposed to RV. Like RV, both viruses can"/>
   <result pre="pregnancy and cause an analogous congenital syndrome. In contrast to" exact="ZIKV" post="and RV, HCMV can not only be vertically transmitted"/>
   <result pre="during the first trimester, albeit with less severe symptoms [41]." exact="ZIKV" post="emerged in 2013/2014 in French Polynesia and in 2015"/>
   <result pre="in Brazil [42,43]. The first evidence of perinatal transmission of" exact="ZIKV" post="was noted for two infants born in French Polynesia"/>
   <result pre="first two cases was eventually followed by solid proof that" exact="ZIKV" post="infection during pregnancy is linked to congenital malformations in"/>
   <result pre="necessary to turn an observed coincidence into the identification of" exact="ZIKV" post="as a cause of birth defects in humans [45]."/>
   <result pre="birth defects in humans [45]. Boppana et al. contrast congenital" exact="ZIKV" post="to non-ZIKV infections and provide a meaningful comparison of"/>
   <result pre="meaningful comparison of the structural damage caused by HCMV and" exact="ZIKV" post="in the brain and spinal cord, as revealed by"/>
   <result pre="a less common manifestation of CRS, whereas congenital HCMV and" exact="ZIKV" post="infections have a devastating influence on CNS development. This"/>
   <result pre="toxin when they induce side effects. In the context of" exact="ZIKV" post="infection, caspase-3 activity is elevated, representing a promising target"/>
   <result pre="Structural-bioinformatics-based methodologies and frameworks are suitable for the design of" exact="ZIKV" post="monoclonal antibodies against five envelope proteins and to estimate"/>
   <result pre="at a higher frequency with symptomatic infections [52]. The two" exact="ZIKV" post="lineages, Asian and African, display differences in their associated"/>
   <result pre="and developmental defects [43]. However, after in utero inoculation of" exact="ZIKV" post="in a fetal pig model, the trans-fetal ZIKV transmission"/>
   <result pre="inoculation of ZIKV in a fetal pig model, the trans-fetal" exact="ZIKV" post="transmission and the viral loads in the placenta, as"/>
   <result pre="that further studies on the epidemiology and the heterogeneity of" exact="ZIKV" post="strains are required [53]. Genomic epidemiology contributes to our"/>
   <result pre="One amino acid substitution within the precursor membrane protein of" exact="ZIKV" post="was sufficient to result in more microcephaly in a"/>
   <result pre="(NPCs) as compared to the parental virus [54]. Furthermore, among" exact="ZIKV" post="strains, differences in the capacity to induce an antiviral"/>
   <result pre="interferons (IFN-α and -β) are a suitable experimental model for" exact="ZIKV" post="[69]. Any type I interferon that is produced by"/>
   <result pre="IFN-associated antiviral state as a crucial determinant of susceptibility to" exact="ZIKV" post="is not generated. Immunocompetent wild-type mice are resistant to"/>
   <result pre="ZIKV is not generated. Immunocompetent wild-type mice are resistant to" exact="ZIKV" post="and lack disease symptoms and signs of virus replication"/>
   <result pre="disease symptoms and signs of virus replication [70]. In humans," exact="ZIKV" post="counteracts IFN pathway activation through targeting signal transducer of"/>
   <result pre="provide, in their study on ex vivo and in vivo" exact="ZIKV" post="infection in mice, a detailed summary of the literature"/>
   <result pre="model and the use of anti-IFNAR1 blocking antibodies along with" exact="ZIKV" post="infection [18], (Supplementary Material, Table 2 of [18]). Eventually,"/>
   <result pre="the generation of a human STAT2-knock-in immunocompetent mouse model for" exact="ZIKV" post="[72]. Pregnant mouse models of ZIKV infection provided valuable"/>
   <result pre="immunocompetent mouse model for ZIKV [72]. Pregnant mouse models of" exact="ZIKV" post="infection provided valuable insights into congenital ZIKV infection through"/>
   <result pre="mouse models of ZIKV infection provided valuable insights into congenital" exact="ZIKV" post="infection through recapitulation of several aspects identified in the"/>
   <result pre="(pigtail and rhesus macaques) used as a model for congenital" exact="ZIKV" post="infection [74]. However, in comparison to humans, these non-human"/>
   <result pre="the validation of their suitability as animal models for congenital" exact="ZIKV" post="infection necessitates further research [73]. Although transplacental passage of"/>
   <result pre="human development and, more specifically as outlined above, on congenital" exact="ZIKV" post="syndrome (CZS) and the associated pathology, it faces important"/>
   <result pre="new approach in congenital virology and, especially during the recent" exact="ZIKV" post="epidemics in Brazil, host genetic factors were identified. A"/>
   <result pre="the following pairs of Brazilian twins that were exposed to" exact="ZIKV" post="during pregnancy: monozygotic twins equally affected (concordant) and dizygotic"/>
   <result pre="participants of in vitro fertilization programs [92]. The application of" exact="ZIKV" post="in the IFNAR-/- mouse model confirmed experimentally in the"/>
   <result pre="by Tan et al. also revealed a dose-dependent effect of" exact="ZIKV" post="on blastocyst proliferation, which complied with the paradigm shift"/>
   <result pre="to infectivity by HCMV, iPSCs are susceptible and permissive to" exact="ZIKV" post="and RV [47,106]. Among the plethora of original research"/>
   <result pre="and hindbrain and spinal cord brain organoids. Their infection with" exact="ZIKV" post="was associated with growth arrest and apoptosis. Additionally, overactivation"/>
   <result pre="days of differentiation as a model for the impact of" exact="ZIKV" post="on neurodevelopmental processes. After five days of infection, a"/>
   <result pre="al., which did not identify boosting of TLR3 signaling during" exact="ZIKV" post="infection [107]. This may be due to the different"/>
   <result pre="congenital virus infections. Complementing this data on the impact of" exact="ZIKV" post="on cerebral organoids, iPSC-derived human retinal epithelium (RPE) was"/>
   <result pre="(RPE) was employed to address ocular defects noted after congenital" exact="ZIKV" post="infection [109]. Transepithelial resistance of the RPE, as well"/>
   <result pre="as cell junctions and, thus, RPE architecture, were impaired after" exact="ZIKV" post="infection. As a follow-up of these observations, a strong"/>
   <result pre="revealed by induction of IFNs, was identified in RPE after" exact="ZIKV" post="infection [110]. The relevance of inflammation as an effective"/>
   <result pre="The relevance of inflammation as an effective host countermeasure against" exact="ZIKV" post="infection is emphasized by the sex determining region Y"/>
   <result pre="also their application in the study of human diseases, including" exact="ZIKV" post="microcephaly [118]. This review by Chen et al. also"/>
   <result pre="Chen et al. also covers recent drug screening approaches against" exact="ZIKV" post="on brain organoids, which allow for assessment of antiviral"/>
   <result pre="enzyme cholesterol 25-hydroxylase and for which an antiviral effectiveness against" exact="ZIKV" post="was shown in animal studies, whereas the reduction of"/>
   <result pre="provide mechanistic insights into the ways neurotropic viruses such as" exact="ZIKV" post="interact with their human host. They also complement vaccine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7140696\results\search\tropicalVirus\results.xml">
   <result pre="for certain pathogens. 2.4. ERAPs and Human Papilloma Virus (HPV)" exact="Human papilloma virus" post="(HPV) is a DNA virus and the causative agent"/>
   <result pre="a DNA virus and the causative agent of cervical cancer." exact="HPV" post="is the most common sexually transmitted infection and indeed"/>
   <result pre="population undergoes this infection sooner or later during life [74]." exact="HPV" post="infection is asymptomatic and spontaneously resolves within a couple"/>
   <result pre="in anus, vulva, vagina, penis, and oropharynx cancers [74]. Actually," exact="HPV" post="is responsible for more than 12% of cancers in"/>
   <result pre="as prevention methods: they all are thoroughly effective in preventing" exact="HPV" post="infection, especially toward types 16 and 18 viruses, responsible"/>
   <result pre="for more than half of cervical cancer cases worldwide [75]." exact="HPV" post="targets epithelial cells of the basal layer in injured"/>
   <result pre="targets epithelial cells of the basal layer in injured regions." exact="HPV" post="infection and growth are absolutely dependent upon the expression"/>
   <result pre="of the epithelium. As these cells can no longer replicate," exact="HPV" post="synthetizes the E6 and E7oncogenes—two viral proteins engaged on"/>
   <result pre="these variants in Javanese and Balinese Indonesian populations, in whom" exact="HPV" post="is almost endemic [87]. Results showed that, as in"/>
   <result pre="[88,89]. Indeed, these two Indonesian areas show a different oncogenic" exact="HPV" post="subtypes distribution suggesting that distinct HPV subtypes may evade"/>
   <result pre="show a different oncogenic HPV subtypes distribution suggesting that distinct" exact="HPV" post="subtypes may evade the immune system by hijacking different"/>
   <result pre="itself [94,95]. The most recent study seeking possible correlations between" exact="HPV" post="infection and ERAP1 has been conducted in 2019 by"/>
   <result pre="carcinoma (OPSCC)—the specificity of tumor-infiltrating CD8+ T lymphocytes (CD8+TILs) for" exact="HPV" post="epitopes has been demonstrated. In particular, analyses showed that"/>
   <result pre="Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated ImmunoevasionCell Rep.20172084685310.1016/j.celrep.2017.06.08428746870 74.DunneE.F.UngerE.R.SternbergM.McQuillanG.SwanD.C.PatelS.S.MarkowitzL.E.Prevalence of" exact="HPV" post="infection among females in the United StatesJAMA200729781381910.1001/jama.297.8.81317327523 75.ChabedaA.YanezR.J.R.LamprechtR.MeyersA.E.RybickiE.P.HitzerothI.I.Therapeutic vaccines"/>
   <result pre="11 K528R HCV, HIV rs27044 Exon 15 Q730E HCV, HIV," exact="HPV" post="rs10050860 Exon 12 D575N HPV rs26618 Exon 5 M276I"/>
   <result pre="Exon 15 Q730E HCV, HIV, HPV rs10050860 Exon 12 D575N" exact="HPV" post="rs26618 Exon 5 M276I HCV rs26653 Exon 2 P127R"/>
   <result pre="rs26618 Exon 5 M276I HCV rs26653 Exon 2 P127R HCV," exact="HPV" post="rs17481856 Exon 17 L848L Toxoplasmosis rs17481334 3’ UTR None"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7141683\results\search\tropicalVirus\results.xml">
   <result pre="influenza A virus which targets the respiratory tract, and the" exact="Zika" post="virus that can infect via the reproductive tract [26]."/>
   <result pre=".30886417 27LazearHM, DanielsBP, PintoAK, HuangAC, VickSC, DoyleSE, et al.Interferon-lambda restricts" exact="West Nile" post="virus neuroinvasion by tightening the blood-brain barrier. Science translational"/>
   <result pre="10.1128/JVI.02695-1526763998 37PanayiotouC, LindqvistR, KurhadeC, VondersteinK, PastoJ, EdlundK, et al.Viperin Restricts" exact="Zika" post="Virus and Tick-Borne Encephalitis Virus Replication by Targeting NS3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7141694\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and life sciences : Organisms :"/>
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : People and Places : Geographical Locations :"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and Life Sciences : Molecular Biology"/>
   <result pre="Pulmonology: Respiratory Infections Comparison of clinical presentation and out-comes of" exact="Chikungunya" post="and Dengue virus infections in patients with acute undifferentiated"/>
   <result pre="Infections Comparison of clinical presentation and out-comes of Chikungunya and" exact="Dengue" post="virus infections in patients with acute undifferentiated febrile illness"/>
   <result pre="acute undifferentiated febrile illness from the Sindh region of Pakistan" exact="Chikungunya" post="and Dengue virus comparison clinical cases ShahidUzmaFormal analysisInvestigationMethodologyWriting –"/>
   <result pre="febrile illness from the Sindh region of Pakistan Chikungunya and" exact="Dengue" post="virus comparison clinical cases ShahidUzmaFormal analysisInvestigationMethodologyWriting – original draftWriting"/>
   <result pre="of acute febrile illness and outbreaks worldwide. Recent outbreaks of" exact="Chikungunya" post="virus (CHIKV) in dengue endemic areas have alarmed clinicians"/>
   <result pre="endemic areas have alarmed clinicians as unique clinical features differentiating" exact="CHIKV" post="from Dengue virus (DENV) are limited. This has complicated"/>
   <result pre="have alarmed clinicians as unique clinical features differentiating CHIKV from" exact="Dengue" post="virus (DENV) are limited. This has complicated diagnostic efforts"/>
   <result pre="of laboratory confirmed cases to assist clinicians in suspecting possible" exact="CHIKV" post="infection at time of clinical presentation. Methodology A prospective"/>
   <result pre="suffering from dengue and that other arboviruses such as Chikungunya," exact="West Nile" post="viruses, Japanese Encephalitis virus and Zika virus are co-circulating"/>
   <result pre="such as Chikungunya, West Nile viruses, Japanese Encephalitis virus and" exact="Zika" post="virus are co-circulating in the Sindh region of Pakistan."/>
   <result pre="study mentioned above. Here-in we compared laboratory confirmed cases of" exact="CHIKV" post="and DENV to assess clinical features and laboratory findings"/>
   <result pre="above. Here-in we compared laboratory confirmed cases of CHIKV and" exact="DENV" post="to assess clinical features and laboratory findings that may"/>
   <result pre="assess clinical features and laboratory findings that may help differentiate" exact="CHIKV" post="from DENV infection at the time of clinical presentation."/>
   <result pre="features and laboratory findings that may help differentiate CHIKV from" exact="DENV" post="infection at the time of clinical presentation. Results Ninety-eight"/>
   <result pre="and PCR and these were selected for comparative analysis with" exact="DENV" post="confirmed cases (n = 171). On multivariable analysis, presence"/>
   <result pre="and thrombocytosis [OR = 2.2 (95% CI:1.1–4.0)] were associated with" exact="CHIKV" post="infection, while atypical lymphocytes [OR = 8.3 (95% CI:4.2–16.7)]"/>
   <result pre="and thrombocytopenia [OR = 8.1 (95% CI:1.7–38.8)] were associated with" exact="DENV" post="cases at time of presentation. These findings may help"/>
   <result pre="time of presentation. These findings may help clinicians in differentiating" exact="CHIKV" post="from DENV infection. Conclusion CHIKV is an important cause"/>
   <result pre="presentation. These findings may help clinicians in differentiating CHIKV from" exact="DENV" post="infection. Conclusion CHIKV is an important cause of illness"/>
   <result pre="may help clinicians in differentiating CHIKV from DENV infection. Conclusion" exact="CHIKV" post="is an important cause of illness amongst patients presenting"/>
   <result pre="presentation among patients with dengue-like illness should prompt suspicion of" exact="CHIKV" post="infection, and laboratory confirmation must be sought. Author summary"/>
   <result pre="CHIKV infection, and laboratory confirmation must be sought. Author summary" exact="Chikungunya" post="and Dengue viral infection are prevalent in South Asia."/>
   <result pre="and laboratory confirmation must be sought. Author summary Chikungunya and" exact="Dengue" post="viral infection are prevalent in South Asia. These are"/>
   <result pre="study we analysed clinical findings of patients with lab confirmed" exact="Dengue" post="virus and Chikungunya virus infection and compared the clinical"/>
   <result pre="clinical findings of patients with lab confirmed Dengue virus and" exact="Chikungunya" post="virus infection and compared the clinical symptoms to assess"/>
   <result pre="Khan University Hospital, Karachi Pakistan. Our study confirms presence of" exact="Chikungunya" post="virus as an etiologic agent of fever among patients"/>
   <result pre="disease spectrum associated with significant morbidity in humans. Amongst these," exact="Dengue" post="virus (DENV) and Chikungunya virus (CHIKV) share geographic and"/>
   <result pre="significant morbidity in humans. Amongst these, Dengue virus (DENV) and" exact="Chikungunya" post="virus (CHIKV) share geographic and vector related features and"/>
   <result pre="illnesses spread by the mosquitos of the Aedes family. While" exact="DENV" post="belongs to the genus Flavivirus, CHIKV is a member"/>
   <result pre="the Aedes family. While DENV belongs to the genus Flavivirus," exact="CHIKV" post="is a member of the genus Alphavirus in the"/>
   <result pre="similar disease manifestations including fever, rash and other non-specific findings." exact="CHIKV" post="presents after an incubation period of 2–3 days, as"/>
   <result pre="it essential to diagnose. First recorded in Tanzania during 1952–53," exact="CHIKV" post="has caused multiple outbreaks worldwide involving all continents but"/>
   <result pre="caused multiple outbreaks worldwide involving all continents but Antarctica [3]." exact="CHIKV" post="has been circulating actively in the Indian subcontinent for"/>
   <result pre="from India to Sri Lanka. India reported around 1.4 million" exact="CHIKV" post="infections in 2006 [4]. Despite this active transmission in"/>
   <result pre="[4]. Despite this active transmission in the region, reports of" exact="CHIKV" post="activity have been reported from Pakistan only very recently"/>
   <result pre="in the backdrop of reports that 20–30% of clinically diagnosed" exact="DENV" post="cases being negative for the virus; referred to in"/>
   <result pre="as non-DENV acute febrile illness (NDFI) [10–11]. Thus possibility of" exact="CHIKV" post="infection misdiagnosed as dengue like illness. In this study,"/>
   <result pre="surveillance study for patients with acute febrile illness and/or suspected" exact="DENV" post="infection in 5 cities of Sindh province in Pakistan."/>
   <result pre="Pakistan. This study aimed firstly to ascertain the presence of" exact="CHIKV" post="as etiologic agent of NDFI in Sindh province, and"/>
   <result pre="province, and secondly, to compare clinical features of laboratory confirmed" exact="CHIKV" post="cases with DENV infection to identify clinical features and"/>
   <result pre="to compare clinical features of laboratory confirmed CHIKV cases with" exact="DENV" post="infection to identify clinical features and laboratory findings that"/>
   <result pre="identify clinical features and laboratory findings that may help differentiate" exact="CHIKV" post="from DENV infection at the time of clinical presentation."/>
   <result pre="features and laboratory findings that may help differentiate CHIKV from" exact="DENV" post="infection at the time of clinical presentation. Methods Ethics"/>
   <result pre="was carried out to assess role of arboviruses namely: Chikungunya," exact="West Nile" post="and Japanese encephalitis virus as cause of fever in"/>
   <result pre="subgroup analysis was performed on patients who tested positive for" exact="DENV" post="and CHIKV. Patient selection and data collection We recruited"/>
   <result pre="were de-identified and stored at -80°C after separation of serum." exact="DENV" post="and CHIKV testing was performed using a commercial IgM"/>
   <result pre="and stored at -80°C after separation of serum. DENV and" exact="CHIKV" post="testing was performed using a commercial IgM Enzyme-Linked Immunosorbent"/>
   <result pre="algorithm was followed (Fig 1). Samples that tested negative for" exact="DENV" post="were considered as NDFI and were then evaluated for"/>
   <result pre="as NDFI and were then evaluated for other viruses including" exact="CHIKV" post="infection by IgM ELISA and RT-PCR. Hence, co-infection with"/>
   <result pre="chikungunya was not evaluated. Fig 1 The diagnostic algorithm for" exact="DENV" post="and CHIKV serologic testing. Flow chart illustrating patient recruitment"/>
   <result pre="not evaluated. Fig 1 The diagnostic algorithm for DENV and" exact="CHIKV" post="serologic testing. Flow chart illustrating patient recruitment according to"/>
   <result pre="recruitment according to inclusion criteria and workflow of specimen for" exact="DENV" post="and CHIKV detection. Serologic interpretation- ELISA CHIKV and DENV"/>
   <result pre="to inclusion criteria and workflow of specimen for DENV and" exact="CHIKV" post="detection. Serologic interpretation- ELISA CHIKV and DENV immunoglobulin M"/>
   <result pre="of specimen for DENV and CHIKV detection. Serologic interpretation- ELISA" exact="CHIKV" post="and DENV immunoglobulin M (IgM) antibodies were detected via"/>
   <result pre="for DENV and CHIKV detection. Serologic interpretation- ELISA CHIKV and" exact="DENV" post="immunoglobulin M (IgM) antibodies were detected via commercial IgM"/>
   <result pre="These are sandwich-type immunoassays that detect human antibodies targeting the" exact="CHIKV" post="and DENV envelope glycoproteins. Any indeterminate or borderline samples"/>
   <result pre="sandwich-type immunoassays that detect human antibodies targeting the CHIKV and" exact="DENV" post="envelope glycoproteins. Any indeterminate or borderline samples were retested"/>
   <result pre="were retested and evaluated in duplicate to verify immune status." exact="Dengue" post="IgM was tested for cross-reactivity with other flaviviruses like"/>
   <result pre="Dengue IgM was tested for cross-reactivity with other flaviviruses like" exact="West Nile," post="Japanese Encephalitis and Zika by Plaque Reduction Neutralization Test"/>
   <result pre="cross-reactivity with other flaviviruses like West Nile, Japanese Encephalitis and" exact="Zika" post="by Plaque Reduction Neutralization Test (PRNT). Dengue subtyping was"/>
   <result pre="Japanese Encephalitis and Zika by Plaque Reduction Neutralization Test (PRNT)." exact="Dengue" post="subtyping was done by PCR for antigen positive samples"/>
   <result pre="between variables. Results 991 patients with a clinical diagnosis of" exact="DENV" post="infection were enrolled. Of these 17.25% (n = 171)"/>
   <result pre="these 17.25% (n = 171) tested positive and confirmed as" exact="DENV" post="infection. 11.95% (n = 98) of NDFI patients tested"/>
   <result pre="11.95% (n = 98) of NDFI patients tested positive for" exact="CHIKV" post="via IgM ELISA and RT-PCR. 79.6% (n = 78)"/>
   <result pre="IgM ELISA and RT-PCR. 79.6% (n = 78) cases of" exact="CHIKV" post="were detected by IgM while 11.2% (n = 11/98)"/>
   <result pre="while 11.2% (n = 11/98) of samples tested positive for" exact="CHIKV" post="by either ELISA or RT-PCR; fulfilling the CDC diagnostic"/>
   <result pre="the CDC diagnostic criteria [12] for a confirmed infection. For" exact="Dengue" post="fever, 63.1% (n = 108) of NS1Ag positive were"/>
   <result pre="of NS1Ag positive were also positive for IgM antibodies, while" exact="DENV" post="was detected by PCR in 45.6% (n = 78)"/>
   <result pre="in 45.6% (n = 78) cases. Patient demographics Patients with" exact="DENV" post="were significantly younger than patients with CHIKV infection. DENV"/>
   <result pre="demographics Patients with DENV were significantly younger than patients with" exact="CHIKV" post="infection. DENV patients had a mean age of 33.6"/>
   <result pre="with DENV were significantly younger than patients with CHIKV infection." exact="DENV" post="patients had a mean age of 33.6 years while"/>
   <result pre="with males comprising 56.7% and 55.10% of the population for" exact="DENV" post="and CHIKV, respectively. 10.1371/journal.pntd.0008086.t001Table 1 Demographics of patients diagnosed"/>
   <result pre="CHIKV, respectively. 10.1371/journal.pntd.0008086.t001Table 1 Demographics of patients diagnosed with either" exact="DENV" post="or CHIKV. Bold font indicates statistical significance. CHIKV DENV"/>
   <result pre="with either DENV or CHIKV. Bold font indicates statistical significance." exact="CHIKV" post="DENV Continuous variable Mean ±SD Mean ±SD Difference (95%CI)"/>
   <result pre="either DENV or CHIKV. Bold font indicates statistical significance. CHIKV" exact="DENV" post="Continuous variable Mean ±SD Mean ±SD Difference (95%CI) Mean"/>
   <result pre="5 (5.1) 11(6.4) - Demographics of patients with dengue and" exact="Chikungunya" post="virus infections. Qualitative variable is represented with frequency count"/>
   <result pre="95%CI = 95% confidence interval. The majority of patients with" exact="DENV" post="were from Karachi (87.1%, n = 149), followed by"/>
   <result pre="1). Karachi was also the site for most of the" exact="CHIKV" post="positive cases (91%, n = 89), then Hyderabad (5.05%,"/>
   <result pre="5) (Table 1). Upper Sindh showed less activity for both" exact="DENV" post="and CHIKV infection with only 4% of DENV patients"/>
   <result pre="1). Upper Sindh showed less activity for both DENV and" exact="CHIKV" post="infection with only 4% of DENV patients from Mirpurkhas"/>
   <result pre="for both DENV and CHIKV infection with only 4% of" exact="DENV" post="patients from Mirpurkhas and 1% from each Sukkhar and"/>
   <result pre="from Mirpurkhas and 1% from each Sukkhar and Larkana. For" exact="CHIKV" post="infection, 2% of patients were enrolled from Sukkhar and"/>
   <result pre="days with mean duration of 4.2 days in patients with" exact="DENV" post="infection as compared to 5.4 days in patients with"/>
   <result pre="DENV infection as compared to 5.4 days in patients with" exact="CHIKV" post="infection. Average fever of patients with CHIKV was 100.5°F"/>
   <result pre="in patients with CHIKV infection. Average fever of patients with" exact="CHIKV" post="was 100.5°F and patients with DENV had an average"/>
   <result pre="fever of patients with CHIKV was 100.5°F and patients with" exact="DENV" post="had an average temperature of 100.3°F. While there were"/>
   <result pre="not differ significantly between the 2 groups, patients with confirmed" exact="CHIKV" post="infection frequently presented with severe musculoskeletal pain and central"/>
   <result pre="nausea, abdominal pain and vomiting were reported in 53.8% of" exact="DENV" post="patients (p&amp;lt;0.001) (Table 2). Haemorrhage was significantly associated with"/>
   <result pre="DENV patients (p&amp;lt;0.001) (Table 2). Haemorrhage was significantly associated with" exact="DENV" post="virus infection with 8% of patients presenting with this"/>
   <result pre="(Table 2). Rash was seen in 15.3% and 15.2% of" exact="CHIKV" post="and DENV cases respectively and was not a significant"/>
   <result pre="Rash was seen in 15.3% and 15.2% of CHIKV and" exact="DENV" post="cases respectively and was not a significant predictor of"/>
   <result pre="Clinical presentation and laboratory findings of acute febrile patients with" exact="Dengue" post="virus and Chikungunya virus infection from Sindh, Pakistan 2015–2017"/>
   <result pre="laboratory findings of acute febrile patients with Dengue virus and" exact="Chikungunya" post="virus infection from Sindh, Pakistan 2015–2017 (Bold font indicates"/>
   <result pre="infection from Sindh, Pakistan 2015–2017 (Bold font indicates statistical significance)." exact="CHIKV" post="DENV Difference (95%CI) OR CHIKV (95%CI) OR DENV (95%CI)"/>
   <result pre="from Sindh, Pakistan 2015–2017 (Bold font indicates statistical significance). CHIKV" exact="DENV" post="Difference (95%CI) OR CHIKV (95%CI) OR DENV (95%CI) Clinical"/>
   <result pre="(Bold font indicates statistical significance). CHIKV DENV Difference (95%CI) OR" exact="CHIKV" post="(95%CI) OR DENV (95%CI) Clinical presentation Mean ±SD Mean"/>
   <result pre="statistical significance). CHIKV DENV Difference (95%CI) OR CHIKV (95%CI) OR" exact="DENV" post="(95%CI) Clinical presentation Mean ±SD Mean ±SD Mean days"/>
   <result pre="clinical presentation and laboratory profile amongst patients with dengue and" exact="Chikungunya" post="virus infections. Qualitative variable is represented with frequency count"/>
   <result pre="haematocrit and haemoglobin levels were within normal range for both" exact="DENV" post="and CHIKV patients though 34.1% of DENV patients exhibited"/>
   <result pre="haemoglobin levels were within normal range for both DENV and" exact="CHIKV" post="patients though 34.1% of DENV patients exhibited elevated haematocrit"/>
   <result pre="range for both DENV and CHIKV patients though 34.1% of" exact="DENV" post="patients exhibited elevated haematocrit p &amp;lt;0.001 (as compared to"/>
   <result pre="exhibited elevated haematocrit p &amp;lt;0.001 (as compared to 20% of" exact="CHIKV" post="patients). For DENV, thrombocytopenia (defined as platelet count &amp;lt;150,000/mm3)."/>
   <result pre="exhibiting this phenomenon (p &amp;lt;0.001) as compared to 18% of" exact="CHIKV" post="patients; almost 150 platelets less than CHIKV (Table 2)."/>
   <result pre="to 18% of CHIKV patients; almost 150 platelets less than" exact="CHIKV" post="(Table 2). While both DENV and CHIKV infected patients"/>
   <result pre="almost 150 platelets less than CHIKV (Table 2). While both" exact="DENV" post="and CHIKV infected patients exhibited, on average, elevated leucocyte"/>
   <result pre="platelets less than CHIKV (Table 2). While both DENV and" exact="CHIKV" post="infected patients exhibited, on average, elevated leucocyte counts, 87%"/>
   <result pre="infected patients exhibited, on average, elevated leucocyte counts, 87% of" exact="DENV" post="infected patients presented with atypical lymphocytes and were 3"/>
   <result pre="likely to present with this sign than patients infected with" exact="CHIKV" post="(Table 2). Altered red blood cell (RBC) morphology was"/>
   <result pre="significant finding and was reported almost twice as frequently in" exact="CHIKV" post="infected patients than DENV infected patients, with 36.7% of"/>
   <result pre="reported almost twice as frequently in CHIKV infected patients than" exact="DENV" post="infected patients, with 36.7% of CHIKV patients showing elevate"/>
   <result pre="CHIKV infected patients than DENV infected patients, with 36.7% of" exact="CHIKV" post="patients showing elevate levels of misshaped RBCs compared to"/>
   <result pre="elevate levels of misshaped RBCs compared to only 20% of" exact="DENV" post="patients (Table 2). Liver function tests Upon enrolment, the"/>
   <result pre="(ALT) and mean aspartate aminotransferase (AST) levels of patients with" exact="CHIKV" post="were within the normal range (55.13 IU/L and 60.90"/>
   <result pre="the normal range (55.13 IU/L and 60.90 IU/L, respectively) while" exact="DENV" post="patients had significantly higher mean levels of ALT (113.4"/>
   <result pre="(113.4 IU/L) and AST (158.7 IU/L) (Table 2). Patients with" exact="DENV" post="were more likely to have elevated liver enzymes, 88.4%"/>
   <result pre="58.3% ALT (OR 2.6, 95% CI: 1.2–5.6) than patients with" exact="CHIKV" post="(68.1% AST and 35.1% ALT). Multivariable analysis On multivariable"/>
   <result pre="and thrombocytosis [OR = 2.2 (95% CI:1.1–4.0)] were associated with" exact="CHIKV" post="infection, while atypical lymphocytes [OR = 8.3 (95% CI:4.2–16.7)]"/>
   <result pre="and thrombocytopenia [OR = 8.1 (95% CI:1.7–38.8)] were associated with" exact="DENV" post="cases at the time of presentation. Clinical management At"/>
   <result pre="the time of presentation. Clinical management At presentation, 83.0% of" exact="DENV" post="patients were clinically diagnosed with a viral infection, while"/>
   <result pre="a viral infection, while only 50% of patients in the" exact="CHIKV" post="group were diagnosed with a viral infection (Table 3)."/>
   <result pre="were diagnosed with a viral infection (Table 3). 10.2% of" exact="CHIKV" post="patients were diagnosed with a bacterial infection and 12%"/>
   <result pre="by physicians (Table 3). Malaria was suspected in 10% of" exact="DENV" post="infected patients and 6% of CHIKV patients (Table 3)."/>
   <result pre="suspected in 10% of DENV infected patients and 6% of" exact="CHIKV" post="patients (Table 3). 10.1371/journal.pntd.0008086.t003Table 3 Clinical diagnosis and management"/>
   <result pre="and management profile with outcomes of patients suffering from acute" exact="Chikungunya" post="and Dengue enrolled from Sindh, Pakistan [2015–2017]. Provisional diagnosis"/>
   <result pre="profile with outcomes of patients suffering from acute Chikungunya and" exact="Dengue" post="enrolled from Sindh, Pakistan [2015–2017]. Provisional diagnosis Chikungunya n"/>
   <result pre="Chikungunya and Dengue enrolled from Sindh, Pakistan [2015–2017]. Provisional diagnosis" exact="Chikungunya" post="n = 98(%) Dengue n = 171(%) OR for"/>
   <result pre="from Sindh, Pakistan [2015–2017]. Provisional diagnosis Chikungunya n = 98(%)" exact="Dengue" post="n = 171(%) OR for CHIKV (95%CI) OR for"/>
   <result pre="Chikungunya n = 98(%) Dengue n = 171(%) OR for" exact="CHIKV" post="(95%CI) OR for DENV (95%CI) Viral infection 49 (50)"/>
   <result pre="Dengue n = 171(%) OR for CHIKV (95%CI) OR for" exact="DENV" post="(95%CI) Viral infection 49 (50) 142 (83.0) 0.6 (0.5"/>
   <result pre="Clinical diagnosis and management profile amongst patients with dengue and" exact="Chikungunya" post="virus infections. Qualitative variable is represented with frequency count"/>
   <result pre="95%CI = 95% confidence interval. Despite have fewer viral diagnoses," exact="CHIKV" post="infected patients were 4 times more likely to receive"/>
   <result pre="times more likely to receive antiviral therapy (primarily acyclovir) than" exact="DENV" post="patients (Table 3). While not significant, use of steroid"/>
   <result pre="significant, use of steroid therapy was documented in 5.1% of" exact="CHIKV" post="patients as compared to 3.5% of patients with DENV"/>
   <result pre="of CHIKV patients as compared to 3.5% of patients with" exact="DENV" post="(Table 3). Fluid replacement therapy was required in 76.6%"/>
   <result pre="(Table 3). Fluid replacement therapy was required in 76.6% of" exact="DENV" post="patients and 51% of CHIKV infected patients (Table 3)."/>
   <result pre="was required in 76.6% of DENV patients and 51% of" exact="CHIKV" post="infected patients (Table 3). Up to 60% of patients"/>
   <result pre="groups (Table 3). Discussion In this study, we show that" exact="CHIKV" post="is an important cause of NDFI cases in the"/>
   <result pre="Reller et al from Sri Lanka, in 2015 reported acute" exact="CHIKV" post="infection in 3.5% of patients with acute febrile illness,"/>
   <result pre="complete laboratory workup [10]. Similarly, studies from India have reported" exact="CHIKV" post="prevalence of 9.6–25% while 37% remained undiagnosed [6,11]. In"/>
   <result pre="standards. This study also included samples from cluster outbreak of" exact="CHIKV" post="infection during November 2016 that made the headline news"/>
   <result pre="headline news in the country with 30,000 patients suspected of" exact="CHIKV" post="infection [9]. Co-circulation of DENV and CHIKV in Karachi"/>
   <result pre="with 30,000 patients suspected of CHIKV infection [9]. Co-circulation of" exact="DENV" post="and CHIKV in Karachi reflects a progressive deterioration of"/>
   <result pre="patients suspected of CHIKV infection [9]. Co-circulation of DENV and" exact="CHIKV" post="in Karachi reflects a progressive deterioration of municipal infra-structure"/>
   <result pre="to control mosquitos [13]. More concerning is the identification of" exact="DENV" post="and CHIKV in less densely populated peri-urban and rural"/>
   <result pre="mosquitos [13]. More concerning is the identification of DENV and" exact="CHIKV" post="in less densely populated peri-urban and rural areas, which"/>
   <result pre="neurological manifestations were significantly associated with CHIKV. Twenty-one percent of" exact="CHIKV" post="positive patients presented with CNS manifestations. This may have"/>
   <result pre="prompted the use of acyclovir in management of patients with" exact="CHIKV" post="infection at time of admission, in lieu of possible"/>
   <result pre="India where altered mental status was seen in 56.67% of" exact="CHIKV" post="patients requiring admission to intensive care units [15]. Literature"/>
   <result pre="to intensive care units [15]. Literature from most of the" exact="CHIKV" post="endemic region (i.e. Indian Ocean, South Asia, the Pacific"/>
   <result pre="the Caribbean, and South America) have reported neurological manifestation of" exact="CHIKV" post="[16]. A study in La Reunion reported 24.1% of"/>
   <result pre="CHIKV [16]. A study in La Reunion reported 24.1% of" exact="CHIKV" post="cases presenting with abnormal neurological signs and symptoms [17]."/>
   <result pre="reported neurological symptoms in almost half of patients with confirmed" exact="CHIKV" post="infections [8]. GI manifestations were most pronounced in patients"/>
   <result pre="infections [8]. GI manifestations were most pronounced in patients with" exact="DENV" post="infection, with 53.8% of DENV cases as compared to"/>
   <result pre="most pronounced in patients with DENV infection, with 53.8% of" exact="DENV" post="cases as compared to 26.2% of CHIKV, a finding"/>
   <result pre="differentiate the two infections in clinical setting. The association of" exact="DENV" post="with GI symptoms has consistently been reported from other"/>
   <result pre="review of 8559 patients reported GI symptoms in 67% of" exact="DENV" post="patients [18]. In vitro studies have also shown DENV"/>
   <result pre="of DENV patients [18]. In vitro studies have also shown" exact="DENV" post="to have a predilection for GI tissue, especially liver"/>
   <result pre="may explain the elevated AST and ALT levels in the" exact="DENV" post="group and other reports from endemic regions [20]. Fernando"/>
   <result pre="increase of ALT/AST from baseline in hepatitis associated with severe" exact="DENV" post="cases [22]. These findings are significant for Pakistan as"/>
   <result pre="in the population. This data should alert physicians to include" exact="DENV" post="in the differential diagnosis of patients presenting with fever,"/>
   <result pre="Pronounced musculoskeletal symptoms including polyarthralgia was reported in 62.2% of" exact="CHIKV" post="patients as compared to 29.8% in DENV patients. These"/>
   <result pre="in 62.2% of CHIKV patients as compared to 29.8% in" exact="DENV" post="patients. These symptoms may have resulted in misdiagnosis of"/>
   <result pre="DENV patients. These symptoms may have resulted in misdiagnosis of" exact="CHIKV" post="infection as non-infectious arthritis by clinicians at time of"/>
   <result pre="were observed for DENV. Significant thrombocytopenia was also found in" exact="DENV" post="patients. This corroborates the findings of Lee et al"/>
   <result pre="the findings of Lee et al in their study on" exact="CHIKV" post="versus DENV infections in adults [1]. While case fatality"/>
   <result pre="of Lee et al in their study on CHIKV versus" exact="DENV" post="infections in adults [1]. While case fatality has been"/>
   <result pre="adults [1]. While case fatality has been associated with both" exact="DENV" post="and CHIKV, all patients in our study survived, [15,"/>
   <result pre="in our study survived, [15, 26–29]. For laboratory diagnostics, the" exact="Dengue" post="Early Rapid NS-1 test was the most effective for"/>
   <result pre="Dengue Early Rapid NS-1 test was the most effective for" exact="DENV" post="detection as most cases of DENV infection were detected"/>
   <result pre="the most effective for DENV detection as most cases of" exact="DENV" post="infection were detected using this assay. Many of these"/>
   <result pre="Ahmed et al who found that the overall performance of" exact="DENV" post="RT-PCR to be no better than NS-1 antigen detection"/>
   <result pre="be no better than NS-1 antigen detection [30]. For the" exact="CHIKV" post="serological diagnosis, 11% were positive with both IgM ELISA"/>
   <result pre="sequencing studies are currently underway to identify any mutations in" exact="CHIKV" post="isolates yielded from Pakistan. Most of our CHIKV patients"/>
   <result pre="mutations in CHIKV isolates yielded from Pakistan. Most of our" exact="CHIKV" post="patients were adult males which is in concordance with"/>
   <result pre="CHIKV patients were adult males which is in concordance with" exact="CHIKV" post="epidemic reports from India and other regions [32, 33]."/>
   <result pre="there was no follow-up, the outcomes and long-term sequelae of" exact="CHIKV" post="infections could not be assessed. Disease severity data was"/>
   <result pre="subgroup of severe dengue cases could not be compared with" exact="CHIKV" post="cases admitted to the hospital. Another shortcoming was the"/>
   <result pre="the hospital. Another shortcoming was the testing algorithm: as only" exact="DENV" post="NS1 negative cases were tested for CHIKV, co-infections and"/>
   <result pre="cases could not be determined. Conclusion Our study confirms that" exact="CHIKV" post="is present in Sindh region of Pakistan and is"/>
   <result pre="is an important cause of acute febrile illness. Patients with" exact="CHIKV" post="infection are more likely to present with severe arthralgia"/>
   <result pre="to present with severe arthralgia and neurological symptoms. The recent" exact="CHIKV" post="outbreak in Karachi highlights the possibility of Karachi having"/>
   <result pre="findings raise concerns for the possible circulation of a virulent" exact="CHIKV" post="genotype known for its high rate of CNS involvement."/>
   <result pre="data file. S1 Table Primer and probe sequences used for" exact="Chikungunya" post="and dengue virus detection. (DOCX) LINK Click here for"/>
   <result pre="CarrascoLR, CookAR, LyeDC, et al.Simple clinical and laboratory predictors of" exact="Chikungunya" post="versus dengue infections in adults. PLoS neglected tropical diseases."/>
   <result pre="HalabiY, LourentsNT, BurgerhofJG, van der VeenHT, BaileyA, GrobuschMP, TamiA. Long-term" exact="Chikungunya" post="Sequelae in Curaçao: Burden, Determinants, and a Novel Classification"/>
   <result pre="13NaqviS, BashirS, RupareliyaC, ShamsA, GiyanwaniPR, AliZ, et al.Clinical Spectrum of" exact="Chikungunya" post="in Pakistan. Cureus. 2017;9(7):e1430 Epub 2017/09/20. 10.7759/cureus.143028924518 14ChaharHS, BharajP,"/>
   <result pre="2018/04/20. 10.1002/rmv.197829671914 17EconomopoulouA, DominguezM, HelynckB, SissokoD, WichmannO, QuenelP, et al.Atypical" exact="Chikungunya" post="virus infections: clinical manifestations, mortality and risk factors for"/>
   <result pre="MdelM, CeronT, ZamudioC, et al. [Abdominal and gastrointestinal symptoms of" exact="Dengue" post="fever. Analysis of a cohort of 8559 patients]. Gastroenterologia"/>
   <result pre="de una cohorte de 8.559 pacientes. 10.1016/j.gastrohep.2011.01.01221474206 19MartinaBE, KorakaP, OsterhausAD." exact="Dengue" post="virus pathogenesis: an integrated view. Clinical microbiology reviews. 2009;22(4):564–81."/>
   <result pre="ChoovichianV. Differences in Liver Impairment Between Adults and Children with" exact="Dengue" post="Infection. The American journal of tropical medicine and hygiene."/>
   <result pre="of tropical medicine and hygiene. 2016;94(5):1073–9. Epub 2016/03/16. 10.4269/ajtmh.15-050726976884 23JahanF." exact="Dengue" post="fever (DF) in Pakistan. Asia Pacific family medicine. 2011;10(1):110.1186/1447-056X-10-121349169"/>
   <result pre="32PatilSS, PatilSR, DurgawalePM, PatilAG. A study of the outbreak of" exact="Chikungunya" post="fever. Journal of clinical and diagnostic research: JCDR. 2013;7(6):1059–62."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7142734\results\search\tropicalVirus\results.xml">
   <result pre="Research and Public Health1661-78271660-4601MDPI pmcid: 7142734 doi: 10.3390/ijerph17062062ijerph-17-02062 : Article" exact="Dengue" post="Surveillance System in Brazil: A Qualitative Study in the"/>
   <result pre="health information urban health health geography 1. Introduction 1.1. Dengue," exact="Dengue" post="Surveillance, and Relevance in Global Public Health Dengue is"/>
   <result pre="1.1. Dengue, Dengue Surveillance, and Relevance in Global Public Health" exact="Dengue" post="is a viral mosquito-borne disease that can lead to"/>
   <result pre="can lead to severe and sometimes fatal consequences caused by" exact="Dengue" post="Virus (DENV), of which five serotypes are known [1]."/>
   <result pre="Dengue Virus (DENV), of which five serotypes are known [1]." exact="Dengue" post="incidence has been steadily growing for the past 15"/>
   <result pre="diseases, dengue’s increasing incidence raises concerns for global health [4,5]." exact="Dengue" post="surveillance is crucial to the strategy of dengue prevention"/>
   <result pre="and inadequate water, sanitation systems, and waste management [21,22,23]. 1.2." exact="Dengue" post="Surveillance in Brazil The national health surveillance system in"/>
   <result pre="is the SINAN (Sistema de Informação de Agravos de Notificação)." exact="Dengue" post="is on the national list of compulsorily notifiable diseases"/>
   <result pre="aim of the research is to analyze how the Brazilian" exact="Dengue" post="surveillance system operates, focusing on the functioning of data"/>
   <result pre="general overview of the surveillance system. 3.1. General Overview of" exact="Dengue" post="Surveillance in the DF To provide an overview, a"/>
   <result pre="and control Gestão do Plano de Prevenção e Controle da" exact="Dengue" post="Geiplan-dengue Unit for social mobilization activities Núcleo de Mobilização"/>
   <result pre="and burden of dengueNature201349650450710.1038/nature1206023563266 2.BradyO.J.GethingP.W.BhattS.MessinaJ.P.BrownsteinJ.S.HoenA.G.MoyesC.L.FarlowA.W.ScottT.W.HayS.I.Refining the Global Spatial Limits of" exact="Dengue" post="Virus Transmission by Evidence-Based ConsensusPLoS Negl. Trop. Dis.20126e176010.1371/journal.pntd.000176022880140 3.BöhmA.W.CostaC.D.NevesR.G.FloresT.R.NunesB.P.Tendência"/>
   <result pre="Infect. Dis.201919e302e31210.1016/S1473-3099(19)30161-631227327 6.collab: WHOTreatment, Prevention and Control Global Strategy for" exact="Dengue" post="Prevention and ControlWorld Health OrganizationGeneve, Switzerland2012 7.SartiE.L’AzouM.MercadoM.KuriP.Siqueira JrJ.B.SolisE.NoriegaF.OchiaiR.L.A comparative"/>
   <result pre="and Animal HealthLiving Territories to Transform the WorldQUAEParis, France20179196 9.ModiA.VaishnavK.PandyaR.SahuG.NaikA.Urban" exact="Dengue" post="Surveillance over Sixteen Years: Integration, Trend Analysis and Participation"/>
   <result pre="Knoema2017Available online: https://knoema.com/atlas/Brazil/Urban-population(accessed on 10 March 2020) 11.FaresR.C.G.SouzaK.P.R.AñezG.RiosM.Epidemiological Scenario of" exact="Dengue" post="in BrazilBioMed Res. Int.2015201532187310.1155/2015/32187326413514 12.collab: WHONational Passive SurveillanceWorld Health"/>
   <result pre="for Research and Training in Tropical Diseases (TDR)Technical Handbook for" exact="Dengue" post="Surveillance, Dengue Outbreak Prediction/Detection and Outbreak Response [&quot;Model Contingency"/>
   <result pre="and Training in Tropical Diseases (TDR)Technical Handbook for Dengue Surveillance," exact="Dengue" post="Outbreak Prediction/Detection and Outbreak Response [&quot;Model Contingency Plan�?]WHO Libr"/>
   <result pre="2020) 15.AzeredoE.L.Dos SantosF.B.BarbosaL.S.SouzaT.M.Badolato-CorrêaJ.Sánchez-ArcilaJ.C.NunesP.C.de-Oliveira-PintoL.M.de FilippisA.M.Dal FabbroM.et al.Clinical and Laboratory Profile of" exact="Zika" post="and Dengue Infected Patients: Lessons Learned From the Co-circulation"/>
   <result pre="SantosF.B.BarbosaL.S.SouzaT.M.Badolato-CorrêaJ.Sánchez-ArcilaJ.C.NunesP.C.de-Oliveira-PintoL.M.de FilippisA.M.Dal FabbroM.et al.Clinical and Laboratory Profile of Zika and" exact="Dengue" post="Infected Patients: Lessons Learned From the Co-circulation of Dengue,"/>
   <result pre="Dengue Infected Patients: Lessons Learned From the Co-circulation of Dengue," exact="Zika" post="and Chikungunya in BrazilPLoS Curr.20181010.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5 16.BoschI.De PuigH.HileyM.Carré-CampsM.Perdomo-CelisF.NarváezC.F.SalgadoD.M.SenthoorD.O’GradyM.PhillipsE.et al.Rapid antigen"/>
   <result pre="Patients: Lessons Learned From the Co-circulation of Dengue, Zika and" exact="Chikungunya" post="in BrazilPLoS Curr.20181010.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5 16.BoschI.De PuigH.HileyM.Carré-CampsM.Perdomo-CelisF.NarváezC.F.SalgadoD.M.SenthoorD.O’GradyM.PhillipsE.et al.Rapid antigen tests for"/>
   <result pre="16.BoschI.De PuigH.HileyM.Carré-CampsM.Perdomo-CelisF.NarváezC.F.SalgadoD.M.SenthoorD.O’GradyM.PhillipsE.et al.Rapid antigen tests for dengue virus serotypes and" exact="Zika" post="virus in patient serumSci. Transl. Med.20179eaan158910.1126/scitranslmed.aan158928954927 17.TeohB.T.SamS.S.TanK.K.JohariJ.Abd-JamilJ.HooiP.S.AbuBakarS.The Use of"/>
   <result pre="Diagnostic Test and qRT-PCR to Complement IgM ELISA for Improved" exact="Dengue" post="Diagnosis from Single SpecimenSci. Rep.201662766310.1038/srep2766327278716 18.HassanS.KhareV.SinghM.AsgharS.A.Comparison of rapid immuno-chromatographic"/>
   <result pre="Portalsinan.Saude.Gov2016Available online: http://www.portalsinan.saude.gov.br/sinan-dengue-chikungunya(accessed on 10 March 2020) 30.SilvaM.M.RodriguesM.S.PaploskiI.A.KikutiM.KasperA.M.CruzJ.S.QueirozT.L.TavaresA.S.SantanaP.M.AraújoJ.M.et al.Accuracy of" exact="Dengue" post="Reporting by National Surveillance System, BrazilEmerg. Infect. Dis.20162233633910.3201/eid2202.15049526812472 31.CoelhoG.E.LealP.L.de"/>
   <result pre="National Surveillance System, BrazilEmerg. Infect. Dis.20162233633910.3201/eid2202.15049526812472 31.CoelhoG.E.LealP.L.de CerroniM.P.SimplicioA.C.R.SiqueiraJ.B.Sensitivity of the" exact="Dengue" post="Surveillance System in Brazil for Detecting Hospitalized CasesPLoS Negl."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7143470\results\search\tropicalVirus\results.xml">
   <result pre="Access Journal from MDPI2076-2615MDPI pmcid: 7143470 doi: 10.3390/ani10030494animals-10-00494 : Article" exact="West Nile" post="Virus and Related Flavivirus in European Wild Boar (Sus"/>
   <result pre="RT-PCR assay. Abstract Background: A retrospective sero-survey for evidence of" exact="West Nile" post="virus (WNV) infection in European wild boar (Sus scorfa)"/>
   <result pre="from 168 European wild boars and screened for antibodies to" exact="WNV" post="and other Flaviviruses by competitive enzyme linked immunosorbent assay"/>
   <result pre="for 7 samples, confirming the presence of specific antibody against" exact="WNV" post="in a single European wild boar serum sample. The"/>
   <result pre="positive/VNT negative samples suggests the occurrence of non-neutralizing antibodies against" exact="WNV" post="or other antigen-related Flaviviruses. No samples resulted positive for"/>
   <result pre="a moderately high percentage of animals with specific antibody for" exact="WNV" post="has been detected in wild boar in other surveillance"/>
   <result pre="these data indicate that European wild boar are exposed to" exact="WNV" post="and/or other related-Flavivirus in central Italy and confirm the"/>
   <result pre="Flavivirus sentinels. European wild boar flavivirus Sus scrofa retrospective study" exact="West Nile" post="virus 1. Introduction Flaviviruses are single-stranded positive-sense RNA viruses"/>
   <result pre="worldwide distribution, and a lot of them, such as the" exact="West Nile" post="virus (WNV) are cause of zoonoses significant for public"/>
   <result pre="virus was first identified in 1999 [2], in Europe, large" exact="WNV" post="outbreaks have been reported. The widest European outbreak happened"/>
   <result pre="Bucharest, Romania [3]. The first human encephalitis outbreak on the" exact="West Nile" post="was identified in Camargue, France, the Mediterranean area in"/>
   <result pre="Volgograd region in Russia, Hungary, Romania, and Greece, cases of" exact="WNV" post="encephalitis have been reported [5]. In 1998, the first"/>
   <result pre="have been reported [5]. In 1998, the first outbreak of" exact="WNV" post="infection was described in horses in Tuscany, Italy [6]."/>
   <result pre="of 2008, by means of the activation of an extraordinary" exact="WNV" post="surveillance program, 9 human cases of West Nile Invasive"/>
   <result pre="of an extraordinary WNV surveillance program, 9 human cases of" exact="West Nile" post="Invasive Disease (WNND) were reported [8,9], another 16 cases"/>
   <result pre="to the Po river. In order to control and monitor" exact="WNV" post="circulation, a virological and serological surveillance program for WND"/>
   <result pre="many aquatic birds, including some migratory birds, aimed to detect" exact="WNV" post="introduction [8]. In fact, the West Nile virus is"/>
   <result pre="birds, aimed to detect WNV introduction [8]. In fact, the" exact="West Nile" post="virus is maintained in nature in an enzootic transmission"/>
   <result pre="other than humans or horses, and the serological sign of" exact="WNV" post="infection has been described in a few domestic and"/>
   <result pre="as they are naturally exposed to flavivirus infections. Although several" exact="WNV" post="surveys have been performed on birds, as far as"/>
   <result pre="Spain [19]. In Central Italy, to monitor the circulation of" exact="WNV" post="and USUV, Coseddu et al. [20] conducted serological surveillance"/>
   <result pre="for evidence of Flavivirus infection. In 2009, in Italy, the" exact="WNV" post="circulation spread and also involved the region of Lazio,"/>
   <result pre="and &amp;gt;36 months old (adults). The presence of antibodies against" exact="WNV" post="and closely related Flaviviruses, like USUV, was analyzed using"/>
   <result pre="analyzed using a commercial competitive enzyme-linked-immunosorbent assay (ELISA ID Screen" exact="West Nile" post="Competition Multi-Species (Innovative Diagnostics, Montpelier, France),) for detection of"/>
   <result pre="Nile Competition Multi-Species (Innovative Diagnostics, Montpelier, France),) for detection of" exact="West Nile" post="virus antibodies against the pr-E and pr-M envelope proteins"/>
   <result pre="flaviviruses, although it has been designed for the diagnosis of" exact="WNV" post="infection. The assay used plates pre-coated with WNV recombinant"/>
   <result pre="diagnosis of WNV infection. The assay used plates pre-coated with" exact="WNV" post="recombinant antigens and assessed the competition between antibodies present"/>
   <result pre="doubtful. To verify cELISA positive samples, neutralizing antibody titers to" exact="WNV" post="were determined by a virus-neutralization test (VNT), according to"/>
   <result pre="VNT titles greater than or equal to 1/10 were considered" exact="WNV" post="specific. To confirm the presence of Flavivirus RNA in"/>
   <result pre="primers, according to Johnson et al. [27]. No template and" exact="WNV" post="field isolate positive samples were used in the RT-PCR"/>
   <result pre="Figure 1 shows the area comprising the geographic distribution of" exact="West Nile" post="Disease virus/Flavivirus positive wild boars. Overall, juveniles were the"/>
   <result pre="of the VNT for 7 samples, confirming the presence of" exact="WNV" post="specific antibody only in a single European wild boar"/>
   <result pre="for Flavivirus by cELISA, but VNT confirmed the presence of" exact="WNV" post="specific antibody only in one European wild boar. ELISA"/>
   <result pre="VNT negative samples indicate the presence of non-neutralizing antibodies versus" exact="WNV" post="or against other antigenically related Flaviviruses, for example, the"/>
   <result pre="of the circulation of Flaviviruses transmitted by mosquitoes such as" exact="WNV" post="and Usutu virus (USUV) has been found with increasing"/>
   <result pre="habitats during 2006–2010 [19], and in Serbia by [34] (17.6%" exact="WNV" post="prevalence). In this study, only four wild boar sera"/>
   <result pre="adult pigs, it has been previously demonstrated than antibodies to" exact="WNV" post="may last for more than 3 years possibly due"/>
   <result pre="until 28 days post infection [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42], the negative relationship between" exact="WNV" post="seropositivity and increasing age is consistent with epidemiological data"/>
   <result pre="seropositivity and increasing age is consistent with epidemiological data of" exact="WNV" post="transmission in Latium region [22] and suggest a recent"/>
   <result pre="In fact, according to the national veterinary surveillance program’s data," exact="WNV" post="was detected in this area in 2009 but not"/>
   <result pre="ungulates, as suitable flavivirus sentinels. The intensity of exposure to" exact="WNV" post="in nature is very complex and depends on many"/>
   <result pre="sentinels of WNV. The advantages of using wild boar as" exact="WNV" post="sentinels include: The opportunity to monitor WNV in a"/>
   <result pre="wild boar as WNV sentinels include: The opportunity to monitor" exact="WNV" post="in a mammalian population (which may reflect human exposure"/>
   <result pre="References References 1.MonathT.P.HeinzF.X.FlavivirusesFeilds Virology3rd ed.FieldsB.N.KnipeD.M.HowleymP.M.Lippincott-RavenvolPhiladelphia, PA, USA1996Volume 19611034 2.NashD.MostashariF.FineA.MillerJ.O’LearyD.MurrayK.HuangA.RosenbergA.GreenbergA.ShermanM.et al.1999" exact="West Nile" post="Outbreak Response Working Group. The outbreak of West Nile"/>
   <result pre="al.1999 West Nile Outbreak Response Working Group. The outbreak of" exact="West Nile" post="virus infection in the New York City area in"/>
   <result pre="present in Eastern EuropePathog. Glob. Health201811223324810.1080/20477724.2018.148356729979950 6.MaciniP.SquintaniG.FinarelliA.C.AngeliniP.MartiniE.TambaM.DottoriM.BelliniR.SantiA.Loli PiccolominiL.et al.Detection of" exact="West Nile" post="virus infection in horses, Italy, September 2008Eur. Surveill.20081318990 7.BarzonL.SquarzonL.CattaiM.FranchinE.PagniS.CusinatoR.PaluG.West"/>
   <result pre="Italian Ministry of HealtApproval of the National Surveillance Plan for" exact="West Nile" post="EncephalomyelitisMinistry of HealthRome, Italy1222008Available online: http://www.normativasanitaria.it/jsp/dettaglio.jsp?aggiornamenti=&amp;amp;attoCompleto=si&amp;amp;id=25243&amp;amp;page=&amp;amp;anno=null(accessed on 7 January"/>
   <result pre="integrated surveillance system 2009Eur. Surveill.20101519547 10.HayesE.B.KomarN.NasciR.S.MontgomeryS.P.O’LearyD.R.CampbellG.L.Epidemiology and transmission dynamics of" exact="West Nile" post="virus diseaseEmerg. Infect. Dis.2005111167117310.3201/eid1108.050289a16102302 11.TurellM.J.O’GuinnM.OliverJ.Potential for New York mosquitoes"/>
   <result pre="diseaseEmerg. Infect. Dis.2005111167117310.3201/eid1108.050289a16102302 11.TurellM.J.O’GuinnM.OliverJ.Potential for New York mosquitoes to transmit" exact="West Nile" post="virusAm. J. Trop. Med. Hyg.20006241341410.4269/ajtmh.2000.62.41311037788 12.SardelisM.R.TurellM.J.DohmD.J.O’GuinnM.L.Vector competence of selected"/>
   <result pre="competence of selected North American Culex and Coquillettidia mosquitoes for" exact="West Nile" post="virusEmerg. Infect. Dis.200171018102210.3201/eid0706.01061711747732 13.Jeffrey RootJ.West Nile virus associations in"/>
   <result pre="associations in wild mammals: A synthesisArch. Virol.201315873575210.1007/s00705-012-1516-323212739 14.GómezA.KilpatrickA.M.KramerL.D.DupuisA.P.MaffeiJ.G.GoetzS.J.MarraP.P.DaszakP.AguirreA.A.Land use and" exact="West Nile" post="virus seroprevalence in wild mammalsEmerg. Infect. Dis.20081496296510.3201/eid1406.07035218507915 15.BlitvichB.J.JuarezL.I.TuckerB.J.RowleyW.A.PlattK.B.Antibodies to"/>
   <result pre="Nile virus seroprevalence in wild mammalsEmerg. Infect. Dis.20081496296510.3201/eid1406.07035218507915 15.BlitvichB.J.JuarezL.I.TuckerB.J.RowleyW.A.PlattK.B.Antibodies to" exact="West Nile" post="virus in raccoons and other wild peridomestic mammals in"/>
   <result pre="mammals in IowaJ. Wildl. Dis.2009451163116810.7589/0090-3558-45.4.116319901390 16.TeeheeM.L.BunningM.L.StevensS.BowenR.A.Experimental infection of pigs with" exact="West Nile" post="virus. Brief ReportArch. Virol.20051501249125610.1007/s00705-004-0478-515770358 17.HalouzkaJ.JuricovaZ.JankovaJ.HubalekZ.Serologic survey of wild boars"/>
   <result pre="mosquito-borne viruses in South Moravia (Czech Republic)Vet. Med.20085326627110.17221/1945-VETMED 18.GibbsS.E.MarleneeN.L.RominesJ.KavanaughD.CornJ.L.StallknechtD.E.Antibodies to" exact="West Nile" post="virus in feral swine from Florida, Georgia, and Texas,"/>
   <result pre="Florida, Georgia, and Texas, USAVector Borne Zoonotic Dis.2006626126510.1089/vbz.2006.6.26116989565 19.Gutiérrez-GuzmánA.V.VicenteJ.SobrinoR.Perez-RamírezE.LlorenteF.HöfleU.Antibodies to" exact="West Nile" post="virus and related Flaviviruses in wild boar, red foxes"/>
   <result pre="Rodents in Central ItalyVector Borne Zoonotic Dis.20171777777910.1089/vbz.2017.214328953448 21.CalistriP.MonacoF.SaviniG.GuercioA.PurpariG.VicariD.CascioS.LelliR.Further spread of" exact="West Nile" post="virus in ItalyVet. Ital.201046471474 22.MonacoF.LelliR.TeodoriL.PinoniC.Di GennaroA.PolciA.CalistriP.SaviniG.Re-Emergence of West Nile"/>
   <result pre="of West Nile virus in ItalyVet. Ital.201046471474 22.MonacoF.LelliR.TeodoriL.PinoniC.Di GennaroA.PolciA.CalistriP.SaviniG.Re-Emergence of" exact="West Nile" post="Virus in ItalyZoonoses Public Health20105747648610.1111/j.1863-2378.2009.01245.x19638165 23.IovaneV.FerraraG.PetruccelliA.VenezianoV.D’AlessioN.CiarciaR.FiorettiA.PagniniU.MontagnaroS.Prevalence of serum antibodies"/>
   <result pre="Med.20167314414810.15835/buasvmcn-vm:11934 25.BeckC.LowenskiS.DurandB.BahuonC.ZientaraS.LecollinetS.Improved reliability of serological tools for the diagnosis of" exact="West Nile" post="fever in horses within EuropePLoS Negl. Trop. Dis.201711e000593610.1371/journal.pntd.000593628915240 26.BournezL.UmhangG.FaureE.BoucherJ.M.BouéF.JourdainE.SarasaM.LlorenteF.Jiménez-ClaveroM.A.MoutaillerS.et"/>
   <result pre="in Campania Region, ItalyVector Borne Zoonotic Dis.20191914214710.1089/vbz.2018.233730160624 36.BowenR.A.NemethN.M.Experimental infections with" exact="West Nile" post="virusCurr. Opin. Infect. Dis.20072029329710.1097/QCO.0b013e32816b5cad17471040 37.ColpittsT.M.ConwayM.J.MontgomeryR.R.FikrigE.West Nile Virus: Biology, transmission,"/>
   <result pre="and human infectionClin. Microbiol. Rev.20122563564810.1128/CMR.00045-1223034323 38.WertheimerA.M.UhrlaubJ.L.HirschA.MedigeshiG.SpragueJ.LegasseA.WilkJ.WileyC.A.DidierP.TeshR.B.et al.Immune response to the" exact="West Nile" post="virus in aged non-human primatesPLoS ONE20105e1551410.1371/journal.pone.001551421151986 39.BeckC.Jimenez-ClaveroM.A.LeblondA.DurandB.NowotnyN.Leparc-GoffartI.ZientaraS.JourdainE.LecollinetS.Flaviviruses in Europe:"/>
   <result pre="patterns and their consequences for the diagnosis and control of" exact="West Nile" post="diseaseInt. J. Environ. Res. Public Health2013126049608310.3390/ijerph10116049 40.ZottolaT.MontagnaroS.MagnaperaC.SassoS.De MartinoL.BragagnoloA.D’AmiciL.CondoleoR.PisanelliG.IovaneG.et al.Prevalence"/>
   <result pre="in Spain?Vector Borne Zoonotic Dis.20121249049510.1089/vbz.2011.084322217171 Figure 1 Geographic distribution of" exact="West Nile" post="Disease virus/Flavivirus positive wild boars. animals-10-00494-t001_Table 1Table 1 Presence"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7144339\results\search\tropicalVirus\results.xml">
   <result pre="likely to worsen in the future due to climate change." exact="Dengue" post="fever is an infectious viral disease from tropical and"/>
   <result pre="considered to be one of the biggest global health crises." exact="Dengue" post="fever was first reported in Nepal in 2004, and"/>
   <result pre="bulletin for &quot;National Guidelines of Prevention, Control &amp;amp; Management of" exact="Dengue" post="in Nepal 2019�? in September 2019 [19]. Central, provincial,"/>
   <result pre="of control sought by the government as outlined in their" exact="Dengue" post="Report [3]. This lag in control is due to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7144666\results\search\tropicalVirus\results.xml">
   <result pre="wax printed MF1-based-μPAD for the detection of the dengue and" exact="Zika" post="NS1 (Non-Structural) viral proteins in blood plasma. The presence"/>
   <result pre="and P82 polyclonal antibodies were used to detect specific antigens." exact="Dengue" post="and Zika NS1 Detection LOD (whole blood)20 ng/mL, for Dengue"/>
   <result pre="polyclonal antibodies were used to detect specific antigens. Dengue and" exact="Zika" post="NS1 Detection LOD (whole blood)20 ng/mL, for Dengue and ZIKV"/>
   <result pre="antigens. Dengue and Zika NS1 Detection LOD (whole blood)20 ng/mL, for" exact="Dengue" post="and ZIKV Whole Blood [25] NSE detecting μPAD •With"/>
   <result pre="and Zika NS1 Detection LOD (whole blood)20 ng/mL, for Dengue and" exact="ZIKV" post="Whole Blood [25] NSE detecting μPAD •With two circular"/>
   <result pre="to print electrodes on the surface of the paper. FOR" exact="ZIKV" post="DETECTION,Viral lysate prepared using a 1% Tritonx-100 solution was"/>
   <result pre="using a 1% Tritonx-100 solution was used after capturing the" exact="ZIKV" post="particles using magnetic beads modified with anti-ZIKV envelope monoclonal"/>
   <result pre="(the increase in concentrations resulted in a decrease in impedance)" exact="Zika" post="Virus, HPV, Alpha-Fetoprotein And Carcinoembryonic Antigen (CEA) LODFor cancer"/>
   <result pre="(CEA) LODFor cancer protein biomarkers, 100 ng/mLFor viral particles, 1000 particle/mLFor" exact="HPV" post="nucleic acid, 100 copies/mL Serum [37] A μPAD for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7147054\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.1186/s13071-020-04042-0 : Research Vector competence of Virginia mosquitoes for" exact="Zika" post="and Cache Valley viruses ChanKevin K.kchan90@vt.edu1AugusteAlbert J.jauguste@vt.edu1BrewsterCarlyle C.carlylb@clemson.edu2PaulsonSally L.spaulson@vt.edu1[1],"/>
   <result pre="major public health concern and cause significant morbidity and mortality." exact="Zika" post="virus (ZIKV) is the etiologic agent of a massive"/>
   <result pre="Brazil in 2015 and shows a strong association with congenital" exact="ZIKV" post="syndrome in newborns. Cache Valley virus (CVV) is a"/>
   <result pre="study, we investigated the vector competence of Virginia mosquitoes for" exact="ZIKV" post="and CVV to explore their abilities to contribute to"/>
   <result pre="virus. The presence of midgut or salivary gland barriers to" exact="ZIKV" post="infection were determined by intrathoracic inoculation vs oral infection."/>
   <result pre="Ae. albopictus orally infected (24%) and intrathoracically inoculated (63%) with" exact="ZIKV" post="was similar to Ae. aegypti (48% and 71%, respectively)."/>
   <result pre="to Ae. aegypti (48% and 71%, respectively). Transmission rates of" exact="ZIKV" post="in Ae. japonicus were low, and showed evidence of"/>
   <result pre="after intrathoracic inoculation (19%). Aedes triseriatus was unable to transmit" exact="ZIKV" post="following oral infection or intrathoracic inoculation. CVV transmission was"/>
   <result pre="7%). Culex pipiens and Cx. restuans were not competent for" exact="ZIKV" post="or CVV. Conclusions This laboratory transmission study provided further"/>
   <result pre="Conclusions This laboratory transmission study provided further understanding of potential" exact="ZIKV" post="and CVV transmission cycles with Aedes mosquitoes from Virginia."/>
   <result pre="mosquitoes from Virginia. The ability for these mosquitoes to transmit" exact="ZIKV" post="and CVV make them a public health concern and"/>
   <result pre="targeted control programs by mosquito and vector abatement districts. Keywords" exact="Zika" post="virus Cache Valley virus Vector competence Aedes japonicus Aedes"/>
   <result pre="pathogen becomes established. For example, since its introduction in 1999," exact="West Nile" post="virus (WNV) (family Flaviviridae, genus Flavivirus) is now the"/>
   <result pre="for several enzootic mosquito-borne viruses in the USA [4, 5]." exact="Zika" post="virus (ZIKV) (family Flaviviridae, genus Flavivirus) is an arthropod-borne"/>
   <result pre="in adults [6]. Since its introduction to Brazil in 2015," exact="ZIKV" post="has spread into many new areas within the Americas"/>
   <result pre="has spread into many new areas within the Americas [7]." exact="ZIKV" post="is transmitted primarily by urban and sylvatic Aedes mosquitoes,"/>
   <result pre="Americas [11, 12]. Due to the lack of knowledge of" exact="ZIKV" post="replication in North American mosquitoes, experimental vector competence studies"/>
   <result pre="studies are necessary to better understand the potential transmission of" exact="ZIKV" post="by additional species. Recent studies have shown that some"/>
   <result pre="from temperate regions of North America were not competent for" exact="ZIKV" post="[13, 14], but this is a small representation of"/>
   <result pre="competent vector for WNV, DENV, YFV, EEE and SLE [34]." exact="WNV" post="has been isolated from Culex pipiens and Cx. restuans"/>
   <result pre="have found that Cx. pipiens is refractory to CVV and" exact="ZIKV" post="infections [13, 23, 25, 37, 38]. Between 2015 and"/>
   <result pre="Between 2015 and 2018, there were more than 5000 imported" exact="ZIKV" post="cases in the USA, with over 100 cases in"/>
   <result pre="of Virginia mosquitoes common in urban and suburban environments for" exact="ZIKV" post="and CVV to explore their abilities to contribute to"/>
   <result pre="photoperiod and provided 10% sucrose solution for sustenance. Table 1" exact="ZIKV" post="and CVV blood meal titers Species CVV high blood"/>
   <result pre="blood meal titer (pfu/ml) CVV low blood meal titer (pfu/ml)" exact="ZIKV" post="blood meal titer (pfu/ml) ZIKV intrathoracic inoculation titer (pfu/ml)"/>
   <result pre="low blood meal titer (pfu/ml) ZIKV blood meal titer (pfu/ml)" exact="ZIKV" post="intrathoracic inoculation titer (pfu/ml) Aedes albopictus 5.25 × 106"/>
   <result pre="significance level of α = 0.05. Results Vector competence for" exact="ZIKV" post="following oral infection There was a significant difference among"/>
   <result pre="albopictus, Ae. japonicus and Ae. triseriatus after oral infection with" exact="ZIKV" post="(Fig. 1). Rates for infection, dissemination and transmission were"/>
   <result pre="pipiens nor Cx. restuans were infected after oral exposure to" exact="ZIKV" post="(Table 2). Fig. 1 Vector competence for ZIKV PRVABC59."/>
   <result pre="exposure to ZIKV (Table 2). Fig. 1 Vector competence for" exact="ZIKV" post="PRVABC59. Aedes albopictus (n = 37), Ae. triseriatus (n"/>
   <result pre="and transmitting, α = 0.05 Table 2 Vector competence of" exact="ZIKV" post="and CVV in Culex pipiens and Cx. restuans Mosquito"/>
   <result pre="non-disseminated infection (%) Mean disseminated infection (%) Mean transmitting (%)" exact="ZIKV" post="Cx. pipiens 30 3.00 × 107 0 0 0"/>
   <result pre="restuans 30 7.70 × 107 0 0 0 Transmission of" exact="ZIKV" post="following parenteral infection Parenteral infection by intrathoracic inoculation resulted"/>
   <result pre="rate of Aedes japonicus and Ae. triseriatus intrathoracically inoculated with" exact="ZIKV" post="Mosquito species Infection method Sample size (n) Virus titer"/>
   <result pre="responses. This study aimed to determine the risk of local" exact="ZIKV" post="transmission and the emergence potential of CVV in Virginia"/>
   <result pre="[49] suggested that the vector competence of Ae. albopictus for" exact="Zika" post="virus varied among geographically disparate populations. We found that"/>
   <result pre="Ae. aegypti. Culex mosquitoes were found to be refractory to" exact="ZIKV" post="infection. Other studies have also observed similar results, suggesting"/>
   <result pre="that it is unlikely this group plays a role in" exact="ZIKV" post="transmission [13, 37, 50, 51]. We also found that"/>
   <result pre="strains of Ae. triseriatus were able to become infected with" exact="ZIKV" post="PRVABC59, the same strain that we used, but no"/>
   <result pre="barriers that limit Ae. japonicus and prevent Ae. triseriatus from" exact="ZIKV" post="transmission. Although Ae. albopictus was capable of ZIKV transmission"/>
   <result pre="triseriatus from ZIKV transmission. Although Ae. albopictus was capable of" exact="ZIKV" post="transmission after oral infection, intrathoracic inoculation significantly increased its"/>
   <result pre="vector competence seen in Ae. aegypti and Ae. albopictus for" exact="ZIKV" post="[58–60]. Although Ae. japonicus was capable of ZIKV transmission,"/>
   <result pre="albopictus for ZIKV [58–60]. Although Ae. japonicus was capable of" exact="ZIKV" post="transmission, it is not an aggressive human biter and"/>
   <result pre="and predominantly inhabits forested areas, which limits its role in" exact="ZIKV" post="transmission. Surprisingly, Ae. triseriatus, Cx, pipiens and Cx. restuans"/>
   <result pre="triseriatus, Cx, pipiens and Cx. restuans were not competent for" exact="ZIKV" post="even though they are competent vectors of other flaviviruses,"/>
   <result pre="though they are competent vectors of other flaviviruses, such as" exact="WNV" post="or SLEV [61–63]. Aedes albopictus, on the other hand,"/>
   <result pre="Aedes albopictus, on the other hand, was highly competent for" exact="ZIKV" post="and exhibits aggressive, anthropophilic behaviour. The likelihood for this"/>
   <result pre="anthropophilic behaviour. The likelihood for this species to contribute to" exact="ZIKV" post="transmission in Virginia is much higher compared to other"/>
   <result pre="susceptibility of the same vector species for viral infection for" exact="DENV" post="[74, 75], CHIKV [76] and ZIKV [59, 77]. In"/>
   <result pre="same vector species for viral infection for DENV [74, 75]," exact="CHIKV" post="[76] and ZIKV [59, 77]. In addition, when arboviruses"/>
   <result pre="for viral infection for DENV [74, 75], CHIKV [76] and" exact="ZIKV" post="[59, 77]. In addition, when arboviruses are detected in"/>
   <result pre="laboratory-reared Cx. quinquefasciatus is able to become infected and transmit" exact="ZIKV" post="[78, 79], while studies using field populations were not"/>
   <result pre="reporting to local or state health departments. In contrast, the" exact="ZIKV" post="outbreak in 2015 sparked high demand for all areas"/>
   <result pre="the virus. Although cases have dropped significantly in the USA," exact="ZIKV" post="is still present in parts of Africa, Asia and"/>
   <result pre="show that a species that has not been tested for" exact="ZIKV" post="vector competency, Ae. japonicus, was able to transmit the"/>
   <result pre="most widespread anthropophilic mosquito in Virginia, was competent for both" exact="ZIKV" post="and CVV. Aedes aegypti was competent for both viruses,"/>
   <result pre="to overwinter in colder climates reduces this species’ likelihood of" exact="ZIKV" post="transmission in Virginia. With the abundance of highly competent"/>
   <result pre="increased CVV transmission in temperate regions of the USA. Abbreviations" exact="ZIKV" post="Zika virus CVV Cache Valley virus WNV West Nile"/>
   <result pre="CVV transmission in temperate regions of the USA. Abbreviations ZIKV" exact="Zika" post="virus CVV Cache Valley virus WNV West Nile virus"/>
   <result pre="the USA. Abbreviations ZIKV Zika virus CVV Cache Valley virus" exact="WNV" post="West Nile virus LACV La Crosse virus DENV dengue"/>
   <result pre="USA. Abbreviations ZIKV Zika virus CVV Cache Valley virus WNV" exact="West Nile" post="virus LACV La Crosse virus DENV dengue virus DPE"/>
   <result pre="Valley virus WNV West Nile virus LACV La Crosse virus" exact="DENV" post="dengue virus DPE days post-exposure lt low titer ht"/>
   <result pre="Bertke from the Virginia-Maryland College of Veterinary Medicine for providing" exact="ZIKV" post="PRVABC59 and Fan Yang for his help on isolating"/>
   <result pre="Med.201714e100220310.1371/journal.pmed.100220328045901 7.ZanlucaCde MeloVCAMosimannALPdos SantosGIVdos SantosCNDLuzKFirst report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem Inst Oswaldo Cruz.201511056957210.1590/0074-0276015019226061233 8.AyllónTCamposRMBrasilPMoroneFCCâmaraDCPMeiraGLSet al.Early evidence"/>
   <result pre="virus in BrazilMem Inst Oswaldo Cruz.201511056957210.1590/0074-0276015019226061233 8.AyllónTCamposRMBrasilPMoroneFCCâmaraDCPMeiraGLSet al.Early evidence for" exact="Zika" post="virus circulation among Aedes aegypti mosquitoes, Rio de Janeiro,"/>
   <result pre="aegypti mosquitoes, Rio de Janeiro, BrazilEmerg Infect Dis.2017231411141210.3201/eid2308.16200728628464 9.AyresCFJIdentification of" exact="Zika" post="virus vectors and implications for controlLancet Infect Dis.20161627827910.1016/S1473-3099(16)00073-626852727 10.MarchetteNJGarciaRRudnickAIsolation"/>
   <result pre="virus vectors and implications for controlLancet Infect Dis.20161627827910.1016/S1473-3099(16)00073-626852727 10.MarchetteNJGarciaRRudnickAIsolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm J Trop"/>
   <result pre="Wkly Rep.201665555810.15585/mmwr.mm6503e126820163 13.AliotaMTPeinadoSAOsorioJEBartholomayLCCulex pipiens and Aedes triseriatus mosquito susceptibility to" exact="Zika" post="virusEmerg Infect Dis2016221857185910.3201/eid2210.16108227434194 14.DibernardoATurellMJRobbin LindsayLLoomerCIranpourMVector competence of some mosquito"/>
   <result pre="14.DibernardoATurellMJRobbin LindsayLLoomerCIranpourMVector competence of some mosquito species from Canada for" exact="Zika" post="virusJ Am Mosq Control Assoc.20173327628110.2987/17-6664.129369018 15.CampbellGLMataczynskiJDReisdorfESPowellJWMartinDALambertAJet al.Second human case"/>
   <result pre="of Aedes aegypti, Ae. albopictus, and Culex quinquefasciatus mosquitoes as" exact="Zika" post="virus vectorsChina. Emerg Infect Dis.2017231085109110.3201/eid2307.16152828430562 26.MillerBRMitchellCJBallingerMEReplication, tissue tropisms and"/>
   <result pre="in Frederick County, Maryland: discovery, distribution, and vector competence for" exact="West Nile" post="virusJ Am Mosq Control Assoc.20011713714111480822 30.SardelisMRDohmDJPagacBAndreRGTurellMJExperimental transmission of eastern"/>
   <result pre="competence of selected North American Culex and Coquillettidia mosquitoes for" exact="West Nile" post="virusEmerg Infect Dis.200171018102210.3201/eid0706.01061711747732 36.TurellMJO’GuinnMOliverJPotential for New York mosquitoes to"/>
   <result pre="virusEmerg Infect Dis.200171018102210.3201/eid0706.01061711747732 36.TurellMJO’GuinnMOliverJPotential for New York mosquitoes to transmit" exact="West Nile" post="virusAm J Trop Med Hyg.20006241341410.4269/ajtmh.2000.62.41311037788 37.AmraouiFAtyame-NtenCVega-RúaALourenço-de-OliveiraRVazeilleMFaillouxABCulex mosquitoes are experimentally"/>
   <result pre="Trop Med Hyg.20006241341410.4269/ajtmh.2000.62.41311037788 37.AmraouiFAtyame-NtenCVega-RúaALourenço-de-OliveiraRVazeilleMFaillouxABCulex mosquitoes are experimentally unable to transmit" exact="Zika" post="virusEuro Surveill.2016213033310.2807/1560-7917.ES.2016.21.35.30333 38.FernandesRSCamposSSFerreira-de-BritoAMirandaRMBarbosa da SilvaKACastroMGet al.Culex quinquefasciatus from Rio"/>
   <result pre="Rio de Janeiro is not competent to transmit the local" exact="Zika" post="virusPLoS Negl Trop Dis.201610e000499310.1371/journal.pntd.000499327598421 39.Centers for Disease Control and"/>
   <result pre="Negl Trop Dis.201610e000499310.1371/journal.pntd.000499327598421 39.Centers for Disease Control and Prevention (CDC)." exact="Zika" post="cases in the United States; 2019. https://www.cdc.gov/zika/reporting/case-counts.html. Accessed 1"/>
   <result pre="https://www.cdc.gov/zika/reporting/case-counts.html. Accessed 1 Mar 2019. 40.LikosAGriffinIBinghamAMet al.Local mosquito-borne transmission of" exact="Zika" post="virus—Miami-Dade and Broward Counties, Florida, June-August 2016MMWR Morb Mortal"/>
   <result pre="Wkly Rep.2016651032103810.15585/mmwr.mm6538e127684886 41.Texas Health and Human Services. Texas announces local" exact="Zika" post="virus case in Rio Grande Valley; 2016. https://www.dshs.texas.gov/news/releases/2016/20161128.aspx. Accessed"/>
   <result pre="Valley; 2016. https://www.dshs.texas.gov/news/releases/2016/20161128.aspx. Accessed 6 Feb 2019. 42.VenturaCVAlbiniTABerrocalAMFirst locally transmitted" exact="Zika" post="virus cases identified in the United StatesJAMA Ophthalmol.20161341219122010.1001/jamaophthalmol.2016.362327685812 43.ArmisteadJSNishimuraNAriasJRLounibosLPCommunity"/>
   <result pre="chi-squared testPLoS ONE.201712e018870910.1371/journal.pone.018870929261690 49.McKenzieBAWilsonAEZohdySAedes albopictus is a competent vector of" exact="Zika" post="virus: a meta-analysisPLoS ONE.201914e021679410.1371/journal.pone.021679431112569 50.DodsonBLPujhariSRasgonJLVector competence of selected North"/>
   <result pre="competence of selected North American Anopheles and Culex mosquitoes for" exact="Zika" post="virusPeerJ.20186e432410.7717/peerj.432429472998 51.MainBJNicholsonJWinokurOCSteinerCRiemersmaKKStuartJet al.Vector competence of Aedes aegypti, Culex tarsalis,"/>
   <result pre="Aedes aegypti, Culex tarsalis, and Culex quinquefasciatus from California for" exact="Zika" post="virusPLoS Negl Trop Dis.201812e000652410.1371/journal.pntd.000652429927940 52.FranzAWKantorAMPassarelliALClemRJTissue barriers to arbovirus infection"/>
   <result pre="Negl Trop Dis.201711e000537710.1371/journal.pntd.000537728245239 58.CalvezEO’ConnorOPolMRoussetDFayeORichardVet al.Differential transmission of Asian and African" exact="Zika" post="virus lineages by Aedes aegypti from New CaledoniaEmerg Microbes"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="virusPLoS Negl Trop Dis.201610e000454310.1371/journal.pntd.000454326938868 60.Garcia-LunaSMWeger-LucarelliJRückertCMurrietaRAYoungMCByasADet al.Variation in competence for"/>
   <result pre="Zika virusPLoS Negl Trop Dis.201610e000454310.1371/journal.pntd.000454326938868 60.Garcia-LunaSMWeger-LucarelliJRückertCMurrietaRAYoungMCByasADet al.Variation in competence for" exact="ZIKV" post="transmission by Aedes aegypti and Aedes albopictus in MexicoPLoS"/>
   <result pre="of Aedes triseriatus (Diptera: Culicidae) as an enzootic vector of" exact="West Nile" post="virusJ Med Entomol.20064396697010.1093/jmedent/43.5.96617017235 64.ArmstrongPMAndersonJFFarajollahiAHealySPUnluICrepeauTNet al.Isolations of Cache Valley virus"/>
   <result pre="vector competency of Aedes albopictus populations from the Americas for" exact="Zika" post="VirusAm J Trop Med Hyg.20179733033910.4269/ajtmh.16-096928829735 71.GoddardLBRothAEReisenWKScottTWVector competence of California"/>
   <result pre="J Trop Med Hyg.20179733033910.4269/ajtmh.16-096928829735 71.GoddardLBRothAEReisenWKScottTWVector competence of California mosquitoes for" exact="West Nile" post="virusEmerg Infect Dis.200281385139110.3201/eid0812.02053612498652 72.KramerLDHardyJLPresserSBHoukEJDissemination barriers for Western equine encephalomyelitis"/>
   <result pre="Med Hyg.19762532633510.4269/ajtmh.1976.25.3261259092 77.RoundyCMAzarSRRossiSLet al.Variation in Aedes aegypti mosquito competence for" exact="Zika" post="virus transmissionEmerg Infect Dis.20172362563210.3201/eid2304.16148428287375 78.GuedesDRPaivaMHDonatoMMBarbosaPPKrokovskyLRochaSWDSet al.Zika virus replication in"/>
   <result pre="Infect.20176e6910.1038/emi.2017.5928790458 79.GuoXXLiCXDengYQXingDLiuQMWuQet al.Culex pipiens quinquefasciatus: a potential vector to transmit" exact="Zika" post="virusEmerg Microbes Infect.20165e10210.1038/emi.2016.10227599470 80.AliotaMTBassitLBradrickSSet al.Zika in the Americas, year"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7148454\results\search\tropicalVirus\results.xml">
   <result pre="high-level recombinant protein expression. Compared to an adenovirus vector, SFV-based" exact="HPV" post="E6-E7 immunization required 100- to 1000-fold lower doses to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149069\results\search\tropicalVirus\results.xml">
   <result pre="and birds that were ultimately linked to the emergence of" exact="West Nile" post="virus in the U.S. in 1999 left public health"/>
   <result pre="on food safety and security. For example, the spread of" exact="Zika" post="virus and CDC’s request to the U.S. government for"/>
   <result pre="natural barriers leads to increased contact between wildlife and people." exact="Yellow fever" post="(YF) is a zoonotic viral hemorrhagic disease [25] that"/>
   <result pre="hosts. Because New World primate hosts are especially susceptible to" exact="YFV" post="infection, acute clusters of mortality in these populations can"/>
   <result pre="infection, acute clusters of mortality in these populations can signal" exact="YFV" post="activity and alert authorities to increased risk of human"/>
   <result pre="infection by a flavivirus, the family of viruses to which" exact="YFV" post="belongs. PREDICT partners reported the results to the Ministry"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149897\results\search\tropicalVirus\results.xml">
   <result pre="hosts or preexisting infections. For example, phylogenetic analysis indicates that" exact="DENV" post="arose through a transfer of nonhuman primates to human"/>
   <result pre="of evolution shared by other RNA arboviruses, evidence from the" exact="DENV" post="studies suggests that the emergence of other arboviral pathogens"/>
   <result pre="4000 years ago. On the other hand the South American" exact="YFV" post="separated from the African YFV approximately 200–400 years ago."/>
   <result pre="other hand the South American YFV separated from the African" exact="YFV" post="approximately 200–400 years ago. These data support the original"/>
   <result pre="These data support the original concept that indicates that the" exact="YFV" post="arrived in the Americas during the period of slave"/>
   <result pre="role in the emergence of the global pandemic caused by" exact="CHIKV" post="and ZIKV (Weaver and Lecuit, 2015, Musso and Gubler,"/>
   <result pre="the emergence of the global pandemic caused by CHIKV and" exact="ZIKV" post="(Weaver and Lecuit, 2015, Musso and Gubler, 2016). Although"/>
   <result pre="ZIKV (Weaver and Lecuit, 2015, Musso and Gubler, 2016). Although" exact="CHIKV" post="is an alphavirus, it shares epidemiological, ecological and biogeographic"/>
   <result pre="it shares epidemiological, ecological and biogeographic characteristics with flavivirus YFV," exact="DENV" post="and ZIKV associated with transmission by A. aegypti, including"/>
   <result pre="epidemiological, ecological and biogeographic characteristics with flavivirus YFV, DENV and" exact="ZIKV" post="associated with transmission by A. aegypti, including the dependence"/>
   <result pre="Africa during the 17th–19th centuries were probably caused by CHIKV." exact="Chikungunya" post="fever, native to East Africa and Zanzibar, had crossed"/>
   <result pre="evolutionary genetics of dengue virusInfect. Genet. Evol.312003192812797969 JerzakG.BernardK.A.KramerL.D.EbelG.D.Genetic variation in" exact="West Nile" post="virus from naturally infected mosquitoes and birds suggests quasispecies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149942\results\search\tropicalVirus\results.xml">
   <result pre="virus and began infecting humans around the 1980s, and the" exact="Zika" post="virus epidemic that is affecting a part of the"/>
   <result pre="flu 18,000–284,000 deaths 2013–16 Ebola 90% fatalities 2015 to date" exact="Zika" post="&amp;gt; 3500 microcephaly cases in Brazil Rhesus monkey The"/>
   <result pre="Table 2 Year Virus 1545 Smallpox epidemic in India 1699" exact="Yellow fever" post="epidemic in America 1798 Edward Jenner publishes his account"/>
   <result pre="1935 Max Theiler develops live-attenuated 17D yellow fever vaccine 1947" exact="Zika" post="virus isolated in Uganda 1960–69 Live attenuated vaccines developed"/>
   <result pre="from Americas 2002 Polio declared eliminated from Europe 2006 First" exact="HPV" post="vaccine is licensed 2013 Ebola virus outbreak in Africa"/>
   <result pre="outbreak in Africa 2014 Polio declared eliminated from India 2015" exact="Zika" post="epidemic in Brazil 2016 Guinea declared Ebola free after"/>
   <result pre="an adjuvant like AS04 is a part of the Cerverix" exact="HPV" post="vaccine. An added advantage of using peptide vaccines over"/>
   <result pre="remain ambiguous: for example, out of 22 genomes of the" exact="Zika" post="virus, 9 have 1 or more nucleotides, and therefore"/>
   <result pre="comments regarding drug design, vaccinomics, and genomic surveillance of the" exact="Zika" post="virusCurrent Computer-Aided Drug Design12201613 DeyS.DeA.NandyA.Rational design of peptide vaccines"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149978\results\search\tropicalVirus\results.xml">
   <result pre="and Reemerging Viral Pathogens pmcid: 7149978B978-0-12-819400-3.00016-8 doi: 10.1016/B978-0-12-819400-3.00016-8 : Article" exact="Dengue" post="Virus MurugesanAmudhanManoharanMythreyee[], EnnajiMoulay Mustapha[], pmc-release: 2019-9-9ppub: 2020epub: 2019-9-9281359(C) Elsevier"/>
   <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Dengue" post="virus (DENV) belongs to the family Flaviviridae, genus Flavivirus."/>
   <result pre="includes other arthropod borne viruses such as yellow fever virus," exact="West Nile" post="virus, Zika virus, tick-borne encephalitis virus. It infects ~50–200"/>
   <result pre="borne viruses such as yellow fever virus, West Nile virus," exact="Zika" post="virus, tick-borne encephalitis virus. It infects ~50–200 million people"/>
   <result pre="also viral evolution. There are four antigenically different serotypes of" exact="DENV" post="based on the differences in their viral structural and"/>
   <result pre="on the differences in their viral structural and nonstructural proteins." exact="DENV" post="infection causes a spectrum of illness ranging from asymptomatic"/>
   <result pre="main stay of prevention is vector control and management. Keywords" exact="Dengue" post="Flavivirus epidemiology dengue hemorrhagic fever dengue shock syndrome vaccine"/>
   <result pre="CM convoluted membrane CS complementary sequence DALYs disability-adjusted life years" exact="DENV" post="dengue virus DF dengue fever DHF dengue hemorrhagic fever"/>
   <result pre="upstream AUG region UTR untranslated region VPs vesicle packets Introduction" exact="Dengue" post="viruses (DENVs) form dengue complex in genus Flavivirus, family"/>
   <result pre="family Flaviviridae, and consists of four antigenically related but distinct" exact="DENV" post="serotypes (DENV-1, DENV-2, DENV-2, DENV-3, and DENV-4). These DENV"/>
   <result pre="distinct DENV serotypes (DENV-1, DENV-2, DENV-2, DENV-3, and DENV-4). These" exact="DENV" post="can cause a spectrum of illness ranging from asymptomatic"/>
   <result pre="in dengue drug and vaccine development. Evolution and Discovery of" exact="Dengue" post="Virus All four DENV original serotypes have similar natural"/>
   <result pre="vaccine development. Evolution and Discovery of Dengue Virus All four" exact="DENV" post="original serotypes have similar natural histories, including an enzootic"/>
   <result pre="by the fact that several mosquito-borne flaviviruses (MBFV) [Koutango, Saboya," exact="West Nile," post="and yellow fever (YF)] have all been isolated from"/>
   <result pre="complex to five serotypes (Normile, 2013). Evolution and Spread of" exact="Dengue" post="Virus Vector Aedes aegypti is most likely of African"/>
   <result pre="has been known ever since (Gubler, 2014). Mosquito Transmission of" exact="Dengue" post="Viruses With documentation that YF was transmitted by mosquitoes"/>
   <result pre="ill with DF. Factors Responsible for the Global Resurgence of" exact="Dengue" post="Disease such as dengue was not considered a major"/>
   <result pre="populations, no effective mosquito control, and are hyperendemic, with multiple" exact="DENV" post="serotypes cocirculating. The DENVs have fully adapted to humans,"/>
   <result pre="(Fig. 16.1 ). Figure 16.1 Global dengue burden. Economic Burden" exact="Dengue" post="represents a substantial economic and disease burden to communities"/>
   <result pre="dengue (Shepard et al., 2014). Taxonomy and Evolutionary Relationship of" exact="Dengue" post="With Other Flaviviruses The flaviviruses form a well-defined genus"/>
   <result pre="(DENV), the genus contains YF virus (YFV), Japanese encephalitis virus," exact="West Nile" post="virus (WNV), and tick-borne encephalitis viruses. The Flavivirus genus"/>
   <result pre="et al., 2011, Wahala and Silva, 2011). Molecular Architecture of" exact="Dengue" post="Virus In recent years a great deal of research"/>
   <result pre="Virus In recent years a great deal of research on" exact="DENV" post="biology has provided an enormous amount of information about"/>
   <result pre="important advance has been the development of genomic and subgenomic" exact="DENV" post="RNAs containing reporter genes, such as luciferase or green"/>
   <result pre="activity as a function of time after RNA transfection. Mature" exact="DENV" post="particles have a diameter of ~500 Å with an"/>
   <result pre="prM protein during viral. Overview of the Viral Life Cycle" exact="DENV" post="enters host cells by receptor-mediated endocytosis, which involves binding"/>
   <result pre="receptor-mediated endocytosis, which involves binding of E to cellular receptors." exact="DENV" post="must recognize a ubiquitous cell surface molecule or utilize"/>
   <result pre="lectin domain family 5, member A (Chen et al., 2008a)" exact="DENV" post="enters mosquito and human cells through clathrin-mediated endocytosis (Krishnan"/>
   <result pre="and human cells through clathrin-mediated endocytosis (Krishnan et al., 2007)." exact="DENV" post="particles diffuse along the cell surface toward a preexisting"/>
   <result pre="of mature, immature, and partially mature particles. Genomic Structure of" exact="Dengue" post="Virus The DENV genome consists of a single, positive-strand"/>
   <result pre="and partially mature particles. Genomic Structure of Dengue Virus The" exact="DENV" post="genome consists of a single, positive-strand RNA of ~11"/>
   <result pre="for viral replication. The 5′ UTR sequences of the four" exact="DENV" post="serotypes (DENV-1 to DENV-4) are between 95 to 101"/>
   <result pre="DENV-1 to ~385 nucleotides in DENV-4. An important feature of" exact="DENV" post="and other flavivirus genomes is the presence of inverted"/>
   <result pre="of predicted RNA elements at the 3′ UTR of the" exact="DENV" post="genome. DENV, Dengue virus; RNA, ribonucleic acid; UTR, untranslated"/>
   <result pre="elements at the 3′ UTR of the DENV genome. DENV," exact="Dengue" post="virus; RNA, ribonucleic acid; UTR, untranslated regions. Figure 16.3"/>
   <result pre="of the translation initiator AUG at the 5′ UTR of" exact="DENV" post="was found to be complementary to a region present"/>
   <result pre="5′–3′ CS were found to be also important for efficient" exact="DENV" post="replication. These sequences were named 5′–3′ downstream AUG region"/>
   <result pre="Atomic force microscopy showed that long-range RNA–RNA interaction occurs in" exact="DENV" post="genome (Alvarez et al., 2005b), also it showed that"/>
   <result pre="genome (Alvarez et al., 2005b), also it showed that full-length" exact="DENV" post="genomic RNA occurred in linear and circular conformations. 5′"/>
   <result pre="5′ Untranslated Region Alignment of the 5′ UTRs from different" exact="DENV" post="serotypes shows high sequence conservation. RNA-folding predictions of these"/>
   <result pre="are separated by a short oligo(U) sequence. SLA portion of" exact="DENV" post="genome shows three helical regions (S1, S2, and S3),"/>
   <result pre="the SLB structures, there is an oligo(U) track conserved in" exact="DENV" post="and other flavivirus genomes that functions as spacer that"/>
   <result pre="region hairpin (cHP); and (3) an RNA element that modulates" exact="DENV" post="replication in mosquito and mammalian cells (Fig. 16.3). The"/>
   <result pre="nucleotides long (134-UCAAUAUGCUG) and is absolutely conserved among the four" exact="DENV" post="serotypes. This region mediates long-range RNA–RNA interactions between the"/>
   <result pre="coding sequence were found to play a regulatory role in" exact="DENV" post="replication (Polacek et al., 2009). Mutations and deletions within"/>
   <result pre="within a predicted hairpin (CCR1) resulted in important defects in" exact="DENV" post="replication in mosquito and mammalian cells (Fig. 16.3). 3′"/>
   <result pre="16.3). 3′ Untranslated Region The 3′ UTRs of the four" exact="DENV" post="genomes contain highly conserved RNA elements (Shurtleff et al.,"/>
   <result pre="few nucleotide variations in this region. Altered sHP formation impaired" exact="DENV" post="replication (Villordo et al., 2010). The TL of the"/>
   <result pre="2010). The TL of the large terminal stem loop in" exact="DENV" post="has a highly conserved ACAGAAC sequence. In DENV the"/>
   <result pre="loop in DENV has a highly conserved ACAGAAC sequence. In" exact="DENV" post="the 3′ SL contains a total of 93 nucleotides."/>
   <result pre="Figure 16.4 Long-range RNA interactions between the ends of the" exact="DENV" post="genome. DENV, Dengue virus; RNA, ribonucleic acid. Viral Replication"/>
   <result pre="RNA interactions between the ends of the DENV genome. DENV," exact="Dengue" post="virus; RNA, ribonucleic acid. Viral Replication Replication of DENV"/>
   <result pre="DENV, Dengue virus; RNA, ribonucleic acid. Viral Replication Replication of" exact="DENV" post="is associated with a dramatic rearrangement of host cellular"/>
   <result pre="the ER origin of the VPs and CMs induced during" exact="DENV" post="infection. CMs have been proposed as putative sites for"/>
   <result pre="a new viral particle (Fig. 16.5 ). Figure 16.5 The" exact="DENV" post="life cycle. Nonstructural Proteins NS1 (48–50 kDa glycoprotein) (Muller"/>
   <result pre="highly immunogenic and is involved in stimulating protective response against" exact="DENV" post="(Mackenzie et al., 1996). It has been implicated in"/>
   <result pre="2006, Lodeiro et al., 2009). The N-terminal of NS5 from" exact="DENV" post="is shown to possess guanine N7 and ribose 2′-O"/>
   <result pre="by binding and promoting STAT2 degradation (Ashour et al., 2009)." exact="DENV" post="RNA synthesis requires specific interaction of NS5 with the"/>
   <result pre="to promote RNA synthesis in vitro (Filomatori et al., 2006)" exact="DENV" post="NS5 binds to the promoter SLA mainly through the"/>
   <result pre="et al., 2011) Crystallographic structures for the RdRp domain of" exact="WNV" post="and DENV (serotype 3) (Egloff et al., 2007, Yap"/>
   <result pre="2011) Crystallographic structures for the RdRp domain of WNV and" exact="DENV" post="(serotype 3) (Egloff et al., 2007, Yap et al.,"/>
   <result pre="An unexpected observation in the structure of the RdRp from" exact="DENV" post="was the presence of two zinc ions in the"/>
   <result pre="mechanism of fusion of E protein leads to internalization of" exact="DENV" post="has been proposed by (Modis et al., 2004) and"/>
   <result pre="and structural proteins of dengue in replication complex. Pathogenesis of" exact="Dengue" post="Viral Factors Viral virulence is influenced by viral genetics"/>
   <result pre="host genetics (factors that are &quot;extrinsic�? to the virus). Certain" exact="DENV" post="strains demonstrate greater epidemic potential, as they replicate better"/>
   <result pre="hypothesis (Rosen, 1977) and is supported by the several studies." exact="DENV" post="virulence is often tightly linked to host immune status,"/>
   <result pre="(OhAinle et al., 2011, Steel et al., 2010). More fit" exact="DENV" post="strains have been proposed to pose increased risk of"/>
   <result pre="target cells and resultant exacerbated cytokine cascade: (1) More pathogenic" exact="DENV" post="strains replicate more productively in human cells and thereby"/>
   <result pre="to higher titers (Cologna and Rico-Hesse, 2003); (2) more pathogenic" exact="DENV" post="strains may evade host adaptive, cross-reactive immune responses (Kochel"/>
   <result pre="infected cells. Also inappropriate cross-reactive adaptive immune response during sequential" exact="DENV" post="infection may lead to the more severe immunopathogenesis, that"/>
   <result pre="2012). Finally, differences in the breadth of diversity of circulating" exact="DENV" post="genomes during acute infection (&quot;intrahost diversity�?) have been hypothesized"/>
   <result pre="addition to mutations that may alter the replicative ability of" exact="DENV" post="viruses in human cells, some viruses may also be"/>
   <result pre="reduced neutralization by the host humoral (antibody-mediated) response. The four" exact="DENV" post="serotypes all have the ability to cause severe and"/>
   <result pre="determining disease outcome (OhAinle et al., 2011). In interepidemic periods," exact="DENV" post="is thought to be maintained in endemic populations through"/>
   <result pre="virus may undergo significant evolution. Also it is seen that" exact="DENV" post="evolves over a single epidemic season, such that viruses"/>
   <result pre="factor for the development of severe disease and death from" exact="DENV" post="infection. Many studies indicate that the incidence of DSS"/>
   <result pre="2000). Host genetics play a vital role in susceptibility to" exact="DENV" post="infection and studies show that people with an African"/>
   <result pre="to protect against the development of clinical disease from secondary" exact="DENV" post="infection (Stephens et al., 2002). Also, HLA-A*A24 was overrepresented"/>
   <result pre="al., 2008). Several other gene polymorphisms are also associated with" exact="DENV" post="infection few such are tumor necrosis factor (TNF)-308A allele"/>
   <result pre="factor (TNF)-308A allele and increased susceptibility to severe manifestations of" exact="DENV" post="infection (Perez et al., 2010), and a possible protective"/>
   <result pre="a possible protective association between the TNF-238A allele and severe" exact="DENV" post="infection (Garcia et al., 2011) and increased frequency of"/>
   <result pre="gene appeared to be protected from the development of severe" exact="DENV" post="infection. Viral binding to platelets via human platelet antigens"/>
   <result pre="The G allele of DC-SIGN1-336 appears to protect against milder" exact="DENV" post="infection, DF, but not against more serious disease (Sakuntabhai"/>
   <result pre="in patients with immunological evidence of a previous history of" exact="DENV" post="exposure or, in the case of infants, those with"/>
   <result pre="phase of IgM production followed by IgG. During a primary" exact="DENV" post="infection, antidengue IgM levels will begin to rise 3–5"/>
   <result pre="its functional avidity for the whole virion. T-Cell Responses in" exact="Dengue" post="Infection T cells recognize short antigenic peptides bound in"/>
   <result pre="has helped us in understanding the T-cell response in a" exact="DENV" post="person. Using these techniques, a large number of epitopes"/>
   <result pre="al., 2010, Kurane et al., 1989). T-Cell Responses in Secondary" exact="Dengue" post="Infection Many of the T cells induced in the"/>
   <result pre="al., 2011, Mongkolsapaya et al., 2006). Innate Immune Responses in" exact="Dengue" post="Virus Infection DENV counteracts two important elements of innate"/>
   <result pre="et al., 2006). Innate Immune Responses in Dengue Virus Infection" exact="DENV" post="counteracts two important elements of innate immunity, namely, the"/>
   <result pre="involved in antiviral innate immune responses are targeted by DENV." exact="DENV" post="has been shown to trigger complement activation in vitro"/>
   <result pre="vivo (Avirutnan et al., 2006). Complement likely functions to limit" exact="DENV" post="infection by stimulating adaptive immune responses and by neutralizing"/>
   <result pre="in vitro and in vivo can paradoxically enhance replication of" exact="DENV" post="(Balsitis et al., 2010, Zellweger et al., 2010). Complement"/>
   <result pre="also augments antibody-mediated neutralization of flaviviruses, including YFV, DENV, and" exact="WNV" post="(Mehlhop et al., 2009). In myeloid cells that express"/>
   <result pre="(Cardosa et al., 1983). Antibody and complement-dependent opsonization may augment" exact="DENV" post="infection in myeloid cells. In early clinical studies, reduced"/>
   <result pre="C3 and C1q were observed, particularly in patients with severe" exact="DENV" post="disease during secondary infection (Bokisch et al., 1973). In"/>
   <result pre="leakage (Malasit, 1987). DENV-infected cells may display sufficient amounts of" exact="DENV" post="antigens (prM, E, or NS1 proteins) on their surface"/>
   <result pre="response elements that have antiviral activity (Kawai and Akira, 2007)." exact="DENV" post="has been reported to be sensed by several TLRs"/>
   <result pre="TLR7, RIG I and MDA5 (Nasirudeen et al., 2011). Several" exact="DENV" post="proteins had been identified as inhibitors of type I"/>
   <result pre="that would trigger the induction of hundreds of ISGs. Also" exact="DENV" post="can inhibit the production of type I IFN in"/>
   <result pre="replication, by inhibiting type I IFN production in human DCs," exact="DENV" post="may affect the quality of the adaptive immune response"/>
   <result pre="the adaptive immune response generated after infection. Clinical Features of" exact="Dengue" post="Symptomatic Dengue Following an infectious mosquito bite there is"/>
   <result pre="immune response generated after infection. Clinical Features of Dengue Symptomatic" exact="Dengue" post="Following an infectious mosquito bite there is an incubation"/>
   <result pre="resolution of the vasculopathy (Qiu et al., 1993). Factors Influencing" exact="Dengue" post="Disease Severity Children and the elderly have a lower"/>
   <result pre="with adults (Anders et al., 2011, Trung et al., 2012)." exact="Dengue" post="associated mortality also appears to be higher in pregnant"/>
   <result pre="be tested for virus/RNA/antigen detection or for serological studies. Acute" exact="Dengue" post="Diagnosis Diagnosis during the acute phase of illness allows"/>
   <result pre="sample is also useful for virus isolation. Molecular Diagnosis of" exact="Dengue" post="DENV RNA can be extracted from serum or plasma,"/>
   <result pre="is also useful for virus isolation. Molecular Diagnosis of Dengue" exact="DENV" post="RNA can be extracted from serum or plasma, as"/>
   <result pre="universal dengue primers targeting the conserved C/prM region of the" exact="DENV" post="genome for an initial reverse transcription and amplification step,"/>
   <result pre="14 (Duyen et al., 2011). Early and Late Convalescent Diagnosis" exact="Dengue" post="viremia correlates with fever onset, with peak levels at"/>
   <result pre="as secondary infection. The assays used for detecting a past" exact="DENV" post="infection are HI, IgG ELISA (Vazquez et al., 1997),"/>
   <result pre="ELISA (Vazquez et al., 1997), and neutralization assay to detect" exact="DENV" post="neutralizing antibodies (Alvarez et al., 2008). Viral Isolation and"/>
   <result pre="mammalian cell lines, VERO, BKH21, and LLC-MK2 were introduced for" exact="DENV" post="isolation. These cell lines have a low sensitivity for"/>
   <result pre="viruses. As a result, they are not used for routine" exact="DENV" post="isolation, although they are useful for the quantitative plaque"/>
   <result pre="inoculation of adult mosquitoes opened a new sensitive way for" exact="DENV" post="isolation. In addition, a method to inoculate mosquito larvae"/>
   <result pre="developed in the 1970s and 1980s provide sensitive systems for" exact="DENV" post="isolation. Three cell lines have commonly been used: AP-61"/>
   <result pre="cytometry as well as NS1 detection have been employed for" exact="DENV" post="identification (Jarman et al., 2011, Kao et al., 2001)."/>
   <result pre="(Jarman et al., 2011, Kao et al., 2001). Management of" exact="Dengue" post="Management of suspected dengue patients depends on the clinical"/>
   <result pre="in the febrile phase is mostly symptomatic and supportive treatment." exact="Dengue" post="patients usually have high sustained fever ranging from 2"/>
   <result pre="done as per existing protocols (Gubler, 2014). Prevention and Control" exact="Dengue" post="Vector Control There is little to no effective vector"/>
   <result pre="tripeptide inhibitors were synthesized to probe the dynamics of the" exact="DENV" post="protease active site with different functional groups that compete"/>
   <result pre="broad acting antivirals have been pursued (Becker et al., 2012)." exact="Dengue" post="Vaccine Development The potential use of safe and effective"/>
   <result pre="vector control could be more effective (Halstead and Deen, 2002)." exact="Dengue" post="vaccines could have beneficial individual-level effects by reducing the"/>
   <result pre="the level of immunogenicity it evokes and the attenuation of" exact="DENV" post="pathogenicity. The immunogenicity induced by the vaccine should be"/>
   <result pre="Yellow Fever Virus as Molecular Backbone Acambis/Sanofi Pasteur Vaccine (CYD)" exact="DENV" post="vaccine is based on dengue–YF vaccine virus chimeras Chimeric"/>
   <result pre="those of DENV-2 NGC. Yet another approach uses a capsid-deleted" exact="WNV" post="vector to produce DENV pseudoinfectious derivatives (Suzuki et al.,"/>
   <result pre="Yet another approach uses a capsid-deleted WNV vector to produce" exact="DENV" post="pseudoinfectious derivatives (Suzuki et al., 2009). The DENV-WNV chimeras"/>
   <result pre="2009). The DENV-WNV chimeras are expected to retain the wild-type" exact="WNV" post="attribute of high replicative efficiency enhancing the productive potential"/>
   <result pre="separately introducing 3′ terminus changes into each of the four" exact="DENV" post="or by making structural gene chimeras, including all four"/>
   <result pre="African green monkey kidney cells. Serial passage of different wild-type" exact="DENV" post="(2 DENV-1, 2 DENV-2, and 3 DENV-4) resulted in"/>
   <result pre="University of North Carolina has developed a vaccine in which" exact="DENV" post="E protein is produced by a Venezuelan encephalitis virus"/>
   <result pre="tetravalent live-attenuated dengue vaccine based on serial passage of wild-type" exact="DENV" post="in PDK cells. Among the selected passage levels, the"/>
   <result pre="Subunit Vaccines T- and B-cell epitopes have been mapped on" exact="DENV" post="structural proteins such as EDIII and NS proteins (Kurane"/>
   <result pre="effective and safe vaccine at moderate cost. Structural and NS" exact="DENV" post="proteins have been produced in adequate amounts in many"/>
   <result pre="in dengue surveillance: a report from the Asia-Pacific and Americas" exact="Dengue" post="Prevention BoardsPLoS Negl. Trop. Dis.4112010e89010.1371/journal.pntd.000089021103381 BeckerG.L.LuY.HardesK.StrehlowB.LevesqueC.LindbergI.Highly potent inhibitors of"/>
   <result pre="helicase catalytic coreVirology3282200420821810.1016/j.virol.2004.07.00415464841 BennettS.N.Taxonomy and evolutionary relationship of flavivirusesOoiE.E.GublerD.J.VasudevanS.FarrarJ.Dengue and" exact="Dengue" post="Hemorrhagic FeverVol. 322–3332014CAB International BernardoL.YndartA.VazquezS.MorierL.GuzmanM.G.Antibody responses to Asian and"/>
   <result pre="Biomed. Sci.922013616723847455 BhuvanakanthamR.ChongM.K.NgM.L.Specific interaction of capsid protein and importin-alpha/beta influences" exact="West Nile" post="virus productionBiochem. Biophys. Res. Commun.38912009636910.1016/j.bbrc.2009.08.10819712667 BiswasH.H.OrtegaO.GordonA.StandishK.BalmasedaA.KuanG.Early clinical features of"/>
   <result pre="dengue virus replicationPLoS One8122013e8250410.1371/journal.pone.008250424376541 D’ArcyA.ChailletM.SchieringN.VillardF.LimS.P.LefeuvreP.Purification and crystallization of dengue and" exact="West Nile" post="virus NS2B-NS3 complexesActa Crystallogr. Sect. F. Struct. Biol. Cryst."/>
   <result pre="two dengue infections spaced 20 years or more apart: Havana," exact="Dengue" post="3 epidemic, 2001-2002Int. J. Infect. Dis.95200528028510.1016/j.ijid.2004.07.01216023878 GrahamJ.D.A unique pig-sticking"/>
   <result pre="endemic area—Puerto Rico, 2007-2008Am. J. Trop. Med. Hyg.825201092292910.4269/ajtmh.2010.09-055220439977 GublerD.Dengue and" exact="West Nile" post="virus—an interview with Duane Gubler, Sc.D., reported by Vicki"/>
   <result pre="history and emergence as a global public health problemOoiE.E.GublerD.J.VasudevanS.FarrarJ.Dengue and" exact="Dengue" post="Hemorrhagic Fever2014CAB International GublerD.J.ClarkG.G.Dengue/dengue hemorrhagic fever: the emergence of"/>
   <result pre="promoter-dependent RNA synthesisJ. Virol.851220115745575610.1128/JVI.02343-1021471248 IglesiasN.G.BykL.A.GamarnikA.V.Molecular virology of dengue virusOoiA.P.E.E.GublerD.J.VasudevanS.FarrarJ.Dengue and" exact="Dengue" post="Hemorrhagic Fever2013CAB International334365 InnisB.L.ThirawuthV.HemachudhaC.Identification of continuous epitopes of the"/>
   <result pre="5 is required for the cellular entry of dengue and" exact="West Nile" post="virusesJ. Virol.81920074881488510.1128/JVI.02210-0617301152 KuberskiT.RosenL.ReedD.MataikaJ.Clinical and laboratory observations on patients with"/>
   <result pre="of dengue controlLancet377977820111630163110.1016/S0140-6736(11)60470-421546075 MehlhopE.FuchsA.EngleM.DiamondM.S.Complement modulates pathogenesis and antibody-dependent neutralization of" exact="West Nile" post="virus infection through a C5-independent mechanismVirology39312009111510.1016/j.virol.2009.08.01919744691 MenR.WyattL.TokimatsuI.ArakakiS.ShameemG.ElkinsR.Immunization of rhesus"/>
   <result pre="Natl. Acad. Sci. U.S.A.109362012146101461510.1073/pnas.121237910922908290 SchullerA.YinZ.Brian ChiaC.S.DoanD.N.KimH.K.ShangL.Tripeptide inhibitors of dengue and" exact="West Nile" post="virus NS2B-NS3 proteaseAntiviral Res.92120119610110.1016/j.antiviral.2011.07.00221763725 SeetR.C.QuekA.M.LimE.C.Post-infectious fatigue syndrome in dengue"/>
   <result pre="Trop. Med. Hyg.875201279680510.4269/ajtmh.2012.12-001923033404 ShepardD.S.HalasaY.A.UndurragaE.A.Economic and disease burden of dengueOoiE.E.GublerD.J.VasudevanS.FarrarJ.Dengue and" exact="Dengue" post="Hemorrhagic Fever2014CAB International ShurtleffA.C.BeasleyD.W.ChenJ.J.NiH.SudermanM.T.WangH.Genetic variation in the 3′ non-coding"/>
   <result pre="sequences of the genome and replicative-from RNA of the flavivirus" exact="West Nile" post="virus: absence of poly(A) and possible role in RNA"/>
   <result pre="XuZ.AndersonR.HobmanT.C.The capsid-binding nucleolar helicase DDX56 is important for infectivity of" exact="West Nile" post="virusJ. Virol.851120115571558010.1128/JVI.01933-1021411523 YangH.LiZ.LinH.WangW.YangJ.LiuL.A novel dengue virus serotype 1 vaccine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150051\results\search\tropicalVirus\results.xml">
   <result pre="some viruses transmitted by mosquito vectors, such as dengue virus," exact="Zika" post="virus, and chikungunya virus, have caused epidemic outbreaks with"/>
   <result pre="as mosquitoes and ticks; wild birds are reservoirs for the" exact="West Nile" post="virus, small wild mammals such as rodents, bats, and"/>
   <result pre="arboviruses, and the ecoepidemiological role of these is unknown. Keywords" exact="Dengue" post="virus arboviruses yellow fever virus chikungunya virus vectors hosts"/>
   <result pre="2012). The major arboviruses that affect humans are DENV, YFV," exact="West Nile" post="virus (WNV), Eastern equine encephalitis virus (EEEV), Western equine"/>
   <result pre="have spread pathogens, vectors, and animal reservoirs, for example, Ebola," exact="WNV" post="by Culex, SARS, and monkey pox virus (Daszak et"/>
   <result pre="and maintenance of arboviruses. Most arboviruses with the exception of" exact="DENV" post="are kept within a jungle cycle, where bloodsucking insects"/>
   <result pre="as hosts. Although in the Americas, the jungle cycle for" exact="DENV" post="has not been verified, in a tropical forest in"/>
   <result pre="and Dobler, 2010, Bueno and Jiménez, 2010). The transmission of" exact="DENV" post="by mosquitoes could be limited in wild ecosystems, where"/>
   <result pre="birds, and other wild animals (Abundes-Gallegos et al., 2018). Recently," exact="DENV" post="was also found in Desmodus, as well as in"/>
   <result pre="since flies could also be involved in the maintenance of" exact="DENV" post="in nature (Abundes-Gallegos et al., 2018). Recently, Zika virus"/>
   <result pre="maintenance of DENV in nature (Abundes-Gallegos et al., 2018). Recently," exact="Zika" post="virus was detected in the salivary glands in female"/>
   <result pre="vertebrates (Elizondo-Quiroga et al., 2018). While the urban cycle of" exact="DENV" post="is maintained between humans and A. aegypti, the mechanisms"/>
   <result pre="maintained between humans and A. aegypti, the mechanisms for maintaining" exact="DENV" post="in the jungle cycle are still unknown, despite the"/>
   <result pre="the jungle cycle are still unknown, despite the fact that" exact="DENV" post="has been detected by molecular methods in wildlife in"/>
   <result pre="aegypti was confirmed at 2302 masl and infection with the" exact="DENV" post="at 1984 masl; this being the highest recorded altitude"/>
   <result pre="are completing their biological cycle at 2450 masl but the" exact="DENV" post="transmission at these altitudes is unknown (Aquino et al.,"/>
   <result pre="are associated with epidemics in urban areas, while MAYV and" exact="YFV" post="are associated with human disease in wild areas (Vasconcelos"/>
   <result pre="day after returning from Rajasthan (India), serum was positive for" exact="CHIKV" post="infection by polymerase chain reaction (PCR); 3 weeks later"/>
   <result pre="patient had no history of travel to endemic areas of" exact="CHIKV" post="and resided at 2.5 km from the index case;"/>
   <result pre="close friend of patient 2, showed clinical symptoms compatible with" exact="CHIKV" post="infection; patient 3 lived near patient 1 and on"/>
   <result pre="CHIKV; their clinical episodes were classified as autochthonous cases of" exact="CHIKV" post="infection. The phylogenetic analysis showed that these viral strains"/>
   <result pre="that is closely related to the strains of India; the" exact="CHIKV" post="isolate of patient 2 could be derived from an"/>
   <result pre="1 (Grandadam et al., 2011). Likewise, in 2010 coinfections with" exact="DENV" post="and CHIKV occurred in this region (La Ruche et"/>
   <result pre="et al., 2011). Likewise, in 2010 coinfections with DENV and" exact="CHIKV" post="occurred in this region (La Ruche et al., 2010)."/>
   <result pre="2003, Hall et al., 2017, Feitoza et al., 2017). The" exact="DENV" post="is mainly transmitted by female mosquitoes of the genus"/>
   <result pre="KFDV Ticks Spondweni virus SPOV Mosquitoes Langat virus LGTV Ticks" exact="Zika" post="virus ZIKV Mosquitoes Omsk virus OHFV Ticks Banzi virus"/>
   <result pre="Spondweni virus SPOV Mosquitoes Langat virus LGTV Ticks Zika virus" exact="ZIKV" post="Mosquitoes Omsk virus OHFV Ticks Banzi virus BANV Mosquitoes"/>
   <result pre="TYUV Ticks Wesselsbron virus WESSV Mosquitoes Aroa virus AROAV Mosquitoes" exact="Yellow fever" post="virus YFV Mosquitoes Dengue virus DENV Mosquitoes Entebbe bat"/>
   <result pre="virus WESSV Mosquitoes Aroa virus AROAV Mosquitoes Yellow fever virus" exact="YFV" post="Mosquitoes Dengue virus DENV Mosquitoes Entebbe bat virus ENTV"/>
   <result pre="Mosquitoes Aroa virus AROAV Mosquitoes Yellow fever virus YFV Mosquitoes" exact="Dengue" post="virus DENV Mosquitoes Entebbe bat virus ENTV Unknown Kedougou"/>
   <result pre="virus AROAV Mosquitoes Yellow fever virus YFV Mosquitoes Dengue virus" exact="DENV" post="Mosquitoes Entebbe bat virus ENTV Unknown Kedougou virus KEDV"/>
   <result pre="Unknown Usutu virus USUV Mosquitoes San Perlita virus SPV Unknown" exact="West Nile" post="virus WNV Mosquitoes Bukalasa bat virus BBV Unknown Yaoundé"/>
   <result pre="USUV Mosquitoes San Perlita virus SPV Unknown West Nile virus" exact="WNV" post="Mosquitoes Bukalasa bat virus BBV Unknown Yaoundé virus YAOV"/>
   <result pre="virus RBV Unknown Ecuador Paraiso Escondido virus EPEV Dipterous The" exact="DENV" post="remains in nature in two cycles: urban and wild"/>
   <result pre="only humans, and the sylvatic cycle involves nonhuman primates. Wild" exact="DENV" post="cycles have been well documented in West Africa and"/>
   <result pre="The majority of the Colombian territory is considered endemic for" exact="DENV" post="as 74% of the municipal capitals are below 1800"/>
   <result pre="state of vegetation, were significantly related to the appearance of" exact="DENV" post="(Meza-Ballesta and Gónima, 2014). Likewise, this department is endemic"/>
   <result pre="its municipalities (Meza-Ballesta and Gónima, 2014). The average incidence of" exact="DENV" post="between 2003 and 2010 was 36.5 cases/100,000 inhabitants, and"/>
   <result pre="RT-PCR-nested the flavivirus circulation was confirmed: DENV-2 in A. aegypti," exact="YFV" post="in Haemagogus splendens, SLEV in Mansonia titillans, Culex spp.,"/>
   <result pre="in Haemagogus splendens, SLEV in Mansonia titillans, Culex spp., and" exact="WNV" post="in Culex spp. (Hoyos-López et al., 2016). It is"/>
   <result pre="In addition, there are different serological or molecular evidences on" exact="DENV" post="in wild bats, in brains and bat sera in"/>
   <result pre="should be implemented to determine their role as reservoirs of" exact="DENV" post="(Cabrera-Romo et al., 2016). Sequences of DENV have been"/>
   <result pre="as reservoirs of DENV (Cabrera-Romo et al., 2016). Sequences of" exact="DENV" post="have been reported in bats; for example, a sequence"/>
   <result pre="South America the MAYV is considered arthrogenic. The reemergence of" exact="CHIKV" post="reiterates the potential threat posed by alphaviruses to human"/>
   <result pre="Virus Vector Host Transmission cycles Human diseases Geographical distribution Flaviridae" exact="DENV" post="Aedes Humans, primates U,S,R FS, FH World (tropics) YFV"/>
   <result pre="Flaviridae DENV Aedes Humans, primates U,S,R FS, FH World (tropics)" exact="YFV" post="Aedes Humans, primates R,S,U FS, FH Africa and South"/>
   <result pre="Aedes Humans, primates R,S,U FS, FH Africa and South America" exact="WNV" post="Aedes, Anopheles, Culex, Coquillettidia, and Ochlerotatus Birds, pigs R,S,U"/>
   <result pre="Aedes, Culex, and Culiseta Birds R FS Africa, Europe Togaviridae" exact="CHIKV" post="Aedes Humans, primates U,S,R FS Africa, Asia, and Australia"/>
   <result pre="Aedes, Anopheles, and Culex Rodents R FS, ME America CHIKV," exact="Chikungunya" post="virus; DENV, dengue virus; EEEV, virus de la Encefalitis"/>
   <result pre="virus; VEEV, Venezuelan equine encephalitis virus; VONN, o'nyong-nyong virus; WNV," exact="West Nile" post="virus; YFV, Yellow fever virus. MAYV was originally isolated"/>
   <result pre="encephalitis virus; VONN, o'nyong-nyong virus; WNV, West Nile virus; YFV," exact="Yellow fever" post="virus. MAYV was originally isolated in Trinidad in 1954"/>
   <result pre="is introduced by sick travelers or migratory birds. MAYV and" exact="CHIKV" post="could also be transmitted by A. aegypti. This background"/>
   <result pre="arthropod-transmitted viruses in the Americas has not been very successful." exact="Dengue" post="continues to cause chaos in many areas of the"/>
   <result pre="the Caribbean. For some arboviruses causing large outbreaks such as" exact="DENV" post="and CHIKV, there is no specific treatment or commercially"/>
   <result pre="of expertise and infrastructure. With the epidemics of ZIKA and" exact="CHIKV" post="reactive reactions, such as the use of spray and"/>
   <result pre="Bolivia: nuevos registros altitudinalesGac Med. Bol. Cochabamba39220168387 BaqarS.HayesC.G.MurphyJ.R.WattsD.M.Vertical transmission of" exact="West Nile" post="virus by Culex and Aedes species mosquitoesAm. J. Trop."/>
   <result pre="on the ability of Culex pipiens (Diptera: Culicidae) to transmit" exact="West Nile" post="virusJ. Med. Entomol.391200222122511931261 Elizondo-QuirogaD.Medina-SánchezA.Sánchez-GonzálezJ.M.EckertK.A.Villalobos-SánchezE.Navarro-ZúñigaA.R.Zika virus in salivary glands of"/>
   <result pre="Americas: chikungunya and MayaroRev. Soc. Bras. Med. Trop.47201467768310.1590/0037-8682-0246-201425626645 GorodnerJ.O.Dengue, fiebre" exact="Zika" post="y fiebre Chikungunya. Patologías conminantes y cambio climático en"/>
   <result pre="of Aedes aegypti—a reviewMem. Inst. Oswaldo Cruz108Suppl 12013111710.1590/0074-027613039524473798 RabaanA.A.BazziA.M.Al-AhmedS.H.Al-GhaithM.H.Al-TawfiqJ.A.Overview of" exact="Zika" post="infection, epidemiology, transmission and control measuresJ. Infect. Public Health10201714114927283926"/>
   <result pre="competence of selected North American Culex and Coquillettidia mosquitoes for" exact="West Nile" post="virusEmerg. Infect. Dis.7620011018102211747732 SarwarM.M.Mosquito-borne viral infections and diseases among"/>
   <result pre="tropical rain forest near Belem, BrazilAm. J. Epidemiol.84319664674776005906 SimonF.TolouH.JeandelP.The unexpected" exact="Chikungunya" post="outbreakRev. Med. Interne276200643744116697081 SotaT.MogiM.Interspecific variation in desiccation survival time"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150362\results\search\tropicalVirus\results.xml">
   <result pre="et al., 2016). Vector-borne viral diseases (West Nile, Chikungunya, Zika," exact="Dengue" post="fever, Rift Valley fever, etc.) generate approximately 1 million"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150815\results\search\tropicalVirus\results.xml">
   <result pre="7150815 doi: 10.3390/v12030296viruses-12-00296 : Brief Report Vector-Borne Transmission of the" exact="Zika" post="Virus Asian Genotype in Europe https://orcid.org/0000-0003-3348-9618DurandGuillaume A.12*PiorkowskiGéraldine2https://orcid.org/0000-0003-4301-2944ThirionLaurence2NinoveLaetitia2GironSandra3ZandottiChristine2DenisJessica14BadautCyril14https://orcid.org/0000-0001-6890-0820FaillouxAnna-Bella5GrardGilda12Leparc-GoffartIsabelle12de LamballerieXavier2[1], jessica.d03@orange.frcbadaut@gmail.comgilda.grard@inserm.frisabelle.leparcgoffart@gmail.com[2],"/>
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Three autochthonous cases of" exact="Zika" post="virus occurred in southern France in August 2019. Diagnosis"/>
   <result pre="on serology and transcription-mediated amplification. Attempts for virus isolation and" exact="ZIKV" post="genome RT-PCR detection remained negative. Since the index case"/>
   <result pre="autochthonous transmission genotyping 1. Introduction The first vector-borne transmission of" exact="Zika" post="virus (ZIKV) in Europe has been reported recently [1]."/>
   <result pre="from France can transmit more efficiently the African genotype of" exact="ZIKV" post="than the Asian genotype [2]. The latter includes both"/>
   <result pre="The aim of the current study was to determine the" exact="ZIKV" post="genotype implicated in cases of local transmission in France,"/>
   <result pre="using in-house ELISA with a whole precipitated and inactivated virus," exact="Zika" post="EDIII recombinant protein (IgM and IgG antibodies to ZIKV),"/>
   <result pre="virus neutralization test. All cases were found positive in ELISA," exact="Zika" post="EDIII-based ELISA and virus neutralization, and negative for neutralizing"/>
   <result pre="virus neutralization, and negative for neutralizing antibodies against West-Nile and" exact="Dengue" post="serotype 1 to 4 viruses [5]. All attempts for"/>
   <result pre="[5]. All attempts for virus isolation and detection of the" exact="ZIKV" post="genome by RT-PCR (RealStar Zika Virus RT-PCR kit, Altona"/>
   <result pre="isolation and detection of the ZIKV genome by RT-PCR (RealStar" exact="Zika" post="Virus RT-PCR kit, Altona Diagnostics, Germany [6]) in serum,"/>
   <result pre="[7]) to identify samples in which residual amounts of the" exact="ZIKV" post="RNA genome could be detected from serum. We performed"/>
   <result pre="with Case 1’s sequence, and all of them corresponding to" exact="ZIKV" post="strains from Southeast Asia; 17 sequences from the same"/>
   <result pre="more mismatches. 5. Discussion In conclusion, the strain implicated in" exact="ZIKV" post="autochthonous vector-borne transmission in the Var region belonged to"/>
   <result pre="&quot;Asian�? and &quot;American�? strains belonging to the Asian genotype of" exact="ZIKV" post="were poorly transmitted by French Ae. albopictus [2]. We"/>
   <result pre="epidemiological findings. First, the actual transmission potential of the incriminated" exact="ZIKV" post="strain by local Ae. albopictus may be higher than"/>
   <result pre="potential of the Asian strain used in competence studies (namely" exact="ZIKV" post="Cambodia isolated from a human case in 2010 (FSS"/>
   <result pre="and the most probable geographical origin (Southeast Asia) of the" exact="ZIKV" post="strain implicated in the first Zika virus local vector-borne"/>
   <result pre="(Southeast Asia) of the ZIKV strain implicated in the first" exact="Zika" post="virus local vector-borne transmission in Europe. It shows that"/>
   <result pre="X.d.L., T.M.A., L.T. and NGS; sequencing and analysis, G.P.; EDIII" exact="Zika" post="ELISA, J.D. and C.B.; writing and supervision, G.A.D., I.L.-G."/>
   <result pre="no conflict of interest. References References 1.GironS.FrankeF.DecoppetA.CadiouB.TravagliniT.ThirionL.DurandG.JeanninC.L’AmbertG.GrardG.et al.Vector-borne transmission of" exact="Zika" post="virus in Europe, southern France, August 2019Euro Surveill.201924190065510.2807/1560-7917.ES.2019.24.45.190065531718742 2.VazeilleM.MadecY.MoussonL.BelloneR.Barré-CardiH.SousaC.A.JiolleD.YébakimaA.de"/>
   <result pre="Infect.201981668167810.1080/22221751.2019.168979731735122 3.PetterssonJ.H.-O.BohlinJ.Dupont-RouzeyrolM.BrynildsrudO.B.AlfsnesK.Cao-LormeauV.-M.GauntM.W.FalconarA.K.de LamballerieX.EldholmV.et al.Re-visiting the evolution, dispersal and epidemiology of" exact="Zika" post="virus in AsiaEmerg. Microbes Infect.201877910.1038/s41426-018-0082-529739925 4.PetterssonJ.H.-O.EldholmV.SeligmanS.J.LundkvistÅ.FalconarA.K.GauntM.W.MussoD.NougairèdeA.CharrelR.GouldE.A.et al.How Did Zika"/>
   <result pre="of Zika virus in AsiaEmerg. Microbes Infect.201877910.1038/s41426-018-0082-529739925 4.PetterssonJ.H.-O.EldholmV.SeligmanS.J.LundkvistÅ.FalconarA.K.GauntM.W.MussoD.NougairèdeA.CharrelR.GouldE.A.et al.How Did" exact="Zika" post="Virus Emerge in the Pacific Islands and Latin America?mBio20167e01239-1610.1128/mBio.01239-1627729507"/>
   <result pre="and Latin America?mBio20167e01239-1610.1128/mBio.01239-1627729507 5.DenisJ.AttoumaniS.GravierP.TenebrayB.GarnierA.BriolantS.de LavalF.ChastresV.GrardG.Leparc-GoffartI.et al.High specificity and sensitivity of" exact="Zika" post="EDIII-based ELISA diagnosis highlighted by a large human reference"/>
   <result pre="reference panelPLoS Negl. Trop. Dis.201913e000774710.1371/journal.pntd.000774731539394 6.ÖlschlägerS.EnfissiA.ZarubaM.KazanjiM.RoussetD.Diagnostic Validation of the RealStar®" exact="Zika" post="Virus Reverse Transcription Polymerase Chain Reaction Kit for Detection"/>
   <result pre="Virus Reverse Transcription Polymerase Chain Reaction Kit for Detection of" exact="Zika" post="Virus RNA in Urine and Serum SpecimensAm. J. Trop."/>
   <result pre="and Serum SpecimensAm. J. Trop. Med. Hyg.2017971070107110.4269/ajtmh.17-026828722641 7.RenP.OrtizD.A.TerzianA.C.B.ColomboT.E.NogueiraM.L.VasilakisN.LoeffelholzM.J.Evaluation of Aptima" exact="Zika" post="Virus AssayJ. Clin. Microbiol.2017552198220310.1128/JCM.00603-1728468854 8.MoutaillerS.YousfiL.MoussonL.DevillersE.VazeilleM.Vega-RúaA.PerrinY.JourdainF.ChandreF.CannetA.et al.A New High-Throughput Tool"/>
   <result pre="8.MoutaillerS.YousfiL.MoussonL.DevillersE.VazeilleM.Vega-RúaA.PerrinY.JourdainF.ChandreF.CannetA.et al.A New High-Throughput Tool to Screen Mosquito-Borne Viruses in" exact="Zika" post="Virus Endemic/Epidemic AreasViruses20191190410.3390/v1110090431569736 Figure 1 Identification of the genotype"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150983\results\search\tropicalVirus\results.xml">
   <result pre="immunodeficiency virus (HIV) [49,50], Ebola [51], dengue virus (DENV) [52]," exact="West Nile" post="virus (WNV) [53] and influenza virus [16,17]. HIV infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7151808\results\search\tropicalVirus\results.xml">
   <result pre="section and outlined in this book, such as Ebola and" exact="Zika" post="viruses. For the clinician, the challenge is to distinguish"/>
   <result pre="(H7N9), chikungunya, yellow fever, cholera, hepatitis E, meningococcus, hepatitis A," exact="Zika" post="virus. 2016 Poliovirus, MERS-CoV, dengue fever, avian influenza (H7N9,"/>
   <result pre="monkeypox, chikungunya, enterohemorrhagic E. coli, yellow fever, Lassa fever, salmonellosis," exact="Zika" post="virus, Elizabethkingia, oropouche. 2015 Poliovirus, MERS-CoV, cholera, avian influenza"/>
   <result pre="Poliovirus, MERS-CoV, cholera, avian influenza (H7N9), chikungunya, plague, Lassa fever," exact="Zika" post="virus, measles, meningococcus, typhoid fever, Ebola. 2014 Ebola, avian"/>
   <result pre="meningococcus, typhoid fever, Ebola. 2014 Ebola, avian influenza (H7N9, H5N6)," exact="West Nile" post="virus, plague, Marburg, polio, MERS-CoV, chikungunya, enterovirus D68, cholera,"/>
   <result pre="influenza (H7N9), yellow fever, polio, cholera, meningococcus, novel coronavirus. 2012" exact="Yellow fever," post="novel coronavirus, Ebola, Marburg, Rift Valley fever, dengue fever,"/>
   <result pre="dengue fever, cholera, hantavirus pulmonary syndrome, enterovirus 71, meningococcus. 2011" exact="Yellow fever," post="polio, cholera, enterohemorrhagic E. coli, Ebola, measles, avian influenza"/>
   <result pre="a minority of patients can produce a severe hemorrhagic disease." exact="Chikungunya" post="and Ross River viruses can produce a generalized febrile"/>
   <result pre="severe joint pains that can persist for months. Japanese encephalitis," exact="West Nile," post="and the equine encephalitis viruses are classic viruses that"/>
   <result pre="that produce a meningo-encephalitis in 1% of the persons infected." exact="Yellow fever" post="and the filoviruses (Ebola and Marburg) are examples of"/>
   <result pre="Marburg) are examples of severe hemorrhagic fever viruses. The recent" exact="Zika" post="virus outbreak and birth defects associated with infection in"/>
   <result pre="hemorrhagic fever, and the filoviruses Marburg and Ebola. LibratyDaniel H.36.1" exact="Dengue" post="and Dengue Hemorrhagic Fever Abstract Dengue is the most"/>
   <result pre="and the filoviruses Marburg and Ebola. LibratyDaniel H.36.1 Dengue and" exact="Dengue" post="Hemorrhagic Fever Abstract Dengue is the most common and"/>
   <result pre="and Ebola. LibratyDaniel H.36.1 Dengue and Dengue Hemorrhagic Fever Abstract" exact="Dengue" post="is the most common and significant arboviral disease throughout"/>
   <result pre="dengue virus serotypes (DENVs 1–4). The clinical manifestations of a" exact="DENV" post="infection can range from an inapparent or mild febrile"/>
   <result pre="developing severe dengue is increased in individuals with sequential heterologous" exact="DENV" post="infections. Patients with dengue, or suspected dengue, who manifest"/>
   <result pre="dengue virus serotypes (DENVs 1–4). •The clinical manifestations of a" exact="DENV" post="infection can range from an inapparent or mild febrile"/>
   <result pre="risk for developing DHF/severe dengue is increased with sequential heterologous" exact="DENV" post="infections. •Patients with dengue, or suspected dengue, who manifest"/>
   <result pre="with early recognition and appropriate supportive care and management. Introduction" exact="Dengue" post="is the most prevalent and widespread human arboviral disease"/>
   <result pre="mosquitoes (Fig. 36.1.1 ). In the Asian tropics, all four" exact="DENV" post="serotypes co-circulate, creating a large region of hyper-endemicity. Dengue"/>
   <result pre="four DENV serotypes co-circulate, creating a large region of hyper-endemicity." exact="Dengue" post="outbreaks occur with predictable seasonality and periodicity. The majority"/>
   <result pre="biology, and environmental conditions, a shift in the dominant circulating" exact="DENV" post="serotype typically occurs every 4 to 6 years. The"/>
   <result pre="4 to 6 years. The shift in the dominant circulating" exact="DENV" post="serotype often leads to waves of large-scale epidemic dengue"/>
   <result pre="single infecting serotype. Over the past several decades, Asian genotype" exact="DENV" post="strains have spread throughout the Americas accompanied by increased"/>
   <result pre="spread throughout the Americas accompanied by increased co-circulation of multiple" exact="DENV" post="serotypes.5 As such, the dengue disease and transmission patterns"/>
   <result pre="Pathogenesis, and Pathology The human dengue cycle is maintained by" exact="DENV" post="transmission back and forth between mosquito vectors and viremic"/>
   <result pre="Thereafter, the virus rapidly disseminates, leading to viremia. The likely" exact="DENV" post="factories are tissue macrophages, dendritic cells, and adipocytes. The"/>
   <result pre="and is transient (hours to days). Primary infection with a" exact="DENV" post="serotype produces long-term protective immunity against re-infection with the"/>
   <result pre="(severe dengue) is increased 15- to 100-fold with sequential heterologous" exact="DENV" post="infections (secondary DENV infection) compared with primary DENV infections.3"/>
   <result pre="increased 15- to 100-fold with sequential heterologous DENV infections (secondary" exact="DENV" post="infection) compared with primary DENV infections.3 Most individuals with"/>
   <result pre="sequential heterologous DENV infections (secondary DENV infection) compared with primary" exact="DENV" post="infections.3 Most individuals with secondary DENV infections do not"/>
   <result pre="infection) compared with primary DENV infections.3 Most individuals with secondary" exact="DENV" post="infections do not develop severe dengue. Primary DENV infections"/>
   <result pre="with secondary DENV infections do not develop severe dengue. Primary" exact="DENV" post="infections in infants &amp;lt;12 months old also appear more"/>
   <result pre="more likely to lead to DHF/DSS (severe dengue) than primary" exact="DENV" post="infections in children or adults.12 Numerous risk factors have"/>
   <result pre="Features The most likely outcome of a primary or secondary" exact="DENV" post="infection is either asymptomatic infection or a mild undifferentiated"/>
   <result pre="non-specific constitutional symptoms. This is particularly true in children, whereas" exact="DENV" post="infections may be more likely to present as classic"/>
   <result pre="sparing. The appearance of this rash is pathognomonic for a" exact="DENV" post="infection. DHF/DSS is the dengue clinical syndrome whose distinguishing"/>
   <result pre="dengue, the majority of serious morbidity and mortality caused by" exact="DENV" post="infections is due to a vascular leakage syndrome with"/>
   <result pre="of vascular leakage, particularly in adults. Other uncommon complications of" exact="DENV" post="infections include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike Zika"/>
   <result pre="of DENV infections include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike" exact="Zika" post="virus infection, DENV infection during pregnancy has not been"/>
   <result pre="include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike Zika virus infection," exact="DENV" post="infection during pregnancy has not been associated with congenital"/>
   <result pre="been associated with congenital malformations. TABLE 36.1.1 Case Definitions for" exact="Dengue" post="Hemorrhagic Fever/Dengue Shock Syndrome, Severe Dengue, and the Warning"/>
   <result pre="Shock Syndrome, Severe Dengue, and the Warning Signs for Severe" exact="Dengue" post="[alt-text] TABLE 36.1.1 Case Definition for Dengue Hemorrhagic Fever"/>
   <result pre="Signs for Severe Dengue [alt-text] TABLE 36.1.1 Case Definition for" exact="Dengue" post="Hemorrhagic Fever (DHF) and DHF Severity Classification Case Definition"/>
   <result pre="Fever (DHF) and DHF Severity Classification Case Definition for Severe" exact="Dengue" post="Warning Signs for Severe Dengue Signs/symptoms of dengue fever"/>
   <result pre="Classification Case Definition for Severe Dengue Warning Signs for Severe" exact="Dengue" post="Signs/symptoms of dengue fever and: 1.thrombocytopenia (platelet count &amp;lt;100,000/mm3),"/>
   <result pre="aminotransferase; AST, aspartate transaminase. Patient Evaluation, Diagnosis, and Differential Diagnosis" exact="Dengue" post="should be considered in all individuals in endemic regions,"/>
   <result pre="febrile illness of &amp;lt;10 to 14 days’ duration during the" exact="DENV" post="transmission season. The initial clinical findings in DENV infections"/>
   <result pre="during the DENV transmission season. The initial clinical findings in" exact="DENV" post="infections are fairly non-specific and can be difficult to"/>
   <result pre="malaria. In the appropriate clinical setting, measles, influenza, chikungunya, or" exact="Zika" post="virus infections are also possibilities. Early in the febrile"/>
   <result pre="possibilities. Early in the febrile course, the suspicion for a" exact="DENV" post="infection can be heightened by the presence of leukopenia,"/>
   <result pre="during the rainy season).17, 19 The critical phase of any" exact="DENV" post="infection is the 24 to 48 hours surrounding defervescence—generally"/>
   <result pre="5 to 7 of the febrile illness in a secondary" exact="DENV" post="infection. This is the time period when plasma leakage"/>
   <result pre="Laboratory diagnosis remains the most reliable way to identify a" exact="DENV" post="infection. Reverse transcriptase polymerase chain reaction (RT-PCR) can detect"/>
   <result pre="infections and 3 to 4 days in secondary infections. However," exact="DENV" post="RT-PCR is not routinely available in most clinical settings."/>
   <result pre="detected by antigen-detection assays that measure circulating levels of a" exact="DENV" post="non-structural protein, NS1. The timeline for detectable circulating soluble"/>
   <result pre="be affected by other flavivirus infections (e.g., Japanese encephalitis virus," exact="Zika" post="virus). Therefore the diagnostic sensitivity and specificity of anti-DENV"/>
   <result pre="with early recognition and appropriate supportive care and management. Prevention" exact="Dengue" post="prevention can be approached by strategies to minimize human–vector"/>
   <result pre="objects (e.g., used tires), and natural habitats (e.g., tree holes)." exact="Dengue" post="vaccine development has moved forward with encouraging advances. Given"/>
   <result pre="potential for increased disease severity upon sequential infection with heterologous" exact="DENV" post="serotypes, a general consensus has been that effective vaccination"/>
   <result pre="effective vaccination strategies will require simultaneous immunization to the four" exact="DENV" post="serotypes (tetravalent vaccines). A chimeric live-attenuated viral vaccine, where"/>
   <result pre="able to enhance the subsequent disease severity with a natural" exact="DENV" post="infection. Another tetravalent live-attenuated dengue vaccine (attenuated by a"/>
   <result pre="open up the possibility of severely halting, or even eradicating," exact="DENV" post="transmission in many endemic regions. References References 1VasilakisNWeaverSCThe history"/>
   <result pre="febrile illnesses in endemic populationsTrop Med Int Health1320081328134018803612 PowersAnn M.36.2" exact="Chikungunya" post="Fever Abstract Chikungunya fever is a re-emerging arboviral disease"/>
   <result pre="endemic populationsTrop Med Int Health1320081328134018803612 PowersAnn M.36.2 Chikungunya Fever Abstract" exact="Chikungunya" post="fever is a re-emerging arboviral disease characterized by the"/>
   <result pre="of the virus is by forest-dwelling Aedes species mosquitoes. Introduction" exact="Chikungunya" post="(CHIK) fever is an arboviral disease that is characterized"/>
   <result pre="cases of chikungunya fever. Fig. 36.2.2 Global distribution of autochthonous" exact="CHIKV" post="(as of 2016). Epidemiology The first recorded epidemic occurred"/>
   <result pre="first recorded epidemic occurred in Tanzania in 1952–1953. In Asia," exact="CHIKV" post="was first detected in Bangkok, Thailand, in 1958. In"/>
   <result pre="Reunion, Mayotte, Mauritius, and Seychelles, beginning in 2004.4, 5, 6" exact="CHIKV" post="then re-emerged in India in December 2005. The 2005–2006"/>
   <result pre="efficiently infect the secondary vector, A. albopictus.3 Imported cases of" exact="CHIKV" post="infection were reported from Europe and North and South"/>
   <result pre="of cases, but deaths are rarely encountered. Diagnosis Symptoms of" exact="CHIKV" post="infection can be clinically indistinguishable from dengue fever. Other"/>
   <result pre="diagnosis of CHIK include malaria, O'nyong nyong, Sindbis, Ross River," exact="West Nile," post="and Zika virus infections.9, 15, 16 The clinical laboratory"/>
   <result pre="include malaria, O'nyong nyong, Sindbis, Ross River, West Nile, and" exact="Zika" post="virus infections.9, 15, 16 The clinical laboratory findings in"/>
   <result pre="Because no vaccine or specific medication is yet available against" exact="CHIKV" post="infection, vector control is very important in controlling or"/>
   <result pre="and vector control of chikungunyaJ Infect Dis2142016S4596527920174 ChenLin H.WilsonMary E.36.3" exact="Zika" post="Abstract Zika virus is a Flavivirus identified in 1947"/>
   <result pre="control of chikungunyaJ Infect Dis2142016S4596527920174 ChenLin H.WilsonMary E.36.3 Zika Abstract" exact="Zika" post="virus is a Flavivirus identified in 1947 transmitted by"/>
   <result pre="in 1947 transmitted by Aedes mosquitoes. It remained obscure until" exact="Zika" post="outbreaks erupted in Yap in 2007, French Polynesia in"/>
   <result pre="Asia and Africa, and importations by travelers are well documented." exact="Zika" post="virus infection causes typically mild symptoms (or is asymptomatic),"/>
   <result pre="to severe microcephaly and other birth defects. The symptoms of" exact="Zika" post="resemble those of dengue and chikungunya virus infections, and"/>
   <result pre="Zika resemble those of dengue and chikungunya virus infections, and" exact="Zika" post="testing has limitations in terms of availability, sensitivity, and"/>
   <result pre="shedding in semen. Transfusion-related transmission has also occurred. Prevention of" exact="Zika" post="virus infection rests on avoidance of vector mosquitoes and"/>
   <result pre="during pregnancy to reduce the occurrence of congenital infection. Keywords" exact="Zika" post="congenital Zika syndrome microcephaly flavivirus arbovirus Guillain–Barré syndrome travel"/>
   <result pre="to reduce the occurrence of congenital infection. Keywords Zika congenital" exact="Zika" post="syndrome microcephaly flavivirus arbovirus Guillain–Barré syndrome travel in utero"/>
   <result pre="severe birth defects. •There is no anti-viral agent to treat" exact="Zika" post="virus infection; supportive care is indicated. •There is no"/>
   <result pre="for pregnant women and persons who are planning conception. Introduction" exact="Zika" post="virus, a single-stranded RNA virus of the Flaviviridae family,"/>
   <result pre="the Americas. Intense research activities have answered key questions about" exact="Zika" post="virus, its spread, and control, but gaps in knowledge"/>
   <result pre="its spread, and control, but gaps in knowledge remain. Epidemiology" exact="Zika" post="virus, first isolated from a sentinel rhesus monkey in"/>
   <result pre="virus, first isolated from a sentinel rhesus monkey in the" exact="Zika" post="forest in Uganda in 1947, was found in the"/>
   <result pre="in mild human infections in Africa and Asia. In 2007" exact="Zika" post="virus caused a large outbreak on Yap Island (western"/>
   <result pre="a major outbreak in French Polynesia in 2013 to 2014.2" exact="Zika" post="virus was first associated with recognized outbreaks in Brazil"/>
   <result pre="but recent analyses using sequencing, molecular mapping, and modeling suggest" exact="Zika" post="reached the Americas as early as 2013, with cryptic"/>
   <result pre="and ecoclimatic conditions are favorable.7 Fig. 36.3.1 Recent status of" exact="Zika" post="virus transmission. Transmission Infection is spread primarily via infected"/>
   <result pre="which can survive in more temperate areas, can also transmit" exact="Zika" post="virus. These mosquito vectors infest most sub-tropical and tropical"/>
   <result pre="chikungunya (and co-transmission can occur). In the past 10 years," exact="Zika" post="transmission has been reported from at least 84 countries.6"/>
   <result pre="Zika transmission has been reported from at least 84 countries.6" exact="Zika" post="virus can be transmitted vertically in A. aegypti mosquitoes."/>
   <result pre="aegypti provides a suitable environment for transmission. Of the 5413" exact="Zika" post="virus disease cases (excluding congenital cases) reported in the"/>
   <result pre="virus up to 69 days. In a longitudinal assessment of" exact="Zika" post="virus RNA in body fluids, 95% of men had"/>
   <result pre="is vector borne and how much infection is sexually transmitted." exact="Zika" post="virus particles and RNA have been found in breast"/>
   <result pre="island found 1.1% viremic.13 Pathogenesis and Pathology Perinatal transmission of" exact="Zika" post="virus was reported to occur in the French Polynesia"/>
   <result pre="Polynesia outbreak in 2013 to 2014, but the association between" exact="Zika" post="virus and microcephaly was not recognized until the observations"/>
   <result pre="was done in 2016 based on serologic and surveillance data.14" exact="Zika" post="virus can infect the placenta, reach the developing fetus,"/>
   <result pre="live-born infants from completed pregnancies with laboratory evidence of possible" exact="Zika" post="virus infection), about 5% had Zika-associated birth defects. The"/>
   <result pre="4%, respectively, for first, second, and third trimesters).18 Clinical Features" exact="Zika" post="virus seroprevalence studies in Yap and French Polynesia estimated"/>
   <result pre="Rarely, some severe complications in adults have been attributed to" exact="Zika" post="virus infection, particularly neurologic disorders (GBS, myelitis, demyelinating polyneuropathy,"/>
   <result pre="immune-mediated thrombocytopenia.23, 25, 26, 27 GBS occurred in about 1/4000" exact="Zika" post="infections in studies from French Polynesia and Brazil, at"/>
   <result pre="(6%), and 51% have chronic pain.27 As described earlier, congenital" exact="Zika" post="syndrome resulting from infection during pregnancy is associated with"/>
   <result pre="Patient Evaluation, Diagnosis, and Differential Diagnosis During acute infection with" exact="Zika" post="virus, laboratory findings may reveal leukopenia, lymphopenia, thrombocytopenia, and"/>
   <result pre="be mildly elevated, as well as transaminases. Recommendations for confirmatory" exact="Zika" post="virus testing vary among countries and have evolved over"/>
   <result pre="recommendations and interpretation of results for symptomatic persons with possible" exact="Zika" post="virus exposure. (A) Pregnant women. Testing recommendations and interpretation"/>
   <result pre="recommendations and interpretation of results for symptomatic persons with possible" exact="Zika" post="virus exposure. (B) Non-pregnant women. Definitive Zika diagnosis can"/>
   <result pre="persons with possible Zika virus exposure. (B) Non-pregnant women. Definitive" exact="Zika" post="diagnosis can be made by detection of viral RNA"/>
   <result pre="symptom onset or exposure28, 29 (see Fig. 36.3.2). Detection of" exact="Zika" post="IgM by IgM-capture enzyme-linked immunosorbent assay (MAC-ELISA) followed by"/>
   <result pre="plaque reduction neutralization test (PRNT) can also establish the diagnosis." exact="Zika" post="IgM may be reactive when performed 2 to 12"/>
   <result pre="to 12 weeks after exposure, but can persist longer. Unfortunately," exact="Zika" post="serology cross-reacts with other flaviviruses, and PRNT, which is"/>
   <result pre="where IgG is available to assess past infection and immunity," exact="Zika" post="IgG is not available in the United States. There"/>
   <result pre="and Drug Administration (FDA)–licensed diagnostic tests for the diagnosis of" exact="Zika" post="virus infection, but several diagnostic tests are available under"/>
   <result pre="performs PRNT. In October 2017, the FDA approved the first" exact="Zika" post="test for screening blood donations. The main differential diagnoses"/>
   <result pre="test for screening blood donations. The main differential diagnoses for" exact="Zika" post="virus infection are other viruses transmitted by Aedes mosquitoes,"/>
   <result pre="followed by PRNT is desirable. Other diagnoses that may resemble" exact="Zika" post="virus infections include rubeola, rubella, parvovirus, West Nile virus,"/>
   <result pre="that may resemble Zika virus infections include rubeola, rubella, parvovirus," exact="West Nile" post="virus, and many other viruses, as well as leptospirosis,"/>
   <result pre="and malaria. Treatment and Prevention Treatment for the typical uncomplicated" exact="Zika" post="virus infection aims to provide symptomatic relief. There is"/>
   <result pre="provide symptomatic relief. There is no known specific medication targeting" exact="Zika" post="virus. However, research is underway to assess the effect"/>
   <result pre="underway to assess the effect of some existing drugs on" exact="Zika" post="virus. Preliminary investigations have identified some candidate drugs: emricasan,"/>
   <result pre="lactoferrin.9 Further evaluation is needed regarding their potential activity against" exact="Zika" post="virus. Currently there is no vaccine to prevent Zika"/>
   <result pre="against Zika virus. Currently there is no vaccine to prevent" exact="Zika" post="virus infection but multiple candidate vaccines are under development"/>
   <result pre="and sexual transmission is fundamental in prevention. The impact of" exact="Zika" post="virus infection is most consequential during pregnancy; thus preventing"/>
   <result pre="conception include the following: avoid travel to areas with active" exact="Zika" post="virus transmission, take measures to avoid mosquito bites, and"/>
   <result pre="to reduce risk from sexual transmission. In areas with active" exact="Zika" post="virus transmission, vector control measures are essential. Updated epidemiology"/>
   <result pre="Med3602420092536254319516034 2MussoDGublerDJZika virusClin Microbiol Rev293201648752427029595 3FariaNRQuickJClaroIMEstablishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping"/>
   <result pre="virus in Brazil and the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping of" exact="Zika" post="spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of Zika virus in the AmericasPNAS114222017E43344328442561 6WHOSituation"/>
   <result pre="the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping of Zika spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of" exact="Zika" post="virus in the AmericasPNAS114222017E43344328442561 6WHOSituation Report: Zika virus, microcephaly,"/>
   <result pre="spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of Zika virus in the AmericasPNAS114222017E43344328442561 6WHOSituation Report:" exact="Zika" post="virus, microcephaly, Guillain-Barre syndromehttp://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/2017 7collab: The Singapore Study GroupOutbreak"/>
   <result pre="virus, microcephaly, Guillain-Barre syndromehttp://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/2017 7collab: The Singapore Study GroupOutbreak of" exact="Zika" post="virus infection in Singapore: an epidemiological, entomological, virological, and"/>
   <result pre="epidemiological, entomological, virological, and clinical analysisLancet Infect Dis17201781382128527892 8AlthouseBMVasilakisNSallAAPotential for" exact="Zika" post="virus to establish a sylvatic transmission cycle in the"/>
   <result pre="Dis10122016e000505527977671 9HamerDHWilsonMEJeanJChenLHEpidemiology, prevention, and potential future treatments of sexually transmitted" exact="Zika" post="virus infectionCurr Infect Dis Rep19420171628281082 10Paz-BaileyGRosenbergESDoyleKPersistence of Zika virus"/>
   <result pre="sexually transmitted Zika virus infectionCurr Infect Dis Rep19420171628281082 10Paz-BaileyGRosenbergESDoyleKPersistence of" exact="Zika" post="virus in body fluids – final reportN Engl J"/>
   <result pre="reportN Engl J Med3791320171234124328195756 11MottaIJFSpencerBRCordeiro da SilvaSGEvidence for transmission of" exact="Zika" post="virus by platelet transfusionN Engl J Med37520161101110327532622 12GalelSAWilliamsonPCBuschMPFirst Zika-positive"/>
   <result pre="in the continental United StatesTransfusion57201776276928164310 13KuehnertMJBasavarajuSVMoseleyRRScreening of blood donations for" exact="Zika" post="virus infection – Puerto Rico, April 3-June 11, 2016MMWR"/>
   <result pre="April 3-June 11, 2016MMWR Morb Mortal Wkly Rep65201662762827337368 14CauchemezSBesnardMBompardPAssociation between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013-15: a retrospective"/>
   <result pre="and microcephaly in French Polynesia, 2013-15: a retrospective studyLancet3871003320162125213226993883 15HoneinMADawsonALPetersenEEUS" exact="Zika" post="pregnancy registry collaboration. Birth defects among fetuses and infants"/>
   <result pre="fetuses and infants of US women with evidence of possible" exact="Zika" post="virus infection during pregnancyJAMA31712017596827960197 16MooreCAStaplesJEDobynsWBCharacterizing the pattern of anomalies"/>
   <result pre="infection during pregnancyJAMA31712017596827960197 16MooreCAStaplesJEDobynsWBCharacterizing the pattern of anomalies in congenital" exact="Zika" post="syndrome for pediatric cliniciansJAMA Pediatr1713201728829527812690 17SousaAQCavalcanteDIMFrancoLMPostmortem findings for 7"/>
   <result pre="pediatric cliniciansJAMA Pediatr1713201728829527812690 17SousaAQCavalcanteDIMFrancoLMPostmortem findings for 7 neotates with congenital" exact="Zika" post="virus infectionEmerg Infect Dis2320171164116728459414 18Shapiro-MendozaCRiceMEGalangRRPregnancy outcomes after maternal Zika"/>
   <result pre="congenital Zika virus infectionEmerg Infect Dis2320171164116728459414 18Shapiro-MendozaCRiceMEGalangRRPregnancy outcomes after maternal" exact="Zika" post="virus infection during pregnancy- U.S. territories, January 1, 2016-April"/>
   <result pre="characterization, epidemiological and virological aspectsPLoS Negl Trop Dis1042016e000463627070912 21DirlikovERyffKRTorres-AponteJUpdate: ongoing" exact="Zika" post="virus transmission, Puerto Rico, November 1, 2015 – April"/>
   <result pre="2015 – April 14, 2016MMWR Morb Mortal Wkly Rep6517201645145527149205 22ArmstrongPHennesseyMAdamsMTravel-associated" exact="Zika" post="virus disease cases among U.S. Residents - United States,"/>
   <result pre="2015-February 2016MMWR Morb Mortal Wkly Rep6511201628628927023833 23HamerDHBarbreKAChenLHGeoSentinel surveillance network. travel-associated" exact="Zika" post="virus disease acquired in the Americas through February 2016:"/>
   <result pre="analysisAnn Intern Med166220179910827893080 24GoodmanABDziubanEJPowellKCharacteristics of children aged &amp;lt;18 years with" exact="Zika" post="virus disease acquired postnatally - U.S. States, January 2015-July"/>
   <result pre="2016MMWR Morb Mortal Wkly Rep653920161082108527711041 25Cao-LormeauVMBlakeAMonsSGuillain-Barré syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet3871002720161531153926948433 26ParraBLizarazoJJiménez-ArangoJAGuillain-Barré"/>
   <result pre="in French Polynesia: a case-control studyLancet3871002720161531153926948433 26ParraBLizarazoJJiménez-ArangoJAGuillain-Barré syndrome associated with" exact="Zika" post="virus infection in ColombiaN Engl J Med3751620161513152327705091 27Da SilvaIRFFronteraJABispo"/>
   <result pre="J Med3751620161513152327705091 27Da SilvaIRFFronteraJABispo de FilippisAMNeurologic complications associated with the" exact="Zika" post="virus in Brazilian adultsJAMA Neurol741020171190119828806453 28OduyeboTPolenKDWalkeHTUpdate: interim guidance for"/>
   <result pre="for health care providers caring for pregnant women with possible" exact="Zika" post="virus exposure - United States (including U.S. territories), July"/>
   <result pre="Morb Mortal Wkly Rep6629201778179328749921 29CDCGuidance for US Laboratories Testing for" exact="Zika" post="Virus Infectionhttps://www.cdc.gov/zika/laboratories/lab-guidance.html2017 DeyeGregoryKorenMichael36.4 O'nyong Nyong Fever Abstract O'nyong nyong"/>
   <result pre="of serologic results because of a well-known, one-way cross-reactivity with" exact="CHIKV" post="(i.e., patients previously infected with chikungunya will develop cross-reactive"/>
   <result pre="molecular biology approaches are more indicated to confirm MAYV and/or" exact="CHIKV" post="infection; indeed, the real-time polymerase chain reaction (PCR) is"/>
   <result pre="of fever, arthralgia, and rash, particularly dengue, Oropouche, chikungunya, and" exact="Zika" post="fever viruses. The laboratory diagnosis of Mayaro fever either"/>
   <result pre="ELISA, and neutralization assays.31 Differential diagnosis may include ehrlichiosis, anaplasmosis," exact="West Nile" post="virus infection, rickettsial infection, leptospirosis, and other etiologies. Treatment"/>
   <result pre="outbreaks have notably been reported in conjunction with outbreaks of" exact="West Nile" post="virus infection as they share the same Culex mosquito"/>
   <result pre="(Pogosta) virus in different parts of FinlandRheumatology425200363263612709538 8McIntoshBJuppPDos SantosIMeenehanGEpidemics of" exact="West Nile" post="and Sindbis viruses in South Africa with Culex (Culex)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7151825\results\search\tropicalVirus\results.xml">
   <result pre="travel-related infections in the significantly immunosuppressed traveler 6.1 Yellow Fever" exact="Yellow fever" post="virus is a flavivirus spread by the Aedes aegypti"/>
   <result pre="to reduce the spread of disease across international boarders [16]." exact="Yellow fever" post="is one of the only infectious diseases where a"/>
   <result pre="[20], and an example may be viewed here https://nathnacyfzone.org.uk/factsheet/6/medical-letter-of-exemption [21]." exact="Yellow fever" post="is a notifiable disease in many countries. 6.2 Typhoid"/>
   <result pre="new geographic area or population [101]. Recent examples include the" exact="Zika" post="virus outbreak in Latin America and the Ebola outbreak"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7151829\results\search\tropicalVirus\results.xml">
   <result pre="New viruses and devastating communicable diseases such as Ebola and" exact="Zika" post="are emerging; diseases previously considered eradicated such as measles"/>
   <result pre="prevent this threat to humankind. Keywords Antibiotic resistance Anti-vaccination movement" exact="Chikungunya" post="Dengue Disease ecology Disease mapping Genotype Globalization HIV/AIDS Polio"/>
   <result pre="this threat to humankind. Keywords Antibiotic resistance Anti-vaccination movement Chikungunya" exact="Dengue" post="Disease ecology Disease mapping Genotype Globalization HIV/AIDS Polio Tuberculosis"/>
   <result pre="Dengue Disease ecology Disease mapping Genotype Globalization HIV/AIDS Polio Tuberculosis" exact="Zika" post="virus Despite technological advances in medicine, communicable diseases are"/>
   <result pre="be endemic in Africa, Southeast Asia, and the Pacific Islands," exact="Zika" post="virus (ZIKAV) was first identified in Brazil in 2015"/>
   <result pre="than 25,000 residents of the Greater Toronto Area in quarantine." exact="Dengue" post="Dengue is transmitted by the mosquitoes Aedes aegypti and"/>
   <result pre="25,000 residents of the Greater Toronto Area in quarantine. Dengue" exact="Dengue" post="is transmitted by the mosquitoes Aedes aegypti and Aedes"/>
   <result pre="large numbers of people become infected during a short period." exact="Dengue" post="epidemics require a coincidence of large numbers of vector"/>
   <result pre="immunity to one of the four virus types (DENV 1," exact="DENV" post="2, DENV 3, DENV 4), and the opportunity for"/>
   <result pre="one of the four virus types (DENV 1, DENV 2," exact="DENV" post="3, DENV 4), and the opportunity for contact between"/>
   <result pre="the four virus types (DENV 1, DENV 2, DENV 3," exact="DENV" post="4), and the opportunity for contact between the two."/>
   <result pre="population, live in areas with a risk of dengue transmission." exact="Dengue" post="is endemic in at least 100 countries in Asia,"/>
   <result pre="including 500,000 DHF cases and 22,000 deaths, mostly among children." exact="Chikungunya" post="Chikungunya virus is most often spread to people by"/>
   <result pre="500,000 DHF cases and 22,000 deaths, mostly among children. Chikungunya" exact="Chikungunya" post="virus is most often spread to people by Aedes"/>
   <result pre="Aedes albopictus mosquitoes, the same mosquitoes that transmit dengue virus." exact="Chikungunya" post="was first described during an outbreak in southern Tanzania"/>
   <result pre="disease tracking, surveillance, and control has burgeoned. Recent examples include" exact="West Nile" post="virus and TB control. Cromley and McLafferty provide an"/>
   <result pre="southern United States and CaliforniaAnnal. Global Health806November–December 2014466475 HallV.WalkerW.L.LindseyN.P.Update: noncongenital" exact="Zika" post="virus disease cases — 50 U.S. States and the"/>
   <result pre="United States, 2010–2014Am. J. Trop. Med. Hyg.95201621221527139440 HerreraB.B.ChangC.A.HamelD.J.Continued transmission of" exact="Zika" post="virus in humans in west Africa, 1992–2016J. Infect. Dis.21520171546155028398562"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152027\results\search\tropicalVirus\results.xml">
   <result pre="tropical infection in travelers, but epidemics of dengue, chikungunya, and" exact="Zika" post="emphasize that clinicians need to be aware of the"/>
   <result pre="Acute schistosomiasis(Katayama)Amebic liver abscessBrucellosisDengueEnteric feverMeningococcus HistoplasmosisOther arbovirus (e.g., Rift Valley," exact="West Nile" post="fever, yellow fever)TrypanosomiasisViral hemorrhagic fever (Lassa, Ebola, Marburg, CCHF)Visceral"/>
   <result pre="hemorrhagic fever) •Acute encephalitis (e.g., Japanese encephalitis, Rift Valley fever," exact="West Nile" post="virus, Eastern and Western equine encephalitis viruses) •Polyarthralgia or"/>
   <result pre="equine encephalitis viruses) •Polyarthralgia or arthritis (e.g., chikungunya, Ross River)" exact="Dengue" post="is the most common arbovirus in travelers. Although widespread,"/>
   <result pre="holiday (sunburn, headache, feverish). Symptoms have not settled. Diagnosis: dengue." exact="Chikungunya" post="has a distribution similar to dengue with large epidemics"/>
   <result pre="with pain, stiffness and swelling lasting months to years.17, 18" exact="Zika" post="virus has caused large outbreaks in the Caribbean, South"/>
   <result pre="However, Guillain–Barré syndrome can be a complication, and during pregnancy" exact="Zika" post="can lead to stillbirth and is associated with congenital"/>
   <result pre="associated with congenital abnormalities, including fetal microcephaly. Sexual transmission of" exact="Zika" post="is well described.19 No clinical features reliably distinguish dengue,"/>
   <result pre="well described.19 No clinical features reliably distinguish dengue, chikungunya, and" exact="Zika" post="infection, although thrombocytopenia is normally more pronounced in dengue.20"/>
   <result pre="to typical causes of encephalitis, travel-related causes are arboviruses (e.g.," exact="West Nile" post="virus, Japanese encephalitis, tick-borne encephalitis), brucellosis, rabies, rickettsial infections,"/>
   <result pre="toxin–related syndromes (e.g., toxic shock syndrome, scarlet fever)SunburnVibrio vulnificus Purpuric" exact="Dengue" post="hemorrhagic syndromeGonococcal infectionHerpes zoster virus, hemorrhagicMeningococcal infectionPlagueRickettsial infection, severeSevere"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152899\results\search\tropicalVirus\results.xml">
   <result pre="•Coronaviridae: severe acute respiratory syndrome virus •Filoviridae: Ebola virus •Flaviviridae:" exact="Dengue" post="virus, West Nile virus, yellow fever virus, Zika virus"/>
   <result pre="acute respiratory syndrome virus •Filoviridae: Ebola virus •Flaviviridae: Dengue virus," exact="West Nile" post="virus, yellow fever virus, Zika virus •Orthomyxoviridae: influenza virus"/>
   <result pre="virus •Flaviviridae: Dengue virus, West Nile virus, yellow fever virus," exact="Zika" post="virus •Orthomyxoviridae: influenza virus •Paramyxoviridae: measles morbillivirus •Parvoviridae: parvovirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7153335\results\search\tropicalVirus\results.xml">
   <result pre="acute respiratory syndrome), MERS (Middle East respiratory syndrome), Ebola, and" exact="Zika" post="viruses. By controlling infections, we can reduce premature death"/>
   <result pre="testing three transmission types of infectious diseases, tuberculosis (air borne)," exact="Dengue" post="(vector borne), and Cholera-India (water/food borne) the authors showed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7153856\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Computer and Information Sciences : Computer Networks:"/>
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Social Sciences : Sociology: Culture : Social"/>
   <result pre="minimize the impact that diseases such as dengue, chikungunya and" exact="Zika" post="have on populations. This study aimed to understand RC"/>
   <result pre="Author summary Vector-borne diseases (VBDs) such as dengue, chikungunya and" exact="Zika" post="are an increasing public health concern worldwide. The mentioned"/>
   <result pre="Health Research Institute) e-mail address: e.martina@cbhri.com. Introduction Dengue, chikungunya, and" exact="Zika" post="are an increasing global public health concern as a"/>
   <result pre="dramatically increased burden of disease and rapid geographical spread [1–4]." exact="Dengue" post="is the most important arthropod-borne viral disease in humans."/>
   <result pre="a proportion of cases progresses to the chronic stage of" exact="CHIKV" post="infection, in which some symptoms, such as arthralgia, last"/>
   <result pre="such as arthralgia, last for months to years [6, 7]." exact="Zika" post="virus (ZIKV) infection has been linked to adverse fetal"/>
   <result pre="aforementioned complications [11]. In the Caribbean, the primary vector of" exact="DENV" post="(Flavivirus), CHIKV (Alphavirus) and ZIKV (Flavivirus) is Aedes aegypti"/>
   <result pre="[11]. In the Caribbean, the primary vector of DENV (Flavivirus)," exact="CHIKV" post="(Alphavirus) and ZIKV (Flavivirus) is Aedes aegypti [12]. Ae."/>
   <result pre="Caribbean, the primary vector of DENV (Flavivirus), CHIKV (Alphavirus) and" exact="ZIKV" post="(Flavivirus) is Aedes aegypti [12]. Ae. aegypti is a"/>
   <result pre="[14]. According to local health authorities, dengue epidemics occur cyclically." exact="CHIKV" post="caused a significant outbreak in 2014–2015, affecting up to"/>
   <result pre="and Nature of Curaçao, 2016). In 2016, the introduction of" exact="ZIKV" post="caused another major outbreak in the country. The Department"/>
   <result pre="2015 up to August 2017, a total of 2314 laboratory-confirmed" exact="ZIKV" post="cases were recorded. However, it should be noted that"/>
   <result pre="were infected, as up to 80% of the individuals with" exact="ZIKV" post="infection are asymptomatic and not everyone experiencing symptoms, which"/>
   <result pre="least 50% of the local population had been infected with" exact="ZIKV" post="(I. Gerstenbluth, personal communication). This is comparable to the"/>
   <result pre="Island (73%) [16, 17]. The treatment of dengue, chikungunya, and" exact="Zika" post="relies on supportive treatment and symptom relief since there"/>
   <result pre="adults. The IDIs were conducted among twenty adults with laboratory-confirmed" exact="CHIKV" post="infection. The number of FGDs and IDIs needed in"/>
   <result pre="2014–2015 chikungunya epidemic, adult subjects with serologically or clinically confirmed" exact="CHIKV" post="infection were selected from a representative patient sample from"/>
   <result pre="and chikungunya chronic disease persistence by applying the Curaçao Long-term" exact="Chikungunya" post="Sequelae Score (CLTCS Score) to measure the perceived severity"/>
   <result pre="agreed that everyone in the community was potentially susceptible to" exact="DENV" post="infection, regardless of his or her age. According to"/>
   <result pre="age. According to the participants of both FGDs and IDIs," exact="DENV" post="infection is not a severe disease, because the symptoms"/>
   <result pre="flu-like. However, they were well-informed about the severe consequences of" exact="DENV" post="infection. In the case of the survey participants, 67%"/>
   <result pre="survey participants, 67% and 60% of them fully agreed that" exact="DENV" post="infection is a serious condition and that people who"/>
   <result pre="a moderate-high perceived susceptibility and a moderate-high perceived severity of" exact="DENV" post="infection. In the case of CHIKV infection, the majority"/>
   <result pre="moderate-high perceived severity of DENV infection. In the case of" exact="CHIKV" post="infection, the majority of the participants of both FGDs"/>
   <result pre="FGDs and IDIs did not expect to be infected with" exact="CHIKV" post="because they were not informed, before the epidemic, about"/>
   <result pre="they were not informed, before the epidemic, about a possible" exact="CHIKV" post="infection outbreak. The qualitative data suggested that the perceived"/>
   <result pre="suggested that the perceived susceptibility and the perceived severity regarding" exact="CHIKV" post="infection were attenuated due to the lack of RC."/>
   <result pre="When prompted to discuss gender and age differences related to" exact="CHIKV" post="infection, a proportion of the participants of the FGDs"/>
   <result pre="IDIs perceived that the youth was less at risk of" exact="CHIKV" post="infection as their immune system was stated to be"/>
   <result pre="with CHIKV. When participants were asked about the severity of" exact="CHIKV" post="infection, all the participants of the qualitative study stated"/>
   <result pre="had a moderate-low perceived susceptibility and moderate-high perceived severity regarding" exact="CHIKV" post="infection. The influence of cultural schemas on information, perceptions"/>
   <result pre="of the participants of the FGDs and IDIs indicated that" exact="CHIKV" post="and DENV are transmitted by infected mosquitoes. However, some"/>
   <result pre="participants of the FGDs and IDIs indicated that CHIKV and" exact="DENV" post="are transmitted by infected mosquitoes. However, some of the"/>
   <result pre="by infected mosquitoes. However, some of the participants reported that" exact="CHIKV" post="was also transmitted via air, unhygienic conditions, water or"/>
   <result pre="were the basis for doubting the vector transmission route of" exact="DENV" post="and CHIKV. Preventive measures Various preventive measures were mentioned"/>
   <result pre="vitamins, and having a good immune system protects them against" exact="CHIKV" post="and DENV infection: Female 1:&quot;Hmm, yes. In my case,"/>
   <result pre="having a good immune system protects them against CHIKV and" exact="DENV" post="infection: Female 1:&quot;Hmm, yes. In my case, someone told"/>
   <result pre="their immune system and subsequently also prevent them from acquiring" exact="CHIKV" post="infection. These perceptions are based on the cultural schemas"/>
   <result pre="their perceptions and expectations regarding the treatment of, mainly, the" exact="CHIKV" post="infection. The participants reported that people went to the"/>
   <result pre="GP, because the GP did not have a cure for" exact="CHIKV" post="infection. Furthermore, some participants indicated that when they failed"/>
   <result pre="indicated that when they failed to find a cure for" exact="CHIKV" post="infection, they became confused: &quot;Yes, because eh, I was"/>
   <result pre="believed to increase the platelet levels in patients infected with" exact="DENV" post="and CHIKV, and in turn, reduced the severity of"/>
   <result pre="medicine, such as papaya, mango and soursop leaves, to treat" exact="CHIKV" post="and possibly DENV infection. The results of the survey"/>
   <result pre="papaya, mango and soursop leaves, to treat CHIKV and possibly" exact="DENV" post="infection. The results of the survey showed that 30.5%"/>
   <result pre="of 337 study participants used mango leaves to treat the" exact="CHIKV" post="infection (Fig 1). The use of mango leaves was"/>
   <result pre="translator, age not documented, IDI. Fig 1 Treatment options for" exact="CHIKV" post="infection. a Values are percentages of available participants who"/>
   <result pre="who reported the remedies that they used to treat the" exact="CHIKV" post="infection. Various options could be indicated. *The variable Non-Steroidal"/>
   <result pre="plenty of liquids, mainly water, would help them combat the" exact="CHIKV" post="infection. The survey showed that 61% of 338 participants"/>
   <result pre="Shilling oil and Alcolado Glacial to treat the symptoms of" exact="CHIKV" post="infection. Alcolado Glacial is a mentholated splash lotion that"/>
   <result pre="study revealed that people used multiple treatment options to treat" exact="CHIKV" post="infection (Fig 1). According to the participant’s narratives, people"/>
   <result pre="the fact that there was no treatment to cure the" exact="CHIKV" post="infection: Moderator:&quot;Okay, Many people used different types of medication."/>
   <result pre="the wide range of interventions people were exploring to treat" exact="CHIKV" post="infection. Trust in the channel of information Some participants"/>
   <result pre="played an essential role in the provision of information regarding" exact="DENV" post="and CHIKV infection. As mentioned above, some participants reported"/>
   <result pre="essential role in the provision of information regarding DENV and" exact="CHIKV" post="infection. As mentioned above, some participants reported turning to"/>
   <result pre="data of our study showed how the risk perception regarding" exact="CHIKV" post="infection was attenuated due to the lack of RC"/>
   <result pre="the direct and indirect experience of the physical manifestation of" exact="CHIKV" post="infection in the peak of the chikungunya epidemic. Based"/>
   <result pre="changes in individuals risk perceptions and protective behaviour regarding the" exact="Zika" post="virus in the United States [34]. They also found"/>
   <result pre="a moderate-high perceived susceptibility and a moderate-high perceived severity of" exact="DENV" post="infection. However, the qualitative data show that people considered"/>
   <result pre="flu-like�?. We believe this relatively high perceived disease severity of" exact="DENV" post="infection is biased by the knowledge of the participants"/>
   <result pre="possible that the participants are aware of the threat of" exact="DENV" post="infection and report it, but that on the other"/>
   <result pre="that on the other hand, they do not really consider" exact="DENV" post="infection as a threat as there have hardly been"/>
   <result pre="the reason for an initially reduced risk perception of the" exact="CHIKV" post="infection. More research is needed to understand the feeling"/>
   <result pre="in our study, with regard to using herbs to treat" exact="CHIKV" post="and possible DENV infection. We showed that individuals’ cultural"/>
   <result pre="with regard to using herbs to treat CHIKV and possible" exact="DENV" post="infection. We showed that individuals’ cultural schemas are possible"/>
   <result pre="herbs did not cure or reduce the symptoms of the" exact="CHIKV" post="infection) did not fit in their cultural schema (e.g."/>
   <result pre="the general practitioners. As the participants perceived that information regarding" exact="CHIKV" post="infection came when the community was already experiencing the"/>
   <result pre="to protect them against health insecurities; in this case, the" exact="CHIKV" post="infection epidemic. This implies that governmental actions during this"/>
   <result pre="10.1016/S1473-3099(16)00026-8 .26874619 3BaudD, GublerDJ, SchaubB, LanteriMC, MussoD. An update on" exact="Zika" post="virus infection. Lancet. 2017;390(10107):2099–109. Epub 2017/06/26. 10.1016/S0140-6736(17)31450-2 .28647173 4Cardona-OspinaJA,"/>
   <result pre="Clin Epidemiol. 2013;5:299–309. Epub 2013/08/31. 10.2147/CLEP.S34440 .23990732 6GanesanVK, DuanB, ReidSP." exact="Chikungunya" post="Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368 Epub 2017/12/02."/>
   <result pre="2017;9(12):368 Epub 2017/12/02. 10.3390/v9120368 .29194359 7GoupilBA, MoresCN. A Review of" exact="Chikungunya" post="Virus-induced Arthralgia: Clinical Manifestations, Therapeutics, and Pathogenesis. Open Rheumatol"/>
   <result pre="NobregaME, VargasA, et al.Increased rates of Guillain-Barre syndrome associated with" exact="Zika" post="virus outbreak in the Salvador metropolitan area, Brazil. PLoS"/>
   <result pre="to Brazil, the major vector of the dengue, chikungunya and" exact="Zika" post="viruses. PLoS Negl Trop Dis. 2017;11(7):e0005653 Epub 2017/07/26. 10.1371/journal.pntd.0005653"/>
   <result pre="OsterhausAD, DuitsAJ, van GorpEC. Climate Factors as Important Determinants of" exact="Dengue" post="Incidence in Curacao. Zoonoses Public Health. 2016;63(2):129–37. 10.1111/zph.12213 .26122819"/>
   <result pre="2016;63(2):129–37. 10.1111/zph.12213 .26122819 15HabyMM, PinartM, EliasV, ReveizL. Prevalence of asymptomatic" exact="Zika" post="virus infection: a systematic review. Bull World Health Organ."/>
   <result pre=".29904223 16CauchemezS, BesnardM, BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–15: a retrospective"/>
   <result pre="J Med. 2009;360(24):2536–43. 10.1056/NEJMoa0805715 .19516034 18SchwameisM, BuchteleN, WadowskiPP, SchoergenhoferC, JilmaB." exact="Chikungunya" post="vaccines in development. Hum Vaccin Immunother. 2016;12(3):716–31. Epub 2015/11/12."/>
   <result pre="Hum Vaccin Immunother. 2016;12(3):716–31. Epub 2015/11/12. 10.1080/21645515.2015.1101197 .26554522 19collab: WHO." exact="Dengue" post="vaccine: WHO position paper—September 2018 [Internet]. Geneva;2018 [cited 2019"/>
   <result pre="November 7]. https://www.who.int/risk-communication/background/en/. 22CovelloVT, PetersRG, WojteckiJG, HydeRC. Risk communication, the" exact="West Nile" post="virus epidemic, and bioterrorism: responding to the communication challenges"/>
   <result pre="during emerging health threats: A multi-wave analysis of communications on" exact="Zika" post="virus cases. Soc Sci Med. 2018;212:50–9. 10.1016/j.socscimed.2018.07.007. 30005224 35Toppenberg-PejcicD,"/>
   <result pre="Epub 2018/03/21. 10.1080/10410236.2017.1405488 .29558199 36AdebayoG, NeumarkY, Gesser-EdelsburgA, Abu AhmadW, LevineH." exact="Zika" post="pandemic online trends, incidence and health risk communication: a"/>
   <result pre="2018;4(1):e16 Epub 2018/02/11. 10.2196/publichealth.8186 .29426815 38OphirY, JamiesonKH. The Effects of" exact="Zika" post="Virus Risk Coverage on Familiarity, Knowledge and Behavior in"/>
   <result pre="46ElsingaJ, GerstenbluthI, van der PloegS, HalabiY, LourentsNT, BurgerhofJG, et al.Long-term" exact="Chikungunya" post="Sequelae in Curacao: Burden, Determinants, and a Novel Classification"/>
   <result pre="everywhere&quot;: A qualitative exploration of knowledge, attitudes and practices towards" exact="Zika" post="virus among women of reproductive age in Iquitos, Peru."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7154088\results\search\tropicalVirus\results.xml">
   <result pre="virus Japanese encephalitis virus (JEV) Mosquitoes CHN, JPN, ROK, TWN" exact="West Nile" post="virus West Nile virus (WNV) Mosquitoes CHN, ROK Kyasanur"/>
   <result pre="virus (JEV) Mosquitoes CHN, JPN, ROK, TWN West Nile virus" exact="West Nile" post="virus (WNV) Mosquitoes CHN, ROK Kyasanur Forest disease virus"/>
   <result pre="Hemorrhagic fever NR BAV Encephalitis NR JEV Encephalomyelitis Encephalomyelitis (cattle)" exact="WNV" post="Febrile illness, encephalitis, meningitis Lymphoplasmacytic meningoencephalitis (sheep) KFDV Hemorrhagic"/>
   <result pre="cattle have been sporadically recorded in Japan (189–193). Outbreaks of" exact="West Nile" post="virus (WNV; species West Nile virus, genus Flavivirus) infection"/>
   <result pre="in Japan (189–193). Outbreaks of West Nile virus (WNV; species" exact="West Nile" post="virus, genus Flavivirus) infection have occurred across the Mediterranean"/>
   <result pre="Europe, Africa, Asia, and North America (194). Human cases of" exact="WNV" post="infection were also reported in western China in 2011,"/>
   <result pre="infection were also reported in western China in 2011, and" exact="WNV" post="was simultaneously isolated from mosquitoes in the affected area"/>
   <result pre="simultaneously isolated from mosquitoes in the affected area (195). The" exact="WNV" post="gene was detected from domestic pigeons in Korea in"/>
   <result pre="that sporadic cases of severe lymphoplasmacytic meningoencephalitis were associated with" exact="WNV" post="in California (197). However, ruminants are not considered hosts"/>
   <result pre="severely affected by WNV, and no ruminant illness associated with" exact="WNV" post="has been recorded in East Asia. Banna virus (BAV),"/>
   <result pre="Japanese encephalitis virus isolate. BMC Vet Res. (2014) 10:6310.1186/1746-6148-10-6324618225 194.McVeyDSWilsonWCGayCG." exact="West Nile" post="virus. Rev Sci Tech. (2015) 34:431–9. 10.20506/rst.34.2.236926601446 195.LuZFuSHCaoLTangCJZhangSLiZXet al.."/>
   <result pre="Sci Tech. (2015) 34:431–9. 10.20506/rst.34.2.236926601446 195.LuZFuSHCaoLTangCJZhangSLiZXet al.. Human infection with" exact="West Nile" post="virus, Xinjiang, China, 2011. Emerg Infect Dis. (2014) 20:1421–3."/>
   <result pre="Infect Dis. (2014) 20:1421–3. 10.3201/eid2008.13143325062043 196.KimCYOhHSongJHurMSuhJHJheongWHet al.. First detection of" exact="West Nile" post="virus in domestic pigeon in Korea. J Vet Sci."/>
   <result pre="pigeon in Korea. J Vet Sci. (2016) 17:587–9. 10.4142/jvs.2016.17.4.58727030190 197.RimoldiGMeteAAdaskaJMAndersonMLSymmesKPDiabS." exact="West Nile" post="virus infection in sheep. Vet Pathol. (2017) 54:155–8. 10.1177/030098581665379627312367"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157200\results\search\tropicalVirus\results.xml">
   <result pre="challenge in nonhuman primatesProc. Natl. Acad. Sci. USA20131101893189810.1073/pnas.120959111023319647 45.EmanuelJ.CallisonJ.DowdK.A.PiersonT.C.FeldmannH.MarziA.A VSV-based" exact="Zika" post="virus vaccine protects mice from lethal challengeSci. Rep.201881104310.1038/s41598-018-29401-x30038228 46.RoseJ.K.ClarkeD.K.PattnaikA.K.WhittM.A.RHABDOVIRUSES"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157486\results\search\tropicalVirus\results.xml">
   <result pre="of vaccines that were in development for such infections as" exact="Zika" post="virus and Lassa virus [11,39,85]. Despite this landmark decision"/>
   <result pre="NatureNew York, NY, USABerlin, Germany2019978-3-319-97636-5 5.SchwartzD.A.Clinical trials and administration of" exact="Zika" post="virus vaccine in pregnant women: Lessons (that should have"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157695\results\search\tropicalVirus\results.xml">
   <result pre="Med.2006121316132210.1038/nm143117057712 28.BiswasS.ChangH.SarkisP.T.N.FikrigE.ZhuQ.MarascoW.A.Humoral immune responses in humanized BLT mice immunized with" exact="West Nile" post="virus and HIV-1 envelope proteins are largely mediated via"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157703\results\search\tropicalVirus\results.xml">
   <result pre="there are no licensed vaccines, such as Ebola, Lassa, or" exact="Zika" post="virus, have been witnessed [5,6,7]. Additionally, the emergence potential"/>
   <result pre="past LAVs, several LAV candidates targeting challenging pathogens such as" exact="Dengue" post="virus [40], Japanese Encephalitis virus [41], West Nile virus"/>
   <result pre="pathogens such as Dengue virus [40], Japanese Encephalitis virus [41]," exact="West Nile" post="virus [42], Zika virus [43], SARS [44], Malaria [45]"/>
   <result pre="virus [40], Japanese Encephalitis virus [41], West Nile virus [42]," exact="Zika" post="virus [43], SARS [44], Malaria [45] or Ebola virus"/>
   <result pre="including yellow fever, measles, polio, and influenza vaccines. Yellow Fever" exact="Yellow fever" post="(YF) is a serious hemorrhagic fever endemic to tropical"/>
   <result pre="Haemogogus, and Sabethes mosquito species [82]. The first isolations of" exact="YFV" post="were obtained through serial passage of the serum of"/>
   <result pre="in macaques and human cohorts and conferred protective immunity against" exact="YFV" post="[85]. This strain is known as YFV-17D and is"/>
   <result pre="is known as YFV-17D and is the basis of all" exact="YFV" post="vaccines used today [86]. Mass vaccination campaigns in Africa"/>
   <result pre="YF have increased [82]. The reason for the spread of" exact="YFV" post="to these areas is unknown, but could be the"/>
   <result pre="of increased human activity in ecosystems where sylvatic cycles of" exact="YFV" post="transmission occur, or due to a widening range of"/>
   <result pre="YFV-17D has a stronger resistance to mutations, and suggested that" exact="YFV" post="attenuation could be related to a higher fidelity of"/>
   <result pre="pathogens such as MV, YFV, dengue virus, Ebola virus or" exact="Zika" post="virus adds an additional layer of limitations to conventional"/>
   <result pre="live-attenuated Venezuelan equine encephalitis virus [222], YFV-17D [151] or live-attenuated" exact="Zika" post="virus [43]. NHP models for LAV research, however, present"/>
   <result pre="a useful system to investigate the replication dynamics of the" exact="Dengue" post="virus (DENV) in vivo, as well as anti-DENV adaptive"/>
   <result pre="immunogenicity, and efficacyJ. Virol.200478124971250710.1128/JVI.78.22.12497-12507.200415507637 43.ShanC.MuruatoA.E.JaggerB.W.RichnerJ.NunesB.T.D.MedeirosD.B.A.XieX.P.NunesJ.G.C.MorabitoK.M.KongW.P.et al.A single-dose live-attenuated vaccine prevents" exact="Zika" post="virus pregnancy transmission and testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 44.EscriouN.CallendretB.LorinV.CombredetC.MarianneauP.FevrierM.TangyF.Protection from"/>
   <result pre="&amp;gt;99.7% (RD1 deletion from M. bovis) [129,130] [175,176,177] Mouse [146,193]" exact="Yellow fever" post="virus (YFV) Attenuation of causative pathogen 1937 [32] 99.37%"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157777\results\search\tropicalVirus\results.xml">
   <result pre="Virus Infection without Inducing Neutralizing Antibodies JE Vaccine Protects against" exact="YFV" post="Infection Mishra et al. https://orcid.org/0000-0002-8679-8847MishraNiraja*https://orcid.org/0000-0002-5984-7279BoudewijnsRobbertahttps://orcid.org/0000-0002-1137-9322SchmidMichael Alexandera*https://orcid.org/0000-0002-6949-0947MarquesRafael Eliasa*https://orcid.org/0000-0003-3493-252XSharmaSapnaahttps://orcid.org/0000-0002-0033-7514NeytsJohanahttps://orcid.org/0000-0002-8117-9166DallmeierKaia[a], KU Leuven"/>
   <result pre="a YFV-17D-based chimeric Japanese encephalitis vaccine, also efficiently protects against" exact="YFV" post="infection in mice. In case of shortage of the"/>
   <result pre="YFV infection in mice. In case of shortage of the" exact="YFV" post="vaccine during yellow fever outbreaks, (off-label) use of JE-CVax/Imojev"/>
   <result pre="JE-CVax/Imojev in Asia may lower the risk of the much-feared" exact="YFV" post="spillover to the continent. More generally, chimeric vaccines that"/>
   <result pre="emergency stockpiles and raised concerns about being unprepared against future" exact="YFV" post="epidemics. Here we report that a live attenuated virus"/>
   <result pre="SA14-14-2 vaccine strain confers full protection in mice against lethal" exact="YFV" post="challenge. In contrast to the YFV-17D-mediated protection against YFV,"/>
   <result pre="with YFV-specific nonneutralizing antibodies and T cell responses against cell-associated" exact="YFV" post="NS1 and other YFV nonstructural (NS) proteins. Our findings"/>
   <result pre="and T cell responses against cell-associated YFV NS1 and other" exact="YFV" post="nonstructural (NS) proteins. Our findings reveal the potential of"/>
   <result pre="YFV nonstructural (NS) proteins. Our findings reveal the potential of" exact="YFV" post="NS proteins to mediate protection and demonstrate that chimeric"/>
   <result pre="of JE-CVax in case of emergency and vaccine shortage during" exact="YFV" post="outbreaks. In addition, populations in Asia that have been"/>
   <result pre="have been vaccinated with Imojev may already be protected against" exact="YFV" post="should outbreaks ever occur on that continent, as several"/>
   <result pre="fever virus (YFV), Japanese encephalitis virus (JEV), dengue virus (DENV)," exact="Zika" post="virus (ZIKV), West Nile virus (WNV), and tick-borne encephalitis"/>
   <result pre="Japanese encephalitis virus (JEV), dengue virus (DENV), Zika virus (ZIKV)," exact="West Nile" post="virus (WNV), and tick-borne encephalitis virus, are important human"/>
   <result pre="a pronounced restriction to defined regions of endemicity, such as" exact="YFV" post="to sub-Saharan Africa and tropical Latin America and JEV"/>
   <result pre="suggests the first autochthonous transmission of JEV in Africa (4)." exact="Yellow fever" post="(YF) is an acute viral hemorrhagic disease which is"/>
   <result pre="highly efficient vaccine (YFV-17D; e.g., Stamaril), an estimated ∼0.2 million" exact="YFV" post="infections with 29,000 to 60,000 deaths occur annually (5)."/>
   <result pre="infections with 29,000 to 60,000 deaths occur annually (5). Recent" exact="YFV" post="outbreaks in Angola (2015-2016), the Democratic Republic of the"/>
   <result pre="outbreaks (6, 7). Since the Aedes aegypti mosquito, the main" exact="YFV" post="vector, is omnipresent in (sub)tropical Asia, YFV spillover to"/>
   <result pre="mosquito, the main YFV vector, is omnipresent in (sub)tropical Asia," exact="YFV" post="spillover to Asia and the establishment of epidemics involving"/>
   <result pre="of dengue disease by preexisting antibodies (antibody-dependent enhancement [ADE]) of" exact="DENV" post="infection (12–14). Vaccination against flaviviruses generally relies on the"/>
   <result pre="cells seem to contribute to the protective activity of current" exact="YFV" post="vaccines (16). Nonetheless, experimental evidence obtained with mice and"/>
   <result pre="Nonetheless, experimental evidence obtained with mice and nonhuman primates for" exact="YFV" post="(17–20) and, more recently, in mice also for WNV"/>
   <result pre="for YFV (17–20) and, more recently, in mice also for" exact="WNV" post="(21) and ZIKV (22) clearly shows that also nonstructural"/>
   <result pre="and, more recently, in mice also for WNV (21) and" exact="ZIKV" post="(22) clearly shows that also nonstructural (NS) proteins, in"/>
   <result pre="obviously in line with the accepted role nAbs play in" exact="YFV" post="infection. Thus, besides humoral immune responses against the E"/>
   <result pre="sequences of antigenically distinct flaviviruses (respectively, JEV and YFV-17D or" exact="DENV" post="and YFV-17D) and may therefore exert some dual protective"/>
   <result pre="to JE-CVax/Imojev provides rapidly complete protection against a massively lethal" exact="YFV" post="challenge, with a single dose being sufficient for full"/>
   <result pre="RESULTS JE-CVax provides full dual protection against lethal JEV and" exact="YFV" post="challenge in mice. JE-CVax is a c-LAV that consists"/>
   <result pre="YFV. This resulted in, respectively, 80 or 100% survival, while" exact="YFV" post="infection was uniformly lethal in all nonvaccinated controls (see"/>
   <result pre="JE-CVax (full survival in vaccinated mice) and 103 PFU of" exact="YFV" post="(full mortality in nonvaccinated mice). JE-CVax was originally developed"/>
   <result pre="resulted also in 97% survival (n = 35/36) against a massively lethal" exact="YFV" post="challenge (Fig. 1B). All placebo-vaccinated (n = 38) and Ixiaro-vaccinated (n = 12)"/>
   <result pre="&amp;gt; 0.0001). Importantly, JE-CVax also conferred similarly vigorous protection against" exact="YFV" post="in C57BL/6 wild-type (wt) mice (n = 16) against intracranial (i.c.)"/>
   <result pre="mice (n = 16) against intracranial (i.c.) challenge with 104 PFU of" exact="YFV" post="(Fig. 1D). In AG129 mice, a benefit (60% survival)"/>
   <result pre="lethal challenge (Fig. 1C). To establish that JE-CVax-mediated protection against" exact="YFV" post="is specific and not the result of some residual"/>
   <result pre="AG129 mice with 104 PFU of the more distantly related" exact="ZIKV" post="(strain MR766). No protective activity was observed (MDE for"/>
   <result pre="JE-CVax provides fast (≤14 dpv) and virus-specific protection against lethal" exact="YFV" post="exposure in mice. FIG 1 In vivo evaluation of"/>
   <result pre="Creative Commons Attribution 4.0 International license. JE-CVax mediates protection against" exact="YFV" post="without involvement of nAbs. To explore whether humoral immunity"/>
   <result pre="raised (log10 CPENT50, 1.66 ± 0.30; determined 28 days after" exact="YFV" post="exposure). Also in serum of JE-CVax- or Ixiaro-vaccinated C57BL/6"/>
   <result pre="presence (n = 8) or absence of MAR1 (n = 9) developed nAbs against" exact="YFV" post="(log10 CPENT50, 2.11 ± 0.25 or 1.78 ± 0.29,"/>
   <result pre="P ≤ 0.0001 for mean log10 CPENT50 titers against JEV or" exact="YFV" post="compared to mean log10 CPENT50 titers before JE-CVax vaccination"/>
   <result pre="are shown. 10.1128/mBio.02494-19.2FIG S2Detection of cross-reactive antibodies against JEV and" exact="YFV" post="in sera of YFV-17D-infected and JE-CVax-vaccinated mice. AG129 mice"/>
   <result pre="Ixiaro-vaccinated mice (D) were analyzed by both JEV (top) and" exact="YFV" post="(bottom) indirect immunofluorescence assay (IIFA; Euroimmun) at a magnification"/>
   <result pre="International license. JE-CVax and YFV-17D induce comparable levels of anti-NS1" exact="YFV" post="antibodies. From the IIFA analysis (Fig. S2), it is"/>
   <result pre="Serum antibodies from JE-CVax-vaccinated mice bound to cells that overexpress" exact="YFV" post="NS1 as well as to cells that had been"/>
   <result pre="that obtained when monoclonal antibody (MAb) 1A5, specifically directed against" exact="YFV" post="NS1, was used (27). JE-CVax induces YFV-specific antibodies mediating"/>
   <result pre="International license. JE-CVax induces polyfunctional T cell responses against both" exact="YFV" post="and JEV antigens. To assess whether also cellular immune"/>
   <result pre="JEV antigens. To assess whether also cellular immune response against" exact="YFV" post="may contribute to the protective activity, enzyme-linked immunosorbent spot"/>
   <result pre="AG129 and C57BL/6 mice when stimulated ex vivo with the" exact="YFV" post="NS3 peptide or YFV-17D total cellular antigen (Fig. 4D"/>
   <result pre="long-lasting T cell responses against YFV, and cellular immunity against" exact="YFV" post="was more vigorous than that elicited against JEV (Fig."/>
   <result pre="and Fig. S4 to S6). This observation is consistent with" exact="YFV" post="NS proteins serving as more immunogenic T cell antigens"/>
   <result pre="of CD4+ and CD8+ T cells in JE-CVax-mediated immunity against" exact="YFV" post="in C57BL/6 mice (n ≥ 7) that had been vaccinated with"/>
   <result pre="i.p. on day −2 and day 0 each prior to" exact="YFV" post="challenge. Log rank (Mantel-Cox) survival analysis test was performed"/>
   <result pre="to CD4-depleted group (n = 8). 10.1128/mBio.02494-19.4FIG S4T cell responses directed against" exact="YFV" post="or JEV antigens in ELISpot assay. Representative wells of"/>
   <result pre="vivo restimulation with an MHC class I-restricted peptide derived from" exact="YFV" post="NS332 or the lysate of YFV-17D- or JEV SA14-14-2-infected"/>
   <result pre="antibodies twice, i.e., 2 days before and immediately prior to" exact="YFV" post="challenge. Unlike for vaccinated (but not further treated) animals"/>
   <result pre="included as immunization controls [n = 5] and that survived an intracranial" exact="YFV" post="challenge), in vaccinated but antibody-treated mice the previously observed"/>
   <result pre="vaccinated but antibody-treated mice the previously observed full protection against" exact="YFV" post="was partially lost by targeting CD4+ (n = 1/8), CD8+ (n = 3/7),"/>
   <result pre="4E). All nonvaccinated animals (n = 5; P = 0.0027) succumbed to" exact="YFV" post="challenge as before (Fig. 1D). The mortality resulting from"/>
   <result pre="and CD8+ T cells contribute to the JE-CVax-mediated protection against" exact="YFV" post="in C57BL/6 mice. CTL epitopes within the YFV-17D NS"/>
   <result pre="YFV-17D-vaccinated controls. Similarly, 80% protection against challenge with the African" exact="YFV" post="strain Dakar 1279 was observed in monkeys following repeated"/>
   <result pre="whether it can offer, besides protection against JEV, protection against" exact="YFV" post="challenge. Since AG129 mice are highly susceptible to lethal"/>
   <result pre="strains as established surrogates for wt JEV (33) and wt" exact="YFV" post="(34, 35), respectively (demanding lower biosafety containment for handling)."/>
   <result pre="protection (35, 36) against a massive (1,000 LD50] challenge with" exact="YFV" post="(Fig. 1B). The protective activity against YFV was raised"/>
   <result pre="LD50] challenge with YFV (Fig. 1B). The protective activity against" exact="YFV" post="was raised fast, and a survival benefit could be"/>
   <result pre="complete protection (21/21) against lethal intracranial challenge (17, 23) with" exact="YFV" post="(Fig. 1D and Fig. 4E). This activity of JE-CVax"/>
   <result pre="(Fig. 1D and Fig. 4E). This activity of JE-CVax was" exact="YFV" post="specific, as AG129 mice that had been vaccinated with"/>
   <result pre="Ixiaro (the inactivated JEV vaccine) were not protected against lethal" exact="YFV" post="challenge. Furthermore, mice that had been vaccinated with JE-CVax"/>
   <result pre="that had been vaccinated with JE-CVax and that later survived" exact="YFV" post="challenge did not survive a subsequent lethal challenge with"/>
   <result pre="challenge did not survive a subsequent lethal challenge with the" exact="ZIKV" post="(Fig. S1). 10.1128/mBio.02494-19.7FIG S7In vivo infectivity of YFV-17D and"/>
   <result pre="JEV-P3 strain-based inactivated vaccine and JEV SA14-14-2)-vaccinated mice challenged with" exact="DENV" post="(26). Likewise, a chimeric Japanese encephalitis/dengue virus 2 experimental"/>
   <result pre="considerable levels of E-specific partially cross-reactive nAbs that neutralized both" exact="DENV" post="and JEV. Additionally, the study (31) demonstrated that vaccination"/>
   <result pre="T cell responses could obviously not be distinguished from what" exact="DENV" post="NS proteins may contribute. In contrast, although we also"/>
   <result pre="In contrast, although we also observed some residual cross-reactivity for" exact="YFV" post="in serum samples of JE-CVax-vaccinated mice (binding antibody in"/>
   <result pre="S2]), JE-CVax failed to induce any detectable nAb titers against" exact="YFV" post="even following repeated boosting (Fig. 2A). This finding is"/>
   <result pre="were variations in the actual levels of anti-YFV nAbs after" exact="YFV" post="challenge. In some animals, no nAbs were detected against"/>
   <result pre="YFV challenge. In some animals, no nAbs were detected against" exact="YFV" post="after YFV-17D-challenge. This lack of YFV nAb indicates that"/>
   <result pre="nAbs were detected against YFV after YFV-17D-challenge. This lack of" exact="YFV" post="nAb indicates that JE-CVax possibly conferred sterilizing immunity in"/>
   <result pre="with anti-NS1 antibodies) to be involved in JE-CVax-mediated protection against" exact="YFV" post="(Fig. 4E). Previously, only humoral immunity and CD4+ T"/>
   <result pre="been implied to be sufficient and required for protection against" exact="YFV" post="(16), with a strong emphasis on nAb as a"/>
   <result pre="nAb as a historically established immunological correlate of protection for" exact="YFV" post="(5) and for flaviviruses (such as JEV) in general"/>
   <result pre="an Fc-dependent manner (for example, via ADCC toward cells expressing" exact="YFV" post="NS1 on their surfaces) (18, 21, 43, 44). Indeed,"/>
   <result pre="of AG129 and C57BL/6 mice with JE-CVax elicited protective polyfunctional" exact="YFV" post="antigen-specific CD4+ and CD8+ T cell responses (expressing the"/>
   <result pre="demonstrated that vaccination with CYD-TDV/Dengvaxia elicits cell-mediated immunity directed against" exact="YFV" post="nonstructural proteins (46, 47). Our comparative in silico analysis"/>
   <result pre="Collectively, our data suggest that JE-CVax-mediated vigorous protection against lethal" exact="YFV" post="challenge depends on the combined effects of several effector"/>
   <result pre="can hence be considered a genuine mouse-adapted neurotropic and neurovirulent" exact="YFV" post="strain. For this reason, it could also be considered"/>
   <result pre="Therefore, in conclusion, similar mechanisms should hold when using wild-type" exact="YFV" post="as the challenge virus (44, 52). Obviously, before proceeding"/>
   <result pre="nonhuman primates, demonstrating protection from subsequent challenge with virulent wt" exact="YFV" post="strains. Live attenuated JE SA14-14-2 and inactivated Vero cell"/>
   <result pre="to address whether Imojev will also induce protective immunity against" exact="YFV" post="in those that have already been vaccinated with one"/>
   <result pre="dual protective effect may be of particular relevance in case" exact="YFV" post="may one day—as is suspected (8, 9)—cause outbreaks in"/>
   <result pre="Given the capacity problems with the production of the current" exact="YFV" post="vaccine, having another licensed vaccine (i.e., JE-CVax/Imojev) available as"/>
   <result pre="(i.e., JE-CVax/Imojev) available as an alternative means to protect against" exact="YFV" post="may at such time help to contain an outbreak."/>
   <result pre="YFV-17D/ZIKV vaccine candidate) (28). Likewise, c-LAVs could be generated against" exact="DENV" post="and other viruses that may cause ADE using the"/>
   <result pre="viruses or serotypes, in line with experimental evidence that the" exact="DENV" post="NS1 protein can also serve as a protective antigen"/>
   <result pre="nAb responses. The same principle may apply to c-LAV for" exact="ZIKV" post="using a ZIKV backbone (58) and prM/E sequences of"/>
   <result pre="same principle may apply to c-LAV for ZIKV using a" exact="ZIKV" post="backbone (58) and prM/E sequences of another flavivirus that"/>
   <result pre="and rapidly induces high cross-protective efficacy (∼100%) in mice against" exact="YFV" post="challenge, even with an exceedingly aggressive challenge inoculum. The"/>
   <result pre="cells to generate virus stocks. As an alternative challenge virus," exact="ZIKV" post="strain MR766 was used (60). Virus titers were determined"/>
   <result pre="serving as a well-established surrogate rodent challenge model for wt" exact="YFV" post="infection (34, 35, 74). Six- to 8-week-old male AG129"/>
   <result pre="JE-CVax and YFV-17D were performed. We did not observe any" exact="YFV" post="nAbs in the hyperimmune sera but did see an"/>
   <result pre="of YFV-17D. At day −2 and day 0 prior to" exact="YFV" post="challenge, 0.5 mg of either anti-mouse CD4 (clone GK1.5; Leinco"/>
   <result pre="To determine the seroconversion of animals, all JEV, YFV, and" exact="ZIKV" post="IgG indirect immunofluorescence assays (IIFAs) were performed as per"/>
   <result pre="good correlation (Pearson correlation [R2] = 0.071; P = 0.02) between log10" exact="YFV" post="PRNT50 and log10 YFV CPENT50 of matched samples (A)."/>
   <result pre="[R2] = 0.071; P = 0.02) between log10 YFV PRNT50 and log10" exact="YFV" post="CPENT50 of matched samples (A). There was no marked"/>
   <result pre="Creative Commons Attribution 4.0 International license. ELISA. Serum antibodies recognizing" exact="YFV" post="NS1 were detected by indirect enzyme-linked immunosorbent assay (ELISA),"/>
   <result pre="MaxiSorp; Thermo Fisher Scientific) were coated with 1 μg/ml of recombinant" exact="YFV" post="NS1 (Bio-Rad; catalog no. PIP052A) in 50 mM carbonate buffer"/>
   <result pre="for 2 h at room temperature. Serial dilutions of the" exact="YFV" post="NS1-specific mouse IgG2a monoclonal antibody (clone 1A5, kindly provided"/>
   <result pre="positive. ADCC bioassay. To assess the possible role of nonneutralizing" exact="YFV" post="antibody-mediated protection against YFV after JE-CVax vaccination, antibody-dependent cell-mediated"/>
   <result pre="assess the possible role of nonneutralizing YFV antibody-mediated protection against" exact="YFV" post="after JE-CVax vaccination, antibody-dependent cell-mediated cytotoxicity (ADCC) bioassays (29)"/>
   <result pre="cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of" exact="West Nile" post="virus-infected cells. J Virol81:9551–9555. doi:10.1128/JVI.00879-07.17582005 22.BaileyMJ, BroeckerF, DuehrJ, ArumemiF,"/>
   <result pre="PaleseP, TanGS2019Antibodies elicited by an NS1-based vaccine protect mice against" exact="Zika" post="virus. mBio10:e02861-18. doi:10.1128/mBio.02861-18.30940710 23.BassiMR, LarsenMA, KongsgaardM, RasmussenM, BuusS, StryhnA,"/>
   <result pre="NeytsJ, DallmeierK2018A yellow fever-Zika chimeric virus vaccine candidate protects against" exact="Zika" post="infection and congenital malformations in mice. NPJ Vaccines3:56. doi:10.1038/s41541-018-0092-2.30564463"/>
   <result pre="GrifoniA, DiamondMS, SetteA, PetersB2016Identifying candidate targets of immune responses in" exact="Zika" post="virus based on homology to epitopes in other flavivirus"/>
   <result pre="YangY, MuruatoAE, ZouJ, ShanC, NunesBT, MedeirosDB, VasconcelosPF, WeaverSC, RossiSL, ShiPY2017Understanding" exact="Zika" post="virus stability and developing a chimeric vaccine through functional"/>
   <result pre="polymerase inhibitor 7-deaza-2′-c-methyladenosine is a potent inhibitor of in vitro" exact="Zika" post="virus replication and delays disease progression in a robust"/>
   <result pre="MasonPW, BloomME, García-SastreA, KhromykhAA, BestSM2010The NS5 protein of the virulent" exact="West Nile" post="virus NY99 strain is a potent antagonist of type"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7164210\results\search\tropicalVirus\results.xml">
   <result pre="http://dx.doi.org/10.13039/501100005669Fundação de Apoio à Pesquisa do Estado da Paraíba Edital" exact="Zika" post="VirusSantosSilvana Background The control of Aedes aegypti, a widespread"/>
   <result pre="which could be the result of the cross-herd immunity to" exact="Zika" post="virus [3]. The differential diagnosis of these diseases is"/>
   <result pre="affected by arboviruses, with 94% of all cases of congenital" exact="Zika" post="syndrome being reported in this region [2, 6, 7]."/>
   <result pre="Brazil since 2003 in accordance with the guidelines of National" exact="Dengue" post="Control Programme (PNCD) [10, 11]. For LIRAa, the municipality"/>
   <result pre="to 2017. This period was delimited considering the hypothesis that" exact="Zika" post="virus were introduced in Brazil during the 2014 FIFA"/>
   <result pre="sharing a common ancestor circulating in French Polynesia [18]. The" exact="Zika" post="virus may have probably been introduced in Pernambuco, which"/>
   <result pre="this state and neighbouring areas, such as Campina Grande [19]." exact="Zika" post="virus was associated with a high prevalence of cases"/>
   <result pre="Aedes aegypti Rapid Index Survey PNCD Brazilian National Ministry of" exact="Dengue" post="Control Programme HI house index BI Breteau index ACEs"/>
   <result pre="Fundação de Apoio à Pesquisa do Estado da Paraíba (FAPESQ/Edital" exact="Zika" post="Virus) and British Council 274560199. The role of the"/>
   <result pre="happened?Rev Inst Med Trop Sao Paulo.201860e4310.1590/s1678-994620186004330133603 3.RibeiroGSKikutiMTauroLBNascimentoLCJCardosoCWCamposGSet al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengue?Lancet Glob Health.20186e140e14110.1016/S2214-109X(17)30496-529389533 4.Villabona-ArenasCJde OliveiraJLCapraCBalariniKLoureiroMFonsecaCRTPet"/>
   <result pre="Marzochi MCA, Tanuri A, Martins RM, Marques ETA, et al." exact="Zika" post="puzzle in Brazil: peculiar conditions of viral introduction and"/>
   <result pre="Gouveia Mendes A, et al. Microcephaly epidemic related to the" exact="Zika" post="virus and living conditions in Recife, Northeast Brazil. BMC"/>
   <result pre="2012Rev Saude Publica.201751798928832752 17.AlbuquerqueMde SouzaWVAraújoTVBBragaMCMiranda FilhoDXimenesRAet al.The microcephaly epidemic and" exact="Zika" post="virus: building knowledge in epidemiologyCad Saude Publica.201834e0006901830328996 18.FariaNRAzevedoRKraemerMUGSouzaRCunhaMSHillSCet al.Zika"/>
   <result pre="epidemiological and genetic findingsScience.201635234534910.1126/science.aaf503627013429 19.BorgesEDVirequeAABerteliTSFerreiraCRSilvaASNavarroPAAn update on the aspects of" exact="Zika" post="virus infection on male reproductive systemJ Assist Reprod Genet.2019361339134910.1007/s10815-019-01493-y31147867"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7168622\results\search\tropicalVirus\results.xml">
   <result pre="PathogensPathogenspathogensPathogens2076-0817MDPI pmcid: 7168622 doi: 10.3390/pathogens9010048pathogens-09-00048 : Review Comparative Pathology of" exact="West Nile" post="Virus in Humans and Non-Human Animals https://orcid.org/0000-0002-0762-7389ByasAlex D.EbelGregory D.*[],"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="West Nile" post="virus (WNV) continues to be a major cause of"/>
   <result pre="such as alligators. This review summarizes the pathology caused by" exact="West Nile" post="virus during natural infections of humans and non-human animals."/>
   <result pre="well-known findings in human infection involve the central nervous system," exact="WNV" post="can also cause significant lesions in the heart, kidneys"/>
   <result pre="has also revealed chronic neurologic sequelae related to prior human" exact="WNV" post="infection. Similarly, neurologic disease is a prominent manifestation of"/>
   <result pre="WNV infection. Similarly, neurologic disease is a prominent manifestation of" exact="WNV" post="infection in most non-human non-host animals. However, in some"/>
   <result pre="some avian species, which serve as the vertebrate host for" exact="WNV" post="maintenance in nature, severe systemic disease can occur, with"/>
   <result pre="to death. The pathology seen in experimental animal models of" exact="West Nile" post="virus infection and knowledge gains on viral pathogenesis derived"/>
   <result pre="literature exists regarding the relationship between the neurotropic nature of" exact="WNV" post="in vertebrates, virus propagation and transmission in nature. This"/>
   <result pre="and other knowledge gaps, and future directions for research into" exact="WNV" post="pathology, are addressed. West Nile virus pathology animal models"/>
   <result pre="and future directions for research into WNV pathology, are addressed." exact="West Nile" post="virus pathology animal models flavivirus review 1. Introduction Twenty"/>
   <result pre="models flavivirus review 1. Introduction Twenty years after its introduction," exact="West Nile" post="virus (WNV, Flaviviridae: Flavivirus) continues to be the leading"/>
   <result pre="of arboviral disease in the continental United States (US) [1]." exact="WNV" post="was first isolated in 1937 from the blood of"/>
   <result pre="in 1937 from the blood of a woman in the" exact="West Nile" post="district of Uganda [2]. During the 1950s, the virus"/>
   <result pre="[10]. The US outbreak represented the first known introduction of" exact="WNV" post="to the Western hemisphere. Outbreaks during the late 1990s"/>
   <result pre="and is now endemic. 2. The Virus and Its Ecology" exact="WNV" post="is a member of the genus Flavivirus within the"/>
   <result pre="member of the genus Flavivirus within the family Flaviviridae. The" exact="WNV" post="genome is a positive-sense, single-stranded RNA molecule of approximately"/>
   <result pre="has now displaced lineage 1 as the primary cause of" exact="WNV" post="disease in Europe [23,27,28,29,30,31]. WNV is maintained in nature"/>
   <result pre="as the primary cause of WNV disease in Europe [23,27,28,29,30,31]." exact="WNV" post="is maintained in nature by ornithophilic Culex mosquitoes and"/>
   <result pre="States. Culex quinquefasciatus and Culex nigripalpus are important vectors for" exact="WNV" post="in the southeastern United States [33,34]. While many avian"/>
   <result pre="[38]. In addition to horizontal circulation between birds and mosquitoes," exact="WNV" post="maintenance also has been described in the absence of"/>
   <result pre="of a mosquito vector. There have been multiple reports of" exact="WNV" post="viral RNA detected in carcasses and feces in crow"/>
   <result pre="transmission mechanism was not specifically elucidated [39,40]. Similar occurrences of" exact="WNV" post="disease during the winter have been seen in Bald"/>
   <result pre="sparrows up to 43 days post inoculation [43]. Overwintering of" exact="WNV" post="may also occur by vertical transmission from adult female"/>
   <result pre="is highly inefficient [44,45]. In addition to the maintenance of" exact="WNV" post="in nature via non-vector mechanisms, WNV disease has also"/>
   <result pre="to the maintenance of WNV in nature via non-vector mechanisms," exact="WNV" post="disease has also been reported in humans potentially as"/>
   <result pre="bird species and mosquitoes which should allow for its maintenance," exact="WNV" post="is not frequently seen in central and South America."/>
   <result pre="due to other circulating flaviviruses or a dilution effect on" exact="WNV" post="due to high disease host diversity [56,57]. Much of"/>
   <result pre="high disease host diversity [56,57]. Much of the research surrounding" exact="West Nile" post="virus focuses on (a) viral and ecological factors which"/>
   <result pre="models have been used to examine the factors that affect" exact="WNV" post="transmission. Some of that work has used wild birds,"/>
   <result pre="[61,62,63], indicating that continued investigation into possible non-avian contributions to" exact="WNV" post="maintenance is warranted. While WNV is primarily transmitted and"/>
   <result pre="into possible non-avian contributions to WNV maintenance is warranted. While" exact="WNV" post="is primarily transmitted and maintained between birds and mosquitoes,"/>
   <result pre="will be discussed in detail in this review. 3. Natural" exact="WNV" post="Disease 3.1. Humans While approximately 80% of people infected"/>
   <result pre="Disease 3.1. Humans While approximately 80% of people infected with" exact="WNV" post="are asymptomatic, the majority of symptomatic patients experience a"/>
   <result pre="disease lasting up to a week, a syndrome known as" exact="West Nile" post="fever (WNF) [64]. In addition to fever, mild disease"/>
   <result pre="characterized by headache, gastrointestinal problems, rash, myalgia, arthralgia and malaise." exact="West Nile" post="neuroinvasive disease (WNND) occurs in less than 1% of"/>
   <result pre="of infected people and is manifested as multiple syndromes including" exact="West Nile" post="meningitis (WNM), West Nile encephalitis (WNE) and West Nile"/>
   <result pre="is manifested as multiple syndromes including West Nile meningitis (WNM)," exact="West Nile" post="encephalitis (WNE) and West Nile poliomyelitis (WNP) [65]. WNM"/>
   <result pre="including West Nile meningitis (WNM), West Nile encephalitis (WNE) and" exact="West Nile" post="poliomyelitis (WNP) [65]. WNM describes inflammation which is primarily"/>
   <result pre="rarer Guillain-Barre syndrome which has been reported in association with" exact="WNV" post="infection [65]. While these classifications are important, clinical presentation"/>
   <result pre="infection [65]. While these classifications are important, clinical presentation of" exact="WNV" post="infection may present as any mixture of these syndromes."/>
   <result pre="present as any mixture of these syndromes. Histological findings in" exact="West Nile" post="neuroinvasive disease are nonspecific and typical of many viral"/>
   <result pre="and neurological disease are the most well-known clinical manifestations of" exact="West Nile" post="virus infection, there are less frequently observed non-neurological clinical"/>
   <result pre="less frequently observed non-neurological clinical findings. Ocular manifestations seen in" exact="WNV" post="infection, specifically those associated with the optic nerve and"/>
   <result pre="of the brain. In one report, 80% of patients with" exact="WNV" post="neurologic disease have chorioretinal involvement, primarily multifocal chorioretinitis, although"/>
   <result pre="chorioretinitis, although it is often asymptomatic and self-limiting [79,80]. Additional" exact="WNV" post="ocular manifestations vitritis, optic neuritis and retinal hemorrhage [81,82,83]."/>
   <result pre="documented in one study as present in 9% of hospitalized" exact="WNV" post="patients and in another study, 21% of deceased WNV"/>
   <result pre="hospitalized WNV patients and in another study, 21% of deceased" exact="WNV" post="patients had renal failure [84,85]. More commonly seen in"/>
   <result pre="strength and abnormal reflexes [93,94]. On magnetic resonance imaging (MRI)," exact="WNV" post="survivors had significant cortical thinning in the frontal and"/>
   <result pre="system. There is also some evidence for persistent infection of" exact="WNV" post="[96,97,98]. Sequelae from systemic infections have been observed with"/>
   <result pre="one of the most common extra-nervous system sites of disease." exact="WNV" post="is able to persist chronically in the kidneys up"/>
   <result pre="chronic kidney disease [97,99]. 3.2. Birds During the introduction of" exact="West Nile" post="virus to the United States, mortality observed in the"/>
   <result pre="systems have been shown to be affected in natural avian" exact="WNV" post="infections. Neurological manifestations are indicative of viral encephalitis and"/>
   <result pre="as well as pathologic findings in birds experimentally infected with" exact="WNV" post="(Table 1) [106,107,108,109,110,111,112,113,114,115,116]. Ocular lesions are seen in raptors"/>
   <result pre="avian species [103,120,121]. While systemic infection is a hallmark of" exact="WNV" post="infection in many species, adult domestic chickens and turkeys"/>
   <result pre="with estimates of 29% loss of abundance since 1970 [124]." exact="WNV" post="likely contributes to some avian losses as it has"/>
   <result pre="as human land use [129,130,131]. 3.3. Horses Clinical signs of" exact="WNV" post="infection in horses, aside from fever, are primarily related"/>
   <result pre="and myocarditis [138]. Several commonalities unite the clinical presentation of" exact="WNV" post="in the most affected vertebrates: birds, horses and humans."/>
   <result pre="Affected Vertebrate Species In addition to birds, humans and horses," exact="WNV" post="infects and causes disease in an extraordinary array of"/>
   <result pre="arctic wolf, renal vasculitis was a significant finding [152]. While" exact="WNV" post="antigen distribution is frequently described in both natural infection"/>
   <result pre="sparse and is typically visible in only 50% of fatal" exact="WNV" post="neuroinvasive disease cases, making this modality relatively insensitive [75]."/>
   <result pre="making this modality relatively insensitive [75]. 4. Biomedical Models of" exact="WNV" post="Infection 4.1. Mice A vast body of knowledge regarding"/>
   <result pre="Mice A vast body of knowledge regarding the pathogenesis of" exact="WNV" post="encephalitis has resulted from experimental infections using animal models."/>
   <result pre="infections using animal models. Interestingly, wild-type mice are resistant to" exact="WNV" post="infection, but all classical laboratory mice strains are susceptible"/>
   <result pre="also frequently seen in birds. An abundance of information about" exact="WNV" post="pathogenesis has been yielded from mouse models of infection."/>
   <result pre="encephalitis disease. The lesions of encephalitis and poliomyelitis seen in" exact="WNV" post="infection cannot be attributed solely to viral replication or"/>
   <result pre="damage [161,170,171,172,173,174,175]. 4.2. Hamsters Golden hamsters are excellent models for" exact="WNV" post="encephalitis because they mimic human disease in regards to"/>
   <result pre="symptoms and clinical signs including tremors [156,176,177,178]. Hamsters infected with" exact="WNV" post="develop neurologic symptoms including tremors and hind limb paralysis"/>
   <result pre="significance of axonal transport as a contributor to entrance of" exact="WNV" post="to the CNS has also been demonstrated in hamsters"/>
   <result pre="Primates In addition to mice, some early experimental work examining" exact="WNV" post="encephalitis was performed in non-human primates. Depending on the"/>
   <result pre="to febrile disease to overt encephalitis [182,183]. Histopathology in acute" exact="WNV" post="encephalitis includes severe perivascular and diffuse lymphoplasmacytic inflammation, neuronal"/>
   <result pre="In contrast, more recent experimental infections examining antibody response to" exact="WNV" post="infection in immunocompetent rhesus macaques and marmosets resulted in"/>
   <result pre="costs and ethical implications, current use of non-human primates in" exact="WNV" post="research is infrequent. However, they may be used in"/>
   <result pre="of a human vaccine. 4.4. Additional Animal Species Used in" exact="WNV" post="Biomedical Research Multiple other species have been used in"/>
   <result pre="WNV Biomedical Research Multiple other species have been used in" exact="WNV" post="biomedical research and contributed to varying aspects of the"/>
   <result pre="were used in some of the earliest experimental work studying" exact="WNV" post="and while older rats were resistant to fatal disease,"/>
   <result pre="related to toxicology studies which assess for the safety of" exact="WNV" post="vaccines [188,189,190]. As the species most frequently and significantly"/>
   <result pre="[188,189,190]. As the species most frequently and significantly affected by" exact="WNV" post="infections aside from birds and humans, horses have been"/>
   <result pre="and in efficacy and safety studies required for approval of" exact="WNV" post="equine vaccines [191,192,193,194,195,196]. There are currently four United States"/>
   <result pre="There are currently four United States Department of Agriculture-licensed equine" exact="WNV" post="vaccines available in the United States [197]. New Zealand"/>
   <result pre="rabbits have been demonstrated to be appropriate models for non-lethal" exact="WNV" post="infections as only weanling rabbits demonstrate severe lesions and"/>
   <result pre="[198]. Rabbits are also commonly used to generate antibodies against" exact="WNV" post="which can be utilized in assays such as immunohistochemistry."/>
   <result pre="Other species which have been examined as animal models for" exact="WNV" post="infection include pigs, dog and cats [199,200]. Experimental infection"/>
   <result pre="care [203,204,205,206,207]. Importantly, wild birds have been used for experimental" exact="WNV" post="infections, not as a model for mammalian disease, but"/>
   <result pre="One of the more interesting features of the emergence of" exact="WNV" post="is its somewhat unique ecological generalism. Whereas most flaviviruses"/>
   <result pre="flaviviruses productively infect a relatively restricted subset of animal species," exact="WNV" post="can infect an extraordinarily wide array of vertebrate taxa."/>
   <result pre="may be conserved. For example, the most notable feature of" exact="WNV" post="disease in humans is neurotropism resulting most frequently in"/>
   <result pre="broadly divergent vertebrate taxa. Renal tropism is a feature of" exact="WNV" post="infection in birds that facilitated early surveillance efforts. Several"/>
   <result pre="that renal failure may contribute to poor long-term outcomes among" exact="WNV" post="survivors [99]. These studies also documented the presence of"/>
   <result pre="WNV survivors [99]. These studies also documented the presence of" exact="WNV" post="in urine sediment from individuals with a history of"/>
   <result pre="WNV in urine sediment from individuals with a history of" exact="WNV" post="[216]. In some of these patients, WNV was detected"/>
   <result pre="a history of WNV [216]. In some of these patients," exact="WNV" post="was detected up to nine years after acute infection."/>
   <result pre="infection. Similarly, avian kidneys have been found to persistently harbor" exact="WNV" post="after natural and experimental infection. WNV, though typically considered"/>
   <result pre="of people and birds raises another important common feature of" exact="WNV" post="pathogenesis that is conserved across several vertebrates and has"/>
   <result pre="has been previously underappreciated. This is the extent to which" exact="WNV" post="can persist within vertebrates despite the induction of a"/>
   <result pre="injury may manifest as the human populations previously affected by" exact="WNV" post="continue to age. An important question that remains to"/>
   <result pre="remains to be answered is whether persistent, chronic infection by" exact="WNV" post="and other flaviviruses, years after acute infection, is an"/>
   <result pre="Acknowledgments We thank Chad B. Frank for the slides of" exact="WNV" post="infection in a sheep. Funding This work was supported"/>
   <result pre="Human Sera in Egypt of a Virus Apparently Identical to" exact="West Nile" post="VirusExp. Biol. Med.19517766166510.3181/00379727-77-1888414891830 4.HurlbutH.S.RizkF.TaylorR.M.WorkT.H.A study of the ecology of"/>
   <result pre="Nile VirusExp. Biol. Med.19517766166510.3181/00379727-77-1888414891830 4.HurlbutH.S.RizkF.TaylorR.M.WorkT.H.A study of the ecology of" exact="West Nile" post="virus in EgyptAm. J. Trop. Med. Hyg.1956557962013354882 5.PerelmanA.SternJ.Acute pancreatitis"/>
   <result pre="virus in EgyptAm. J. Trop. Med. Hyg.1956557962013354882 5.PerelmanA.SternJ.Acute pancreatitis in" exact="West Nile" post="feverAm. J. Trop. Med. Hyg.1974231150115210.4269/ajtmh.1974.23.11504429184 6.LvovD.K.ButenkoA.M.GromashevskyV.L.LarichevV.P.GaidamovichS.Y.VyshemirskyO.I.ZhukovA.N.LazorenkoV.V.SalkoV.N.KovtunovA.I.et al.Isolation of two"/>
   <result pre="J. Trop. Med. Hyg.1974231150115210.4269/ajtmh.1974.23.11504429184 6.LvovD.K.ButenkoA.M.GromashevskyV.L.LarichevV.P.GaidamovichS.Y.VyshemirskyO.I.ZhukovA.N.LazorenkoV.V.SalkoV.N.KovtunovA.I.et al.Isolation of two strains of" exact="West Nile" post="virus during an outbreak in southern Russia, 1999Emerg. Infect."/>
   <result pre="outbreak in southern Russia, 1999Emerg. Infect. Dis.2000637337610.3201/eid0604.00040810905970 7.Siegel-ItzkovichJ.Twelve die of" exact="West Nile" post="virus in IsraelBr. Med. J.2000321724 8.RossiS.L.RossT.M.EvansJ.D.West Nile virusClin. Lab."/>
   <result pre="and emergence of arboviral diseaseNat. Rev. Microbiol.2004278980110.1038/nrmicro100615378043 10.O’LearyD.R.MarfinA.A.MontgomeryS.P.KippA.M.LehmanJ.A.BiggerstaffB.J.ElkoV.L.CollinsP.D.JonesJ.E.CampbellG.L.The epidemic of" exact="West Nile" post="virus in the United States, 2002Vector-Borne Zoonotic Dis.20044617010.1089/15303660477308300415018774 11.Outbreak"/>
   <result pre="viral disease in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 13.LanciottiR.S.RoehrigJ.T.DeubelV.SmithJ.ParkerM.SteeleK.CriseB.VolpeK.E.CrabtreeM.B.ScherretJ.H.et al.Origin of the" exact="West Nile" post="virus responsible for an outbreak of encephalitis in the"/>
   <result pre="1999: The New York ConnectionEmerg. Infect. Dis.2001765966110.3201/eid0704.01741011585528 15.AndersonJ.F.AndreadisT.G.VossbrinckC.R.TirrellS.WakemE.M.FrenchR.A.GarmendiaA.E.Van KruiningenH.J.Isolation of" exact="West Nile" post="virus from mosquitoes, crows, and a Cooper’s hawk in"/>
   <result pre="Cooper’s hawk in ConnecticutScience19992862331233310.1126/science.286.5448.233110600741 16.BakonyiT.HubálekZ.RudolfI.NowotnyN.Novel flavivirus or new lineage of" exact="West Nile" post="virus, central EuropeEmerg. Infect. Dis.20051122510.3201/eid1102.04102815752439 17.MayF.J.DavisC.T.TeshR.B.BarrettA.D.T.Phylogeography of West Nile"/>
   <result pre="of West Nile virus, central EuropeEmerg. Infect. Dis.20051122510.3201/eid1102.04102815752439 17.MayF.J.DavisC.T.TeshR.B.BarrettA.D.T.Phylogeography of" exact="West Nile" post="Virus: From the Cradle of Evolution in Africa to"/>
   <result pre="a distinct genetic lineageJ. Gen. Virol.20078887588410.1099/vir.0.82403-017325360 19.VázquezA.Sánchez-SecoM.RuizS.MoleroF.HernandezL.MorenoJ.MagallanesA.TejedorC.G.TenorioA.Putative new lineage of" exact="West Nile" post="virus, SpainEmerg. Infect. Dis.20101654955210.3201/eid1603.09103320202444 20.KingA.LefkowitzE.AdamsM.CarstensE.Virus Taxonomy: Ninth Report of"/>
   <result pre="NY, USA2011 21.CharrelR.N.BraultA.C.GallianP.LemassonJ.J.MurgueB.MurriS.PastorinoB.ZellerH.De ChesseR.De MiccoP.et al.Evolutionary relationship between Old World" exact="West Nile" post="virus strains: Evidence for viral gene flow between Africa,"/>
   <result pre="and EuropeVirology200331538138810.1016/S0042-6822(03)00536-114585341 22.LanciottiR.S.EbelG.D.DeubelV.KerstA.J.MurriS.MeyerR.BowenM.McKinneyN.MorrillW.E.CrabtreeM.B.et al.Complete genome sequences and phylogenetic analysis of" exact="West Nile" post="virus strains isolated from the United States, Europe, and"/>
   <result pre="the Middle EastVirology20022989610510.1006/viro.2002.144912093177 23.BakonyiT.IvanicsE.ErdélyiK.UrsuK.FerencziE.WeissenböckH.NowotnyN.Lineage 1 and 2 strains of encephalitic" exact="West Nile" post="virus, central EuropeEmerg. Infect. Dis.20061261862310.3201/eid1204.05137916704810 24.PapaA.XanthopoulouK.GewehrS.MourelatosS.Detection of West Nile"/>
   <result pre="encephalitic West Nile virus, central EuropeEmerg. Infect. Dis.20061261862310.3201/eid1204.05137916704810 24.PapaA.XanthopoulouK.GewehrS.MourelatosS.Detection of" exact="West Nile" post="virus lineage 2 in mosquitoes during a human outbreak"/>
   <result pre="in GreeceClin. Microbiol. Infect.2011171176118010.1111/j.1469-0691.2010.03438.x21781205 25.ValiakosG.TouloudiA.IacovakisC.AthanasiouL.BirtsasP.SpyrouV.BillinisC.Molecular detection and phylogenetic analysis of" exact="West Nile" post="virus lineage 2 in sedentary wild birds (Eurasian magpie),"/>
   <result pre="Entomological Investigation, Austria, 2014PLoS ONE201510e012638110.1371/journal.pone.012638125961567 29.WodakE.RichterS.BagóZ.Revilla-FernándezS.WeissenböckH.NowotnyN.WinterP.Detection and molecular analysis of" exact="West Nile" post="virus infections in birds of prey in the eastern"/>
   <result pre="Austria in 2008 and 2009Vet. Microbiol.201114935836610.1016/j.vetmic.2010.12.01221276665 30.BusquetsN.Laranjo-GonzálezM.SolerM.NicolásO.RivasR.TalaveraS.VillalbaR.San MiguelE.TornerN.ArandaC.et al.Detection of" exact="West Nile" post="virus lineage 2 in North-Eastern Spain (Catalonia)Transbound. Emerg. Dis.20196661762110.1111/tbed.1308630506625"/>
   <result pre="(Catalonia)Transbound. Emerg. Dis.20196661762110.1111/tbed.1308630506625 31.Vilibic-CavlekT.SavicV.PetrovicT.ToplakI.BarbicL.PetricD.TabainI.Hrnjakovic-CvjetkovicI.BogdanicM.KlobucarA.et al.Emerging Trends in the Epidemiology of" exact="West Nile" post="and Usutu Virus Infections in Southern EuropeFront. Vet. Sci.2019643710.3389/fvets.2019.0043731867347"/>
   <result pre="EuropeFront. Vet. Sci.2019643710.3389/fvets.2019.0043731867347 32.KramerL.D.StyerL.M.EbelG.D.A Global Perspective on the Epidemiology of" exact="West Nile" post="VirusAnnu. Rev. Entomol.200853618110.1146/annurev.ento.53.103106.09325817645411 33.GodseyM.S.KingR.J.BurkhalterK.DeloreyM.ColtonL.CharnetzkyD.SutherlandG.EzenwaV.O.WilsonL.A.CoffeyM.et al.Ecology of potential West Nile"/>
   <result pre="of West Nile VirusAnnu. Rev. Entomol.200853618110.1146/annurev.ento.53.103106.09325817645411 33.GodseyM.S.KingR.J.BurkhalterK.DeloreyM.ColtonL.CharnetzkyD.SutherlandG.EzenwaV.O.WilsonL.A.CoffeyM.et al.Ecology of potential" exact="West Nile" post="virus vectors in Southeastern Louisiana: Enzootic transmission in the"/>
   <result pre="along the Colorado Front Range during a Period of Intense" exact="West Nile" post="virus activityJ. Am. Mosq. Control Assoc.200723374610.2987/8756-971X(2007)23[37:ESATCF]2.0.CO;217536366 35.HamerG.L.ChavesL.F.AndersonT.K.KitronU.D.BrawnJ.D.RuizM.O.LossS.R.WalkerE.D.GoldbergT.L.Fine-scale variation in"/>
   <result pre="host use and force of infection drive localized patterns of" exact="West Nile" post="virus transmissionPLoS ONE20116e2376710.1371/journal.pone.002376721886821 36.KentR.JuliussonL.WeissmannM.EvansS.KomarN.Seasonal Blood–Feeding Behavior of Culex tarsalis"/>
   <result pre="Weld County, Colorado, 2007J. Med. Entomol.20094638039010.1603/033.046.022619351092 37.KilpatrickA.M.DaszakP.JonesM.J.MarraP.P.KramerL.D.Marm KilpatrickA.DaszakP.JonesM.J.MarraP.P.KramerL.D.Host heterogeneity dominates" exact="West Nile" post="virus transmissionProc. R. Soc. B Biol. Sci.20062732327233310.1098/rspb.2006.3575 38.KilpatrickA.M.KramerL.D.JonesM.J.MarraP.P.DaszakP.West Nile"/>
   <result pre="shifts in mosquito feeding behaviorPLoS Biol.2006460661010.1371/journal.pbio.0040082 39.DawsonJ.R.StoneW.B.EbelG.D.YoungD.S.GalinskiD.S.PensabeneJ.P.FrankeM.A.EidsonM.KramerL.D.Crow deaths caused by" exact="West Nile" post="virus during winterEmerg. Infect. Dis.2007131912191410.3201/eid1312.07041318258045 40.HintonM.G.ReisenW.K.WheelerS.S.TownsendA.K.West Nile Virus Activity"/>
   <result pre="and Eared Grebes Mortality EventPLoS Curr.2014610.1371/currents.outbreaks.b0f031fc8db2a827d9da0f30f0766871 42.Banet-NoachC.SimanovL.MalkinsonM.Direct (non-vector) transmission of" exact="West Nile" post="virus in geeseAvian Pathol.20033248949410.1080/030794503100015408014522704 43.NemethN.YoungG.NdalukaC.Bielefeldt-OhmannH.KomarN.BowenR.Persistent West Nile virus infection"/>
   <result pre="(non-vector) transmission of West Nile virus in geeseAvian Pathol.20033248949410.1080/030794503100015408014522704 43.NemethN.YoungG.NdalukaC.Bielefeldt-OhmannH.KomarN.BowenR.Persistent" exact="West Nile" post="virus infection in the house sparrow (Passer domesticus)Arch. Virol.200915478378910.1007/s00705-009-0369-x19347246"/>
   <result pre="City, 2000Emerg. Infect. Dis.2001774274410.3201/eid0704.01742611585542 45.NelmsB.M.Fechter-LeggettE.CarrollB.D.MacedoP.KluhS.ReisenW.K.Experimental and natural vertical transmission of" exact="West Nile" post="virus by California Culex (Diptera: Culicidae) mosquitoesJ. Med. Entomol.20135037137810.1603/ME1226423540126"/>
   <result pre="virus by California Culex (Diptera: Culicidae) mosquitoesJ. Med. Entomol.20135037137810.1603/ME1226423540126 46.Laboratory-acquired" exact="West Nile" post="virus infections—United States, 2002Morb. Mortal. Wkly. Rep.20025111331135 47.collab: Centers"/>
   <result pre="Wkly. Rep.2003521017101914574276 48.Centers for Disease Control and Prevention (CDC) Intrauterine" exact="West Nile" post="virus infection—New York, 2002Morb. Mortal. Wkly. Rep.20025111351136 49.HinckleyA.F.O’LearyD.R.HayesE.B.Transmission of"/>
   <result pre="Nile virus infection—New York, 2002Morb. Mortal. Wkly. Rep.20025111351136 49.HinckleyA.F.O’LearyD.R.HayesE.B.Transmission of" exact="West Nile" post="virus through human breast milk seems to be rarePediatrics2007119e666e67110.1542/peds.2006-210717332186"/>
   <result pre="milk seems to be rarePediatrics2007119e666e67110.1542/peds.2006-210717332186 50.DoddR.Y.FosterG.A.StramerS.L.Keeping Blood Transfusion Safe From" exact="West Nile" post="Virus: American Red Cross Experience, 2003 to 2012Transfus. Med."/>
   <result pre="Med. Rev.20152915316110.1016/j.tmrv.2015.03.00125841631 51.AnesiJ.A.SilveiraF.P.AST Infectious Diseases Community of Practice Arenaviruses and" exact="West Nile" post="Virus in solid organ transplant recipients: Guidelines from the"/>
   <result pre="from equines in Argentina, 2006Emerg. Infect. Dis.2006121559156110.3201/eid1210.06085217176571 53.BlitvichB.J.Fernandez-SalasI.Contreras-CorderoJ.F.MarleneeN.L.Gonzalez-RojasJ.I.KomarN.GublerD.J.CalisherC.H.BeatyB.J.Serologic evidence of" exact="West Nile" post="virus infection in horses, Coahuila State, MexicoEmerg. Infect. Dis.2003985385610.3201/eid0907.03016612890327"/>
   <result pre="of yellow fever and Japanese encephalitis vaccines for immunization against" exact="West Nile" post="virusVaccine2005234785479210.1016/j.vaccine.2005.04.03615939510 57.SwaddleJ.P.CalosS.E.Increased avian diversity is associated with lower incidence"/>
   <result pre="57.SwaddleJ.P.CalosS.E.Increased avian diversity is associated with lower incidence of human" exact="West Nile" post="infection: Observation of the dilution effectPLoS ONE20083e248810.1371/journal.pone.000248818575599 58.GrubaughN.D.SmithD.R.BrackneyD.E.Bosco-LauthA.M.FauverJ.R.CampbellC.L.FelixT.A.RomoH.DuggalN.K.DietrichE.A.et al.Experimental"/>
   <result pre="Population Structure and Competitive FitnessPLoS Pathog.201511e100487410.1371/journal.ppat.100487425993022 59.BraultA.C.HuangC.Y.-H.LangevinS.A.KinneyR.M.BowenR.A.RameyW.N.PanellaN.A.HolmesE.C.PowersA.M.MillerB.R.A single positively selected" exact="West Nile" post="viral mutation confers increased virogenesis in American crowsNat. Genet.200739116210.1038/ng209717694056"/>
   <result pre="Robins: New insights on dose responsePLoS ONE20138e6853710.1371/journal.pone.006853723844218 61.KlenkK.SnowJ.MorganK.BowenR.StephensM.FosterF.GordyP.BeckettS.KomarN.GublerD.et al.Alligators as" exact="West Nile" post="Virus AmplifiersEmerg. Infect. Dis.2004102150215510.3201/eid1012.04026415663852 62.PlattK.B.TuckerB.J.HalburP.G.BlitvichB.J.FabiosaF.G.MullinK.ParikhG.R.KitikoonP.BartholomayL.C.RowleyW.A.Fox squirrels (Sciurus niger) develop"/>
   <result pre="Nile Virus AmplifiersEmerg. Infect. Dis.2004102150215510.3201/eid1012.04026415663852 62.PlattK.B.TuckerB.J.HalburP.G.BlitvichB.J.FabiosaF.G.MullinK.ParikhG.R.KitikoonP.BartholomayL.C.RowleyW.A.Fox squirrels (Sciurus niger) develop" exact="West Nile" post="virus viremias sufficient for infecting select mosquito speciesVector Borne"/>
   <result pre="speciesVector Borne Zoonotic Dis.2008822523310.1089/vbz.2007.018218240969 63.TiawsirisupS.PlattK.B.TuckerB.J.RowleyW.A.Eastern cottontail rabbits (Sylvilagus floridanus) develop" exact="West Nile" post="virus viremias sufficient for infecting select mosquito speciesVector-Borne Zoonotic"/>
   <result pre="Laboratory MedicineIsmailN.SnyderJ.William PasculleA.SaundersPhiladelphia, PA, USA2017 65.SejvarJ.J.Clinical manifestations and outcomes of" exact="West Nile" post="virus infectionViruses2014660662310.3390/v602060624509812 66.SejvarJ.J.HaddadM.B.TierneyB.C.CampbellG.L.MarfinA.A.Van GerpenJ.A.FleischauerA.LeisA.A.StokicD.S.PetersenL.R.Neurologic Manifestations and Outcome of West"/>
   <result pre="West Nile virus infectionViruses2014660662310.3390/v602060624509812 66.SejvarJ.J.HaddadM.B.TierneyB.C.CampbellG.L.MarfinA.A.Van GerpenJ.A.FleischauerA.LeisA.A.StokicD.S.PetersenL.R.Neurologic Manifestations and Outcome of" exact="West Nile" post="Virus InfectionJ. Am. Med. Assoc.200329051151510.1001/jama.290.4.511 67.AgamanolisD.P.LeslieM.J.CavenyE.A.GuarnerJ.ShiehW.J.ZakiS.R.Neuropathological findings in West"/>
   <result pre="West Nile Virus InfectionJ. Am. Med. Assoc.200329051151510.1001/jama.290.4.511 67.AgamanolisD.P.LeslieM.J.CavenyE.A.GuarnerJ.ShiehW.J.ZakiS.R.Neuropathological findings in" exact="West Nile" post="virus encephalitis: A case reportAnn. Neurol.20035454755110.1002/ana.1073114520673 68.DoronS.I.DasheJ.F.AdelmanL.S.BrownW.F.WernerB.G.HadleyS.Histopathologically proven poliomyelitis"/>
   <result pre="poliomyelitis with quadriplegia and loss of brainstem function due to" exact="West Nile" post="virus infectionClin. Infect. Dis.200337e74e7710.1086/37717712942423 69.FanE.NeedhamD.M.BruntonJ.KernR.Z.StewartT.E.West Nile virus infection in"/>
   <result pre="case series and literature reviewCan. Respir. J.20041135435810.1155/2004/90615015332138 70.KelleyT.W.PraysonR.A.RuizA.I.IsadaC.M.GordonS.M.KelleyT.W.RuizA.I.PraysonR.A.GordonS.M.IsadaC.M.The Neuropathology of" exact="West Nile" post="Virus Meningoencephalitis: A Report of Two Cases and Review"/>
   <result pre="Pathol.200311974975310.1309/PU4R76JJMG1F81RP12760295 71.BouffardJ.P.RiudavetsM.A.HolmanR.RushingE.J.Neuropathology of the brain and spinal cord in human" exact="West Nile" post="virus infectionClin. Neuropathol.200423596115074579 72.ShiehW.J.GuarnerJ.LaytonM.FineA.MillerJ.NashD.CampbellG.L.RoehrigJ.T.GublerD.J.ZakiS.R.The role of pathology in an"/>
   <result pre="role of pathology in an investigation of an outbreak of" exact="West Nile" post="encephalitis in New York, 1999Emerg. Infect. Dis.2000637037210.3201/eid0604.00040710905969 73.SchafernakK.T.BigioE.H.West Nile"/>
   <result pre="nigral degenerationCan. J. Neurol. Sci.20063340741017168167 74.FratkinJ.D.LeisA.A.StokicD.S.SlavinskiS.A.GeissR.W.Spinal Cord Neuropathology in Human" exact="West Nile" post="Virus InfectionArch. Pathol. Lab. Med.200412853353715086282 75.GuarnerJ.ShiehW.-J.HunterS.PaddockC.D.MorkenT.CampbellG.L.MarfinA.A.ZakiS.R.Clinicopathologic study and laboratory"/>
   <result pre="Med.200412853353715086282 75.GuarnerJ.ShiehW.-J.HunterS.PaddockC.D.MorkenT.CampbellG.L.MarfinA.A.ZakiS.R.Clinicopathologic study and laboratory diagnosis of 23 cases with" exact="West Nile" post="virus encephalomyelitisHum. Pathol.20043598399010.1016/j.humpath.2004.04.00815297965 76.OmaluB.I.ShakirA.A.WangG.LipkinW.I.WileyC.A.Fatal fulminant pan-meningo-polioencephalitis due to West"/>
   <result pre="West Nile virus encephalomyelitisHum. Pathol.20043598399010.1016/j.humpath.2004.04.00815297965 76.OmaluB.I.ShakirA.A.WangG.LipkinW.I.WileyC.A.Fatal fulminant pan-meningo-polioencephalitis due to" exact="West Nile" post="virusBrain Pathol.20031346547210.1111/j.1750-3639.2003.tb00477.x14655752 77.LeisA.A.FratkinJ.StokicD.S.HarringtonT.WebbR.M.SlavinskiS.A.West nile poliomyelitisLancet Infect. Dis.2003391010.1016/S1473-3099(03)00478-X12505023 78.SampsonB.A.NieldsH.ArmbrustmacherV.AsnisD.S.Muscle weakness"/>
   <result pre="virusBrain Pathol.20031346547210.1111/j.1750-3639.2003.tb00477.x14655752 77.LeisA.A.FratkinJ.StokicD.S.HarringtonT.WebbR.M.SlavinskiS.A.West nile poliomyelitisLancet Infect. Dis.2003391010.1016/S1473-3099(03)00478-X12505023 78.SampsonB.A.NieldsH.ArmbrustmacherV.AsnisD.S.Muscle weakness in" exact="West Nile" post="encephalitis is due to destruction of motor neuronsHum. Pathol.20033462862910.1016/S0046-8177(03)00203-X12827621"/>
   <result pre="the blood-retinal barrierViruses20181053010.3390/v1010053030274199 80.KhairallahM.Ben YahiaS.LadjimiA.ZeghidiH.Ben RomdhaneF.BesbesL.ZaoualiS.MessaoudR.Chorioretinal involvement in patients with" exact="West Nile" post="virus infectionOphthalmology20041112065207010.1016/j.ophtha.2004.03.03215522373 81.GargS.JampolL.M.Systemic and intraocular manifestations of West Nile"/>
   <result pre="with West Nile virus infectionOphthalmology20041112065207010.1016/j.ophtha.2004.03.03215522373 81.GargS.JampolL.M.Systemic and intraocular manifestations of" exact="West Nile" post="virus infectionSurv. Ophthalmol.20055031310.1016/j.survophthal.2004.10.00115621074 82.BainsH.S.JampolL.M.CaughronM.C.ParnellJ.R.Vitritis and chorioretinitis in a patient"/>
   <result pre="virus infectionSurv. Ophthalmol.20055031310.1016/j.survophthal.2004.10.00115621074 82.BainsH.S.JampolL.M.CaughronM.C.ParnellJ.R.Vitritis and chorioretinitis in a patient with" exact="West Nile" post="virus infectionArch. Ophthalmol.200312120520712583786 83.HershbergerV.S.AugsburgerJ.J.HutchinsR.K.MillerS.A.HorwitzJ.A.BergmannM.Chorioretinal lesions in nonfatal cases of"/>
   <result pre="Nile virus infectionArch. Ophthalmol.200312120520712583786 83.HershbergerV.S.AugsburgerJ.J.HutchinsR.K.MillerS.A.HorwitzJ.A.BergmannM.Chorioretinal lesions in nonfatal cases of" exact="West Nile" post="virus infectionOphthalmology20031101732173610.1016/S0161-6420(03)00720-613129870 84.MurrayK.O.BaraniukS.ResnickM.ArafatR.KilbornC.ShallenbergerR.YorkT.L.MartinezD.MalkoffM.ElgawleyN.et al.Clinical investigation of hospitalized human cases"/>
   <result pre="virus infectionOphthalmology20031101732173610.1016/S0161-6420(03)00720-613129870 84.MurrayK.O.BaraniukS.ResnickM.ArafatR.KilbornC.ShallenbergerR.YorkT.L.MartinezD.MalkoffM.ElgawleyN.et al.Clinical investigation of hospitalized human cases of" exact="West Nile" post="virus infection in Houston, Texas, 2002–2004Vector Borne Zoonotic Dis.2008816717410.1089/vbz.2007.010918399781"/>
   <result pre="Dis.2008816717410.1089/vbz.2007.010918399781 85.LindseyN.P.SejvarJ.J.BodeA.V.PapeW.J.CampbellG.L.Delayed mortality in a cohort of persons hospitalized with" exact="West Nile" post="virus disease in Colorado in 2003Vector Borne Zoonotic Dis.20121223023510.1089/vbz.2011.072122022816"/>
   <result pre="in Colorado in 2003Vector Borne Zoonotic Dis.20121223023510.1089/vbz.2011.072122022816 86.AlbagaliC.ChaimoffR.A case of" exact="West Nile" post="myocarditisHarefuah19595727427613792333 87.KushawahaA.JadonathS.MobarakaiN.West nile virus myocarditis causing a fatal arrhythmia:"/>
   <result pre="causing a fatal arrhythmia: A case reportCases J.20092714710.1186/1757-1626-2-714719829922 88.PergamS.A.DeLongC.E.EchevarriaL.ScullyG.GoadeD.E.Myocarditis in" exact="West Nile" post="Virus infectionAm. J. Trop. Med. Hyg.2006751232123310.4269/ajtmh.2006.75.123217172398 89.MathiotC.C.GonzalezJ.P.GeorgesA.J.Current problems of"/>
   <result pre="encephalitis with myositis and orchitisHum. Pathol.20043525425810.1016/j.humpath.2003.09.00714991545 91.SampsonB.A.AmbrosiC.CharlotA.ReiberK.VeressJ.F.ArmbrustmacherV.The pathology of human" exact="West Nile" post="virus infectionHum. Pathol.20003152753110.1053/hp.2000.804710836291 92.SejvarJ.J.CurnsA.T.WelburgL.JonesJ.F.LundgrenL.M.CapuronL.PapeJ.ReevesW.C.CampbelG.L.Neurocognitive and functional outcomes in persons"/>
   <result pre="infectionHum. Pathol.20003152753110.1053/hp.2000.804710836291 92.SejvarJ.J.CurnsA.T.WelburgL.JonesJ.F.LundgrenL.M.CapuronL.PapeJ.ReevesW.C.CampbelG.L.Neurocognitive and functional outcomes in persons recovering from" exact="West Nile" post="virus illnessJ. Neuropsychol.2008247749910.1348/174866407X21831219824176 93.MurrayK.O.NolanM.S.RoncaS.E.DattaS.GovindarajanK.NarayanaP.A.SalazarL.WoodsS.P.HasbunR.The neurocognitive and Mri Outcomes of"/>
   <result pre="control group KristyFront. Neurol.2018911110.3389/fneur.2018.0011129636722 94.CarsonP.J.KonewkoP.WoldK.S.MarianiP.GoliS.BergloffP.CrosbyR.D.Long-Term Clinical and Neuropsychological Outcomes of" exact="West Nile" post="Virus InfectionClin. Infect. Dis.20064372373010.1086/50693916912946 95.CookR.L.XuX.YablonskyE.J.SakataN.TrippJ.H.HessR.PiazzaP.RinaldoC.R.Demographic and clinical factors associated"/>
   <result pre="Dis.20064372373010.1086/50693916912946 95.CookR.L.XuX.YablonskyE.J.SakataN.TrippJ.H.HessR.PiazzaP.RinaldoC.R.Demographic and clinical factors associated with persistent symptoms after" exact="West Nile" post="virus infectionAm. J. Trop. Med. Hyg.2010831133113610.4269/ajtmh.2010.09-071721036852 96.BuschM.P.KleinmanS.H.ToblerL.H.KamelH.T.NorrisP.J.WalshI.MatudJ.L.PrinceH.E.LanciottiR.S.WrightD.J.et al.Virus and"/>
   <result pre="Trop. Med. Hyg.2010831133113610.4269/ajtmh.2010.09-071721036852 96.BuschM.P.KleinmanS.H.ToblerL.H.KamelH.T.NorrisP.J.WalshI.MatudJ.L.PrinceH.E.LanciottiR.S.WrightD.J.et al.Virus and Antibody Dynamics in Acute" exact="West Nile" post="Virus InfectionJ. Infect. Dis.200819898499310.1086/59146718729783 97.MurrayK.WalkerC.HerringtonE.LewisJ.A.McCormickJ.BeasleyD.W.C.TeshR.B.Fisher-HochS.Persistent Infection with West Nile"/>
   <result pre="Acute West Nile Virus InfectionJ. Infect. Dis.200819898499310.1086/59146718729783 97.MurrayK.WalkerC.HerringtonE.LewisJ.A.McCormickJ.BeasleyD.W.C.TeshR.B.Fisher-HochS.Persistent Infection with" exact="West Nile" post="Virus Years after Initial InfectionJ. Infect. Dis.20102012410.1086/64873119961306 98.PennR.G.GuarnerJ.SejvarJ.J.HartmanH.McCombR.D.NevinsD.L.BhatnagarJ.ZakiS.R.Persistent neuroinvasive"/>
   <result pre="Nile Virus Years after Initial InfectionJ. Infect. Dis.20102012410.1086/64873119961306 98.PennR.G.GuarnerJ.SejvarJ.J.HartmanH.McCombR.D.NevinsD.L.BhatnagarJ.ZakiS.R.Persistent neuroinvasive" exact="West Nile" post="virus infection in an immunocompromised patientClin. Infect. Dis.20064268068310.1086/50021616447115 99.NolanM.S.PodollA.S.HauseA.M.AkersK.M.FinkelK.W.MurrayK.O.Prevalence"/>
   <result pre="of disease over time among patients enrolled in the Houston" exact="West Nile" post="virus cohortPLoS ONE20127e4037410.1371/journal.pone.004037422792293 100.SteeleK.E.LinnM.J.SchoeppR.J.KomarN.GeisbertT.W.ManducaR.M.CalleP.P.RaphaelB.L.ClippingerT.L.LarsenT.et al.Pathology of fatal West Nile"/>
   <result pre="Houston West Nile virus cohortPLoS ONE20127e4037410.1371/journal.pone.004037422792293 100.SteeleK.E.LinnM.J.SchoeppR.J.KomarN.GeisbertT.W.ManducaR.M.CalleP.P.RaphaelB.L.ClippingerT.L.LarsenT.et al.Pathology of fatal" exact="West Nile" post="virus infections in native and exotic birds during the"/>
   <result pre="City, New YorkVet. Pathol.20003720822410.1354/vp.37-3-20810810985 101.GaminoV.HöfleU.Pathology and tissue tropism of natural" exact="West Nile" post="virus infection in birds: A reviewVet. Res.2013443910.1186/1297-9716-44-3923731695 102.KomarN.LangevinS.HintenS.NemethN.EdwardsE.HettlerD.DavisB.BowenR.BunningM.Experimental infection"/>
   <result pre="North American birds with the New York 1999 strain of" exact="West Nile" post="virusEmerg. Infect. Dis.2003931132210.3201/eid0903.02062812643825 103.NemethN.GouldD.BowenR.KomarN.Natural and experimental West Nile virus"/>
   <result pre="strain of West Nile virusEmerg. Infect. Dis.2003931132210.3201/eid0903.02062812643825 103.NemethN.GouldD.BowenR.KomarN.Natural and experimental" exact="West Nile" post="virus infection in five raptor speciesJ. Wildl. Dis.20064211310.7589/0090-3558-42.1.116699143 104.PalmieriC.FrancaM.UzalF.AndersonM.BarrB.WoodsL.MooreJ.WoolcockP.ShivaprasadH.L.Pathology"/>
   <result pre="five raptor speciesJ. Wildl. Dis.20064211310.7589/0090-3558-42.1.116699143 104.PalmieriC.FrancaM.UzalF.AndersonM.BarrB.WoodsL.MooreJ.WoolcockP.ShivaprasadH.L.Pathology and Immunohistochemical Findings of" exact="West Nile" post="Virus Infection in PsittaciformesVet. Pathol.20114897598410.1177/030098581039111221160024 105.EckstrandC.D.WoodsL.W.DiabS.S.CrossleyB.M.GiannittiF.Diagnostic exercise: High mortality"/>
   <result pre="umbellus): Experimental Infection and Protective Effects of VaccinationVet. Pathol.20175490191110.1177/030098581771777028675106 107.BakonyiT.GajdonG.K.SchwingR.VoglW.HäbichA.C.ThallerD.WeissenböckH.RudolfI.HubálekZ.NowotnyN.Chronic" exact="West Nile" post="virus infection in kea (Nestor notabilis)Vet. Microbiol.201618313513910.1016/j.vetmic.2015.12.01226790946 108.GaminoV.Escribano-RomeroE.Gutiérrez-GuzmánA.V.BlázquezA.B.SaizJ.C.HöfleU.Oculopathologic Findings"/>
   <result pre="in Flavivirus-Infected Gallinaceous BirdsVet. Pathol.2014511113111610.1177/030098581351664024395913 109.ZieglerU.AngenvoortJ.FischerD.FastC.EidenM.RodriguezA.V.Revilla-FernándezS.NowotnyN.de la FuenteJ.G.LierzM.et al.Pathogenesis of" exact="West Nile" post="virus lineage 1 and 2 in experimentally infected large"/>
   <result pre="(Haliaeetus leucocephalus) and golden eagles (Aquila chrysaetos) naturally infected with" exact="West Nile" post="virusJ. Vet. Diagn. Investig.20142659960910.1177/104063871453996025085868 111.HofmeisterE.PorterR.E.Christian FransonJ.Experimental susceptibility of Wood"/>
   <result pre="Investig.20142659960910.1177/104063871453996025085868 111.HofmeisterE.PorterR.E.Christian FransonJ.Experimental susceptibility of Wood Ducks (Aix sponsa) for" exact="West Nile" post="virusJ. Wildl. Dis.20155141141810.7589/2014-08-21625588010 112.CoxS.L.CampbellG.D.NemethN.M.Outbreaks of West Nile virus in"/>
   <result pre="(Aix sponsa) for West Nile virusJ. Wildl. Dis.20155141141810.7589/2014-08-21625588010 112.CoxS.L.CampbellG.D.NemethN.M.Outbreaks of" exact="West Nile" post="virus in captive waterfowl in Ontario, CanadaAvian Pathol.20154413514110.1080/03079457.2015.101160425636141 113.GaminoV.Escribano-RomeroE.BlázquezA.B.Gutiérrez-GuzmánA.V.Martín-AcebesM.SaizJ.C.HöfleU.Experimental"/>
   <result pre="in captive waterfowl in Ontario, CanadaAvian Pathol.20154413514110.1080/03079457.2015.101160425636141 113.GaminoV.Escribano-RomeroE.BlázquezA.B.Gutiérrez-GuzmánA.V.Martín-AcebesM.SaizJ.C.HöfleU.Experimental North American" exact="West Nile" post="Virus Infection in the Red-legged Partridge (Alectoris rufa)Vet. Pathol.20165358559310.1177/030098581561255426508695"/>
   <result pre="Lesions in Red-Tailed Hawks (Buteo jamaicensis ) With Naturally Acquired" exact="West Nile" post="DiseaseVet. Pathol.20175427728710.1177/030098581666940427694424 117.LopesH.RedigP.GlaserA.ArmienA.WünschmannA.Clinical findings, lesions, and viral antigen distribution"/>
   <result pre="owls (Strix nebulosa) and barred owls (Strix varia) with spontaneous" exact="West Nile" post="virus infectionAvian Dis.20075114014510.1637/0005-2086(2007)051[0140:CFLAVA]2.0.CO;217461282 118.WünschmannA.ShiversJ.BenderJ.CarrollL.FullerS.SaggeseM.van WettereA.RedigP.Pathologic and Immunohistochemical Findings in"/>
   <result pre="gentilis) and Great Horned Owls (Bubo virginianus) Naturally Infected with" exact="West Nile" post="VirusAvian Dis.20054925225910.1637/7297-103104R16094831 119.PauliA.M.Cruz-MartinezL.A.PonderJ.B.RedigP.T.GlaserA.L.KlaussG.SchosterJ.V.WünschmannA.Ophthalmologic and oculopathologic findings in red-tailed hawks"/>
   <result pre="findings in red-tailed hawks and Cooper’s hawks with naturally acquired" exact="West Nile" post="virus infectionJ. Am. Vet. Med. Assoc.20072311240124810.2460/javma.231.8.124017937556 120.NemethN.M.ThomsenB.V.SprakerT.R.BensonJ.M.Bosco-LauthA.M.OesterleP.T.BrightJ.M.MuthJ.P.CampbellT.W.GidlewskiT.L.et al.Clinical and"/>
   <result pre="Crows (Corvus brachyrhynchos) and Fish Crows (C ossifragus) to Experimental" exact="West Nile" post="Virus InfectionVet. Pathol.2011481061107410.1177/030098581139824921383115 121.ErnestH.B.WoodsL.W.HoarB.R.Pathology associated with West Nile virus"/>
   <result pre="to Experimental West Nile Virus InfectionVet. Pathol.2011481061107410.1177/030098581139824921383115 121.ErnestH.B.WoodsL.W.HoarB.R.Pathology associated with" exact="West Nile" post="virus infections in the yellow-billed magpie (Pica nuttalli): A"/>
   <result pre="(Pica nuttalli): A California endemic birdJ. Wildl. Dis.20104640140810.7589/0090-3558-46.2.40120688633 122.SwayneD.E.BeckJ.R.ZakiS.Pathogenicity of" exact="West Nile" post="Virus for TurkeysAvian Dis.20004493210.2307/159306711195649 123.SenneD.A.PedersenJ.C.HuttoD.L.TaylorW.D.SchmittB.J.PanigrahyB.Pathogenicity of West Nile Virus"/>
   <result pre="122.SwayneD.E.BeckJ.R.ZakiS.Pathogenicity of West Nile Virus for TurkeysAvian Dis.20004493210.2307/159306711195649 123.SenneD.A.PedersenJ.C.HuttoD.L.TaylorW.D.SchmittB.J.PanigrahyB.Pathogenicity of" exact="West Nile" post="Virus in ChickensAvian Dis.20004464210.2307/159310511007013 124.RosenbergK.V.DokterA.M.BlancherP.J.SauerJ.R.SmithA.C.SmithP.A.StantonJ.C.PanjabiA.HelftL.ParrM.et al.Decline of the North"/>
   <result pre="124.RosenbergK.V.DokterA.M.BlancherP.J.SauerJ.R.SmithA.C.SmithP.A.StantonJ.C.PanjabiA.HelftL.ParrM.et al.Decline of the North American avifaunaScience201936612012410.1126/science.aaw131331604313 125.GeorgeT.L.HarriganR.J.LamannaJ.A.DesanteD.F.SaraccoJ.F.SmithT.B.Persistent impacts of" exact="West Nile" post="virus on North American bird populationsProc. Natl. Acad. Sci."/>
   <result pre="large-scale declines of North American bird populationsNature200744771071310.1038/nature0582917507930 127.WheelerS.S.BarkerC.M.FangY.ArmijosM.V.CarrollB.D.HustedS.JohnsonW.O.ReisenW.K.Differential Impact of" exact="West Nile" post="Virus on California BirdsCondor200911112010.1525/cond.2009.08001320589226 128.KilpatrickA.M.WheelerS.S.Impact of West Nile Virus"/>
   <result pre="Impact of West Nile Virus on California BirdsCondor200911112010.1525/cond.2009.08001320589226 128.KilpatrickA.M.WheelerS.S.Impact of" exact="West Nile" post="Virus on Bird Populations: Limited Lasting Effects, Evidence for"/>
   <result pre="on EcosystemsJ. Med. Entomol.2019561491149710.1093/jme/tjz14931549723 129.GibbsS.E.J.WimberlyM.C.MaddenM.MasourJ.YabsleyM.J.StallknechtD.E.Factors affecting the geographic distribution of" exact="West Nile" post="virus in Georgia, USA: 2002–2004Vector Borne Zoonotic Dis.20066738210.1089/vbz.2006.6.7316584329 130.CrowderD.W.DykstraE.A.BraunerJ.M.DuffyA.ReedC.MartinE.PetersonW.CarrièreY.DutilleulP.OwenJ.P.West"/>
   <result pre="on vector and host communitiesPLoS ONE20138e5500610.1371/journal.pone.005500623383032 131.BradleyC.A.GibbsS.E.J.AltizerS.Urban land use predicts" exact="West Nile" post="virus exposure in songbirdsEcol. Appl.2008181083109210.1890/07-0822.118686573 132.ReisenW.K.HahnD.C.Comparison of immune responses"/>
   <result pre="of immune responses of brown-headed cowbird and related blackbirds to" exact="West Nile" post="and other mosquito-borne encephalitis virusesJ. Wildl. Dis.20074343944910.7589/0090-3558-43.3.43917699082 133.WardM.P.SchuermannJ.A.HighfieldL.D.MurrayK.O.Characteristics of"/>
   <result pre="mosquito-borne encephalitis virusesJ. Wildl. Dis.20074343944910.7589/0090-3558-43.3.43917699082 133.WardM.P.SchuermannJ.A.HighfieldL.D.MurrayK.O.Characteristics of an outbreak of" exact="West Nile" post="virus encephalomyelitis in a previously uninfected population of horsesVet."/>
   <result pre="cell populations in the brains of horses experimentally infected with" exact="West Nile" post="virusEquine Vet. J.20174981582010.1111/evj.1269728470955 138.CantileC.Del PieroF.Di GuardoG.ArispiciM.Del PieroF.Di GuardoG.ArispiciM.Pathologic and"/>
   <result pre="PieroF.Di GuardoG.ArispiciM.Del PieroF.Di GuardoG.ArispiciM.Pathologic and Immunohistochemical Findings in Naturally Occurring" exact="West Nile" post="Virus Infection in HorsesVet Pathol.20013841442110.1354/vp.38-4-41411467475 139.YaegerM.YoonK.-J.SchwartzK.BerklandL.West Nile virus meningoencephalitis"/>
   <result pre="Investig.20041621922210.1177/10406387040160030715152836 142.DuttonC.J.QuinnellM.LindsayR.DeLayJ.BarkerI.K.Paraparesis in a polar bear (Ursus maritimus) associated with" exact="West Nile" post="virus infectionJ. Zoo Wildl. Med.20094056857110.1638/2008-0121.119746875 143.MillerD.L.RadiZ.A.BaldwinC.IngramD.Fatal West Nile virus"/>
   <result pre="associated with West Nile virus infectionJ. Zoo Wildl. Med.20094056857110.1638/2008-0121.119746875 143.MillerD.L.RadiZ.A.BaldwinC.IngramD.Fatal" exact="West Nile" post="virus infection in a white-tailed deer (Odocoileus virginianus)J. Wildl."/>
   <result pre="SheepVet. Pathol.20175415515810.1177/030098581665379627312367 147.RootJ.J.OesterleP.T.NemethN.M.KlenkK.GouldD.H.McLeanR.G.ClarkL.HallJ.S.Experimental infection of fox squirrels (Sciurus niger) with" exact="West Nile" post="virusAm. J. Trop. Med. Hyg.20067569770110.4269/ajtmh.2006.75.69717038697 148.NevarezJ.G.MitchellM.A.MorganT.RoyA.JohnsonA.Association of West Nile"/>
   <result pre="with West Nile virusAm. J. Trop. Med. Hyg.20067569770110.4269/ajtmh.2006.75.69717038697 148.NevarezJ.G.MitchellM.A.MorganT.RoyA.JohnsonA.Association of" exact="West Nile" post="Virus with Lymphohistiocytic Proliferative Cutaneous Lesions in American Alligators"/>
   <result pre="alligatorsEmerg. Infect. Dis.2003979479910.3201/eid0907.03008512890319 151.CannonA.B.LuffJ.A.BraultA.C.MacLachlanN.J.CaseJ.B.GreenE.N.G.SykesJ.E.Acute encephalitis, polyarthritis, and myocarditis associated with" exact="West Nile" post="virus infection in a dogJ. Vet. Intern. Med.2006201219122310.1111/j.1939-1676.2006.tb00726.x17063720 152.LanthierI.HébertM.TremblayD.HarelJ.DallaireA.D.GirardC.Natural"/>
   <result pre="Nile virus infection in a dogJ. Vet. Intern. Med.2006201219122310.1111/j.1939-1676.2006.tb00726.x17063720 152.LanthierI.HébertM.TremblayD.HarelJ.DallaireA.D.GirardC.Natural" exact="West Nile" post="virus infection in a captive juvenile Arctic wolf (Canis"/>
   <result pre="lupus)J. Vet. Diagn. Investig.20041632632910.1177/10406387040160041215305745 153.PaddockC.D.NicholsonW.L.BhatnagarJ.GoldsmithC.S.GreerP.W.HayesE.B.RiskoJ.A.HendersonC.BlackmoreC.G.LanciottiR.S.et al.Fatal Hemorrhagic Fever Caused by" exact="West Nile" post="Virus in the United StatesClin. Infect. Dis.2006421527153510.1086/50384116652309 154.Garcia-TapiaD.HassettD.E.MitchellW.J.JohnsonG.C.KleiboekerS.B.West Nile"/>
   <result pre="in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with" exact="West Nile" post="virus susceptibility in laboratory miceProc. Natl. Acad. Sci. USA200299113111131610.1073/pnas.17219539912186974"/>
   <result pre="flavivirus encephalitisAdv. Virus Res.20036027334214689697 161.ShresthaB.GottliebD.DiamondM.S.Infection and Injury of Neurons by" exact="West Nile" post="Encephalitis VirusJ. Virol.200377132031321310.1128/JVI.77.24.13203-13213.200314645577 162.HimsworthC.G.GurneyK.E.B.NeimanisA.S.WobeserG.A.LeightonF.A.An outbreak of West Nile virus"/>
   <result pre="Neurons by West Nile Encephalitis VirusJ. Virol.200377132031321310.1128/JVI.77.24.13203-13213.200314645577 162.HimsworthC.G.GurneyK.E.B.NeimanisA.S.WobeserG.A.LeightonF.A.An outbreak of" exact="West Nile" post="virus infection in captive lesser scaup (Aythya affinis) ducklingsAvian"/>
   <result pre="Pathology of Neurovirulent Lineage 1 (NY99/385) and Lineage 2 (SPU93/01)" exact="West Nile" post="Virus Infections in BALBc MiceVet. Pathol.20155214015110.1177/030098581352024624513801 164.WhiteJ.P.XiongS.MalvinN.P.Khoury-HanoldW.HeuckerothR.O.StappenbeckT.S.DiamondM.S.Intestinal Dysmotility Syndromes"/>
   <result pre="Virol.1996704761476610.1128/JVI.70.7.4761-4766.19968676503 166.ByrneS.N.HallidayG.M.JohnstonL.J.KingN.J.C.Interleukin-1β but not tumor necrosis factor is involved in" exact="West Nile" post="virus-induced Langerhans cell migration from the skin in C57BL/6"/>
   <result pre="Critical Roles in the Immediate Defense of Disseminated Infection by" exact="West Nile" post="Encephalitis VirusJ. Virol.2003772578258610.1128/JVI.77.4.2578-2586.200312551996 169.ShresthaB.WangT.SamuelM.A.WhitbyK.CraftJ.FikrigE.DiamondM.S.Gamma Interferon Plays a Crucial Early"/>
   <result pre="Interferon Plays a Crucial Early Antiviral Role in Protection against" exact="West Nile" post="Virus InfectionJ. Virol.2006805338534810.1128/JVI.00274-0616699014 170.ShresthaB.DiamondM.S.Role of CD8+ T Cells in"/>
   <result pre="InfectionJ. Virol.2006805338534810.1128/JVI.00274-0616699014 170.ShresthaB.DiamondM.S.Role of CD8+ T Cells in Control of" exact="West Nile" post="Virus InfectionJ. Virol.2004788312832110.1128/JVI.78.15.8312-8321.200415254203 171.ShresthaB.SamuelM.A.DiamondM.S.CD8+ T Cells Require Perforin To"/>
   <result pre="Virus InfectionJ. Virol.2004788312832110.1128/JVI.78.15.8312-8321.200415254203 171.ShresthaB.SamuelM.A.DiamondM.S.CD8+ T Cells Require Perforin To Clear" exact="West Nile" post="Virus from Infected NeuronsJ. Virol.20068011912910.1128/JVI.80.1.119-129.200616352536 172.WangY.LobigsM.LeeE.MullbacherA.CD8+ T Cells Mediate"/>
   <result pre="NeuronsJ. Virol.20068011912910.1128/JVI.80.1.119-129.200616352536 172.WangY.LobigsM.LeeE.MullbacherA.CD8+ T Cells Mediate Recovery and Immunopathology in" exact="West Nile" post="Virus EncephalitisJ. Virol.200377133231333410.1128/JVI.77.24.13323-13334.200314645588 173.KleinR.S.LinE.ZhangB.LusterA.D.TollettJ.SamuelM.A.EngleM.DiamondM.S.Neuronal CXCL10 Directs CD8+ T-Cell Recruitment"/>
   <result pre="Virol.200377133231333410.1128/JVI.77.24.13323-13334.200314645588 173.KleinR.S.LinE.ZhangB.LusterA.D.TollettJ.SamuelM.A.EngleM.DiamondM.S.Neuronal CXCL10 Directs CD8+ T-Cell Recruitment and Control of" exact="West Nile" post="Virus EncephalitisJ. Virol.200579114571146610.1128/JVI.79.17.11457-11466.200516103196 174.GlassW.G.LimJ.K.CholeraR.PletnevA.G.GaoJ.L.MurphyP.M.Chemokine receptor CCR5 promotes leukocyte trafficking"/>
   <result pre="CCR5 promotes leukocyte trafficking to the brain and survival in" exact="West Nile" post="virus infectionJ. Exp. Med.20052021087109810.1084/jem.2004253016230476 175.ShiratoK.KimuraT.MizutaniT.KariwaH.TakashimaI.Different chemokine expression in lethal"/>
   <result pre="Exp. Med.20052021087109810.1084/jem.2004253016230476 175.ShiratoK.KimuraT.MizutaniT.KariwaH.TakashimaI.Different chemokine expression in lethal and non-lethal murine" exact="West Nile" post="virus infectionJ. Med. Virol.20047450751310.1002/jmv.2020515368509 176.XiaoS.Y.GuzmanH.ZhangH.Travassos da RosaA.P.TeshR.B.West Nile virus"/>
   <result pre="infection in the golden hamster (Mesocricetus auratus): A model for" exact="West Nile" post="encephalitisEmerg. Infect. Dis.2001771472110.3201/eid0704.01742011585537 177.WangT.Role of γδ T cells in"/>
   <result pre="Nile encephalitisEmerg. Infect. Dis.2001771472110.3201/eid0704.01742011585537 177.WangT.Role of γδ T cells in" exact="West Nile" post="virus-induced encephalitis: Friend or foe?J. Neuroimmunol.2011240222710.1016/j.jneuroim.2011.10.00422078709 178.ZukorK.WangH.HurstB.L.SiddharthanV.Van WettereA.PilowskyP.M.MorreyJ.D.Phrenic nerve"/>
   <result pre="178.ZukorK.WangH.HurstB.L.SiddharthanV.Van WettereA.PilowskyP.M.MorreyJ.D.Phrenic nerve deficits and neurological immunopathology associated with acute" exact="West Nile" post="virus infection in mice and hamstersJ. Neurovirol.20172318620410.1007/s13365-016-0488-627761801 179.MorreyJ.SiddharthanV.WangH.HallJ.SkirpstunasR.OlsenA.NordstromJ.KoenigS.JohnsonS.DiamondM.West Nile"/>
   <result pre="after infection of spinal cord neuronsJ. Neurovirol.20081415216310.1080/1355028080195893018444087 180.SamuelM.A.WangH.SiddharthanV.MorreyJ.D.DiamondM.S.Axonal transport mediates" exact="West Nile" post="virus entry into the central nervous system and induces"/>
   <result pre="acute flaccid paralysisProc. Natl. Acad. Sci. USA2007104171401714510.1073/pnas.070583710417939996 181.TeshR.B.SiirinM.GuzmanH.Travassos da RosaA.P.A.WuX.DuanT.LeiH.NunesM.R.XiaoS.Persistent" exact="West Nile" post="Virus Infection in the Golden Hamster: Studies on Its"/>
   <result pre="Implications for Other Flavivirus InfectionsJ. Infect. Dis.200519228729510.1086/43115315962223 182.ManuelidisE.E.Neuropathology of experimental" exact="West Nile" post="virus infection in monkeysJ. Neuropathol. Exp. Neurol.19561544846010.1097/00005072-195610000-0000713367865 183.PogodinaV.V.FrolovaM.P.MalenkoG.V.FokinaG.I.KoreshkovaG.V.KiselevaL.L.BochkovaN.G.RalphN.M.Study on"/>
   <result pre="Nile virus infection in monkeysJ. Neuropathol. Exp. Neurol.19561544846010.1097/00005072-195610000-0000713367865 183.PogodinaV.V.FrolovaM.P.MalenkoG.V.FokinaG.I.KoreshkovaG.V.KiselevaL.L.BochkovaN.G.RalphN.M.Study on" exact="West Nile" post="virus persistence in monkeysArch. Virol.198375718610.1007/BF013141286299247 184.RatterreeM.S.GutierrezR.A.Travassos da RosaA.P.A.DilleB.J.BeasleyD.W.C.BohmR.P.DesaiS.M.DidierP.J.BikenmeyerL.G.DawsonG.J.et al.Experimental"/>
   <result pre="Virol.198375718610.1007/BF013141286299247 184.RatterreeM.S.GutierrezR.A.Travassos da RosaA.P.A.DilleB.J.BeasleyD.W.C.BohmR.P.DesaiS.M.DidierP.J.BikenmeyerL.G.DawsonG.J.et al.Experimental infection of rhesus macaques with" exact="West Nile" post="virus: Level and duration of viremia and kinetics of"/>
   <result pre="rhesus macaques and common marmosets with a European strain of" exact="West Nile" post="virusPLoS Negl. Trop. Dis.20148e279710.1371/journal.pntd.000279724743302 186.EldadahA.H.NathansonN.SarsitisR.Pathogenesis of West Nile virus"/>
   <result pre="strain of West Nile virusPLoS Negl. Trop. Dis.20148e279710.1371/journal.pntd.000279724743302 186.EldadahA.H.NathansonN.SarsitisR.Pathogenesis of" exact="West Nile" post="virus encephalitis in mice and rats. I. Influence of"/>
   <result pre="and species on mortality and infectionAm. J. Epidemiol.19678676577510.1093/oxfordjournals.aje.a1207856081390 187.EldadahA.H.NathansonN.Pathogenesis of" exact="West Nile" post="virus encephalitis in mice and rats. II. Virus multiplication,"/>
   <result pre="Epidemiol.19678677679010.1093/oxfordjournals.aje.a1207864866286 188.Posadas-HerreraG.InoueS.FukeI.MurakiY.MapuaC.A.KhanA.H.del Carmen ParquetM.ManabeS.TanishitaO.IshikawaT.et al.Development and evaluation of a formalin-inactivated" exact="West Nile" post="Virus vaccine (WN-VAX) for a human vaccine candidateVaccine2010287939794610.1016/j.vaccine.2010.09.07620933564 189.BonaféN.RiningerJ.A.ChubetR.G.FoellmerH.G.FaderS.AndersonJ.F.BushmichS.L.AnthonyK.LedizetM.FikrigE.et"/>
   <result pre="vaccine (WN-VAX) for a human vaccine candidateVaccine2010287939794610.1016/j.vaccine.2010.09.07620933564 189.BonaféN.RiningerJ.A.ChubetR.G.FoellmerH.G.FaderS.AndersonJ.F.BushmichS.L.AnthonyK.LedizetM.FikrigE.et al.A recombinant" exact="West Nile" post="virus envelope protein vaccine candidate produced in Spodoptera frugiperda"/>
   <result pre="frugiperda expresSF+ cellsVaccine20092721322210.1016/j.vaccine.2008.10.04618996430 190.PooreE.A.SlifkaD.K.RauéH.P.ThomasA.HammarlundE.QuintelB.K.TorreyL.L.SlifkaA.M.RichnerJ.M.DuboisM.E.et al.Pre-clinical development of a hydrogen peroxide-inactivated" exact="West Nile" post="virus vaccineVaccine20173528329210.1016/j.vaccine.2016.11.08027919629 191.SeinoK.K.LongM.T.GibbsE.P.J.BowenR.A.BeachboardS.E.HumphreyP.P.DixonM.A.BourgeoisM.A.Comparative efficacies of three commercially available vaccines"/>
   <result pre="virus vaccineVaccine20173528329210.1016/j.vaccine.2016.11.08027919629 191.SeinoK.K.LongM.T.GibbsE.P.J.BowenR.A.BeachboardS.E.HumphreyP.P.DixonM.A.BourgeoisM.A.Comparative efficacies of three commercially available vaccines against" exact="West Nile" post="Virus (WNV) in a short-duration challenge trial involving an"/>
   <result pre="Virus (WNV) in a short-duration challenge trial involving an equine" exact="WNV" post="encephalitis modelClin. Vaccine Immunol.2007141465147110.1128/CVI.00249-0717687109 192.SigerL.BowenR.KaracaK.MurrayM.JagannathaS.EcholsB.NordgrenR.MinkeJ.M.Evaluation of the efficacy provided"/>
   <result pre="192.SigerL.BowenR.KaracaK.MurrayM.JagannathaS.EcholsB.NordgrenR.MinkeJ.M.Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine" exact="West Nile" post="Virus vaccine against an experimental West Nile Virus intrathecal"/>
   <result pre="Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental" exact="West Nile" post="Virus intrathecal challenge in horsesVet. Ther.2006724925617039448 193.ChaintoutisS.C.DiakakisN.PapanastassopoulouM.BanosG.DovasC.I.Evaluation of cross-protection"/>
   <result pre="in horsesVet. Ther.2006724925617039448 193.ChaintoutisS.C.DiakakisN.PapanastassopoulouM.BanosG.DovasC.I.Evaluation of cross-protection of a lineage 1" exact="West Nile" post="virus inactivated vaccine against natural infections from a virulent"/>
   <result pre="conditionsClin. Vaccine Immunol.2015221040104910.1128/CVI.00302-1526178384 194.BunningM.L.BowenR.A.Bruce CroppC.SullivanK.G.DavisB.S.KomarN.GodseyM.S.BakerD.HettlerD.L.HolmesD.A.et al.Experimental infection of horses with" exact="West Nile" post="virusEmerg. Infect. Dis.2002838038610.3201/eid0804.01023911971771 195.Castillo-OlivaresJ.MansfieldK.L.PhippsL.P.JohnsonN.TearleJ.FooksA.R.Antibody response in horses following experimental"/>
   <result pre="Infect. Dis.2002838038610.3201/eid0804.01023911971771 195.Castillo-OlivaresJ.MansfieldK.L.PhippsL.P.JohnsonN.TearleJ.FooksA.R.Antibody response in horses following experimental infection with" exact="West Nile" post="Virus lineages 1 and 2Transbound. Emerg. Dis.20115820621210.1111/j.1865-1682.2010.01197.x21223533 196.LongM.T.GibbsE.P.J.MellencampM.W.ZhangS.BarnettD.C.SeinoK.K.BeachboardS.E.HumphreyP.P.Safety of"/>
   <result pre="lineages 1 and 2Transbound. Emerg. Dis.20115820621210.1111/j.1865-1682.2010.01197.x21223533 196.LongM.T.GibbsE.P.J.MellencampM.W.ZhangS.BarnettD.C.SeinoK.K.BeachboardS.E.HumphreyP.P.Safety of an attenuated" exact="West Nile" post="virus vaccine, live Flavivirus chimera in horsesEquine Vet. J.20073948649010.2746/042516407X21447318065304"/>
   <result pre="of disease and virus controlPathogens2015452955810.3390/pathogens403052926184326 199.TeeheeM.L.BunningM.L.StevensS.BowenR.A.Experimental infection of pigs with" exact="West Nile" post="virus. Brief ReportArch. Virol.20051501249125610.1007/s00705-004-0478-515770358 200.AustgenL.E.BowenR.A.BunningM.L.DavisB.S.MitchellC.J.ChangG.J.J.Experimental Infection of Cats and"/>
   <result pre="Brief ReportArch. Virol.20051501249125610.1007/s00705-004-0478-515770358 200.AustgenL.E.BowenR.A.BunningM.L.DavisB.S.MitchellC.J.ChangG.J.J.Experimental Infection of Cats and Dogs with" exact="West Nile" post="VirusEmerg. Infect. Dis.200410828610.3201/eid1001.02061615078601 201.SteinmanA.Banet-NoachC.SimanovL.GrinfeldN.AizenbergZ.LeviO.LahavD.MalkinsonM.PerkS.ShpigelN.Y.Experimental infection of common garter snakes"/>
   <result pre="Dis.200410828610.3201/eid1001.02061615078601 201.SteinmanA.Banet-NoachC.SimanovL.GrinfeldN.AizenbergZ.LeviO.LahavD.MalkinsonM.PerkS.ShpigelN.Y.Experimental infection of common garter snakes (Thamnophis sirtalis) with" exact="West Nile" post="virusVector Borne Zoonotic Dis.2006636136810.1089/vbz.2006.6.36117187570 202.FagreA.C.KadingR.C.Can bats serve as reservoirs"/>
   <result pre="reservoirs for Arboviruses?Viruses20191121510.3390/v1103021530832426 203.DridiM.Van Den BergT.LecollinetS.LambrechtB.Evaluation of the pathogenicity of" exact="West Nile" post="virus (WNV) lineage 2 strains in a SPF chicken"/>
   <result pre="the trade-off hypothesisPLoS Pathog.20117e100233510.1371/journal.ppat.100233522102808 205.JerzakG.V.S.BrownI.ShiP.-Y.KramerL.D.EbelG.D.Genetic diversity and purifying selection in" exact="West Nile" post="virus populations are maintained during host switchingVirology200837425626010.1016/j.virol.2008.02.03218395240 206.KadingR.C.BiggerstaffB.J.YoungG.KomarN.Mosquitoes used"/>
   <result pre="arbovirus viremia determinations in small vertebratesPLoS ONE20149e9934210.1371/journal.pone.009934224901448 207.GrubaughN.D.FauverJ.R.RückertC.Weger-LucarelliJ.Garcia-LunaS.MurrietaR.A.GendernalikA.SmithD.R.BrackneyD.E.EbelG.D.Mosquitoes Transmit Unique" exact="West Nile" post="Virus Populations during Each Feeding EpisodeCell Rep.20171970971810.1016/j.celrep.2017.03.07628445723 208.WorwaG.HuttonA.A.FreyM.DuggalN.K.BraultA.C.ReisenW.K.Increases in"/>
   <result pre="Each Feeding EpisodeCell Rep.20171970971810.1016/j.celrep.2017.03.07628445723 208.WorwaG.HuttonA.A.FreyM.DuggalN.K.BraultA.C.ReisenW.K.Increases in the competitive fitness of" exact="West Nile" post="virus isolates after introduction into CaliforniaVirology201851417018110.1016/j.virol.2017.11.01729195094 209.DuggalN.K.Bosco-LauthA.BowenR.A.WheelerS.S.ReisenW.K.FelixT.A.MannB.R.RomoH.SwetnamD.M.BarrettA.D.T.et al.Evidence for"/>
   <result pre="isolates after introduction into CaliforniaVirology201851417018110.1016/j.virol.2017.11.01729195094 209.DuggalN.K.Bosco-LauthA.BowenR.A.WheelerS.S.ReisenW.K.FelixT.A.MannB.R.RomoH.SwetnamD.M.BarrettA.D.T.et al.Evidence for Co-evolution of" exact="West Nile" post="Virus and House Sparrows in North AmericaPLoS Negl. Trop."/>
   <result pre="in North AmericaPLoS Negl. Trop. Dis.20148e326210.1371/journal.pntd.000326225357248 210.LangevinS.A.BraultA.C.PanellaN.A.BowenR.A.KomarN.Variation in virulence of" exact="West Nile" post="virus strains for house sparrows (Passer domesticus)Am. J. Trop."/>
   <result pre="Hyg.2005729910210.4269/ajtmh.2005.72.9915728874 211.LangevinS.A.BowenR.A.ReisenW.K.AndradeC.C.RameyW.N.MaharajP.D.AnishchenkoM.KenneyJ.L.DuggalN.K.RomoH.et al.Host Competence and Helicase Activity Differences Exhibited by" exact="West Nile" post="Viral Variants Expressing NS3-249 Amino Acid PolymorphismsPLoS ONE20149e10080210.1371/journal.pone.010080224971589 212.DietrichE.A.LangevinS.A.HuangC.Y.-H.MaharajP.D.DeloreyM.J.BowenR.A.KinneyR.M.BraultA.C.West"/>
   <result pre="Carrion Crows to Experimental Infection with Lineage 1 and 2" exact="West Nile" post="VirusesEmerg. Infect. Dis.2015211357136510.3201/eid2108.14071426197093 216.MurrayK.O.KolodziejS.RoncaS.E.GorchakovR.NavarroP.NolanM.S.PodollA.FinkelK.MandayamS.Visualization of West Nile Virus in"/>
   <result pre="1 and 2 West Nile VirusesEmerg. Infect. Dis.2015211357136510.3201/eid2108.14071426197093 216.MurrayK.O.KolodziejS.RoncaS.E.GorchakovR.NavarroP.NolanM.S.PodollA.FinkelK.MandayamS.Visualization of" exact="West Nile" post="Virus in Urine Sediment using Electron Microscopy and Immunogold"/>
   <result pre="13 years after Russian spring–summer encephalitisJ. Neurol. Sci.19731936337310.1016/0022-510X(73)90100-74716851 Figure 1" exact="West Nile" post="virus transmission cycle. West Nile virus circulates between Culex"/>
   <result pre="encephalitisJ. Neurol. Sci.19731936337310.1016/0022-510X(73)90100-74716851 Figure 1 West Nile virus transmission cycle." exact="West Nile" post="virus circulates between Culex species mosquitoes and avian amplifying"/>
   <result pre="B. Frank, Colorado State University. pathogens-09-00048-t001_Table 1Table 1 Distribution of" exact="West Nile" post="virus (WNV)-infected bird lesions in natural and experimental infections."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7168633\results\search\tropicalVirus\results.xml">
   <result pre="half are mosquito-borne, including the heavily studied: yellow fever (YFV)," exact="West Nile" post="(WNV), dengue (DENV), Japanese encephalitis (JEV), and Zika (ZIKV)"/>
   <result pre="(YFV), West Nile (WNV), dengue (DENV), Japanese encephalitis (JEV), and" exact="Zika" post="(ZIKV) viruses, which will be the focus of this"/>
   <result pre="fever or encephalitis to potentially death. The 2015–2016 outbreak of" exact="ZIKV" post="in South America was also associated with microcephaly in"/>
   <result pre="few mosquito-borne flaviviruses (namely YFV, JEV, and DENV). However, the" exact="DENV" post="vaccine has shown limited efficacy against all DENV serotypes"/>
   <result pre="However, the DENV vaccine has shown limited efficacy against all" exact="DENV" post="serotypes [7,8] and resulted in injury to children in"/>
   <result pre="packaging [28,29]. It has recently been shown that dengue and" exact="ZIKV" post="NS2A recruits the viral genome by binding specifically to"/>
   <result pre="structures for capsid have been solved for ZIKV, JEV, and" exact="WNV" post="[35,42,43]. The DENV C structure is similar to that"/>
   <result pre="have been solved for ZIKV, JEV, and WNV [35,42,43]. The" exact="DENV" post="C structure is similar to that of the other"/>
   <result pre="an artifact of crystallization conditions. Initially, the three-dimensional structures of" exact="DENV" post="and WNV capsid were solved using NMR and crystallography"/>
   <result pre="of crystallization conditions. Initially, the three-dimensional structures of DENV and" exact="WNV" post="capsid were solved using NMR and crystallography respectively [42,46]."/>
   <result pre="regions within the N-terminal domain (first 18 residues) of the" exact="DENV" post="capsid resulted in very slow propagation of virus due"/>
   <result pre="example, L50 and L54 residues in the α2 helices of" exact="DENV" post="C dimers are necessary for the capsid protein’s association"/>
   <result pre="they can be either pro- or anti-viral. The presence of" exact="ZIKV" post="C in nucleoli has been associated with ribosomal stress"/>
   <result pre="localization of capsid in the nucleolus is not specific to" exact="ZIKV" post="as it has been shown for DENV, WNV, and"/>
   <result pre="A closer look into the effects of JEV C and" exact="DENV" post="C in the nucleolus indicated interactions with ribosome biogenesis"/>
   <result pre="factors such as B23 and NPM1 or nucleolin, respectively [21,56]." exact="WNV" post="capsid appears to sequester p53 inhibitor MDM2/HDM2 in the"/>
   <result pre="be considered anti-viral. However, it has also been shown that" exact="YFV" post="C has the ability to suppress the anti-viral RNA"/>
   <result pre="has also been shown to aid in the removal of" exact="WNV" post="C from the nucleolus and present the viral protein"/>
   <result pre="in human lung carcinoma cell lines such as H1299 [19]." exact="WNV" post="C has also been shown to up-regulate protein phosphatase"/>
   <result pre="alternative splicing, or decay of transcripts. In the case of" exact="DENV" post="serotype 1 in Huh7 cells, the largest changes observed"/>
   <result pre="observed were in differential isoforms, indicating alternative splicing [38]. However," exact="ZIKV" post="C has been shown to modulate the non-sense mediated"/>
   <result pre="their own signatures. Affinity purification and mass spectrometry determined that" exact="ZIKV" post="C interacts with various NMD proteins, including poly-A binding"/>
   <result pre="global transcriptome changes, but there has also been evidence of" exact="DENV" post="C binding core histones in the nucleus and death"/>
   <result pre="isothermal titration calorimetry assay to measure the binding affinity of" exact="ZIKV" post="C to four types of nucleic acid: 5′ UTR"/>
   <result pre="to four types of nucleic acid: 5′ UTR of the" exact="ZIKV" post="genome (ssRNA), dsRNA, ssDNA, and dsDNA, which may be"/>
   <result pre="be found in the nucleus. Interestingly their studies indicated that" exact="ZIKV" post="C bound all nucleic acids with affinities in the"/>
   <result pre="mosquitos, as noted previously [48], and others have shown that" exact="ZIKV" post="capsid’s ability to bind ssDNA is made possible by"/>
   <result pre="the specificity appears to be low. The dissociation constant for" exact="DENV" post="capsid is roughly 20 nM [15,17]. Considering the wide"/>
   <result pre="cell entry. One example is the small molecule inhibitor of" exact="DENV" post="C, ST-148 [68,69]. This small molecule binds in the"/>
   <result pre="with host proteins are also valuable targets (see Table 1)." exact="DENV" post="capsid binds nucleolin, as noted previously, disrupting ribosome biogenesis."/>
   <result pre="effective flavivirus antivirals [39]. In 2012, Martins et al. investigated" exact="DENV" post="capsid interactions to lipid droplets by producing peptides mimicking"/>
   <result pre="RecombiTEK (Merial) available since 2004, used to vaccinate horses against" exact="West Nile" post="virus. This recombinant virus uses canarypox as a vector"/>
   <result pre="This recombinant virus uses canarypox as a vector to express" exact="WNV" post="E and prM proteins. Interestingly there are multiple equine"/>
   <result pre="WNV E and prM proteins. Interestingly there are multiple equine" exact="WNV" post="vaccines commercially available: RecombiTEK, a live-attenuated vaccine, and a"/>
   <result pre="and a chimeric vaccine containing the 17D backbone but expressing" exact="WNV" post="E and prM [75]. All of these allow the"/>
   <result pre="of these allow the survival of all horses challenged with" exact="WNV" post="infection, compared to the devastating ~30% fatality rate seen"/>
   <result pre="available to humans. The two most notable are the live-attenuated" exact="YFV" post="17D vaccine and Dengvaxia (a tetravalent DENV chimeric vaccine),"/>
   <result pre="are the live-attenuated YFV 17D vaccine and Dengvaxia (a tetravalent" exact="DENV" post="chimeric vaccine), but there are also vaccines available for"/>
   <result pre="genes for the E and prM proteins from the different" exact="DENV" post="serotypes. It is a tetravalent vaccine, but has only"/>
   <result pre="culture or animal tissue until virulence greatly decreased [77,82]. The" exact="YFV" post="vaccine noted above, 17D, was generated roughly 80 years"/>
   <result pre="attenuation in 17D is its reduced genetic diversity within the" exact="YFV" post="quasi-species, indicating high fidelity caused by mutations within nonstructural"/>
   <result pre="of these attenuated viral genomes for many flaviviruses, including WNV," exact="ZIKV" post="and DENV [86,87,88]. These are initially produced in cells"/>
   <result pre="attenuated viral genomes for many flaviviruses, including WNV, ZIKV and" exact="DENV" post="[86,87,88]. These are initially produced in cells expressing wild-type/full-length"/>
   <result pre="This is common across the dengue serotypes and extends to" exact="Zika" post="virus as well [95,96]. Therefore, there may also be"/>
   <result pre="having a stabilizing effect, preventing uncoating and genome release of" exact="DENV" post="upon viral entry [69,70]. Of course, the canonical function"/>
   <result pre="the Arbovirus Vectors Aedes Aegypti and Ae. AlbopictusElife20154e0834710.7554/eLife.0834726126267 6.MingG.L.TangH.SongH.Advances in" exact="Zika" post="Virus Research: Stem Cell Models, Challenges, and OpportunitiesCell Stem"/>
   <result pre="Challenges, and OpportunitiesCell Stem Cell20161969070210.1016/j.stem.2016.11.01427912090 7.VillarL.DayanG.H.Arredondo-GarcíaJ.L.RiveraD.M.CunhaR.DesedaC.ReynalesH.CostaM.S.Morales-RamírezJ.O.CarrasquillaG.et al.Efficacy of a Tetravalent" exact="Dengue" post="Vaccine in Children in Latin AmericaN. Engl. J. Med.201537211312310.1056/NEJMoa141103725365753"/>
   <result pre="Engl. J. Med.201537211312310.1056/NEJMoa141103725365753 8.HadinegoroS.R.Arredondo-GarcíaJ.L.CapedingM.R.DesedaC.ChotpitayasunondhT.DietzeR.IsmailH.I.M.ReynalesH.LimkittikulK.Rivera-MedinaD.M.et al.Efficacy and Long-Term Safety of a" exact="Dengue" post="Vaccine in Regions of Endemic DiseaseN. Engl. J. Med.20153731195120610.1056/NEJMoa150622326214039"/>
   <result pre="contains a lipid-droplet-binding motifBiochem. J.201244440541510.1042/BJ2011221922428600 15.BykL.A.GamarnikA.V.Properties and Functions of the" exact="Dengue" post="Virus Capsid ProteinAnnu. Rev. Virol.2016326328110.1146/annurev-virology-110615-04233427501261 16.IglesiasN.G.MondotteJ.A.BykL.A.De MaioF.A.SamsaM.M.AlvarezC.GamarnikA.V.Dengue Virus Uses"/>
   <result pre="Virus ProductionJ. Virol.20199310.1128/JVI.00612-19 19.OhW.YangM.R.LeeE.W.ParkK.M.PyoS.YangJ.S.LeeH.W.SongJ.Jab1 Mediates Cytoplasmic Localization and Degradation of" exact="West Nile" post="Virus Capsid ProteinJ. Boil. Chem.2006281301663017410.1074/jbc.M602651200 20.SlomnickiL.P.ChungN.H.ParkerA.HermannT.BoydN.L.HetmanM.Ribosomal stress and Tp53-mediated"/>
   <result pre="Tp53-mediated neuronal apoptosis in response to capsid protein of the" exact="Zika" post="virusSci. Rep.201771665210.1038/s41598-017-16952-829192272 21.TsudaY.MoriY.AbeT.YamashitaT.OkamotoT.IchimuraT.MoriishiK.MatsuuraY.Nucleolar protein B23 interacts with Japanese encephalitis"/>
   <result pre="22.XuZ.AndersonR.HobmanT.C.The Capsid-Binding Nucleolar Helicase DDX56 Is Important for Infectivity of" exact="West Nile" post="VirusJ. Virol.2011855571558010.1128/JVI.01933-1021411523 23.YangM.R.LeeS.R.OhW.LeeE.W.YehJ.Y.NahJ.J.JooY.S.ShinJ.LeeH.W.PyoS.et al.West Nile Virus Capsid Protein Induces"/>
   <result pre="Virol.201084104381044710.1128/JVI.00986-1020686019 25.JunjhonJ.PenningtonJ.G.EdwardsT.J.PereraR.LanmanJ.KuhnR.J.Ultrastructural Characterization and Three-Dimensional Architecture of Replication Sites in" exact="Dengue" post="Virus-Infected Mosquito CellsJ. Virol.2014884687469710.1128/JVI.00118-1424522909 26.WelschS.MillerS.Romero-BreyI.MerzA.BleckC.K.WaltherP.FullerS.D.AntonyC.Krijnse-LockerJ.BartenschlagerR.Composition and Three-Dimensional Architecture of"/>
   <result pre="Virus-Infected Mosquito CellsJ. Virol.2014884687469710.1128/JVI.00118-1424522909 26.WelschS.MillerS.Romero-BreyI.MerzA.BleckC.K.WaltherP.FullerS.D.AntonyC.Krijnse-LockerJ.BartenschlagerR.Composition and Three-Dimensional Architecture of the" exact="Dengue" post="Virus Replication and Assembly SitesCell Host Microbe2009536537510.1016/j.chom.2009.03.00719380115 27.CorteseM.GoellnerS.AcostaE.G.NeufeldtC.J.OleksiukO.LampeM.HaselmannU.FunayaC.SchieberN.RonchiP.et al.Ultrastructural"/>
   <result pre="Replication and Assembly SitesCell Host Microbe2009536537510.1016/j.chom.2009.03.00719380115 27.CorteseM.GoellnerS.AcostaE.G.NeufeldtC.J.OleksiukO.LampeM.HaselmannU.FunayaC.SchieberN.RonchiP.et al.Ultrastructural Characterization of" exact="Zika" post="Virus Replication FactoriesCell Rep.2017182113212310.1016/j.celrep.2017.02.01428249158 28.KümmererB.M.RiceC.M.Mutations in the Yellow Fever"/>
   <result pre="RNA-interacting proteinsFEBS Lett.20115852575258110.1016/j.febslet.2011.06.03821771593 35.ShangZ.SongH.ShiY.QiJ.GaoG.F.Crystal Structure of the Capsid Protein from" exact="Zika" post="VirusJ. Mol. Biol.201843094896210.1016/j.jmb.2018.02.00629454707 36.BhuvanakanthamR.ChongM.K.NgM.L.Specific Interaction of Capsid Protein and"/>
   <result pre="Mol. Biol.201843094896210.1016/j.jmb.2018.02.00629454707 36.BhuvanakanthamR.ChongM.K.NgM.L.Specific Interaction of Capsid Protein and Importin-Alpha/Beta Influences" exact="West Nile" post="Virus ProductionBiochem. Biophys. Res. Commun.2009389636910.1016/j.bbrc.2009.08.10819712667 37.YangJ.S.RamanathanM.P.MuthumaniK.ChooA.Y.JinS.H.YuQ.C.HwangD.S.ChooD.K.LeeM.D.DangK.et al.Induction of Inflammation"/>
   <result pre="Virus ProductionBiochem. Biophys. Res. Commun.2009389636910.1016/j.bbrc.2009.08.10819712667 37.YangJ.S.RamanathanM.P.MuthumaniK.ChooA.Y.JinS.H.YuQ.C.HwangD.S.ChooD.K.LeeM.D.DangK.et al.Induction of Inflammation by" exact="West Nile" post="virus Capsid through the Caspase-9 Apoptotic PathwayEmerg. Infect. Dis.200281379138410.3201/eid0812.02022412498651"/>
   <result pre="Infect. Dis.200281379138410.3201/eid0812.02022412498651 38.SessionsO.M.TanY.GohK.C.LiuY.TanP.RozenS.OoiE.E.Host Cell Transcriptome Profile during Wild-Type and Attenuated" exact="Dengue" post="Virus InfectionPLoS Negl. Trop. Dis.20137e210710.1371/journal.pntd.000210723516652 39.SinghP.K.KhatriI.JhaA.PrettoC.D.SpindlerK.R.ArumugaswamiV.GiriS.KumarA.BhasinM.K.Determination of system level"/>
   <result pre="39.SinghP.K.KhatriI.JhaA.PrettoC.D.SpindlerK.R.ArumugaswamiV.GiriS.KumarA.BhasinM.K.Determination of system level alterations in host transcriptome due to" exact="Zika" post="virus (ZIKV) Infection in retinal pigment epitheliumSci. Rep.201881120910.1038/s41598-018-29329-230046058 40.EtebariK.HegdeS.SaldanaM.A.WidenS.G.WoodT.G.AsgariS.HughesG.L.Global"/>
   <result pre="40.EtebariK.HegdeS.SaldanaM.A.WidenS.G.WoodT.G.AsgariS.HughesG.L.Global transcriptome analysis of Aedes aegypti mosquitoes in response to" exact="Zika" post="virus infectionMSphere2017210.1128/mSphere.00456-17 41.YoshiiK.Epidemiology and pathological mechanisms of tick-borne encephalitisJ."/>
   <result pre="Coding Sequences Revealed a Requirement of the N-Terminal Region of" exact="Dengue" post="Virus Capsid Protein in Virus Particle FormationJ. Virol.2012861046105810.1128/JVI.05431-1122072762 46.MaL.JonesC.T.GroeschT.D.KuhnR.J.PostC.B.Solution"/>
   <result pre="RNAProc. Natl. Acad. Sci. USA2016113138631386810.1073/pnas.160054411327849599 49.LiT.ZhaoQ.YangX.ChenC.YangK.WuC.ZhangT.DuanY.XueX.MiK.et al.Structural Insight into the" exact="Zika" post="Virus Capsid Encapsulating the Viral GenomeCell Res.20182849749910.1038/s41422-018-0007-929467384 50.AllanJ.Participation of"/>
   <result pre="by RNA virus capsid proteinsCell. Signal.2008201227123610.1016/j.cellsig.2007.12.01818258415 56.BalinskyC.A.SchmeisserH.GanesanS.SinghK.PiersonT.C.ZoonK.C.Nucleolin Interacts with the" exact="Dengue" post="Virus Capsid Protein and Plays a Role in Formation"/>
   <result pre="in Formation of Infectious Virus ParticlesJ. Virol.201387130941310610.1128/JVI.00704-1324027323 57.VarjakM.DonaldC.L.MottramT.J.SreenuV.B.MeritsA.MaringerK.SchnettlerE.KohlA.Characterization of the" exact="Zika" post="virus induced small RNA response in Aedes aegypti cellsPLoS"/>
   <result pre="cellsPLoS Negl. Trop. Dis.201711e000601010.1371/journal.pntd.000601029040304 58.FontaineK.A.LeonK.E.KhalidM.M.TomarS.Jimenez-MoralesD.DunlapM.KayeJ.A.ShahP.S.FinkbeinerS.KroganN.J.et al.The Cellular NMD Pathway Restricts" exact="Zika" post="Virus Infection and Is Targeted by the Viral Capsid"/>
   <result pre="apoptosisVirus Res.201014727528310.1016/j.virusres.2009.11.01219944121 61.CoyaudE.RanadheeraC.ChengD.T.GoncalvesJ.DyakovB.J.A.LaurentE.M.N.St-GermainJ.R.PelletierL.GingrasA.C.BrumellJ.H.et al.Global Interactomics Uncovers Extensive Organellar Targeting by" exact="Zika" post="VirusMol. Cell. Proteom.2018172242225510.1074/mcp.TIR118.00080030037810 62.MacharaA.LuxV.KožíšekM.ŠaškováK.G.ŠtěpánekO.KotoraM.ParkanK.PávováM.GlassB.SehrP.et al.Specific Inhibitors of HIV Capsid"/>
   <result pre="antiviral designVirus Res.201216938841010.1016/j.virusres.2012.06.01622728445 65.AggarwalM.KaurR.SahaA.MudgalR.YadavR.DashP.K.ParidaM.KumarP.TomarS.Evaluation of antiviral activity of piperazine against" exact="Chikungunya" post="virus targeting hydrophobic pocket of alphavirus capsid proteinAntivir. Res.201714610211110.1016/j.antiviral.2017.08.01528842264"/>
   <result pre="in dengue drug discoveryAntivir. Res.201916810911310.1016/j.antiviral.2019.05.00531085207 69.ByrdC.M.DaiD.GrosenbachD.W.BerhanuA.JonesK.F.CardwellK.B.SchneiderC.WineingerK.A.PageJ.M.HarverC.et al.A Novel Inhibitor of" exact="Dengue" post="Virus Replication That Targets the Capsid ProteinAntimicrob. Agents Chemother.201357152510.1128/AAC.01429-1223070172"/>
   <result pre="Chemother.201357152510.1128/AAC.01429-1223070172 70.ScaturroP.TristI.M.L.PaulD.KumarA.AcostaE.G.ByrdC.M.JordanR.BrancaleA.BartenschlagerR.Characterization of the Mode of Action of a Potent" exact="Dengue" post="Virus Capsid InhibitorJ. Virol.201488115401155510.1128/JVI.01745-1425056895 71.BoonP.L.S.MartinsA.S.EnguitaF.J.LimX.N.SantosN.C.MatsudairaP.T.MartinsI.C.YueW.BondP.J.HuberR.G.Genome-Wide Associations of Flavivirus Capsid"/>
   <result pre="J. Med.201637495195810.1056/NEJMoa160065126862926 75.SeinoK.K.LongM.T.GibbsE.P.J.BowenR.A.BeachboardS.E.HumphreyP.P.DixonM.A.BourgeoisM.A.Comparative Efficacies of Three Commercially Available Vaccines against" exact="West Nile" post="Virus (WNV) in a Short-Duration Challenge Trial Involving an"/>
   <result pre="Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine" exact="WNV" post="Encephalitis ModelClin. Vaccine Immunol.2007141465147110.1128/CVI.00249-0717687109 76.OstlundE.N.CromR.L.PedersenD.D.JohnsonD.J.WilliamsW.O.SchmittB.J.Equine West Nile Encephalitis, United"/>
   <result pre="Trial Involving an Equine WNV Encephalitis ModelClin. Vaccine Immunol.2007141465147110.1128/CVI.00249-0717687109 76.OstlundE.N.CromR.L.PedersenD.D.JohnsonD.J.WilliamsW.O.SchmittB.J.Equine" exact="West Nile" post="Encephalitis, United StatesEmerg. Infect. Dis.2001766566910.3201/eid0704.01741211589171 77.GallerR.FreireM.JaborA.MannG.The yellow fever 17D"/>
   <result pre="Mutants: Basics, Benefits, and BarriersViral Immunol.20041746147210.1089/vim.2004.17.46115671744 86.XieX.KumD.B.XiaH.LuoH.ShanC.ZouJ.MuruatoA.E.MedeirosD.B.NunesB.T.DallmeierK.et al.A Single-Dose Live-Attenuated" exact="Zika" post="Virus Vaccine with Controlled Infection Rounds that Protects against"/>
   <result pre="Rounds that Protects against Vertical TransmissionCell Host Microbe20182448749910.1016/j.chom.2018.09.00830308155 87.SchlickP.KoflerR.M.SchittlB.TaucherC.NagyE.MeinkeA.MandlC.W.Characterization of" exact="West Nile" post="virus live vaccine candidates attenuated by capsid deletion mutationsVaccine2010285903590910.1016/j.vaccine.2010.06.04520600500"/>
   <result pre="89.BarrettA.D.T.Flavivirus DNA vaccine with a kickNat. Biotechnol.20082652552610.1038/nbt0508-52518464782 90.BarrettA.D.T.Current status of" exact="Zika" post="vaccine development: Zika vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012"/>
   <result pre="with a kickNat. Biotechnol.20082652552610.1038/nbt0508-52518464782 90.BarrettA.D.T.Current status of Zika vaccine development:" exact="Zika" post="vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012 91.BeckettC.G.TjadenJ.BurgessT.DankoJ.R.TammingaC.SimmonsM.WuS.J.SunP.KochelT.RaviprakashK.et al.Evaluation of"/>
   <result pre="1 clinical trialVaccine20112996096810.1016/j.vaccine.2010.11.05021111785 92.GaudinskiM.R.HouserK.V.MorabitoK.M.HuZ.YamshchikovG.RothwellR.S.BerkowitzN.MendozaF.SaundersJ.G.NovikL.et al.Safety, Tolerability, and Immunogenicity of Two" exact="Zika" post="Virus DNA Vaccine Candidates in Healthy Adults: Randomised, Open-Label,"/>
   <result pre="93.ChangD.C.LiuW.J.AnrakuI.ClarkD.C.PollittC.C.SuhrbierA.HallR.A.KhromykhA.A.Single-round infectious particles enhance immunogenicity of a DNA vaccine against" exact="West Nile" post="virusNat. Biotechnol.20082657157710.1038/nbt140018425125 94.RobyJ.A.Bielefeldt-OhmannH.ProwN.A.ChangD.C.HallR.A.KhromykhA.A.Increased expression of capsid protein in trans"/>
   <result pre="protein in trans enhances production of single-round infectious particles by" exact="West Nile" post="virus DNA vaccine candidateJ. Gen. Virol.2014952176219110.1099/vir.0.064121-024958626 95.DejnirattisaiW.SupasaP.WongwiwatW.RouvinskiA.Barba-SpaethG.DuangchindaT.SakuntabhaiA.Cao-LormeauV.M.MalasitP.ReyF.A.et al.Dengue virus"/>
   <result pre="replication and assembly in flavivirusesCurr. Opin. Virol.2014913414210.1016/j.coviro.2014.09.02025462445 104.HasanS.S.SevvanaM.KuhnR.J.RossmannM.G.Structural biology of" exact="Zika" post="virus and other flavivirusesNat. Struct. Mol. Biol.201825132010.1038/s41594-017-0010-829323278 105.PaulD.BartenschlagerR.Flaviviridae Replication"/>
   <result pre="genome (blue line). Figure 2 Flavivirus capsid structure. (Top left)" exact="Zika" post="virus (ZIKV) C bottom view, 5YGH.pdb. (Top right) West"/>
   <result pre="left) Zika virus (ZIKV) C bottom view, 5YGH.pdb. (Top right)" exact="West Nile" post="virus (WNV) C bottom view. Color key provided bottom"/>
   <result pre="key provided bottom left, 1SFK.pdb. (Bottom right) side view of" exact="ZIKV" post="C dimer with its orientation to the lipid bilayer,"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
